data_2vcd_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2vcd _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 . . . . . 0 CA--C 1.517 -0.321 0 CA-C-O 121.861 0.839 . . . . 1.0 110.633 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.611 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 3.7 m-20 -58.55 -38.42 77.79 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 107.528 -1.286 . . . . 1.0 107.528 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -63.93 -50.98 66.55 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 113.125 -1.852 . . . . 1.0 111.806 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 70.7 t -73.82 -48.62 38.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 119.812 -0.755 . . . . 1.0 111.713 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.45 ' O ' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -60.36 -40.63 91.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.827 -1.175 . . . . 1.0 107.827 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.74 -48.07 70.4 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.374 -0.83 . . . . 1.0 112.133 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.473 ' O ' ' OG1' ' A' ' 17' ' ' THR . 95.5 mt-10 -61.71 -31.25 71.39 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.01 -0.737 . . . . 1.0 109.01 178.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.22 -33.79 43.44 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.121 -0.945 . . . . 1.0 109.957 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' O ' ' A' ' 11' ' ' LYS . 64.3 t80 -61.14 -50.78 71.81 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 114.445 -1.252 . . . . 1.0 110.414 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mp -68.44 -41.59 80.07 Favored 'General case' 0 CA--C 1.513 -0.452 0 C-N-CA 119.963 -0.695 . . . . 1.0 109.649 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 29.8 m -62.14 -41.31 98.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.569 -0.741 . . . . 1.0 109.474 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -75.74 -45.29 37.38 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.584 -0.734 . . . . 1.0 111.637 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.1 t30 -61.34 -45.03 96.12 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 113.135 0.791 . . . . 1.0 113.135 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -57.68 -31.36 66.27 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 119.305 -0.958 . . . . 1.0 108.833 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -80.74 -31.48 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.72 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 41.2 mtmt -56.97 139.85 78.02 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 120.19 -0.604 . . . . 1.0 110.905 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -56.27 148.49 60.5 Favored 'Trans proline' 0 N--CA 1.502 2.0 0 C-N-CA 122.069 1.846 . . . . 1.0 113.879 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.1 -19.5 10.06 Favored Glycine 0 C--O 1.227 -0.318 0 CA-C-N 114.937 -1.029 . . . . 1.0 111.992 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.5 t -83.35 138.17 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.123 0.487 . . . . 1.0 110.929 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.5 t -122.35 122.41 66.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.8 p -96.76 146.22 7.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.653 0 CA-C-O 121.569 0.699 . . . . 1.0 111.847 -178.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.7 mt -114.08 166.09 12.23 Favored Pre-proline 0 C--O 1.232 0.146 0 CA-C-N 114.484 -1.235 . . . . 1.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -62.07 -30.46 82.71 Favored 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 121.985 1.79 . . . . 1.0 111.499 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 m -68.84 -13.3 62.33 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.955 -0.566 . . . . 1.0 109.811 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.96 -1.56 68.14 Favored Glycine 0 CA--C 1.517 0.199 0 N-CA-C 109.811 -1.316 . . . . 1.0 109.811 -179.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.9 tm? -80.95 133.98 35.62 Favored 'General case' 0 CA--C 1.518 -0.258 0 N-CA-C 108.591 -0.892 . . . . 1.0 108.591 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.421 ' H ' HD23 ' A' ' 32' ' ' LEU . 18.9 mp0 -122.42 138.42 54.54 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 116.448 -0.342 . . . . 1.0 111.087 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -133.56 145.5 50.15 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.525 0.679 . . . . 1.0 111.054 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -127.66 132.82 49.66 Favored 'General case' 0 CA--C 1.505 -0.751 0 CA-C-N 114.552 -1.204 . . . . 1.0 109.499 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.57 104.26 14.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 122.2 1.0 . . . . 1.0 112.122 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.8 mm -70.24 -41.69 78.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.027 -0.988 . . . . 1.0 108.523 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -143.11 128.34 18.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 114.595 -1.184 . . . . 1.0 109.495 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.0 p -88.12 131.84 34.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.746 0.308 . . . . 1.0 110.239 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.21 -35.44 0.81 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.624 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 57.23 30.66 18.77 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.251 -0.474 . . . . 1.0 111.169 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.12 -161.73 37.55 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.828 0.682 . . . . 1.0 111.756 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 25.9 m -69.01 -178.4 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.153 -1.023 . . . . 1.0 109.576 178.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.477 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.62 154.26 0.4 Allowed Pre-proline 0 C--N 1.32 -0.711 0 O-C-N 123.682 0.614 . . . . 1.0 109.523 179.554 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -87.83 157.81 7.46 Favored 'Trans proline' 0 N--CA 1.5 1.894 0 C-N-CA 123.363 2.709 . . . . 1.0 117.242 -174.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.457 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.84 176.17 44.05 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 109.205 -1.558 . . . . 1.0 109.205 176.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.5 -25.46 6.6 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.189 -0.506 . . . . 1.0 112.055 -179.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -108.61 -8.42 15.47 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 112.834 0.679 . . . . 1.0 112.834 -177.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.457 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.3 m-20 -82.96 166.47 18.82 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.327 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.7 m -105.35 150.59 25.08 Favored 'General case' 0 CA--C 1.511 -0.551 0 CA-C-O 121.334 0.588 . . . . 1.0 110.146 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -128.94 160.68 39.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.19 -0.914 . . . . 1.0 112.009 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.8 m -127.69 119.87 26.78 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.125 -1.065 . . . . 1.0 108.125 177.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.48 ' O ' ' N ' ' A' ' 75' ' ' ALA . 7.2 m -148.9 164.74 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 114.507 1.299 . . . . 1.0 114.507 -176.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -118.22 150.74 38.92 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 106.305 -1.739 . . . . 1.0 106.305 174.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.552 ' O ' ' N ' ' A' ' 68' ' ' THR . 32.5 p90 -163.32 162.9 25.34 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 115.09 1.515 . . . . 1.0 115.09 -177.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -126.27 129.47 48.97 Favored 'General case' 0 C--O 1.217 -0.608 0 CA-C-N 115.086 -0.961 . . . . 1.0 108.515 175.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.76 134.61 12.09 Favored Glycine 0 N--CA 1.471 1.011 0 N-CA-C 111.472 -0.651 . . . . 1.0 111.472 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.53 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 8.6 ptp85 -147.03 167.43 24.05 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.701 0.763 . . . . 1.0 112.389 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.5 mp -84.46 165.06 18.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 114.349 -1.296 . . . . 1.0 110.236 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.79 -26.55 38.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.265 -0.879 . . . . 1.0 110.524 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -92.0 3.18 55.81 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.044 -1.434 . . . . 1.0 111.701 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.24 -4.09 76.97 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 121.337 -0.458 . . . . 1.0 113.177 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.3 m -68.01 104.06 1.65 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 118.141 0.97 . . . . 1.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.6 t -76.43 120.04 25.79 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.079 0.466 . . . . 1.0 110.153 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -109.28 -11.79 14.84 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 115.231 -0.895 . . . . 1.0 112.308 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -161.99 153.08 17.99 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.316 -0.554 . . . . 1.0 111.511 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.429 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 94.4 p -159.23 154.21 24.97 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.41 0.624 . . . . 1.0 112.558 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.552 ' N ' ' O ' ' A' ' 55' ' ' TYR . 62.3 m -150.15 -40.74 0.13 Allowed 'General case' 0 C--O 1.223 -0.337 0 CA-C-N 115.024 -0.989 . . . . 1.0 110.305 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.41 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.6 pp20? -62.22 -26.62 68.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.241 -0.583 . . . . 1.0 109.637 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.9 mmmt -57.0 -42.91 81.17 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.426 -1.324 . . . . 1.0 107.426 178.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.549 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.4 p -73.28 -33.72 65.39 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.732 -1.122 . . . . 1.0 108.365 176.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.13 17.04 75.27 Favored Glycine 0 C--N 1.334 0.425 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.359 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.6 mttm -101.44 116.7 63.3 Favored Pre-proline 0 N--CA 1.469 0.524 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.693 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -60.08 152.76 63.06 Favored 'Trans proline' 0 N--CA 1.485 0.982 0 C-N-CA 121.786 1.657 . . . . 1.0 114.377 -178.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -122.29 147.26 46.45 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 113.827 -1.533 . . . . 1.0 107.548 177.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.46 128.12 52.3 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 121.072 0.463 . . . . 1.0 112.014 -179.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -136.06 150.59 49.22 Favored 'General case' 0 CA--C 1.493 -1.24 0 CA-C-O 121.797 0.808 . . . . 1.0 110.844 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -94.14 123.63 37.65 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 105.828 -1.915 . . . . 1.0 105.828 174.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.3 t -49.44 -25.61 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.795 -0.638 . . . . 1.0 110.663 -176.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 15.3 t -78.11 -24.33 47.53 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 120.308 -0.557 . . . . 1.0 112.189 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -96.6 -10.28 27.48 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.112 0.412 . . . . 1.0 112.112 -179.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.68 166.8 2.4 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 N-CA-C 112.59 0.589 . . . . 1.0 112.59 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -57.24 146.7 60.84 Favored Pre-proline 0 CA--C 1.545 0.753 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -48.88 -46.11 26.05 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.686 1.591 . . . . 1.0 113.03 -178.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.68 -47.56 87.66 Favored Glycine 0 C--N 1.319 -0.398 0 N-CA-C 109.753 -1.339 . . . . 1.0 109.753 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -64.4 -36.23 83.49 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.147 -1.027 . . . . 1.0 110.199 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.5 m -51.17 -54.5 24.87 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.313 -0.403 . . . . 1.0 111.25 -177.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -72.96 -41.62 64.21 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.604 0.594 . . . . 1.0 112.604 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.51 -46.46 83.78 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 113.615 0.969 . . . . 1.0 113.615 -177.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 38.3 mt -58.85 -41.58 87.29 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 109.192 -0.67 . . . . 1.0 109.192 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.6 mt-30 -62.95 -23.85 67.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 114.938 -1.028 . . . . 1.0 110.696 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.448 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 83.9 mt -103.34 -12.96 16.88 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.255 -0.429 . . . . 1.0 111.327 -179.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.8 ttp -87.6 108.66 21.34 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-O 119.349 -0.358 . . . . 1.0 111.899 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.477 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.44 147.88 83.19 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 122.377 2.051 . . . . 1.0 112.365 178.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -66.46 132.37 48.12 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.519 -0.764 . . . . 1.0 111.438 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 99.52 -18.81 55.73 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 108.567 -1.813 . . . . 1.0 108.567 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.1 p -88.63 136.45 32.99 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 120.959 0.409 . . . . 1.0 110.387 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 90.5 m -108.27 114.39 28.22 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 115.803 -0.635 . . . . 1.0 109.708 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.448 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.1 m0 -115.4 167.6 10.72 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 121.596 0.712 . . . . 1.0 111.228 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 85.2 mt-10 -127.37 128.11 45.33 Favored 'General case' 0 CA--C 1.508 -0.639 0 N-CA-C 106.673 -1.603 . . . . 1.0 106.673 175.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.6 pt -123.32 138.07 54.5 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.6 0 CA-C-O 121.894 0.855 . . . . 1.0 110.27 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.658 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.44 103.9 13.13 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.957 -1.868 . . . . 1.0 105.957 -177.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.7 t -90.42 115.4 64.02 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 115.076 1.51 . . . . 1.0 115.076 -174.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -51.15 141.96 36.97 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 121.323 1.348 . . . . 1.0 109.858 175.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.3 p -48.46 -34.28 10.81 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.149 -0.62 . . . . 1.0 110.943 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.87 -32.32 80.72 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.144 -0.782 . . . . 1.0 111.144 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 68.0 mt -98.55 1.67 46.75 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 121.393 -0.123 . . . . 1.0 110.74 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.8 -113.39 0.3 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.052 0.39 . . . . 1.0 112.052 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -98.2 3.77 48.95 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 112.487 0.551 . . . . 1.0 112.487 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 109.49 162.75 19.67 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 121.014 -0.612 . . . . 1.0 112.768 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -74.75 -9.29 21.04 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 123.556 2.837 . . . . 1.0 111.695 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -103.63 166.59 10.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.126 -0.488 . . . . 1.0 109.839 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.57 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -72.3 84.99 1.07 Allowed 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.0 t -100.72 62.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.985 0.422 . . . . 1.0 110.513 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 168.36 -179.98 41.09 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 111.502 -0.639 . . . . 1.0 111.502 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.84 -103.98 0.01 OUTLIER Glycine 0 CA--C 1.535 1.322 0 N-CA-C 110.992 -0.843 . . . . 1.0 110.992 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -61.33 -14.78 36.39 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.549 2.166 . . . . 1.0 110.669 -178.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.1 mp -65.83 113.25 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 106.672 -1.603 . . . . 1.0 106.672 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.31 -172.79 40.14 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.378 -0.828 . . . . 1.0 112.28 -177.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.57 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.2 Cg_endo -62.88 138.11 66.58 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 C-N-CA 122.38 2.053 . . . . 1.0 112.405 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.34 51.82 12.4 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 121.039 -0.264 . . . . 1.0 111.061 178.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.611 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -98.82 130.06 45.24 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.921 0.712 . . . . 1.0 112.921 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 43.5 m -96.66 129.13 44.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 106.063 -1.829 . . . . 1.0 106.063 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -110.94 145.15 38.87 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.308 0.575 . . . . 1.0 111.105 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 2.1 tt -124.31 148.55 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 CA-C-N 115.233 -0.894 . . . . 1.0 108.884 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.597 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -140.93 151.17 44.0 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.242 -0.583 . . . . 1.0 111.515 177.536 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.53 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 12.9 mmtt -99.36 125.32 45.01 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 105.46 -2.052 . . . . 1.0 105.46 177.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.02 118.4 56.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.267 -0.973 . . . . 1.0 112.418 -176.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 -109.68 123.88 50.25 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 114.128 -1.397 . . . . 1.0 108.649 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.07 111.17 23.02 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 120.246 -0.582 . . . . 1.0 112.39 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -94.29 -42.69 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 115.995 -0.548 . . . . 1.0 111.676 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -153.44 156.0 37.38 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.502 -0.479 . . . . 1.0 110.796 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.7 t -130.65 138.82 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 116.156 -0.475 . . . . 1.0 111.452 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.4 tptm . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 121.494 0.664 . . . . 1.0 109.564 178.452 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 . . . . . 0 CA--C 1.515 -0.366 0 CA-C-O 121.655 0.74 . . . . 1.0 110.505 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.4 m-20 -59.67 -35.31 74.19 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.204 -1.035 . . . . 1.0 108.204 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.452 ' O ' ' N ' ' A' ' 13' ' ' GLU . 59.3 tttt -66.59 -50.5 62.86 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 113.757 -1.565 . . . . 1.0 111.919 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.15 -48.0 82.81 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 C-N-CA 119.813 -0.755 . . . . 1.0 111.253 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -62.84 -38.1 89.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 178.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.15 -44.76 52.9 Favored Glycine 0 CA--C 1.525 0.703 0 CA-C-N 114.847 -1.069 . . . . 1.0 112.366 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 9' ' ' LYS . 92.1 mt-10 -60.44 -31.78 70.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 119.494 -0.882 . . . . 1.0 108.692 179.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.99 -35.5 57.12 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.809 -1.087 . . . . 1.0 109.87 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.1 t80 -61.39 -51.34 69.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.621 -1.172 . . . . 1.0 110.847 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.3 mp -68.12 -38.37 82.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 119.995 -0.682 . . . . 1.0 109.41 179.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 99.3 m -62.16 -41.65 98.51 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.553 -0.749 . . . . 1.0 109.296 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -74.62 -46.81 35.96 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.056 -0.975 . . . . 1.0 111.655 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.638 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -55.73 -50.49 70.24 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 112.496 0.554 . . . . 1.0 112.496 -178.783 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.0 ptmt -60.1 -26.74 66.45 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.379 -0.928 . . . . 1.0 109.831 -177.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -83.55 -31.23 26.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.377 -0.829 . . . . 1.0 111.186 179.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -58.7 136.45 86.57 Favored Pre-proline 0 CA--C 1.548 0.871 0 CA-C-N 116.52 -0.309 . . . . 1.0 111.576 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -56.75 148.58 64.84 Favored 'Trans proline' 0 N--CA 1.503 2.071 0 C-N-CA 122.138 1.892 . . . . 1.0 113.334 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.14 -19.32 18.11 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.495 -0.775 . . . . 1.0 111.49 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -86.42 137.71 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.165 0.507 . . . . 1.0 110.547 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.93 121.78 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 107.582 -1.266 . . . . 1.0 107.582 177.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.19 145.99 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.642 0 CA-C-O 121.361 0.601 . . . . 1.0 111.228 -178.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 92.8 mt -111.94 164.81 14.25 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.85 -1.068 . . . . 1.0 110.462 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -61.54 -30.48 86.28 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.745 1.63 . . . . 1.0 110.91 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -68.83 -14.44 63.03 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.473 -0.785 . . . . 1.0 109.828 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.41 -3.89 66.43 Favored Glycine 0 C--N 1.329 0.157 0 N-CA-C 109.671 -1.371 . . . . 1.0 109.671 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.43 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.16 133.93 36.71 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 108.457 -0.942 . . . . 1.0 108.457 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.43 ' H ' HD23 ' A' ' 32' ' ' LEU . 15.2 mp0 -123.07 143.38 50.0 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 116.286 -0.416 . . . . 1.0 110.887 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.4 p90 -138.21 143.59 40.25 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-O 121.635 0.731 . . . . 1.0 110.757 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -127.51 131.24 50.14 Favored 'General case' 0 CA--C 1.501 -0.924 0 CA-C-N 114.594 -1.184 . . . . 1.0 109.188 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 p -88.85 104.62 15.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 122.279 1.038 . . . . 1.0 111.688 -178.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 16.0 mm -69.25 -42.2 81.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.881 -1.054 . . . . 1.0 108.453 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -143.36 124.55 14.54 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.501 -1.227 . . . . 1.0 109.907 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -85.83 129.64 34.77 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.611 -0.436 . . . . 1.0 109.9 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.23 -33.24 1.26 Allowed Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.895 -1.282 . . . . 1.0 109.895 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.645 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 57.04 31.67 20.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.477 -0.361 . . . . 1.0 111.157 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.08 -162.18 37.92 Favored Glycine 0 C--N 1.332 0.329 0 CA-C-O 121.819 0.677 . . . . 1.0 111.822 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.4 m -68.17 -177.93 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 114.061 -1.069 . . . . 1.0 109.127 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.515 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.32 154.82 0.39 Allowed Pre-proline 0 C--N 1.317 -0.834 0 N-CA-C 109.338 -0.616 . . . . 1.0 109.338 179.553 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -86.71 158.78 9.09 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 123.11 2.54 . . . . 1.0 115.741 -175.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 177.29 41.72 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 108.766 -1.734 . . . . 1.0 108.766 176.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.522 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.48 -23.02 9.07 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.882 -0.327 . . . . 1.0 111.07 -179.713 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 57.9 m -108.05 -9.22 15.67 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 113.629 0.974 . . . . 1.0 113.629 -176.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.438 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.7 m-20 -84.74 166.87 16.64 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 119.883 -0.727 . . . . 1.0 109.468 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.5 m -104.56 148.44 26.5 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.612 -0.514 . . . . 1.0 109.612 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -126.57 161.79 32.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.478 0 CA-C-N 115.857 -0.611 . . . . 1.0 112.278 -176.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -130.48 118.18 20.74 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 75' ' ' ALA . 2.5 m -148.14 166.43 4.79 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 112.577 0.584 . . . . 1.0 112.577 -177.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.39 157.7 24.66 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 106.469 -1.678 . . . . 1.0 106.469 175.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.47 ' O ' ' N ' ' A' ' 68' ' ' THR . 34.6 p90 -167.2 160.91 14.15 Favored 'General case' 0 C--N 1.346 0.415 0 N-CA-C 114.846 1.425 . . . . 1.0 114.846 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.8 m -124.76 127.81 47.8 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.119 -1.067 . . . . 1.0 108.119 174.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.89 134.03 11.39 Favored Glycine 0 N--CA 1.47 0.955 0 C-N-CA 120.748 -0.739 . . . . 1.0 111.915 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -146.48 166.84 25.22 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.715 0.769 . . . . 1.0 112.169 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.0 162.66 20.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.391 -1.277 . . . . 1.0 110.062 177.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.05 -25.33 29.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.913 0.863 . . . . 1.0 110.206 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -92.22 2.84 56.37 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 113.947 -1.479 . . . . 1.0 111.852 -177.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.96 -4.98 78.86 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 121.016 -0.611 . . . . 1.0 112.781 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.7 m -68.82 105.75 2.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 118.068 0.934 . . . . 1.0 109.63 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 67.7 t -77.69 121.82 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.691 0 CA-C-O 121.229 0.538 . . . . 1.0 110.301 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -110.41 -11.53 14.5 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.089 -0.959 . . . . 1.0 111.688 -179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -159.84 154.13 23.66 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.192 0.52 . . . . 1.0 111.497 177.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 83.3 p -159.29 151.43 20.98 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.41 -0.814 . . . . 1.0 111.213 178.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 55' ' ' TYR . 96.9 m -154.38 -41.78 0.09 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.645 -0.707 . . . . 1.0 110.649 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.426 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -62.38 -26.33 68.41 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.862 -0.608 . . . . 1.0 110.313 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -55.34 -41.88 73.06 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 108.153 -1.054 . . . . 1.0 108.153 179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.462 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.7 p -80.05 -30.82 39.47 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.067 177.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.1 16.99 68.19 Favored Glycine 0 C--N 1.336 0.531 0 CA-C-N 115.689 -0.687 . . . . 1.0 111.592 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -97.28 115.73 65.8 Favored Pre-proline 0 N--CA 1.471 0.591 0 C-N-CA 120.716 -0.394 . . . . 1.0 110.342 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -60.32 156.23 41.93 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.177 1.918 . . . . 1.0 114.687 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.67 145.36 49.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 113.908 -1.496 . . . . 1.0 107.595 177.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.513 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 1.4 t -104.0 133.91 48.16 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.395 0.617 . . . . 1.0 112.075 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 76' ' ' THR . 22.6 m-85 -144.18 152.45 40.9 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.837 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -94.52 125.15 38.99 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.878 -1.527 . . . . 1.0 106.878 175.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.95 -30.87 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 C-N-CA 120.04 -0.664 . . . . 1.0 110.57 -177.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -73.42 -24.25 60.24 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.299 -0.561 . . . . 1.0 112.349 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 86.1 mm-40 -99.72 -14.67 18.79 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.888 0.699 . . . . 1.0 112.888 -177.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -73.14 169.43 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 112.434 0.531 . . . . 1.0 112.434 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -56.09 149.08 37.06 Favored Pre-proline 0 CA--C 1.547 0.831 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -51.49 -45.01 40.18 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 121.359 1.372 . . . . 1.0 112.941 -178.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.93 -46.78 93.13 Favored Glycine 0 N--CA 1.45 -0.428 0 N-CA-C 110.29 -1.124 . . . . 1.0 110.29 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.6 m95 -65.87 -33.5 75.99 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.389 -0.906 . . . . 1.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.7 m -54.91 -54.16 46.18 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.703 -0.399 . . . . 1.0 111.359 -178.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -72.74 -42.44 64.07 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 112.771 0.656 . . . . 1.0 112.771 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.73 -46.8 83.95 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.903 1.075 . . . . 1.0 113.903 -177.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.2 mt -58.5 -41.56 85.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.347 0.594 . . . . 1.0 109.811 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -63.74 -23.59 67.43 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.095 -0.957 . . . . 1.0 110.515 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.528 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 81.3 mt -102.59 -10.03 19.63 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 116.032 -0.531 . . . . 1.0 111.422 -179.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.6 ttp -91.89 107.81 25.43 Favored Pre-proline 0 CA--C 1.546 0.823 0 N-CA-C 111.835 0.309 . . . . 1.0 111.835 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.515 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 20.0 Cg_exo -65.78 147.66 85.76 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 122.488 2.125 . . . . 1.0 112.357 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.74 137.55 58.12 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.666 0.746 . . . . 1.0 111.508 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.73 53.27 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 108.546 -1.822 . . . . 1.0 108.546 -178.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 p -87.18 134.6 33.51 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.009 0.433 . . . . 1.0 110.178 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.9 m -107.59 114.68 28.83 Favored 'General case' 0 CA--C 1.51 -0.582 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.052 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.528 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.6 m0 -115.71 164.38 14.43 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.708 0.766 . . . . 1.0 111.23 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -124.96 126.39 45.4 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 106.815 -1.55 . . . . 1.0 106.815 175.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -121.92 138.39 52.32 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.688 0 CA-C-O 121.899 0.857 . . . . 1.0 109.969 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.638 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.64 103.25 12.08 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.646 -1.983 . . . . 1.0 105.646 -178.231 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.2 115.45 64.07 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 114.75 1.389 . . . . 1.0 114.75 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -50.84 143.2 30.75 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 C-N-CA 121.433 1.422 . . . . 1.0 109.783 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 96.5 p -49.1 -35.26 15.75 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.273 -0.571 . . . . 1.0 110.531 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.86 -32.15 81.89 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 111.388 -0.685 . . . . 1.0 111.388 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 53.3 mt -100.59 2.91 42.2 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 121.499 -0.08 . . . . 1.0 110.832 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.66 -107.95 0.33 Allowed 'General case' 0 N--CA 1.457 -0.11 0 CA-C-O 120.923 0.392 . . . . 1.0 111.037 -178.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -100.03 4.89 45.01 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 111.965 0.357 . . . . 1.0 111.965 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.78 160.97 25.76 Favored Glycine 0 CA--C 1.529 0.927 0 C-N-CA 121.395 -0.431 . . . . 1.0 112.925 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.567 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.2 Cg_endo -70.56 -15.94 34.12 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 123.316 2.677 . . . . 1.0 112.676 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -96.75 169.48 9.84 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.22 -0.659 . . . . 1.0 109.22 179.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.426 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.3 m -75.76 82.78 2.72 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.352 -0.539 . . . . 1.0 110.096 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.5 t -98.36 60.11 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.771 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 172.68 -172.7 45.16 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.534 -0.841 . . . . 1.0 112.033 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.81 -103.78 0.05 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 111.036 -0.826 . . . . 1.0 111.036 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -59.3 -16.88 36.79 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.219 1.946 . . . . 1.0 110.397 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.487 ' CG2' ' OE2' ' A' ' 122' ' ' GLU . 5.0 mp -67.75 114.7 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 107.889 -1.152 . . . . 1.0 107.889 179.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.611 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -94.89 -158.5 33.09 Favored Glycine 0 C--O 1.212 -1.253 0 N-CA-C 110.968 -0.853 . . . . 1.0 110.968 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.511 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 44.6 Cg_endo -70.09 147.45 60.75 Favored 'Trans proline' 0 C--N 1.299 -2.034 0 C-N-CA 121.892 1.728 . . . . 1.0 113.098 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.567 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.5 t-20 39.99 60.74 1.65 Allowed 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.254 0.835 . . . . 1.0 113.254 177.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.639 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.03 135.85 53.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.571 0.7 . . . . 1.0 111.355 -179.423 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.2 m -93.69 129.0 40.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.329 178.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.51 140.97 42.63 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.142 0.496 . . . . 1.0 110.133 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.4 tt -121.11 143.68 32.6 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.729 0 CA-C-N 115.506 -0.77 . . . . 1.0 109.014 178.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -134.89 150.66 50.46 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.082 0.468 . . . . 1.0 111.08 177.269 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 14.3 mmtt -99.63 126.02 45.56 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 104.85 -2.278 . . . . 1.0 104.85 176.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.8 mt -119.72 119.54 60.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 119.16 -1.016 . . . . 1.0 111.851 -177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -111.92 120.94 43.63 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 114.091 -1.413 . . . . 1.0 108.816 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.63 112.45 24.41 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 120.236 -0.585 . . . . 1.0 112.326 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.9 mp -94.84 -47.49 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.875 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.5 p -148.14 157.54 43.56 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.93 0.395 . . . . 1.0 111.246 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 54.7 t -130.07 139.25 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 116.043 -0.526 . . . . 1.0 111.396 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.5 tptt . . . . . 0 CA--C 1.536 0.409 0 CA-C-N 115.424 -0.807 . . . . 1.0 110.298 179.089 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 . . . . . 0 C--O 1.223 -0.331 0 CA-C-O 121.487 0.661 . . . . 1.0 110.694 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 30.4 m-20 -59.51 -34.0 72.07 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-O 121.964 0.888 . . . . 1.0 108.617 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.8 tttt -64.43 -49.71 70.42 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 114.108 -1.405 . . . . 1.0 111.664 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.31 -47.26 74.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.408 -0.517 . . . . 1.0 112.112 -178.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -62.2 -36.91 83.36 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.79 -44.15 39.53 Favored Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.925 -1.034 . . . . 1.0 112.408 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -60.66 -30.97 70.22 Favored 'General case' 0 CA--C 1.514 -0.416 0 C-N-CA 119.701 -0.8 . . . . 1.0 108.883 179.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.8 -35.68 51.13 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.129 -0.941 . . . . 1.0 109.849 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 t80 -61.96 -50.8 70.66 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.728 -1.124 . . . . 1.0 110.901 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -66.82 -38.74 87.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.48 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 99.0 m -61.27 -43.0 99.59 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.498 -0.773 . . . . 1.0 109.584 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -75.32 -46.48 33.08 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.591 -0.731 . . . . 1.0 112.111 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.655 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 51.3 t30 -61.47 -45.12 95.58 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 113.145 0.795 . . . . 1.0 113.145 -177.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -58.02 -33.69 69.23 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 119.321 -0.952 . . . . 1.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 17' ' ' THR . 43.6 m-80 -75.46 -33.91 60.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.305 -0.861 . . . . 1.0 111.538 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -58.99 137.41 87.72 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 120.593 -0.443 . . . . 1.0 111.8 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -53.85 149.13 34.77 Favored 'Trans proline' 0 N--CA 1.507 2.302 0 C-N-CA 122.723 2.282 . . . . 1.0 114.757 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.76 -21.91 5.2 Favored Glycine 0 CA--C 1.508 -0.368 0 CA-C-N 114.421 -1.263 . . . . 1.0 111.265 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 54.3 t -80.21 132.0 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 N-CA-C 109.34 -0.615 . . . . 1.0 109.34 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.77 120.4 64.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.327 -0.99 . . . . 1.0 108.327 177.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.3 p -95.5 145.91 7.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 CA-C-O 121.471 0.653 . . . . 1.0 111.265 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.0 mt -114.17 165.26 14.07 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.597 -1.183 . . . . 1.0 110.955 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.76 -30.44 90.28 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 C-N-CA 121.828 1.685 . . . . 1.0 111.006 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.5 m -68.4 -15.82 63.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.608 -0.724 . . . . 1.0 109.801 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.95 -2.77 64.26 Favored Glycine 0 C--O 1.229 -0.192 0 N-CA-C 110.016 -1.234 . . . . 1.0 110.016 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.422 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -78.78 134.1 37.04 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.422 ' H ' HD23 ' A' ' 32' ' ' LEU . 20.0 mp0 -123.64 142.93 50.58 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.393 -0.367 . . . . 1.0 111.525 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -140.6 142.26 35.08 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.919 0.866 . . . . 1.0 112.183 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.465 ' CE ' ' CD1' ' A' ' 37' ' ' ILE . 8.6 ttpt -123.99 126.57 46.52 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.173 -1.376 . . . . 1.0 108.45 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -82.61 113.52 21.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.128 -178.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.466 ' HB ' HD21 ' A' ' 38' ' ' ASN . 4.8 mm -77.27 -42.24 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 CA-C-O 121.541 0.686 . . . . 1.0 109.844 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.466 HD21 ' HB ' ' A' ' 37' ' ' ILE . 27.0 m-80 -144.34 124.01 13.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.725 -1.125 . . . . 1.0 109.917 -177.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -81.84 129.58 34.79 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.539 -0.464 . . . . 1.0 110.527 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.15 -36.13 1.05 Allowed Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.106 -1.198 . . . . 1.0 110.106 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.598 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 57.81 31.22 20.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.447 -0.376 . . . . 1.0 111.49 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.67 -161.8 37.25 Favored Glycine 0 C--N 1.332 0.35 0 CA-C-O 121.984 0.769 . . . . 1.0 111.731 179.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.2 m -68.97 -177.86 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.093 -1.053 . . . . 1.0 109.086 178.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.515 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.18 154.23 0.38 Allowed Pre-proline 0 C--N 1.32 -0.676 0 O-C-N 123.757 0.661 . . . . 1.0 109.556 179.734 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -87.71 158.01 7.63 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 123.336 2.691 . . . . 1.0 116.45 -175.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.0 175.57 41.68 Favored Glycine 0 N--CA 1.449 -0.449 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 176.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.403 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.84 -22.31 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.778 -0.369 . . . . 1.0 111.274 -179.383 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 53.5 m -107.88 -9.3 15.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.534 0.939 . . . . 1.0 113.534 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.4 m-20 -85.19 165.43 17.4 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.436 -0.949 . . . . 1.0 108.436 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.7 m -104.72 150.53 24.66 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 109.869 -0.419 . . . . 1.0 109.869 -179.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -127.09 163.37 30.06 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 112.599 0.592 . . . . 1.0 112.599 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.1 m -131.55 120.18 22.55 Favored 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 108.488 -0.93 . . . . 1.0 108.488 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 15.8 m -148.75 165.28 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 114.438 1.273 . . . . 1.0 114.438 -176.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -118.35 147.92 43.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 174.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.489 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.3 p90 -163.63 162.14 24.11 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 114.68 1.363 . . . . 1.0 114.68 -176.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.49 133.11 54.6 Favored 'General case' 0 C--O 1.216 -0.675 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 175.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.83 135.96 11.79 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 120.972 -0.633 . . . . 1.0 111.855 -178.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.611 ' CZ ' ' HZ3' ' A' ' 127' ' ' LYS . 7.8 ptp85 -148.61 167.5 25.28 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.745 0.783 . . . . 1.0 112.997 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.69 163.79 18.99 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 114.377 -1.283 . . . . 1.0 110.989 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.417 HD11 ' N ' ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.58 -25.65 35.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 122.272 1.034 . . . . 1.0 109.589 177.468 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.4 ' H ' HD11 ' A' ' 60' ' ' ILE . 32.5 t70 -89.86 0.72 56.87 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 113.378 -1.737 . . . . 1.0 111.688 -177.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.69 81.74 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 121.182 -0.533 . . . . 1.0 112.351 178.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.4 m -68.9 104.13 1.99 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 119.92 -0.712 . . . . 1.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.7 t -77.08 121.13 28.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 CA-C-N 116.059 -0.519 . . . . 1.0 110.062 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 22.0 p90 -110.59 -14.26 14.09 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.184 -0.916 . . . . 1.0 112.056 -178.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -159.58 148.19 17.7 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.156 -0.618 . . . . 1.0 111.511 177.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 89.5 p -153.63 156.25 37.58 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.541 179.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.508 ' O ' ' OG1' ' A' ' 71' ' ' THR . 55.8 m -155.17 -39.51 0.09 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.984 -0.553 . . . . 1.0 110.78 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -63.12 -26.19 68.71 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.632 -0.427 . . . . 1.0 109.895 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -56.49 -41.3 76.4 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.085 -1.45 . . . . 1.0 107.085 178.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.508 ' OG1' ' O ' ' A' ' 68' ' ' THR . 23.1 p -76.74 -32.66 57.93 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.203 -1.362 . . . . 1.0 109.042 177.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.48 15.18 80.32 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.922 -0.871 . . . . 1.0 110.922 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -96.55 115.26 65.56 Favored Pre-proline 0 N--CA 1.47 0.537 0 C-N-CA 120.827 -0.349 . . . . 1.0 110.962 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -61.41 151.75 77.46 Favored 'Trans proline' 0 N--CA 1.482 0.827 0 C-N-CA 121.539 1.493 . . . . 1.0 114.405 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.8 150.34 46.45 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.089 -1.414 . . . . 1.0 107.78 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -107.53 136.07 47.93 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 112.882 0.697 . . . . 1.0 112.882 -178.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -144.48 151.01 38.55 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 114.858 -1.064 . . . . 1.0 109.032 177.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -90.14 125.87 35.6 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 106.434 -1.691 . . . . 1.0 106.434 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.0 t -50.6 -31.4 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 C-N-CA 119.926 -0.71 . . . . 1.0 110.545 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.691 ' HG ' ' NE2' ' A' ' 81' ' ' GLN . 2.8 t -73.57 -27.37 61.28 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 120.116 -0.634 . . . . 1.0 111.994 -177.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.691 ' NE2' ' HG ' ' A' ' 80' ' ' SER . 43.9 mm-40 -101.35 -8.72 21.8 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 113.219 0.822 . . . . 1.0 113.219 -178.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.5 p -80.32 172.84 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 C-N-CA 119.457 -0.897 . . . . 1.0 110.151 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.03 145.83 31.97 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 120.165 -0.614 . . . . 1.0 109.976 -176.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -51.42 -44.21 44.94 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.081 1.854 . . . . 1.0 112.783 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.05 -47.5 88.76 Favored Glycine 0 C--N 1.319 -0.4 0 N-CA-C 109.343 -1.503 . . . . 1.0 109.343 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -64.9 -35.21 80.4 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.796 -1.202 . . . . 1.0 110.565 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.24 -54.23 27.75 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.822 0.344 . . . . 1.0 111.172 -178.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -72.64 -43.14 63.59 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.745 0.646 . . . . 1.0 112.745 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.53 -45.84 84.56 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 113.957 1.095 . . . . 1.0 113.957 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.51 -41.12 84.7 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.457 0.646 . . . . 1.0 109.625 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.6 mt-30 -64.59 -23.85 67.4 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.836 -1.075 . . . . 1.0 110.805 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.482 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 80.6 mt -103.81 -10.73 18.03 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 116.207 -0.451 . . . . 1.0 111.41 -178.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 46.7 ttp -92.18 108.4 30.32 Favored Pre-proline 0 CA--C 1.55 0.978 0 CA-C-O 119.445 -0.312 . . . . 1.0 111.345 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.515 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 21.0 Cg_exo -65.35 148.26 88.12 Favored 'Trans proline' 0 N--CA 1.5 1.881 0 C-N-CA 122.681 2.254 . . . . 1.0 112.777 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.76 136.86 57.77 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.368 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.23 -19.31 53.12 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 108.954 -1.659 . . . . 1.0 108.954 -178.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.7 p -87.88 135.45 33.39 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 120.851 0.358 . . . . 1.0 110.473 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 72.0 m -107.89 114.94 29.24 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 115.952 -0.567 . . . . 1.0 110.142 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.482 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.4 m0 -114.99 164.24 14.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.491 0.662 . . . . 1.0 111.404 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -124.35 127.78 48.1 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.642 -1.614 . . . . 1.0 106.642 175.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -123.77 138.72 52.58 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.461 0 CA-C-O 121.768 0.794 . . . . 1.0 110.288 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.655 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.23 103.85 12.89 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.864 -1.902 . . . . 1.0 105.864 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.67 115.65 64.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 N-CA-C 115.466 1.654 . . . . 1.0 115.466 -174.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -50.71 143.25 29.7 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 C-N-CA 121.611 1.541 . . . . 1.0 110.017 176.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.5 p -50.09 -34.66 22.57 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.524 -0.47 . . . . 1.0 110.986 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.8 -31.89 76.68 Favored Glycine 0 CA--C 1.52 0.396 0 N-CA-C 110.812 -0.915 . . . . 1.0 110.812 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 54.9 mt -98.97 2.38 46.36 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 121.436 -0.106 . . . . 1.0 110.878 -179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -107.86 0.33 Allowed 'General case' 0 C--N 1.34 0.166 0 CA-C-O 120.503 0.192 . . . . 1.0 111.338 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 38.0 m-85 -99.45 4.64 46.22 Favored 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 113.279 0.844 . . . . 1.0 113.279 -177.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.33 164.52 22.81 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 120.756 -0.735 . . . . 1.0 113.352 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 121' ' ' ASN . 79.5 Cg_endo -73.98 -16.89 22.77 Favored 'Trans proline' 0 N--CA 1.493 1.46 0 C-N-CA 123.531 2.821 . . . . 1.0 110.9 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 60.4 ttt180 -96.06 165.12 12.4 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.477 -1.238 . . . . 1.0 109.685 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.522 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 8.1 m -77.02 91.97 3.68 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.565 -0.531 . . . . 1.0 109.565 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.3 t -107.56 60.66 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.113 -0.494 . . . . 1.0 111.199 -179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 171.23 178.05 41.45 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 120.201 -0.999 . . . . 1.0 112.145 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.23 -103.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 111.072 -0.811 . . . . 1.0 111.072 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -62.35 -16.04 48.91 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.567 2.178 . . . . 1.0 110.779 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.473 ' CG2' ' OE2' ' A' ' 122' ' ' GLU . 5.2 mp -66.67 115.92 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 108.233 -1.025 . . . . 1.0 108.233 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -96.52 -158.96 31.78 Favored Glycine 0 C--O 1.213 -1.194 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.522 ' N ' ' OG ' ' A' ' 113' ' ' SER . 46.9 Cg_endo -70.89 147.39 55.51 Favored 'Trans proline' 0 C--N 1.297 -2.141 0 C-N-CA 121.766 1.644 . . . . 1.0 113.326 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.484 ' C ' HD21 ' A' ' 121' ' ' ASN . 0.1 OUTLIER 41.17 60.6 2.0 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.195 0.813 . . . . 1.0 113.195 177.515 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.613 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.38 137.71 51.47 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 121.683 0.754 . . . . 1.0 111.225 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 81.8 m -94.43 130.09 40.91 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.332 -1.304 . . . . 1.0 108.624 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.29 141.3 46.17 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.05 -0.523 . . . . 1.0 109.8 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.7 tt -119.72 146.05 25.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 N-CA-C 108.368 -0.975 . . . . 1.0 108.368 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.574 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -137.98 151.0 47.5 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.394 -0.522 . . . . 1.0 111.759 177.838 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.611 ' HZ3' ' CZ ' ' A' ' 58' ' ' ARG . 4.1 mmtt -101.16 122.91 44.46 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 105.741 -1.948 . . . . 1.0 105.741 177.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.0 mt -117.51 119.19 60.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.956 0.884 . . . . 1.0 113.257 -176.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -109.95 124.03 50.67 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 113.935 -1.484 . . . . 1.0 108.354 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.93 111.12 23.2 Favored 'General case' 0 N--CA 1.465 0.293 0 C-N-CA 120.162 -0.615 . . . . 1.0 112.369 -178.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -94.01 -45.03 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 115.881 -0.599 . . . . 1.0 111.729 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.7 p -150.63 155.82 40.13 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.683 -0.407 . . . . 1.0 110.79 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 46.4 t -129.71 137.21 57.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 121.05 0.452 . . . . 1.0 111.772 -177.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 tptt . . . . . 0 N--CA 1.447 -0.581 0 CA-C-N 115.723 -0.671 . . . . 1.0 110.098 178.793 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 121.663 0.744 . . . . 1.0 110.439 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.7 m-20 -58.0 -35.11 70.77 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.255 -1.017 . . . . 1.0 108.255 179.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.505 ' O ' ' N ' ' A' ' 13' ' ' GLU . 18.7 tttm -65.22 -51.07 63.26 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.691 178.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.52 -46.67 82.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 119.974 -0.69 . . . . 1.0 111.538 -178.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.425 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.51 -37.11 86.04 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.418 -1.327 . . . . 1.0 107.418 178.728 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.71 -41.37 50.44 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 114.758 -1.11 . . . . 1.0 112.213 179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.505 ' N ' ' O ' ' A' ' 9' ' ' LYS . 49.0 mt-10 -62.83 -31.73 72.79 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.719 -0.845 . . . . 1.0 108.719 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.79 -37.08 59.51 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 115.099 -0.955 . . . . 1.0 109.483 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -60.92 -51.01 71.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.199 -1.364 . . . . 1.0 110.789 -179.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -69.01 -37.9 78.93 Favored 'General case' 0 CA--C 1.512 -0.497 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.583 178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 93.9 m -61.03 -43.67 98.55 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.757 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -76.34 -45.63 31.25 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.813 -0.63 . . . . 1.0 112.58 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.639 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.4 t30 -60.75 -44.15 97.06 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.309 0.855 . . . . 1.0 113.309 -177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -59.65 -32.46 70.48 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.275 -0.97 . . . . 1.0 109.313 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.2 m-80 -77.96 -29.97 50.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.405 -0.816 . . . . 1.0 111.714 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 26.7 mtmt -60.45 137.69 92.29 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 120.457 -0.497 . . . . 1.0 111.499 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -55.66 149.4 49.49 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 C-N-CA 122.341 2.027 . . . . 1.0 113.726 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.34 -19.26 14.27 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-N 114.811 -1.086 . . . . 1.0 111.302 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 41.0 t -87.49 135.06 26.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 121.067 0.461 . . . . 1.0 110.77 -179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.08 121.79 66.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 107.981 -1.118 . . . . 1.0 107.981 177.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.5 p -96.74 145.87 8.22 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.622 0 CA-C-O 121.676 0.751 . . . . 1.0 111.872 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 74.7 mt -112.34 163.57 17.45 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 114.327 -1.306 . . . . 1.0 110.719 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.03 -29.91 90.35 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.058 1.839 . . . . 1.0 110.69 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.6 m -67.69 -15.54 63.69 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.284 -0.871 . . . . 1.0 109.456 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.94 -3.74 70.8 Favored Glycine 0 C--N 1.328 0.115 0 N-CA-C 109.815 -1.314 . . . . 1.0 109.815 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.6 133.51 38.43 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.421 ' H ' HD23 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.5 139.26 54.08 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.284 -0.417 . . . . 1.0 110.865 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -134.95 145.81 48.52 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-O 121.642 0.734 . . . . 1.0 110.619 178.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? -130.84 134.1 46.52 Favored 'General case' 0 N--CA 1.443 -0.804 0 CA-C-N 114.503 -1.226 . . . . 1.0 109.084 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -90.48 105.38 16.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 122.18 0.991 . . . . 1.0 111.54 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.7 mm -70.55 -42.36 78.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 108.594 -0.891 . . . . 1.0 108.594 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -141.82 128.93 20.88 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.816 -1.084 . . . . 1.0 109.767 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.5 p -87.89 123.06 32.26 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.956 0.408 . . . . 1.0 110.182 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.81 -36.22 1.73 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.585 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.7 m120 57.58 32.46 21.87 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.22 -0.49 . . . . 1.0 111.64 179.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.24 -161.65 37.41 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.907 0.726 . . . . 1.0 111.408 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.594 ' O ' ' N ' ' A' ' 95' ' ' ALA . 31.2 m -69.48 -177.92 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.17 -1.015 . . . . 1.0 109.374 178.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.445 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.75 154.59 0.48 Allowed Pre-proline 0 C--N 1.319 -0.729 0 O-C-N 123.569 0.543 . . . . 1.0 110.11 179.646 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -87.75 154.29 7.44 Favored 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.697 2.932 . . . . 1.0 117.055 -174.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.435 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -84.8 175.74 50.59 Favored Glycine 0 C--N 1.334 0.42 0 N-CA-C 109.601 -1.4 . . . . 1.0 109.601 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.832 ' H ' ' HZ2' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.31 -22.34 11.75 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.315 -0.443 . . . . 1.0 111.667 -179.328 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.4 m -109.18 -7.17 15.34 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 112.651 0.612 . . . . 1.0 112.651 -178.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 78.7 m-20 -82.83 167.88 17.67 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.182 -0.303 . . . . 1.0 110.182 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.3 m -107.5 147.75 30.1 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-O 121.06 0.457 . . . . 1.0 109.949 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.3 p -127.17 163.05 30.91 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 CA-C-N 115.705 -0.679 . . . . 1.0 111.591 -176.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 95.3 m -129.78 120.15 24.57 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 108.077 -1.083 . . . . 1.0 108.077 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' A' ' 75' ' ' ALA . 4.3 m -148.38 165.62 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 114.227 1.195 . . . . 1.0 114.227 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -118.69 147.92 43.3 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 105.913 -1.884 . . . . 1.0 105.913 173.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.475 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 30.0 p90 -161.48 162.84 30.57 Favored 'General case' 0 C--N 1.343 0.292 0 N-CA-C 114.769 1.396 . . . . 1.0 114.769 -177.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OE1' ' A' ' 69' ' ' GLU . 1.7 m -126.06 132.9 51.85 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.872 175.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.87 134.92 11.77 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 111.302 -0.719 . . . . 1.0 111.302 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.656 ' CZ ' ' HZ3' ' A' ' 127' ' ' LYS . 6.2 ptp85 -143.65 163.61 32.75 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-O 121.553 0.692 . . . . 1.0 111.929 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.0 mp -85.01 162.54 19.31 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.664 -1.153 . . . . 1.0 109.844 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -57.64 -25.82 25.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.305 -0.861 . . . . 1.0 110.395 178.517 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -93.34 2.98 56.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 114.279 -1.328 . . . . 1.0 111.603 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -6.14 79.18 Favored Glycine 0 CA--C 1.525 0.68 0 C-N-CA 121.069 -0.586 . . . . 1.0 112.832 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.2 m -65.0 105.3 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 119.548 -0.861 . . . . 1.0 109.103 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.3 t -74.08 117.3 17.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 C-N-CA 120.225 -0.59 . . . . 1.0 110.072 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -103.52 -10.47 18.48 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.064 -0.971 . . . . 1.0 112.228 -179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -168.12 155.34 8.03 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 119.838 -0.745 . . . . 1.0 111.636 177.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.1 p -157.84 154.8 28.59 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.656 -0.702 . . . . 1.0 111.914 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.442 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.9 m -153.28 -40.7 0.1 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.528 -0.76 . . . . 1.0 110.357 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.442 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.8 pp20? -63.0 -26.27 68.77 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.657 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -52.11 -44.24 64.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 108.279 -1.008 . . . . 1.0 108.279 179.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 68' ' ' THR . 16.5 p -79.64 -27.94 40.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.707 -1.133 . . . . 1.0 109.246 177.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.11 16.2 77.12 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.441 -0.8 . . . . 1.0 111.74 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.42 114.95 64.27 Favored Pre-proline 0 N--CA 1.47 0.545 0 C-N-CA 120.553 -0.459 . . . . 1.0 110.628 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -61.24 152.49 71.81 Favored 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 121.809 1.673 . . . . 1.0 114.601 -178.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.87 152.17 42.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.048 -1.433 . . . . 1.0 107.247 177.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.7 t -110.42 131.2 55.26 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.605 0.717 . . . . 1.0 112.771 -178.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -136.58 154.7 50.62 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.824 -1.08 . . . . 1.0 109.652 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.409 ' O ' ' N ' ' A' ' 81' ' ' GLN . 18.8 mt-30 -96.32 124.03 40.17 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 105.801 -1.926 . . . . 1.0 105.801 174.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.7 t -47.39 -29.14 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.398 -176.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.9 t -75.86 -24.3 55.72 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 111.974 0.361 . . . . 1.0 111.974 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLN . 92.3 mm-40 -98.23 -12.71 21.35 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.353 0.871 . . . . 1.0 113.353 -177.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.1 p -83.93 169.12 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.101 -0.64 . . . . 1.0 112.022 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.12 148.72 21.06 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 -177.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.63 -43.14 47.18 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.794 1.662 . . . . 1.0 112.833 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.85 -48.69 80.44 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 119.517 -1.325 . . . . 1.0 109.852 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 8.7 m95 -63.26 -38.14 90.01 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 113.902 -1.149 . . . . 1.0 110.438 179.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.9 m -51.13 -53.53 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.265 -0.425 . . . . 1.0 111.594 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -72.42 -41.59 66.03 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.642 0.608 . . . . 1.0 112.642 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.64 -48.21 82.56 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.917 1.08 . . . . 1.0 113.917 -177.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.0 mt -56.93 -39.95 75.47 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 121.133 0.492 . . . . 1.0 110.511 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -63.05 -23.24 67.36 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.607 -0.724 . . . . 1.0 110.753 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.432 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 45.5 mt -105.25 -11.4 16.54 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.307 -0.406 . . . . 1.0 110.935 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 33.4 ttm -86.04 106.81 10.83 Favored Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.669 0.606 . . . . 1.0 111.89 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.445 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 14.6 Cg_exo -68.46 145.7 65.72 Favored 'Trans proline' 0 N--CA 1.501 1.964 0 C-N-CA 122.576 2.184 . . . . 1.0 113.008 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.594 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.55 132.96 54.18 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.53 -0.759 . . . . 1.0 111.17 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.95 -17.82 58.61 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 109.147 -1.581 . . . . 1.0 109.147 -179.067 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -88.86 136.46 33.0 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-O 120.838 0.351 . . . . 1.0 110.247 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 57.3 m -107.61 113.76 27.27 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.979 -0.555 . . . . 1.0 109.752 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.432 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.6 m0 -115.51 164.68 13.95 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.728 0.775 . . . . 1.0 110.902 -178.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -126.25 126.01 43.31 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 106.943 -1.503 . . . . 1.0 106.943 175.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.4 137.12 56.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.733 0 CA-C-O 121.704 0.764 . . . . 1.0 109.649 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.639 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -108.53 103.59 12.74 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 105.894 -1.891 . . . . 1.0 105.894 -177.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.53 115.54 64.39 Favored Pre-proline 0 C--N 1.326 -0.438 0 N-CA-C 115.077 1.51 . . . . 1.0 115.077 -174.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -51.52 146.72 24.99 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.578 1.519 . . . . 1.0 109.748 176.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 58.4 p -51.6 -36.43 45.62 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.192 -0.603 . . . . 1.0 110.901 -178.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.29 -32.52 83.99 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.251 -0.74 . . . . 1.0 111.251 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.0 mt -99.26 1.51 44.75 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.498 -0.186 . . . . 1.0 110.498 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -109.28 -103.34 0.37 Allowed 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 120.352 0.12 . . . . 1.0 110.819 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 -107.6 5.97 27.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 114.915 1.45 . . . . 1.0 114.915 -176.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.15 169.43 22.2 Favored Glycine 0 N--CA 1.473 1.127 0 C-N-CA 120.245 -0.978 . . . . 1.0 114.139 176.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 121' ' ' ASN . 57.0 Cg_endo -78.47 -12.76 15.29 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 123.697 2.931 . . . . 1.0 110.645 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 113' ' ' SER . 60.0 ttt180 -104.77 165.55 10.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.75 -1.113 . . . . 1.0 109.403 -179.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.56 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 3.5 m -76.28 97.65 4.25 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.171 -0.677 . . . . 1.0 109.171 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -108.74 61.38 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.576 -0.283 . . . . 1.0 110.597 -179.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.22 -170.84 42.8 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 120.455 -0.879 . . . . 1.0 112.188 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -66.09 -105.19 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 N-CA-C 111.842 -0.503 . . . . 1.0 111.842 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.03 -16.08 47.71 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.439 2.093 . . . . 1.0 111.387 -178.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 3.6 mp -66.97 114.24 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 109.26 -0.645 . . . . 1.0 109.26 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.26 -168.14 42.44 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 110.566 -1.014 . . . . 1.0 110.566 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.566 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 39.3 Cg_endo -65.53 142.62 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.257 1.971 . . . . 1.0 113.34 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.471 ' O ' ' ND2' ' A' ' 121' ' ' ASN . 2.1 t30 50.55 53.62 12.62 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.158 -0.474 . . . . 1.0 111.859 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.427 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 54.9 mm-40 -99.76 133.01 44.74 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.146 -0.479 . . . . 1.0 111.527 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 52.8 m -93.86 128.58 40.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 106.571 -1.641 . . . . 1.0 106.571 175.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -112.13 138.86 48.22 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.394 0.616 . . . . 1.0 111.096 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.6 tt -118.6 145.22 24.93 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.679 0 CA-C-N 114.976 -1.011 . . . . 1.0 108.523 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.561 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -136.89 150.78 48.45 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 120.217 -0.593 . . . . 1.0 111.201 177.129 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.656 ' HZ3' ' CZ ' ' A' ' 58' ' ' ARG . 5.3 mmtt -100.14 122.39 42.9 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 105.031 -2.211 . . . . 1.0 105.031 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.42 118.27 57.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 C-N-CA 119.395 -0.922 . . . . 1.0 112.432 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.2 t-160 -108.67 123.6 49.22 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 114.121 -1.4 . . . . 1.0 108.563 178.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.82 111.31 23.32 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 120.478 -0.489 . . . . 1.0 112.197 -177.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -94.3 -45.05 13.61 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.486 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.1 p -151.07 155.81 39.76 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.305 0.574 . . . . 1.0 111.137 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.8 t -128.8 135.91 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.757 -0.656 . . . . 1.0 109.958 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 tptm . . . . . 0 N--CA 1.443 -0.782 0 CA-C-O 121.87 0.843 . . . . 1.0 111.586 -179.233 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 . . . . . 0 CA--C 1.518 -0.27 0 CA-C-O 121.502 0.668 . . . . 1.0 111.12 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 9.5 m-20 -62.85 -37.09 85.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 107.81 -1.182 . . . . 1.0 107.81 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 64.6 tttt -65.95 -51.38 59.04 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 113.297 -1.774 . . . . 1.0 111.485 179.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.2 t -67.31 -46.59 83.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 C-N-CA 120.238 -0.585 . . . . 1.0 111.423 -179.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.523 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 1.2 mptp? -62.05 -38.94 90.66 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.649 -1.241 . . . . 1.0 107.649 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.6 -44.55 49.26 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 114.629 -1.169 . . . . 1.0 112.444 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.415 ' O ' ' OG1' ' A' ' 17' ' ' THR . 87.9 mt-10 -59.71 -34.1 72.47 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.526 -0.916 . . . . 1.0 108.526 179.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.87 -37.08 62.26 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.892 -1.049 . . . . 1.0 110.111 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.19 -49.33 78.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.753 -1.112 . . . . 1.0 111.198 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mp -68.78 -38.26 79.88 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.14 -0.624 . . . . 1.0 109.385 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 55.9 m -60.76 -43.47 97.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.352 -0.84 . . . . 1.0 109.688 179.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -76.9 -44.69 30.86 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.85 -0.614 . . . . 1.0 111.973 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.649 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 54.6 t30 -60.33 -44.78 95.17 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.475 0.917 . . . . 1.0 113.475 -177.165 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -58.26 -31.7 67.69 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 119.441 -0.904 . . . . 1.0 109.613 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -80.98 -27.61 35.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.734 -0.667 . . . . 1.0 111.683 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.1 mtmt -59.47 146.22 80.21 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 120.335 -0.546 . . . . 1.0 111.517 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.45 148.93 59.8 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.543 2.162 . . . . 1.0 114.048 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.65 -18.48 2.96 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 115.167 -0.924 . . . . 1.0 112.576 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -83.75 134.66 26.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.549 -0.46 . . . . 1.0 110.202 -179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.2 121.96 66.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 107.838 -1.171 . . . . 1.0 107.838 177.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.9 p -93.53 146.16 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 CA-C-O 121.637 0.732 . . . . 1.0 111.981 -177.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 97.9 mt -113.03 163.17 18.68 Favored Pre-proline 0 N--CA 1.461 0.119 0 CA-C-N 114.469 -1.242 . . . . 1.0 110.892 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -60.32 -30.71 91.63 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.844 1.696 . . . . 1.0 111.249 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -69.44 -11.16 60.59 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.828 -0.624 . . . . 1.0 109.737 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.02 -2.49 75.77 Favored Glycine 0 C--O 1.229 -0.174 0 N-CA-C 109.949 -1.26 . . . . 1.0 109.949 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.41 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.08 133.7 36.13 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 108.59 -0.893 . . . . 1.0 108.59 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.41 ' H ' HD23 ' A' ' 32' ' ' LEU . 17.6 mp0 -121.82 138.53 54.34 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 116.319 -0.4 . . . . 1.0 111.086 -179.32 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -133.5 146.55 51.19 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-O 121.591 0.71 . . . . 1.0 111.089 178.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -129.86 135.8 48.81 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.495 -1.23 . . . . 1.0 109.233 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.25 104.67 15.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-O 122.153 0.978 . . . . 1.0 112.248 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.0 mm -70.69 -42.36 77.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.249 -0.887 . . . . 1.0 108.848 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -144.07 127.33 16.71 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.845 -1.071 . . . . 1.0 110.634 -178.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.2 p -84.51 126.9 33.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.043 0.449 . . . . 1.0 110.499 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -115.86 -36.78 1.11 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.64 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 56.49 30.39 17.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.465 -0.367 . . . . 1.0 111.187 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.07 -159.68 35.86 Favored Glycine 0 C--N 1.334 0.421 0 CA-C-O 121.87 0.706 . . . . 1.0 111.955 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.603 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.0 m -69.57 -178.73 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.239 -0.981 . . . . 1.0 109.411 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.431 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 155.14 0.38 Allowed Pre-proline 0 C--N 1.319 -0.731 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.785 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -87.76 161.49 7.69 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 123.011 2.474 . . . . 1.0 115.273 -175.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.426 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -93.2 171.45 32.5 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 108.049 -2.02 . . . . 1.0 108.049 175.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.613 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -45.75 -24.9 0.42 Allowed 'General case' 0 C--N 1.297 -1.701 0 CA-C-N 114.59 -0.805 . . . . 1.0 111.374 178.452 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.0 m -107.63 -9.64 15.83 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.863 1.06 . . . . 1.0 113.863 -177.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.426 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 96.9 m-20 -85.37 166.34 16.5 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 119.39 -0.924 . . . . 1.0 109.136 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.3 m -104.16 146.97 27.99 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.167 -0.679 . . . . 1.0 109.167 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.1 p -124.39 160.3 29.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 112.554 0.575 . . . . 1.0 112.554 -175.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 87.6 m -127.23 119.51 26.54 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.408 -0.96 . . . . 1.0 108.408 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -148.84 165.76 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 113.968 1.099 . . . . 1.0 113.968 -176.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.53 151.25 38.2 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.519 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 35.2 p90 -164.23 161.88 22.29 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 114.536 1.31 . . . . 1.0 114.536 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.436 ' OG1' ' OE2' ' A' ' 69' ' ' GLU . 1.8 m -123.51 127.04 47.78 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.201 -0.908 . . . . 1.0 108.691 175.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.25 136.38 13.54 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.93 -0.652 . . . . 1.0 111.775 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.534 ' HE ' ' HZ3' ' A' ' 127' ' ' LYS . 4.8 ptp180 -147.25 166.49 26.88 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 121.805 0.812 . . . . 1.0 112.395 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.5 mp -83.16 164.07 20.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 114.129 -1.396 . . . . 1.0 110.037 177.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.412 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.38 -24.38 30.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.127 -0.942 . . . . 1.0 110.139 177.889 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -93.1 2.58 56.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 113.855 -1.52 . . . . 1.0 111.741 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.36 -4.69 80.52 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.19 -0.529 . . . . 1.0 112.735 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -69.76 105.06 2.62 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.682 -0.807 . . . . 1.0 110.212 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.5 t -73.66 122.06 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.139 0.495 . . . . 1.0 110.471 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -110.76 -15.54 13.8 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 115.145 -0.934 . . . . 1.0 111.75 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.503 ' OD2' ' N ' ' A' ' 67' ' ' SER . 55.4 t0 -155.49 147.31 23.25 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 120.704 -0.399 . . . . 1.0 110.883 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.503 ' N ' ' OD2' ' A' ' 66' ' ' ASP . 97.5 p -154.25 152.71 30.63 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.217 -0.447 . . . . 1.0 111.612 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.483 ' N ' ' O ' ' A' ' 55' ' ' TYR . 84.9 m -156.58 -38.05 0.08 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.031 -0.531 . . . . 1.0 111.289 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.436 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.0 pp20? -65.99 -26.77 67.7 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.203 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -57.46 -39.7 76.9 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 108.173 -1.047 . . . . 1.0 108.173 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.9 p -81.76 -27.03 34.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.94 -1.027 . . . . 1.0 108.493 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 76.63 16.99 80.3 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.384 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -97.35 114.79 65.34 Favored Pre-proline 0 N--CA 1.471 0.622 0 C-N-CA 120.855 -0.338 . . . . 1.0 110.419 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -61.99 154.19 63.54 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 121.916 1.744 . . . . 1.0 114.457 -178.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -126.05 150.61 48.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.262 -1.335 . . . . 1.0 108.407 178.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -104.57 134.35 47.9 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 113.006 0.743 . . . . 1.0 113.006 -178.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -142.42 148.76 38.33 Favored 'General case' 0 CA--C 1.495 -1.141 0 CA-C-N 115.009 -0.996 . . . . 1.0 110.602 178.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 -90.31 124.5 34.96 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.004 -1.85 . . . . 1.0 106.004 175.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.0 t -52.07 -32.05 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 C-N-CA 119.774 -0.771 . . . . 1.0 110.509 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -74.02 -27.56 61.01 Favored 'General case' 0 CA--C 1.514 -0.413 0 C-N-CA 120.248 -0.581 . . . . 1.0 112.138 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -101.29 -12.62 18.53 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 113.348 0.87 . . . . 1.0 113.348 -178.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.5 p -71.04 172.03 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 119.288 -0.965 . . . . 1.0 109.94 -177.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.402 HD12 ' HH ' ' A' ' 109' ' ' TYR . 0.1 OUTLIER -53.8 148.36 20.1 Favored Pre-proline 0 CA--C 1.55 0.945 0 N-CA-C 108.812 -0.81 . . . . 1.0 108.812 -178.803 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -49.42 -47.51 22.2 Favored 'Trans proline' 0 N--CA 1.503 2.084 0 C-N-CA 122.151 1.9 . . . . 1.0 113.773 -178.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.3 -48.16 77.15 Favored Glycine 0 C--N 1.318 -0.44 0 N-CA-C 110.021 -1.232 . . . . 1.0 110.021 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -63.78 -34.14 77.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 114.047 -1.076 . . . . 1.0 111.562 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -51.94 -54.1 33.48 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.744 -0.382 . . . . 1.0 110.888 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -74.17 -44.29 54.02 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.177 0.806 . . . . 1.0 113.177 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -55.71 -44.37 77.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 113.796 1.035 . . . . 1.0 113.796 -177.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.3 mt -58.47 -41.52 85.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.243 0.544 . . . . 1.0 110.142 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -65.7 -23.09 66.69 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.252 -0.885 . . . . 1.0 111.145 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.485 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 55.1 mt -103.09 -9.94 19.3 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.596 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 5.2 ttt -91.11 107.14 18.99 Favored Pre-proline 0 CA--C 1.549 0.942 0 O-C-N 123.729 0.643 . . . . 1.0 111.638 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.431 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 17.9 Cg_exo -66.37 149.11 85.01 Favored 'Trans proline' 0 N--CA 1.499 1.846 0 C-N-CA 122.904 2.402 . . . . 1.0 112.656 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.603 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.96 136.16 55.7 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 115.422 -0.808 . . . . 1.0 111.459 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.02 -19.74 51.4 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.415 -1.874 . . . . 1.0 108.415 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -85.99 134.49 33.85 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.053 0.454 . . . . 1.0 110.269 178.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.4 m -108.26 115.01 29.32 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.689 -0.687 . . . . 1.0 109.659 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.485 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.5 m0 -116.12 166.87 11.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.528 0.68 . . . . 1.0 110.79 -179.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -126.9 128.57 46.68 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 106.683 -1.599 . . . . 1.0 106.683 175.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -123.16 138.2 53.96 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 CA-C-O 121.809 0.814 . . . . 1.0 109.699 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.649 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.31 103.71 12.7 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 105.424 -2.065 . . . . 1.0 105.424 -177.905 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.5 t -90.73 116.12 65.71 Favored Pre-proline 0 C--N 1.327 -0.4 0 N-CA-C 114.674 1.361 . . . . 1.0 114.674 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -51.03 144.67 27.44 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 121.261 1.307 . . . . 1.0 109.79 176.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 55.3 p -50.49 -35.44 29.2 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.338 -0.545 . . . . 1.0 110.561 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.58 -32.78 84.32 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.19 -0.764 . . . . 1.0 111.19 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 82.8 mt -98.92 1.3 45.51 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 121.314 -0.154 . . . . 1.0 110.655 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.18 -106.62 0.34 Allowed 'General case' 0 C--N 1.342 0.264 0 N-CA-C 111.643 0.238 . . . . 1.0 111.643 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.402 ' HH ' HD12 ' A' ' 83' ' ' ILE . 48.1 m-85 -101.97 5.05 40.56 Favored 'General case' 0 C--N 1.341 0.234 0 N-CA-C 113.705 1.002 . . . . 1.0 113.705 -177.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 99.93 167.28 29.36 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 120.645 -0.788 . . . . 1.0 114.043 176.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.513 ' O ' ' N ' ' A' ' 121' ' ' ASN . 73.8 Cg_endo -70.97 -19.99 29.66 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 C-N-CA 123.742 2.962 . . . . 1.0 113.038 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -93.74 167.15 11.84 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.009 -0.367 . . . . 1.0 110.009 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.651 ' HG ' ' N ' ' A' ' 120' ' ' PRO . 5.7 m -74.46 76.32 1.93 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 177.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.0 t -92.21 61.53 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.268 -0.423 . . . . 1.0 110.967 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.97 179.61 42.27 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 120.967 -0.635 . . . . 1.0 111.516 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -60.66 -107.14 0.01 OUTLIER Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.449 -0.66 . . . . 1.0 111.449 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -59.24 -13.15 18.64 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 C-N-CA 122.222 1.948 . . . . 1.0 110.725 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.564 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 3.3 mp -66.74 113.17 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 N-CA-C 108.185 -1.043 . . . . 1.0 108.185 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.54 ' C ' ' HG ' ' A' ' 113' ' ' SER . . . -91.66 -166.9 40.25 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 110.548 -1.021 . . . . 1.0 110.548 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.651 ' N ' ' HG ' ' A' ' 113' ' ' SER . 37.6 Cg_endo -64.09 147.21 91.59 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.14 1.893 . . . . 1.0 112.7 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 44.82 57.53 4.53 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.96 -0.564 . . . . 1.0 112.072 178.219 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 53.9 mm-40 -102.64 132.06 49.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.28 0.562 . . . . 1.0 112.334 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 36.2 m -96.34 129.08 43.76 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 106.418 -1.697 . . . . 1.0 106.418 175.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.98 146.17 40.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.387 0.613 . . . . 1.0 111.042 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.6 tt -123.58 148.28 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.764 0 CA-C-N 115.088 -0.96 . . . . 1.0 108.543 178.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -139.41 151.43 46.27 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 120.286 -0.566 . . . . 1.0 111.288 177.848 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.534 ' HZ3' ' HE ' ' A' ' 58' ' ' ARG . 11.4 mmtt -100.15 124.88 46.07 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.162 -2.162 . . . . 1.0 105.162 176.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.7 mt -119.35 119.21 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 119.075 -1.05 . . . . 1.0 111.998 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -111.85 125.42 54.0 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.048 -1.433 . . . . 1.0 108.714 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.02 114.51 26.71 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 112.869 0.692 . . . . 1.0 112.869 -178.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -96.05 -45.42 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 115.992 -0.549 . . . . 1.0 110.88 178.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.3 p -151.29 157.78 42.98 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 120.877 0.37 . . . . 1.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.37 134.66 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-O 121.325 0.583 . . . . 1.0 111.451 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 21.6 tptt . . . . . 0 N--CA 1.449 -0.519 0 CA-C-N 115.152 -0.931 . . . . 1.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 . . . . . 0 CA--C 1.513 -0.47 0 CA-C-O 121.886 0.85 . . . . 1.0 110.24 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.571 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.0 m-20 -57.48 -35.64 70.45 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.737 -1.12 . . . . 1.0 108.543 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 45.1 tttt -64.74 -50.64 66.09 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 113.793 -1.549 . . . . 1.0 111.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.7 t -72.31 -47.52 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 119.964 -0.694 . . . . 1.0 112.152 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.403 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.4 OUTLIER -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.305 -0.998 . . . . 1.0 108.305 -179.919 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.95 -46.86 50.01 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 115.188 -0.915 . . . . 1.0 112.546 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.448 ' O ' ' OG1' ' A' ' 17' ' ' THR . 93.1 mt-10 -58.68 -34.26 71.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 108.804 -0.813 . . . . 1.0 108.804 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.55 -36.55 63.12 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.183 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -62.35 -49.37 75.85 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.579 -1.191 . . . . 1.0 111.134 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.8 mp -70.75 -39.61 73.19 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 119.954 -0.698 . . . . 1.0 109.922 178.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.469 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 75.6 m -60.97 -43.35 98.92 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.443 -0.798 . . . . 1.0 109.702 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -76.28 -46.07 29.61 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.91 -0.587 . . . . 1.0 111.816 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.654 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 55.4 t30 -59.88 -44.58 94.1 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.473 0.916 . . . . 1.0 113.473 -177.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.75 -31.61 68.5 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.337 -0.945 . . . . 1.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.469 ' ND2' ' O ' ' A' ' 17' ' ' THR . 50.0 m-80 -77.54 -34.23 53.97 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.514 -0.766 . . . . 1.0 111.653 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -57.94 137.03 83.71 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 120.628 -0.429 . . . . 1.0 111.76 -177.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.13 148.84 57.11 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 122.167 1.911 . . . . 1.0 113.442 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.13 -20.84 14.16 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.972 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.6 t -85.16 135.71 24.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.0 109.789 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.1 t -120.74 121.37 65.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.743 -1.206 . . . . 1.0 107.743 178.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.0 p -97.63 144.8 10.39 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.677 0 CA-C-O 121.746 0.784 . . . . 1.0 111.773 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 95.2 mt -111.32 164.28 15.37 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.314 -1.312 . . . . 1.0 110.688 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -60.84 -30.82 90.87 Favored 'Trans proline' 0 N--CA 1.485 0.983 0 C-N-CA 121.72 1.613 . . . . 1.0 110.83 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -67.81 -12.1 59.91 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.568 -0.742 . . . . 1.0 109.346 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.9 -1.59 78.28 Favored Glycine 0 C--O 1.228 -0.269 0 N-CA-C 109.962 -1.255 . . . . 1.0 109.962 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.412 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -78.68 133.66 37.18 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 108.375 -0.972 . . . . 1.0 108.375 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.412 ' H ' HD23 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.23 137.46 54.83 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.681 -0.236 . . . . 1.0 111.289 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -134.23 142.65 47.43 Favored 'General case' 0 CA--C 1.506 -0.725 0 CA-C-O 121.638 0.733 . . . . 1.0 111.116 178.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -123.9 130.89 53.32 Favored 'General case' 0 CA--C 1.503 -0.831 0 CA-C-N 114.528 -1.215 . . . . 1.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -88.92 104.48 14.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 122.294 1.045 . . . . 1.0 112.025 -178.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.1 mm -69.42 -41.84 80.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 114.766 -1.107 . . . . 1.0 108.471 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -144.26 126.1 15.27 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.522 -1.217 . . . . 1.0 109.752 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.8 p -85.23 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.027 0.441 . . . . 1.0 110.487 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.11 -37.54 1.02 Allowed Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.247 -1.141 . . . . 1.0 110.247 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.634 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 58.02 31.67 20.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.541 -0.329 . . . . 1.0 111.399 179.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.83 -159.78 35.64 Favored Glycine 0 C--N 1.333 0.376 0 CA-C-O 122.316 0.953 . . . . 1.0 112.51 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.608 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.9 m -69.68 -177.93 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 113.627 -1.286 . . . . 1.0 108.951 178.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.457 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.29 155.25 0.4 Allowed Pre-proline 0 C--N 1.318 -0.784 0 O-C-N 123.619 0.574 . . . . 1.0 109.932 179.459 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -87.7 156.4 7.57 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 123.305 2.67 . . . . 1.0 115.941 -174.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.427 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.35 176.59 45.17 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 108.874 -1.691 . . . . 1.0 108.874 176.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.498 ' CE ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.06 -22.38 15.82 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 120.501 -0.48 . . . . 1.0 111.517 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.458 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 35.8 m -106.97 -7.33 17.03 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.874 0.694 . . . . 1.0 112.874 -177.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.427 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 87.6 m-20 -84.58 170.81 13.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.952 -0.388 . . . . 1.0 109.952 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.4 ' HG1' ' HG2' ' A' ' 78' ' ' GLN . 13.3 m -110.76 147.04 35.28 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.285 0.564 . . . . 1.0 109.907 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -127.9 163.11 32.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 115.357 -0.838 . . . . 1.0 112.676 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.1 m -130.12 121.21 25.9 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 177.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.1 m -149.02 165.76 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 114.635 1.346 . . . . 1.0 114.635 -176.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -118.08 147.28 43.42 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.991 -1.855 . . . . 1.0 105.991 174.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.1 p90 -164.7 168.89 17.52 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 114.525 1.306 . . . . 1.0 114.525 -176.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.2 m -131.78 129.25 40.3 Favored 'General case' 0 C--O 1.217 -0.658 0 CA-C-N 114.771 -1.104 . . . . 1.0 108.267 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.65 131.73 9.84 Favored Glycine 0 N--CA 1.473 1.115 0 N-CA-C 111.292 -0.723 . . . . 1.0 111.292 -179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 11.7 ptp180 -146.4 167.3 23.94 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.705 0.764 . . . . 1.0 112.219 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.9 mp -82.48 164.17 21.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.325 -1.307 . . . . 1.0 110.063 177.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.44 HD12 ' H ' ' A' ' 61' ' ' ASP . 0.2 OUTLIER -61.37 -24.44 33.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 122.411 1.1 . . . . 1.0 109.858 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.44 ' H ' HD12 ' A' ' 60' ' ' ILE . 53.6 t0 -89.71 -0.02 57.27 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 113.21 -1.813 . . . . 1.0 111.882 -177.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.04 -1.71 78.07 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.904 -0.665 . . . . 1.0 112.317 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -71.82 102.46 2.87 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 119.805 -0.758 . . . . 1.0 110.021 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.2 127.41 36.77 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.519 0.676 . . . . 1.0 110.507 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -121.14 -11.07 8.91 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 114.705 -1.134 . . . . 1.0 111.486 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -154.46 143.87 21.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.132 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 20.5 p -157.93 156.12 30.71 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 113.038 0.755 . . . . 1.0 113.038 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 55' ' ' TYR . 65.3 m -159.15 -45.57 0.06 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 114.861 -1.063 . . . . 1.0 110.72 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -58.63 -26.1 63.38 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 116.391 -0.368 . . . . 1.0 110.114 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.8 mmtt -49.51 -41.08 39.91 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.523 -1.288 . . . . 1.0 107.523 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 27.6 p -83.31 -32.26 26.42 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 113.923 -1.489 . . . . 1.0 109.668 177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.64 13.16 81.98 Favored Glycine 0 C--N 1.332 0.338 0 N-CA-C 110.954 -0.858 . . . . 1.0 110.954 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -94.18 116.91 66.99 Favored Pre-proline 0 N--CA 1.466 0.34 0 C-N-CA 121.104 -0.238 . . . . 1.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -61.1 150.7 83.09 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 121.972 1.781 . . . . 1.0 115.112 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -125.65 150.81 47.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 114.107 -1.406 . . . . 1.0 108.301 177.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.04 135.42 47.52 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 113.593 0.96 . . . . 1.0 113.593 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -142.24 153.89 44.33 Favored 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.162 -0.926 . . . . 1.0 109.449 177.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.4 ' HG2' ' HG1' ' A' ' 50' ' ' THR . 25.2 mt-30 -90.75 130.35 36.74 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.912 -1.884 . . . . 1.0 105.912 173.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.7 -29.98 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 C-N-CA 119.734 -0.786 . . . . 1.0 110.506 -177.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.0 t -73.32 -25.21 60.55 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 120.244 -0.582 . . . . 1.0 112.212 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 62.6 mm-40 -98.14 -15.39 19.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.553 0.575 . . . . 1.0 112.553 -178.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.0 p -78.47 172.71 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 120.021 -0.672 . . . . 1.0 111.147 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -56.48 151.24 30.19 Favored Pre-proline 0 CA--C 1.55 0.974 0 C-N-CA 119.973 -0.691 . . . . 1.0 110.814 -178.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -53.89 -46.26 34.97 Favored 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 122.13 1.887 . . . . 1.0 112.876 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.4 -47.82 80.26 Favored Glycine 0 N--CA 1.451 -0.336 0 N-CA-C 109.132 -1.587 . . . . 1.0 109.132 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 7.7 m95 -64.29 -39.0 93.04 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 113.542 -1.329 . . . . 1.0 109.669 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 m -51.76 -53.61 37.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 1.0 111.185 -178.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -72.4 -40.88 66.84 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.23 -48.17 82.85 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 113.995 1.109 . . . . 1.0 113.995 -177.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 52.1 mt -57.95 -40.85 81.56 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 121.545 0.688 . . . . 1.0 109.814 -178.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -63.89 -24.53 67.77 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.839 -1.073 . . . . 1.0 111.221 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.8 mt -101.86 -15.64 16.82 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.394 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' MET . . . . . 0.48 ' CE ' ' H ' ' A' ' 99' ' ' TRP . 8.2 ttt -83.4 108.48 13.29 Favored Pre-proline 0 C--N 1.321 -0.642 0 O-C-N 123.811 0.694 . . . . 1.0 112.689 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -68.91 146.38 65.24 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.34 2.026 . . . . 1.0 112.082 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.608 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.89 136.69 57.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.472 -0.785 . . . . 1.0 111.731 -179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.7 57.08 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 108.92 -1.672 . . . . 1.0 108.92 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.0 p -89.5 139.62 30.34 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 120.707 0.289 . . . . 1.0 110.49 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.6 m -110.31 112.48 24.46 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.004 -0.543 . . . . 1.0 109.902 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.48 ' H ' ' CE ' ' A' ' 93' ' ' MET . 40.8 m0 -115.25 161.34 18.6 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.805 0.812 . . . . 1.0 111.566 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -120.96 124.31 44.59 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 106.713 -1.588 . . . . 1.0 106.713 175.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -118.49 137.37 52.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-O 121.882 0.848 . . . . 1.0 110.61 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.654 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.28 103.05 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.722 -1.955 . . . . 1.0 105.722 -178.756 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 t -90.61 115.94 65.3 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 114.921 1.452 . . . . 1.0 114.921 -174.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -51.27 142.11 37.67 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 121.166 1.244 . . . . 1.0 109.868 176.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.3 p -48.11 -35.62 11.75 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 120.692 -0.403 . . . . 1.0 110.722 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.66 -33.19 85.42 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.181 -0.767 . . . . 1.0 111.181 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 71.9 mt -99.01 3.39 46.9 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.768 -0.216 . . . . 1.0 111.431 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.96 -114.98 0.28 Allowed 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.526 -0.546 . . . . 1.0 109.526 -179.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -91.25 5.06 50.62 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.821 0.344 . . . . 1.0 111.636 -179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.59 164.19 22.55 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.157 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.511 ' O ' ' N ' ' A' ' 121' ' ' ASN . 86.9 Cg_endo -74.23 -9.35 21.79 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 123.362 2.708 . . . . 1.0 110.247 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -107.7 162.95 13.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.495 -1.229 . . . . 1.0 109.745 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.5 m -72.01 89.94 1.14 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.671 -0.411 . . . . 1.0 109.939 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -104.52 62.23 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 121.118 -0.233 . . . . 1.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 164.62 -175.34 40.63 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 120.309 -0.948 . . . . 1.0 112.705 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.98 -104.81 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 N-CA-C 111.639 -0.584 . . . . 1.0 111.639 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -63.76 -15.36 48.39 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.545 2.163 . . . . 1.0 111.322 -178.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 4.8 mp -67.25 111.8 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.02 0 N-CA-C 108.295 -1.002 . . . . 1.0 108.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.62 -170.72 43.5 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.054 -0.976 . . . . 1.0 111.223 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.571 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 28.6 Cg_endo -61.86 143.56 95.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.461 2.108 . . . . 1.0 112.788 179.178 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.8 t-20 49.07 48.84 20.39 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.792 0.664 . . . . 1.0 112.792 178.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.406 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 45.9 mm-40 -93.94 129.27 40.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 113.164 0.802 . . . . 1.0 113.164 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 17.5 m -95.63 129.1 42.94 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 105.796 -1.927 . . . . 1.0 105.796 174.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -116.0 143.64 45.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.369 0.605 . . . . 1.0 110.69 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.2 tt -119.54 148.11 22.74 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.649 0 CA-C-N 115.157 -0.928 . . . . 1.0 109.076 179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.591 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.96 149.94 45.32 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.478 0.656 . . . . 1.0 111.527 177.356 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 8.6 mmtt -100.12 124.4 45.49 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 105.229 -2.137 . . . . 1.0 105.229 177.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -122.01 127.61 75.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 119.497 -0.881 . . . . 1.0 112.327 -176.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.7 t-160 -118.97 124.31 46.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.321 -1.309 . . . . 1.0 107.633 178.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.78 110.39 22.87 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 120.225 -0.59 . . . . 1.0 112.374 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -94.34 -47.22 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.518 -0.765 . . . . 1.0 112.117 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.4 p -146.7 156.94 43.56 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.655 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 46.5 t -132.48 140.0 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.203 0.525 . . . . 1.0 111.942 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.54 0.56 0 CA-C-N 115.703 -0.68 . . . . 1.0 109.613 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 . . . . . 0 CA--C 1.514 -0.433 0 CA-C-O 121.627 0.727 . . . . 1.0 110.864 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.612 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 14.3 m-20 -60.49 -35.75 76.67 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 13' ' ' GLU . 48.9 tttt -66.16 -51.38 58.39 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.687 -1.597 . . . . 1.0 111.444 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.61 -48.03 78.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 C-N-CA 120.352 -0.539 . . . . 1.0 111.702 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.405 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.81 -38.73 91.86 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.552 -1.277 . . . . 1.0 107.552 179.119 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.15 -42.74 66.36 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 114.942 -1.027 . . . . 1.0 111.831 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.461 ' O ' ' OG1' ' A' ' 17' ' ' THR . 83.2 mt-10 -62.36 -32.18 72.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.972 -0.751 . . . . 1.0 108.972 178.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -35.05 49.6 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.261 -0.881 . . . . 1.0 109.878 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -61.17 -50.24 73.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 114.459 -1.246 . . . . 1.0 111.043 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.4 mp -70.92 -39.8 72.5 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.213 -0.595 . . . . 1.0 109.945 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 96.3 m -61.69 -42.63 99.19 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.541 -0.754 . . . . 1.0 109.315 -179.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -76.71 -44.53 33.09 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-N 115.485 -0.78 . . . . 1.0 112.019 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.653 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.6 t30 -60.67 -44.77 96.09 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 113.375 0.879 . . . . 1.0 113.375 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.19 -31.93 67.76 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 119.517 -0.873 . . . . 1.0 109.237 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -79.83 -30.35 40.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.151 -0.931 . . . . 1.0 111.647 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 33.0 mtmt -58.18 136.43 84.61 Favored Pre-proline 0 CA--C 1.547 0.857 0 C-N-CA 120.425 -0.51 . . . . 1.0 111.396 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -52.92 148.66 28.76 Favored 'Trans proline' 0 N--CA 1.501 1.965 0 C-N-CA 122.271 1.981 . . . . 1.0 113.547 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -19.51 10.33 Favored Glycine 0 C--O 1.225 -0.413 0 CA-C-N 115.094 -0.957 . . . . 1.0 111.829 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.3 t -86.56 136.56 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.162 0.506 . . . . 1.0 110.896 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.7 t -120.99 123.97 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 N-CA-C 107.952 -1.129 . . . . 1.0 107.952 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.02 145.89 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-O 121.796 0.808 . . . . 1.0 112.008 -178.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.2 mt -113.03 165.18 13.7 Favored Pre-proline 0 C--O 1.231 0.126 0 CA-C-N 114.328 -1.305 . . . . 1.0 111.111 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -61.42 -30.03 86.31 Favored 'Trans proline' 0 C--N 1.32 -0.965 0 C-N-CA 122.167 1.911 . . . . 1.0 111.274 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 m -68.66 -14.97 63.37 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.713 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.5 -3.07 65.56 Favored Glycine 0 C--N 1.329 0.168 0 N-CA-C 109.688 -1.365 . . . . 1.0 109.688 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.42 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.99 133.84 36.2 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.42 ' H ' HD23 ' A' ' 32' ' ' LEU . 22.0 mp0 -121.47 140.13 52.57 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 1.0 110.984 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -135.97 144.52 45.44 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.629 0.728 . . . . 1.0 110.935 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -127.54 134.8 49.74 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.427 -1.261 . . . . 1.0 109.041 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -92.82 104.04 15.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 122.158 0.98 . . . . 1.0 111.929 -178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.4 mm -69.41 -41.48 80.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -143.73 130.01 19.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.676 -1.147 . . . . 1.0 109.697 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -86.15 131.8 34.16 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.025 -0.361 . . . . 1.0 110.025 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.75 -35.34 0.85 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.636 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 54.61 30.07 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.659 -0.271 . . . . 1.0 111.104 179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.21 -161.23 37.12 Favored Glycine 0 C--N 1.331 0.256 0 CA-C-O 121.997 0.776 . . . . 1.0 111.752 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.8 m -68.94 -178.58 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 114.128 -1.036 . . . . 1.0 109.506 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.482 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.26 154.86 0.39 Allowed Pre-proline 0 C--N 1.32 -0.708 0 CA-C-N 115.608 -0.723 . . . . 1.0 109.391 179.536 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -87.72 156.72 7.56 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 123.195 2.597 . . . . 1.0 116.054 -175.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.421 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -87.44 178.37 47.52 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 108.579 -1.808 . . . . 1.0 108.579 176.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.703 ' H ' ' HZ2' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -56.32 -20.47 19.09 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.409 -0.516 . . . . 1.0 111.153 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.2 m -108.48 -7.84 15.69 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.386 0.884 . . . . 1.0 113.386 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.421 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.7 m-20 -87.57 164.59 16.01 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 120.202 -0.599 . . . . 1.0 109.466 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.7 m -101.88 150.53 23.09 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.156 0.503 . . . . 1.0 110.114 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.19 160.21 38.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.335 0 CA-C-N 115.374 -0.83 . . . . 1.0 111.925 -177.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.0 m -129.87 120.79 25.48 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.441 -0.948 . . . . 1.0 108.441 178.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.9 m -149.19 166.27 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 113.832 1.049 . . . . 1.0 113.832 -176.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -118.4 149.6 40.96 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 105.748 -1.945 . . . . 1.0 105.748 173.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.462 ' O ' ' N ' ' A' ' 68' ' ' THR . 41.3 p90 -163.29 162.4 25.18 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 118.285 -1.366 . . . . 1.0 114.338 -177.069 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.436 ' OG1' ' OE1' ' A' ' 69' ' ' GLU . 1.4 m -124.33 131.78 53.53 Favored 'General case' 0 C--O 1.217 -0.654 0 N-CA-C 108.183 -1.043 . . . . 1.0 108.183 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -117.76 137.83 13.52 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.39 -0.684 . . . . 1.0 111.39 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.84 168.01 23.29 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.769 0.795 . . . . 1.0 112.183 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.1 mp -85.07 164.73 18.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.376 -1.284 . . . . 1.0 109.772 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.13 -26.07 35.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 121.925 0.869 . . . . 1.0 110.061 178.294 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.4 ' H ' HD12 ' A' ' 60' ' ' ILE . 47.6 t0 -92.22 2.96 56.29 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 113.808 -1.542 . . . . 1.0 111.764 -177.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.02 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 120.932 -0.651 . . . . 1.0 112.962 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.0 m -70.05 102.44 2.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 118.105 0.952 . . . . 1.0 110.026 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -72.95 120.07 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.819 0 CA-C-O 121.465 0.65 . . . . 1.0 110.354 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.472 ' CE2' ' OD2' ' A' ' 66' ' ' ASP . 18.8 p90 -114.78 -8.72 12.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.641 -1.163 . . . . 1.0 111.966 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -155.1 146.45 22.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.104 -0.498 . . . . 1.0 110.692 178.184 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.9 p -157.49 150.08 22.97 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 115.81 -0.632 . . . . 1.0 111.681 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.462 ' N ' ' O ' ' A' ' 55' ' ' TYR . 92.4 m -156.04 -40.46 0.08 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.759 -0.655 . . . . 1.0 110.884 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.436 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 2.6 pp20? -63.6 -26.06 68.51 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.222 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -55.93 -43.76 77.7 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.967 -1.124 . . . . 1.0 107.967 178.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.457 ' OG1' ' O ' ' A' ' 68' ' ' THR . 72.9 p -73.79 -34.5 64.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.878 -1.055 . . . . 1.0 108.521 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.93 16.16 70.76 Favored Glycine 0 C--N 1.334 0.453 0 CA-C-N 115.036 -0.984 . . . . 1.0 111.012 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.42 116.31 65.52 Favored Pre-proline 0 N--CA 1.471 0.576 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.592 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -60.98 153.69 62.1 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 121.723 1.615 . . . . 1.0 114.483 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.4 150.88 45.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.307 -1.315 . . . . 1.0 107.786 178.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 t -110.29 133.81 52.89 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -143.01 152.51 42.0 Favored 'General case' 0 CA--C 1.503 -0.832 0 CA-C-N 114.577 -1.192 . . . . 1.0 109.505 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -92.34 125.2 36.9 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 106.334 -1.728 . . . . 1.0 106.334 174.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.6 t -47.02 -32.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 115.773 -0.649 . . . . 1.0 110.609 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.9 t -74.42 -24.41 59.09 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 120.347 -0.541 . . . . 1.0 111.859 -178.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 89.1 mm-40 -98.82 -9.2 24.69 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 112.928 0.714 . . . . 1.0 112.928 -178.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 p -88.04 170.71 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 118.196 0.453 . . . . 1.0 111.494 -177.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.46 145.02 29.58 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 120.871 -0.331 . . . . 1.0 110.58 -176.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.32 -44.87 36.75 Favored 'Trans proline' 0 N--CA 1.498 1.737 0 C-N-CA 121.952 1.768 . . . . 1.0 112.74 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.39 -47.48 82.64 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 109.281 -1.528 . . . . 1.0 109.281 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 9.7 m95 -66.22 -37.02 84.54 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 113.791 -1.205 . . . . 1.0 110.261 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.19 -53.31 36.12 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.856 -0.338 . . . . 1.0 110.942 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tp10 -71.89 -43.98 64.5 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.085 0.402 . . . . 1.0 112.085 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.94 -46.43 85.09 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 114.022 1.119 . . . . 1.0 114.022 -177.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.3 -41.58 84.75 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.154 -0.618 . . . . 1.0 109.634 -178.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -65.69 -23.41 66.77 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.187 -0.915 . . . . 1.0 111.197 -179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.422 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 85.4 mt -102.93 -10.34 19.1 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.459 -0.337 . . . . 1.0 110.741 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' MET . . . . . 0.497 ' HE2' ' H ' ' A' ' 99' ' ' TRP . 25.5 ttt -90.62 107.47 20.53 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.734 -0.666 . . . . 1.0 112.032 -178.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.482 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 16.0 Cg_exo -68.89 148.09 69.9 Favored 'Trans proline' 0 N--CA 1.498 1.77 0 C-N-CA 122.546 2.164 . . . . 1.0 112.361 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.585 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.67 137.67 57.47 Favored 'General case' 0 CA--C 1.509 -0.602 0 CA-C-N 115.546 -0.752 . . . . 1.0 111.664 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.16 -19.19 54.65 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 108.873 -1.691 . . . . 1.0 108.873 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.2 p -88.19 129.98 35.19 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 115.475 -0.362 . . . . 1.0 110.443 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 60.7 m -102.12 115.02 29.67 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 109.438 -0.579 . . . . 1.0 109.438 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.497 ' H ' ' HE2' ' A' ' 93' ' ' MET . 39.4 m0 -116.28 168.31 10.24 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.817 0.818 . . . . 1.0 111.278 -178.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 81.5 mt-10 -129.25 129.57 45.12 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 106.63 -1.619 . . . . 1.0 106.63 175.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 pt -125.58 138.45 54.42 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.533 0 CA-C-O 121.771 0.796 . . . . 1.0 109.78 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.653 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.26 103.25 12.18 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 106.021 -1.844 . . . . 1.0 106.021 -178.032 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.1 t -90.01 115.74 64.7 Favored Pre-proline 0 C--N 1.326 -0.442 0 N-CA-C 115.248 1.573 . . . . 1.0 115.248 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -51.44 143.77 34.11 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.188 1.259 . . . . 1.0 109.634 176.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 88.1 p -50.37 -33.76 21.66 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.517 -178.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.5 -32.73 82.58 Favored Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.03 -0.828 . . . . 1.0 111.03 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -99.78 1.73 43.43 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.981 -0.11 . . . . 1.0 110.859 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -111.83 0.3 Allowed 'General case' 0 C--N 1.342 0.264 0 CA-C-O 120.754 0.312 . . . . 1.0 110.816 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 -98.12 5.41 48.62 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 113.567 0.951 . . . . 1.0 113.567 -177.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.81 164.07 18.59 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 121.018 -0.61 . . . . 1.0 113.483 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 121' ' ' ASN . 93.9 Cg_endo -77.02 -9.99 17.98 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.571 2.847 . . . . 1.0 111.173 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -106.65 169.29 8.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.252 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.4 m -75.26 97.21 3.49 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.743 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.2 t -110.77 60.08 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 121.059 -0.256 . . . . 1.0 111.125 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 168.68 -177.95 42.34 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 120.514 -0.85 . . . . 1.0 111.998 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.04 -103.77 0.01 OUTLIER Glycine 0 CA--C 1.535 1.338 0 N-CA-C 111.141 -0.783 . . . . 1.0 111.141 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -63.21 -14.05 39.48 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.732 2.288 . . . . 1.0 111.159 -178.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.3 mp -65.86 114.93 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 108.273 -1.01 . . . . 1.0 108.273 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.432 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -95.03 -171.88 37.1 Favored Glycine 0 CA--C 1.52 0.354 0 CA-C-N 115.512 -0.767 . . . . 1.0 111.553 -178.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.529 ' N ' ' OG ' ' A' ' 113' ' ' SER . 26.3 Cg_endo -63.25 138.2 65.2 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.562 2.174 . . . . 1.0 112.535 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.53 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 53.17 51.41 15.69 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 120.962 -0.295 . . . . 1.0 111.3 178.531 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.612 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -96.74 131.27 43.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.294 -0.412 . . . . 1.0 111.6 -179.608 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 49.1 m -95.97 128.66 43.05 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.34 138.9 48.41 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.064 0.459 . . . . 1.0 110.998 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.4 tt -117.91 147.35 21.42 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.583 0 CA-C-N 115.724 -0.671 . . . . 1.0 109.195 178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.584 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.83 150.92 47.58 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.441 -0.504 . . . . 1.0 111.629 177.855 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.424 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.0 mmtt -100.76 123.97 45.72 Favored 'General case' 0 CA--C 1.501 -0.907 0 N-CA-C 105.807 -1.923 . . . . 1.0 105.807 177.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.9 mt -117.0 125.61 73.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 119.592 -0.843 . . . . 1.0 112.732 -176.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -118.03 124.58 48.46 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.172 -1.377 . . . . 1.0 108.484 178.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.23 114.22 25.98 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 119.746 -0.782 . . . . 1.0 112.808 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.4 mp -95.46 -43.01 12.74 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 115.732 -0.667 . . . . 1.0 110.996 178.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -154.21 156.5 37.2 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.604 -0.439 . . . . 1.0 111.265 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.7 t -129.82 138.43 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.111 -0.495 . . . . 1.0 111.273 -178.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 8.9 tptm . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 1.0 109.931 178.851 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 22.7 mt-10 . . . . . 0 C--O 1.223 -0.302 0 CA-C-O 121.842 0.83 . . . . 1.0 110.104 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -58.75 -34.07 70.99 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 115.002 -0.999 . . . . 1.0 108.409 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 17.7 tttp -66.1 -51.47 57.77 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.073 -1.422 . . . . 1.0 111.493 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.3 t -67.32 -46.88 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 C-N-CA 119.845 -0.742 . . . . 1.0 111.663 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.4 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.59 -37.58 86.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.893 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.95 -44.66 29.65 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.861 -1.063 . . . . 1.0 112.317 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' OG1' ' A' ' 17' ' ' THR . 58.3 mt-10 -60.73 -34.5 74.51 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.53 -0.915 . . . . 1.0 108.53 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.56 -36.07 65.56 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.016 -0.993 . . . . 1.0 109.826 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -61.14 -50.22 74.08 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.762 -1.108 . . . . 1.0 110.3 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.7 mp -66.22 -38.43 87.92 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.387 -0.597 . . . . 1.0 109.387 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.484 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 30.3 m -61.51 -42.59 99.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.739 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -75.62 -44.61 41.93 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.6 -0.727 . . . . 1.0 111.887 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.628 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -56.98 -49.52 75.48 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -178.486 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.3 ptmt -58.93 -29.47 67.13 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.355 -0.938 . . . . 1.0 110.021 -176.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -81.79 -29.1 32.86 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.311 -0.859 . . . . 1.0 111.482 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 mtmt -60.69 145.63 87.52 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 120.625 -0.43 . . . . 1.0 112.005 -178.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.439 ' C ' ' H ' ' A' ' 25' ' ' VAL . 31.7 Cg_exo -57.0 149.05 64.52 Favored 'Trans proline' 0 N--CA 1.507 2.296 0 C-N-CA 122.946 2.431 . . . . 1.0 114.708 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.44 -20.53 2.11 Favored Glycine 0 N--CA 1.462 0.41 0 CA-C-N 114.957 -1.02 . . . . 1.0 111.894 178.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' A' ' 23' ' ' PRO . 47.2 t -79.2 131.55 34.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 C-N-CA 120.138 -0.625 . . . . 1.0 109.925 -178.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 67.4 t -116.03 120.33 64.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.103 -1.073 . . . . 1.0 108.103 177.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.6 p -93.32 145.94 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 CA-C-O 121.688 0.756 . . . . 1.0 111.366 -178.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.33 163.55 18.0 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-N 114.534 -1.212 . . . . 1.0 110.446 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.4 -30.99 92.1 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 121.668 1.579 . . . . 1.0 111.294 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.3 m -69.34 -13.44 62.38 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.676 -0.693 . . . . 1.0 110.114 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.32 -4.0 64.29 Favored Glycine 0 CA--C 1.518 0.252 0 N-CA-C 110.179 -1.169 . . . . 1.0 110.179 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.432 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.8 tm? -77.45 134.56 38.34 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 108.565 -0.902 . . . . 1.0 108.565 179.573 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.432 ' H ' HD23 ' A' ' 32' ' ' LEU . 14.2 mp0 -125.1 141.68 51.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 116.341 -0.391 . . . . 1.0 111.609 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.1 p90 -137.01 142.58 42.52 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.745 0.783 . . . . 1.0 112.087 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.459 ' CE ' ' CD1' ' A' ' 37' ' ' ILE . 6.2 ttpt -124.85 124.63 42.5 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 114.282 -1.327 . . . . 1.0 108.296 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.88 113.39 21.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 CA-C-N 115.199 -0.91 . . . . 1.0 111.107 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.496 ' HB ' HD21 ' A' ' 38' ' ' ASN . 4.7 mm -77.02 -42.15 31.77 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 CA-C-O 121.808 0.813 . . . . 1.0 109.63 178.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.496 HD21 ' HB ' ' A' ' 37' ' ' ILE . 24.8 m-80 -143.81 128.76 18.49 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.208 -1.36 . . . . 1.0 109.655 -177.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.9 p -90.83 128.57 36.77 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.941 0.401 . . . . 1.0 109.996 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.89 -32.64 1.39 Allowed Glycine 0 CA--C 1.52 0.368 0 N-CA-C 110.045 -1.222 . . . . 1.0 110.045 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.64 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 56.6 31.92 20.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.532 -0.334 . . . . 1.0 111.126 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.13 -161.01 37.0 Favored Glycine 0 C--N 1.334 0.445 0 CA-C-O 121.833 0.685 . . . . 1.0 111.553 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.586 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.6 m -68.41 -178.49 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.108 -1.046 . . . . 1.0 109.301 178.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.426 ' HZ2' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.66 154.59 0.36 Allowed Pre-proline 0 C--N 1.319 -0.741 0 O-C-N 123.84 0.712 . . . . 1.0 109.213 179.529 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -86.99 157.9 8.62 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.933 2.422 . . . . 1.0 115.781 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.439 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.31 172.69 38.25 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 108.446 -1.862 . . . . 1.0 108.446 176.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.618 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -47.04 -25.27 0.78 Allowed 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 114.83 -0.685 . . . . 1.0 111.62 178.773 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.438 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 20.7 m -108.25 -9.14 15.56 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 113.363 0.875 . . . . 1.0 113.363 -177.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.439 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.7 m-20 -84.72 167.39 16.19 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 119.717 -0.793 . . . . 1.0 109.005 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.8 m -106.14 149.93 26.31 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.096 0.474 . . . . 1.0 109.918 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -126.53 162.35 30.93 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.297 0 CA-C-N 115.477 -0.783 . . . . 1.0 112.21 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 77.9 m -130.23 119.96 23.72 Favored 'General case' 0 N--CA 1.464 0.24 0 N-CA-C 108.333 -0.988 . . . . 1.0 108.333 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.408 ' O ' ' N ' ' A' ' 75' ' ' ALA . 12.8 m -148.99 166.62 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 114.28 1.215 . . . . 1.0 114.28 -176.631 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -118.4 152.19 36.34 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 106.386 -1.709 . . . . 1.0 106.386 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.5 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 32.8 p90 -163.63 160.71 23.16 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 118.423 -1.311 . . . . 1.0 114.538 -178.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.6 m -122.15 130.29 53.09 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.769 -0.826 . . . . 1.0 108.769 175.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.2 137.08 13.93 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.881 -0.676 . . . . 1.0 112.02 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -147.84 167.28 25.17 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.617 0.722 . . . . 1.0 112.227 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -86.89 166.05 15.46 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.491 -1.231 . . . . 1.0 111.404 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.01 -26.24 35.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 114.809 -1.087 . . . . 1.0 110.266 178.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -93.79 2.38 56.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.173 -1.376 . . . . 1.0 111.416 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -2.25 75.67 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 120.998 -0.62 . . . . 1.0 112.767 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.4 m -69.03 103.44 1.86 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.821 0.81 . . . . 1.0 110.326 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.9 t -74.03 122.7 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 C-N-CA 120.287 -0.565 . . . . 1.0 109.601 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -116.35 -8.46 11.64 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 115.003 -0.999 . . . . 1.0 111.598 -178.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 33.7 t0 -158.29 152.42 24.09 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.467 -0.493 . . . . 1.0 111.335 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 96.4 p -159.29 153.23 23.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.729 -0.668 . . . . 1.0 111.623 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.491 ' O ' ' OG1' ' A' ' 71' ' ' THR . 66.2 m -155.86 -39.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.643 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.411 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 1.4 pp20? -65.8 -27.15 68.06 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -58.15 -43.83 87.55 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 107.808 -1.182 . . . . 1.0 107.808 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.491 ' OG1' ' O ' ' A' ' 68' ' ' THR . 3.5 p -73.99 -31.32 62.92 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.865 -1.062 . . . . 1.0 108.797 176.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.71 18.31 68.42 Favored Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.81 178.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 115.03 65.43 Favored Pre-proline 0 N--CA 1.47 0.539 0 C-N-CA 120.682 -0.407 . . . . 1.0 110.98 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_exo -60.83 152.49 69.67 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.823 1.682 . . . . 1.0 114.366 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.26 152.21 41.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.042 -1.436 . . . . 1.0 107.833 178.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 130.9 55.38 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 121.408 0.623 . . . . 1.0 112.511 -178.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -138.82 148.44 43.77 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.0 -1.0 . . . . 1.0 109.853 178.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.3 mt-30 -90.35 125.39 35.52 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 106.335 -1.728 . . . . 1.0 106.335 174.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.8 t -53.69 -28.85 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 C-N-CA 119.394 -0.922 . . . . 1.0 110.15 -177.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.7 t -73.97 -25.59 60.02 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.025 -0.67 . . . . 1.0 111.835 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 84.5 mm-40 -100.1 -16.07 17.97 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.717 -0.393 . . . . 1.0 112.022 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -64.99 164.75 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 112.109 0.411 . . . . 1.0 112.109 -177.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.58 148.96 23.19 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.501 -0.925 . . . . 1.0 108.501 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -51.33 -42.62 53.68 Favored 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 121.061 1.174 . . . . 1.0 112.093 -178.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.76 -48.09 87.73 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 119.872 -1.156 . . . . 1.0 110.54 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 9.5 m95 -65.56 -35.5 81.04 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.301 -0.949 . . . . 1.0 111.144 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.2 m -51.19 -54.38 26.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.987 -0.285 . . . . 1.0 111.637 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.89 -40.8 68.65 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.456 0.539 . . . . 1.0 112.456 -179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.1 -48.1 82.84 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 114.136 1.162 . . . . 1.0 114.136 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.4 mt -58.32 -42.25 86.31 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.299 0.571 . . . . 1.0 109.896 -177.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -63.25 -23.9 67.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.332 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.517 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.7 mt -100.95 -12.45 18.91 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.902 -0.59 . . . . 1.0 111.246 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.5 ttp -90.17 107.45 19.64 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 111.863 0.32 . . . . 1.0 111.863 -178.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.426 ' HG3' ' HZ2' ' A' ' 44' ' ' LYS . 16.3 Cg_exo -67.28 148.02 79.38 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.614 2.209 . . . . 1.0 112.426 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.586 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.61 135.6 55.26 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-O 121.546 0.688 . . . . 1.0 110.926 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.46 57.49 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 107.788 -2.125 . . . . 1.0 107.788 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' A' ' 94' ' ' PRO . 4.8 p -90.24 133.51 34.88 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.956 -0.622 . . . . 1.0 110.676 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.0 m -108.8 115.42 30.06 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.581 -0.736 . . . . 1.0 109.426 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.517 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 40.6 m0 -115.43 168.52 9.92 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.777 0.799 . . . . 1.0 111.081 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -127.89 129.91 47.65 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 106.449 -1.686 . . . . 1.0 106.449 175.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.7 pt -126.33 137.83 56.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.782 0.801 . . . . 1.0 109.707 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.628 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -108.91 103.62 12.71 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 105.866 -1.901 . . . . 1.0 105.866 -178.078 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 t -90.48 115.57 64.43 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 115.162 1.541 . . . . 1.0 115.162 -174.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -51.07 145.6 24.96 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.525 1.483 . . . . 1.0 109.89 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.7 p -51.7 -36.24 45.92 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.241 -0.584 . . . . 1.0 111.046 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.43 -32.48 83.62 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.862 -0.895 . . . . 1.0 110.862 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.6 mt -99.19 2.28 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.856 -0.172 . . . . 1.0 111.001 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.82 -103.81 0.37 Allowed 'General case' 0 C--O 1.219 -0.54 0 N-CA-C 112.197 0.443 . . . . 1.0 112.197 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -104.07 3.96 33.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 113.435 0.902 . . . . 1.0 113.435 -177.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.78 167.8 17.22 Favored Glycine 0 N--CA 1.47 0.922 0 C-N-CA 120.673 -0.775 . . . . 1.0 113.786 177.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.575 ' O ' ' N ' ' A' ' 121' ' ' ASN . 91.0 Cg_endo -76.37 -17.74 16.41 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 124.013 3.142 . . . . 1.0 111.764 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -103.67 169.69 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.848 -0.615 . . . . 1.0 110.066 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.406 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.2 m -74.16 102.95 4.42 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.673 -0.491 . . . . 1.0 109.673 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.7 t -111.62 61.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-O 120.699 0.285 . . . . 1.0 110.795 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 162.95 178.32 36.67 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.631 -0.795 . . . . 1.0 111.793 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.46 -103.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.156 0 N-CA-C 111.09 -0.804 . . . . 1.0 111.09 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -61.76 -16.64 50.12 Favored 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.672 2.248 . . . . 1.0 111.734 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 4.9 mp -66.46 117.2 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 107.475 -1.305 . . . . 1.0 107.475 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -93.47 -170.15 39.09 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.622 -0.717 . . . . 1.0 111.926 -178.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.406 ' N ' ' OG ' ' A' ' 113' ' ' SER . 30.1 Cg_endo -67.55 145.56 70.84 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 C-N-CA 122.413 2.075 . . . . 1.0 111.614 178.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.575 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 42.99 48.76 5.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.324 0.583 . . . . 1.0 110.415 179.078 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -100.86 128.97 46.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.126 -0.943 . . . . 1.0 111.226 -178.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 46.7 m -91.29 131.38 36.83 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.299 -0.864 . . . . 1.0 109.404 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -113.14 147.98 36.27 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.876 0.37 . . . . 1.0 110.28 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.2 tt -126.39 143.22 40.62 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.595 0 N-CA-C 108.546 -0.909 . . . . 1.0 108.546 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.565 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.5 m-85 -134.15 149.9 51.08 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.378 -0.529 . . . . 1.0 111.657 177.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.5 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 6.9 mmtt -100.16 124.39 45.52 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 105.728 -1.953 . . . . 1.0 105.728 177.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.2 118.95 59.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.878 0.846 . . . . 1.0 113.031 -176.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 -109.64 127.12 54.32 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 113.98 -1.464 . . . . 1.0 108.536 178.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.6 111.61 23.68 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 120.041 -0.664 . . . . 1.0 112.41 -178.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.2 mp -93.86 -44.79 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 CA-C-N 116.119 -0.492 . . . . 1.0 111.1 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.5 p -152.39 158.39 42.61 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.89 0.376 . . . . 1.0 110.744 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.4 t -130.88 139.68 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.516 -177.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 7.2 tptt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 121.356 0.598 . . . . 1.0 109.906 178.719 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 . . . . . 0 CA--C 1.516 -0.337 0 CA-C-O 121.599 0.714 . . . . 1.0 110.512 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 28.5 m-20 -59.7 -35.66 74.95 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.171 -0.922 . . . . 1.0 108.657 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttpm? -65.74 -50.83 63.37 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.197 -1.365 . . . . 1.0 111.139 179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -67.21 -48.81 77.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 119.58 -0.848 . . . . 1.0 112.015 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -62.16 -38.04 87.53 Favored 'General case' 0 N--CA 1.444 -0.757 0 N-CA-C 107.703 -1.221 . . . . 1.0 107.703 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.2 -47.96 41.66 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 114.897 -1.047 . . . . 1.0 112.296 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -59.86 -30.81 69.23 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 119.882 -0.727 . . . . 1.0 109.248 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.4 -35.31 47.29 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.266 -0.879 . . . . 1.0 109.978 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.5 t80 -60.55 -49.43 77.58 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.764 -1.107 . . . . 1.0 110.379 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.0 mp -66.99 -40.01 87.29 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 109.199 -0.667 . . . . 1.0 109.199 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 98.0 m -61.96 -41.75 98.35 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.488 -0.778 . . . . 1.0 109.733 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -75.73 -43.38 47.23 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.69 -0.687 . . . . 1.0 111.36 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.666 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 47.4 t30 -61.53 -45.31 94.72 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 112.793 0.664 . . . . 1.0 112.793 -178.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -58.89 -30.74 68.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.48 -0.888 . . . . 1.0 108.947 -179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -79.07 -31.65 44.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.261 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 29.4 mtmt -58.55 142.72 82.45 Favored Pre-proline 0 CA--C 1.547 0.865 0 C-N-CA 120.525 -0.47 . . . . 1.0 111.163 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.68 149.06 61.3 Favored 'Trans proline' 0 N--CA 1.503 2.042 0 C-N-CA 122.422 2.081 . . . . 1.0 114.297 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.73 -19.31 5.12 Favored Glycine 0 C--O 1.228 -0.243 0 CA-C-N 115.021 -0.99 . . . . 1.0 112.226 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.54 136.53 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.02 0.438 . . . . 1.0 110.754 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.3 t -121.41 122.91 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 107.963 -1.125 . . . . 1.0 107.963 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.92 146.0 8.1 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.753 0.787 . . . . 1.0 111.896 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.8 mt -114.86 166.5 11.59 Favored Pre-proline 0 C--O 1.231 0.119 0 CA-C-N 114.35 -1.296 . . . . 1.0 111.048 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -61.57 -31.6 87.27 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 122.241 1.961 . . . . 1.0 111.97 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 m -69.94 -10.71 59.53 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.25 0.548 . . . . 1.0 109.855 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.25 0.94 72.89 Favored Glycine 0 CA--C 1.517 0.185 0 N-CA-C 109.952 -1.259 . . . . 1.0 109.952 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.429 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -82.64 133.58 35.17 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 108.555 -0.905 . . . . 1.0 108.555 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.429 ' H ' HD23 ' A' ' 32' ' ' LEU . 16.5 mp0 -121.84 143.46 49.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.413 -0.358 . . . . 1.0 111.164 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 26.7 p90 -137.4 145.27 43.04 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.733 0.778 . . . . 1.0 111.072 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -128.66 132.63 48.1 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 114.38 -1.282 . . . . 1.0 109.08 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.85 104.63 15.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 122.314 1.055 . . . . 1.0 112.02 -178.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.9 mm -69.77 -41.35 79.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.992 -1.004 . . . . 1.0 108.551 179.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -143.92 129.38 19.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.661 -1.154 . . . . 1.0 109.73 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.3 p -89.43 128.81 35.98 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.734 -0.469 . . . . 1.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.48 -35.15 1.22 Allowed Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.606 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.2 m120 58.07 29.9 18.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 1.0 111.138 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.93 -161.99 37.84 Favored Glycine 0 C--N 1.331 0.259 0 CA-C-O 121.888 0.716 . . . . 1.0 111.713 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.9 m -68.61 -177.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.061 -1.07 . . . . 1.0 108.841 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 177.67 155.4 0.49 Allowed Pre-proline 0 C--N 1.317 -0.836 0 O-C-N 123.628 0.58 . . . . 1.0 109.516 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -83.84 165.23 13.64 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 123.241 2.627 . . . . 1.0 116.292 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.44 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -98.08 175.02 29.37 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 108.633 -1.787 . . . . 1.0 108.633 176.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.456 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.84 -23.53 18.8 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.618 -0.433 . . . . 1.0 111.492 -179.086 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 36.4 m -107.02 -6.31 17.55 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 112.9 0.704 . . . . 1.0 112.9 -177.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.727 ' OD1' ' N ' ' A' ' 50' ' ' THR . 67.2 t0 -82.33 170.68 15.07 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.282 0.563 . . . . 1.0 110.595 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.727 ' N ' ' OD1' ' A' ' 49' ' ' ASP . 8.9 m -112.38 144.06 42.44 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.697 -0.853 . . . . 1.0 108.697 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.39 160.34 31.52 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 CA-C-N 115.182 -0.917 . . . . 1.0 111.974 -175.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.3 m -125.5 119.74 29.03 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.602 -0.888 . . . . 1.0 108.602 178.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.415 ' O ' ' N ' ' A' ' 75' ' ' ALA . 4.5 m -148.48 166.93 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 114.341 1.237 . . . . 1.0 114.341 -177.191 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -119.36 147.68 44.06 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 106.283 -1.747 . . . . 1.0 106.283 173.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 68' ' ' THR . 36.4 p90 -162.19 163.4 28.36 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 115.083 1.512 . . . . 1.0 115.083 -176.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.456 ' OG1' ' OE2' ' A' ' 69' ' ' GLU . 1.5 m -127.45 127.5 44.18 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 115.254 -0.884 . . . . 1.0 109.332 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.74 136.07 13.19 Favored Glycine 0 N--CA 1.471 1.001 0 C-N-CA 121.094 -0.574 . . . . 1.0 112.355 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -147.4 168.55 21.57 Favored 'General case' 0 C--N 1.341 0.199 0 CA-C-O 121.498 0.666 . . . . 1.0 112.266 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.2 mp -84.93 164.7 18.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.519 -1.219 . . . . 1.0 110.761 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.57 -25.49 34.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 114.883 -1.053 . . . . 1.0 110.018 177.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -92.65 3.02 56.36 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.926 -1.488 . . . . 1.0 111.622 -177.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.27 -2.03 80.56 Favored Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.822 -0.704 . . . . 1.0 112.668 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.4 m -71.37 104.49 3.21 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 119.722 -0.791 . . . . 1.0 109.785 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.1 t -75.46 126.34 36.11 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.81 0 CA-C-O 121.202 0.525 . . . . 1.0 110.332 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -115.0 -11.68 12.1 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.032 -0.986 . . . . 1.0 111.425 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -162.5 153.35 17.3 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.838 -0.745 . . . . 1.0 112.158 178.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 93.3 p -160.44 154.88 23.6 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 115.706 -0.679 . . . . 1.0 112.124 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.491 ' O ' ' OG1' ' A' ' 71' ' ' THR . 90.4 m -152.26 -43.51 0.1 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.688 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.456 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.8 pp20? -59.04 -25.98 64.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.152 -0.476 . . . . 1.0 110.427 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -54.98 -42.55 72.56 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.674 -1.232 . . . . 1.0 107.674 178.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.491 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.9 p -77.06 -34.83 57.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.525 -1.216 . . . . 1.0 109.193 177.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 85.05 16.75 64.37 Favored Glycine 0 C--N 1.333 0.362 0 CA-C-N 115.452 -0.795 . . . . 1.0 111.57 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.5 116.14 65.15 Favored Pre-proline 0 N--CA 1.472 0.672 0 C-N-CA 120.488 -0.485 . . . . 1.0 110.874 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -59.7 151.65 68.71 Favored 'Trans proline' 0 N--CA 1.481 0.752 0 C-N-CA 121.458 1.438 . . . . 1.0 114.438 -178.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.36 149.52 46.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.027 -1.442 . . . . 1.0 107.257 177.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.4 t -103.34 136.99 42.07 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.358 0.599 . . . . 1.0 112.493 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -140.23 148.3 41.31 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 114.933 -1.031 . . . . 1.0 110.767 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.5 mt-30 -92.0 125.19 36.6 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.752 -1.944 . . . . 1.0 105.752 174.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.6 t -56.45 -29.98 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 C-N-CA 118.704 -1.198 . . . . 1.0 110.126 -176.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LYS . 3.1 t -73.53 -25.78 60.57 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 120.074 -0.65 . . . . 1.0 112.577 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 87.0 mm-40 -101.37 -15.9 17.07 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 111.885 0.328 . . . . 1.0 111.885 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.6 p -69.94 170.52 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 119.42 -0.912 . . . . 1.0 111.886 -176.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.08 146.99 27.34 Favored Pre-proline 0 CA--C 1.548 0.875 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 -178.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -52.13 -43.64 51.6 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.814 1.676 . . . . 1.0 113.105 -178.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.65 -47.15 92.36 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 109.574 -1.41 . . . . 1.0 109.574 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -63.03 -35.31 79.8 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.153 -1.024 . . . . 1.0 110.387 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 24.8 m -51.56 -53.54 36.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.063 0.458 . . . . 1.0 111.063 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -71.9 -44.91 62.92 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.617 -0.72 . . . . 1.0 112.687 -179.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -58.81 -46.8 86.75 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 114.509 1.3 . . . . 1.0 114.509 -177.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 19.4 mt -57.84 -42.88 85.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.362 0.601 . . . . 1.0 109.478 -178.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -62.95 -20.08 64.89 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.942 -1.026 . . . . 1.0 110.434 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.537 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 96.2 mt -105.93 -11.05 16.33 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.968 -0.56 . . . . 1.0 111.352 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 54.2 ttp -92.52 107.18 21.93 Favored Pre-proline 0 CA--C 1.547 0.842 0 O-C-N 123.273 0.358 . . . . 1.0 111.376 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -64.43 147.7 90.65 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.398 2.065 . . . . 1.0 112.936 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.599 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -61.87 132.66 53.77 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 115.482 -0.781 . . . . 1.0 111.579 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.49 -19.26 55.09 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 108.492 -1.843 . . . . 1.0 108.492 -178.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -84.61 131.83 34.56 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.038 0.447 . . . . 1.0 109.994 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.5 m -105.24 113.67 27.4 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 115.923 -0.58 . . . . 1.0 109.604 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.9 m0 -115.65 165.69 12.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.871 0.843 . . . . 1.0 111.258 -178.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -125.84 132.88 52.13 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 106.277 -1.749 . . . . 1.0 106.277 175.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.7 pt -128.66 139.71 51.17 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-O 121.84 0.829 . . . . 1.0 109.925 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.666 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.88 103.07 11.8 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 105.742 -1.947 . . . . 1.0 105.742 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 t -90.64 116.23 65.94 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 115.614 1.709 . . . . 1.0 115.614 -174.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.81 144.56 26.38 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.66 1.574 . . . . 1.0 109.766 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.5 p -50.45 -36.24 32.42 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 120.434 -0.506 . . . . 1.0 111.363 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.98 -32.2 80.2 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.977 -0.849 . . . . 1.0 110.977 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.4 mt -98.4 2.32 47.75 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 121.364 -0.134 . . . . 1.0 110.746 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.95 -103.22 0.36 Allowed 'General case' 0 C--O 1.216 -0.665 0 N-CA-C 110.069 -0.345 . . . . 1.0 110.069 -179.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -105.29 5.17 31.74 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 113.397 0.888 . . . . 1.0 113.397 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 105.46 166.7 23.69 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 120.814 -0.707 . . . . 1.0 113.075 177.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 121' ' ' ASN . 72.6 Cg_endo -72.64 -18.46 25.38 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 123.454 2.769 . . . . 1.0 112.45 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -98.03 169.3 9.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.303 -0.408 . . . . 1.0 109.947 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.7 m -76.33 85.82 3.11 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.7 t -98.04 59.23 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.51 -0.314 . . . . 1.0 110.923 -179.114 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.75 179.9 41.76 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 120.629 -0.796 . . . . 1.0 112.088 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.01 -105.87 0.01 OUTLIER Glycine 0 CA--C 1.537 1.418 0 N-CA-C 111.747 -0.541 . . . . 1.0 111.747 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -61.15 -13.72 29.68 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 C-N-CA 122.399 2.066 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.46 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 4.1 mp -68.24 112.22 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 108.334 -0.987 . . . . 1.0 108.334 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -91.21 -167.11 40.9 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.691 -0.964 . . . . 1.0 110.691 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.503 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 38.0 Cg_endo -64.76 146.65 88.81 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 122.242 1.961 . . . . 1.0 112.973 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.532 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 46.16 49.87 12.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.67 -0.695 . . . . 1.0 111.925 178.353 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.437 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 49.1 mm-40 -93.21 132.69 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.093 0.473 . . . . 1.0 111.978 179.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.4 m -96.2 127.82 42.55 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.243 -1.762 . . . . 1.0 106.243 175.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.97 143.16 45.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.517 0.675 . . . . 1.0 110.747 -179.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.7 tt -119.28 146.38 24.04 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.659 0 CA-C-N 115.078 -0.965 . . . . 1.0 108.508 178.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.562 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.84 152.27 48.92 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.314 -0.554 . . . . 1.0 111.376 177.63 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.476 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 3.4 mmtt -100.47 124.03 45.46 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 105.697 -1.964 . . . . 1.0 105.697 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -118.61 119.05 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 119.41 -0.916 . . . . 1.0 112.394 -176.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.6 t-160 -110.81 122.66 48.38 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 114.096 -1.411 . . . . 1.0 108.654 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.49 112.13 23.89 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 120.364 -0.534 . . . . 1.0 112.378 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -95.55 -45.04 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 116.015 -0.539 . . . . 1.0 111.412 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -151.05 157.82 43.31 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.827 0.346 . . . . 1.0 110.691 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.79 140.67 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 121.039 0.447 . . . . 1.0 111.51 -177.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.7 tptt . . . . . 0 CA--C 1.534 0.33 0 CA-C-O 121.942 0.877 . . . . 1.0 111.22 179.911 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 . . . . . 0 CA--C 1.515 -0.378 0 CA-C-O 122.023 0.916 . . . . 1.0 110.646 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.562 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.8 m-20 -59.59 -37.47 78.63 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 114.608 -1.178 . . . . 1.0 108.221 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.428 ' O ' ' N ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -67.46 -52.14 42.97 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.183 -1.371 . . . . 1.0 111.495 179.541 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.92 -48.37 75.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 119.736 -0.786 . . . . 1.0 112.058 -177.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.402 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -63.36 -35.54 80.73 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.015 -1.106 . . . . 1.0 108.015 178.982 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -74.54 -43.57 29.61 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 114.754 -1.112 . . . . 1.0 112.054 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.503 ' O ' ' OG1' ' A' ' 17' ' ' THR . 86.3 mt-10 -61.72 -31.25 71.39 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.907 -0.775 . . . . 1.0 108.907 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.39 -32.08 48.67 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.441 -0.8 . . . . 1.0 110.04 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -62.44 -49.12 76.7 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.579 -1.191 . . . . 1.0 110.762 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.5 mp -69.73 -40.1 76.4 Favored 'General case' 0 C--N 1.32 -0.686 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.892 178.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.503 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.4 m -61.04 -41.7 97.09 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.814 -0.63 . . . . 1.0 109.481 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -75.48 -46.52 31.94 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.31 -0.859 . . . . 1.0 111.575 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.9 t30 -60.37 -44.91 95.17 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 113.016 0.747 . . . . 1.0 113.016 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -60.42 -28.84 68.58 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 119.47 -0.892 . . . . 1.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -80.25 -30.02 38.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.191 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -59.4 142.95 86.35 Favored Pre-proline 0 CA--C 1.55 0.951 0 N-CA-C 112.268 0.47 . . . . 1.0 112.268 -177.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.06 149.05 65.08 Favored 'Trans proline' 0 N--CA 1.505 2.195 0 C-N-CA 122.499 2.132 . . . . 1.0 113.362 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.72 -19.37 5.08 Favored Glycine 0 C--O 1.225 -0.412 0 CA-C-N 115.601 -0.727 . . . . 1.0 112.189 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.5 t -85.11 136.28 23.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.148 0.499 . . . . 1.0 110.833 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.91 124.24 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 107.854 -1.165 . . . . 1.0 107.854 177.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -97.24 146.32 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-O 121.71 0.767 . . . . 1.0 111.811 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.29 165.05 14.11 Favored Pre-proline 0 C--O 1.232 0.14 0 CA-C-N 114.355 -1.293 . . . . 1.0 110.856 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -61.37 -30.24 87.01 Favored 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 121.983 1.789 . . . . 1.0 111.379 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -68.51 -14.47 63.03 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.591 -0.731 . . . . 1.0 109.387 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.93 -2.1 68.88 Favored Glycine 0 C--O 1.229 -0.158 0 N-CA-C 109.734 -1.346 . . . . 1.0 109.734 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -80.54 132.78 35.71 Favored 'General case' 0 CA--C 1.519 -0.25 0 N-CA-C 108.411 -0.959 . . . . 1.0 108.411 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.7 mp0 -119.62 140.96 49.77 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-N 116.196 -0.456 . . . . 1.0 110.869 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -136.37 147.85 47.56 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 121.6 0.714 . . . . 1.0 111.143 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -130.64 132.54 45.51 Favored 'General case' 0 CA--C 1.501 -0.932 0 CA-C-N 114.479 -1.237 . . . . 1.0 109.317 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.16 104.85 15.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.281 1.038 . . . . 1.0 112.356 -178.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.3 mm -70.7 -41.64 77.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.039 -0.982 . . . . 1.0 108.72 178.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -143.6 131.52 21.59 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 114.639 -1.164 . . . . 1.0 109.792 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.8 p -90.3 129.1 36.57 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.857 -0.423 . . . . 1.0 109.857 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.74 -33.2 1.32 Allowed Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.592 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 54.32 30.83 13.22 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.287 -0.457 . . . . 1.0 110.577 179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.33 -162.22 37.78 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-O 121.789 0.66 . . . . 1.0 111.669 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 23.4 m -68.28 -177.54 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.266 -0.967 . . . . 1.0 109.375 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.468 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.56 154.58 0.35 Allowed Pre-proline 0 C--N 1.317 -0.832 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 179.54 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -88.21 160.4 7.03 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.162 2.575 . . . . 1.0 116.189 -175.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.445 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 174.22 39.06 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 108.096 -2.001 . . . . 1.0 108.096 175.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.607 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -49.26 -25.81 2.58 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.99 -0.605 . . . . 1.0 111.439 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.453 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 9.4 m -107.24 -9.21 16.15 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -177.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.445 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.6 m-20 -84.18 165.92 18.01 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 119.708 -0.797 . . . . 1.0 108.975 179.222 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.2 m -103.24 151.86 22.17 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-O 121.224 0.535 . . . . 1.0 109.948 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.66 161.82 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.389 0 CA-C-N 115.292 -0.867 . . . . 1.0 112.114 -176.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -132.12 118.17 19.26 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 108.67 -0.863 . . . . 1.0 108.67 177.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.5 m -148.1 166.98 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.883 0.697 . . . . 1.0 112.883 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -116.93 154.04 31.53 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 106.909 -1.515 . . . . 1.0 106.909 175.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.519 ' O ' ' N ' ' A' ' 68' ' ' THR . 41.1 p90 -165.07 163.55 20.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 114.82 1.415 . . . . 1.0 114.82 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.5 m -126.24 128.97 48.03 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 107.895 -1.15 . . . . 1.0 107.895 174.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.68 12.25 Favored Glycine 0 N--CA 1.47 0.905 0 C-N-CA 120.687 -0.768 . . . . 1.0 111.757 -178.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.3 ptp180 -146.23 167.02 24.52 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.95 0.881 . . . . 1.0 112.632 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.0 mp -81.76 163.79 22.16 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.065 -1.425 . . . . 1.0 110.147 178.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.19 -24.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 114.942 -1.026 . . . . 1.0 109.77 177.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -96.25 4.69 52.19 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 113.648 -1.615 . . . . 1.0 111.791 -177.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.05 80.51 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.788 -0.72 . . . . 1.0 113.316 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 m -72.83 111.51 8.03 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.112 -1.035 . . . . 1.0 109.422 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.02 120.17 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-O 121.543 0.687 . . . . 1.0 111.171 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.507 ' CD1' ' OD1' ' A' ' 66' ' ' ASP . 23.3 p90 -108.47 -9.81 15.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.884 -1.053 . . . . 1.0 111.613 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.578 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 4.1 p-10 -161.62 149.24 14.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.977 -0.556 . . . . 1.0 110.829 178.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 68.9 p -156.15 149.44 24.51 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.61 -0.723 . . . . 1.0 111.108 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.519 ' N ' ' O ' ' A' ' 55' ' ' TYR . 46.1 m -155.98 -42.0 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.602 -0.726 . . . . 1.0 110.967 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.413 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.8 pp20? -63.18 -26.95 69.04 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.742 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.7 mmtp -54.37 -43.15 71.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.699 -1.223 . . . . 1.0 107.699 178.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.484 ' OG1' ' O ' ' A' ' 68' ' ' THR . 28.5 p -76.3 -34.85 59.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.096 -1.411 . . . . 1.0 109.102 177.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.6 15.5 70.78 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.357 -0.838 . . . . 1.0 111.144 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -97.97 115.27 65.77 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 120.402 -0.519 . . . . 1.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -59.83 153.24 58.11 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 122.022 1.814 . . . . 1.0 114.114 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.97 150.73 46.36 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.059 -1.428 . . . . 1.0 108.069 178.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.29 129.65 55.7 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.014 0.746 . . . . 1.0 113.014 -178.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -140.98 153.02 45.4 Favored 'General case' 0 CA--C 1.502 -0.88 0 CA-C-N 114.678 -1.146 . . . . 1.0 108.795 177.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.5 mt-30 -90.44 127.18 36.14 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 106.359 -1.719 . . . . 1.0 106.359 174.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.4 t -46.79 -34.45 2.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.351 -0.539 . . . . 1.0 110.471 -178.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -73.56 -24.34 60.09 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 120.467 -0.493 . . . . 1.0 112.323 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 82.8 mm-40 -100.13 -12.0 20.0 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 113.618 0.969 . . . . 1.0 113.618 -177.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.4 p -84.44 177.93 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 119.656 -0.818 . . . . 1.0 110.455 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.95 146.51 37.76 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.595 -177.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -51.54 -44.55 43.2 Favored 'Trans proline' 0 N--CA 1.499 1.817 0 C-N-CA 121.896 1.73 . . . . 1.0 112.527 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.48 -47.4 90.06 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.549 -1.42 . . . . 1.0 109.549 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.1 m95 -63.83 -36.06 82.68 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.287 -0.956 . . . . 1.0 110.04 179.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.2 m -52.23 -52.95 49.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.674 -0.411 . . . . 1.0 110.904 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -72.32 -45.35 60.34 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.891 -0.595 . . . . 1.0 112.444 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.34 -48.46 76.72 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 113.925 1.083 . . . . 1.0 113.925 -177.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 32.7 mt -57.93 -42.66 85.31 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-O 121.084 0.469 . . . . 1.0 109.959 -177.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -62.65 -23.27 67.01 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 115.615 -0.721 . . . . 1.0 110.289 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.6 mt -101.79 -14.4 17.31 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.876 -0.602 . . . . 1.0 111.266 -179.131 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.2 ttp -88.98 108.18 22.25 Favored Pre-proline 0 CA--C 1.547 0.833 0 N-CA-C 111.991 0.367 . . . . 1.0 111.991 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.468 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 21.2 Cg_exo -66.06 148.08 85.07 Favored 'Trans proline' 0 N--CA 1.499 1.842 0 C-N-CA 122.438 2.092 . . . . 1.0 112.162 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.96 137.53 58.05 Favored 'General case' 0 CA--C 1.507 -0.695 0 CA-C-O 121.493 0.663 . . . . 1.0 111.331 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.16 -18.57 55.91 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.252 -1.939 . . . . 1.0 108.252 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.4 p -89.39 128.41 35.92 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 121.263 0.554 . . . . 1.0 110.735 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 89.9 m -103.56 114.24 28.36 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 115.392 -0.822 . . . . 1.0 109.944 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.483 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.6 m0 -116.04 164.9 13.77 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 121.442 0.639 . . . . 1.0 110.882 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -123.59 129.14 50.71 Favored 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 106.394 -1.706 . . . . 1.0 106.394 175.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -125.93 138.9 53.07 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.665 0 CA-C-O 121.926 0.869 . . . . 1.0 110.376 -179.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.658 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.27 104.12 13.2 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.928 -1.878 . . . . 1.0 105.928 -178.16 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.6 t -90.4 115.95 65.28 Favored Pre-proline 0 C--N 1.326 -0.415 0 N-CA-C 114.879 1.437 . . . . 1.0 114.879 -174.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -51.21 143.49 32.86 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 121.276 1.317 . . . . 1.0 110.021 175.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 92.4 p -49.26 -35.17 16.99 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.426 -0.51 . . . . 1.0 110.423 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.0 81.51 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 111.174 -0.77 . . . . 1.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -101.25 3.24 40.67 Favored 'General case' 0 C--O 1.225 -0.189 0 CA-C-O 119.771 -0.157 . . . . 1.0 110.872 -179.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.23 -112.33 0.29 Allowed 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.487 0.184 . . . . 1.0 110.554 -178.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -98.32 4.85 48.66 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 113.405 0.891 . . . . 1.0 113.405 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 115.14 162.97 13.87 Favored Glycine 0 N--CA 1.47 0.911 0 C-N-CA 120.996 -0.621 . . . . 1.0 112.969 177.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 121' ' ' ASN . 96.3 Cg_endo -76.16 -9.4 19.15 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 123.626 2.884 . . . . 1.0 111.0 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -109.19 168.9 9.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.498 -0.774 . . . . 1.0 109.446 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.1 m -73.86 96.37 2.58 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.0 t -111.91 60.25 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-N 116.244 -0.434 . . . . 1.0 110.444 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.55 172.46 36.19 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.35 -0.7 . . . . 1.0 111.35 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.59 -103.19 0.01 OUTLIER Glycine 0 CA--C 1.535 1.337 0 N-CA-C 111.226 -0.75 . . . . 1.0 111.226 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -58.04 -11.42 10.03 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.754 2.303 . . . . 1.0 111.628 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 14.9 mm -66.96 125.55 24.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-N 114.716 -1.129 . . . . 1.0 109.138 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -102.63 -175.86 27.12 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.321 -0.854 . . . . 1.0 111.249 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.562 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 21.6 Cg_endo -62.38 142.23 90.09 Favored 'Trans proline' 0 C--N 1.295 -2.25 0 C-N-CA 122.384 2.056 . . . . 1.0 111.756 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.531 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 45.79 55.39 6.93 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 120.796 -0.362 . . . . 1.0 111.103 178.11 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.521 ' OE2' ' ND2' ' A' ' 8' ' ' ASN . 3.3 tp10 -102.34 130.03 48.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.987 -0.552 . . . . 1.0 111.412 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 46.4 m -95.36 129.79 42.38 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.007 -1.109 . . . . 1.0 108.007 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.64 148.8 33.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.423 0.63 . . . . 1.0 111.114 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.8 tt -124.58 149.29 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.041 -0.981 . . . . 1.0 108.485 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.6 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -140.52 149.82 42.94 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 120.479 -0.488 . . . . 1.0 111.522 178.033 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 13.9 mmtt -99.42 127.07 45.44 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 104.768 -2.308 . . . . 1.0 104.768 176.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -121.18 121.13 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 119.259 -0.976 . . . . 1.0 112.138 -177.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -113.75 120.71 41.73 Favored 'General case' 0 C--O 1.223 -0.327 0 CA-C-N 114.157 -1.383 . . . . 1.0 108.612 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.35 111.89 23.63 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 120.014 -0.675 . . . . 1.0 112.519 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -94.14 -45.14 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-N 116.222 -0.444 . . . . 1.0 111.12 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -150.74 155.58 39.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.85 0.357 . . . . 1.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 46.7 t -128.7 139.09 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.285 -0.416 . . . . 1.0 111.326 -178.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.6 tptm . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 121.599 0.714 . . . . 1.0 110.057 178.997 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 121.785 0.803 . . . . 1.0 110.54 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.608 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 12.9 m-20 -61.49 -35.33 77.36 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.004 -1.11 . . . . 1.0 108.004 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 55.6 tttt -66.76 -51.02 60.68 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.385 -1.734 . . . . 1.0 111.571 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.8 t -66.87 -48.85 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.276 0 C-N-CA 119.979 -0.688 . . . . 1.0 111.393 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.84 -38.64 91.59 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.639 -1.245 . . . . 1.0 107.639 179.034 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.54 -42.77 71.51 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 114.868 -1.06 . . . . 1.0 111.875 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.435 ' N ' ' O ' ' A' ' 9' ' ' LYS . 33.8 mt-10 -62.67 -33.27 74.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.438 -0.949 . . . . 1.0 108.438 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.3 -34.25 59.05 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 114.791 -1.095 . . . . 1.0 109.798 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -61.89 -51.11 69.5 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 114.492 -1.231 . . . . 1.0 110.762 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.5 mp -69.66 -40.18 76.6 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.061 -0.656 . . . . 1.0 109.733 178.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.441 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 97.7 m -61.07 -42.06 97.78 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.505 -0.771 . . . . 1.0 109.13 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -75.74 -47.35 26.35 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.006 -0.997 . . . . 1.0 111.9 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.661 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 49.5 t30 -58.7 -45.4 89.6 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -177.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.5 -29.35 67.79 Favored 'General case' 0 C--N 1.315 -0.909 0 C-N-CA 119.303 -0.959 . . . . 1.0 109.154 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.441 ' ND2' ' O ' ' A' ' 17' ' ' THR . 7.4 m-80 -82.0 -29.69 31.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.372 -0.831 . . . . 1.0 111.591 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -59.74 146.08 81.92 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 120.48 -0.488 . . . . 1.0 111.371 -178.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.14 148.47 69.35 Favored 'Trans proline' 0 N--CA 1.504 2.094 0 C-N-CA 122.525 2.15 . . . . 1.0 113.791 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.89 -18.61 5.88 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.492 -0.776 . . . . 1.0 112.625 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.2 136.95 21.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.219 0.533 . . . . 1.0 111.286 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -121.66 126.03 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 107.64 -1.244 . . . . 1.0 107.64 177.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -100.73 145.62 10.81 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 CA-C-O 121.828 0.823 . . . . 1.0 112.266 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.1 mt -112.31 166.17 11.52 Favored Pre-proline 0 CA--C 1.529 0.155 0 CA-C-N 114.1 -1.409 . . . . 1.0 111.357 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.87 -30.7 84.4 Favored 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.188 1.926 . . . . 1.0 111.358 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.1 m -68.52 -14.42 62.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.839 -0.618 . . . . 1.0 109.8 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.14 -0.96 66.94 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 109.593 -1.403 . . . . 1.0 109.593 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.411 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -81.21 133.39 35.44 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.511 -0.922 . . . . 1.0 108.511 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.411 ' H ' HD23 ' A' ' 32' ' ' LEU . 21.2 mp0 -120.94 143.38 49.01 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.91 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -138.2 143.86 40.4 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 121.712 0.767 . . . . 1.0 110.734 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -127.53 132.83 49.86 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-N 114.504 -1.225 . . . . 1.0 109.106 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 p -90.82 104.9 15.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 122.148 0.975 . . . . 1.0 111.86 -178.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.6 mm -70.09 -42.34 79.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.222 -0.899 . . . . 1.0 108.671 178.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.6 m-80 -140.27 128.04 21.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 114.619 -1.173 . . . . 1.0 109.627 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 p -88.57 127.22 35.54 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.736 -0.468 . . . . 1.0 109.736 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.36 -34.53 1.19 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 110.683 -0.967 . . . . 1.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.633 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.6 m120 56.02 32.01 19.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.99 0.424 . . . . 1.0 110.737 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.41 -161.0 36.84 Favored Glycine 0 C--N 1.333 0.37 0 CA-C-O 121.924 0.736 . . . . 1.0 111.769 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.596 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.3 m -69.69 -178.09 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 114.084 -1.058 . . . . 1.0 109.289 178.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.449 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 154.84 0.37 Allowed Pre-proline 0 C--N 1.32 -0.694 0 O-C-N 123.829 0.705 . . . . 1.0 109.549 179.387 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -87.15 156.17 8.3 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 123.091 2.528 . . . . 1.0 115.993 -175.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.413 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.29 175.12 44.22 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 108.778 -1.729 . . . . 1.0 108.778 176.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.455 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.68 -22.44 5.14 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 120.82 -0.352 . . . . 1.0 111.14 -179.402 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.8 m -107.41 -9.9 15.88 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.245 0.831 . . . . 1.0 113.245 -177.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 91.6 m-20 -84.58 168.99 14.85 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 119.867 -0.733 . . . . 1.0 109.028 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.7 m -107.66 152.1 24.76 Favored 'General case' 0 CA--C 1.513 -0.466 0 N-CA-C 109.618 -0.512 . . . . 1.0 109.618 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -128.31 160.1 38.83 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.405 0 CA-C-N 115.741 -0.663 . . . . 1.0 112.285 -176.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 85.9 m -126.3 120.19 29.3 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 107.729 -1.212 . . . . 1.0 107.729 177.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -148.98 163.32 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 N-CA-C 114.291 1.219 . . . . 1.0 114.291 -175.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -118.44 150.67 39.18 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 106.41 -1.7 . . . . 1.0 106.41 174.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.499 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 36.9 p90 -163.75 163.53 24.03 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 118.393 -1.323 . . . . 1.0 114.506 -177.567 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.541 ' HG1' ' CD ' ' A' ' 69' ' ' GLU . 1.4 m -125.11 130.05 51.44 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 115.261 -0.881 . . . . 1.0 108.848 175.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.38 136.56 13.6 Favored Glycine 0 N--CA 1.468 0.787 0 C-N-CA 121.005 -0.617 . . . . 1.0 111.602 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -148.72 166.88 27.07 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.674 0.749 . . . . 1.0 112.533 179.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -84.28 164.38 19.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 114.456 -1.247 . . . . 1.0 110.502 178.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.45 -24.88 32.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.918 -1.037 . . . . 1.0 110.528 178.149 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.67 4.5 53.76 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.566 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.95 -5.23 81.95 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.016 178.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.6 m -67.14 103.39 1.2 Allowed 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.569 -0.853 . . . . 1.0 110.067 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.4 t -74.93 125.99 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.853 0 C-N-CA 120.347 -0.541 . . . . 1.0 109.702 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -117.48 -10.81 10.59 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 114.993 -1.003 . . . . 1.0 111.471 -179.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t0 -157.41 150.76 23.79 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.401 -0.52 . . . . 1.0 111.65 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -159.59 151.79 20.89 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.632 -0.713 . . . . 1.0 111.817 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 55' ' ' TYR . 96.3 m -151.25 -42.1 0.12 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.342 -0.845 . . . . 1.0 110.183 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.541 ' CD ' ' HG1' ' A' ' 56' ' ' THR . 0.6 OUTLIER -62.09 -27.93 69.26 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-N 116.018 -0.537 . . . . 1.0 109.672 179.379 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -56.73 -43.3 80.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 107.741 -1.207 . . . . 1.0 107.741 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.449 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.6 OUTLIER -75.14 -33.4 61.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.632 -1.167 . . . . 1.0 107.974 176.682 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.12 18.39 67.28 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 115.639 -0.71 . . . . 1.0 111.957 178.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -101.18 115.87 64.61 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 120.882 -0.327 . . . . 1.0 110.629 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.61 152.5 68.23 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 121.754 1.636 . . . . 1.0 114.282 -179.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.35 150.99 42.97 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.094 -1.412 . . . . 1.0 107.926 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.99 125.31 50.84 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.589 0.588 . . . . 1.0 112.589 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -132.93 147.8 52.29 Favored 'General case' 0 CA--C 1.502 -0.892 0 CA-C-N 115.367 -0.833 . . . . 1.0 109.222 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -90.63 127.93 36.45 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.268 -1.752 . . . . 1.0 106.268 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.1 t -52.75 -33.5 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 C-N-CA 119.6 -0.84 . . . . 1.0 110.149 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 3.3 t -74.06 -26.66 60.52 Favored 'General case' 0 CA--C 1.515 -0.401 0 C-N-CA 120.21 -0.596 . . . . 1.0 111.651 -178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -100.29 -3.76 30.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.312 -0.404 . . . . 1.0 111.873 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -84.3 166.58 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 CA-C-N 118.233 0.469 . . . . 1.0 111.406 -178.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.8 147.28 15.94 Favored Pre-proline 0 N--CA 1.474 0.756 0 N-CA-C 109.093 -0.706 . . . . 1.0 109.093 -177.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -50.9 -43.55 46.59 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.747 1.631 . . . . 1.0 112.701 -178.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.19 92.29 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 119.57 -1.3 . . . . 1.0 110.018 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -64.32 -35.91 82.41 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.369 -0.916 . . . . 1.0 110.398 179.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 25.1 m -51.0 -53.11 36.22 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.721 0.296 . . . . 1.0 111.67 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 20.5 tp10 -72.39 -41.62 66.11 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.738 0.644 . . . . 1.0 112.738 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.66 -45.45 91.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 114.036 1.125 . . . . 1.0 114.036 -177.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.04 -41.91 88.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.263 0.554 . . . . 1.0 109.761 -177.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.0 mt-30 -64.66 -24.61 67.64 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.705 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.496 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 59.8 mt -101.9 -10.67 19.62 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.182 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.7 ttp -91.78 107.39 22.08 Favored Pre-proline 0 CA--C 1.546 0.789 0 O-C-N 123.154 0.283 . . . . 1.0 111.639 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.449 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -66.93 147.69 80.8 Favored 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.508 2.139 . . . . 1.0 111.98 178.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.596 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.59 139.55 58.78 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-O 121.686 0.755 . . . . 1.0 111.429 -179.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.78 -18.76 54.81 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.123 -1.991 . . . . 1.0 108.123 -178.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.4 p -89.88 129.6 36.22 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.037 0.446 . . . . 1.0 110.621 179.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 85.1 m -103.44 114.22 28.33 Favored 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 115.659 -0.701 . . . . 1.0 109.855 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.496 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -115.98 161.94 18.11 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.742 0.782 . . . . 1.0 111.487 -178.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -121.57 125.61 47.16 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.162 -1.421 . . . . 1.0 107.162 175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -120.9 138.03 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.564 0 CA-C-O 121.8 0.81 . . . . 1.0 109.838 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.661 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.0 103.4 12.42 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -177.983 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.27 116.25 65.94 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 115.022 1.49 . . . . 1.0 115.022 -174.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -51.39 142.58 37.44 Favored 'Trans proline' 0 C--N 1.315 -1.191 0 C-N-CA 121.361 1.374 . . . . 1.0 109.81 176.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 97.6 p -48.61 -35.28 13.25 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.31 -0.556 . . . . 1.0 111.185 -178.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.75 -32.77 82.22 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.153 -0.779 . . . . 1.0 111.153 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.5 mt -98.46 2.49 47.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.957 -0.121 . . . . 1.0 110.91 -179.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.45 -110.77 0.31 Allowed 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 112.029 0.381 . . . . 1.0 112.029 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -96.88 4.31 51.7 Favored 'General case' 0 C--N 1.342 0.249 0 N-CA-C 112.288 0.477 . . . . 1.0 112.288 -177.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.11 162.87 17.93 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 121.172 -0.537 . . . . 1.0 112.831 177.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 121' ' ' ASN . 83.3 Cg_endo -76.9 -10.23 18.17 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 123.423 2.749 . . . . 1.0 111.4 179.229 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . 0.407 ' HG2' ' H ' ' A' ' 113' ' ' SER . 5.9 ttm-85 -105.15 168.45 9.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.252 -0.885 . . . . 1.0 109.51 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.518 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -74.18 100.04 3.56 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.3 -0.629 . . . . 1.0 109.3 178.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.9 61.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.76 0.314 . . . . 1.0 110.831 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 159.15 175.73 30.41 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 120.472 -0.87 . . . . 1.0 112.44 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.42 -103.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.328 0 CA-C-N 114.963 -0.619 . . . . 1.0 111.87 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -61.87 -16.95 52.62 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 122.613 2.208 . . . . 1.0 111.773 -177.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.3 mp -67.4 114.56 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 108.343 -0.984 . . . . 1.0 108.343 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.416 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.98 -171.02 38.53 Favored Glycine 0 N--CA 1.452 -0.258 0 N-CA-C 110.949 -0.86 . . . . 1.0 110.949 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.518 ' N ' ' OG ' ' A' ' 113' ' ' SER . 34.1 Cg_endo -64.01 139.55 67.97 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.318 2.012 . . . . 1.0 112.627 179.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.529 ' N ' ' O ' ' A' ' 111' ' ' PRO . 17.1 t-20 52.59 48.85 21.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.439 -0.346 . . . . 1.0 111.371 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.608 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -93.14 132.58 37.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.541 -0.3 . . . . 1.0 110.716 179.843 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 52.1 m -96.2 127.77 42.5 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 175.326 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -111.28 145.33 38.97 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.128 0.489 . . . . 1.0 110.468 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.4 tt -122.63 146.14 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.476 -0.783 . . . . 1.0 108.937 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.622 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.6 m-85 -136.33 149.65 48.49 Favored 'General case' 0 CA--C 1.517 -0.319 0 C-N-CA 120.26 -0.576 . . . . 1.0 111.509 178.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 12.6 mmtt -99.5 123.57 43.89 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 105.423 -2.065 . . . . 1.0 105.423 177.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.7 mt -118.94 118.1 56.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 119.112 -1.035 . . . . 1.0 112.879 -176.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -108.65 126.22 52.73 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 113.572 -1.649 . . . . 1.0 108.278 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 111.3 23.42 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 119.871 -0.732 . . . . 1.0 112.271 -178.124 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.2 mp -93.71 -45.93 13.76 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.852 -0.613 . . . . 1.0 111.676 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.6 p -150.84 156.03 40.41 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.575 -0.45 . . . . 1.0 110.84 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 56.9 t -128.0 141.45 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.969 -0.559 . . . . 1.0 111.395 -178.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 9.2 tptm . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.638 -0.71 . . . . 1.0 110.33 179.513 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.687 0.756 . . . . 1.0 110.419 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.4 m-20 -58.02 -34.01 69.57 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.501 -0.926 . . . . 1.0 108.501 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -66.21 -51.08 61.1 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.406 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.99 -48.22 82.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 119.942 -0.703 . . . . 1.0 111.614 -178.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.8 -38.95 92.74 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.785 -1.191 . . . . 1.0 107.785 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.08 -46.27 52.11 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-N 114.779 -1.101 . . . . 1.0 112.631 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.505 ' O ' ' OG1' ' A' ' 17' ' ' THR . 74.0 mt-10 -59.53 -34.97 73.32 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.288 -0.965 . . . . 1.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.58 -36.14 65.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.94 -1.027 . . . . 1.0 110.401 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -61.31 -50.4 73.12 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.879 -1.055 . . . . 1.0 110.628 -179.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -67.1 -39.81 86.78 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 119.783 -0.767 . . . . 1.0 109.461 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.505 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.9 m -61.86 -42.16 98.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.743 -0.662 . . . . 1.0 109.657 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -75.24 -45.46 39.98 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.661 -0.699 . . . . 1.0 111.845 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.647 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.8 t30 -61.65 -44.65 96.57 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 113.18 0.807 . . . . 1.0 113.18 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -59.74 -34.9 73.55 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.27 -0.972 . . . . 1.0 108.578 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -71.51 -36.29 71.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.158 -0.928 . . . . 1.0 111.991 178.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 mtmt -55.78 135.66 72.24 Favored Pre-proline 0 CA--C 1.546 0.808 0 CA-C-N 116.412 -0.358 . . . . 1.0 111.588 -178.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.76 148.37 66.33 Favored 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.202 1.935 . . . . 1.0 113.627 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.06 -19.71 20.4 Favored Glycine 0 C--O 1.226 -0.394 0 CA-C-N 115.136 -0.938 . . . . 1.0 111.004 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.5 t -85.17 136.0 23.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.161 0.505 . . . . 1.0 110.155 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.07 121.46 65.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 107.767 -1.197 . . . . 1.0 107.767 178.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 p -95.93 145.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.648 0.737 . . . . 1.0 111.703 -177.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.55 164.15 16.06 Favored Pre-proline 0 C--N 1.334 -0.106 0 CA-C-N 114.455 -1.248 . . . . 1.0 110.437 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.57 -30.81 86.6 Favored 'Trans proline' 0 C--N 1.318 -1.059 0 C-N-CA 121.634 1.556 . . . . 1.0 111.339 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 m -69.33 -10.73 59.23 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.925 -0.579 . . . . 1.0 109.912 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.35 -2.8 71.5 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 110.232 -1.147 . . . . 1.0 110.232 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.42 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -79.17 133.27 36.72 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 108.628 -0.879 . . . . 1.0 108.628 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.42 ' H ' HD23 ' A' ' 32' ' ' LEU . 17.4 mp0 -122.8 139.54 53.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.395 -0.366 . . . . 1.0 110.983 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -135.5 143.13 45.63 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.675 0.75 . . . . 1.0 110.913 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -126.58 132.9 51.19 Favored 'General case' 0 CA--C 1.503 -0.86 0 CA-C-N 114.645 -1.161 . . . . 1.0 109.183 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.78 104.66 15.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.167 0.984 . . . . 1.0 111.906 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.5 mm -69.58 -41.86 80.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 108.007 -1.108 . . . . 1.0 108.007 178.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -142.36 129.64 21.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.573 -1.194 . . . . 1.0 109.804 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.7 p -88.49 131.35 34.93 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.764 -0.458 . . . . 1.0 109.764 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.0 -33.25 1.08 Allowed Glycine 0 C--N 1.331 0.291 0 N-CA-C 110.051 -1.219 . . . . 1.0 110.051 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.639 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 54.7 30.93 14.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.375 -0.413 . . . . 1.0 110.958 179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.31 -162.3 37.85 Favored Glycine 0 C--N 1.331 0.281 0 CA-C-O 121.905 0.725 . . . . 1.0 111.957 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.5 m -68.81 -178.63 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 113.905 -1.148 . . . . 1.0 109.125 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.47 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.49 154.77 0.4 Allowed Pre-proline 0 C--N 1.321 -0.631 0 O-C-N 123.705 0.628 . . . . 1.0 109.948 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -87.33 154.43 8.0 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 123.439 2.759 . . . . 1.0 116.971 -174.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.446 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.55 177.2 48.47 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 109.141 -1.584 . . . . 1.0 109.141 175.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.406 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.37 -25.43 15.43 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.963 -0.295 . . . . 1.0 111.507 -179.722 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.6 m -108.03 -5.11 17.23 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.815 0.672 . . . . 1.0 112.815 -176.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.446 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 66.6 m-20 -83.49 165.36 19.2 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.4 m -106.52 150.31 26.25 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 109.636 -0.505 . . . . 1.0 109.636 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -129.39 162.94 35.9 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.465 0 CA-C-N 116.126 -0.488 . . . . 1.0 111.982 -176.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 98.5 m -130.15 119.63 23.3 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 108.52 -0.918 . . . . 1.0 108.52 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.18 165.17 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 114.885 1.439 . . . . 1.0 114.885 -177.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -118.89 145.07 46.02 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 106.568 -1.642 . . . . 1.0 106.568 174.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.525 ' O ' ' N ' ' A' ' 68' ' ' THR . 38.8 p90 -161.11 164.07 30.94 Favored 'General case' 0 C--N 1.344 0.357 0 N-CA-C 114.825 1.417 . . . . 1.0 114.825 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -127.13 127.86 45.26 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 115.158 -0.928 . . . . 1.0 108.792 175.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.8 134.1 11.61 Favored Glycine 0 N--CA 1.473 1.114 0 C-N-CA 120.933 -0.651 . . . . 1.0 111.92 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.644 ' CZ ' ' HZ3' ' A' ' 127' ' ' LYS . 7.7 ptp85 -147.86 170.31 17.92 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.866 0.841 . . . . 1.0 113.071 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -83.58 164.08 19.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 114.126 -1.397 . . . . 1.0 110.795 178.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.406 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.3 -25.86 35.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.017 -0.992 . . . . 1.0 110.769 178.329 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -95.25 6.01 50.18 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.564 -1.198 . . . . 1.0 111.857 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.39 -3.46 75.69 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 121.01 -0.614 . . . . 1.0 113.313 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 m -71.78 106.58 4.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 118.157 0.978 . . . . 1.0 110.228 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 54.5 t -76.33 130.41 36.25 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.232 0.539 . . . . 1.0 110.575 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -120.37 -14.45 8.73 Favored 'General case' 0 CA--C 1.522 -0.112 0 CA-C-N 115.11 -0.95 . . . . 1.0 111.208 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 67' ' ' SER . 30.4 t0 -155.38 151.83 28.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.379 -0.373 . . . . 1.0 111.098 178.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 87.8 p -160.84 154.61 22.41 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 112.723 0.638 . . . . 1.0 112.723 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 55' ' ' TYR . 85.3 m -155.3 -42.01 0.08 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.143 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.405 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 2.0 pp20? -61.32 -26.19 67.63 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.602 -0.439 . . . . 1.0 110.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -53.83 -42.73 68.8 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.212 -1.033 . . . . 1.0 108.212 178.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 21.6 p -78.36 -30.61 48.08 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.957 -1.019 . . . . 1.0 108.956 177.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.75 17.16 73.56 Favored Glycine 0 C--N 1.337 0.593 0 N-CA-C 111.363 -0.695 . . . . 1.0 111.363 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 7.2 mptt -99.89 115.94 65.12 Favored Pre-proline 0 N--CA 1.469 0.492 0 C-N-CA 120.987 -0.285 . . . . 1.0 110.498 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -61.13 152.49 71.33 Favored 'Trans proline' 0 N--CA 1.483 0.867 0 C-N-CA 121.646 1.564 . . . . 1.0 113.964 -178.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.31 149.53 46.44 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.335 -1.302 . . . . 1.0 107.612 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -103.58 131.76 50.43 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.226 0.536 . . . . 1.0 112.219 -178.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -137.71 150.05 47.0 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 115.29 -0.868 . . . . 1.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -93.47 124.65 37.6 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.162 -1.792 . . . . 1.0 106.162 174.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.4 t -51.46 -27.1 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 C-N-CA 119.778 -0.769 . . . . 1.0 110.608 -176.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 42.4 t -76.32 -24.58 54.31 Favored 'General case' 0 CA--C 1.519 -0.224 0 C-N-CA 120.344 -0.542 . . . . 1.0 112.287 -179.159 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -98.56 -8.27 26.8 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 112.233 0.457 . . . . 1.0 112.233 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.4 p -83.08 168.8 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 119.961 -0.696 . . . . 1.0 111.852 -177.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -55.19 153.32 13.05 Favored Pre-proline 0 CA--C 1.548 0.867 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 -177.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.28 -45.65 39.5 Favored 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.633 1.556 . . . . 1.0 112.948 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.11 -48.09 85.16 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -64.07 -35.74 81.74 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.101 -1.05 . . . . 1.0 110.108 179.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.4 m -52.17 -54.0 36.2 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.649 -0.42 . . . . 1.0 111.294 -178.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -72.71 -42.73 63.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.976 -0.557 . . . . 1.0 112.338 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.57 -47.36 79.69 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 113.848 1.055 . . . . 1.0 113.848 -177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.2 mt -58.25 -41.76 84.9 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.365 0.603 . . . . 1.0 109.799 -178.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.5 mt-30 -63.24 -24.78 68.02 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.952 -1.022 . . . . 1.0 110.904 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.42 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 70.1 mt -101.65 -13.27 17.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.252 -0.431 . . . . 1.0 111.29 -179.209 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 36.5 ttp -88.04 108.99 24.31 Favored Pre-proline 0 CA--C 1.547 0.847 0 N-CA-C 112.249 0.463 . . . . 1.0 112.249 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.47 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 17.8 Cg_exo -66.37 147.77 83.33 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.274 1.983 . . . . 1.0 112.289 178.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.78 136.85 57.75 Favored 'General case' 0 CA--C 1.509 -0.627 0 CA-C-O 121.492 0.663 . . . . 1.0 111.503 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.08 -18.48 56.06 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 109.001 -1.64 . . . . 1.0 109.001 -178.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -86.99 133.67 33.56 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 120.894 0.378 . . . . 1.0 110.165 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 84.4 m -106.06 112.96 26.22 Favored 'General case' 0 CA--C 1.511 -0.557 0 CA-C-N 115.986 -0.552 . . . . 1.0 109.938 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.42 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.3 m0 -115.1 163.75 15.18 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.677 0.751 . . . . 1.0 111.544 -178.53 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -124.02 124.56 42.82 Favored 'General case' 0 CA--C 1.51 -0.566 0 N-CA-C 107.101 -1.444 . . . . 1.0 107.101 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -119.0 137.84 51.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.866 0.841 . . . . 1.0 110.086 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.647 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.84 103.42 12.21 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 105.707 -1.96 . . . . 1.0 105.707 -178.303 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 t -90.63 116.12 65.7 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 115.529 1.678 . . . . 1.0 115.529 -174.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -50.75 143.32 29.77 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 121.611 1.54 . . . . 1.0 110.23 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 79.9 p -49.76 -35.43 22.39 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.282 -0.567 . . . . 1.0 110.524 -178.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.02 -32.39 82.37 Favored Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.985 -0.846 . . . . 1.0 110.985 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 42.9 mt -100.87 2.64 41.17 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.877 -0.162 . . . . 1.0 110.898 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.37 -104.53 0.34 Allowed 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 117.693 0.224 . . . . 1.0 110.511 -178.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -104.99 5.39 32.61 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 113.564 0.95 . . . . 1.0 113.564 -178.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 108.54 164.68 20.88 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.924 -0.655 . . . . 1.0 113.506 176.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.475 ' O ' ' N ' ' A' ' 121' ' ' ASN . 89.9 Cg_endo -75.11 -14.75 20.8 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 C-N-CA 123.618 2.878 . . . . 1.0 111.404 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -101.28 165.98 11.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.115 -0.948 . . . . 1.0 109.586 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.448 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -75.21 97.71 3.58 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.411 -0.516 . . . . 1.0 109.844 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.2 t -110.34 59.0 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.858 -179.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 167.81 -178.29 41.73 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 120.117 -1.04 . . . . 1.0 112.247 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -58.35 -106.4 0.01 OUTLIER Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.972 -0.451 . . . . 1.0 111.972 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -14.87 38.9 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 122.028 1.819 . . . . 1.0 111.011 -178.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.519 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -67.03 115.89 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 107.922 -1.14 . . . . 1.0 107.922 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.598 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -93.88 -160.72 34.98 Favored Glycine 0 C--O 1.215 -1.047 0 N-CA-C 110.398 -1.081 . . . . 1.0 110.398 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.448 ' N ' ' OG ' ' A' ' 113' ' ' SER . 74.2 Cg_endo -73.35 145.39 38.29 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 122.112 1.874 . . . . 1.0 112.756 178.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 111' ' ' PRO . 1.1 t30 45.24 59.92 3.28 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.782 0.66 . . . . 1.0 112.782 177.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.614 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -115.06 138.44 50.88 Favored 'General case' 0 N--CA 1.473 0.702 0 CA-C-O 121.62 0.724 . . . . 1.0 111.185 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 97.5 m -94.57 129.53 41.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.658 -1.155 . . . . 1.0 108.71 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -111.96 143.57 42.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.248 0.547 . . . . 1.0 110.076 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.2 tt -122.44 148.15 26.25 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 108.659 -0.867 . . . . 1.0 108.659 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.34 150.94 47.08 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.051 0.453 . . . . 1.0 111.166 177.435 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.644 ' HZ3' ' CZ ' ' A' ' 58' ' ' ARG . 7.5 mmtt -100.25 123.33 44.35 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 105.721 -1.955 . . . . 1.0 105.721 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -119.8 119.0 58.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 119.143 -1.023 . . . . 1.0 113.056 -176.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -109.96 123.25 49.3 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 113.885 -1.507 . . . . 1.0 108.682 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.49 111.29 23.22 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 120.346 -0.542 . . . . 1.0 112.186 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.46 -44.69 13.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.33 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -152.12 156.55 40.08 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.068 0.461 . . . . 1.0 111.03 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 49.1 t -129.82 134.71 62.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.969 -0.56 . . . . 1.0 110.446 -178.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.9 tptm . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 122.011 0.91 . . . . 1.0 110.452 179.471 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 . . . . . 0 CA--C 1.511 -0.543 0 CA-C-O 121.929 0.871 . . . . 1.0 110.29 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.545 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 9.6 m-20 -57.28 -35.75 70.16 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.549 -1.205 . . . . 1.0 108.462 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 tttm -65.96 -51.9 54.36 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 113.651 -1.613 . . . . 1.0 111.602 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.5 t -69.96 -48.41 63.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 C-N-CA 119.881 -0.728 . . . . 1.0 112.162 -178.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.18 -39.77 93.79 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 108.113 -1.069 . . . . 1.0 108.113 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.14 73.53 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-N 115.148 -0.933 . . . . 1.0 111.913 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' OG1' ' A' ' 17' ' ' THR . 88.9 mt-10 -61.35 -31.6 71.48 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.974 -0.75 . . . . 1.0 108.974 178.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -34.08 50.2 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.135 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -63.12 -50.45 70.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.388 -1.278 . . . . 1.0 110.774 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.8 mp -73.41 -39.73 64.83 Favored 'General case' 0 CA--C 1.509 -0.618 0 C-N-CA 119.912 -0.715 . . . . 1.0 110.225 178.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.492 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 91.1 m -62.0 -42.84 99.59 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.347 -179.243 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -75.85 -46.79 28.46 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.859 -0.609 . . . . 1.0 112.243 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 59.8 t30 -60.89 -44.63 96.83 Favored 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 113.573 0.953 . . . . 1.0 113.573 -177.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -59.2 -35.08 72.96 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 119.706 -0.798 . . . . 1.0 109.7 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -73.75 -33.99 64.53 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.221 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -60.37 125.51 82.07 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-N 115.956 -0.565 . . . . 1.0 112.066 -178.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.27 149.92 15.64 Favored 'Trans proline' 0 N--CA 1.5 1.854 0 C-N-CA 122.168 1.912 . . . . 1.0 112.847 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.77 -20.14 33.53 Favored Glycine 0 C--O 1.224 -0.523 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 -179.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.9 t -93.36 133.01 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 1.0 109.614 179.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.1 t -117.41 120.83 66.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 108.528 -0.916 . . . . 1.0 108.528 177.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.34 146.08 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.623 0 CA-C-O 121.676 0.75 . . . . 1.0 111.393 -178.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 62.5 mt -113.56 164.22 16.42 Favored Pre-proline 0 C--N 1.332 -0.167 0 CA-C-N 114.438 -1.255 . . . . 1.0 110.958 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.07 -30.35 93.04 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.894 1.73 . . . . 1.0 110.913 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.5 m -67.93 -15.17 63.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.785 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.66 68.57 Favored Glycine 0 C--O 1.23 -0.139 0 N-CA-C 110.089 -1.205 . . . . 1.0 110.089 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.74 133.97 38.18 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 109.056 -0.72 . . . . 1.0 109.056 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.421 ' H ' HD23 ' A' ' 32' ' ' LEU . 24.0 mp0 -123.12 137.77 54.83 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.1 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -133.73 143.16 48.31 Favored 'General case' 0 CA--C 1.504 -0.797 0 CA-C-O 121.739 0.78 . . . . 1.0 110.927 178.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -126.96 131.84 50.97 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 114.432 -1.258 . . . . 1.0 109.562 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -88.39 105.12 15.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 122.045 0.926 . . . . 1.0 111.922 -178.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 16.1 mm -69.44 -42.34 80.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.036 -0.984 . . . . 1.0 108.447 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.419 ' O ' ' OG ' ' A' ' 97' ' ' SER . 23.0 m-80 -141.96 127.19 18.61 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.524 -1.216 . . . . 1.0 109.72 -179.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -86.73 130.96 34.27 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.803 0.335 . . . . 1.0 110.399 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.469 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -121.33 -36.01 0.77 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 109.914 -1.275 . . . . 1.0 109.914 179.597 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.624 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 58.48 32.81 22.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 1.0 111.593 179.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.9 -161.67 37.58 Favored Glycine 0 C--N 1.331 0.255 0 CA-C-O 121.861 0.7 . . . . 1.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 26.4 m -69.6 -178.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.07 -1.065 . . . . 1.0 109.494 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.5 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.47 154.43 0.45 Allowed Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 109.61 -0.515 . . . . 1.0 109.61 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -88.02 157.47 7.18 Favored 'Trans proline' 0 N--CA 1.503 2.077 0 C-N-CA 123.72 2.946 . . . . 1.0 117.454 -174.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.42 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.45 177.6 48.75 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 109.725 -1.35 . . . . 1.0 109.725 175.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.409 ' HD2' ' H ' ' A' ' 48' ' ' SER . 0.0 OUTLIER -55.05 -25.54 31.42 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.216 -0.492 . . . . 1.0 111.904 -179.612 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.409 ' H ' ' HD2' ' A' ' 47' ' ' LYS . 3.7 m -108.94 -4.84 16.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.551 0.574 . . . . 1.0 112.551 -177.622 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.42 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.5 m-20 -82.18 169.56 16.46 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.046 -0.724 . . . . 1.0 109.046 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.6 m -111.4 151.46 28.47 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.699 -0.482 . . . . 1.0 109.699 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -129.96 162.56 37.46 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 CA-C-N 115.754 -0.657 . . . . 1.0 111.716 -176.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 73.6 m -129.67 120.16 24.72 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.288 -1.004 . . . . 1.0 108.288 177.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.5 m -149.06 164.86 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 N-CA-C 114.379 1.252 . . . . 1.0 114.379 -176.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -118.72 146.26 44.88 Favored 'General case' 0 N--CA 1.486 1.352 0 N-CA-C 106.056 -1.831 . . . . 1.0 106.056 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.519 ' O ' ' N ' ' A' ' 68' ' ' THR . 41.1 p90 -162.98 164.61 25.63 Favored 'General case' 0 C--N 1.342 0.275 0 N-CA-C 114.971 1.471 . . . . 1.0 114.971 -176.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.448 ' OG1' ' OE1' ' A' ' 69' ' ' GLU . 1.2 m -125.97 130.45 51.24 Favored 'General case' 0 C--O 1.216 -0.679 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.706 175.526 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.48 132.86 10.72 Favored Glycine 0 N--CA 1.473 1.113 0 N-CA-C 111.356 -0.698 . . . . 1.0 111.356 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 -147.06 167.54 23.82 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.788 0.804 . . . . 1.0 112.658 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.6 mp -81.9 164.83 21.28 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 114.252 -1.34 . . . . 1.0 110.274 178.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 -26.27 37.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 114.794 -1.094 . . . . 1.0 110.243 178.173 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.415 ' OD2' ' O ' ' A' ' 61' ' ' ASP . 7.0 t70 -94.04 5.26 52.27 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.019 -1.446 . . . . 1.0 111.919 -176.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.56 -4.53 79.7 Favored Glycine 0 CA--C 1.528 0.883 0 C-N-CA 121.0 -0.619 . . . . 1.0 113.227 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -70.29 103.88 2.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 118.073 0.937 . . . . 1.0 110.028 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -75.55 128.3 37.18 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.727 0 C-N-CA 120.642 -0.423 . . . . 1.0 110.059 179.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -116.08 -10.34 11.55 Favored 'General case' 0 CA--C 1.521 -0.165 0 CA-C-N 115.439 -0.8 . . . . 1.0 111.116 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -164.24 153.32 13.55 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.443 -0.503 . . . . 1.0 111.677 177.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.7 p -159.41 158.08 31.46 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 115.763 -0.653 . . . . 1.0 111.869 179.214 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.519 ' N ' ' O ' ' A' ' 55' ' ' TYR . 67.2 m -152.78 -40.61 0.1 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.358 -0.837 . . . . 1.0 110.254 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.448 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.3 pp20? -59.86 -27.59 66.8 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.373 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -55.45 -40.23 71.33 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.641 -1.244 . . . . 1.0 107.641 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.8 -34.94 57.92 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.029 -1.442 . . . . 1.0 108.642 178.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.54 17.87 69.9 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 110.69 -0.964 . . . . 1.0 110.69 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -105.07 116.26 60.94 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 121.155 -0.218 . . . . 1.0 110.754 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.36 149.93 83.31 Favored 'Trans proline' 0 N--CA 1.479 0.67 0 C-N-CA 121.255 1.303 . . . . 1.0 113.358 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -122.83 151.27 41.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 114.483 -1.235 . . . . 1.0 108.204 178.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.1 t -106.41 127.44 53.29 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 113.13 0.789 . . . . 1.0 113.13 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 54.6 m-85 -133.97 150.02 51.26 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-N 115.148 -0.933 . . . . 1.0 108.973 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -90.38 125.05 35.41 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 106.353 -1.721 . . . . 1.0 106.353 174.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.5 t -48.48 -30.43 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 120.06 -0.656 . . . . 1.0 110.199 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.9 t -75.13 -25.12 58.17 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.27 -0.572 . . . . 1.0 111.681 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -98.87 -8.2 26.08 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 113.518 0.933 . . . . 1.0 113.518 -177.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.9 p -88.22 170.49 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 118.907 0.776 . . . . 1.0 111.974 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.98 148.51 13.85 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 120.256 -0.578 . . . . 1.0 109.623 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.75 -44.34 41.48 Favored 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 122.25 1.967 . . . . 1.0 113.143 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.63 -47.43 90.19 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.818 -1.313 . . . . 1.0 109.818 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 9.2 m95 -63.79 -36.97 85.63 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.747 -1.227 . . . . 1.0 110.128 178.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 20.9 m -50.89 -54.19 26.1 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 116.258 -0.428 . . . . 1.0 111.041 -177.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.0 tp10 -72.84 -42.6 63.58 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.541 0.571 . . . . 1.0 112.541 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.52 -47.21 79.83 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 113.552 0.945 . . . . 1.0 113.552 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 79.3 mt -57.84 -41.28 82.01 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.406 0.622 . . . . 1.0 109.995 -178.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -64.57 -23.74 67.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.26 -0.882 . . . . 1.0 111.126 -179.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.8 mt -105.3 -12.23 16.15 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.505 -0.316 . . . . 1.0 111.075 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 17.6 ttm -88.77 108.4 23.08 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 116.014 -0.539 . . . . 1.0 111.925 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.5 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 20.2 Cg_exo -65.54 149.14 87.9 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.853 2.369 . . . . 1.0 113.318 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.86 133.43 51.88 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-N 115.591 -0.731 . . . . 1.0 111.359 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.4 -19.06 54.8 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 109.67 -1.372 . . . . 1.0 109.67 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.707 ' HG ' ' HE1' ' A' ' 99' ' ' TRP . 23.8 t -84.08 125.96 32.62 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.967 0.413 . . . . 1.0 109.946 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 44.1 m -96.94 111.86 23.88 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 116.151 -0.477 . . . . 1.0 110.044 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.707 ' HE1' ' HG ' ' A' ' 97' ' ' SER . 39.8 m0 -114.95 164.47 14.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.863 0.84 . . . . 1.0 111.476 -178.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 88.6 mt-10 -125.81 126.52 44.65 Favored 'General case' 0 CA--C 1.508 -0.636 0 N-CA-C 106.582 -1.636 . . . . 1.0 106.582 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.0 pt -120.4 137.15 55.13 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.767 0.794 . . . . 1.0 109.792 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.35 103.27 12.39 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 105.77 -1.937 . . . . 1.0 105.77 -178.13 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.95 115.09 63.57 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 114.969 1.47 . . . . 1.0 114.969 -174.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -51.32 144.53 30.45 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.121 1.214 . . . . 1.0 109.768 175.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.4 p -49.0 -36.67 18.21 Favored 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 120.653 -0.419 . . . . 1.0 110.961 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.18 -32.29 81.8 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.377 -0.689 . . . . 1.0 111.377 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 59.1 mt -98.58 2.07 47.06 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 122.926 -0.161 . . . . 1.0 110.645 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.37 -111.26 0.31 Allowed 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 110.035 -0.358 . . . . 1.0 110.035 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -98.88 4.21 47.42 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 112.327 0.492 . . . . 1.0 112.327 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.85 157.9 15.36 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 121.387 -0.435 . . . . 1.0 112.592 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.445 ' O ' ' N ' ' A' ' 121' ' ' ASN . 88.4 Cg_endo -74.12 -11.72 23.28 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 123.506 2.804 . . . . 1.0 110.562 179.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 70.2 ttt180 -100.85 165.12 11.51 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.8 -1.091 . . . . 1.0 108.946 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.51 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.1 m -72.28 97.17 1.95 Allowed 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 119.989 -0.684 . . . . 1.0 109.173 178.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.4 t -112.08 60.9 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 121.049 -0.261 . . . . 1.0 111.322 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 163.19 169.39 26.56 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.333 -0.937 . . . . 1.0 111.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.21 -103.47 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.191 -0.764 . . . . 1.0 111.191 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -60.81 -19.39 61.44 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 122.46 2.107 . . . . 1.0 111.608 -178.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.4 mp -68.05 118.7 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 107.54 -1.282 . . . . 1.0 107.54 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -101.31 -168.0 27.87 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 115.225 -0.898 . . . . 1.0 113.796 -176.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 19.5 Cg_endo -63.6 144.71 90.48 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.859 2.373 . . . . 1.0 112.289 178.313 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.445 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 43.25 50.93 5.84 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.717 0.294 . . . . 1.0 111.004 179.108 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.545 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 3.9 tp10 -106.15 127.51 53.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.623 0.725 . . . . 1.0 112.627 -177.604 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 25.7 m -95.61 135.24 37.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.649 -1.16 . . . . 1.0 108.52 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -115.32 142.16 47.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.232 0.539 . . . . 1.0 110.862 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.5 tt -120.84 149.37 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 115.468 -0.787 . . . . 1.0 108.951 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.581 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -139.62 149.84 44.26 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.507 -0.477 . . . . 1.0 111.046 177.019 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.9 mmtt -100.5 122.35 43.08 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 105.577 -2.008 . . . . 1.0 105.577 178.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -119.18 119.37 60.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 C-N-CA 119.311 -0.956 . . . . 1.0 113.564 -175.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -108.53 122.58 47.34 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 113.912 -1.495 . . . . 1.0 108.451 177.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.7 110.58 22.69 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.173 0.511 . . . . 1.0 111.64 -178.483 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.69 -46.86 13.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.212 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.3 p -150.99 158.45 44.15 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.237 0.542 . . . . 1.0 111.188 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.05 141.99 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 115.492 -0.776 . . . . 1.0 110.001 -178.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.3 tptm . . . . . 0 N--CA 1.449 -0.503 0 CA-C-O 121.45 0.643 . . . . 1.0 111.929 -178.847 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 . . . . . 0 CA--C 1.508 -0.647 0 CA-C-O 121.571 0.7 . . . . 1.0 110.709 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.549 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 4.0 m-20 -59.6 -36.98 77.35 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.145 -1.057 . . . . 1.0 108.145 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.3 ttpm? -66.74 -50.54 62.43 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 113.762 -1.563 . . . . 1.0 111.867 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.4 t -65.14 -48.67 82.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 119.614 -0.834 . . . . 1.0 110.993 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.83 -38.32 90.66 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.35 -46.97 46.22 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 115.094 -0.957 . . . . 1.0 112.199 179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.436 ' O ' ' OG1' ' A' ' 17' ' ' THR . 91.9 mt-10 -57.69 -34.81 69.81 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 108.645 -0.872 . . . . 1.0 108.645 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.05 -31.01 44.38 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.853 -1.067 . . . . 1.0 110.364 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -61.68 -49.23 77.32 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.147 -179.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 mp -66.57 -38.23 86.63 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 119.69 -0.804 . . . . 1.0 109.304 178.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.436 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.8 m -61.85 -42.97 99.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.549 0.69 . . . . 1.0 109.275 178.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -74.21 -44.29 53.8 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-N 115.334 -0.848 . . . . 1.0 111.609 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -56.83 -50.16 73.24 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.111 0.481 . . . . 1.0 111.883 -178.874 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 9.5 ptmt -60.01 -28.63 67.88 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.221 -0.992 . . . . 1.0 109.545 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -81.87 -29.57 32.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.33 -0.85 . . . . 1.0 111.442 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -58.95 136.35 87.52 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 120.848 -0.341 . . . . 1.0 111.177 -179.152 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -55.75 148.47 55.29 Favored 'Trans proline' 0 N--CA 1.506 2.234 0 C-N-CA 122.48 2.12 . . . . 1.0 114.179 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.76 -18.59 11.56 Favored Glycine 0 N--CA 1.462 0.428 0 CA-C-N 115.097 -0.956 . . . . 1.0 111.397 178.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 41.4 t -85.08 136.27 23.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.04 0.448 . . . . 1.0 111.074 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.5 t -120.47 122.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 N-CA-C 107.716 -1.216 . . . . 1.0 107.716 176.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.27 147.0 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 121.414 0.626 . . . . 1.0 111.812 -178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 54.6 mt -115.79 163.77 19.86 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.758 -1.11 . . . . 1.0 110.779 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.22 -31.91 93.67 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.584 1.523 . . . . 1.0 111.974 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.4 m -68.14 -12.23 60.54 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 109.294 -0.632 . . . . 1.0 109.294 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.0 -1.57 68.05 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 109.365 -1.494 . . . . 1.0 109.365 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.451 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -79.98 134.39 36.25 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.434 -0.95 . . . . 1.0 108.434 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.451 ' H ' HD23 ' A' ' 32' ' ' LEU . 13.0 mp0 -124.84 145.54 49.73 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-N 115.891 -0.595 . . . . 1.0 110.929 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -139.39 150.11 44.9 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.521 0.677 . . . . 1.0 110.733 178.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -135.13 134.94 40.73 Favored 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 114.563 -1.199 . . . . 1.0 109.119 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -92.33 103.75 14.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 122.211 1.005 . . . . 1.0 111.742 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.3 mm -69.02 -41.74 81.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.039 -0.982 . . . . 1.0 109.197 179.438 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -142.04 128.0 19.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.109 -0.95 . . . . 1.0 109.942 -178.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.9 p -87.55 124.46 33.51 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.858 0.361 . . . . 1.0 110.101 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.402 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.19 -32.77 2.1 Favored Glycine 0 CA--C 1.517 0.218 0 N-CA-C 109.539 -1.424 . . . . 1.0 109.539 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.597 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 56.49 32.43 20.75 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.3 -0.45 . . . . 1.0 110.995 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.75 -163.01 38.66 Favored Glycine 0 C--N 1.329 0.167 0 CA-C-O 121.977 0.765 . . . . 1.0 111.536 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.602 ' O ' ' N ' ' A' ' 95' ' ' ALA . 29.2 m -69.43 -177.94 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.009 -1.095 . . . . 1.0 108.42 177.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.532 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.25 154.27 0.38 Allowed Pre-proline 0 C--N 1.316 -0.852 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.6 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 70.3 Cg_endo -87.79 152.78 7.36 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.827 2.351 . . . . 1.0 115.265 -175.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.53 178.98 51.54 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.612 -1.795 . . . . 1.0 108.612 176.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.621 ' H ' ' HZ2' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.95 -21.48 11.86 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.445 -0.502 . . . . 1.0 110.847 -179.666 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.4 m -107.64 -11.03 15.52 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 113.587 0.958 . . . . 1.0 113.587 -177.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -85.69 166.1 16.42 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 119.632 -0.827 . . . . 1.0 109.331 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.8 m -103.79 151.01 23.57 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.23 0.538 . . . . 1.0 110.43 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.421 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.3 p -128.06 157.56 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.421 0 CA-C-N 115.278 -0.874 . . . . 1.0 112.343 -176.338 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 98.1 m -124.07 120.54 32.68 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 107.923 -1.14 . . . . 1.0 107.923 177.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.7 m -149.23 163.18 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 114.698 1.37 . . . . 1.0 114.698 -175.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.4 152.61 35.52 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 106.384 -1.71 . . . . 1.0 106.384 173.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.484 ' H ' ' HB ' ' A' ' 68' ' ' THR . 33.6 p90 -164.09 160.73 21.89 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.528 1.307 . . . . 1.0 114.528 -177.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.415 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -123.37 128.46 49.91 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.953 -0.758 . . . . 1.0 108.953 175.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.8 137.69 14.45 Favored Glycine 0 N--CA 1.467 0.716 0 C-N-CA 120.925 -0.655 . . . . 1.0 112.138 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.451 ' HE ' ' HZ2' ' A' ' 127' ' ' LYS . 8.1 ptp180 -146.18 165.91 27.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.714 0.769 . . . . 1.0 112.574 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.2 mp -82.91 163.28 21.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 114.276 -1.329 . . . . 1.0 110.052 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.408 HD12 ' H ' ' A' ' 61' ' ' ASP . 0.2 OUTLIER -60.33 -26.2 36.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.155 -0.929 . . . . 1.0 110.276 178.08 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.408 ' H ' HD12 ' A' ' 60' ' ' ILE . 39.1 t0 -93.82 7.76 43.69 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.376 -1.284 . . . . 1.0 111.78 -177.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.83 -7.27 81.46 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 121.241 -0.504 . . . . 1.0 113.31 178.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -68.19 105.79 2.22 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 119.444 -0.902 . . . . 1.0 110.565 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 99.2 t -76.84 118.98 24.34 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.82 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -106.34 -20.22 13.45 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.016 -0.993 . . . . 1.0 111.897 -178.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.414 ' OD2' ' N ' ' A' ' 67' ' ' SER . 10.2 t70 -154.82 155.4 34.35 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.228 0.537 . . . . 1.0 111.972 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.415 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 92.9 p -157.4 159.8 37.75 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.341 -0.845 . . . . 1.0 111.57 178.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.512 ' O ' ' OG1' ' A' ' 71' ' ' THR . 89.9 m -155.25 -38.51 0.09 Allowed 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 115.567 -0.742 . . . . 1.0 110.01 -179.309 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -65.29 -25.37 67.61 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.638 -1.245 . . . . 1.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.6 mmtt -59.53 -45.63 91.2 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 176.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.512 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.8 OUTLIER -73.05 -33.36 65.64 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.505 -1.225 . . . . 1.0 108.194 177.423 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.55 18.93 67.27 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 111.497 -0.641 . . . . 1.0 111.497 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.9 115.37 60.4 Favored Pre-proline 0 N--CA 1.47 0.549 0 C-N-CA 120.936 -0.306 . . . . 1.0 110.919 -179.023 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -59.9 151.26 72.75 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 121.826 1.684 . . . . 1.0 114.185 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -120.68 148.63 43.67 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 113.915 -1.493 . . . . 1.0 107.498 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.15 124.57 49.89 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.335 0.588 . . . . 1.0 112.378 -178.245 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -133.32 149.34 51.9 Favored 'General case' 0 CA--C 1.493 -1.221 0 CA-C-N 115.286 -0.87 . . . . 1.0 109.707 178.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -90.75 130.36 36.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 105.09 -2.189 . . . . 1.0 105.09 174.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 38.2 t -57.23 -31.61 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 119.099 -1.04 . . . . 1.0 110.108 -176.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.1 t -73.67 -25.99 60.52 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.424 -0.51 . . . . 1.0 112.038 -178.27 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 56.2 mm-40 -102.26 -6.64 22.91 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 112.959 0.726 . . . . 1.0 112.959 -177.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.2 p -78.91 168.58 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 121.046 -0.262 . . . . 1.0 111.242 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.56 146.81 16.22 Favored Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 107.903 -1.147 . . . . 1.0 107.903 -178.133 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.53 -43.29 45.78 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 121.433 1.422 . . . . 1.0 112.648 -177.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.11 -47.34 91.25 Favored Glycine 0 C--N 1.317 -0.479 0 C-N-CA 119.747 -1.216 . . . . 1.0 110.946 -178.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 7.8 m95 -66.68 -32.3 73.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 113.973 -1.113 . . . . 1.0 110.748 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.5 m -51.37 -54.48 26.06 Favored 'General case' 0 C--N 1.322 -0.603 0 O-C-N 122.029 -0.42 . . . . 1.0 111.812 -178.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -72.7 -40.27 66.33 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.7 -44.06 97.0 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 114.432 1.271 . . . . 1.0 114.432 -176.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.4 mt -58.6 -41.56 86.11 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.147 0.499 . . . . 1.0 110.323 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -64.55 -23.89 67.42 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.368 -0.833 . . . . 1.0 110.401 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.524 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 88.6 mt -99.61 -14.84 18.81 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.964 -0.562 . . . . 1.0 111.718 -178.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 48.7 ttp -91.2 108.68 30.23 Favored Pre-proline 0 CA--C 1.548 0.892 0 O-C-N 123.224 0.327 . . . . 1.0 111.826 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.532 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 24.0 Cg_exo -63.79 149.1 91.51 Favored 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.586 2.191 . . . . 1.0 113.052 178.115 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.602 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.99 133.4 54.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.436 0.636 . . . . 1.0 110.76 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.61 -13.79 66.53 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 108.744 -1.742 . . . . 1.0 108.744 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.402 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 7.7 t -90.83 122.66 33.74 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.012 0.434 . . . . 1.0 109.839 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.8 m -97.07 115.07 26.82 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.402 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 31.7 m0 -115.76 167.95 10.48 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.657 0.741 . . . . 1.0 110.996 -178.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -128.44 134.74 48.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 106.453 -1.684 . . . . 1.0 106.453 175.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -130.91 139.03 52.14 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.654 0 CA-C-O 121.724 0.773 . . . . 1.0 109.601 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.3 OUTLIER -109.39 102.9 11.76 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.995 -1.854 . . . . 1.0 105.995 -177.408 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 t -90.33 116.23 65.9 Favored Pre-proline 0 N--CA 1.453 -0.302 0 N-CA-C 115.093 1.516 . . . . 1.0 115.093 -174.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.33 143.56 26.26 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.519 1.479 . . . . 1.0 109.601 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.7 p -53.7 -27.97 31.16 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.411 -0.515 . . . . 1.0 110.929 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.61 -29.48 65.6 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 110.194 -1.163 . . . . 1.0 110.194 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.9 mt -101.03 2.28 40.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.301 -0.45 . . . . 1.0 111.173 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -110.43 -108.34 0.35 Allowed 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.852 0.316 . . . . 1.0 111.852 -178.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -99.24 3.39 46.26 Favored 'General case' 0 C--N 1.339 0.118 0 N-CA-C 112.136 0.421 . . . . 1.0 112.136 -178.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.03 163.98 22.13 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.23 -0.509 . . . . 1.0 112.396 178.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.551 ' O ' ' N ' ' A' ' 121' ' ' ASN . 84.9 Cg_endo -75.77 -11.55 20.1 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 123.404 2.736 . . . . 1.0 111.955 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -98.62 167.17 10.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.065 -0.516 . . . . 1.0 109.729 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.613 ' HG ' ' N ' ' A' ' 120' ' ' PRO . 4.8 m -74.05 78.18 1.71 Allowed 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.301 -0.56 . . . . 1.0 109.842 178.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.1 t -93.68 60.44 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.084 -0.507 . . . . 1.0 109.949 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.59 177.09 40.42 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 120.224 -0.988 . . . . 1.0 112.295 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.97 -106.74 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 N-CA-C 111.293 -0.723 . . . . 1.0 111.293 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.31 -13.72 17.47 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 121.905 1.737 . . . . 1.0 110.522 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.532 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 3.5 mp -67.26 111.84 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 107.383 -1.34 . . . . 1.0 107.383 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.52 ' C ' ' HG ' ' A' ' 113' ' ' SER . . . -93.16 -167.1 38.54 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.473 -1.051 . . . . 1.0 110.473 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.613 ' N ' ' HG ' ' A' ' 113' ' ' SER . 29.5 Cg_endo -62.91 144.99 94.35 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.227 1.951 . . . . 1.0 112.7 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 47.33 56.78 6.5 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.221 0.452 . . . . 1.0 112.221 177.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 52.1 mm-40 -103.1 128.47 50.0 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 112.308 0.484 . . . . 1.0 112.308 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.8 m -93.94 128.4 40.23 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.191 -1.411 . . . . 1.0 107.191 176.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.41 147.95 31.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 121.482 0.658 . . . . 1.0 111.156 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.8 tt -126.79 144.21 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.64 0 N-CA-C 108.477 -0.935 . . . . 1.0 108.477 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.543 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.9 OUTLIER -135.0 151.95 51.28 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 120.499 -0.48 . . . . 1.0 111.305 177.81 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.479 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.7 mmtt -100.18 125.12 46.28 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.044 -2.206 . . . . 1.0 105.044 176.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.3 mt -118.61 118.49 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 119.153 -1.019 . . . . 1.0 112.331 -176.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -109.77 121.7 45.81 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 113.569 -1.65 . . . . 1.0 108.232 178.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.33 112.16 24.01 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 120.235 -0.586 . . . . 1.0 112.064 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -91.57 -47.1 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.68 -0.691 . . . . 1.0 110.974 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.9 t -150.02 158.12 43.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.833 0.349 . . . . 1.0 111.013 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.9 t -130.26 136.91 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 116.192 -0.458 . . . . 1.0 111.609 -178.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 20.3 tptt . . . . . 0 CA--C 1.533 0.318 0 CA-C-O 121.661 0.743 . . . . 1.0 110.075 178.49 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 CA--C 1.517 -0.3 0 CA-C-O 121.682 0.753 . . . . 1.0 110.593 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.567 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 7.0 m-20 -60.13 -34.44 73.53 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.223 -0.899 . . . . 1.0 108.599 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.543 ' NZ ' ' OE1' ' A' ' 13' ' ' GLU . 19.9 tttp -66.93 -51.23 57.76 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.164 -1.38 . . . . 1.0 111.649 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.1 t -67.41 -46.83 82.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.082 -0.647 . . . . 1.0 111.887 -177.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.67 -38.22 90.29 Favored 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 107.442 -1.318 . . . . 1.0 107.442 178.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.04 -44.35 61.37 Favored Glycine 0 CA--C 1.528 0.905 0 CA-C-N 114.845 -1.071 . . . . 1.0 112.44 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.543 ' OE1' ' NZ ' ' A' ' 9' ' ' LYS . 87.0 mt-10 -61.98 -32.06 72.48 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 119.342 -0.943 . . . . 1.0 108.72 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.17 -35.3 64.01 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.133 -0.94 . . . . 1.0 109.682 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -63.83 -50.3 69.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.213 -179.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.5 mp -71.11 -37.87 72.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 109.178 -0.675 . . . . 1.0 109.178 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.447 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 86.2 m -62.03 -43.08 99.59 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.791 -0.641 . . . . 1.0 109.482 179.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -75.02 -45.78 39.52 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.655 -0.702 . . . . 1.0 112.154 -179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 46.0 t30 -61.62 -44.62 96.66 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 113.126 0.787 . . . . 1.0 113.126 -177.545 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.68 -30.36 68.72 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 119.406 -0.917 . . . . 1.0 109.505 -179.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 26.2 m-80 -81.15 -29.49 34.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.667 -0.697 . . . . 1.0 111.782 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 18.7 mtmt -59.55 136.52 89.36 Favored Pre-proline 0 CA--C 1.545 0.774 0 C-N-CA 120.687 -0.405 . . . . 1.0 111.188 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.75 147.49 60.61 Favored 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 121.719 1.612 . . . . 1.0 112.807 178.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.76 -20.23 25.14 Favored Glycine 0 C--O 1.225 -0.417 0 CA-C-N 115.27 -0.877 . . . . 1.0 111.486 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.9 t -88.13 134.38 28.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.05 0.453 . . . . 1.0 110.751 -179.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 83.8 t -118.67 122.26 69.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 108.062 -1.088 . . . . 1.0 108.062 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.79 146.06 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.721 0.772 . . . . 1.0 111.789 -178.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.6 mt -114.77 162.29 24.53 Favored Pre-proline 0 N--CA 1.465 0.316 0 CA-C-N 114.418 -1.264 . . . . 1.0 110.612 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.16 -30.92 94.39 Favored 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 121.681 1.588 . . . . 1.0 111.277 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 m -66.99 -15.04 63.47 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.509 -0.769 . . . . 1.0 109.389 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.28 -0.72 66.39 Favored Glycine 0 CA--C 1.51 -0.221 0 N-CA-C 109.432 -1.467 . . . . 1.0 109.432 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.424 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -80.56 134.21 35.89 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.355 -0.98 . . . . 1.0 108.355 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.424 ' H ' HD23 ' A' ' 32' ' ' LEU . 20.2 mp0 -122.82 138.8 54.54 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.965 -0.561 . . . . 1.0 110.564 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -133.54 147.16 51.56 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.878 0.847 . . . . 1.0 111.0 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -134.1 136.48 43.93 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-N 114.174 -1.375 . . . . 1.0 109.724 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -92.79 105.73 17.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 122.366 1.079 . . . . 1.0 111.589 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 17.7 mm -70.54 -42.25 78.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.082 -0.963 . . . . 1.0 109.124 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.434 ' O ' ' OG ' ' A' ' 97' ' ' SER . 56.6 m-80 -143.07 124.48 14.72 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 113.998 -1.456 . . . . 1.0 109.09 -178.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.1 p -88.61 125.58 34.88 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.596 -0.52 . . . . 1.0 109.596 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.442 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.11 -33.76 1.93 Allowed Glycine 0 CA--C 1.516 0.129 0 N-CA-C 110.345 -1.102 . . . . 1.0 110.345 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.593 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 57.98 32.97 22.68 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 123.679 0.281 . . . . 1.0 111.441 179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.37 -161.08 36.92 Favored Glycine 0 C--N 1.335 0.502 0 CA-C-O 121.763 0.646 . . . . 1.0 111.929 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.584 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.8 m -68.74 -179.75 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 114.309 -0.945 . . . . 1.0 109.025 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.475 ' HZ2' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 178.0 155.84 0.52 Allowed Pre-proline 0 N--CA 1.476 0.831 0 CA-C-O 120.953 0.406 . . . . 1.0 110.886 179.234 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -85.02 167.03 11.09 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 123.433 2.756 . . . . 1.0 117.521 -173.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.482 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -102.91 165.62 16.29 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 113.571 -1.649 . . . . 1.0 109.566 177.021 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.516 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -44.97 -25.86 0.36 Allowed 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.657 -0.771 . . . . 1.0 111.886 -179.636 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 66.5 m -108.32 -5.57 16.7 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 112.759 0.651 . . . . 1.0 112.759 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.706 ' OD2' ' N ' ' A' ' 50' ' ' THR . 66.4 t0 -82.29 169.08 16.93 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.151 0.501 . . . . 1.0 110.841 -179.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.706 ' N ' ' OD2' ' A' ' 49' ' ' ASP . 7.6 m -110.91 142.7 42.63 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.656 -0.868 . . . . 1.0 108.656 177.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.12 160.34 30.82 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.534 0 CA-C-N 114.994 -1.003 . . . . 1.0 112.252 -175.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.1 m -124.69 120.3 31.43 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.873 -0.788 . . . . 1.0 108.873 178.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 75' ' ' ALA . 11.4 m -148.75 165.44 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 114.636 1.347 . . . . 1.0 114.636 -176.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -119.32 151.99 37.5 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 173.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.52 ' O ' ' N ' ' A' ' 68' ' ' THR . 33.6 p90 -164.96 164.83 20.6 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 118.425 -1.31 . . . . 1.0 113.973 -177.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.3 m -123.88 130.82 53.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 108.021 -1.103 . . . . 1.0 108.021 175.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.6 131.44 9.98 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.093 -1.203 . . . . 1.0 110.093 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.711 ' NE ' ' HZ3' ' A' ' 127' ' ' LYS . 5.1 ptp180 -145.77 169.29 18.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.977 0.894 . . . . 1.0 112.762 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.7 mp -84.59 165.89 17.61 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 113.912 -1.495 . . . . 1.0 109.941 177.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.429 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.06 -25.62 30.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.431 178.889 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -100.22 10.17 41.65 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.134 -0.939 . . . . 1.0 112.026 -177.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.94 -6.62 81.81 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 120.403 -0.903 . . . . 1.0 113.771 178.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.7 m -65.18 102.02 0.6 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 118.727 1.263 . . . . 1.0 109.182 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 88.4 t -74.86 117.4 18.99 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.408 0.623 . . . . 1.0 111.1 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -103.76 -15.63 15.67 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 114.903 -1.044 . . . . 1.0 112.092 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -159.24 153.91 24.47 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.27 -0.572 . . . . 1.0 110.375 177.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.0 p -157.19 158.55 36.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.826 -0.625 . . . . 1.0 111.802 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.2 m -153.07 -43.89 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.171 -0.922 . . . . 1.0 109.799 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.437 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -61.07 -28.02 68.78 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-N 115.888 -0.597 . . . . 1.0 109.66 179.42 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -57.24 -42.9 82.37 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 107.434 -1.321 . . . . 1.0 107.434 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.8 -33.47 60.13 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.299 -1.319 . . . . 1.0 107.558 176.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.02 17.75 73.87 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.314 -0.857 . . . . 1.0 112.118 178.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -98.13 116.35 65.61 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 121.265 -0.174 . . . . 1.0 110.557 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -58.54 150.52 68.44 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 121.501 1.467 . . . . 1.0 114.204 -179.464 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.483 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.77 145.82 48.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.354 -1.293 . . . . 1.0 108.472 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.3 t -103.8 131.3 51.12 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-O 121.453 0.644 . . . . 1.0 112.452 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -139.8 149.6 43.71 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.994 -1.003 . . . . 1.0 110.42 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -90.81 127.54 36.39 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 105.766 -1.938 . . . . 1.0 105.766 174.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.1 t -51.64 -29.2 9.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 C-N-CA 118.981 -1.088 . . . . 1.0 110.512 -176.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 48.3 t -77.68 -23.17 49.65 Favored 'General case' 0 CA--C 1.521 -0.171 0 C-N-CA 120.306 -0.558 . . . . 1.0 111.835 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -98.56 -6.6 29.77 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 113.728 1.01 . . . . 1.0 113.728 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -87.59 172.36 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 119.775 -0.77 . . . . 1.0 110.924 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.48 152.31 9.12 Favored Pre-proline 0 N--CA 1.478 0.954 0 N-CA-C 109.301 -0.629 . . . . 1.0 109.301 -176.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.26 -45.14 41.35 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.098 1.866 . . . . 1.0 112.061 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.77 -46.86 91.81 Favored Glycine 0 CA--C 1.522 0.512 0 C-N-CA 119.957 -1.116 . . . . 1.0 110.876 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 9.1 m95 -64.58 -35.44 80.98 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.342 -0.929 . . . . 1.0 111.495 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 30.7 m -50.78 -55.29 17.48 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.55 -0.46 . . . . 1.0 112.14 -177.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -73.27 -40.42 64.6 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 112.365 0.506 . . . . 1.0 112.365 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.47 -45.76 84.45 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 114.154 1.168 . . . . 1.0 114.154 -178.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.1 mt -57.84 -41.59 82.66 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.197 0.522 . . . . 1.0 110.629 -177.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.9 mt-30 -65.43 -19.1 65.79 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.277 -0.874 . . . . 1.0 111.346 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.502 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 57.5 mt -106.01 -13.4 15.48 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.116 -0.493 . . . . 1.0 110.7 -178.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.0 ttp -88.91 109.13 28.02 Favored Pre-proline 0 CA--C 1.553 1.063 0 N-CA-C 112.101 0.408 . . . . 1.0 112.101 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.475 ' HG3' ' HZ2' ' A' ' 44' ' ' LYS . 22.3 Cg_exo -64.58 149.53 89.72 Favored 'Trans proline' 0 N--CA 1.504 2.11 0 C-N-CA 122.979 2.453 . . . . 1.0 113.296 178.346 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.584 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.33 132.58 50.58 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.495 0.664 . . . . 1.0 111.154 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.76 -18.21 57.65 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 108.505 -1.838 . . . . 1.0 108.505 -178.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.442 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 9.3 t -86.02 128.64 34.9 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 109.944 -0.391 . . . . 1.0 109.944 179.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.7 m -103.33 114.8 29.36 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 115.594 -0.73 . . . . 1.0 109.696 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . 0.502 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -114.14 167.96 10.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.781 0.8 . . . . 1.0 111.336 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 80.7 mt-10 -128.46 124.5 36.33 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.171 -1.418 . . . . 1.0 107.171 175.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.6 pt -120.68 135.49 60.72 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.868 0 N-CA-C 108.735 -0.839 . . . . 1.0 108.735 179.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.64 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -107.12 104.0 13.53 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.725 -1.954 . . . . 1.0 105.725 -177.258 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 t -90.51 115.53 64.36 Favored Pre-proline 0 C--N 1.32 -0.675 0 N-CA-C 115.256 1.576 . . . . 1.0 115.256 -173.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -51.35 146.03 25.91 Favored 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 121.941 1.761 . . . . 1.0 110.569 176.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.0 p -53.58 -24.51 13.95 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.456 -178.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -78.56 -29.5 52.31 Favored Glycine 0 N--CA 1.46 0.268 0 N-CA-C 110.697 -0.961 . . . . 1.0 110.697 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.2 mt -102.16 2.77 37.71 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.523 -0.338 . . . . 1.0 110.49 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.26 -102.43 0.35 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 110.11 -0.33 . . . . 1.0 110.11 -178.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -108.96 5.46 24.33 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.753 1.02 . . . . 1.0 113.753 -177.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.57 163.05 17.4 Favored Glycine 0 N--CA 1.473 1.128 0 C-N-CA 121.285 -0.483 . . . . 1.0 113.209 177.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.553 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.1 Cg_endo -71.13 -18.67 30.55 Favored 'Trans proline' 0 N--CA 1.494 1.527 0 C-N-CA 123.535 2.823 . . . . 1.0 112.37 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -104.01 171.56 7.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.229 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.633 ' HG ' ' N ' ' A' ' 120' ' ' PRO . 2.0 m -73.64 97.28 2.63 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.926 -0.579 . . . . 1.0 110.171 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.6 t -109.55 61.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.596 -0.274 . . . . 1.0 110.873 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 168.36 -168.53 40.98 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 120.892 -0.671 . . . . 1.0 111.715 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.12 -104.9 0.04 OUTLIER Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.457 -0.657 . . . . 1.0 111.457 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -58.9 -19.05 45.5 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.237 1.958 . . . . 1.0 111.621 -178.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 3.8 mp -66.56 112.83 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 119.901 -0.72 . . . . 1.0 109.166 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.545 ' C ' ' HG ' ' A' ' 113' ' ' SER . . . -90.65 -164.84 39.93 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.679 -0.968 . . . . 1.0 110.679 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.633 ' N ' ' HG ' ' A' ' 113' ' ' SER . 23.5 Cg_endo -63.22 152.05 81.74 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.359 2.039 . . . . 1.0 113.272 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.553 ' N ' ' O ' ' A' ' 111' ' ' PRO . 11.9 t30 37.17 53.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.807 177.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.423 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 41.7 mm-40 -97.36 132.29 43.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.29 0.567 . . . . 1.0 111.768 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 84.6 m -95.66 127.44 41.7 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.451 -1.314 . . . . 1.0 107.451 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.82 140.79 47.31 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.338 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 2.2 tt -119.43 147.05 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 N-CA-C 108.435 -0.95 . . . . 1.0 108.435 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.626 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -134.4 145.53 49.01 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 121.12 0.486 . . . . 1.0 110.324 177.314 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.711 ' HZ3' ' NE ' ' A' ' 58' ' ' ARG . 5.5 mmtt -99.61 121.83 41.76 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 104.673 -2.343 . . . . 1.0 104.673 178.394 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -116.09 120.36 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 119.438 -0.905 . . . . 1.0 113.176 -175.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.4 t-160 -110.3 123.18 49.34 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 113.927 -1.488 . . . . 1.0 108.486 178.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.64 113.17 24.79 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 112.384 0.513 . . . . 1.0 112.384 -178.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.4 mp -96.25 -46.98 13.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 115.775 -0.648 . . . . 1.0 111.301 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.95 155.86 42.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.168 0.509 . . . . 1.0 111.574 -178.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.1 t -128.96 142.19 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.706 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.401 ' C ' ' OD2' ' A' ' 49' ' ' ASP . 3.9 tptt . . . . . 0 N--CA 1.453 -0.294 0 CA-C-O 121.712 0.768 . . . . 1.0 110.765 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 . . . . . 0 C--O 1.222 -0.372 0 CA-C-O 121.428 0.633 . . . . 1.0 110.867 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 2.3 m-20 -62.74 -35.76 80.83 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.094 -1.076 . . . . 1.0 108.094 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 13' ' ' GLU . 76.8 tttt -65.72 -49.45 68.42 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.42 -1.718 . . . . 1.0 112.095 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.0 t -66.36 -48.67 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 C-N-CA 119.79 -0.764 . . . . 1.0 110.9 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.61 -36.22 82.05 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.799 -1.185 . . . . 1.0 107.799 178.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.59 -41.81 42.38 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.836 -1.074 . . . . 1.0 112.213 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.472 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.7 mt-10 -62.79 -31.35 72.3 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 119.464 -0.895 . . . . 1.0 108.634 179.54 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.55 -34.76 53.72 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 115.138 -0.937 . . . . 1.0 109.925 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -60.84 -49.07 78.96 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.499 -1.228 . . . . 1.0 111.11 -178.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.1 mp -70.18 -36.76 74.87 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.195 -0.602 . . . . 1.0 109.495 178.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 96.3 m -61.66 -44.36 97.1 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.593 -0.731 . . . . 1.0 109.715 179.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -76.6 -44.83 32.73 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 114.985 -1.007 . . . . 1.0 112.517 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.3 t30 -60.07 -44.99 94.36 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 113.089 0.774 . . . . 1.0 113.089 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -61.02 -28.5 69.09 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 119.969 -0.693 . . . . 1.0 109.761 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -82.99 -28.08 29.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.571 -0.741 . . . . 1.0 111.235 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.4 mtmt -59.25 139.01 88.45 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 120.834 -0.346 . . . . 1.0 111.478 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_exo -56.5 148.54 62.56 Favored 'Trans proline' 0 N--CA 1.502 2.008 0 C-N-CA 122.167 1.911 . . . . 1.0 113.353 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.415 ' HA2' ' HZ1' ' A' ' 35' ' ' LYS . . . 80.78 -18.84 8.25 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.247 -0.888 . . . . 1.0 111.592 179.209 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.46 137.29 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.444 . . . . 1.0 109.964 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.6 t -122.98 119.62 58.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 108.242 -1.021 . . . . 1.0 108.242 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.93 145.44 8.12 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 CA-C-O 121.689 0.757 . . . . 1.0 111.429 -179.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.9 mt -111.92 165.11 13.57 Favored Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 114.189 -1.369 . . . . 1.0 110.481 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -61.21 -29.43 86.63 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.764 1.643 . . . . 1.0 111.048 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -68.34 -16.88 64.1 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 115.678 -0.692 . . . . 1.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.74 -7.0 60.85 Favored Glycine 0 CA--C 1.517 0.196 0 N-CA-C 110.142 -1.183 . . . . 1.0 110.142 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.434 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.38 134.52 38.42 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 179.528 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.434 ' H ' HD23 ' A' ' 32' ' ' LEU . 26.2 mp0 -121.24 142.91 49.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.454 -0.339 . . . . 1.0 110.641 179.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -136.97 148.13 46.74 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-O 121.56 0.695 . . . . 1.0 110.75 178.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . 0.415 ' HZ1' ' HA2' ' A' ' 24' ' ' GLY . 0.3 OUTLIER -135.27 134.74 40.27 Favored 'General case' 0 N--CA 1.44 -0.948 0 CA-C-N 114.48 -1.236 . . . . 1.0 109.88 -179.174 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 p -93.3 105.34 16.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 122.063 0.935 . . . . 1.0 111.472 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.9 mm -70.33 -41.76 78.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.177 -0.92 . . . . 1.0 109.303 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -145.46 119.75 9.57 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.797 -1.092 . . . . 1.0 110.48 -177.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 p -80.32 123.85 28.34 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.264 0.554 . . . . 1.0 110.352 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 -29.24 4.07 Favored Glycine 0 CA--C 1.519 0.286 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . 0.587 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.6 m120 54.73 32.12 16.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.756 -0.722 . . . . 1.0 111.412 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.95 -163.26 38.78 Favored Glycine 0 C--N 1.33 0.247 0 CA-C-O 121.923 0.735 . . . . 1.0 111.548 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.3 m -68.28 -177.77 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 114.154 -1.023 . . . . 1.0 108.615 178.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . 0.425 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.36 154.47 0.39 Allowed Pre-proline 0 C--N 1.317 -0.806 0 N-CA-C 109.454 -0.573 . . . . 1.0 109.454 179.631 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -88.02 159.64 7.28 Favored 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 123.137 2.558 . . . . 1.0 116.355 -174.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.452 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -91.53 175.02 38.69 Favored Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 109.06 -1.616 . . . . 1.0 109.06 176.375 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.534 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.47 -23.91 4.48 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.112 -0.544 . . . . 1.0 110.69 -179.691 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.441 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 40.6 m -107.72 -10.09 15.68 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 113.983 1.105 . . . . 1.0 113.983 -177.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.452 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.7 m-20 -84.7 165.51 17.81 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 119.618 -0.833 . . . . 1.0 108.835 179.724 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -103.36 148.93 25.27 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.515 -0.55 . . . . 1.0 109.515 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -125.62 162.44 28.65 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 CA-C-N 115.87 -0.605 . . . . 1.0 112.201 -176.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 87.8 m -130.55 120.37 23.95 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.039 -1.097 . . . . 1.0 108.039 177.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 9.9 m -148.51 164.99 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.004 1.113 . . . . 1.0 114.004 -176.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.4 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 10.4 mt-10 -118.61 152.3 36.3 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 106.425 -1.694 . . . . 1.0 106.425 174.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.473 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 34.1 p90 -162.1 159.57 26.31 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 114.856 1.428 . . . . 1.0 114.856 -177.576 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.5 m -121.24 129.74 53.33 Favored 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.157 -0.929 . . . . 1.0 108.988 176.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.5 133.9 11.78 Favored Glycine 0 N--CA 1.47 0.935 0 N-CA-C 111.185 -0.766 . . . . 1.0 111.185 -178.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -145.54 166.43 25.73 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.69 0.757 . . . . 1.0 112.101 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -87.46 160.08 18.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.578 -1.192 . . . . 1.0 111.272 178.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.444 HD11 ' N ' ' A' ' 60' ' ' ILE . 0.2 OUTLIER -55.12 -26.01 17.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 114.462 -1.244 . . . . 1.0 110.465 177.811 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -96.04 5.63 50.71 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.49 -1.232 . . . . 1.0 111.075 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.73 -9.51 77.47 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.021 -0.536 . . . . 1.0 113.642 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -61.13 97.01 0.06 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 118.331 1.066 . . . . 1.0 110.634 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 98.2 t -68.73 125.69 27.1 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 C-N-CA 119.639 -0.824 . . . . 1.0 108.854 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.401 ' CD2' ' CD1' ' A' ' 118' ' ' ILE . 19.4 p90 -117.38 -15.53 10.33 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.163 -0.926 . . . . 1.0 111.696 -178.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -154.6 149.87 27.1 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.249 0.547 . . . . 1.0 111.735 178.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -155.87 151.32 26.97 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.395 -0.821 . . . . 1.0 111.776 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.475 ' O ' ' OG1' ' A' ' 71' ' ' THR . 99.5 m -148.04 -37.8 0.19 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.201 -0.908 . . . . 1.0 110.157 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.43 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 1.1 pp20? -66.62 -27.37 67.65 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 116.14 -0.482 . . . . 1.0 110.04 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -59.4 -43.39 92.99 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 107.744 -1.206 . . . . 1.0 107.744 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 18.5 p -73.01 -32.88 65.42 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 114.876 -1.056 . . . . 1.0 108.523 176.747 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.36 17.68 66.08 Favored Glycine 0 CA--C 1.522 0.484 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.977 178.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.4 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -100.29 114.59 65.76 Favored Pre-proline 0 N--CA 1.471 0.602 0 C-N-CA 120.448 -0.501 . . . . 1.0 111.164 -179.591 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -61.7 152.87 71.25 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.012 1.808 . . . . 1.0 114.097 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.08 145.19 48.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 113.681 -1.599 . . . . 1.0 107.847 178.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.516 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 2.7 t -105.59 136.36 45.32 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.267 0.556 . . . . 1.0 112.482 -178.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.516 ' CD2' ' O ' ' A' ' 76' ' ' THR . 19.5 m-85 -150.07 151.25 32.92 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.546 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -87.93 128.32 35.37 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 107.652 -1.24 . . . . 1.0 107.652 175.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.5 t -54.86 -32.28 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 120.135 -0.626 . . . . 1.0 110.899 -177.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -72.48 -26.93 61.98 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.8 -0.76 . . . . 1.0 112.063 -177.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -98.52 -11.1 22.59 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 112.789 0.662 . . . . 1.0 112.789 -178.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -71.54 169.07 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.798 0.666 . . . . 1.0 112.798 -175.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -51.69 145.76 15.19 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 107.134 -1.432 . . . . 1.0 107.134 -178.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -49.73 -44.86 34.32 Favored 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 121.19 1.26 . . . . 1.0 112.654 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.25 91.99 Favored Glycine 0 C--N 1.317 -0.523 0 C-N-CA 120.007 -1.092 . . . . 1.0 111.295 -179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -63.76 -31.26 72.38 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 114.028 -1.086 . . . . 1.0 111.523 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 99.4 m -56.4 -53.54 56.18 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 121.913 -0.492 . . . . 1.0 111.655 -178.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -71.76 -38.49 70.38 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.284 0.846 . . . . 1.0 113.284 -177.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -64.01 -44.1 93.64 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 114.477 1.288 . . . . 1.0 114.477 -176.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 26.9 mt -58.71 -37.99 77.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.275 0.559 . . . . 1.0 110.778 -177.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -64.92 -24.1 67.42 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.294 -0.866 . . . . 1.0 111.345 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 27.6 mt -102.06 -18.96 15.36 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.173 -0.467 . . . . 1.0 111.212 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.4 ttp -81.34 109.36 13.8 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 112.639 0.607 . . . . 1.0 112.639 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.428 ' O ' ' OG ' ' A' ' 97' ' ' SER . 17.0 Cg_exo -66.39 148.32 84.04 Favored 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 122.679 2.253 . . . . 1.0 113.116 178.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.592 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.91 131.48 46.8 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-O 121.606 0.717 . . . . 1.0 111.811 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.71 -16.51 60.87 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 108.177 -1.969 . . . . 1.0 108.177 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.428 ' OG ' ' O ' ' A' ' 94' ' ' PRO . 5.7 p -88.46 139.13 30.79 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.089 -0.556 . . . . 1.0 110.139 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 50.9 m -110.27 117.43 33.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.12 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -117.49 169.64 9.37 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.95 0.881 . . . . 1.0 110.546 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -130.24 132.65 46.06 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.935 -1.506 . . . . 1.0 106.935 175.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.48 137.13 58.62 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 108.603 -0.888 . . . . 1.0 108.603 179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.64 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.65 102.82 11.85 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 105.83 -1.915 . . . . 1.0 105.83 -177.8 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.6 t -89.94 115.1 63.11 Favored Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 114.516 1.302 . . . . 1.0 114.516 -174.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -51.57 144.33 33.33 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 121.072 1.181 . . . . 1.0 109.696 176.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 87.6 p -49.97 -31.98 13.9 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.377 -0.529 . . . . 1.0 110.959 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.71 -31.78 70.52 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.558 -0.617 . . . . 1.0 111.558 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.09 3.09 43.78 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 110.548 -0.167 . . . . 1.0 110.548 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.84 -109.06 0.33 Allowed 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 120.736 0.303 . . . . 1.0 111.256 -178.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -98.32 -4.66 34.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 114.379 1.251 . . . . 1.0 114.379 -176.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.32 172.68 18.95 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 120.497 -0.859 . . . . 1.0 113.174 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.561 ' O ' ' N ' ' A' ' 121' ' ' ASN . 71.9 Cg_endo -73.75 -31.4 8.49 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 123.649 2.899 . . . . 1.0 112.388 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -82.23 170.81 14.98 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.365 0.602 . . . . 1.0 111.435 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.418 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 7.3 m -79.34 88.3 4.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.279 -0.873 . . . . 1.0 109.039 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.3 t -97.88 55.26 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.341 -0.39 . . . . 1.0 111.383 -178.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 173.37 -175.25 46.18 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 120.509 -0.853 . . . . 1.0 112.087 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.34 -103.34 0.01 OUTLIER Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.268 -0.733 . . . . 1.0 111.268 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -62.13 -15.91 47.04 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.478 2.119 . . . . 1.0 110.518 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.502 ' CG2' ' OE2' ' A' ' 122' ' ' GLU . 4.6 mp -66.39 115.03 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.376 -1.342 . . . . 1.0 107.376 178.44 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -97.26 -157.79 30.82 Favored Glycine 0 C--O 1.213 -1.186 0 N-CA-C 110.814 -0.914 . . . . 1.0 110.814 -178.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.48 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 53.4 Cg_endo -71.02 147.58 55.08 Favored 'Trans proline' 0 C--N 1.297 -2.156 0 C-N-CA 121.51 1.474 . . . . 1.0 112.982 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.561 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 39.48 60.97 1.47 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 113.216 0.821 . . . . 1.0 113.216 177.503 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.67 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -112.69 140.35 47.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.038 0.447 . . . . 1.0 110.611 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 85.5 m -93.93 127.73 39.86 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.1 -1.074 . . . . 1.0 108.1 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -108.85 136.41 48.45 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.516 -0.55 . . . . 1.0 109.516 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.8 tt -117.6 146.87 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 108.706 -0.849 . . . . 1.0 108.706 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 126' ' ' PHE . 4.0 m-85 -135.8 149.49 49.12 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.236 -0.586 . . . . 1.0 111.334 178.137 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.473 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 9.5 mmtt -99.46 124.57 44.73 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 104.948 -2.242 . . . . 1.0 104.948 177.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.9 mt -115.77 118.37 58.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 C-N-CA 119.167 -1.013 . . . . 1.0 111.9 -177.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -110.39 123.05 49.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.655 -1.611 . . . . 1.0 108.484 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.76 112.95 24.55 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 112.544 0.572 . . . . 1.0 112.544 -177.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.405 HD13 ' N ' ' A' ' 131' ' ' ILE . 4.4 mp -94.49 -49.17 12.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 CA-C-N 115.749 -0.66 . . . . 1.0 111.17 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.6 p -145.32 157.39 44.06 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.014 0.435 . . . . 1.0 110.601 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.3 t -130.09 137.56 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.288 -0.414 . . . . 1.0 110.993 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 tptt . . . . . 0 N--CA 1.449 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.541 178.64 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.121 -0.696 . . . . 1.0 109.121 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -61.92 -18.49 60.45 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.131 -0.692 . . . . 1.0 109.131 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -49.57 -41.05 40.59 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.361 -0.978 . . . . 1.0 108.361 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 0.3 OUTLIER -64.68 -35.94 82.67 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.239 -179.38 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.62 -38.02 59.44 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 116.191 -0.459 . . . . 1.0 110.384 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -65.08 -37.48 87.64 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.603 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -66.9 -51.4 55.87 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.861 0.839 . . . . 1.0 110.633 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.611 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 3.7 m-20 -58.55 -38.42 77.79 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 107.528 -1.286 . . . . 1.0 107.528 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -63.93 -50.98 66.55 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 113.125 -1.852 . . . . 1.0 111.806 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 70.7 t -73.82 -48.62 38.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 119.812 -0.755 . . . . 1.0 111.713 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.45 ' O ' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -60.36 -40.63 91.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.827 -1.175 . . . . 1.0 107.827 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.74 -48.07 70.4 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.374 -0.83 . . . . 1.0 112.133 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.473 ' O ' ' OG1' ' A' ' 17' ' ' THR . 95.5 mt-10 -61.71 -31.25 71.39 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.01 -0.737 . . . . 1.0 109.01 178.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.22 -33.79 43.44 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.121 -0.945 . . . . 1.0 109.957 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' O ' ' A' ' 11' ' ' LYS . 64.3 t80 -61.14 -50.78 71.81 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 114.445 -1.252 . . . . 1.0 110.414 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mp -68.44 -41.59 80.07 Favored 'General case' 0 CA--C 1.513 -0.452 0 C-N-CA 119.963 -0.695 . . . . 1.0 109.649 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 29.8 m -62.14 -41.31 98.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.569 -0.741 . . . . 1.0 109.474 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -75.74 -45.29 37.38 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.584 -0.734 . . . . 1.0 111.637 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.1 t30 -61.34 -45.03 96.12 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 113.135 0.791 . . . . 1.0 113.135 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -57.68 -31.36 66.27 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 119.305 -0.958 . . . . 1.0 108.833 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -80.74 -31.48 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.72 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 41.2 mtmt -56.97 139.85 78.02 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 120.19 -0.604 . . . . 1.0 110.905 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -56.27 148.49 60.5 Favored 'Trans proline' 0 N--CA 1.502 2.0 0 C-N-CA 122.069 1.846 . . . . 1.0 113.879 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.1 -19.5 10.06 Favored Glycine 0 C--O 1.227 -0.318 0 CA-C-N 114.937 -1.029 . . . . 1.0 111.992 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.5 t -83.35 138.17 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.123 0.487 . . . . 1.0 110.929 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.5 t -122.35 122.41 66.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.8 p -96.76 146.22 7.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.653 0 CA-C-O 121.569 0.699 . . . . 1.0 111.847 -178.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.7 mt -114.08 166.09 12.23 Favored Pre-proline 0 C--O 1.232 0.146 0 CA-C-N 114.484 -1.235 . . . . 1.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -62.07 -30.46 82.71 Favored 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 121.985 1.79 . . . . 1.0 111.499 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 m -68.84 -13.3 62.33 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.955 -0.566 . . . . 1.0 109.811 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.96 -1.56 68.14 Favored Glycine 0 CA--C 1.517 0.199 0 N-CA-C 109.811 -1.316 . . . . 1.0 109.811 -179.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.9 tm? -80.95 133.98 35.62 Favored 'General case' 0 CA--C 1.518 -0.258 0 N-CA-C 108.591 -0.892 . . . . 1.0 108.591 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.421 ' H ' HD23 ' A' ' 32' ' ' LEU . 18.9 mp0 -122.42 138.42 54.54 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 116.448 -0.342 . . . . 1.0 111.087 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -133.56 145.5 50.15 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.525 0.679 . . . . 1.0 111.054 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -127.66 132.82 49.66 Favored 'General case' 0 CA--C 1.505 -0.751 0 CA-C-N 114.552 -1.204 . . . . 1.0 109.499 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.57 104.26 14.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 122.2 1.0 . . . . 1.0 112.122 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.8 mm -70.24 -41.69 78.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.027 -0.988 . . . . 1.0 108.523 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -143.11 128.34 18.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 114.595 -1.184 . . . . 1.0 109.495 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.0 p -88.12 131.84 34.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.746 0.308 . . . . 1.0 110.239 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.21 -35.44 0.81 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.624 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 57.23 30.66 18.77 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.251 -0.474 . . . . 1.0 111.169 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.12 -161.73 37.55 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.828 0.682 . . . . 1.0 111.756 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 25.9 m -69.01 -178.4 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.153 -1.023 . . . . 1.0 109.576 178.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.477 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.62 154.26 0.4 Allowed Pre-proline 0 C--N 1.32 -0.711 0 O-C-N 123.682 0.614 . . . . 1.0 109.523 179.554 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -87.83 157.81 7.46 Favored 'Trans proline' 0 N--CA 1.5 1.894 0 C-N-CA 123.363 2.709 . . . . 1.0 117.242 -174.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.457 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.84 176.17 44.05 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 109.205 -1.558 . . . . 1.0 109.205 176.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.5 -25.46 6.6 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.189 -0.506 . . . . 1.0 112.055 -179.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -108.61 -8.42 15.47 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 112.834 0.679 . . . . 1.0 112.834 -177.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.457 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.3 m-20 -82.96 166.47 18.82 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.327 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.7 m -105.35 150.59 25.08 Favored 'General case' 0 CA--C 1.511 -0.551 0 CA-C-O 121.334 0.588 . . . . 1.0 110.146 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -128.94 160.68 39.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.19 -0.914 . . . . 1.0 112.009 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.8 m -127.69 119.87 26.78 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.125 -1.065 . . . . 1.0 108.125 177.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.48 ' O ' ' N ' ' A' ' 75' ' ' ALA . 7.2 m -148.9 164.74 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 114.507 1.299 . . . . 1.0 114.507 -176.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -118.22 150.74 38.92 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 106.305 -1.739 . . . . 1.0 106.305 174.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.552 ' O ' ' N ' ' A' ' 68' ' ' THR . 32.5 p90 -163.32 162.9 25.34 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 115.09 1.515 . . . . 1.0 115.09 -177.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -126.27 129.47 48.97 Favored 'General case' 0 C--O 1.217 -0.608 0 CA-C-N 115.086 -0.961 . . . . 1.0 108.515 175.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.76 134.61 12.09 Favored Glycine 0 N--CA 1.471 1.011 0 N-CA-C 111.472 -0.651 . . . . 1.0 111.472 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.53 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 8.6 ptp85 -147.03 167.43 24.05 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.701 0.763 . . . . 1.0 112.389 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.5 mp -84.46 165.06 18.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 114.349 -1.296 . . . . 1.0 110.236 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.79 -26.55 38.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.265 -0.879 . . . . 1.0 110.524 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -92.0 3.18 55.81 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.044 -1.434 . . . . 1.0 111.701 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.24 -4.09 76.97 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 121.337 -0.458 . . . . 1.0 113.177 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.3 m -68.01 104.06 1.65 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 118.141 0.97 . . . . 1.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.6 t -76.43 120.04 25.79 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.079 0.466 . . . . 1.0 110.153 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -109.28 -11.79 14.84 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 115.231 -0.895 . . . . 1.0 112.308 -178.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.496 ' CB ' H431 ' A' ' 138' ' ' RAP . 11.5 t70 -161.99 153.08 17.99 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.316 -0.554 . . . . 1.0 111.511 178.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.429 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 94.4 p -159.23 154.21 24.97 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.41 0.624 . . . . 1.0 112.558 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.552 ' N ' ' O ' ' A' ' 55' ' ' TYR . 62.3 m -150.15 -40.74 0.13 Allowed 'General case' 0 C--O 1.223 -0.337 0 CA-C-N 115.024 -0.989 . . . . 1.0 110.305 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.41 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.6 pp20? -62.22 -26.62 68.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.241 -0.583 . . . . 1.0 109.637 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.9 mmmt -57.0 -42.91 81.17 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.426 -1.324 . . . . 1.0 107.426 178.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.549 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.4 p -73.28 -33.72 65.39 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.732 -1.122 . . . . 1.0 108.365 176.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.13 17.04 75.27 Favored Glycine 0 C--N 1.334 0.425 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.359 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.6 mttm -101.44 116.7 63.3 Favored Pre-proline 0 N--CA 1.469 0.524 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.693 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -60.08 152.76 63.06 Favored 'Trans proline' 0 N--CA 1.485 0.982 0 C-N-CA 121.786 1.657 . . . . 1.0 114.377 -178.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -122.29 147.26 46.45 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 113.827 -1.533 . . . . 1.0 107.548 177.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.46 128.12 52.3 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 121.072 0.463 . . . . 1.0 112.014 -179.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.517 ' CD2' ' H31' ' A' ' 138' ' ' RAP . 25.5 m-85 -136.06 150.59 49.22 Favored 'General case' 0 CA--C 1.493 -1.24 0 CA-C-O 121.797 0.808 . . . . 1.0 110.844 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -94.14 123.63 37.65 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 105.828 -1.915 . . . . 1.0 105.828 174.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.3 t -49.44 -25.61 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.795 -0.638 . . . . 1.0 110.663 -176.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 15.3 t -78.11 -24.33 47.53 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 120.308 -0.557 . . . . 1.0 112.189 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.494 ' O ' ' H34' ' A' ' 138' ' ' RAP . 92.7 mm-40 -96.6 -10.28 27.48 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.112 0.412 . . . . 1.0 112.112 -179.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.585 ' CG2' H31A ' A' ' 138' ' ' RAP . 0.5 OUTLIER -79.68 166.8 2.4 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 N-CA-C 112.59 0.589 . . . . 1.0 112.59 -176.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -57.24 146.7 60.84 Favored Pre-proline 0 CA--C 1.545 0.753 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -48.88 -46.11 26.05 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.686 1.591 . . . . 1.0 113.03 -178.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.68 -47.56 87.66 Favored Glycine 0 C--N 1.319 -0.398 0 N-CA-C 109.753 -1.339 . . . . 1.0 109.753 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.588 ' CD2' ' H41' ' A' ' 138' ' ' RAP . 7.3 m95 -64.4 -36.23 83.49 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.147 -1.027 . . . . 1.0 110.199 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.5 m -51.17 -54.5 24.87 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.313 -0.403 . . . . 1.0 111.25 -177.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -72.96 -41.62 64.21 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.604 0.594 . . . . 1.0 112.604 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.51 -46.46 83.78 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 113.615 0.969 . . . . 1.0 113.615 -177.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 38.3 mt -58.85 -41.58 87.29 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 109.192 -0.67 . . . . 1.0 109.192 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.6 mt-30 -62.95 -23.85 67.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 114.938 -1.028 . . . . 1.0 110.696 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.448 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 83.9 mt -103.34 -12.96 16.88 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.255 -0.429 . . . . 1.0 111.327 -179.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.8 ttp -87.6 108.66 21.34 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-O 119.349 -0.358 . . . . 1.0 111.899 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.477 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.44 147.88 83.19 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 122.377 2.051 . . . . 1.0 112.365 178.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -66.46 132.37 48.12 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.519 -0.764 . . . . 1.0 111.438 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 99.52 -18.81 55.73 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 108.567 -1.813 . . . . 1.0 108.567 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.1 p -88.63 136.45 32.99 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 120.959 0.409 . . . . 1.0 110.387 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 90.5 m -108.27 114.39 28.22 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 115.803 -0.635 . . . . 1.0 109.708 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.448 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.1 m0 -115.4 167.6 10.72 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 121.596 0.712 . . . . 1.0 111.228 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 85.2 mt-10 -127.37 128.11 45.33 Favored 'General case' 0 CA--C 1.508 -0.639 0 N-CA-C 106.673 -1.603 . . . . 1.0 106.673 175.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.6 pt -123.32 138.07 54.5 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.6 0 CA-C-O 121.894 0.855 . . . . 1.0 110.27 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.658 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.44 103.9 13.13 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.957 -1.868 . . . . 1.0 105.957 -177.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.7 t -90.42 115.4 64.02 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 115.076 1.51 . . . . 1.0 115.076 -174.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -51.15 141.96 36.97 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 121.323 1.348 . . . . 1.0 109.858 175.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.3 p -48.46 -34.28 10.81 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.149 -0.62 . . . . 1.0 110.943 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.87 -32.32 80.72 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.144 -0.782 . . . . 1.0 111.144 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 68.0 mt -98.55 1.67 46.75 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 121.393 -0.123 . . . . 1.0 110.74 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.8 -113.39 0.3 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.052 0.39 . . . . 1.0 112.052 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.655 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 58.4 m-85 -98.2 3.77 48.95 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 112.487 0.551 . . . . 1.0 112.487 -177.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 109.49 162.75 19.67 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 121.014 -0.612 . . . . 1.0 112.768 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -74.75 -9.29 21.04 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 123.556 2.837 . . . . 1.0 111.695 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -103.63 166.59 10.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.126 -0.488 . . . . 1.0 109.839 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.57 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -72.3 84.99 1.07 Allowed 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.0 t -100.72 62.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.985 0.422 . . . . 1.0 110.513 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 168.36 -179.98 41.09 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 111.502 -0.639 . . . . 1.0 111.502 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.84 -103.98 0.01 OUTLIER Glycine 0 CA--C 1.535 1.322 0 N-CA-C 110.992 -0.843 . . . . 1.0 110.992 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -61.33 -14.78 36.39 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.549 2.166 . . . . 1.0 110.669 -178.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.1 mp -65.83 113.25 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 106.672 -1.603 . . . . 1.0 106.672 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.31 -172.79 40.14 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.378 -0.828 . . . . 1.0 112.28 -177.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.57 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.2 Cg_endo -62.88 138.11 66.58 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 C-N-CA 122.38 2.053 . . . . 1.0 112.405 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.34 51.82 12.4 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 121.039 -0.264 . . . . 1.0 111.061 178.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.611 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -98.82 130.06 45.24 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.921 0.712 . . . . 1.0 112.921 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 43.5 m -96.66 129.13 44.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 106.063 -1.829 . . . . 1.0 106.063 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -110.94 145.15 38.87 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.308 0.575 . . . . 1.0 111.105 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 2.1 tt -124.31 148.55 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 CA-C-N 115.233 -0.894 . . . . 1.0 108.884 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.597 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -140.93 151.17 44.0 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.242 -0.583 . . . . 1.0 111.515 177.536 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.53 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 12.9 mmtt -99.36 125.32 45.01 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 105.46 -2.052 . . . . 1.0 105.46 177.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.02 118.4 56.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.267 -0.973 . . . . 1.0 112.418 -176.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 -109.68 123.88 50.25 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 114.128 -1.397 . . . . 1.0 108.649 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.07 111.17 23.02 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 120.246 -0.582 . . . . 1.0 112.39 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -94.29 -42.69 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 115.995 -0.548 . . . . 1.0 111.676 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -153.44 156.0 37.38 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.502 -0.479 . . . . 1.0 110.796 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.7 t -130.65 138.82 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 116.156 -0.475 . . . . 1.0 111.452 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.44 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 9.4 tptm -99.65 -151.9 0.4 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 121.494 0.664 . . . . 1.0 109.564 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.44 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -172.17 137.47 0.91 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.198 -0.91 . . . . 1.0 110.486 178.333 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.499 ' OG ' ' N ' ' A' ' 137' ' ' SER . 5.3 p -68.16 -57.81 5.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 1.0 111.043 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.499 ' N ' ' OG ' ' A' ' 136' ' ' SER . 1.2 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.929 -1.034 . . . . 1.0 110.134 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.725 ' O2 ' ' O3 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.441 ' H1 ' ' H ' ' A' ' 2' ' ' ASN . 26.4 m-85 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.441 ' H ' ' H1 ' ' A' ' 1' ' ' PHE . 11.2 m120 -65.17 -36.46 84.3 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.883 -0.327 . . . . 1.0 110.813 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.516 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 58.6 pttt -46.29 -43.6 15.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.12 0.486 . . . . 1.0 110.276 -178.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.516 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 6.6 tmtt? -70.37 -38.8 74.81 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.866 0.841 . . . . 1.0 109.589 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -51.84 -35.07 43.37 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 114.908 -1.042 . . . . 1.0 110.165 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -65.12 -37.68 88.23 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.395 -0.82 . . . . 1.0 110.889 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -65.79 -51.89 55.34 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.655 0.74 . . . . 1.0 110.505 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.4 m-20 -59.67 -35.31 74.19 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.204 -1.035 . . . . 1.0 108.204 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.452 ' O ' ' N ' ' A' ' 13' ' ' GLU . 59.3 tttt -66.59 -50.5 62.86 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 113.757 -1.565 . . . . 1.0 111.919 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.15 -48.0 82.81 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 C-N-CA 119.813 -0.755 . . . . 1.0 111.253 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -62.84 -38.1 89.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 178.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.15 -44.76 52.9 Favored Glycine 0 CA--C 1.525 0.703 0 CA-C-N 114.847 -1.069 . . . . 1.0 112.366 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 9' ' ' LYS . 92.1 mt-10 -60.44 -31.78 70.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 119.494 -0.882 . . . . 1.0 108.692 179.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.99 -35.5 57.12 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.809 -1.087 . . . . 1.0 109.87 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.1 t80 -61.39 -51.34 69.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.621 -1.172 . . . . 1.0 110.847 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.3 mp -68.12 -38.37 82.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 119.995 -0.682 . . . . 1.0 109.41 179.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.427 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 99.3 m -62.16 -41.65 98.51 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.553 -0.749 . . . . 1.0 109.296 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -74.62 -46.81 35.96 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.056 -0.975 . . . . 1.0 111.655 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.638 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -55.73 -50.49 70.24 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 112.496 0.554 . . . . 1.0 112.496 -178.783 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.0 ptmt -60.1 -26.74 66.45 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.379 -0.928 . . . . 1.0 109.831 -177.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -83.55 -31.23 26.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.377 -0.829 . . . . 1.0 111.186 179.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -58.7 136.45 86.57 Favored Pre-proline 0 CA--C 1.548 0.871 0 CA-C-N 116.52 -0.309 . . . . 1.0 111.576 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -56.75 148.58 64.84 Favored 'Trans proline' 0 N--CA 1.503 2.071 0 C-N-CA 122.138 1.892 . . . . 1.0 113.334 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.14 -19.32 18.11 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.495 -0.775 . . . . 1.0 111.49 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -86.42 137.71 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.165 0.507 . . . . 1.0 110.547 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.93 121.78 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 107.582 -1.266 . . . . 1.0 107.582 177.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.19 145.99 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.642 0 CA-C-O 121.361 0.601 . . . . 1.0 111.228 -178.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 92.8 mt -111.94 164.81 14.25 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.85 -1.068 . . . . 1.0 110.462 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -61.54 -30.48 86.28 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.745 1.63 . . . . 1.0 110.91 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -68.83 -14.44 63.03 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.473 -0.785 . . . . 1.0 109.828 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.41 -3.89 66.43 Favored Glycine 0 C--N 1.329 0.157 0 N-CA-C 109.671 -1.371 . . . . 1.0 109.671 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.43 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.16 133.93 36.71 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 108.457 -0.942 . . . . 1.0 108.457 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.43 ' H ' HD23 ' A' ' 32' ' ' LEU . 15.2 mp0 -123.07 143.38 50.0 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 116.286 -0.416 . . . . 1.0 110.887 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.4 p90 -138.21 143.59 40.25 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-O 121.635 0.731 . . . . 1.0 110.757 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -127.51 131.24 50.14 Favored 'General case' 0 CA--C 1.501 -0.924 0 CA-C-N 114.594 -1.184 . . . . 1.0 109.188 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 p -88.85 104.62 15.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 122.279 1.038 . . . . 1.0 111.688 -178.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 16.0 mm -69.25 -42.2 81.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.881 -1.054 . . . . 1.0 108.453 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -143.36 124.55 14.54 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.501 -1.227 . . . . 1.0 109.907 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -85.83 129.64 34.77 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.611 -0.436 . . . . 1.0 109.9 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.23 -33.24 1.26 Allowed Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.895 -1.282 . . . . 1.0 109.895 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.645 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 57.04 31.67 20.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.477 -0.361 . . . . 1.0 111.157 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.08 -162.18 37.92 Favored Glycine 0 C--N 1.332 0.329 0 CA-C-O 121.819 0.677 . . . . 1.0 111.822 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.4 m -68.17 -177.93 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 114.061 -1.069 . . . . 1.0 109.127 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.515 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.32 154.82 0.39 Allowed Pre-proline 0 C--N 1.317 -0.834 0 N-CA-C 109.338 -0.616 . . . . 1.0 109.338 179.553 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -86.71 158.78 9.09 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 123.11 2.54 . . . . 1.0 115.741 -175.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 177.29 41.72 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 108.766 -1.734 . . . . 1.0 108.766 176.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.522 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.48 -23.02 9.07 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.882 -0.327 . . . . 1.0 111.07 -179.713 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 57.9 m -108.05 -9.22 15.67 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 113.629 0.974 . . . . 1.0 113.629 -176.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.438 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.7 m-20 -84.74 166.87 16.64 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 119.883 -0.727 . . . . 1.0 109.468 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.5 m -104.56 148.44 26.5 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.612 -0.514 . . . . 1.0 109.612 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -126.57 161.79 32.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.478 0 CA-C-N 115.857 -0.611 . . . . 1.0 112.278 -176.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -130.48 118.18 20.74 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 75' ' ' ALA . 2.5 m -148.14 166.43 4.79 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 112.577 0.584 . . . . 1.0 112.577 -177.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.39 157.7 24.66 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 106.469 -1.678 . . . . 1.0 106.469 175.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.47 ' O ' ' N ' ' A' ' 68' ' ' THR . 34.6 p90 -167.2 160.91 14.15 Favored 'General case' 0 C--N 1.346 0.415 0 N-CA-C 114.846 1.425 . . . . 1.0 114.846 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.8 m -124.76 127.81 47.8 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.119 -1.067 . . . . 1.0 108.119 174.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.89 134.03 11.39 Favored Glycine 0 N--CA 1.47 0.955 0 C-N-CA 120.748 -0.739 . . . . 1.0 111.915 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -146.48 166.84 25.22 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.715 0.769 . . . . 1.0 112.169 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.0 162.66 20.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.391 -1.277 . . . . 1.0 110.062 177.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.05 -25.33 29.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.913 0.863 . . . . 1.0 110.206 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -92.22 2.84 56.37 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 113.947 -1.479 . . . . 1.0 111.852 -177.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.96 -4.98 78.86 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 121.016 -0.611 . . . . 1.0 112.781 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.7 m -68.82 105.75 2.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 118.068 0.934 . . . . 1.0 109.63 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 67.7 t -77.69 121.82 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.691 0 CA-C-O 121.229 0.538 . . . . 1.0 110.301 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CE2' H433 ' A' ' 138' ' ' RAP . 17.6 p90 -110.41 -11.53 14.5 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.089 -0.959 . . . . 1.0 111.688 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -159.84 154.13 23.66 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.192 0.52 . . . . 1.0 111.497 177.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 83.3 p -159.29 151.43 20.98 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.41 -0.814 . . . . 1.0 111.213 178.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 55' ' ' TYR . 96.9 m -154.38 -41.78 0.09 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.645 -0.707 . . . . 1.0 110.649 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.426 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -62.38 -26.33 68.41 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.862 -0.608 . . . . 1.0 110.313 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -55.34 -41.88 73.06 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 108.153 -1.054 . . . . 1.0 108.153 179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.462 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.7 p -80.05 -30.82 39.47 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.067 177.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.1 16.99 68.19 Favored Glycine 0 C--N 1.336 0.531 0 CA-C-N 115.689 -0.687 . . . . 1.0 111.592 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -97.28 115.73 65.8 Favored Pre-proline 0 N--CA 1.471 0.591 0 C-N-CA 120.716 -0.394 . . . . 1.0 110.342 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -60.32 156.23 41.93 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.177 1.918 . . . . 1.0 114.687 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.67 145.36 49.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 113.908 -1.496 . . . . 1.0 107.595 177.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.513 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 1.4 t -104.0 133.91 48.16 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.395 0.617 . . . . 1.0 112.075 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.681 ' CZ ' ' H52' ' A' ' 138' ' ' RAP . 22.6 m-85 -144.18 152.45 40.9 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.837 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -94.52 125.15 38.99 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.878 -1.527 . . . . 1.0 106.878 175.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.95 -30.87 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 C-N-CA 120.04 -0.664 . . . . 1.0 110.57 -177.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -73.42 -24.25 60.24 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.299 -0.561 . . . . 1.0 112.349 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.506 ' O ' ' H34' ' A' ' 138' ' ' RAP . 86.1 mm-40 -99.72 -14.67 18.79 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.888 0.699 . . . . 1.0 112.888 -177.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.657 ' CG2' H31A ' A' ' 138' ' ' RAP . 0.8 OUTLIER -73.14 169.43 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 112.434 0.531 . . . . 1.0 112.434 -176.745 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -56.09 149.08 37.06 Favored Pre-proline 0 CA--C 1.547 0.831 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 -179.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -51.49 -45.01 40.18 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 121.359 1.372 . . . . 1.0 112.941 -178.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.93 -46.78 93.13 Favored Glycine 0 N--CA 1.45 -0.428 0 N-CA-C 110.29 -1.124 . . . . 1.0 110.29 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.6 m95 -65.87 -33.5 75.99 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.389 -0.906 . . . . 1.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.7 m -54.91 -54.16 46.18 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.703 -0.399 . . . . 1.0 111.359 -178.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -72.74 -42.44 64.07 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 112.771 0.656 . . . . 1.0 112.771 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.73 -46.8 83.95 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.903 1.075 . . . . 1.0 113.903 -177.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.2 mt -58.5 -41.56 85.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.347 0.594 . . . . 1.0 109.811 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -63.74 -23.59 67.43 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.095 -0.957 . . . . 1.0 110.515 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.528 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 81.3 mt -102.59 -10.03 19.63 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 116.032 -0.531 . . . . 1.0 111.422 -179.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.6 ttp -91.89 107.81 25.43 Favored Pre-proline 0 CA--C 1.546 0.823 0 N-CA-C 111.835 0.309 . . . . 1.0 111.835 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.515 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 20.0 Cg_exo -65.78 147.66 85.76 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 122.488 2.125 . . . . 1.0 112.357 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.74 137.55 58.12 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.666 0.746 . . . . 1.0 111.508 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.73 53.27 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 108.546 -1.822 . . . . 1.0 108.546 -178.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 p -87.18 134.6 33.51 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.009 0.433 . . . . 1.0 110.178 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.9 m -107.59 114.68 28.83 Favored 'General case' 0 CA--C 1.51 -0.582 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.052 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.528 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.6 m0 -115.71 164.38 14.43 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.708 0.766 . . . . 1.0 111.23 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -124.96 126.39 45.4 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 106.815 -1.55 . . . . 1.0 106.815 175.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -121.92 138.39 52.32 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.688 0 CA-C-O 121.899 0.857 . . . . 1.0 109.969 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.638 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.64 103.25 12.08 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.646 -1.983 . . . . 1.0 105.646 -178.231 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.2 115.45 64.07 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 114.75 1.389 . . . . 1.0 114.75 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -50.84 143.2 30.75 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 C-N-CA 121.433 1.422 . . . . 1.0 109.783 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 96.5 p -49.1 -35.26 15.75 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.273 -0.571 . . . . 1.0 110.531 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.86 -32.15 81.89 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 111.388 -0.685 . . . . 1.0 111.388 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 53.3 mt -100.59 2.91 42.2 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 121.499 -0.08 . . . . 1.0 110.832 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.66 -107.95 0.33 Allowed 'General case' 0 N--CA 1.457 -0.11 0 CA-C-O 120.923 0.392 . . . . 1.0 111.037 -178.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.628 ' CZ ' H121 ' A' ' 138' ' ' RAP . 52.7 m-85 -100.03 4.89 45.01 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 111.965 0.357 . . . . 1.0 111.965 -178.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.78 160.97 25.76 Favored Glycine 0 CA--C 1.529 0.927 0 C-N-CA 121.395 -0.431 . . . . 1.0 112.925 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.567 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.2 Cg_endo -70.56 -15.94 34.12 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 123.316 2.677 . . . . 1.0 112.676 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -96.75 169.48 9.84 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.22 -0.659 . . . . 1.0 109.22 179.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.426 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.3 m -75.76 82.78 2.72 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.352 -0.539 . . . . 1.0 110.096 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.5 t -98.36 60.11 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.771 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 172.68 -172.7 45.16 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.534 -0.841 . . . . 1.0 112.033 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.81 -103.78 0.05 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 111.036 -0.826 . . . . 1.0 111.036 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -59.3 -16.88 36.79 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.219 1.946 . . . . 1.0 110.397 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.487 ' CG2' ' OE2' ' A' ' 122' ' ' GLU . 5.0 mp -67.75 114.7 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 107.889 -1.152 . . . . 1.0 107.889 179.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.611 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -94.89 -158.5 33.09 Favored Glycine 0 C--O 1.212 -1.253 0 N-CA-C 110.968 -0.853 . . . . 1.0 110.968 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.511 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 44.6 Cg_endo -70.09 147.45 60.75 Favored 'Trans proline' 0 C--N 1.299 -2.034 0 C-N-CA 121.892 1.728 . . . . 1.0 113.098 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.567 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.5 t-20 39.99 60.74 1.65 Allowed 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.254 0.835 . . . . 1.0 113.254 177.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.639 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.03 135.85 53.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.571 0.7 . . . . 1.0 111.355 -179.423 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.2 m -93.69 129.0 40.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.329 178.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.51 140.97 42.63 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.142 0.496 . . . . 1.0 110.133 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.4 tt -121.11 143.68 32.6 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.729 0 CA-C-N 115.506 -0.77 . . . . 1.0 109.014 178.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -134.89 150.66 50.46 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.082 0.468 . . . . 1.0 111.08 177.269 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 14.3 mmtt -99.63 126.02 45.56 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 104.85 -2.278 . . . . 1.0 104.85 176.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.8 mt -119.72 119.54 60.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 119.16 -1.016 . . . . 1.0 111.851 -177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -111.92 120.94 43.63 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 114.091 -1.413 . . . . 1.0 108.816 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.63 112.45 24.41 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 120.236 -0.585 . . . . 1.0 112.326 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.9 mp -94.84 -47.49 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.875 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.5 p -148.14 157.54 43.56 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.93 0.395 . . . . 1.0 111.246 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 54.7 t -130.07 139.25 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 116.043 -0.526 . . . . 1.0 111.396 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.564 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 12.5 tptt -94.98 -142.83 0.25 Allowed 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 115.424 -0.807 . . . . 1.0 110.298 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.564 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -171.77 149.9 2.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 114.685 -1.143 . . . . 1.0 109.751 177.877 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 87.7 p -40.51 -26.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.324 -0.853 . . . . 1.0 111.304 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 135' ' ' LYS . 97.7 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.686 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.774 H331 ' O2 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.504 ' CG ' ' N ' ' A' ' 2' ' ' ASN . 49.4 t80 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 108.935 -0.765 . . . . 1.0 108.935 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.504 ' N ' ' CG ' ' A' ' 1' ' ' PHE . 87.8 m-20 -71.08 -19.38 62.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.633 -0.258 . . . . 1.0 111.344 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 62.5 pttt -46.69 -41.58 15.19 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.578 -0.449 . . . . 1.0 110.482 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.474 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 4.4 tmtt? -69.21 -36.76 77.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.957 0.884 . . . . 1.0 109.951 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -51.34 -33.88 31.38 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 114.796 -1.093 . . . . 1.0 110.66 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -64.24 -36.85 85.43 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.197 -0.911 . . . . 1.0 110.804 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -66.79 -52.69 41.1 Favored 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 119.933 -0.707 . . . . 1.0 110.694 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 30.4 m-20 -59.51 -34.0 72.07 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-O 121.964 0.888 . . . . 1.0 108.617 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.8 tttt -64.43 -49.71 70.42 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 114.108 -1.405 . . . . 1.0 111.664 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.31 -47.26 74.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.408 -0.517 . . . . 1.0 112.112 -178.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -62.2 -36.91 83.36 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.79 -44.15 39.53 Favored Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.925 -1.034 . . . . 1.0 112.408 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -60.66 -30.97 70.22 Favored 'General case' 0 CA--C 1.514 -0.416 0 C-N-CA 119.701 -0.8 . . . . 1.0 108.883 179.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.8 -35.68 51.13 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.129 -0.941 . . . . 1.0 109.849 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 t80 -61.96 -50.8 70.66 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.728 -1.124 . . . . 1.0 110.901 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -66.82 -38.74 87.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.48 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 99.0 m -61.27 -43.0 99.59 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.498 -0.773 . . . . 1.0 109.584 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -75.32 -46.48 33.08 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.591 -0.731 . . . . 1.0 112.111 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.655 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 51.3 t30 -61.47 -45.12 95.58 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 113.145 0.795 . . . . 1.0 113.145 -177.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -58.02 -33.69 69.23 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 119.321 -0.952 . . . . 1.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 17' ' ' THR . 43.6 m-80 -75.46 -33.91 60.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.305 -0.861 . . . . 1.0 111.538 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -58.99 137.41 87.72 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 120.593 -0.443 . . . . 1.0 111.8 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -53.85 149.13 34.77 Favored 'Trans proline' 0 N--CA 1.507 2.302 0 C-N-CA 122.723 2.282 . . . . 1.0 114.757 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.76 -21.91 5.2 Favored Glycine 0 CA--C 1.508 -0.368 0 CA-C-N 114.421 -1.263 . . . . 1.0 111.265 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 54.3 t -80.21 132.0 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 N-CA-C 109.34 -0.615 . . . . 1.0 109.34 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.77 120.4 64.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.327 -0.99 . . . . 1.0 108.327 177.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.3 p -95.5 145.91 7.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 CA-C-O 121.471 0.653 . . . . 1.0 111.265 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.0 mt -114.17 165.26 14.07 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.597 -1.183 . . . . 1.0 110.955 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.76 -30.44 90.28 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 C-N-CA 121.828 1.685 . . . . 1.0 111.006 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.5 m -68.4 -15.82 63.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.608 -0.724 . . . . 1.0 109.801 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.95 -2.77 64.26 Favored Glycine 0 C--O 1.229 -0.192 0 N-CA-C 110.016 -1.234 . . . . 1.0 110.016 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.422 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -78.78 134.1 37.04 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.422 ' H ' HD23 ' A' ' 32' ' ' LEU . 20.0 mp0 -123.64 142.93 50.58 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.393 -0.367 . . . . 1.0 111.525 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -140.6 142.26 35.08 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.919 0.866 . . . . 1.0 112.183 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.465 ' CE ' ' CD1' ' A' ' 37' ' ' ILE . 8.6 ttpt -123.99 126.57 46.52 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.173 -1.376 . . . . 1.0 108.45 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -82.61 113.52 21.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.128 -178.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.466 ' HB ' HD21 ' A' ' 38' ' ' ASN . 4.8 mm -77.27 -42.24 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 CA-C-O 121.541 0.686 . . . . 1.0 109.844 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.466 HD21 ' HB ' ' A' ' 37' ' ' ILE . 27.0 m-80 -144.34 124.01 13.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.725 -1.125 . . . . 1.0 109.917 -177.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -81.84 129.58 34.79 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.539 -0.464 . . . . 1.0 110.527 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.15 -36.13 1.05 Allowed Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.106 -1.198 . . . . 1.0 110.106 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.598 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 57.81 31.22 20.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.447 -0.376 . . . . 1.0 111.49 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.67 -161.8 37.25 Favored Glycine 0 C--N 1.332 0.35 0 CA-C-O 121.984 0.769 . . . . 1.0 111.731 179.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.2 m -68.97 -177.86 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.093 -1.053 . . . . 1.0 109.086 178.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.515 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.18 154.23 0.38 Allowed Pre-proline 0 C--N 1.32 -0.676 0 O-C-N 123.757 0.661 . . . . 1.0 109.556 179.734 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -87.71 158.01 7.63 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 123.336 2.691 . . . . 1.0 116.45 -175.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.0 175.57 41.68 Favored Glycine 0 N--CA 1.449 -0.449 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 176.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.403 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.84 -22.31 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.778 -0.369 . . . . 1.0 111.274 -179.383 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 53.5 m -107.88 -9.3 15.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.534 0.939 . . . . 1.0 113.534 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.4 m-20 -85.19 165.43 17.4 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.436 -0.949 . . . . 1.0 108.436 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.7 m -104.72 150.53 24.66 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 109.869 -0.419 . . . . 1.0 109.869 -179.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -127.09 163.37 30.06 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 112.599 0.592 . . . . 1.0 112.599 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.1 m -131.55 120.18 22.55 Favored 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 108.488 -0.93 . . . . 1.0 108.488 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 15.8 m -148.75 165.28 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 114.438 1.273 . . . . 1.0 114.438 -176.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -118.35 147.92 43.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 174.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.558 ' CZ ' ' C5 ' ' A' ' 138' ' ' RAP . 37.3 p90 -163.63 162.14 24.11 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 114.68 1.363 . . . . 1.0 114.68 -176.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.49 133.11 54.6 Favored 'General case' 0 C--O 1.216 -0.675 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 175.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.83 135.96 11.79 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 120.972 -0.633 . . . . 1.0 111.855 -178.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.611 ' CZ ' ' HZ3' ' A' ' 127' ' ' LYS . 7.8 ptp85 -148.61 167.5 25.28 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.745 0.783 . . . . 1.0 112.997 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.69 163.79 18.99 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 114.377 -1.283 . . . . 1.0 110.989 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.417 HD11 ' N ' ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.58 -25.65 35.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 122.272 1.034 . . . . 1.0 109.589 177.468 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.4 ' H ' HD11 ' A' ' 60' ' ' ILE . 32.5 t70 -89.86 0.72 56.87 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 113.378 -1.737 . . . . 1.0 111.688 -177.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.69 81.74 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 121.182 -0.533 . . . . 1.0 112.351 178.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.4 m -68.9 104.13 1.99 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 119.92 -0.712 . . . . 1.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.7 t -77.08 121.13 28.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 CA-C-N 116.059 -0.519 . . . . 1.0 110.062 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 22.0 p90 -110.59 -14.26 14.09 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.184 -0.916 . . . . 1.0 112.056 -178.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.464 ' OD2' H431 ' A' ' 138' ' ' RAP . 38.7 t0 -159.58 148.19 17.7 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.156 -0.618 . . . . 1.0 111.511 177.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 89.5 p -153.63 156.25 37.58 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.541 179.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.508 ' O ' ' OG1' ' A' ' 71' ' ' THR . 55.8 m -155.17 -39.51 0.09 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.984 -0.553 . . . . 1.0 110.78 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -63.12 -26.19 68.71 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.632 -0.427 . . . . 1.0 109.895 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -56.49 -41.3 76.4 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.085 -1.45 . . . . 1.0 107.085 178.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.508 ' OG1' ' O ' ' A' ' 68' ' ' THR . 23.1 p -76.74 -32.66 57.93 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.203 -1.362 . . . . 1.0 109.042 177.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.48 15.18 80.32 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.922 -0.871 . . . . 1.0 110.922 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -96.55 115.26 65.56 Favored Pre-proline 0 N--CA 1.47 0.537 0 C-N-CA 120.827 -0.349 . . . . 1.0 110.962 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -61.41 151.75 77.46 Favored 'Trans proline' 0 N--CA 1.482 0.827 0 C-N-CA 121.539 1.493 . . . . 1.0 114.405 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.8 150.34 46.45 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.089 -1.414 . . . . 1.0 107.78 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -107.53 136.07 47.93 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 112.882 0.697 . . . . 1.0 112.882 -178.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.6 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 48.0 m-85 -144.48 151.01 38.55 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 114.858 -1.064 . . . . 1.0 109.032 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -90.14 125.87 35.6 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 106.434 -1.691 . . . . 1.0 106.434 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.0 t -50.6 -31.4 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 C-N-CA 119.926 -0.71 . . . . 1.0 110.545 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.691 ' HG ' ' NE2' ' A' ' 81' ' ' GLN . 2.8 t -73.57 -27.37 61.28 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 120.116 -0.634 . . . . 1.0 111.994 -177.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.691 ' NE2' ' HG ' ' A' ' 80' ' ' SER . 43.9 mm-40 -101.35 -8.72 21.8 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 113.219 0.822 . . . . 1.0 113.219 -178.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.702 ' CG2' H31A ' A' ' 138' ' ' RAP . 3.5 p -80.32 172.84 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 C-N-CA 119.457 -0.897 . . . . 1.0 110.151 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.03 145.83 31.97 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 120.165 -0.614 . . . . 1.0 109.976 -176.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -51.42 -44.21 44.94 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.081 1.854 . . . . 1.0 112.783 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.05 -47.5 88.76 Favored Glycine 0 C--N 1.319 -0.4 0 N-CA-C 109.343 -1.503 . . . . 1.0 109.343 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.785 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 8.1 m95 -64.9 -35.21 80.4 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.796 -1.202 . . . . 1.0 110.565 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.24 -54.23 27.75 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.822 0.344 . . . . 1.0 111.172 -178.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -72.64 -43.14 63.59 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.745 0.646 . . . . 1.0 112.745 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.53 -45.84 84.56 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 113.957 1.095 . . . . 1.0 113.957 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.51 -41.12 84.7 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.457 0.646 . . . . 1.0 109.625 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.6 mt-30 -64.59 -23.85 67.4 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.836 -1.075 . . . . 1.0 110.805 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.482 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 80.6 mt -103.81 -10.73 18.03 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 116.207 -0.451 . . . . 1.0 111.41 -178.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 46.7 ttp -92.18 108.4 30.32 Favored Pre-proline 0 CA--C 1.55 0.978 0 CA-C-O 119.445 -0.312 . . . . 1.0 111.345 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.515 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 21.0 Cg_exo -65.35 148.26 88.12 Favored 'Trans proline' 0 N--CA 1.5 1.881 0 C-N-CA 122.681 2.254 . . . . 1.0 112.777 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.76 136.86 57.77 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.368 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.23 -19.31 53.12 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 108.954 -1.659 . . . . 1.0 108.954 -178.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.7 p -87.88 135.45 33.39 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 120.851 0.358 . . . . 1.0 110.473 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 72.0 m -107.89 114.94 29.24 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 115.952 -0.567 . . . . 1.0 110.142 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.482 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.4 m0 -114.99 164.24 14.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.491 0.662 . . . . 1.0 111.404 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -124.35 127.78 48.1 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.642 -1.614 . . . . 1.0 106.642 175.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -123.77 138.72 52.58 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.461 0 CA-C-O 121.768 0.794 . . . . 1.0 110.288 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.655 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.23 103.85 12.89 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.864 -1.902 . . . . 1.0 105.864 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.67 115.65 64.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 N-CA-C 115.466 1.654 . . . . 1.0 115.466 -174.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -50.71 143.25 29.7 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 C-N-CA 121.611 1.541 . . . . 1.0 110.017 176.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.5 p -50.09 -34.66 22.57 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.524 -0.47 . . . . 1.0 110.986 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.8 -31.89 76.68 Favored Glycine 0 CA--C 1.52 0.396 0 N-CA-C 110.812 -0.915 . . . . 1.0 110.812 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 54.9 mt -98.97 2.38 46.36 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 121.436 -0.106 . . . . 1.0 110.878 -179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -107.86 0.33 Allowed 'General case' 0 C--N 1.34 0.166 0 CA-C-O 120.503 0.192 . . . . 1.0 111.338 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.71 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 38.0 m-85 -99.45 4.64 46.22 Favored 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 113.279 0.844 . . . . 1.0 113.279 -177.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.33 164.52 22.81 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 120.756 -0.735 . . . . 1.0 113.352 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 121' ' ' ASN . 79.5 Cg_endo -73.98 -16.89 22.77 Favored 'Trans proline' 0 N--CA 1.493 1.46 0 C-N-CA 123.531 2.821 . . . . 1.0 110.9 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 60.4 ttt180 -96.06 165.12 12.4 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.477 -1.238 . . . . 1.0 109.685 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.522 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 8.1 m -77.02 91.97 3.68 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.565 -0.531 . . . . 1.0 109.565 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.3 t -107.56 60.66 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.113 -0.494 . . . . 1.0 111.199 -179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 171.23 178.05 41.45 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 120.201 -0.999 . . . . 1.0 112.145 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.23 -103.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 111.072 -0.811 . . . . 1.0 111.072 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -62.35 -16.04 48.91 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.567 2.178 . . . . 1.0 110.779 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.473 ' CG2' ' OE2' ' A' ' 122' ' ' GLU . 5.2 mp -66.67 115.92 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 108.233 -1.025 . . . . 1.0 108.233 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -96.52 -158.96 31.78 Favored Glycine 0 C--O 1.213 -1.194 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.522 ' N ' ' OG ' ' A' ' 113' ' ' SER . 46.9 Cg_endo -70.89 147.39 55.51 Favored 'Trans proline' 0 C--N 1.297 -2.141 0 C-N-CA 121.766 1.644 . . . . 1.0 113.326 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.484 ' C ' HD21 ' A' ' 121' ' ' ASN . 0.1 OUTLIER 41.17 60.6 2.0 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.195 0.813 . . . . 1.0 113.195 177.515 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.613 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.38 137.71 51.47 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 121.683 0.754 . . . . 1.0 111.225 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 81.8 m -94.43 130.09 40.91 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.332 -1.304 . . . . 1.0 108.624 178.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.29 141.3 46.17 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.05 -0.523 . . . . 1.0 109.8 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.7 tt -119.72 146.05 25.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 N-CA-C 108.368 -0.975 . . . . 1.0 108.368 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.574 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -137.98 151.0 47.5 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.394 -0.522 . . . . 1.0 111.759 177.838 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.611 ' HZ3' ' CZ ' ' A' ' 58' ' ' ARG . 4.1 mmtt -101.16 122.91 44.46 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 105.741 -1.948 . . . . 1.0 105.741 177.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.0 mt -117.51 119.19 60.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.956 0.884 . . . . 1.0 113.257 -176.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -109.95 124.03 50.67 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 113.935 -1.484 . . . . 1.0 108.354 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.93 111.12 23.2 Favored 'General case' 0 N--CA 1.465 0.293 0 C-N-CA 120.162 -0.615 . . . . 1.0 112.369 -178.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -94.01 -45.03 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 115.881 -0.599 . . . . 1.0 111.729 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.7 p -150.63 155.82 40.13 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.683 -0.407 . . . . 1.0 110.79 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 46.4 t -129.71 137.21 57.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 121.05 0.452 . . . . 1.0 111.772 -177.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.478 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 17.5 tptt -88.62 -151.28 0.2 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.723 -0.671 . . . . 1.0 110.098 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.478 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -178.07 131.48 0.14 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.653 0.74 . . . . 1.0 111.716 179.178 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.8 t -65.08 -47.05 78.62 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.376 -1.283 . . . . 1.0 110.96 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 117.99 -1.005 . . . . 1.0 109.937 -179.82 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.856 H491 H382 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.577 ' O ' ' N ' ' A' ' 5' ' ' ALA . 11.1 m120 -62.12 -34.33 76.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.051 -0.522 . . . . 1.0 110.461 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -46.79 -32.58 3.77 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.533 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 4.0 tmtt? -68.3 -35.04 77.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 122.134 0.969 . . . . 1.0 108.935 178.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.577 ' N ' ' O ' ' A' ' 2' ' ' ASN . . . -51.21 -36.6 42.35 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 114.592 -1.185 . . . . 1.0 110.794 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.44 -35.65 78.19 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.087 -179.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -66.11 -52.58 47.28 Favored 'General case' 0 C--O 1.222 -0.346 0 CA-C-O 121.663 0.744 . . . . 1.0 110.439 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.7 m-20 -58.0 -35.11 70.77 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.255 -1.017 . . . . 1.0 108.255 179.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.505 ' O ' ' N ' ' A' ' 13' ' ' GLU . 18.7 tttm -65.22 -51.07 63.26 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.691 178.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.52 -46.67 82.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 119.974 -0.69 . . . . 1.0 111.538 -178.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.425 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.51 -37.11 86.04 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.418 -1.327 . . . . 1.0 107.418 178.728 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.71 -41.37 50.44 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 114.758 -1.11 . . . . 1.0 112.213 179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.505 ' N ' ' O ' ' A' ' 9' ' ' LYS . 49.0 mt-10 -62.83 -31.73 72.79 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.719 -0.845 . . . . 1.0 108.719 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.79 -37.08 59.51 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 115.099 -0.955 . . . . 1.0 109.483 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -60.92 -51.01 71.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.199 -1.364 . . . . 1.0 110.789 -179.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -69.01 -37.9 78.93 Favored 'General case' 0 CA--C 1.512 -0.497 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.583 178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 93.9 m -61.03 -43.67 98.55 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.757 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -76.34 -45.63 31.25 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.813 -0.63 . . . . 1.0 112.58 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.639 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.4 t30 -60.75 -44.15 97.06 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.309 0.855 . . . . 1.0 113.309 -177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -59.65 -32.46 70.48 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.275 -0.97 . . . . 1.0 109.313 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.2 m-80 -77.96 -29.97 50.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.405 -0.816 . . . . 1.0 111.714 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 26.7 mtmt -60.45 137.69 92.29 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 120.457 -0.497 . . . . 1.0 111.499 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -55.66 149.4 49.49 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 C-N-CA 122.341 2.027 . . . . 1.0 113.726 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.34 -19.26 14.27 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-N 114.811 -1.086 . . . . 1.0 111.302 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 41.0 t -87.49 135.06 26.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 121.067 0.461 . . . . 1.0 110.77 -179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.08 121.79 66.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 107.981 -1.118 . . . . 1.0 107.981 177.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.5 p -96.74 145.87 8.22 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.622 0 CA-C-O 121.676 0.751 . . . . 1.0 111.872 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 74.7 mt -112.34 163.57 17.45 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 114.327 -1.306 . . . . 1.0 110.719 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.03 -29.91 90.35 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.058 1.839 . . . . 1.0 110.69 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.6 m -67.69 -15.54 63.69 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.284 -0.871 . . . . 1.0 109.456 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.94 -3.74 70.8 Favored Glycine 0 C--N 1.328 0.115 0 N-CA-C 109.815 -1.314 . . . . 1.0 109.815 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.6 133.51 38.43 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.421 ' H ' HD23 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.5 139.26 54.08 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.284 -0.417 . . . . 1.0 110.865 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -134.95 145.81 48.52 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-O 121.642 0.734 . . . . 1.0 110.619 178.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? -130.84 134.1 46.52 Favored 'General case' 0 N--CA 1.443 -0.804 0 CA-C-N 114.503 -1.226 . . . . 1.0 109.084 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -90.48 105.38 16.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 122.18 0.991 . . . . 1.0 111.54 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.7 mm -70.55 -42.36 78.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 108.594 -0.891 . . . . 1.0 108.594 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -141.82 128.93 20.88 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.816 -1.084 . . . . 1.0 109.767 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.5 p -87.89 123.06 32.26 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.956 0.408 . . . . 1.0 110.182 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.81 -36.22 1.73 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.585 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.7 m120 57.58 32.46 21.87 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.22 -0.49 . . . . 1.0 111.64 179.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.24 -161.65 37.41 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.907 0.726 . . . . 1.0 111.408 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.594 ' O ' ' N ' ' A' ' 95' ' ' ALA . 31.2 m -69.48 -177.92 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.17 -1.015 . . . . 1.0 109.374 178.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.445 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.75 154.59 0.48 Allowed Pre-proline 0 C--N 1.319 -0.729 0 O-C-N 123.569 0.543 . . . . 1.0 110.11 179.646 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -87.75 154.29 7.44 Favored 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.697 2.932 . . . . 1.0 117.055 -174.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.435 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -84.8 175.74 50.59 Favored Glycine 0 C--N 1.334 0.42 0 N-CA-C 109.601 -1.4 . . . . 1.0 109.601 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.832 ' H ' ' HZ2' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.31 -22.34 11.75 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.315 -0.443 . . . . 1.0 111.667 -179.328 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.4 m -109.18 -7.17 15.34 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 112.651 0.612 . . . . 1.0 112.651 -178.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.435 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 78.7 m-20 -82.83 167.88 17.67 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.182 -0.303 . . . . 1.0 110.182 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.3 m -107.5 147.75 30.1 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-O 121.06 0.457 . . . . 1.0 109.949 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.3 p -127.17 163.05 30.91 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 CA-C-N 115.705 -0.679 . . . . 1.0 111.591 -176.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 95.3 m -129.78 120.15 24.57 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 108.077 -1.083 . . . . 1.0 108.077 177.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' A' ' 75' ' ' ALA . 4.3 m -148.38 165.62 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 114.227 1.195 . . . . 1.0 114.227 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -118.69 147.92 43.3 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 105.913 -1.884 . . . . 1.0 105.913 173.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.503 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 30.0 p90 -161.48 162.84 30.57 Favored 'General case' 0 C--N 1.343 0.292 0 N-CA-C 114.769 1.396 . . . . 1.0 114.769 -177.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.442 ' OG1' ' OE1' ' A' ' 69' ' ' GLU . 1.7 m -126.06 132.9 51.85 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.872 175.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.87 134.92 11.77 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 111.302 -0.719 . . . . 1.0 111.302 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.656 ' CZ ' ' HZ3' ' A' ' 127' ' ' LYS . 6.2 ptp85 -143.65 163.61 32.75 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-O 121.553 0.692 . . . . 1.0 111.929 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.0 mp -85.01 162.54 19.31 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.664 -1.153 . . . . 1.0 109.844 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -57.64 -25.82 25.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.305 -0.861 . . . . 1.0 110.395 178.517 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -93.34 2.98 56.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 114.279 -1.328 . . . . 1.0 111.603 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -6.14 79.18 Favored Glycine 0 CA--C 1.525 0.68 0 C-N-CA 121.069 -0.586 . . . . 1.0 112.832 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.2 m -65.0 105.3 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 119.548 -0.861 . . . . 1.0 109.103 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.3 t -74.08 117.3 17.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 C-N-CA 120.225 -0.59 . . . . 1.0 110.072 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.465 ' CE2' H432 ' A' ' 138' ' ' RAP . 13.9 p90 -103.52 -10.47 18.48 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.064 -0.971 . . . . 1.0 112.228 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.505 ' CB ' H431 ' A' ' 138' ' ' RAP . 1.0 OUTLIER -168.12 155.34 8.03 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 119.838 -0.745 . . . . 1.0 111.636 177.847 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.1 p -157.84 154.8 28.59 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.656 -0.702 . . . . 1.0 111.914 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.442 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.9 m -153.28 -40.7 0.1 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.528 -0.76 . . . . 1.0 110.357 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.442 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.8 pp20? -63.0 -26.27 68.77 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.657 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -52.11 -44.24 64.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 108.279 -1.008 . . . . 1.0 108.279 179.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 68' ' ' THR . 16.5 p -79.64 -27.94 40.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.707 -1.133 . . . . 1.0 109.246 177.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.11 16.2 77.12 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.441 -0.8 . . . . 1.0 111.74 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.42 114.95 64.27 Favored Pre-proline 0 N--CA 1.47 0.545 0 C-N-CA 120.553 -0.459 . . . . 1.0 110.628 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -61.24 152.49 71.81 Favored 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 121.809 1.673 . . . . 1.0 114.601 -178.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.87 152.17 42.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.048 -1.433 . . . . 1.0 107.247 177.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.7 t -110.42 131.2 55.26 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.605 0.717 . . . . 1.0 112.771 -178.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.557 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 32.2 m-85 -136.58 154.7 50.62 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.824 -1.08 . . . . 1.0 109.652 178.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.409 ' O ' ' N ' ' A' ' 81' ' ' GLN . 18.8 mt-30 -96.32 124.03 40.17 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 105.801 -1.926 . . . . 1.0 105.801 174.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.7 t -47.39 -29.14 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.398 -176.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.9 t -75.86 -24.3 55.72 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 111.974 0.361 . . . . 1.0 111.974 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.487 ' OE1' H461 ' A' ' 138' ' ' RAP . 92.3 mm-40 -98.23 -12.71 21.35 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.353 0.871 . . . . 1.0 113.353 -177.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.569 ' CG2' ' H32' ' A' ' 138' ' ' RAP . 4.1 p -83.93 169.12 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.101 -0.64 . . . . 1.0 112.022 -177.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.12 148.72 21.06 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 -177.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.63 -43.14 47.18 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.794 1.662 . . . . 1.0 112.833 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.85 -48.69 80.44 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 119.517 -1.325 . . . . 1.0 109.852 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.536 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 8.7 m95 -63.26 -38.14 90.01 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 113.902 -1.149 . . . . 1.0 110.438 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.9 m -51.13 -53.53 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.265 -0.425 . . . . 1.0 111.594 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -72.42 -41.59 66.03 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.642 0.608 . . . . 1.0 112.642 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.64 -48.21 82.56 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.917 1.08 . . . . 1.0 113.917 -177.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.0 mt -56.93 -39.95 75.47 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 121.133 0.492 . . . . 1.0 110.511 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -63.05 -23.24 67.36 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.607 -0.724 . . . . 1.0 110.753 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.432 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 45.5 mt -105.25 -11.4 16.54 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.307 -0.406 . . . . 1.0 110.935 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 33.4 ttm -86.04 106.81 10.83 Favored Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.669 0.606 . . . . 1.0 111.89 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.445 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 14.6 Cg_exo -68.46 145.7 65.72 Favored 'Trans proline' 0 N--CA 1.501 1.964 0 C-N-CA 122.576 2.184 . . . . 1.0 113.008 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.594 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.55 132.96 54.18 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.53 -0.759 . . . . 1.0 111.17 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.95 -17.82 58.61 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 109.147 -1.581 . . . . 1.0 109.147 -179.067 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -88.86 136.46 33.0 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-O 120.838 0.351 . . . . 1.0 110.247 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 57.3 m -107.61 113.76 27.27 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.979 -0.555 . . . . 1.0 109.752 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.432 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.6 m0 -115.51 164.68 13.95 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.728 0.775 . . . . 1.0 110.902 -178.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -126.25 126.01 43.31 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 106.943 -1.503 . . . . 1.0 106.943 175.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.4 137.12 56.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.733 0 CA-C-O 121.704 0.764 . . . . 1.0 109.649 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.639 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -108.53 103.59 12.74 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 105.894 -1.891 . . . . 1.0 105.894 -177.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.53 115.54 64.39 Favored Pre-proline 0 C--N 1.326 -0.438 0 N-CA-C 115.077 1.51 . . . . 1.0 115.077 -174.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -51.52 146.72 24.99 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.578 1.519 . . . . 1.0 109.748 176.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 58.4 p -51.6 -36.43 45.62 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.192 -0.603 . . . . 1.0 110.901 -178.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.29 -32.52 83.99 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.251 -0.74 . . . . 1.0 111.251 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.0 mt -99.26 1.51 44.75 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.498 -0.186 . . . . 1.0 110.498 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.496 ' O ' H521 ' A' ' 138' ' ' RAP . . . -109.28 -103.34 0.37 Allowed 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 120.352 0.12 . . . . 1.0 110.819 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.597 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 44.2 m-85 -107.6 5.97 27.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 114.915 1.45 . . . . 1.0 114.915 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.15 169.43 22.2 Favored Glycine 0 N--CA 1.473 1.127 0 C-N-CA 120.245 -0.978 . . . . 1.0 114.139 176.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 121' ' ' ASN . 57.0 Cg_endo -78.47 -12.76 15.29 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 123.697 2.931 . . . . 1.0 110.645 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 113' ' ' SER . 60.0 ttt180 -104.77 165.55 10.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.75 -1.113 . . . . 1.0 109.403 -179.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.56 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 3.5 m -76.28 97.65 4.25 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.171 -0.677 . . . . 1.0 109.171 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -108.74 61.38 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.576 -0.283 . . . . 1.0 110.597 -179.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.22 -170.84 42.8 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 120.455 -0.879 . . . . 1.0 112.188 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -66.09 -105.19 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 N-CA-C 111.842 -0.503 . . . . 1.0 111.842 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.03 -16.08 47.71 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.439 2.093 . . . . 1.0 111.387 -178.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 3.6 mp -66.97 114.24 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 109.26 -0.645 . . . . 1.0 109.26 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.26 -168.14 42.44 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 110.566 -1.014 . . . . 1.0 110.566 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.566 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 39.3 Cg_endo -65.53 142.62 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.257 1.971 . . . . 1.0 113.34 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.471 ' O ' ' ND2' ' A' ' 121' ' ' ASN . 2.1 t30 50.55 53.62 12.62 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.158 -0.474 . . . . 1.0 111.859 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.427 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 54.9 mm-40 -99.76 133.01 44.74 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.146 -0.479 . . . . 1.0 111.527 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 52.8 m -93.86 128.58 40.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 106.571 -1.641 . . . . 1.0 106.571 175.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -112.13 138.86 48.22 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.394 0.616 . . . . 1.0 111.096 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.6 tt -118.6 145.22 24.93 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.679 0 CA-C-N 114.976 -1.011 . . . . 1.0 108.523 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.561 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -136.89 150.78 48.45 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 120.217 -0.593 . . . . 1.0 111.201 177.129 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.656 ' HZ3' ' CZ ' ' A' ' 58' ' ' ARG . 5.3 mmtt -100.14 122.39 42.9 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 105.031 -2.211 . . . . 1.0 105.031 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.42 118.27 57.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 C-N-CA 119.395 -0.922 . . . . 1.0 112.432 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.2 t-160 -108.67 123.6 49.22 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 114.121 -1.4 . . . . 1.0 108.563 178.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.82 111.31 23.32 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 120.478 -0.489 . . . . 1.0 112.197 -177.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -94.3 -45.05 13.61 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.486 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.1 p -151.07 155.81 39.76 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.305 0.574 . . . . 1.0 111.137 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.8 t -128.8 135.91 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.757 -0.656 . . . . 1.0 109.958 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.411 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 14.6 tptm -77.72 -84.03 0.08 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.87 0.843 . . . . 1.0 111.586 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.53 ' C ' ' H ' ' A' ' 137' ' ' SER . 0.0 OUTLIER 85.45 127.93 0.04 OUTLIER 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 113.777 -1.556 . . . . 1.0 110.47 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -47.47 -7.29 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 113.84 -1.527 . . . . 1.0 112.151 -178.22 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.53 ' H ' ' C ' ' A' ' 135' ' ' LYS . 16.1 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.002 -0.999 . . . . 1.0 111.135 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.885 H492 H382 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.505 -0.554 . . . . 1.0 109.505 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -65.05 -31.95 73.42 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 112.366 0.506 . . . . 1.0 112.366 -179.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.425 ' HG3' ' H ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -46.38 -41.46 13.58 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.323 -0.551 . . . . 1.0 111.078 -178.392 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.581 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 6.1 tmtt? -69.99 -35.93 74.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.596 0.712 . . . . 1.0 109.806 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.59 -34.5 51.07 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 115.47 -0.786 . . . . 1.0 110.753 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -61.33 -39.4 90.37 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.142 -0.935 . . . . 1.0 110.401 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -64.84 -48.63 73.64 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.502 0.668 . . . . 1.0 111.12 -179.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.581 ' OD1' ' NZ ' ' A' ' 4' ' ' LYS . 9.5 m-20 -62.85 -37.09 85.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 107.81 -1.182 . . . . 1.0 107.81 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 64.6 tttt -65.95 -51.38 59.04 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 113.297 -1.774 . . . . 1.0 111.485 179.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.2 t -67.31 -46.59 83.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 C-N-CA 120.238 -0.585 . . . . 1.0 111.423 -179.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.523 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 1.2 mptp? -62.05 -38.94 90.66 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.649 -1.241 . . . . 1.0 107.649 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.6 -44.55 49.26 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 114.629 -1.169 . . . . 1.0 112.444 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.415 ' O ' ' OG1' ' A' ' 17' ' ' THR . 87.9 mt-10 -59.71 -34.1 72.47 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.526 -0.916 . . . . 1.0 108.526 179.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.87 -37.08 62.26 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.892 -1.049 . . . . 1.0 110.111 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.19 -49.33 78.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.753 -1.112 . . . . 1.0 111.198 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mp -68.78 -38.26 79.88 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.14 -0.624 . . . . 1.0 109.385 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 55.9 m -60.76 -43.47 97.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.352 -0.84 . . . . 1.0 109.688 179.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -76.9 -44.69 30.86 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.85 -0.614 . . . . 1.0 111.973 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.649 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 54.6 t30 -60.33 -44.78 95.17 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.475 0.917 . . . . 1.0 113.475 -177.165 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -58.26 -31.7 67.69 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 119.441 -0.904 . . . . 1.0 109.613 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -80.98 -27.61 35.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.734 -0.667 . . . . 1.0 111.683 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.1 mtmt -59.47 146.22 80.21 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 120.335 -0.546 . . . . 1.0 111.517 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.45 148.93 59.8 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.543 2.162 . . . . 1.0 114.048 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.65 -18.48 2.96 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 115.167 -0.924 . . . . 1.0 112.576 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -83.75 134.66 26.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.549 -0.46 . . . . 1.0 110.202 -179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.2 121.96 66.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 107.838 -1.171 . . . . 1.0 107.838 177.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.9 p -93.53 146.16 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 CA-C-O 121.637 0.732 . . . . 1.0 111.981 -177.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 97.9 mt -113.03 163.17 18.68 Favored Pre-proline 0 N--CA 1.461 0.119 0 CA-C-N 114.469 -1.242 . . . . 1.0 110.892 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -60.32 -30.71 91.63 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.844 1.696 . . . . 1.0 111.249 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -69.44 -11.16 60.59 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.828 -0.624 . . . . 1.0 109.737 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.02 -2.49 75.77 Favored Glycine 0 C--O 1.229 -0.174 0 N-CA-C 109.949 -1.26 . . . . 1.0 109.949 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.41 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.08 133.7 36.13 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 108.59 -0.893 . . . . 1.0 108.59 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.41 ' H ' HD23 ' A' ' 32' ' ' LEU . 17.6 mp0 -121.82 138.53 54.34 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 116.319 -0.4 . . . . 1.0 111.086 -179.32 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -133.5 146.55 51.19 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-O 121.591 0.71 . . . . 1.0 111.089 178.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -129.86 135.8 48.81 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.495 -1.23 . . . . 1.0 109.233 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.25 104.67 15.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-O 122.153 0.978 . . . . 1.0 112.248 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.0 mm -70.69 -42.36 77.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.249 -0.887 . . . . 1.0 108.848 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -144.07 127.33 16.71 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.845 -1.071 . . . . 1.0 110.634 -178.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.2 p -84.51 126.9 33.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.043 0.449 . . . . 1.0 110.499 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -115.86 -36.78 1.11 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.64 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 56.49 30.39 17.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.465 -0.367 . . . . 1.0 111.187 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.07 -159.68 35.86 Favored Glycine 0 C--N 1.334 0.421 0 CA-C-O 121.87 0.706 . . . . 1.0 111.955 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.603 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.0 m -69.57 -178.73 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.239 -0.981 . . . . 1.0 109.411 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.431 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 155.14 0.38 Allowed Pre-proline 0 C--N 1.319 -0.731 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.785 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -87.76 161.49 7.69 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 123.011 2.474 . . . . 1.0 115.273 -175.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.426 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -93.2 171.45 32.5 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 108.049 -2.02 . . . . 1.0 108.049 175.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.613 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -45.75 -24.9 0.42 Allowed 'General case' 0 C--N 1.297 -1.701 0 CA-C-N 114.59 -0.805 . . . . 1.0 111.374 178.452 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.0 m -107.63 -9.64 15.83 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.863 1.06 . . . . 1.0 113.863 -177.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.426 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 96.9 m-20 -85.37 166.34 16.5 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 119.39 -0.924 . . . . 1.0 109.136 179.175 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.3 m -104.16 146.97 27.99 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.167 -0.679 . . . . 1.0 109.167 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.1 p -124.39 160.3 29.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 112.554 0.575 . . . . 1.0 112.554 -175.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 87.6 m -127.23 119.51 26.54 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.408 -0.96 . . . . 1.0 108.408 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -148.84 165.76 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 113.968 1.099 . . . . 1.0 113.968 -176.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.53 151.25 38.2 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.519 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 35.2 p90 -164.23 161.88 22.29 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 114.536 1.31 . . . . 1.0 114.536 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.436 ' OG1' ' OE2' ' A' ' 69' ' ' GLU . 1.8 m -123.51 127.04 47.78 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.201 -0.908 . . . . 1.0 108.691 175.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.25 136.38 13.54 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.93 -0.652 . . . . 1.0 111.775 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.534 ' HE ' ' HZ3' ' A' ' 127' ' ' LYS . 4.8 ptp180 -147.25 166.49 26.88 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 121.805 0.812 . . . . 1.0 112.395 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.5 mp -83.16 164.07 20.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 114.129 -1.396 . . . . 1.0 110.037 177.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.412 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.38 -24.38 30.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.127 -0.942 . . . . 1.0 110.139 177.889 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -93.1 2.58 56.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 113.855 -1.52 . . . . 1.0 111.741 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.36 -4.69 80.52 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.19 -0.529 . . . . 1.0 112.735 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -69.76 105.06 2.62 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.682 -0.807 . . . . 1.0 110.212 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.5 t -73.66 122.06 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.139 0.495 . . . . 1.0 110.471 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -110.76 -15.54 13.8 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 115.145 -0.934 . . . . 1.0 111.75 -179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.503 ' OD2' ' N ' ' A' ' 67' ' ' SER . 55.4 t0 -155.49 147.31 23.25 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 120.704 -0.399 . . . . 1.0 110.883 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.503 ' N ' ' OD2' ' A' ' 66' ' ' ASP . 97.5 p -154.25 152.71 30.63 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.217 -0.447 . . . . 1.0 111.612 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.483 ' N ' ' O ' ' A' ' 55' ' ' TYR . 84.9 m -156.58 -38.05 0.08 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.031 -0.531 . . . . 1.0 111.289 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.436 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.0 pp20? -65.99 -26.77 67.7 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.203 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -57.46 -39.7 76.9 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 108.173 -1.047 . . . . 1.0 108.173 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.9 p -81.76 -27.03 34.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.94 -1.027 . . . . 1.0 108.493 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 76.63 16.99 80.3 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.384 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -97.35 114.79 65.34 Favored Pre-proline 0 N--CA 1.471 0.622 0 C-N-CA 120.855 -0.338 . . . . 1.0 110.419 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_exo -61.99 154.19 63.54 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 121.916 1.744 . . . . 1.0 114.457 -178.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -126.05 150.61 48.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.262 -1.335 . . . . 1.0 108.407 178.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -104.57 134.35 47.9 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 113.006 0.743 . . . . 1.0 113.006 -178.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.62 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 55.1 m-85 -142.42 148.76 38.33 Favored 'General case' 0 CA--C 1.495 -1.141 0 CA-C-N 115.009 -0.996 . . . . 1.0 110.602 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 -90.31 124.5 34.96 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.004 -1.85 . . . . 1.0 106.004 175.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.0 t -52.07 -32.05 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 C-N-CA 119.774 -0.771 . . . . 1.0 110.509 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -74.02 -27.56 61.01 Favored 'General case' 0 CA--C 1.514 -0.413 0 C-N-CA 120.248 -0.581 . . . . 1.0 112.138 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.466 ' HB3' ' H27' ' A' ' 138' ' ' RAP . 70.9 mm-40 -101.29 -12.62 18.53 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 113.348 0.87 . . . . 1.0 113.348 -178.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.604 ' CG2' H31A ' A' ' 138' ' ' RAP . 4.5 p -71.04 172.03 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 119.288 -0.965 . . . . 1.0 109.94 -177.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.402 HD12 ' HH ' ' A' ' 109' ' ' TYR . 0.1 OUTLIER -53.8 148.36 20.1 Favored Pre-proline 0 CA--C 1.55 0.945 0 N-CA-C 108.812 -0.81 . . . . 1.0 108.812 -178.803 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -49.42 -47.51 22.2 Favored 'Trans proline' 0 N--CA 1.503 2.084 0 C-N-CA 122.151 1.9 . . . . 1.0 113.773 -178.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.3 -48.16 77.15 Favored Glycine 0 C--N 1.318 -0.44 0 N-CA-C 110.021 -1.232 . . . . 1.0 110.021 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.627 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 7.8 m95 -63.78 -34.14 77.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 114.047 -1.076 . . . . 1.0 111.562 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -51.94 -54.1 33.48 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.744 -0.382 . . . . 1.0 110.888 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -74.17 -44.29 54.02 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.177 0.806 . . . . 1.0 113.177 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -55.71 -44.37 77.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 113.796 1.035 . . . . 1.0 113.796 -177.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.3 mt -58.47 -41.52 85.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.243 0.544 . . . . 1.0 110.142 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -65.7 -23.09 66.69 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.252 -0.885 . . . . 1.0 111.145 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.485 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 55.1 mt -103.09 -9.94 19.3 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.596 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 5.2 ttt -91.11 107.14 18.99 Favored Pre-proline 0 CA--C 1.549 0.942 0 O-C-N 123.729 0.643 . . . . 1.0 111.638 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.431 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 17.9 Cg_exo -66.37 149.11 85.01 Favored 'Trans proline' 0 N--CA 1.499 1.846 0 C-N-CA 122.904 2.402 . . . . 1.0 112.656 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.603 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.96 136.16 55.7 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 115.422 -0.808 . . . . 1.0 111.459 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.02 -19.74 51.4 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.415 -1.874 . . . . 1.0 108.415 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -85.99 134.49 33.85 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.053 0.454 . . . . 1.0 110.269 178.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.4 m -108.26 115.01 29.32 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.689 -0.687 . . . . 1.0 109.659 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.485 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.5 m0 -116.12 166.87 11.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.528 0.68 . . . . 1.0 110.79 -179.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -126.9 128.57 46.68 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 106.683 -1.599 . . . . 1.0 106.683 175.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -123.16 138.2 53.96 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 CA-C-O 121.809 0.814 . . . . 1.0 109.699 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.649 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.31 103.71 12.7 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 105.424 -2.065 . . . . 1.0 105.424 -177.905 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.5 t -90.73 116.12 65.71 Favored Pre-proline 0 C--N 1.327 -0.4 0 N-CA-C 114.674 1.361 . . . . 1.0 114.674 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -51.03 144.67 27.44 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 121.261 1.307 . . . . 1.0 109.79 176.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 55.3 p -50.49 -35.44 29.2 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.338 -0.545 . . . . 1.0 110.561 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.58 -32.78 84.32 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.19 -0.764 . . . . 1.0 111.19 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 82.8 mt -98.92 1.3 45.51 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 121.314 -0.154 . . . . 1.0 110.655 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.18 -106.62 0.34 Allowed 'General case' 0 C--N 1.342 0.264 0 N-CA-C 111.643 0.238 . . . . 1.0 111.643 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.576 ' CZ ' ' C12' ' A' ' 138' ' ' RAP . 48.1 m-85 -101.97 5.05 40.56 Favored 'General case' 0 C--N 1.341 0.234 0 N-CA-C 113.705 1.002 . . . . 1.0 113.705 -177.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 99.93 167.28 29.36 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 120.645 -0.788 . . . . 1.0 114.043 176.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.513 ' O ' ' N ' ' A' ' 121' ' ' ASN . 73.8 Cg_endo -70.97 -19.99 29.66 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 C-N-CA 123.742 2.962 . . . . 1.0 113.038 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 11.7 mpt_? -93.74 167.15 11.84 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.009 -0.367 . . . . 1.0 110.009 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.651 ' HG ' ' N ' ' A' ' 120' ' ' PRO . 5.7 m -74.46 76.32 1.93 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 177.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.0 t -92.21 61.53 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.268 -0.423 . . . . 1.0 110.967 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.97 179.61 42.27 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 120.967 -0.635 . . . . 1.0 111.516 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -60.66 -107.14 0.01 OUTLIER Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.449 -0.66 . . . . 1.0 111.449 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -59.24 -13.15 18.64 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 C-N-CA 122.222 1.948 . . . . 1.0 110.725 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.564 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 3.3 mp -66.74 113.17 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 N-CA-C 108.185 -1.043 . . . . 1.0 108.185 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.54 ' C ' ' HG ' ' A' ' 113' ' ' SER . . . -91.66 -166.9 40.25 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 110.548 -1.021 . . . . 1.0 110.548 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.651 ' N ' ' HG ' ' A' ' 113' ' ' SER . 37.6 Cg_endo -64.09 147.21 91.59 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.14 1.893 . . . . 1.0 112.7 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 44.82 57.53 4.53 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.96 -0.564 . . . . 1.0 112.072 178.219 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 53.9 mm-40 -102.64 132.06 49.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.28 0.562 . . . . 1.0 112.334 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 36.2 m -96.34 129.08 43.76 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 106.418 -1.697 . . . . 1.0 106.418 175.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.98 146.17 40.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.387 0.613 . . . . 1.0 111.042 -179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.6 tt -123.58 148.28 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.764 0 CA-C-N 115.088 -0.96 . . . . 1.0 108.543 178.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -139.41 151.43 46.27 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 120.286 -0.566 . . . . 1.0 111.288 177.848 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.534 ' HZ3' ' HE ' ' A' ' 58' ' ' ARG . 11.4 mmtt -100.15 124.88 46.07 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.162 -2.162 . . . . 1.0 105.162 176.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.7 mt -119.35 119.21 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 119.075 -1.05 . . . . 1.0 111.998 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -111.85 125.42 54.0 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.048 -1.433 . . . . 1.0 108.714 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.02 114.51 26.71 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 112.869 0.692 . . . . 1.0 112.869 -178.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -96.05 -45.42 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 115.992 -0.549 . . . . 1.0 110.88 178.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.3 p -151.29 157.78 42.98 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 120.877 0.37 . . . . 1.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.37 134.66 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-O 121.325 0.583 . . . . 1.0 111.451 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.556 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 21.6 tptt -93.89 -143.71 0.24 Allowed 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.152 -0.931 . . . . 1.0 111.115 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.556 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -160.26 156.04 25.81 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.455 -1.248 . . . . 1.0 109.606 178.18 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.432 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 90.3 p -45.72 -33.17 2.84 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.465 -0.789 . . . . 1.0 111.139 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 34.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.381 179.507 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.795 H331 ' O2 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -66.08 -30.88 71.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.186 -0.461 . . . . 1.0 111.159 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.481 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 62.9 pttt -47.79 -40.43 20.9 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 119.896 -0.722 . . . . 1.0 109.513 -179.496 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.894 ' HZ1' HD22 ' A' ' 8' ' ' ASN . 4.9 tmtt? -66.33 -38.25 87.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.646 -0.707 . . . . 1.0 109.444 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.78 -35.26 63.64 Favored 'General case' 0 CA--C 1.509 -0.625 0 CA-C-N 115.181 -0.918 . . . . 1.0 109.801 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -69.32 -35.03 75.54 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.25 -0.886 . . . . 1.0 110.527 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -66.7 -54.49 22.54 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 121.886 0.85 . . . . 1.0 110.24 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.894 HD22 ' HZ1' ' A' ' 4' ' ' LYS . 16.0 m-20 -57.48 -35.64 70.45 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.737 -1.12 . . . . 1.0 108.543 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 45.1 tttt -64.74 -50.64 66.09 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 113.793 -1.549 . . . . 1.0 111.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.7 t -72.31 -47.52 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 119.964 -0.694 . . . . 1.0 112.152 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.403 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.4 OUTLIER -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.305 -0.998 . . . . 1.0 108.305 -179.919 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.95 -46.86 50.01 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 115.188 -0.915 . . . . 1.0 112.546 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.448 ' O ' ' OG1' ' A' ' 17' ' ' THR . 93.1 mt-10 -58.68 -34.26 71.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 108.804 -0.813 . . . . 1.0 108.804 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.55 -36.55 63.12 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.183 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -62.35 -49.37 75.85 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.579 -1.191 . . . . 1.0 111.134 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.8 mp -70.75 -39.61 73.19 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 119.954 -0.698 . . . . 1.0 109.922 178.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.469 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 75.6 m -60.97 -43.35 98.92 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.443 -0.798 . . . . 1.0 109.702 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -76.28 -46.07 29.61 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.91 -0.587 . . . . 1.0 111.816 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.654 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 55.4 t30 -59.88 -44.58 94.1 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.473 0.916 . . . . 1.0 113.473 -177.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.75 -31.61 68.5 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.337 -0.945 . . . . 1.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.469 ' ND2' ' O ' ' A' ' 17' ' ' THR . 50.0 m-80 -77.54 -34.23 53.97 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.514 -0.766 . . . . 1.0 111.653 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -57.94 137.03 83.71 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 120.628 -0.429 . . . . 1.0 111.76 -177.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.13 148.84 57.11 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 122.167 1.911 . . . . 1.0 113.442 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.13 -20.84 14.16 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.972 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.6 t -85.16 135.71 24.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.0 109.789 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.1 t -120.74 121.37 65.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.743 -1.206 . . . . 1.0 107.743 178.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.0 p -97.63 144.8 10.39 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.677 0 CA-C-O 121.746 0.784 . . . . 1.0 111.773 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 95.2 mt -111.32 164.28 15.37 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.314 -1.312 . . . . 1.0 110.688 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -60.84 -30.82 90.87 Favored 'Trans proline' 0 N--CA 1.485 0.983 0 C-N-CA 121.72 1.613 . . . . 1.0 110.83 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -67.81 -12.1 59.91 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.568 -0.742 . . . . 1.0 109.346 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.9 -1.59 78.28 Favored Glycine 0 C--O 1.228 -0.269 0 N-CA-C 109.962 -1.255 . . . . 1.0 109.962 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.412 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -78.68 133.66 37.18 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 108.375 -0.972 . . . . 1.0 108.375 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.412 ' H ' HD23 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.23 137.46 54.83 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.681 -0.236 . . . . 1.0 111.289 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -134.23 142.65 47.43 Favored 'General case' 0 CA--C 1.506 -0.725 0 CA-C-O 121.638 0.733 . . . . 1.0 111.116 178.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -123.9 130.89 53.32 Favored 'General case' 0 CA--C 1.503 -0.831 0 CA-C-N 114.528 -1.215 . . . . 1.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -88.92 104.48 14.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 122.294 1.045 . . . . 1.0 112.025 -178.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.1 mm -69.42 -41.84 80.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 114.766 -1.107 . . . . 1.0 108.471 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -144.26 126.1 15.27 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.522 -1.217 . . . . 1.0 109.752 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.8 p -85.23 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.027 0.441 . . . . 1.0 110.487 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.11 -37.54 1.02 Allowed Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.247 -1.141 . . . . 1.0 110.247 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.634 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 58.02 31.67 20.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.541 -0.329 . . . . 1.0 111.399 179.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.83 -159.78 35.64 Favored Glycine 0 C--N 1.333 0.376 0 CA-C-O 122.316 0.953 . . . . 1.0 112.51 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.608 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.9 m -69.68 -177.93 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 113.627 -1.286 . . . . 1.0 108.951 178.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.457 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.29 155.25 0.4 Allowed Pre-proline 0 C--N 1.318 -0.784 0 O-C-N 123.619 0.574 . . . . 1.0 109.932 179.459 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -87.7 156.4 7.57 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 123.305 2.67 . . . . 1.0 115.941 -174.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.427 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.35 176.59 45.17 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 108.874 -1.691 . . . . 1.0 108.874 176.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.498 ' CE ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.06 -22.38 15.82 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 120.501 -0.48 . . . . 1.0 111.517 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.458 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 35.8 m -106.97 -7.33 17.03 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.874 0.694 . . . . 1.0 112.874 -177.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.427 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 87.6 m-20 -84.58 170.81 13.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.952 -0.388 . . . . 1.0 109.952 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.4 ' HG1' ' HG2' ' A' ' 78' ' ' GLN . 13.3 m -110.76 147.04 35.28 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.285 0.564 . . . . 1.0 109.907 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -127.9 163.11 32.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 115.357 -0.838 . . . . 1.0 112.676 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.1 m -130.12 121.21 25.9 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 177.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.1 m -149.02 165.76 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 114.635 1.346 . . . . 1.0 114.635 -176.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -118.08 147.28 43.42 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.991 -1.855 . . . . 1.0 105.991 174.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.1 p90 -164.7 168.89 17.52 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 114.525 1.306 . . . . 1.0 114.525 -176.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.2 m -131.78 129.25 40.3 Favored 'General case' 0 C--O 1.217 -0.658 0 CA-C-N 114.771 -1.104 . . . . 1.0 108.267 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.65 131.73 9.84 Favored Glycine 0 N--CA 1.473 1.115 0 N-CA-C 111.292 -0.723 . . . . 1.0 111.292 -179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 11.7 ptp180 -146.4 167.3 23.94 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.705 0.764 . . . . 1.0 112.219 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.9 mp -82.48 164.17 21.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.325 -1.307 . . . . 1.0 110.063 177.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.44 HD12 ' H ' ' A' ' 61' ' ' ASP . 0.2 OUTLIER -61.37 -24.44 33.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 122.411 1.1 . . . . 1.0 109.858 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.44 ' H ' HD12 ' A' ' 60' ' ' ILE . 53.6 t0 -89.71 -0.02 57.27 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 113.21 -1.813 . . . . 1.0 111.882 -177.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.04 -1.71 78.07 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.904 -0.665 . . . . 1.0 112.317 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -71.82 102.46 2.87 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 119.805 -0.758 . . . . 1.0 110.021 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.2 127.41 36.77 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.519 0.676 . . . . 1.0 110.507 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -121.14 -11.07 8.91 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 114.705 -1.134 . . . . 1.0 111.486 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -154.46 143.87 21.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.132 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 20.5 p -157.93 156.12 30.71 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 113.038 0.755 . . . . 1.0 113.038 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 55' ' ' TYR . 65.3 m -159.15 -45.57 0.06 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 114.861 -1.063 . . . . 1.0 110.72 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -58.63 -26.1 63.38 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 116.391 -0.368 . . . . 1.0 110.114 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.8 mmtt -49.51 -41.08 39.91 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.523 -1.288 . . . . 1.0 107.523 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 27.6 p -83.31 -32.26 26.42 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 113.923 -1.489 . . . . 1.0 109.668 177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.64 13.16 81.98 Favored Glycine 0 C--N 1.332 0.338 0 N-CA-C 110.954 -0.858 . . . . 1.0 110.954 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -94.18 116.91 66.99 Favored Pre-proline 0 N--CA 1.466 0.34 0 C-N-CA 121.104 -0.238 . . . . 1.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -61.1 150.7 83.09 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 121.972 1.781 . . . . 1.0 115.112 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -125.65 150.81 47.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 114.107 -1.406 . . . . 1.0 108.301 177.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.04 135.42 47.52 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 113.593 0.96 . . . . 1.0 113.593 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.557 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 60.4 m-85 -142.24 153.89 44.33 Favored 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.162 -0.926 . . . . 1.0 109.449 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.4 ' HG2' ' HG1' ' A' ' 50' ' ' THR . 25.2 mt-30 -90.75 130.35 36.74 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.912 -1.884 . . . . 1.0 105.912 173.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.7 -29.98 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 C-N-CA 119.734 -0.786 . . . . 1.0 110.506 -177.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.0 t -73.32 -25.21 60.55 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 120.244 -0.582 . . . . 1.0 112.212 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.544 ' C ' H481 ' A' ' 138' ' ' RAP . 62.6 mm-40 -98.14 -15.39 19.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.553 0.575 . . . . 1.0 112.553 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.53 ' CG2' H31A ' A' ' 138' ' ' RAP . 2.0 p -78.47 172.71 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 120.021 -0.672 . . . . 1.0 111.147 -176.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -56.48 151.24 30.19 Favored Pre-proline 0 CA--C 1.55 0.974 0 C-N-CA 119.973 -0.691 . . . . 1.0 110.814 -178.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -53.89 -46.26 34.97 Favored 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 122.13 1.887 . . . . 1.0 112.876 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.4 -47.82 80.26 Favored Glycine 0 N--CA 1.451 -0.336 0 N-CA-C 109.132 -1.587 . . . . 1.0 109.132 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.66 ' CH2' ' H42' ' A' ' 138' ' ' RAP . 7.7 m95 -64.29 -39.0 93.04 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 113.542 -1.329 . . . . 1.0 109.669 178.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 m -51.76 -53.61 37.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 1.0 111.185 -178.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -72.4 -40.88 66.84 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.23 -48.17 82.85 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 113.995 1.109 . . . . 1.0 113.995 -177.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 52.1 mt -57.95 -40.85 81.56 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 121.545 0.688 . . . . 1.0 109.814 -178.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -63.89 -24.53 67.77 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.839 -1.073 . . . . 1.0 111.221 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.8 mt -101.86 -15.64 16.82 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.394 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' MET . . . . . 0.48 ' CE ' ' H ' ' A' ' 99' ' ' TRP . 8.2 ttt -83.4 108.48 13.29 Favored Pre-proline 0 C--N 1.321 -0.642 0 O-C-N 123.811 0.694 . . . . 1.0 112.689 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -68.91 146.38 65.24 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.34 2.026 . . . . 1.0 112.082 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.608 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.89 136.69 57.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.472 -0.785 . . . . 1.0 111.731 -179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.7 57.08 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 108.92 -1.672 . . . . 1.0 108.92 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.0 p -89.5 139.62 30.34 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 120.707 0.289 . . . . 1.0 110.49 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.6 m -110.31 112.48 24.46 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.004 -0.543 . . . . 1.0 109.902 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.48 ' H ' ' CE ' ' A' ' 93' ' ' MET . 40.8 m0 -115.25 161.34 18.6 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.805 0.812 . . . . 1.0 111.566 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -120.96 124.31 44.59 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 106.713 -1.588 . . . . 1.0 106.713 175.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -118.49 137.37 52.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-O 121.882 0.848 . . . . 1.0 110.61 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.654 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.28 103.05 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.722 -1.955 . . . . 1.0 105.722 -178.756 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 t -90.61 115.94 65.3 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 114.921 1.452 . . . . 1.0 114.921 -174.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -51.27 142.11 37.67 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 121.166 1.244 . . . . 1.0 109.868 176.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.3 p -48.11 -35.62 11.75 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 120.692 -0.403 . . . . 1.0 110.722 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.66 -33.19 85.42 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.181 -0.767 . . . . 1.0 111.181 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 71.9 mt -99.01 3.39 46.9 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.768 -0.216 . . . . 1.0 111.431 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.96 -114.98 0.28 Allowed 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.526 -0.546 . . . . 1.0 109.526 -179.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.588 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 62.3 m-85 -91.25 5.06 50.62 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.821 0.344 . . . . 1.0 111.636 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.59 164.19 22.55 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.157 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.511 ' O ' ' N ' ' A' ' 121' ' ' ASN . 86.9 Cg_endo -74.23 -9.35 21.79 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 123.362 2.708 . . . . 1.0 110.247 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -107.7 162.95 13.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.495 -1.229 . . . . 1.0 109.745 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.5 m -72.01 89.94 1.14 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.671 -0.411 . . . . 1.0 109.939 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -104.52 62.23 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 121.118 -0.233 . . . . 1.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 164.62 -175.34 40.63 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 120.309 -0.948 . . . . 1.0 112.705 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.98 -104.81 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 N-CA-C 111.639 -0.584 . . . . 1.0 111.639 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -63.76 -15.36 48.39 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.545 2.163 . . . . 1.0 111.322 -178.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 4.8 mp -67.25 111.8 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.02 0 N-CA-C 108.295 -1.002 . . . . 1.0 108.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.62 -170.72 43.5 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.054 -0.976 . . . . 1.0 111.223 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.571 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 28.6 Cg_endo -61.86 143.56 95.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.461 2.108 . . . . 1.0 112.788 179.178 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.8 t-20 49.07 48.84 20.39 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.792 0.664 . . . . 1.0 112.792 178.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.538 ' OE1' ' NZ ' ' A' ' 4' ' ' LYS . 45.9 mm-40 -93.94 129.27 40.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 113.164 0.802 . . . . 1.0 113.164 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 17.5 m -95.63 129.1 42.94 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 105.796 -1.927 . . . . 1.0 105.796 174.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -116.0 143.64 45.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.369 0.605 . . . . 1.0 110.69 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.2 tt -119.54 148.11 22.74 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.649 0 CA-C-N 115.157 -0.928 . . . . 1.0 109.076 179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.591 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.96 149.94 45.32 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.478 0.656 . . . . 1.0 111.527 177.356 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 8.6 mmtt -100.12 124.4 45.49 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 105.229 -2.137 . . . . 1.0 105.229 177.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -122.01 127.61 75.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 119.497 -0.881 . . . . 1.0 112.327 -176.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.7 t-160 -118.97 124.31 46.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.321 -1.309 . . . . 1.0 107.633 178.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.78 110.39 22.87 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 120.225 -0.59 . . . . 1.0 112.374 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -94.34 -47.22 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.518 -0.765 . . . . 1.0 112.117 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.4 p -146.7 156.94 43.56 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.655 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 46.5 t -132.48 140.0 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.203 0.525 . . . . 1.0 111.942 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.652 ' HG3' ' H ' ' A' ' 135' ' ' LYS . 0.1 OUTLIER -97.46 -145.7 0.3 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.703 -0.68 . . . . 1.0 109.613 178.177 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.652 ' H ' ' HG3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -174.08 142.2 0.82 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.777 178.676 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 10.7 t -52.47 -39.7 61.47 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.801 -1.09 . . . . 1.0 111.443 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 13.1 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.02 -0.991 . . . . 1.0 110.513 179.899 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.733 ' O3 ' H492 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.057 -0.72 . . . . 1.0 109.057 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -67.17 -18.33 65.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.841 -0.618 . . . . 1.0 110.401 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.4 ' HG3' ' H ' ' A' ' 4' ' ' LYS . 1.2 pttt -45.2 -37.57 4.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.612 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.4 ' H ' ' HG3' ' A' ' 3' ' ' LYS . 3.7 tmtm? -73.65 -38.74 64.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.756 0.789 . . . . 1.0 109.532 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -51.01 -33.82 26.65 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.397 -0.82 . . . . 1.0 110.237 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -65.98 -39.65 90.54 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.229 -0.896 . . . . 1.0 111.457 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -64.94 -50.11 67.72 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 121.627 0.727 . . . . 1.0 110.864 -178.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.612 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 14.3 m-20 -60.49 -35.75 76.67 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 13' ' ' GLU . 48.9 tttt -66.16 -51.38 58.39 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.687 -1.597 . . . . 1.0 111.444 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.61 -48.03 78.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 C-N-CA 120.352 -0.539 . . . . 1.0 111.702 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.405 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.81 -38.73 91.86 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.552 -1.277 . . . . 1.0 107.552 179.119 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.15 -42.74 66.36 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 114.942 -1.027 . . . . 1.0 111.831 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.461 ' O ' ' OG1' ' A' ' 17' ' ' THR . 83.2 mt-10 -62.36 -32.18 72.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.972 -0.751 . . . . 1.0 108.972 178.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -35.05 49.6 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.261 -0.881 . . . . 1.0 109.878 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -61.17 -50.24 73.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 114.459 -1.246 . . . . 1.0 111.043 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.4 mp -70.92 -39.8 72.5 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.213 -0.595 . . . . 1.0 109.945 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 96.3 m -61.69 -42.63 99.19 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.541 -0.754 . . . . 1.0 109.315 -179.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -76.71 -44.53 33.09 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-N 115.485 -0.78 . . . . 1.0 112.019 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.653 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.6 t30 -60.67 -44.77 96.09 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 113.375 0.879 . . . . 1.0 113.375 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.19 -31.93 67.76 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 119.517 -0.873 . . . . 1.0 109.237 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -79.83 -30.35 40.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.151 -0.931 . . . . 1.0 111.647 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 33.0 mtmt -58.18 136.43 84.61 Favored Pre-proline 0 CA--C 1.547 0.857 0 C-N-CA 120.425 -0.51 . . . . 1.0 111.396 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -52.92 148.66 28.76 Favored 'Trans proline' 0 N--CA 1.501 1.965 0 C-N-CA 122.271 1.981 . . . . 1.0 113.547 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -19.51 10.33 Favored Glycine 0 C--O 1.225 -0.413 0 CA-C-N 115.094 -0.957 . . . . 1.0 111.829 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.3 t -86.56 136.56 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.162 0.506 . . . . 1.0 110.896 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.7 t -120.99 123.97 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 N-CA-C 107.952 -1.129 . . . . 1.0 107.952 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.02 145.89 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-O 121.796 0.808 . . . . 1.0 112.008 -178.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.2 mt -113.03 165.18 13.7 Favored Pre-proline 0 C--O 1.231 0.126 0 CA-C-N 114.328 -1.305 . . . . 1.0 111.111 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -61.42 -30.03 86.31 Favored 'Trans proline' 0 C--N 1.32 -0.965 0 C-N-CA 122.167 1.911 . . . . 1.0 111.274 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 m -68.66 -14.97 63.37 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.713 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.5 -3.07 65.56 Favored Glycine 0 C--N 1.329 0.168 0 N-CA-C 109.688 -1.365 . . . . 1.0 109.688 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.42 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.99 133.84 36.2 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.42 ' H ' HD23 ' A' ' 32' ' ' LEU . 22.0 mp0 -121.47 140.13 52.57 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 1.0 110.984 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -135.97 144.52 45.44 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.629 0.728 . . . . 1.0 110.935 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -127.54 134.8 49.74 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.427 -1.261 . . . . 1.0 109.041 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -92.82 104.04 15.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 122.158 0.98 . . . . 1.0 111.929 -178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.4 mm -69.41 -41.48 80.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -143.73 130.01 19.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.676 -1.147 . . . . 1.0 109.697 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -86.15 131.8 34.16 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.025 -0.361 . . . . 1.0 110.025 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.75 -35.34 0.85 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.636 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 54.61 30.07 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.659 -0.271 . . . . 1.0 111.104 179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.21 -161.23 37.12 Favored Glycine 0 C--N 1.331 0.256 0 CA-C-O 121.997 0.776 . . . . 1.0 111.752 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.8 m -68.94 -178.58 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 114.128 -1.036 . . . . 1.0 109.506 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.482 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.26 154.86 0.39 Allowed Pre-proline 0 C--N 1.32 -0.708 0 CA-C-N 115.608 -0.723 . . . . 1.0 109.391 179.536 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -87.72 156.72 7.56 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 123.195 2.597 . . . . 1.0 116.054 -175.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.421 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -87.44 178.37 47.52 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 108.579 -1.808 . . . . 1.0 108.579 176.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.703 ' H ' ' HZ2' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -56.32 -20.47 19.09 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.409 -0.516 . . . . 1.0 111.153 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.2 m -108.48 -7.84 15.69 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.386 0.884 . . . . 1.0 113.386 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.421 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.7 m-20 -87.57 164.59 16.01 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 120.202 -0.599 . . . . 1.0 109.466 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.7 m -101.88 150.53 23.09 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.156 0.503 . . . . 1.0 110.114 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.19 160.21 38.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.335 0 CA-C-N 115.374 -0.83 . . . . 1.0 111.925 -177.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.0 m -129.87 120.79 25.48 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.441 -0.948 . . . . 1.0 108.441 178.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.9 m -149.19 166.27 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 113.832 1.049 . . . . 1.0 113.832 -176.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -118.4 149.6 40.96 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 105.748 -1.945 . . . . 1.0 105.748 173.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.579 ' CZ ' ' C5 ' ' A' ' 138' ' ' RAP . 41.3 p90 -163.29 162.4 25.18 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 118.285 -1.366 . . . . 1.0 114.338 -177.069 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.436 ' OG1' ' OE1' ' A' ' 69' ' ' GLU . 1.4 m -124.33 131.78 53.53 Favored 'General case' 0 C--O 1.217 -0.654 0 N-CA-C 108.183 -1.043 . . . . 1.0 108.183 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -117.76 137.83 13.52 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.39 -0.684 . . . . 1.0 111.39 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.84 168.01 23.29 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.769 0.795 . . . . 1.0 112.183 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.1 mp -85.07 164.73 18.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.376 -1.284 . . . . 1.0 109.772 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.13 -26.07 35.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 121.925 0.869 . . . . 1.0 110.061 178.294 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.4 ' H ' HD12 ' A' ' 60' ' ' ILE . 47.6 t0 -92.22 2.96 56.29 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 113.808 -1.542 . . . . 1.0 111.764 -177.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.02 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 120.932 -0.651 . . . . 1.0 112.962 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.0 m -70.05 102.44 2.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 118.105 0.952 . . . . 1.0 110.026 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -72.95 120.07 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.819 0 CA-C-O 121.465 0.65 . . . . 1.0 110.354 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.472 ' CE2' ' OD2' ' A' ' 66' ' ' ASP . 18.8 p90 -114.78 -8.72 12.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.641 -1.163 . . . . 1.0 111.966 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -155.1 146.45 22.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.104 -0.498 . . . . 1.0 110.692 178.184 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.9 p -157.49 150.08 22.97 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 115.81 -0.632 . . . . 1.0 111.681 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.462 ' N ' ' O ' ' A' ' 55' ' ' TYR . 92.4 m -156.04 -40.46 0.08 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.759 -0.655 . . . . 1.0 110.884 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.436 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 2.6 pp20? -63.6 -26.06 68.51 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.222 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -55.93 -43.76 77.7 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.967 -1.124 . . . . 1.0 107.967 178.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.457 ' OG1' ' O ' ' A' ' 68' ' ' THR . 72.9 p -73.79 -34.5 64.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.878 -1.055 . . . . 1.0 108.521 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.93 16.16 70.76 Favored Glycine 0 C--N 1.334 0.453 0 CA-C-N 115.036 -0.984 . . . . 1.0 111.012 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.42 116.31 65.52 Favored Pre-proline 0 N--CA 1.471 0.576 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.592 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -60.98 153.69 62.1 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 121.723 1.615 . . . . 1.0 114.483 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.4 150.88 45.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.307 -1.315 . . . . 1.0 107.786 178.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 t -110.29 133.81 52.89 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.541 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 58.9 m-85 -143.01 152.51 42.0 Favored 'General case' 0 CA--C 1.503 -0.832 0 CA-C-N 114.577 -1.192 . . . . 1.0 109.505 178.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -92.34 125.2 36.9 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 106.334 -1.728 . . . . 1.0 106.334 174.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.6 t -47.02 -32.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 115.773 -0.649 . . . . 1.0 110.609 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.9 t -74.42 -24.41 59.09 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 120.347 -0.541 . . . . 1.0 111.859 -178.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.461 ' O ' H361 ' A' ' 138' ' ' RAP . 89.1 mm-40 -98.82 -9.2 24.69 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 112.928 0.714 . . . . 1.0 112.928 -178.25 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.618 ' CG2' H31A ' A' ' 138' ' ' RAP . 3.3 p -88.04 170.71 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 118.196 0.453 . . . . 1.0 111.494 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.46 145.02 29.58 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 120.871 -0.331 . . . . 1.0 110.58 -176.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.32 -44.87 36.75 Favored 'Trans proline' 0 N--CA 1.498 1.737 0 C-N-CA 121.952 1.768 . . . . 1.0 112.74 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.39 -47.48 82.64 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 109.281 -1.528 . . . . 1.0 109.281 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.734 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 9.7 m95 -66.22 -37.02 84.54 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 113.791 -1.205 . . . . 1.0 110.261 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.19 -53.31 36.12 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.856 -0.338 . . . . 1.0 110.942 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tp10 -71.89 -43.98 64.5 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.085 0.402 . . . . 1.0 112.085 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.94 -46.43 85.09 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 114.022 1.119 . . . . 1.0 114.022 -177.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.3 -41.58 84.75 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.154 -0.618 . . . . 1.0 109.634 -178.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -65.69 -23.41 66.77 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.187 -0.915 . . . . 1.0 111.197 -179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.422 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 85.4 mt -102.93 -10.34 19.1 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.459 -0.337 . . . . 1.0 110.741 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' MET . . . . . 0.497 ' HE2' ' H ' ' A' ' 99' ' ' TRP . 25.5 ttt -90.62 107.47 20.53 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.734 -0.666 . . . . 1.0 112.032 -178.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.482 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 16.0 Cg_exo -68.89 148.09 69.9 Favored 'Trans proline' 0 N--CA 1.498 1.77 0 C-N-CA 122.546 2.164 . . . . 1.0 112.361 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.585 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.67 137.67 57.47 Favored 'General case' 0 CA--C 1.509 -0.602 0 CA-C-N 115.546 -0.752 . . . . 1.0 111.664 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.16 -19.19 54.65 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 108.873 -1.691 . . . . 1.0 108.873 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.2 p -88.19 129.98 35.19 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 115.475 -0.362 . . . . 1.0 110.443 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 60.7 m -102.12 115.02 29.67 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 109.438 -0.579 . . . . 1.0 109.438 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.497 ' H ' ' HE2' ' A' ' 93' ' ' MET . 39.4 m0 -116.28 168.31 10.24 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.817 0.818 . . . . 1.0 111.278 -178.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 81.5 mt-10 -129.25 129.57 45.12 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 106.63 -1.619 . . . . 1.0 106.63 175.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 pt -125.58 138.45 54.42 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.533 0 CA-C-O 121.771 0.796 . . . . 1.0 109.78 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.653 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.26 103.25 12.18 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 106.021 -1.844 . . . . 1.0 106.021 -178.032 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.1 t -90.01 115.74 64.7 Favored Pre-proline 0 C--N 1.326 -0.442 0 N-CA-C 115.248 1.573 . . . . 1.0 115.248 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -51.44 143.77 34.11 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.188 1.259 . . . . 1.0 109.634 176.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 88.1 p -50.37 -33.76 21.66 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.517 -178.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.5 -32.73 82.58 Favored Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.03 -0.828 . . . . 1.0 111.03 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -99.78 1.73 43.43 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.981 -0.11 . . . . 1.0 110.859 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -111.83 0.3 Allowed 'General case' 0 C--N 1.342 0.264 0 CA-C-O 120.754 0.312 . . . . 1.0 110.816 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.507 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 53.3 m-85 -98.12 5.41 48.62 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 113.567 0.951 . . . . 1.0 113.567 -177.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.81 164.07 18.59 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 121.018 -0.61 . . . . 1.0 113.483 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 121' ' ' ASN . 93.9 Cg_endo -77.02 -9.99 17.98 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.571 2.847 . . . . 1.0 111.173 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -106.65 169.29 8.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.252 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.4 m -75.26 97.21 3.49 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.743 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.2 t -110.77 60.08 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 121.059 -0.256 . . . . 1.0 111.125 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 168.68 -177.95 42.34 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 120.514 -0.85 . . . . 1.0 111.998 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.04 -103.77 0.01 OUTLIER Glycine 0 CA--C 1.535 1.338 0 N-CA-C 111.141 -0.783 . . . . 1.0 111.141 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -63.21 -14.05 39.48 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.732 2.288 . . . . 1.0 111.159 -178.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.3 mp -65.86 114.93 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 108.273 -1.01 . . . . 1.0 108.273 179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.432 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -95.03 -171.88 37.1 Favored Glycine 0 CA--C 1.52 0.354 0 CA-C-N 115.512 -0.767 . . . . 1.0 111.553 -178.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.529 ' N ' ' OG ' ' A' ' 113' ' ' SER . 26.3 Cg_endo -63.25 138.2 65.2 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.562 2.174 . . . . 1.0 112.535 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.53 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 53.17 51.41 15.69 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 120.962 -0.295 . . . . 1.0 111.3 178.531 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.612 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -96.74 131.27 43.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.294 -0.412 . . . . 1.0 111.6 -179.608 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 49.1 m -95.97 128.66 43.05 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.34 138.9 48.41 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.064 0.459 . . . . 1.0 110.998 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.4 tt -117.91 147.35 21.42 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.583 0 CA-C-N 115.724 -0.671 . . . . 1.0 109.195 178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.584 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.83 150.92 47.58 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.441 -0.504 . . . . 1.0 111.629 177.855 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.424 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.0 mmtt -100.76 123.97 45.72 Favored 'General case' 0 CA--C 1.501 -0.907 0 N-CA-C 105.807 -1.923 . . . . 1.0 105.807 177.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.9 mt -117.0 125.61 73.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 119.592 -0.843 . . . . 1.0 112.732 -176.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -118.03 124.58 48.46 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.172 -1.377 . . . . 1.0 108.484 178.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.23 114.22 25.98 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 119.746 -0.782 . . . . 1.0 112.808 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.4 mp -95.46 -43.01 12.74 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 115.732 -0.667 . . . . 1.0 110.996 178.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -154.21 156.5 37.2 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.604 -0.439 . . . . 1.0 111.265 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.7 t -129.82 138.43 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.111 -0.495 . . . . 1.0 111.273 -178.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.489 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 8.9 tptm -97.16 -148.93 0.32 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 1.0 109.931 178.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER -167.54 146.26 4.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.28 178.024 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.484 ' HG ' ' N ' ' A' ' 137' ' ' SER . 96.4 p -59.15 -35.15 73.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.011 -0.995 . . . . 1.0 110.947 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.484 ' N ' ' HG ' ' A' ' 136' ' ' SER . 1.0 OUTLIER . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.963 -1.018 . . . . 1.0 110.043 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.752 ' H62' ' O4 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 . . . . . 0 N--CA 1.492 1.64 0 N-CA-C 109.773 -0.454 . . . . 1.0 109.773 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -64.36 -17.7 63.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.797 -0.638 . . . . 1.0 111.685 -179.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -50.04 -43.58 51.0 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.99 0.424 . . . . 1.0 109.888 -178.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.535 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 4.9 tmtt? -68.91 -37.05 78.7 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-O 121.612 0.72 . . . . 1.0 109.971 179.12 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -51.3 -33.35 28.55 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.482 -0.781 . . . . 1.0 110.8 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -62.73 -36.92 84.57 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.32 -0.855 . . . . 1.0 110.751 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 22.7 mt-10 -66.68 -52.38 45.45 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-O 121.842 0.83 . . . . 1.0 110.104 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.535 ' OD1' ' NZ ' ' A' ' 4' ' ' LYS . 88.5 m-20 -58.75 -34.07 70.99 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 115.002 -0.999 . . . . 1.0 108.409 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 17.7 tttp -66.1 -51.47 57.77 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.073 -1.422 . . . . 1.0 111.493 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.3 t -67.32 -46.88 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 C-N-CA 119.845 -0.742 . . . . 1.0 111.663 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.4 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.59 -37.58 86.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.893 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.95 -44.66 29.65 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.861 -1.063 . . . . 1.0 112.317 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.484 ' O ' ' OG1' ' A' ' 17' ' ' THR . 58.3 mt-10 -60.73 -34.5 74.51 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.53 -0.915 . . . . 1.0 108.53 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.56 -36.07 65.56 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.016 -0.993 . . . . 1.0 109.826 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -61.14 -50.22 74.08 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.762 -1.108 . . . . 1.0 110.3 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.7 mp -66.22 -38.43 87.92 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.387 -0.597 . . . . 1.0 109.387 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.484 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 30.3 m -61.51 -42.59 99.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.739 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -75.62 -44.61 41.93 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.6 -0.727 . . . . 1.0 111.887 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.628 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -56.98 -49.52 75.48 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -178.486 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.3 ptmt -58.93 -29.47 67.13 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.355 -0.938 . . . . 1.0 110.021 -176.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -81.79 -29.1 32.86 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.311 -0.859 . . . . 1.0 111.482 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 mtmt -60.69 145.63 87.52 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 120.625 -0.43 . . . . 1.0 112.005 -178.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.439 ' C ' ' H ' ' A' ' 25' ' ' VAL . 31.7 Cg_exo -57.0 149.05 64.52 Favored 'Trans proline' 0 N--CA 1.507 2.296 0 C-N-CA 122.946 2.431 . . . . 1.0 114.708 -179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.44 -20.53 2.11 Favored Glycine 0 N--CA 1.462 0.41 0 CA-C-N 114.957 -1.02 . . . . 1.0 111.894 178.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' A' ' 23' ' ' PRO . 47.2 t -79.2 131.55 34.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 C-N-CA 120.138 -0.625 . . . . 1.0 109.925 -178.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 67.4 t -116.03 120.33 64.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.103 -1.073 . . . . 1.0 108.103 177.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.6 p -93.32 145.94 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 CA-C-O 121.688 0.756 . . . . 1.0 111.366 -178.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.33 163.55 18.0 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-N 114.534 -1.212 . . . . 1.0 110.446 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.4 -30.99 92.1 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 121.668 1.579 . . . . 1.0 111.294 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.3 m -69.34 -13.44 62.38 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.676 -0.693 . . . . 1.0 110.114 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.32 -4.0 64.29 Favored Glycine 0 CA--C 1.518 0.252 0 N-CA-C 110.179 -1.169 . . . . 1.0 110.179 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.432 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.8 tm? -77.45 134.56 38.34 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 108.565 -0.902 . . . . 1.0 108.565 179.573 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.432 ' H ' HD23 ' A' ' 32' ' ' LEU . 14.2 mp0 -125.1 141.68 51.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 116.341 -0.391 . . . . 1.0 111.609 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.1 p90 -137.01 142.58 42.52 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.745 0.783 . . . . 1.0 112.087 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.459 ' CE ' ' CD1' ' A' ' 37' ' ' ILE . 6.2 ttpt -124.85 124.63 42.5 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 114.282 -1.327 . . . . 1.0 108.296 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.88 113.39 21.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 CA-C-N 115.199 -0.91 . . . . 1.0 111.107 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.496 ' HB ' HD21 ' A' ' 38' ' ' ASN . 4.7 mm -77.02 -42.15 31.77 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 CA-C-O 121.808 0.813 . . . . 1.0 109.63 178.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.496 HD21 ' HB ' ' A' ' 37' ' ' ILE . 24.8 m-80 -143.81 128.76 18.49 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.208 -1.36 . . . . 1.0 109.655 -177.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.9 p -90.83 128.57 36.77 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.941 0.401 . . . . 1.0 109.996 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.89 -32.64 1.39 Allowed Glycine 0 CA--C 1.52 0.368 0 N-CA-C 110.045 -1.222 . . . . 1.0 110.045 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.64 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 56.6 31.92 20.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.532 -0.334 . . . . 1.0 111.126 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.13 -161.01 37.0 Favored Glycine 0 C--N 1.334 0.445 0 CA-C-O 121.833 0.685 . . . . 1.0 111.553 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.586 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.6 m -68.41 -178.49 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.108 -1.046 . . . . 1.0 109.301 178.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.426 ' HZ2' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.66 154.59 0.36 Allowed Pre-proline 0 C--N 1.319 -0.741 0 O-C-N 123.84 0.712 . . . . 1.0 109.213 179.529 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -86.99 157.9 8.62 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.933 2.422 . . . . 1.0 115.781 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.439 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.31 172.69 38.25 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 108.446 -1.862 . . . . 1.0 108.446 176.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.618 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -47.04 -25.27 0.78 Allowed 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 114.83 -0.685 . . . . 1.0 111.62 178.773 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.438 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 20.7 m -108.25 -9.14 15.56 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 113.363 0.875 . . . . 1.0 113.363 -177.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.439 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.7 m-20 -84.72 167.39 16.19 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 119.717 -0.793 . . . . 1.0 109.005 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.8 m -106.14 149.93 26.31 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.096 0.474 . . . . 1.0 109.918 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -126.53 162.35 30.93 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.297 0 CA-C-N 115.477 -0.783 . . . . 1.0 112.21 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 77.9 m -130.23 119.96 23.72 Favored 'General case' 0 N--CA 1.464 0.24 0 N-CA-C 108.333 -0.988 . . . . 1.0 108.333 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.408 ' O ' ' N ' ' A' ' 75' ' ' ALA . 12.8 m -148.99 166.62 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 114.28 1.215 . . . . 1.0 114.28 -176.631 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -118.4 152.19 36.34 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 106.386 -1.709 . . . . 1.0 106.386 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.5 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 32.8 p90 -163.63 160.71 23.16 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 118.423 -1.311 . . . . 1.0 114.538 -178.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.6 m -122.15 130.29 53.09 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.769 -0.826 . . . . 1.0 108.769 175.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.2 137.08 13.93 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.881 -0.676 . . . . 1.0 112.02 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -147.84 167.28 25.17 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.617 0.722 . . . . 1.0 112.227 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -86.89 166.05 15.46 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.491 -1.231 . . . . 1.0 111.404 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.01 -26.24 35.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 114.809 -1.087 . . . . 1.0 110.266 178.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -93.79 2.38 56.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.173 -1.376 . . . . 1.0 111.416 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -2.25 75.67 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 120.998 -0.62 . . . . 1.0 112.767 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.4 m -69.03 103.44 1.86 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.821 0.81 . . . . 1.0 110.326 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.9 t -74.03 122.7 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 C-N-CA 120.287 -0.565 . . . . 1.0 109.601 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.414 ' CE2' H431 ' A' ' 138' ' ' RAP . 17.3 p90 -116.35 -8.46 11.64 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 115.003 -0.999 . . . . 1.0 111.598 -178.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.452 ' OD1' H433 ' A' ' 138' ' ' RAP . 33.7 t0 -158.29 152.42 24.09 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.467 -0.493 . . . . 1.0 111.335 178.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 96.4 p -159.29 153.23 23.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.729 -0.668 . . . . 1.0 111.623 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.491 ' O ' ' OG1' ' A' ' 71' ' ' THR . 66.2 m -155.86 -39.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.643 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.411 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 1.4 pp20? -65.8 -27.15 68.06 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -58.15 -43.83 87.55 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 107.808 -1.182 . . . . 1.0 107.808 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.491 ' OG1' ' O ' ' A' ' 68' ' ' THR . 3.5 p -73.99 -31.32 62.92 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.865 -1.062 . . . . 1.0 108.797 176.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.71 18.31 68.42 Favored Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.81 178.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 115.03 65.43 Favored Pre-proline 0 N--CA 1.47 0.539 0 C-N-CA 120.682 -0.407 . . . . 1.0 110.98 -179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_exo -60.83 152.49 69.67 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.823 1.682 . . . . 1.0 114.366 -178.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.26 152.21 41.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.042 -1.436 . . . . 1.0 107.833 178.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 130.9 55.38 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 121.408 0.623 . . . . 1.0 112.511 -178.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.59 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 42.3 m-85 -138.82 148.44 43.77 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.0 -1.0 . . . . 1.0 109.853 178.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.3 mt-30 -90.35 125.39 35.52 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 106.335 -1.728 . . . . 1.0 106.335 174.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.8 t -53.69 -28.85 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 C-N-CA 119.394 -0.922 . . . . 1.0 110.15 -177.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.7 t -73.97 -25.59 60.02 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.025 -0.67 . . . . 1.0 111.835 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.541 ' O ' ' C33' ' A' ' 138' ' ' RAP . 84.5 mm-40 -100.1 -16.07 17.97 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.717 -0.393 . . . . 1.0 112.022 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.89 ' HA ' H332 ' A' ' 138' ' ' RAP . 0.4 OUTLIER -64.99 164.75 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 112.109 0.411 . . . . 1.0 112.109 -177.637 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.58 148.96 23.19 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.501 -0.925 . . . . 1.0 108.501 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -51.33 -42.62 53.68 Favored 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 121.061 1.174 . . . . 1.0 112.093 -178.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.76 -48.09 87.73 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 119.872 -1.156 . . . . 1.0 110.54 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.681 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 9.5 m95 -65.56 -35.5 81.04 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.301 -0.949 . . . . 1.0 111.144 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.2 m -51.19 -54.38 26.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.987 -0.285 . . . . 1.0 111.637 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.89 -40.8 68.65 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.456 0.539 . . . . 1.0 112.456 -179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.1 -48.1 82.84 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 114.136 1.162 . . . . 1.0 114.136 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.4 mt -58.32 -42.25 86.31 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.299 0.571 . . . . 1.0 109.896 -177.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -63.25 -23.9 67.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.332 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.517 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.7 mt -100.95 -12.45 18.91 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.902 -0.59 . . . . 1.0 111.246 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.5 ttp -90.17 107.45 19.64 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 111.863 0.32 . . . . 1.0 111.863 -178.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.426 ' HG3' ' HZ2' ' A' ' 44' ' ' LYS . 16.3 Cg_exo -67.28 148.02 79.38 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.614 2.209 . . . . 1.0 112.426 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.586 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.61 135.6 55.26 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-O 121.546 0.688 . . . . 1.0 110.926 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.46 57.49 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 107.788 -2.125 . . . . 1.0 107.788 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' A' ' 94' ' ' PRO . 4.8 p -90.24 133.51 34.88 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.956 -0.622 . . . . 1.0 110.676 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.0 m -108.8 115.42 30.06 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.581 -0.736 . . . . 1.0 109.426 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.517 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 40.6 m0 -115.43 168.52 9.92 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.777 0.799 . . . . 1.0 111.081 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -127.89 129.91 47.65 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 106.449 -1.686 . . . . 1.0 106.449 175.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.7 pt -126.33 137.83 56.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.782 0.801 . . . . 1.0 109.707 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.628 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -108.91 103.62 12.71 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 105.866 -1.901 . . . . 1.0 105.866 -178.078 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 t -90.48 115.57 64.43 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 115.162 1.541 . . . . 1.0 115.162 -174.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -51.07 145.6 24.96 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.525 1.483 . . . . 1.0 109.89 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.7 p -51.7 -36.24 45.92 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.241 -0.584 . . . . 1.0 111.046 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.43 -32.48 83.62 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.862 -0.895 . . . . 1.0 110.862 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.6 mt -99.19 2.28 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.856 -0.172 . . . . 1.0 111.001 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.499 ' O ' ' C52' ' A' ' 138' ' ' RAP . . . -108.82 -103.81 0.37 Allowed 'General case' 0 C--O 1.219 -0.54 0 N-CA-C 112.197 0.443 . . . . 1.0 112.197 -177.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.674 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 31.9 m-85 -104.07 3.96 33.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 113.435 0.902 . . . . 1.0 113.435 -177.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.78 167.8 17.22 Favored Glycine 0 N--CA 1.47 0.922 0 C-N-CA 120.673 -0.775 . . . . 1.0 113.786 177.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.575 ' O ' ' N ' ' A' ' 121' ' ' ASN . 91.0 Cg_endo -76.37 -17.74 16.41 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 124.013 3.142 . . . . 1.0 111.764 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -103.67 169.69 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.848 -0.615 . . . . 1.0 110.066 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.406 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.2 m -74.16 102.95 4.42 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.673 -0.491 . . . . 1.0 109.673 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.7 t -111.62 61.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-O 120.699 0.285 . . . . 1.0 110.795 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 162.95 178.32 36.67 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.631 -0.795 . . . . 1.0 111.793 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.46 -103.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.156 0 N-CA-C 111.09 -0.804 . . . . 1.0 111.09 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -61.76 -16.64 50.12 Favored 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.672 2.248 . . . . 1.0 111.734 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 4.9 mp -66.46 117.2 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 107.475 -1.305 . . . . 1.0 107.475 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -93.47 -170.15 39.09 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.622 -0.717 . . . . 1.0 111.926 -178.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.406 ' N ' ' OG ' ' A' ' 113' ' ' SER . 30.1 Cg_endo -67.55 145.56 70.84 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 C-N-CA 122.413 2.075 . . . . 1.0 111.614 178.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.575 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 42.99 48.76 5.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.324 0.583 . . . . 1.0 110.415 179.078 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -100.86 128.97 46.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.126 -0.943 . . . . 1.0 111.226 -178.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 46.7 m -91.29 131.38 36.83 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.299 -0.864 . . . . 1.0 109.404 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -113.14 147.98 36.27 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.876 0.37 . . . . 1.0 110.28 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.2 tt -126.39 143.22 40.62 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.595 0 N-CA-C 108.546 -0.909 . . . . 1.0 108.546 178.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.565 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.5 m-85 -134.15 149.9 51.08 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.378 -0.529 . . . . 1.0 111.657 177.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.5 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 6.9 mmtt -100.16 124.39 45.52 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 105.728 -1.953 . . . . 1.0 105.728 177.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.2 118.95 59.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.878 0.846 . . . . 1.0 113.031 -176.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 -109.64 127.12 54.32 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 113.98 -1.464 . . . . 1.0 108.536 178.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.6 111.61 23.68 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 120.041 -0.664 . . . . 1.0 112.41 -178.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.2 mp -93.86 -44.79 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 CA-C-N 116.119 -0.492 . . . . 1.0 111.1 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.5 p -152.39 158.39 42.61 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.89 0.376 . . . . 1.0 110.744 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.4 t -130.88 139.68 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.516 -177.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.523 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 7.2 tptt -93.6 -148.56 0.26 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.356 0.598 . . . . 1.0 109.906 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.523 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -176.58 137.4 0.27 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.646 178.234 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.4 t -86.79 -71.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.844 -1.071 . . . . 1.0 110.881 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.6 t . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.449 -179.668 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.89 H332 ' HA ' ' A' ' 82' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 34.7 p90 . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -69.94 -24.09 63.3 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.758 -0.377 . . . . 1.0 110.982 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 59.7 pttt -45.31 -42.59 9.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.135 0.493 . . . . 1.0 110.404 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.567 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 3.1 tmtt? -67.51 -35.81 79.83 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.959 0.885 . . . . 1.0 109.502 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -51.78 -33.66 36.32 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 114.83 -1.077 . . . . 1.0 111.039 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.511 ' OD2' ' NZ ' ' A' ' 9' ' ' LYS . 52.7 m-20 -62.73 -39.39 93.95 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 115.456 -0.793 . . . . 1.0 109.982 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -63.03 -52.87 61.19 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.599 0.714 . . . . 1.0 110.512 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.567 ' OD1' ' NZ ' ' A' ' 4' ' ' LYS . 28.5 m-20 -59.7 -35.66 74.95 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.171 -0.922 . . . . 1.0 108.657 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.511 ' NZ ' ' OD2' ' A' ' 6' ' ' ASP . 1.9 ttpm? -65.74 -50.83 63.37 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.197 -1.365 . . . . 1.0 111.139 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -67.21 -48.81 77.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 119.58 -0.848 . . . . 1.0 112.015 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -62.16 -38.04 87.53 Favored 'General case' 0 N--CA 1.444 -0.757 0 N-CA-C 107.703 -1.221 . . . . 1.0 107.703 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.2 -47.96 41.66 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 114.897 -1.047 . . . . 1.0 112.296 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -59.86 -30.81 69.23 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 119.882 -0.727 . . . . 1.0 109.248 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.4 -35.31 47.29 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.266 -0.879 . . . . 1.0 109.978 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.5 t80 -60.55 -49.43 77.58 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.764 -1.107 . . . . 1.0 110.379 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.0 mp -66.99 -40.01 87.29 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 109.199 -0.667 . . . . 1.0 109.199 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 98.0 m -61.96 -41.75 98.35 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.488 -0.778 . . . . 1.0 109.733 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -75.73 -43.38 47.23 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.69 -0.687 . . . . 1.0 111.36 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.666 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 47.4 t30 -61.53 -45.31 94.72 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 112.793 0.664 . . . . 1.0 112.793 -178.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -58.89 -30.74 68.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.48 -0.888 . . . . 1.0 108.947 -179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -79.07 -31.65 44.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.261 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 29.4 mtmt -58.55 142.72 82.45 Favored Pre-proline 0 CA--C 1.547 0.865 0 C-N-CA 120.525 -0.47 . . . . 1.0 111.163 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.68 149.06 61.3 Favored 'Trans proline' 0 N--CA 1.503 2.042 0 C-N-CA 122.422 2.081 . . . . 1.0 114.297 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.73 -19.31 5.12 Favored Glycine 0 C--O 1.228 -0.243 0 CA-C-N 115.021 -0.99 . . . . 1.0 112.226 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.54 136.53 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.02 0.438 . . . . 1.0 110.754 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.3 t -121.41 122.91 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 107.963 -1.125 . . . . 1.0 107.963 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.92 146.0 8.1 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.753 0.787 . . . . 1.0 111.896 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.8 mt -114.86 166.5 11.59 Favored Pre-proline 0 C--O 1.231 0.119 0 CA-C-N 114.35 -1.296 . . . . 1.0 111.048 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -61.57 -31.6 87.27 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 122.241 1.961 . . . . 1.0 111.97 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 m -69.94 -10.71 59.53 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.25 0.548 . . . . 1.0 109.855 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.25 0.94 72.89 Favored Glycine 0 CA--C 1.517 0.185 0 N-CA-C 109.952 -1.259 . . . . 1.0 109.952 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.429 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -82.64 133.58 35.17 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 108.555 -0.905 . . . . 1.0 108.555 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.429 ' H ' HD23 ' A' ' 32' ' ' LEU . 16.5 mp0 -121.84 143.46 49.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.413 -0.358 . . . . 1.0 111.164 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 26.7 p90 -137.4 145.27 43.04 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.733 0.778 . . . . 1.0 111.072 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -128.66 132.63 48.1 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 114.38 -1.282 . . . . 1.0 109.08 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.85 104.63 15.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 122.314 1.055 . . . . 1.0 112.02 -178.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.9 mm -69.77 -41.35 79.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.992 -1.004 . . . . 1.0 108.551 179.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -143.92 129.38 19.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.661 -1.154 . . . . 1.0 109.73 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.3 p -89.43 128.81 35.98 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.734 -0.469 . . . . 1.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.48 -35.15 1.22 Allowed Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.606 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.2 m120 58.07 29.9 18.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 1.0 111.138 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.93 -161.99 37.84 Favored Glycine 0 C--N 1.331 0.259 0 CA-C-O 121.888 0.716 . . . . 1.0 111.713 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.9 m -68.61 -177.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.061 -1.07 . . . . 1.0 108.841 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 177.67 155.4 0.49 Allowed Pre-proline 0 C--N 1.317 -0.836 0 O-C-N 123.628 0.58 . . . . 1.0 109.516 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -83.84 165.23 13.64 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 123.241 2.627 . . . . 1.0 116.292 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.44 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -98.08 175.02 29.37 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 108.633 -1.787 . . . . 1.0 108.633 176.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.456 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.84 -23.53 18.8 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.618 -0.433 . . . . 1.0 111.492 -179.086 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 36.4 m -107.02 -6.31 17.55 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 112.9 0.704 . . . . 1.0 112.9 -177.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.727 ' OD1' ' N ' ' A' ' 50' ' ' THR . 67.2 t0 -82.33 170.68 15.07 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.282 0.563 . . . . 1.0 110.595 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.727 ' N ' ' OD1' ' A' ' 49' ' ' ASP . 8.9 m -112.38 144.06 42.44 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.697 -0.853 . . . . 1.0 108.697 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.39 160.34 31.52 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 CA-C-N 115.182 -0.917 . . . . 1.0 111.974 -175.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.3 m -125.5 119.74 29.03 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.602 -0.888 . . . . 1.0 108.602 178.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.415 ' O ' ' N ' ' A' ' 75' ' ' ALA . 4.5 m -148.48 166.93 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 114.341 1.237 . . . . 1.0 114.341 -177.191 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -119.36 147.68 44.06 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 106.283 -1.747 . . . . 1.0 106.283 173.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.481 ' O ' ' N ' ' A' ' 68' ' ' THR . 36.4 p90 -162.19 163.4 28.36 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 115.083 1.512 . . . . 1.0 115.083 -176.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.456 ' OG1' ' OE2' ' A' ' 69' ' ' GLU . 1.5 m -127.45 127.5 44.18 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 115.254 -0.884 . . . . 1.0 109.332 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.74 136.07 13.19 Favored Glycine 0 N--CA 1.471 1.001 0 C-N-CA 121.094 -0.574 . . . . 1.0 112.355 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.3 ptp180 -147.4 168.55 21.57 Favored 'General case' 0 C--N 1.341 0.199 0 CA-C-O 121.498 0.666 . . . . 1.0 112.266 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.2 mp -84.93 164.7 18.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.519 -1.219 . . . . 1.0 110.761 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.57 -25.49 34.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 114.883 -1.053 . . . . 1.0 110.018 177.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -92.65 3.02 56.36 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.926 -1.488 . . . . 1.0 111.622 -177.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.27 -2.03 80.56 Favored Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.822 -0.704 . . . . 1.0 112.668 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.4 m -71.37 104.49 3.21 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 119.722 -0.791 . . . . 1.0 109.785 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.1 t -75.46 126.34 36.11 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.81 0 CA-C-O 121.202 0.525 . . . . 1.0 110.332 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -115.0 -11.68 12.1 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.032 -0.986 . . . . 1.0 111.425 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.424 ' CB ' ' C43' ' A' ' 138' ' ' RAP . 21.1 t0 -162.5 153.35 17.3 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.838 -0.745 . . . . 1.0 112.158 178.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 93.3 p -160.44 154.88 23.6 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 115.706 -0.679 . . . . 1.0 112.124 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.491 ' O ' ' OG1' ' A' ' 71' ' ' THR . 90.4 m -152.26 -43.51 0.1 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.688 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.456 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.8 pp20? -59.04 -25.98 64.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.152 -0.476 . . . . 1.0 110.427 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -54.98 -42.55 72.56 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.674 -1.232 . . . . 1.0 107.674 178.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.491 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.9 p -77.06 -34.83 57.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.525 -1.216 . . . . 1.0 109.193 177.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 85.05 16.75 64.37 Favored Glycine 0 C--N 1.333 0.362 0 CA-C-N 115.452 -0.795 . . . . 1.0 111.57 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.5 116.14 65.15 Favored Pre-proline 0 N--CA 1.472 0.672 0 C-N-CA 120.488 -0.485 . . . . 1.0 110.874 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -59.7 151.65 68.71 Favored 'Trans proline' 0 N--CA 1.481 0.752 0 C-N-CA 121.458 1.438 . . . . 1.0 114.438 -178.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.36 149.52 46.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.027 -1.442 . . . . 1.0 107.257 177.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.4 t -103.34 136.99 42.07 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.358 0.599 . . . . 1.0 112.493 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.546 ' CE1' ' H42' ' A' ' 138' ' ' RAP . 38.7 m-85 -140.23 148.3 41.31 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 114.933 -1.031 . . . . 1.0 110.767 179.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.536 ' H ' H482 ' A' ' 138' ' ' RAP . 20.5 mt-30 -92.0 125.19 36.6 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.752 -1.944 . . . . 1.0 105.752 174.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.6 t -56.45 -29.98 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 C-N-CA 118.704 -1.198 . . . . 1.0 110.126 -176.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LYS . 3.1 t -73.53 -25.78 60.57 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 120.074 -0.65 . . . . 1.0 112.577 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.631 ' O ' ' O11' ' A' ' 138' ' ' RAP . 87.0 mm-40 -101.37 -15.9 17.07 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 111.885 0.328 . . . . 1.0 111.885 -179.099 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.685 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.6 p -69.94 170.52 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 119.42 -0.912 . . . . 1.0 111.886 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.08 146.99 27.34 Favored Pre-proline 0 CA--C 1.548 0.875 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 -178.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -52.13 -43.64 51.6 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.814 1.676 . . . . 1.0 113.105 -178.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.65 -47.15 92.36 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 109.574 -1.41 . . . . 1.0 109.574 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.608 ' CD2' ' H41' ' A' ' 138' ' ' RAP . 6.7 m95 -63.03 -35.31 79.8 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.153 -1.024 . . . . 1.0 110.387 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 24.8 m -51.56 -53.54 36.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.063 0.458 . . . . 1.0 111.063 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -71.9 -44.91 62.92 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.617 -0.72 . . . . 1.0 112.687 -179.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -58.81 -46.8 86.75 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 114.509 1.3 . . . . 1.0 114.509 -177.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 19.4 mt -57.84 -42.88 85.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.362 0.601 . . . . 1.0 109.478 -178.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -62.95 -20.08 64.89 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.942 -1.026 . . . . 1.0 110.434 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.537 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 96.2 mt -105.93 -11.05 16.33 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.968 -0.56 . . . . 1.0 111.352 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 54.2 ttp -92.52 107.18 21.93 Favored Pre-proline 0 CA--C 1.547 0.842 0 O-C-N 123.273 0.358 . . . . 1.0 111.376 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -64.43 147.7 90.65 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.398 2.065 . . . . 1.0 112.936 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.599 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -61.87 132.66 53.77 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 115.482 -0.781 . . . . 1.0 111.579 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.49 -19.26 55.09 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 108.492 -1.843 . . . . 1.0 108.492 -178.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -84.61 131.83 34.56 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.038 0.447 . . . . 1.0 109.994 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.5 m -105.24 113.67 27.4 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 115.923 -0.58 . . . . 1.0 109.604 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.9 m0 -115.65 165.69 12.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.871 0.843 . . . . 1.0 111.258 -178.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -125.84 132.88 52.13 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 106.277 -1.749 . . . . 1.0 106.277 175.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.7 pt -128.66 139.71 51.17 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-O 121.84 0.829 . . . . 1.0 109.925 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.666 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.88 103.07 11.8 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 105.742 -1.947 . . . . 1.0 105.742 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 t -90.64 116.23 65.94 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 115.614 1.709 . . . . 1.0 115.614 -174.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.81 144.56 26.38 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.66 1.574 . . . . 1.0 109.766 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.5 p -50.45 -36.24 32.42 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 120.434 -0.506 . . . . 1.0 111.363 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.98 -32.2 80.2 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.977 -0.849 . . . . 1.0 110.977 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.4 mt -98.4 2.32 47.75 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 121.364 -0.134 . . . . 1.0 110.746 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.533 ' O ' H522 ' A' ' 138' ' ' RAP . . . -107.95 -103.22 0.36 Allowed 'General case' 0 C--O 1.216 -0.665 0 N-CA-C 110.069 -0.345 . . . . 1.0 110.069 -179.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.542 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 35.7 m-85 -105.29 5.17 31.74 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 113.397 0.888 . . . . 1.0 113.397 -178.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 105.46 166.7 23.69 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 120.814 -0.707 . . . . 1.0 113.075 177.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.532 ' O ' ' N ' ' A' ' 121' ' ' ASN . 72.6 Cg_endo -72.64 -18.46 25.38 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 123.454 2.769 . . . . 1.0 112.45 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -98.03 169.3 9.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.303 -0.408 . . . . 1.0 109.947 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.7 m -76.33 85.82 3.11 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.7 t -98.04 59.23 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.51 -0.314 . . . . 1.0 110.923 -179.114 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.75 179.9 41.76 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 120.629 -0.796 . . . . 1.0 112.088 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.01 -105.87 0.01 OUTLIER Glycine 0 CA--C 1.537 1.418 0 N-CA-C 111.747 -0.541 . . . . 1.0 111.747 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -61.15 -13.72 29.68 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 C-N-CA 122.399 2.066 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.46 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 4.1 mp -68.24 112.22 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 108.334 -0.987 . . . . 1.0 108.334 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -91.21 -167.11 40.9 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.691 -0.964 . . . . 1.0 110.691 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.503 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 38.0 Cg_endo -64.76 146.65 88.81 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 122.242 1.961 . . . . 1.0 112.973 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.532 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 46.16 49.87 12.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.67 -0.695 . . . . 1.0 111.925 178.353 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.437 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 49.1 mm-40 -93.21 132.69 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.093 0.473 . . . . 1.0 111.978 179.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.4 m -96.2 127.82 42.55 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.243 -1.762 . . . . 1.0 106.243 175.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.97 143.16 45.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.517 0.675 . . . . 1.0 110.747 -179.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.7 tt -119.28 146.38 24.04 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.659 0 CA-C-N 115.078 -0.965 . . . . 1.0 108.508 178.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.562 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.84 152.27 48.92 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.314 -0.554 . . . . 1.0 111.376 177.63 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.476 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 3.4 mmtt -100.47 124.03 45.46 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 105.697 -1.964 . . . . 1.0 105.697 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -118.61 119.05 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 119.41 -0.916 . . . . 1.0 112.394 -176.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.6 t-160 -110.81 122.66 48.38 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 114.096 -1.411 . . . . 1.0 108.654 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.49 112.13 23.89 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 120.364 -0.534 . . . . 1.0 112.378 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.3 mp -95.55 -45.04 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 116.015 -0.539 . . . . 1.0 111.412 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -151.05 157.82 43.31 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.827 0.346 . . . . 1.0 110.691 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.5 t -128.79 140.67 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 121.039 0.447 . . . . 1.0 111.51 -177.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.548 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 14.7 tptt -97.5 -151.47 0.37 Allowed 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.942 0.877 . . . . 1.0 111.22 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.548 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.4 OUTLIER -174.18 126.42 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 114.056 -1.429 . . . . 1.0 110.533 177.811 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -70.63 -47.1 61.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 113.869 -1.514 . . . . 1.0 111.98 -178.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.135 -0.936 . . . . 1.0 110.301 -179.594 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.685 H31A ' CG2' ' A' ' 82' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.095 -0.706 . . . . 1.0 109.095 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -65.67 -27.3 68.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 120.155 -0.618 . . . . 1.0 110.718 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.514 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 40.2 pttt -55.26 -40.52 71.07 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.558 -0.457 . . . . 1.0 109.982 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.541 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 6.7 tmtt? -73.45 -39.39 65.0 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 121.854 0.835 . . . . 1.0 109.154 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -50.75 -33.41 23.06 Favored 'General case' 0 CA--C 1.505 -0.77 0 CA-C-N 114.834 -1.075 . . . . 1.0 110.424 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -62.09 -44.08 97.43 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.666 -0.697 . . . . 1.0 110.294 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -59.61 -52.08 67.05 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 122.023 0.916 . . . . 1.0 110.646 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.562 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.8 m-20 -59.59 -37.47 78.63 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 114.608 -1.178 . . . . 1.0 108.221 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.428 ' O ' ' N ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -67.46 -52.14 42.97 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.183 -1.371 . . . . 1.0 111.495 179.541 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.92 -48.37 75.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 119.736 -0.786 . . . . 1.0 112.058 -177.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.402 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -63.36 -35.54 80.73 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.015 -1.106 . . . . 1.0 108.015 178.982 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -74.54 -43.57 29.61 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 114.754 -1.112 . . . . 1.0 112.054 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.503 ' O ' ' OG1' ' A' ' 17' ' ' THR . 86.3 mt-10 -61.72 -31.25 71.39 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.907 -0.775 . . . . 1.0 108.907 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.39 -32.08 48.67 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.441 -0.8 . . . . 1.0 110.04 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -62.44 -49.12 76.7 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.579 -1.191 . . . . 1.0 110.762 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.5 mp -69.73 -40.1 76.4 Favored 'General case' 0 C--N 1.32 -0.686 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.892 178.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.503 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.4 m -61.04 -41.7 97.09 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.814 -0.63 . . . . 1.0 109.481 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -75.48 -46.52 31.94 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.31 -0.859 . . . . 1.0 111.575 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.9 t30 -60.37 -44.91 95.17 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 113.016 0.747 . . . . 1.0 113.016 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -60.42 -28.84 68.58 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 119.47 -0.892 . . . . 1.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -80.25 -30.02 38.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.191 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -59.4 142.95 86.35 Favored Pre-proline 0 CA--C 1.55 0.951 0 N-CA-C 112.268 0.47 . . . . 1.0 112.268 -177.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.06 149.05 65.08 Favored 'Trans proline' 0 N--CA 1.505 2.195 0 C-N-CA 122.499 2.132 . . . . 1.0 113.362 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.72 -19.37 5.08 Favored Glycine 0 C--O 1.225 -0.412 0 CA-C-N 115.601 -0.727 . . . . 1.0 112.189 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.5 t -85.11 136.28 23.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.148 0.499 . . . . 1.0 110.833 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.91 124.24 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 107.854 -1.165 . . . . 1.0 107.854 177.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -97.24 146.32 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-O 121.71 0.767 . . . . 1.0 111.811 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.29 165.05 14.11 Favored Pre-proline 0 C--O 1.232 0.14 0 CA-C-N 114.355 -1.293 . . . . 1.0 110.856 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -61.37 -30.24 87.01 Favored 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 121.983 1.789 . . . . 1.0 111.379 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -68.51 -14.47 63.03 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.591 -0.731 . . . . 1.0 109.387 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.93 -2.1 68.88 Favored Glycine 0 C--O 1.229 -0.158 0 N-CA-C 109.734 -1.346 . . . . 1.0 109.734 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -80.54 132.78 35.71 Favored 'General case' 0 CA--C 1.519 -0.25 0 N-CA-C 108.411 -0.959 . . . . 1.0 108.411 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.7 mp0 -119.62 140.96 49.77 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-N 116.196 -0.456 . . . . 1.0 110.869 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -136.37 147.85 47.56 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 121.6 0.714 . . . . 1.0 111.143 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -130.64 132.54 45.51 Favored 'General case' 0 CA--C 1.501 -0.932 0 CA-C-N 114.479 -1.237 . . . . 1.0 109.317 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.16 104.85 15.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.281 1.038 . . . . 1.0 112.356 -178.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.3 mm -70.7 -41.64 77.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.039 -0.982 . . . . 1.0 108.72 178.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -143.6 131.52 21.59 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 114.639 -1.164 . . . . 1.0 109.792 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.8 p -90.3 129.1 36.57 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.857 -0.423 . . . . 1.0 109.857 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.74 -33.2 1.32 Allowed Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.592 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 54.32 30.83 13.22 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.287 -0.457 . . . . 1.0 110.577 179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.33 -162.22 37.78 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-O 121.789 0.66 . . . . 1.0 111.669 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 23.4 m -68.28 -177.54 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.266 -0.967 . . . . 1.0 109.375 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.468 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.56 154.58 0.35 Allowed Pre-proline 0 C--N 1.317 -0.832 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 179.54 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -88.21 160.4 7.03 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.162 2.575 . . . . 1.0 116.189 -175.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.445 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 174.22 39.06 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 108.096 -2.001 . . . . 1.0 108.096 175.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.607 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -49.26 -25.81 2.58 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.99 -0.605 . . . . 1.0 111.439 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.453 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 9.4 m -107.24 -9.21 16.15 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -177.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.445 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.6 m-20 -84.18 165.92 18.01 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 119.708 -0.797 . . . . 1.0 108.975 179.222 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.2 m -103.24 151.86 22.17 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-O 121.224 0.535 . . . . 1.0 109.948 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -129.66 161.82 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.389 0 CA-C-N 115.292 -0.867 . . . . 1.0 112.114 -176.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -132.12 118.17 19.26 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 108.67 -0.863 . . . . 1.0 108.67 177.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.5 m -148.1 166.98 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.883 0.697 . . . . 1.0 112.883 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -116.93 154.04 31.53 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 106.909 -1.515 . . . . 1.0 106.909 175.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.519 ' O ' ' N ' ' A' ' 68' ' ' THR . 41.1 p90 -165.07 163.55 20.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 114.82 1.415 . . . . 1.0 114.82 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.5 m -126.24 128.97 48.03 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 107.895 -1.15 . . . . 1.0 107.895 174.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.68 12.25 Favored Glycine 0 N--CA 1.47 0.905 0 C-N-CA 120.687 -0.768 . . . . 1.0 111.757 -178.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.3 ptp180 -146.23 167.02 24.52 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.95 0.881 . . . . 1.0 112.632 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.0 mp -81.76 163.79 22.16 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.065 -1.425 . . . . 1.0 110.147 178.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.19 -24.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 114.942 -1.026 . . . . 1.0 109.77 177.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -96.25 4.69 52.19 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 113.648 -1.615 . . . . 1.0 111.791 -177.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.05 80.51 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.788 -0.72 . . . . 1.0 113.316 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 m -72.83 111.51 8.03 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.112 -1.035 . . . . 1.0 109.422 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.02 120.17 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-O 121.543 0.687 . . . . 1.0 111.171 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.507 ' CD1' ' OD1' ' A' ' 66' ' ' ASP . 23.3 p90 -108.47 -9.81 15.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.884 -1.053 . . . . 1.0 111.613 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.578 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 4.1 p-10 -161.62 149.24 14.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.977 -0.556 . . . . 1.0 110.829 178.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 68.9 p -156.15 149.44 24.51 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.61 -0.723 . . . . 1.0 111.108 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.519 ' N ' ' O ' ' A' ' 55' ' ' TYR . 46.1 m -155.98 -42.0 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.602 -0.726 . . . . 1.0 110.967 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.413 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.8 pp20? -63.18 -26.95 69.04 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.742 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.7 mmtp -54.37 -43.15 71.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.699 -1.223 . . . . 1.0 107.699 178.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.484 ' OG1' ' O ' ' A' ' 68' ' ' THR . 28.5 p -76.3 -34.85 59.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.096 -1.411 . . . . 1.0 109.102 177.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.6 15.5 70.78 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.357 -0.838 . . . . 1.0 111.144 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -97.97 115.27 65.77 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 120.402 -0.519 . . . . 1.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -59.83 153.24 58.11 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 122.022 1.814 . . . . 1.0 114.114 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.97 150.73 46.36 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.059 -1.428 . . . . 1.0 108.069 178.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.29 129.65 55.7 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.014 0.746 . . . . 1.0 113.014 -178.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.512 ' CE1' ' C4 ' ' A' ' 138' ' ' RAP . 36.0 m-85 -140.98 153.02 45.4 Favored 'General case' 0 CA--C 1.502 -0.88 0 CA-C-N 114.678 -1.146 . . . . 1.0 108.795 177.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.5 mt-30 -90.44 127.18 36.14 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 106.359 -1.719 . . . . 1.0 106.359 174.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.4 t -46.79 -34.45 2.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.351 -0.539 . . . . 1.0 110.471 -178.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -73.56 -24.34 60.09 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 120.467 -0.493 . . . . 1.0 112.323 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.526 ' OE1' H242 ' A' ' 138' ' ' RAP . 82.8 mm-40 -100.13 -12.0 20.0 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 113.618 0.969 . . . . 1.0 113.618 -177.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.508 ' CG2' ' H32' ' A' ' 138' ' ' RAP . 5.4 p -84.44 177.93 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 119.656 -0.818 . . . . 1.0 110.455 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.476 ' CD1' ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -54.95 146.51 37.76 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.595 -177.198 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -51.54 -44.55 43.2 Favored 'Trans proline' 0 N--CA 1.499 1.817 0 C-N-CA 121.896 1.73 . . . . 1.0 112.527 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.48 -47.4 90.06 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.549 -1.42 . . . . 1.0 109.549 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.741 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 6.1 m95 -63.83 -36.06 82.68 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.287 -0.956 . . . . 1.0 110.04 179.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.2 m -52.23 -52.95 49.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.674 -0.411 . . . . 1.0 110.904 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -72.32 -45.35 60.34 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.891 -0.595 . . . . 1.0 112.444 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.34 -48.46 76.72 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 113.925 1.083 . . . . 1.0 113.925 -177.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 32.7 mt -57.93 -42.66 85.31 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-O 121.084 0.469 . . . . 1.0 109.959 -177.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -62.65 -23.27 67.01 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 115.615 -0.721 . . . . 1.0 110.289 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.6 mt -101.79 -14.4 17.31 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.876 -0.602 . . . . 1.0 111.266 -179.131 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.2 ttp -88.98 108.18 22.25 Favored Pre-proline 0 CA--C 1.547 0.833 0 N-CA-C 111.991 0.367 . . . . 1.0 111.991 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.468 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 21.2 Cg_exo -66.06 148.08 85.07 Favored 'Trans proline' 0 N--CA 1.499 1.842 0 C-N-CA 122.438 2.092 . . . . 1.0 112.162 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.96 137.53 58.05 Favored 'General case' 0 CA--C 1.507 -0.695 0 CA-C-O 121.493 0.663 . . . . 1.0 111.331 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.16 -18.57 55.91 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.252 -1.939 . . . . 1.0 108.252 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.4 p -89.39 128.41 35.92 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 121.263 0.554 . . . . 1.0 110.735 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 89.9 m -103.56 114.24 28.36 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 115.392 -0.822 . . . . 1.0 109.944 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.483 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.6 m0 -116.04 164.9 13.77 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 121.442 0.639 . . . . 1.0 110.882 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -123.59 129.14 50.71 Favored 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 106.394 -1.706 . . . . 1.0 106.394 175.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -125.93 138.9 53.07 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.665 0 CA-C-O 121.926 0.869 . . . . 1.0 110.376 -179.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.658 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -109.27 104.12 13.2 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.928 -1.878 . . . . 1.0 105.928 -178.16 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.6 t -90.4 115.95 65.28 Favored Pre-proline 0 C--N 1.326 -0.415 0 N-CA-C 114.879 1.437 . . . . 1.0 114.879 -174.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -51.21 143.49 32.86 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 121.276 1.317 . . . . 1.0 110.021 175.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 92.4 p -49.26 -35.17 16.99 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.426 -0.51 . . . . 1.0 110.423 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.0 81.51 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 111.174 -0.77 . . . . 1.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -101.25 3.24 40.67 Favored 'General case' 0 C--O 1.225 -0.189 0 CA-C-O 119.771 -0.157 . . . . 1.0 110.872 -179.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.23 -112.33 0.29 Allowed 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.487 0.184 . . . . 1.0 110.554 -178.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.626 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 68.1 m-85 -98.32 4.85 48.66 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 113.405 0.891 . . . . 1.0 113.405 -178.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 115.14 162.97 13.87 Favored Glycine 0 N--CA 1.47 0.911 0 C-N-CA 120.996 -0.621 . . . . 1.0 112.969 177.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 121' ' ' ASN . 96.3 Cg_endo -76.16 -9.4 19.15 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 123.626 2.884 . . . . 1.0 111.0 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -109.19 168.9 9.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.498 -0.774 . . . . 1.0 109.446 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.1 m -73.86 96.37 2.58 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.0 t -111.91 60.25 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-N 116.244 -0.434 . . . . 1.0 110.444 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.55 172.46 36.19 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.35 -0.7 . . . . 1.0 111.35 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.59 -103.19 0.01 OUTLIER Glycine 0 CA--C 1.535 1.337 0 N-CA-C 111.226 -0.75 . . . . 1.0 111.226 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -58.04 -11.42 10.03 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.754 2.303 . . . . 1.0 111.628 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 14.9 mm -66.96 125.55 24.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-N 114.716 -1.129 . . . . 1.0 109.138 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -102.63 -175.86 27.12 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.321 -0.854 . . . . 1.0 111.249 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.562 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 21.6 Cg_endo -62.38 142.23 90.09 Favored 'Trans proline' 0 C--N 1.295 -2.25 0 C-N-CA 122.384 2.056 . . . . 1.0 111.756 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.531 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 45.79 55.39 6.93 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 120.796 -0.362 . . . . 1.0 111.103 178.11 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.521 ' OE2' ' ND2' ' A' ' 8' ' ' ASN . 3.3 tp10 -102.34 130.03 48.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.987 -0.552 . . . . 1.0 111.412 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 46.4 m -95.36 129.79 42.38 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.007 -1.109 . . . . 1.0 108.007 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.64 148.8 33.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.423 0.63 . . . . 1.0 111.114 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.8 tt -124.58 149.29 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.041 -0.981 . . . . 1.0 108.485 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.6 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -140.52 149.82 42.94 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 120.479 -0.488 . . . . 1.0 111.522 178.033 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 13.9 mmtt -99.42 127.07 45.44 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 104.768 -2.308 . . . . 1.0 104.768 176.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -121.18 121.13 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 119.259 -0.976 . . . . 1.0 112.138 -177.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -113.75 120.71 41.73 Favored 'General case' 0 C--O 1.223 -0.327 0 CA-C-N 114.157 -1.383 . . . . 1.0 108.612 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.35 111.89 23.63 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 120.014 -0.675 . . . . 1.0 112.519 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -94.14 -45.14 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-N 116.222 -0.444 . . . . 1.0 111.12 179.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -150.74 155.58 39.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.85 0.357 . . . . 1.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 46.7 t -128.7 139.09 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.285 -0.416 . . . . 1.0 111.326 -178.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.452 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 9.6 tptm -95.74 -150.16 0.32 Allowed 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.599 0.714 . . . . 1.0 110.057 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.452 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -173.41 143.42 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.849 -1.069 . . . . 1.0 110.865 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 15.3 t -113.25 -49.18 2.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.511 -1.222 . . . . 1.0 109.977 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 117.943 -1.027 . . . . 1.0 110.351 -179.633 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.741 ' H41' ' CZ3' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.842 -0.799 . . . . 1.0 108.842 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 69.7 m-80 -65.64 -31.15 72.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.949 -0.569 . . . . 1.0 111.233 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -41.91 9.92 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.305 -0.407 . . . . 1.0 111.054 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.567 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 5.2 tmtt? -71.8 -38.83 70.18 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 121.994 0.902 . . . . 1.0 109.772 179.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -50.67 -33.86 24.21 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 114.889 -1.05 . . . . 1.0 110.538 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.63 -38.13 89.06 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.153 -0.93 . . . . 1.0 111.144 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -67.02 -48.83 67.17 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.785 0.803 . . . . 1.0 110.54 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.608 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 12.9 m-20 -61.49 -35.33 77.36 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.004 -1.11 . . . . 1.0 108.004 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 55.6 tttt -66.76 -51.02 60.68 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.385 -1.734 . . . . 1.0 111.571 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.8 t -66.87 -48.85 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.276 0 C-N-CA 119.979 -0.688 . . . . 1.0 111.393 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.84 -38.64 91.59 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.639 -1.245 . . . . 1.0 107.639 179.034 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.54 -42.77 71.51 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 114.868 -1.06 . . . . 1.0 111.875 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.435 ' N ' ' O ' ' A' ' 9' ' ' LYS . 33.8 mt-10 -62.67 -33.27 74.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.438 -0.949 . . . . 1.0 108.438 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.3 -34.25 59.05 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 114.791 -1.095 . . . . 1.0 109.798 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -61.89 -51.11 69.5 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 114.492 -1.231 . . . . 1.0 110.762 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.5 mp -69.66 -40.18 76.6 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.061 -0.656 . . . . 1.0 109.733 178.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.441 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 97.7 m -61.07 -42.06 97.78 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.505 -0.771 . . . . 1.0 109.13 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -75.74 -47.35 26.35 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.006 -0.997 . . . . 1.0 111.9 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.661 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 49.5 t30 -58.7 -45.4 89.6 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -177.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.5 -29.35 67.79 Favored 'General case' 0 C--N 1.315 -0.909 0 C-N-CA 119.303 -0.959 . . . . 1.0 109.154 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.441 ' ND2' ' O ' ' A' ' 17' ' ' THR . 7.4 m-80 -82.0 -29.69 31.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.372 -0.831 . . . . 1.0 111.591 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -59.74 146.08 81.92 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 120.48 -0.488 . . . . 1.0 111.371 -178.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.14 148.47 69.35 Favored 'Trans proline' 0 N--CA 1.504 2.094 0 C-N-CA 122.525 2.15 . . . . 1.0 113.791 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.89 -18.61 5.88 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.492 -0.776 . . . . 1.0 112.625 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.2 136.95 21.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.219 0.533 . . . . 1.0 111.286 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -121.66 126.03 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 107.64 -1.244 . . . . 1.0 107.64 177.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -100.73 145.62 10.81 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 CA-C-O 121.828 0.823 . . . . 1.0 112.266 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.1 mt -112.31 166.17 11.52 Favored Pre-proline 0 CA--C 1.529 0.155 0 CA-C-N 114.1 -1.409 . . . . 1.0 111.357 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.87 -30.7 84.4 Favored 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.188 1.926 . . . . 1.0 111.358 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.1 m -68.52 -14.42 62.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.839 -0.618 . . . . 1.0 109.8 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.14 -0.96 66.94 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 109.593 -1.403 . . . . 1.0 109.593 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.411 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -81.21 133.39 35.44 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.511 -0.922 . . . . 1.0 108.511 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.411 ' H ' HD23 ' A' ' 32' ' ' LEU . 21.2 mp0 -120.94 143.38 49.01 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.91 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -138.2 143.86 40.4 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 121.712 0.767 . . . . 1.0 110.734 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -127.53 132.83 49.86 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-N 114.504 -1.225 . . . . 1.0 109.106 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 p -90.82 104.9 15.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 122.148 0.975 . . . . 1.0 111.86 -178.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.6 mm -70.09 -42.34 79.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.222 -0.899 . . . . 1.0 108.671 178.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.6 m-80 -140.27 128.04 21.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 114.619 -1.173 . . . . 1.0 109.627 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 p -88.57 127.22 35.54 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.736 -0.468 . . . . 1.0 109.736 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.36 -34.53 1.19 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 110.683 -0.967 . . . . 1.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.633 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.6 m120 56.02 32.01 19.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.99 0.424 . . . . 1.0 110.737 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.41 -161.0 36.84 Favored Glycine 0 C--N 1.333 0.37 0 CA-C-O 121.924 0.736 . . . . 1.0 111.769 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.596 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.3 m -69.69 -178.09 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 114.084 -1.058 . . . . 1.0 109.289 178.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.449 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 154.84 0.37 Allowed Pre-proline 0 C--N 1.32 -0.694 0 O-C-N 123.829 0.705 . . . . 1.0 109.549 179.387 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -87.15 156.17 8.3 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 123.091 2.528 . . . . 1.0 115.993 -175.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.413 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.29 175.12 44.22 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 108.778 -1.729 . . . . 1.0 108.778 176.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.455 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.68 -22.44 5.14 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 120.82 -0.352 . . . . 1.0 111.14 -179.402 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.8 m -107.41 -9.9 15.88 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.245 0.831 . . . . 1.0 113.245 -177.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 91.6 m-20 -84.58 168.99 14.85 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 119.867 -0.733 . . . . 1.0 109.028 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.7 m -107.66 152.1 24.76 Favored 'General case' 0 CA--C 1.513 -0.466 0 N-CA-C 109.618 -0.512 . . . . 1.0 109.618 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -128.31 160.1 38.83 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.405 0 CA-C-N 115.741 -0.663 . . . . 1.0 112.285 -176.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 85.9 m -126.3 120.19 29.3 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 107.729 -1.212 . . . . 1.0 107.729 177.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -148.98 163.32 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 N-CA-C 114.291 1.219 . . . . 1.0 114.291 -175.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -118.44 150.67 39.18 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 106.41 -1.7 . . . . 1.0 106.41 174.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.499 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 36.9 p90 -163.75 163.53 24.03 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 118.393 -1.323 . . . . 1.0 114.506 -177.567 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.541 ' HG1' ' CD ' ' A' ' 69' ' ' GLU . 1.4 m -125.11 130.05 51.44 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 115.261 -0.881 . . . . 1.0 108.848 175.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.38 136.56 13.6 Favored Glycine 0 N--CA 1.468 0.787 0 C-N-CA 121.005 -0.617 . . . . 1.0 111.602 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -148.72 166.88 27.07 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.674 0.749 . . . . 1.0 112.533 179.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -84.28 164.38 19.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 114.456 -1.247 . . . . 1.0 110.502 178.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.45 -24.88 32.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.918 -1.037 . . . . 1.0 110.528 178.149 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.67 4.5 53.76 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.566 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.95 -5.23 81.95 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.016 178.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.6 m -67.14 103.39 1.2 Allowed 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.569 -0.853 . . . . 1.0 110.067 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.4 t -74.93 125.99 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.853 0 C-N-CA 120.347 -0.541 . . . . 1.0 109.702 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.0 p90 -117.48 -10.81 10.59 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 114.993 -1.003 . . . . 1.0 111.471 -179.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.481 ' OD1' ' O4 ' ' A' ' 138' ' ' RAP . 32.7 t0 -157.41 150.76 23.79 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.401 -0.52 . . . . 1.0 111.65 179.261 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -159.59 151.79 20.89 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.632 -0.713 . . . . 1.0 111.817 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 55' ' ' TYR . 96.3 m -151.25 -42.1 0.12 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.342 -0.845 . . . . 1.0 110.183 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.541 ' CD ' ' HG1' ' A' ' 56' ' ' THR . 0.6 OUTLIER -62.09 -27.93 69.26 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-N 116.018 -0.537 . . . . 1.0 109.672 179.379 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -56.73 -43.3 80.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 107.741 -1.207 . . . . 1.0 107.741 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.449 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.6 OUTLIER -75.14 -33.4 61.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.632 -1.167 . . . . 1.0 107.974 176.682 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.12 18.39 67.28 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 115.639 -0.71 . . . . 1.0 111.957 178.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -101.18 115.87 64.61 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 120.882 -0.327 . . . . 1.0 110.629 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.61 152.5 68.23 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 121.754 1.636 . . . . 1.0 114.282 -179.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.35 150.99 42.97 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.094 -1.412 . . . . 1.0 107.926 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.99 125.31 50.84 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.589 0.588 . . . . 1.0 112.589 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.555 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 35.3 m-85 -132.93 147.8 52.29 Favored 'General case' 0 CA--C 1.502 -0.892 0 CA-C-N 115.367 -0.833 . . . . 1.0 109.222 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -90.63 127.93 36.45 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.268 -1.752 . . . . 1.0 106.268 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.1 t -52.75 -33.5 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 C-N-CA 119.6 -0.84 . . . . 1.0 110.149 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 3.3 t -74.06 -26.66 60.52 Favored 'General case' 0 CA--C 1.515 -0.401 0 C-N-CA 120.21 -0.596 . . . . 1.0 111.651 -178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.512 ' CB ' ' H30' ' A' ' 138' ' ' RAP . 79.3 mm-40 -100.29 -3.76 30.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.312 -0.404 . . . . 1.0 111.873 -178.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.53 ' HA ' ' C32' ' A' ' 138' ' ' RAP . 1.0 OUTLIER -84.3 166.58 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 CA-C-N 118.233 0.469 . . . . 1.0 111.406 -178.943 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.8 147.28 15.94 Favored Pre-proline 0 N--CA 1.474 0.756 0 N-CA-C 109.093 -0.706 . . . . 1.0 109.093 -177.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -50.9 -43.55 46.59 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.747 1.631 . . . . 1.0 112.701 -178.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.19 92.29 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 119.57 -1.3 . . . . 1.0 110.018 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.602 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 7.4 m95 -64.32 -35.91 82.41 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.369 -0.916 . . . . 1.0 110.398 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 25.1 m -51.0 -53.11 36.22 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.721 0.296 . . . . 1.0 111.67 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 20.5 tp10 -72.39 -41.62 66.11 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.738 0.644 . . . . 1.0 112.738 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.66 -45.45 91.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 114.036 1.125 . . . . 1.0 114.036 -177.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.04 -41.91 88.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.263 0.554 . . . . 1.0 109.761 -177.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.0 mt-30 -64.66 -24.61 67.64 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.705 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.496 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 59.8 mt -101.9 -10.67 19.62 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.182 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.7 ttp -91.78 107.39 22.08 Favored Pre-proline 0 CA--C 1.546 0.789 0 O-C-N 123.154 0.283 . . . . 1.0 111.639 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.449 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -66.93 147.69 80.8 Favored 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.508 2.139 . . . . 1.0 111.98 178.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.596 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.59 139.55 58.78 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-O 121.686 0.755 . . . . 1.0 111.429 -179.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.78 -18.76 54.81 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.123 -1.991 . . . . 1.0 108.123 -178.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.4 p -89.88 129.6 36.22 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.037 0.446 . . . . 1.0 110.621 179.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 85.1 m -103.44 114.22 28.33 Favored 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 115.659 -0.701 . . . . 1.0 109.855 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.496 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -115.98 161.94 18.11 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.742 0.782 . . . . 1.0 111.487 -178.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -121.57 125.61 47.16 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.162 -1.421 . . . . 1.0 107.162 175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -120.9 138.03 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.564 0 CA-C-O 121.8 0.81 . . . . 1.0 109.838 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.661 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.0 103.4 12.42 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -177.983 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.27 116.25 65.94 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 115.022 1.49 . . . . 1.0 115.022 -174.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -51.39 142.58 37.44 Favored 'Trans proline' 0 C--N 1.315 -1.191 0 C-N-CA 121.361 1.374 . . . . 1.0 109.81 176.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 97.6 p -48.61 -35.28 13.25 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.31 -0.556 . . . . 1.0 111.185 -178.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.75 -32.77 82.22 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.153 -0.779 . . . . 1.0 111.153 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.5 mt -98.46 2.49 47.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.957 -0.121 . . . . 1.0 110.91 -179.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.45 -110.77 0.31 Allowed 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 112.029 0.381 . . . . 1.0 112.029 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.668 ' CE2' H493 ' A' ' 138' ' ' RAP . 44.4 m-85 -96.88 4.31 51.7 Favored 'General case' 0 C--N 1.342 0.249 0 N-CA-C 112.288 0.477 . . . . 1.0 112.288 -177.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.11 162.87 17.93 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 121.172 -0.537 . . . . 1.0 112.831 177.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 121' ' ' ASN . 83.3 Cg_endo -76.9 -10.23 18.17 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 123.423 2.749 . . . . 1.0 111.4 179.229 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . 0.407 ' HG2' ' H ' ' A' ' 113' ' ' SER . 5.9 ttm-85 -105.15 168.45 9.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.252 -0.885 . . . . 1.0 109.51 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.518 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -74.18 100.04 3.56 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.3 -0.629 . . . . 1.0 109.3 178.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.0 t -110.9 61.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.76 0.314 . . . . 1.0 110.831 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 159.15 175.73 30.41 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 120.472 -0.87 . . . . 1.0 112.44 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.42 -103.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.328 0 CA-C-N 114.963 -0.619 . . . . 1.0 111.87 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -61.87 -16.95 52.62 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 122.613 2.208 . . . . 1.0 111.773 -177.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.3 mp -67.4 114.56 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 108.343 -0.984 . . . . 1.0 108.343 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.416 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.98 -171.02 38.53 Favored Glycine 0 N--CA 1.452 -0.258 0 N-CA-C 110.949 -0.86 . . . . 1.0 110.949 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.518 ' N ' ' OG ' ' A' ' 113' ' ' SER . 34.1 Cg_endo -64.01 139.55 67.97 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.318 2.012 . . . . 1.0 112.627 179.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.529 ' N ' ' O ' ' A' ' 111' ' ' PRO . 17.1 t-20 52.59 48.85 21.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.439 -0.346 . . . . 1.0 111.371 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.608 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -93.14 132.58 37.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.541 -0.3 . . . . 1.0 110.716 179.843 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 52.1 m -96.2 127.77 42.5 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 175.326 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -111.28 145.33 38.97 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.128 0.489 . . . . 1.0 110.468 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.4 tt -122.63 146.14 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.476 -0.783 . . . . 1.0 108.937 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.622 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.6 m-85 -136.33 149.65 48.49 Favored 'General case' 0 CA--C 1.517 -0.319 0 C-N-CA 120.26 -0.576 . . . . 1.0 111.509 178.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 12.6 mmtt -99.5 123.57 43.89 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 105.423 -2.065 . . . . 1.0 105.423 177.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.7 mt -118.94 118.1 56.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 119.112 -1.035 . . . . 1.0 112.879 -176.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -108.65 126.22 52.73 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 113.572 -1.649 . . . . 1.0 108.278 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 111.3 23.42 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 119.871 -0.732 . . . . 1.0 112.271 -178.124 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.2 mp -93.71 -45.93 13.76 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.852 -0.613 . . . . 1.0 111.676 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.6 p -150.84 156.03 40.41 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.575 -0.45 . . . . 1.0 110.84 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 56.9 t -128.0 141.45 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.969 -0.559 . . . . 1.0 111.395 -178.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.492 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 9.2 tptm -100.13 -147.86 0.35 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.638 -0.71 . . . . 1.0 110.33 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.492 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER -164.47 143.15 7.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.72 -1.127 . . . . 1.0 110.477 178.016 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 96.1 p -59.48 -33.3 71.14 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.803 -1.09 . . . . 1.0 111.232 -179.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 34.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.384 -179.751 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.701 ' C1 ' ' O3 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 65.7 t80 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 108.963 -0.754 . . . . 1.0 108.963 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.421 ' O ' ' N ' ' A' ' 5' ' ' ALA . 76.7 m-20 -69.47 -24.32 63.77 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.637 -0.425 . . . . 1.0 110.722 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.439 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 63.3 pttt -47.56 -40.82 20.04 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 109.283 -0.636 . . . . 1.0 109.283 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.439 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 5.9 tmtm? -64.16 -37.05 86.05 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.221 -0.899 . . . . 1.0 109.274 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 2' ' ' ASN . . . -51.4 -35.95 41.34 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-N 115.048 -0.978 . . . . 1.0 110.799 -179.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.46 -37.38 87.06 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.241 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -66.15 -53.1 41.78 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.687 0.756 . . . . 1.0 110.419 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.4 m-20 -58.02 -34.01 69.57 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.501 -0.926 . . . . 1.0 108.501 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -66.21 -51.08 61.1 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.406 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.99 -48.22 82.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 119.942 -0.703 . . . . 1.0 111.614 -178.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.8 -38.95 92.74 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.785 -1.191 . . . . 1.0 107.785 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.08 -46.27 52.11 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-N 114.779 -1.101 . . . . 1.0 112.631 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.505 ' O ' ' OG1' ' A' ' 17' ' ' THR . 74.0 mt-10 -59.53 -34.97 73.32 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.288 -0.965 . . . . 1.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.58 -36.14 65.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.94 -1.027 . . . . 1.0 110.401 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -61.31 -50.4 73.12 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.879 -1.055 . . . . 1.0 110.628 -179.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -67.1 -39.81 86.78 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 119.783 -0.767 . . . . 1.0 109.461 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.505 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.9 m -61.86 -42.16 98.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.743 -0.662 . . . . 1.0 109.657 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -75.24 -45.46 39.98 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.661 -0.699 . . . . 1.0 111.845 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.647 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.8 t30 -61.65 -44.65 96.57 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 113.18 0.807 . . . . 1.0 113.18 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -59.74 -34.9 73.55 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.27 -0.972 . . . . 1.0 108.578 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -71.51 -36.29 71.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.158 -0.928 . . . . 1.0 111.991 178.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 mtmt -55.78 135.66 72.24 Favored Pre-proline 0 CA--C 1.546 0.808 0 CA-C-N 116.412 -0.358 . . . . 1.0 111.588 -178.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.76 148.37 66.33 Favored 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.202 1.935 . . . . 1.0 113.627 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.06 -19.71 20.4 Favored Glycine 0 C--O 1.226 -0.394 0 CA-C-N 115.136 -0.938 . . . . 1.0 111.004 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.5 t -85.17 136.0 23.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.161 0.505 . . . . 1.0 110.155 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.07 121.46 65.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 107.767 -1.197 . . . . 1.0 107.767 178.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 p -95.93 145.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.648 0.737 . . . . 1.0 111.703 -177.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.55 164.15 16.06 Favored Pre-proline 0 C--N 1.334 -0.106 0 CA-C-N 114.455 -1.248 . . . . 1.0 110.437 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.57 -30.81 86.6 Favored 'Trans proline' 0 C--N 1.318 -1.059 0 C-N-CA 121.634 1.556 . . . . 1.0 111.339 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 m -69.33 -10.73 59.23 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.925 -0.579 . . . . 1.0 109.912 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.35 -2.8 71.5 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 110.232 -1.147 . . . . 1.0 110.232 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.42 HD23 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -79.17 133.27 36.72 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 108.628 -0.879 . . . . 1.0 108.628 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.42 ' H ' HD23 ' A' ' 32' ' ' LEU . 17.4 mp0 -122.8 139.54 53.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.395 -0.366 . . . . 1.0 110.983 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -135.5 143.13 45.63 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.675 0.75 . . . . 1.0 110.913 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -126.58 132.9 51.19 Favored 'General case' 0 CA--C 1.503 -0.86 0 CA-C-N 114.645 -1.161 . . . . 1.0 109.183 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.78 104.66 15.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.167 0.984 . . . . 1.0 111.906 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.5 mm -69.58 -41.86 80.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 108.007 -1.108 . . . . 1.0 108.007 178.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -142.36 129.64 21.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.573 -1.194 . . . . 1.0 109.804 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.7 p -88.49 131.35 34.93 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.764 -0.458 . . . . 1.0 109.764 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.0 -33.25 1.08 Allowed Glycine 0 C--N 1.331 0.291 0 N-CA-C 110.051 -1.219 . . . . 1.0 110.051 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.639 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.3 m120 54.7 30.93 14.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.375 -0.413 . . . . 1.0 110.958 179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.31 -162.3 37.85 Favored Glycine 0 C--N 1.331 0.281 0 CA-C-O 121.905 0.725 . . . . 1.0 111.957 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.5 m -68.81 -178.63 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 113.905 -1.148 . . . . 1.0 109.125 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.47 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.49 154.77 0.4 Allowed Pre-proline 0 C--N 1.321 -0.631 0 O-C-N 123.705 0.628 . . . . 1.0 109.948 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -87.33 154.43 8.0 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 123.439 2.759 . . . . 1.0 116.971 -174.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.446 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.55 177.2 48.47 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 109.141 -1.584 . . . . 1.0 109.141 175.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.406 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.37 -25.43 15.43 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.963 -0.295 . . . . 1.0 111.507 -179.722 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.6 m -108.03 -5.11 17.23 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.815 0.672 . . . . 1.0 112.815 -176.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.446 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 66.6 m-20 -83.49 165.36 19.2 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.4 m -106.52 150.31 26.25 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 109.636 -0.505 . . . . 1.0 109.636 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -129.39 162.94 35.9 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.465 0 CA-C-N 116.126 -0.488 . . . . 1.0 111.982 -176.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 98.5 m -130.15 119.63 23.3 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 108.52 -0.918 . . . . 1.0 108.52 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.18 165.17 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 114.885 1.439 . . . . 1.0 114.885 -177.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -118.89 145.07 46.02 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 106.568 -1.642 . . . . 1.0 106.568 174.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.556 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 38.8 p90 -161.11 164.07 30.94 Favored 'General case' 0 C--N 1.344 0.357 0 N-CA-C 114.825 1.417 . . . . 1.0 114.825 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -127.13 127.86 45.26 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 115.158 -0.928 . . . . 1.0 108.792 175.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.8 134.1 11.61 Favored Glycine 0 N--CA 1.473 1.114 0 C-N-CA 120.933 -0.651 . . . . 1.0 111.92 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.644 ' CZ ' ' HZ3' ' A' ' 127' ' ' LYS . 7.7 ptp85 -147.86 170.31 17.92 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.866 0.841 . . . . 1.0 113.071 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -83.58 164.08 19.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 114.126 -1.397 . . . . 1.0 110.795 178.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.406 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.3 -25.86 35.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.017 -0.992 . . . . 1.0 110.769 178.329 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -95.25 6.01 50.18 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.564 -1.198 . . . . 1.0 111.857 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.39 -3.46 75.69 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 121.01 -0.614 . . . . 1.0 113.313 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 m -71.78 106.58 4.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 118.157 0.978 . . . . 1.0 110.228 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 54.5 t -76.33 130.41 36.25 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.232 0.539 . . . . 1.0 110.575 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -120.37 -14.45 8.73 Favored 'General case' 0 CA--C 1.522 -0.112 0 CA-C-N 115.11 -0.95 . . . . 1.0 111.208 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 67' ' ' SER . 30.4 t0 -155.38 151.83 28.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.379 -0.373 . . . . 1.0 111.098 178.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 87.8 p -160.84 154.61 22.41 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 112.723 0.638 . . . . 1.0 112.723 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 55' ' ' TYR . 85.3 m -155.3 -42.01 0.08 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.143 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.405 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 2.0 pp20? -61.32 -26.19 67.63 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.602 -0.439 . . . . 1.0 110.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -53.83 -42.73 68.8 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.212 -1.033 . . . . 1.0 108.212 178.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 21.6 p -78.36 -30.61 48.08 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.957 -1.019 . . . . 1.0 108.956 177.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.75 17.16 73.56 Favored Glycine 0 C--N 1.337 0.593 0 N-CA-C 111.363 -0.695 . . . . 1.0 111.363 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 7.2 mptt -99.89 115.94 65.12 Favored Pre-proline 0 N--CA 1.469 0.492 0 C-N-CA 120.987 -0.285 . . . . 1.0 110.498 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -61.13 152.49 71.33 Favored 'Trans proline' 0 N--CA 1.483 0.867 0 C-N-CA 121.646 1.564 . . . . 1.0 113.964 -178.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.31 149.53 46.44 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.335 -1.302 . . . . 1.0 107.612 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -103.58 131.76 50.43 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.226 0.536 . . . . 1.0 112.219 -178.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.531 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 20.3 m-85 -137.71 150.05 47.0 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 115.29 -0.868 . . . . 1.0 110.482 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -93.47 124.65 37.6 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.162 -1.792 . . . . 1.0 106.162 174.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.4 t -51.46 -27.1 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 C-N-CA 119.778 -0.769 . . . . 1.0 110.608 -176.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 42.4 t -76.32 -24.58 54.31 Favored 'General case' 0 CA--C 1.519 -0.224 0 C-N-CA 120.344 -0.542 . . . . 1.0 112.287 -179.159 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.46 ' OE1' ' C46' ' A' ' 138' ' ' RAP . 88.4 mm-40 -98.56 -8.27 26.8 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 112.233 0.457 . . . . 1.0 112.233 -178.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.674 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.4 p -83.08 168.8 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 119.961 -0.696 . . . . 1.0 111.852 -177.512 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -55.19 153.32 13.05 Favored Pre-proline 0 CA--C 1.548 0.867 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 -177.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.28 -45.65 39.5 Favored 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.633 1.556 . . . . 1.0 112.948 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.11 -48.09 85.16 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.679 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 8.1 m95 -64.07 -35.74 81.74 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.101 -1.05 . . . . 1.0 110.108 179.267 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.4 m -52.17 -54.0 36.2 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.649 -0.42 . . . . 1.0 111.294 -178.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -72.71 -42.73 63.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.976 -0.557 . . . . 1.0 112.338 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.57 -47.36 79.69 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 113.848 1.055 . . . . 1.0 113.848 -177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.2 mt -58.25 -41.76 84.9 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.365 0.603 . . . . 1.0 109.799 -178.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.5 mt-30 -63.24 -24.78 68.02 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.952 -1.022 . . . . 1.0 110.904 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.42 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 70.1 mt -101.65 -13.27 17.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.252 -0.431 . . . . 1.0 111.29 -179.209 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 36.5 ttp -88.04 108.99 24.31 Favored Pre-proline 0 CA--C 1.547 0.847 0 N-CA-C 112.249 0.463 . . . . 1.0 112.249 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.47 ' HB3' ' HZ3' ' A' ' 44' ' ' LYS . 17.8 Cg_exo -66.37 147.77 83.33 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.274 1.983 . . . . 1.0 112.289 178.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.78 136.85 57.75 Favored 'General case' 0 CA--C 1.509 -0.627 0 CA-C-O 121.492 0.663 . . . . 1.0 111.503 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.08 -18.48 56.06 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 109.001 -1.64 . . . . 1.0 109.001 -178.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -86.99 133.67 33.56 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 120.894 0.378 . . . . 1.0 110.165 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 84.4 m -106.06 112.96 26.22 Favored 'General case' 0 CA--C 1.511 -0.557 0 CA-C-N 115.986 -0.552 . . . . 1.0 109.938 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.42 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.3 m0 -115.1 163.75 15.18 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.677 0.751 . . . . 1.0 111.544 -178.53 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -124.02 124.56 42.82 Favored 'General case' 0 CA--C 1.51 -0.566 0 N-CA-C 107.101 -1.444 . . . . 1.0 107.101 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -119.0 137.84 51.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.866 0.841 . . . . 1.0 110.086 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.647 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -109.84 103.42 12.21 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 105.707 -1.96 . . . . 1.0 105.707 -178.303 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 t -90.63 116.12 65.7 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 115.529 1.678 . . . . 1.0 115.529 -174.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -50.75 143.32 29.77 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 121.611 1.54 . . . . 1.0 110.23 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 79.9 p -49.76 -35.43 22.39 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.282 -0.567 . . . . 1.0 110.524 -178.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.02 -32.39 82.37 Favored Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.985 -0.846 . . . . 1.0 110.985 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 42.9 mt -100.87 2.64 41.17 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.877 -0.162 . . . . 1.0 110.898 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.37 -104.53 0.34 Allowed 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 117.693 0.224 . . . . 1.0 110.511 -178.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.617 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 53.5 m-85 -104.99 5.39 32.61 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 113.564 0.95 . . . . 1.0 113.564 -178.24 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 108.54 164.68 20.88 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.924 -0.655 . . . . 1.0 113.506 176.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.475 ' O ' ' N ' ' A' ' 121' ' ' ASN . 89.9 Cg_endo -75.11 -14.75 20.8 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 C-N-CA 123.618 2.878 . . . . 1.0 111.404 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -101.28 165.98 11.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.115 -0.948 . . . . 1.0 109.586 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.448 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -75.21 97.71 3.58 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.411 -0.516 . . . . 1.0 109.844 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.2 t -110.34 59.0 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.858 -179.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 167.81 -178.29 41.73 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 120.117 -1.04 . . . . 1.0 112.247 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -58.35 -106.4 0.01 OUTLIER Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.972 -0.451 . . . . 1.0 111.972 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -14.87 38.9 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 122.028 1.819 . . . . 1.0 111.011 -178.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.519 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -67.03 115.89 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 107.922 -1.14 . . . . 1.0 107.922 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.598 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -93.88 -160.72 34.98 Favored Glycine 0 C--O 1.215 -1.047 0 N-CA-C 110.398 -1.081 . . . . 1.0 110.398 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.448 ' N ' ' OG ' ' A' ' 113' ' ' SER . 74.2 Cg_endo -73.35 145.39 38.29 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 122.112 1.874 . . . . 1.0 112.756 178.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 111' ' ' PRO . 1.1 t30 45.24 59.92 3.28 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.782 0.66 . . . . 1.0 112.782 177.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.614 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -115.06 138.44 50.88 Favored 'General case' 0 N--CA 1.473 0.702 0 CA-C-O 121.62 0.724 . . . . 1.0 111.185 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 97.5 m -94.57 129.53 41.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.658 -1.155 . . . . 1.0 108.71 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -111.96 143.57 42.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.248 0.547 . . . . 1.0 110.076 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.2 tt -122.44 148.15 26.25 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 108.659 -0.867 . . . . 1.0 108.659 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.34 150.94 47.08 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.051 0.453 . . . . 1.0 111.166 177.435 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.644 ' HZ3' ' CZ ' ' A' ' 58' ' ' ARG . 7.5 mmtt -100.25 123.33 44.35 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 105.721 -1.955 . . . . 1.0 105.721 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -119.8 119.0 58.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 119.143 -1.023 . . . . 1.0 113.056 -176.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -109.96 123.25 49.3 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 113.885 -1.507 . . . . 1.0 108.682 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.49 111.29 23.22 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 120.346 -0.542 . . . . 1.0 112.186 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.46 -44.69 13.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.33 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -152.12 156.55 40.08 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.068 0.461 . . . . 1.0 111.03 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 49.1 t -129.82 134.71 62.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.969 -0.56 . . . . 1.0 110.446 -178.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.437 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 16.9 tptm -72.77 -82.86 0.05 OUTLIER 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 122.011 0.91 . . . . 1.0 110.452 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.566 ' HZ3' ' CB ' ' A' ' 137' ' ' SER . 0.0 OUTLIER 88.31 124.69 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 113.609 -1.632 . . . . 1.0 111.705 179.216 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.458 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 3.4 t -122.89 -43.48 2.24 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 113.963 -1.472 . . . . 1.0 111.099 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.566 ' CB ' ' HZ3' ' A' ' 135' ' ' LYS . 48.1 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.044 -0.979 . . . . 1.0 110.547 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.679 ' H42' ' CZ3' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 73.1 t80 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.181 -0.674 . . . . 1.0 109.181 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -66.79 -26.79 67.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.003 -0.544 . . . . 1.0 110.391 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.42 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 59.4 pttt -46.13 -41.78 12.89 Favored 'General case' 0 C--O 1.224 -0.283 0 C-N-CA 120.356 -0.538 . . . . 1.0 110.396 -178.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.733 ' HZ1' HD22 ' A' ' 8' ' ' ASN . 5.6 tmtt? -62.29 -41.21 98.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 120.167 -0.613 . . . . 1.0 109.358 -178.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.57 -36.36 64.29 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 115.713 -0.676 . . . . 1.0 109.673 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -67.9 -37.21 81.44 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.399 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -65.77 -52.57 49.9 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-O 121.929 0.871 . . . . 1.0 110.29 -179.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.733 HD22 ' HZ1' ' A' ' 4' ' ' LYS . 9.6 m-20 -57.28 -35.75 70.16 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.549 -1.205 . . . . 1.0 108.462 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 tttm -65.96 -51.9 54.36 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 113.651 -1.613 . . . . 1.0 111.602 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.5 t -69.96 -48.41 63.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 C-N-CA 119.881 -0.728 . . . . 1.0 112.162 -178.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -62.18 -39.77 93.79 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 108.113 -1.069 . . . . 1.0 108.113 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.14 73.53 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-N 115.148 -0.933 . . . . 1.0 111.913 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.492 ' O ' ' OG1' ' A' ' 17' ' ' THR . 88.9 mt-10 -61.35 -31.6 71.48 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.974 -0.75 . . . . 1.0 108.974 178.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -34.08 50.2 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.135 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -63.12 -50.45 70.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.388 -1.278 . . . . 1.0 110.774 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.8 mp -73.41 -39.73 64.83 Favored 'General case' 0 CA--C 1.509 -0.618 0 C-N-CA 119.912 -0.715 . . . . 1.0 110.225 178.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.492 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 91.1 m -62.0 -42.84 99.59 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.347 -179.243 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -75.85 -46.79 28.46 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.859 -0.609 . . . . 1.0 112.243 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 59.8 t30 -60.89 -44.63 96.83 Favored 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 113.573 0.953 . . . . 1.0 113.573 -177.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -59.2 -35.08 72.96 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 119.706 -0.798 . . . . 1.0 109.7 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -73.75 -33.99 64.53 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.221 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -60.37 125.51 82.07 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-N 115.956 -0.565 . . . . 1.0 112.066 -178.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.27 149.92 15.64 Favored 'Trans proline' 0 N--CA 1.5 1.854 0 C-N-CA 122.168 1.912 . . . . 1.0 112.847 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.77 -20.14 33.53 Favored Glycine 0 C--O 1.224 -0.523 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 -179.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.9 t -93.36 133.01 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 1.0 109.614 179.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.1 t -117.41 120.83 66.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 108.528 -0.916 . . . . 1.0 108.528 177.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.34 146.08 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.623 0 CA-C-O 121.676 0.75 . . . . 1.0 111.393 -178.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 62.5 mt -113.56 164.22 16.42 Favored Pre-proline 0 C--N 1.332 -0.167 0 CA-C-N 114.438 -1.255 . . . . 1.0 110.958 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.07 -30.35 93.04 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.894 1.73 . . . . 1.0 110.913 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.5 m -67.93 -15.17 63.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.785 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.66 68.57 Favored Glycine 0 C--O 1.23 -0.139 0 N-CA-C 110.089 -1.205 . . . . 1.0 110.089 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.74 133.97 38.18 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 109.056 -0.72 . . . . 1.0 109.056 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.421 ' H ' HD23 ' A' ' 32' ' ' LEU . 24.0 mp0 -123.12 137.77 54.83 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.1 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -133.73 143.16 48.31 Favored 'General case' 0 CA--C 1.504 -0.797 0 CA-C-O 121.739 0.78 . . . . 1.0 110.927 178.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -126.96 131.84 50.97 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 114.432 -1.258 . . . . 1.0 109.562 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -88.39 105.12 15.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 122.045 0.926 . . . . 1.0 111.922 -178.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 16.1 mm -69.44 -42.34 80.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.036 -0.984 . . . . 1.0 108.447 178.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.419 ' O ' ' OG ' ' A' ' 97' ' ' SER . 23.0 m-80 -141.96 127.19 18.61 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.524 -1.216 . . . . 1.0 109.72 -179.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -86.73 130.96 34.27 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.803 0.335 . . . . 1.0 110.399 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.469 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -121.33 -36.01 0.77 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 109.914 -1.275 . . . . 1.0 109.914 179.597 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.624 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.4 m120 58.48 32.81 22.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 1.0 111.593 179.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.9 -161.67 37.58 Favored Glycine 0 C--N 1.331 0.255 0 CA-C-O 121.861 0.7 . . . . 1.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 26.4 m -69.6 -178.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.07 -1.065 . . . . 1.0 109.494 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.5 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.47 154.43 0.45 Allowed Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 109.61 -0.515 . . . . 1.0 109.61 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -88.02 157.47 7.18 Favored 'Trans proline' 0 N--CA 1.503 2.077 0 C-N-CA 123.72 2.946 . . . . 1.0 117.454 -174.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.42 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.45 177.6 48.75 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 109.725 -1.35 . . . . 1.0 109.725 175.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.409 ' HD2' ' H ' ' A' ' 48' ' ' SER . 0.0 OUTLIER -55.05 -25.54 31.42 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.216 -0.492 . . . . 1.0 111.904 -179.612 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.409 ' H ' ' HD2' ' A' ' 47' ' ' LYS . 3.7 m -108.94 -4.84 16.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.551 0.574 . . . . 1.0 112.551 -177.622 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.42 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.5 m-20 -82.18 169.56 16.46 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.046 -0.724 . . . . 1.0 109.046 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.6 m -111.4 151.46 28.47 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.699 -0.482 . . . . 1.0 109.699 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -129.96 162.56 37.46 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 CA-C-N 115.754 -0.657 . . . . 1.0 111.716 -176.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 73.6 m -129.67 120.16 24.72 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.288 -1.004 . . . . 1.0 108.288 177.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.5 m -149.06 164.86 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 N-CA-C 114.379 1.252 . . . . 1.0 114.379 -176.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -118.72 146.26 44.88 Favored 'General case' 0 N--CA 1.486 1.352 0 N-CA-C 106.056 -1.831 . . . . 1.0 106.056 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.604 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 41.1 p90 -162.98 164.61 25.63 Favored 'General case' 0 C--N 1.342 0.275 0 N-CA-C 114.971 1.471 . . . . 1.0 114.971 -176.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.448 ' OG1' ' OE1' ' A' ' 69' ' ' GLU . 1.2 m -125.97 130.45 51.24 Favored 'General case' 0 C--O 1.216 -0.679 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.706 175.526 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.48 132.86 10.72 Favored Glycine 0 N--CA 1.473 1.113 0 N-CA-C 111.356 -0.698 . . . . 1.0 111.356 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 -147.06 167.54 23.82 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.788 0.804 . . . . 1.0 112.658 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.6 mp -81.9 164.83 21.28 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 114.252 -1.34 . . . . 1.0 110.274 178.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -60.82 -26.27 37.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 114.794 -1.094 . . . . 1.0 110.243 178.173 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.415 ' OD2' ' O ' ' A' ' 61' ' ' ASP . 7.0 t70 -94.04 5.26 52.27 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.019 -1.446 . . . . 1.0 111.919 -176.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.56 -4.53 79.7 Favored Glycine 0 CA--C 1.528 0.883 0 C-N-CA 121.0 -0.619 . . . . 1.0 113.227 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -70.29 103.88 2.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 118.073 0.937 . . . . 1.0 110.028 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -75.55 128.3 37.18 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.727 0 C-N-CA 120.642 -0.423 . . . . 1.0 110.059 179.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.407 ' CE2' H431 ' A' ' 138' ' ' RAP . 9.2 p90 -116.08 -10.34 11.55 Favored 'General case' 0 CA--C 1.521 -0.165 0 CA-C-N 115.439 -0.8 . . . . 1.0 111.116 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -164.24 153.32 13.55 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.443 -0.503 . . . . 1.0 111.677 177.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.7 p -159.41 158.08 31.46 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 115.763 -0.653 . . . . 1.0 111.869 179.214 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.519 ' N ' ' O ' ' A' ' 55' ' ' TYR . 67.2 m -152.78 -40.61 0.1 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.358 -0.837 . . . . 1.0 110.254 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.448 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.3 pp20? -59.86 -27.59 66.8 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.373 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -55.45 -40.23 71.33 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.641 -1.244 . . . . 1.0 107.641 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.8 -34.94 57.92 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.029 -1.442 . . . . 1.0 108.642 178.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.54 17.87 69.9 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 110.69 -0.964 . . . . 1.0 110.69 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -105.07 116.26 60.94 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 121.155 -0.218 . . . . 1.0 110.754 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -60.36 149.93 83.31 Favored 'Trans proline' 0 N--CA 1.479 0.67 0 C-N-CA 121.255 1.303 . . . . 1.0 113.358 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -122.83 151.27 41.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 114.483 -1.235 . . . . 1.0 108.204 178.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.1 t -106.41 127.44 53.29 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 113.13 0.789 . . . . 1.0 113.13 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.478 ' CZ ' ' H62' ' A' ' 138' ' ' RAP . 54.6 m-85 -133.97 150.02 51.26 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-N 115.148 -0.933 . . . . 1.0 108.973 177.087 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -90.38 125.05 35.41 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 106.353 -1.721 . . . . 1.0 106.353 174.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.5 t -48.48 -30.43 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 120.06 -0.656 . . . . 1.0 110.199 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.9 t -75.13 -25.12 58.17 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.27 -0.572 . . . . 1.0 111.681 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.495 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 94.4 mm-40 -98.87 -8.2 26.08 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 113.518 0.933 . . . . 1.0 113.518 -177.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.576 ' HA ' H482 ' A' ' 138' ' ' RAP . 3.9 p -88.22 170.49 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 118.907 0.776 . . . . 1.0 111.974 -178.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.98 148.51 13.85 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 120.256 -0.578 . . . . 1.0 109.623 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.75 -44.34 41.48 Favored 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 122.25 1.967 . . . . 1.0 113.143 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.63 -47.43 90.19 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.818 -1.313 . . . . 1.0 109.818 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.688 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 9.2 m95 -63.79 -36.97 85.63 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.747 -1.227 . . . . 1.0 110.128 178.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 20.9 m -50.89 -54.19 26.1 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 116.258 -0.428 . . . . 1.0 111.041 -177.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.0 tp10 -72.84 -42.6 63.58 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.541 0.571 . . . . 1.0 112.541 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.52 -47.21 79.83 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 113.552 0.945 . . . . 1.0 113.552 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 79.3 mt -57.84 -41.28 82.01 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.406 0.622 . . . . 1.0 109.995 -178.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -64.57 -23.74 67.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.26 -0.882 . . . . 1.0 111.126 -179.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.8 mt -105.3 -12.23 16.15 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.505 -0.316 . . . . 1.0 111.075 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 17.6 ttm -88.77 108.4 23.08 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 116.014 -0.539 . . . . 1.0 111.925 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.5 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 20.2 Cg_exo -65.54 149.14 87.9 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.853 2.369 . . . . 1.0 113.318 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.86 133.43 51.88 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-N 115.591 -0.731 . . . . 1.0 111.359 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.4 -19.06 54.8 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 109.67 -1.372 . . . . 1.0 109.67 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.707 ' HG ' ' HE1' ' A' ' 99' ' ' TRP . 23.8 t -84.08 125.96 32.62 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.967 0.413 . . . . 1.0 109.946 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 44.1 m -96.94 111.86 23.88 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 116.151 -0.477 . . . . 1.0 110.044 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.707 ' HE1' ' HG ' ' A' ' 97' ' ' SER . 39.8 m0 -114.95 164.47 14.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.863 0.84 . . . . 1.0 111.476 -178.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 88.6 mt-10 -125.81 126.52 44.65 Favored 'General case' 0 CA--C 1.508 -0.636 0 N-CA-C 106.582 -1.636 . . . . 1.0 106.582 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.0 pt -120.4 137.15 55.13 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.767 0.794 . . . . 1.0 109.792 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.35 103.27 12.39 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 105.77 -1.937 . . . . 1.0 105.77 -178.13 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.95 115.09 63.57 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 114.969 1.47 . . . . 1.0 114.969 -174.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -51.32 144.53 30.45 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.121 1.214 . . . . 1.0 109.768 175.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.4 p -49.0 -36.67 18.21 Favored 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 120.653 -0.419 . . . . 1.0 110.961 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.18 -32.29 81.8 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.377 -0.689 . . . . 1.0 111.377 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 59.1 mt -98.58 2.07 47.06 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 122.926 -0.161 . . . . 1.0 110.645 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.46 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.37 -111.26 0.31 Allowed 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 110.035 -0.358 . . . . 1.0 110.035 -179.276 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.598 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 52.3 m-85 -98.88 4.21 47.42 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 112.327 0.492 . . . . 1.0 112.327 -178.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.85 157.9 15.36 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 121.387 -0.435 . . . . 1.0 112.592 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.445 ' O ' ' N ' ' A' ' 121' ' ' ASN . 88.4 Cg_endo -74.12 -11.72 23.28 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 123.506 2.804 . . . . 1.0 110.562 179.222 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 70.2 ttt180 -100.85 165.12 11.51 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.8 -1.091 . . . . 1.0 108.946 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.51 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.1 m -72.28 97.17 1.95 Allowed 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 119.989 -0.684 . . . . 1.0 109.173 178.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.4 t -112.08 60.9 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 121.049 -0.261 . . . . 1.0 111.322 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 163.19 169.39 26.56 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.333 -0.937 . . . . 1.0 111.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.21 -103.47 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.191 -0.764 . . . . 1.0 111.191 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -60.81 -19.39 61.44 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 122.46 2.107 . . . . 1.0 111.608 -178.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 5.4 mp -68.05 118.7 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 107.54 -1.282 . . . . 1.0 107.54 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -101.31 -168.0 27.87 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 115.225 -0.898 . . . . 1.0 113.796 -176.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 19.5 Cg_endo -63.6 144.71 90.48 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.859 2.373 . . . . 1.0 112.289 178.313 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.445 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 43.25 50.93 5.84 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.717 0.294 . . . . 1.0 111.004 179.108 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.545 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 3.9 tp10 -106.15 127.51 53.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.623 0.725 . . . . 1.0 112.627 -177.604 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 25.7 m -95.61 135.24 37.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.649 -1.16 . . . . 1.0 108.52 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -115.32 142.16 47.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.232 0.539 . . . . 1.0 110.862 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.5 tt -120.84 149.37 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 115.468 -0.787 . . . . 1.0 108.951 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.581 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -139.62 149.84 44.26 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.507 -0.477 . . . . 1.0 111.046 177.019 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.9 mmtt -100.5 122.35 43.08 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 105.577 -2.008 . . . . 1.0 105.577 178.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -119.18 119.37 60.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 C-N-CA 119.311 -0.956 . . . . 1.0 113.564 -175.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -108.53 122.58 47.34 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 113.912 -1.495 . . . . 1.0 108.451 177.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.7 110.58 22.69 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.173 0.511 . . . . 1.0 111.64 -178.483 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.69 -46.86 13.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.212 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.3 p -150.99 158.45 44.15 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.237 0.542 . . . . 1.0 111.188 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.05 141.99 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 115.492 -0.776 . . . . 1.0 110.001 -178.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.452 ' O ' ' CB ' ' A' ' 135' ' ' LYS . 12.3 tptm -84.6 -83.98 0.15 Allowed 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.45 0.643 . . . . 1.0 111.929 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.452 ' CB ' ' O ' ' A' ' 134' ' ' LYS . 1.5 tmtt? 94.78 128.0 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 113.99 -1.459 . . . . 1.0 110.342 -178.367 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.419 ' N ' ' CD ' ' A' ' 135' ' ' LYS . 28.8 t -72.54 35.46 0.07 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 113.719 -1.582 . . . . 1.0 111.795 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.442 ' H ' ' C ' ' A' ' 135' ' ' LYS . 13.9 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.861 -1.066 . . . . 1.0 110.435 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.758 H491 H382 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 110.431 -0.211 . . . . 1.0 110.431 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -64.36 -30.87 71.91 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 119.941 -0.704 . . . . 1.0 110.51 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.9 ttpt -51.23 -43.52 61.47 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.098 -0.641 . . . . 1.0 110.095 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.561 ' HZ3' HD22 ' A' ' 8' ' ' ASN . 6.4 tmtt? -68.81 -43.23 76.01 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 108.776 -0.824 . . . . 1.0 108.776 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.15 -34.49 45.06 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 114.816 -1.084 . . . . 1.0 110.339 179.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.517 ' OD2' ' NZ ' ' A' ' 9' ' ' LYS . 60.6 m-20 -64.57 -40.2 95.13 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.406 -0.815 . . . . 1.0 110.163 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -60.89 -54.74 41.36 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-O 121.571 0.7 . . . . 1.0 110.709 -179.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.561 HD22 ' HZ3' ' A' ' 4' ' ' LYS . 4.0 m-20 -59.6 -36.98 77.35 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.145 -1.057 . . . . 1.0 108.145 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.517 ' NZ ' ' OD2' ' A' ' 6' ' ' ASP . 4.3 ttpm? -66.74 -50.54 62.43 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 113.762 -1.563 . . . . 1.0 111.867 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.4 t -65.14 -48.67 82.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 119.614 -0.834 . . . . 1.0 110.993 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.83 -38.32 90.66 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.35 -46.97 46.22 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 115.094 -0.957 . . . . 1.0 112.199 179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.436 ' O ' ' OG1' ' A' ' 17' ' ' THR . 91.9 mt-10 -57.69 -34.81 69.81 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 108.645 -0.872 . . . . 1.0 108.645 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.05 -31.01 44.38 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.853 -1.067 . . . . 1.0 110.364 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -61.68 -49.23 77.32 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.147 -179.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 mp -66.57 -38.23 86.63 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 119.69 -0.804 . . . . 1.0 109.304 178.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.436 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.8 m -61.85 -42.97 99.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.549 0.69 . . . . 1.0 109.275 178.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -74.21 -44.29 53.8 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-N 115.334 -0.848 . . . . 1.0 111.609 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -56.83 -50.16 73.24 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.111 0.481 . . . . 1.0 111.883 -178.874 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 9.5 ptmt -60.01 -28.63 67.88 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.221 -0.992 . . . . 1.0 109.545 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -81.87 -29.57 32.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.33 -0.85 . . . . 1.0 111.442 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -58.95 136.35 87.52 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 120.848 -0.341 . . . . 1.0 111.177 -179.152 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -55.75 148.47 55.29 Favored 'Trans proline' 0 N--CA 1.506 2.234 0 C-N-CA 122.48 2.12 . . . . 1.0 114.179 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.76 -18.59 11.56 Favored Glycine 0 N--CA 1.462 0.428 0 CA-C-N 115.097 -0.956 . . . . 1.0 111.397 178.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 41.4 t -85.08 136.27 23.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.04 0.448 . . . . 1.0 111.074 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.5 t -120.47 122.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 N-CA-C 107.716 -1.216 . . . . 1.0 107.716 176.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.27 147.0 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 121.414 0.626 . . . . 1.0 111.812 -178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 54.6 mt -115.79 163.77 19.86 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.758 -1.11 . . . . 1.0 110.779 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.22 -31.91 93.67 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.584 1.523 . . . . 1.0 111.974 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.4 m -68.14 -12.23 60.54 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 109.294 -0.632 . . . . 1.0 109.294 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.0 -1.57 68.05 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 109.365 -1.494 . . . . 1.0 109.365 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.451 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -79.98 134.39 36.25 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.434 -0.95 . . . . 1.0 108.434 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.451 ' H ' HD23 ' A' ' 32' ' ' LEU . 13.0 mp0 -124.84 145.54 49.73 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-N 115.891 -0.595 . . . . 1.0 110.929 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -139.39 150.11 44.9 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.521 0.677 . . . . 1.0 110.733 178.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -135.13 134.94 40.73 Favored 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 114.563 -1.199 . . . . 1.0 109.119 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -92.33 103.75 14.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 122.211 1.005 . . . . 1.0 111.742 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 14.3 mm -69.02 -41.74 81.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.039 -0.982 . . . . 1.0 109.197 179.438 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -142.04 128.0 19.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.109 -0.95 . . . . 1.0 109.942 -178.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.9 p -87.55 124.46 33.51 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.858 0.361 . . . . 1.0 110.101 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.402 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.19 -32.77 2.1 Favored Glycine 0 CA--C 1.517 0.218 0 N-CA-C 109.539 -1.424 . . . . 1.0 109.539 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.597 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 56.49 32.43 20.75 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.3 -0.45 . . . . 1.0 110.995 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.75 -163.01 38.66 Favored Glycine 0 C--N 1.329 0.167 0 CA-C-O 121.977 0.765 . . . . 1.0 111.536 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.602 ' O ' ' N ' ' A' ' 95' ' ' ALA . 29.2 m -69.43 -177.94 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.009 -1.095 . . . . 1.0 108.42 177.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.532 ' HZ3' ' CB ' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.25 154.27 0.38 Allowed Pre-proline 0 C--N 1.316 -0.852 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.6 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 70.3 Cg_endo -87.79 152.78 7.36 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.827 2.351 . . . . 1.0 115.265 -175.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.53 178.98 51.54 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.612 -1.795 . . . . 1.0 108.612 176.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.621 ' H ' ' HZ2' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.95 -21.48 11.86 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.445 -0.502 . . . . 1.0 110.847 -179.666 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.4 m -107.64 -11.03 15.52 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 113.587 0.958 . . . . 1.0 113.587 -177.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -85.69 166.1 16.42 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 119.632 -0.827 . . . . 1.0 109.331 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.8 m -103.79 151.01 23.57 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.23 0.538 . . . . 1.0 110.43 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.421 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.3 p -128.06 157.56 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.421 0 CA-C-N 115.278 -0.874 . . . . 1.0 112.343 -176.338 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 98.1 m -124.07 120.54 32.68 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 107.923 -1.14 . . . . 1.0 107.923 177.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.7 m -149.23 163.18 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 114.698 1.37 . . . . 1.0 114.698 -175.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.4 152.61 35.52 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 106.384 -1.71 . . . . 1.0 106.384 173.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.484 ' H ' ' HB ' ' A' ' 68' ' ' THR . 33.6 p90 -164.09 160.73 21.89 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.528 1.307 . . . . 1.0 114.528 -177.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.415 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -123.37 128.46 49.91 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.953 -0.758 . . . . 1.0 108.953 175.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.8 137.69 14.45 Favored Glycine 0 N--CA 1.467 0.716 0 C-N-CA 120.925 -0.655 . . . . 1.0 112.138 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.451 ' HE ' ' HZ2' ' A' ' 127' ' ' LYS . 8.1 ptp180 -146.18 165.91 27.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.714 0.769 . . . . 1.0 112.574 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.2 mp -82.91 163.28 21.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 114.276 -1.329 . . . . 1.0 110.052 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.408 HD12 ' H ' ' A' ' 61' ' ' ASP . 0.2 OUTLIER -60.33 -26.2 36.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.155 -0.929 . . . . 1.0 110.276 178.08 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.408 ' H ' HD12 ' A' ' 60' ' ' ILE . 39.1 t0 -93.82 7.76 43.69 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.376 -1.284 . . . . 1.0 111.78 -177.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.83 -7.27 81.46 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 121.241 -0.504 . . . . 1.0 113.31 178.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -68.19 105.79 2.22 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 119.444 -0.902 . . . . 1.0 110.565 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 99.2 t -76.84 118.98 24.34 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.82 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -106.34 -20.22 13.45 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.016 -0.993 . . . . 1.0 111.897 -178.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.479 ' OD1' ' O6 ' ' A' ' 138' ' ' RAP . 10.2 t70 -154.82 155.4 34.35 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.228 0.537 . . . . 1.0 111.972 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.415 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 92.9 p -157.4 159.8 37.75 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.341 -0.845 . . . . 1.0 111.57 178.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.512 ' O ' ' OG1' ' A' ' 71' ' ' THR . 89.9 m -155.25 -38.51 0.09 Allowed 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 115.567 -0.742 . . . . 1.0 110.01 -179.309 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -65.29 -25.37 67.61 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.638 -1.245 . . . . 1.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.6 mmtt -59.53 -45.63 91.2 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 176.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.512 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.8 OUTLIER -73.05 -33.36 65.64 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.505 -1.225 . . . . 1.0 108.194 177.423 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.55 18.93 67.27 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 111.497 -0.641 . . . . 1.0 111.497 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.9 115.37 60.4 Favored Pre-proline 0 N--CA 1.47 0.549 0 C-N-CA 120.936 -0.306 . . . . 1.0 110.919 -179.023 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -59.9 151.26 72.75 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 121.826 1.684 . . . . 1.0 114.185 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -120.68 148.63 43.67 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 113.915 -1.493 . . . . 1.0 107.498 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.15 124.57 49.89 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.335 0.588 . . . . 1.0 112.378 -178.245 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.566 ' CE1' ' H32' ' A' ' 138' ' ' RAP . 47.3 m-85 -133.32 149.34 51.9 Favored 'General case' 0 CA--C 1.493 -1.221 0 CA-C-N 115.286 -0.87 . . . . 1.0 109.707 178.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -90.75 130.36 36.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 105.09 -2.189 . . . . 1.0 105.09 174.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 38.2 t -57.23 -31.61 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 119.099 -1.04 . . . . 1.0 110.108 -176.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.1 t -73.67 -25.99 60.52 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.424 -0.51 . . . . 1.0 112.038 -178.27 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.536 ' CB ' ' H30' ' A' ' 138' ' ' RAP . 56.2 mm-40 -102.26 -6.64 22.91 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 112.959 0.726 . . . . 1.0 112.959 -177.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.509 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.2 p -78.91 168.58 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 121.046 -0.262 . . . . 1.0 111.242 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.56 146.81 16.22 Favored Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 107.903 -1.147 . . . . 1.0 107.903 -178.133 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.53 -43.29 45.78 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 121.433 1.422 . . . . 1.0 112.648 -177.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.11 -47.34 91.25 Favored Glycine 0 C--N 1.317 -0.479 0 C-N-CA 119.747 -1.216 . . . . 1.0 110.946 -178.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.702 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 7.8 m95 -66.68 -32.3 73.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 113.973 -1.113 . . . . 1.0 110.748 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.5 m -51.37 -54.48 26.06 Favored 'General case' 0 C--N 1.322 -0.603 0 O-C-N 122.029 -0.42 . . . . 1.0 111.812 -178.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -72.7 -40.27 66.33 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.7 -44.06 97.0 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 114.432 1.271 . . . . 1.0 114.432 -176.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.4 mt -58.6 -41.56 86.11 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.147 0.499 . . . . 1.0 110.323 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -64.55 -23.89 67.42 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.368 -0.833 . . . . 1.0 110.401 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.524 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 88.6 mt -99.61 -14.84 18.81 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.964 -0.562 . . . . 1.0 111.718 -178.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 48.7 ttp -91.2 108.68 30.23 Favored Pre-proline 0 CA--C 1.548 0.892 0 O-C-N 123.224 0.327 . . . . 1.0 111.826 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.532 ' CB ' ' HZ3' ' A' ' 44' ' ' LYS . 24.0 Cg_exo -63.79 149.1 91.51 Favored 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.586 2.191 . . . . 1.0 113.052 178.115 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.602 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.99 133.4 54.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.436 0.636 . . . . 1.0 110.76 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.61 -13.79 66.53 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 108.744 -1.742 . . . . 1.0 108.744 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.402 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 7.7 t -90.83 122.66 33.74 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.012 0.434 . . . . 1.0 109.839 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.8 m -97.07 115.07 26.82 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.402 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 31.7 m0 -115.76 167.95 10.48 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.657 0.741 . . . . 1.0 110.996 -178.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -128.44 134.74 48.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 106.453 -1.684 . . . . 1.0 106.453 175.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -130.91 139.03 52.14 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.654 0 CA-C-O 121.724 0.773 . . . . 1.0 109.601 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.3 OUTLIER -109.39 102.9 11.76 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.995 -1.854 . . . . 1.0 105.995 -177.408 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 t -90.33 116.23 65.9 Favored Pre-proline 0 N--CA 1.453 -0.302 0 N-CA-C 115.093 1.516 . . . . 1.0 115.093 -174.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.33 143.56 26.26 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.519 1.479 . . . . 1.0 109.601 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.7 p -53.7 -27.97 31.16 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.411 -0.515 . . . . 1.0 110.929 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.61 -29.48 65.6 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 110.194 -1.163 . . . . 1.0 110.194 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.9 mt -101.03 2.28 40.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.301 -0.45 . . . . 1.0 111.173 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.462 ' O ' H522 ' A' ' 138' ' ' RAP . . . -110.43 -108.34 0.35 Allowed 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.852 0.316 . . . . 1.0 111.852 -178.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.599 ' CE2' H492 ' A' ' 138' ' ' RAP . 42.4 m-85 -99.24 3.39 46.26 Favored 'General case' 0 C--N 1.339 0.118 0 N-CA-C 112.136 0.421 . . . . 1.0 112.136 -178.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.03 163.98 22.13 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.23 -0.509 . . . . 1.0 112.396 178.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.551 ' O ' ' N ' ' A' ' 121' ' ' ASN . 84.9 Cg_endo -75.77 -11.55 20.1 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 123.404 2.736 . . . . 1.0 111.955 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -98.62 167.17 10.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.065 -0.516 . . . . 1.0 109.729 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.613 ' HG ' ' N ' ' A' ' 120' ' ' PRO . 4.8 m -74.05 78.18 1.71 Allowed 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.301 -0.56 . . . . 1.0 109.842 178.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.1 t -93.68 60.44 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.084 -0.507 . . . . 1.0 109.949 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.59 177.09 40.42 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 120.224 -0.988 . . . . 1.0 112.295 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.97 -106.74 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 N-CA-C 111.293 -0.723 . . . . 1.0 111.293 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.31 -13.72 17.47 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 121.905 1.737 . . . . 1.0 110.522 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.532 ' CD1' ' H ' ' A' ' 118' ' ' ILE . 3.5 mp -67.26 111.84 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 107.383 -1.34 . . . . 1.0 107.383 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.52 ' C ' ' HG ' ' A' ' 113' ' ' SER . . . -93.16 -167.1 38.54 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.473 -1.051 . . . . 1.0 110.473 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.613 ' N ' ' HG ' ' A' ' 113' ' ' SER . 29.5 Cg_endo -62.91 144.99 94.35 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.227 1.951 . . . . 1.0 112.7 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 47.33 56.78 6.5 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.221 0.452 . . . . 1.0 112.221 177.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 52.1 mm-40 -103.1 128.47 50.0 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 112.308 0.484 . . . . 1.0 112.308 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.8 m -93.94 128.4 40.23 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.191 -1.411 . . . . 1.0 107.191 176.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.41 147.95 31.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 121.482 0.658 . . . . 1.0 111.156 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.8 tt -126.79 144.21 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.64 0 N-CA-C 108.477 -0.935 . . . . 1.0 108.477 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.543 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.9 OUTLIER -135.0 151.95 51.28 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 120.499 -0.48 . . . . 1.0 111.305 177.81 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.479 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.7 mmtt -100.18 125.12 46.28 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.044 -2.206 . . . . 1.0 105.044 176.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.3 mt -118.61 118.49 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 119.153 -1.019 . . . . 1.0 112.331 -176.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -109.77 121.7 45.81 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 113.569 -1.65 . . . . 1.0 108.232 178.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.33 112.16 24.01 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 120.235 -0.586 . . . . 1.0 112.064 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -91.57 -47.1 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.68 -0.691 . . . . 1.0 110.974 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.9 t -150.02 158.12 43.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.833 0.349 . . . . 1.0 111.013 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.9 t -130.26 136.91 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 116.192 -0.458 . . . . 1.0 111.609 -178.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.566 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 20.3 tptt -92.83 -148.4 0.24 Allowed 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.661 0.743 . . . . 1.0 110.075 178.49 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.566 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -172.37 137.62 0.88 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 114.841 -1.072 . . . . 1.0 110.006 178.42 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.4 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 6.5 t -95.85 -63.59 1.14 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.371 -0.831 . . . . 1.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 117.918 -1.039 . . . . 1.0 110.57 -179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.702 ' H51' ' CZ2' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.819 -0.808 . . . . 1.0 108.819 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -64.95 -37.23 86.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.271 -0.422 . . . . 1.0 110.788 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.66 -38.52 6.83 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.474 -0.491 . . . . 1.0 110.339 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.47 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 3.1 tmtt? -72.34 -40.54 67.32 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 121.49 0.662 . . . . 1.0 109.61 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -51.51 -32.57 28.13 Favored 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 115.003 -0.998 . . . . 1.0 110.537 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -61.8 -39.79 92.96 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.537 -0.756 . . . . 1.0 110.109 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -62.2 -53.38 56.04 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 121.682 0.753 . . . . 1.0 110.593 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.567 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 7.0 m-20 -60.13 -34.44 73.53 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.223 -0.899 . . . . 1.0 108.599 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.543 ' NZ ' ' OE1' ' A' ' 13' ' ' GLU . 19.9 tttp -66.93 -51.23 57.76 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.164 -1.38 . . . . 1.0 111.649 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.1 t -67.41 -46.83 82.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.082 -0.647 . . . . 1.0 111.887 -177.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.67 -38.22 90.29 Favored 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 107.442 -1.318 . . . . 1.0 107.442 178.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.04 -44.35 61.37 Favored Glycine 0 CA--C 1.528 0.905 0 CA-C-N 114.845 -1.071 . . . . 1.0 112.44 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.543 ' OE1' ' NZ ' ' A' ' 9' ' ' LYS . 87.0 mt-10 -61.98 -32.06 72.48 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 119.342 -0.943 . . . . 1.0 108.72 179.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.17 -35.3 64.01 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.133 -0.94 . . . . 1.0 109.682 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -63.83 -50.3 69.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.213 -179.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.5 mp -71.11 -37.87 72.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 109.178 -0.675 . . . . 1.0 109.178 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.447 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 86.2 m -62.03 -43.08 99.59 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.791 -0.641 . . . . 1.0 109.482 179.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -75.02 -45.78 39.52 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.655 -0.702 . . . . 1.0 112.154 -179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 46.0 t30 -61.62 -44.62 96.66 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 113.126 0.787 . . . . 1.0 113.126 -177.545 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.68 -30.36 68.72 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 119.406 -0.917 . . . . 1.0 109.505 -179.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 26.2 m-80 -81.15 -29.49 34.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.667 -0.697 . . . . 1.0 111.782 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 18.7 mtmt -59.55 136.52 89.36 Favored Pre-proline 0 CA--C 1.545 0.774 0 C-N-CA 120.687 -0.405 . . . . 1.0 111.188 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.75 147.49 60.61 Favored 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 121.719 1.612 . . . . 1.0 112.807 178.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.76 -20.23 25.14 Favored Glycine 0 C--O 1.225 -0.417 0 CA-C-N 115.27 -0.877 . . . . 1.0 111.486 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.9 t -88.13 134.38 28.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.05 0.453 . . . . 1.0 110.751 -179.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 83.8 t -118.67 122.26 69.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 108.062 -1.088 . . . . 1.0 108.062 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.79 146.06 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.721 0.772 . . . . 1.0 111.789 -178.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.6 mt -114.77 162.29 24.53 Favored Pre-proline 0 N--CA 1.465 0.316 0 CA-C-N 114.418 -1.264 . . . . 1.0 110.612 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.16 -30.92 94.39 Favored 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 121.681 1.588 . . . . 1.0 111.277 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 m -66.99 -15.04 63.47 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.509 -0.769 . . . . 1.0 109.389 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.28 -0.72 66.39 Favored Glycine 0 CA--C 1.51 -0.221 0 N-CA-C 109.432 -1.467 . . . . 1.0 109.432 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.424 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -80.56 134.21 35.89 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.355 -0.98 . . . . 1.0 108.355 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.424 ' H ' HD23 ' A' ' 32' ' ' LEU . 20.2 mp0 -122.82 138.8 54.54 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.965 -0.561 . . . . 1.0 110.564 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -133.54 147.16 51.56 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.878 0.847 . . . . 1.0 111.0 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -134.1 136.48 43.93 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-N 114.174 -1.375 . . . . 1.0 109.724 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -92.79 105.73 17.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 122.366 1.079 . . . . 1.0 111.589 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 17.7 mm -70.54 -42.25 78.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.082 -0.963 . . . . 1.0 109.124 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.434 ' O ' ' OG ' ' A' ' 97' ' ' SER . 56.6 m-80 -143.07 124.48 14.72 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 113.998 -1.456 . . . . 1.0 109.09 -178.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.1 p -88.61 125.58 34.88 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.596 -0.52 . . . . 1.0 109.596 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.442 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.11 -33.76 1.93 Allowed Glycine 0 CA--C 1.516 0.129 0 N-CA-C 110.345 -1.102 . . . . 1.0 110.345 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.593 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.5 m120 57.98 32.97 22.68 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 123.679 0.281 . . . . 1.0 111.441 179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.37 -161.08 36.92 Favored Glycine 0 C--N 1.335 0.502 0 CA-C-O 121.763 0.646 . . . . 1.0 111.929 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.584 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.8 m -68.74 -179.75 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 114.309 -0.945 . . . . 1.0 109.025 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.475 ' HZ2' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 178.0 155.84 0.52 Allowed Pre-proline 0 N--CA 1.476 0.831 0 CA-C-O 120.953 0.406 . . . . 1.0 110.886 179.234 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -85.02 167.03 11.09 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 123.433 2.756 . . . . 1.0 117.521 -173.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -102.91 165.62 16.29 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 113.571 -1.649 . . . . 1.0 109.566 177.021 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.516 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -44.97 -25.86 0.36 Allowed 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.657 -0.771 . . . . 1.0 111.886 -179.636 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 66.5 m -108.32 -5.57 16.7 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 112.759 0.651 . . . . 1.0 112.759 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.706 ' OD2' ' N ' ' A' ' 50' ' ' THR . 66.4 t0 -82.29 169.08 16.93 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.151 0.501 . . . . 1.0 110.841 -179.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.706 ' N ' ' OD2' ' A' ' 49' ' ' ASP . 7.6 m -110.91 142.7 42.63 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.656 -0.868 . . . . 1.0 108.656 177.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.12 160.34 30.82 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.534 0 CA-C-N 114.994 -1.003 . . . . 1.0 112.252 -175.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.1 m -124.69 120.3 31.43 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.873 -0.788 . . . . 1.0 108.873 178.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 75' ' ' ALA . 11.4 m -148.75 165.44 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 114.636 1.347 . . . . 1.0 114.636 -176.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -119.32 151.99 37.5 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 173.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.52 ' O ' ' N ' ' A' ' 68' ' ' THR . 33.6 p90 -164.96 164.83 20.6 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 118.425 -1.31 . . . . 1.0 113.973 -177.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.3 m -123.88 130.82 53.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 108.021 -1.103 . . . . 1.0 108.021 175.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.6 131.44 9.98 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.093 -1.203 . . . . 1.0 110.093 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.711 ' NE ' ' HZ3' ' A' ' 127' ' ' LYS . 5.1 ptp180 -145.77 169.29 18.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.977 0.894 . . . . 1.0 112.762 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.7 mp -84.59 165.89 17.61 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 113.912 -1.495 . . . . 1.0 109.941 177.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.429 ' N ' HD12 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.06 -25.62 30.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.431 178.889 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -100.22 10.17 41.65 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.134 -0.939 . . . . 1.0 112.026 -177.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.94 -6.62 81.81 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 120.403 -0.903 . . . . 1.0 113.771 178.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.7 m -65.18 102.02 0.6 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 118.727 1.263 . . . . 1.0 109.182 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 88.4 t -74.86 117.4 18.99 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.408 0.623 . . . . 1.0 111.1 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -103.76 -15.63 15.67 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 114.903 -1.044 . . . . 1.0 112.092 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.416 ' OD2' H433 ' A' ' 138' ' ' RAP . 0.2 OUTLIER -159.24 153.91 24.47 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.27 -0.572 . . . . 1.0 110.375 177.811 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.0 p -157.19 158.55 36.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.826 -0.625 . . . . 1.0 111.802 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.2 m -153.07 -43.89 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.171 -0.922 . . . . 1.0 109.799 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.437 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -61.07 -28.02 68.78 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-N 115.888 -0.597 . . . . 1.0 109.66 179.42 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -57.24 -42.9 82.37 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 107.434 -1.321 . . . . 1.0 107.434 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.8 -33.47 60.13 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.299 -1.319 . . . . 1.0 107.558 176.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.02 17.75 73.87 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.314 -0.857 . . . . 1.0 112.118 178.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -98.13 116.35 65.61 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 121.265 -0.174 . . . . 1.0 110.557 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -58.54 150.52 68.44 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 121.501 1.467 . . . . 1.0 114.204 -179.464 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.483 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.77 145.82 48.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.354 -1.293 . . . . 1.0 108.472 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.3 t -103.8 131.3 51.12 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-O 121.453 0.644 . . . . 1.0 112.452 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.65 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 36.0 m-85 -139.8 149.6 43.71 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.994 -1.003 . . . . 1.0 110.42 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -90.81 127.54 36.39 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 105.766 -1.938 . . . . 1.0 105.766 174.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.1 t -51.64 -29.2 9.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 C-N-CA 118.981 -1.088 . . . . 1.0 110.512 -176.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 48.3 t -77.68 -23.17 49.65 Favored 'General case' 0 CA--C 1.521 -0.171 0 C-N-CA 120.306 -0.558 . . . . 1.0 111.835 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.499 ' O ' H512 ' A' ' 138' ' ' RAP . 97.3 mm-40 -98.56 -6.6 29.77 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 113.728 1.01 . . . . 1.0 113.728 -178.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.588 ' HA ' H481 ' A' ' 138' ' ' RAP . 4.6 p -87.59 172.36 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 119.775 -0.77 . . . . 1.0 110.924 -178.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.406 ' CD1' ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -53.48 152.31 9.12 Favored Pre-proline 0 N--CA 1.478 0.954 0 N-CA-C 109.301 -0.629 . . . . 1.0 109.301 -176.956 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.26 -45.14 41.35 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.098 1.866 . . . . 1.0 112.061 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.77 -46.86 91.81 Favored Glycine 0 CA--C 1.522 0.512 0 C-N-CA 119.957 -1.116 . . . . 1.0 110.876 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.596 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 9.1 m95 -64.58 -35.44 80.98 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.342 -0.929 . . . . 1.0 111.495 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 30.7 m -50.78 -55.29 17.48 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.55 -0.46 . . . . 1.0 112.14 -177.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -73.27 -40.42 64.6 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 112.365 0.506 . . . . 1.0 112.365 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.47 -45.76 84.45 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 114.154 1.168 . . . . 1.0 114.154 -178.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.1 mt -57.84 -41.59 82.66 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.197 0.522 . . . . 1.0 110.629 -177.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.9 mt-30 -65.43 -19.1 65.79 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.277 -0.874 . . . . 1.0 111.346 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.502 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 57.5 mt -106.01 -13.4 15.48 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.116 -0.493 . . . . 1.0 110.7 -178.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.0 ttp -88.91 109.13 28.02 Favored Pre-proline 0 CA--C 1.553 1.063 0 N-CA-C 112.101 0.408 . . . . 1.0 112.101 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.475 ' HG3' ' HZ2' ' A' ' 44' ' ' LYS . 22.3 Cg_exo -64.58 149.53 89.72 Favored 'Trans proline' 0 N--CA 1.504 2.11 0 C-N-CA 122.979 2.453 . . . . 1.0 113.296 178.346 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.584 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.33 132.58 50.58 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.495 0.664 . . . . 1.0 111.154 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.76 -18.21 57.65 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 108.505 -1.838 . . . . 1.0 108.505 -178.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.442 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 9.3 t -86.02 128.64 34.9 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 109.944 -0.391 . . . . 1.0 109.944 179.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.7 m -103.33 114.8 29.36 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 115.594 -0.73 . . . . 1.0 109.696 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . 0.502 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -114.14 167.96 10.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.781 0.8 . . . . 1.0 111.336 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 80.7 mt-10 -128.46 124.5 36.33 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.171 -1.418 . . . . 1.0 107.171 175.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.6 pt -120.68 135.49 60.72 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.868 0 N-CA-C 108.735 -0.839 . . . . 1.0 108.735 179.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.64 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.1 OUTLIER -107.12 104.0 13.53 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.725 -1.954 . . . . 1.0 105.725 -177.258 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 t -90.51 115.53 64.36 Favored Pre-proline 0 C--N 1.32 -0.675 0 N-CA-C 115.256 1.576 . . . . 1.0 115.256 -173.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -51.35 146.03 25.91 Favored 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 121.941 1.761 . . . . 1.0 110.569 176.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.0 p -53.58 -24.51 13.95 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.456 -178.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -78.56 -29.5 52.31 Favored Glycine 0 N--CA 1.46 0.268 0 N-CA-C 110.697 -0.961 . . . . 1.0 110.697 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.2 mt -102.16 2.77 37.71 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.523 -0.338 . . . . 1.0 110.49 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.26 -102.43 0.35 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 110.11 -0.33 . . . . 1.0 110.11 -178.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.641 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 47.6 m-85 -108.96 5.46 24.33 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.753 1.02 . . . . 1.0 113.753 -177.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.57 163.05 17.4 Favored Glycine 0 N--CA 1.473 1.128 0 C-N-CA 121.285 -0.483 . . . . 1.0 113.209 177.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.553 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.1 Cg_endo -71.13 -18.67 30.55 Favored 'Trans proline' 0 N--CA 1.494 1.527 0 C-N-CA 123.535 2.823 . . . . 1.0 112.37 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -104.01 171.56 7.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.229 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.633 ' HG ' ' N ' ' A' ' 120' ' ' PRO . 2.0 m -73.64 97.28 2.63 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.926 -0.579 . . . . 1.0 110.171 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.6 t -109.55 61.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.596 -0.274 . . . . 1.0 110.873 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 168.36 -168.53 40.98 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 120.892 -0.671 . . . . 1.0 111.715 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.12 -104.9 0.04 OUTLIER Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.457 -0.657 . . . . 1.0 111.457 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -58.9 -19.05 45.5 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.237 1.958 . . . . 1.0 111.621 -178.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 3.8 mp -66.56 112.83 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 119.901 -0.72 . . . . 1.0 109.166 179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.545 ' C ' ' HG ' ' A' ' 113' ' ' SER . . . -90.65 -164.84 39.93 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.679 -0.968 . . . . 1.0 110.679 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.633 ' N ' ' HG ' ' A' ' 113' ' ' SER . 23.5 Cg_endo -63.22 152.05 81.74 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.359 2.039 . . . . 1.0 113.272 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.553 ' N ' ' O ' ' A' ' 111' ' ' PRO . 11.9 t30 37.17 53.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.807 177.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.423 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 41.7 mm-40 -97.36 132.29 43.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.29 0.567 . . . . 1.0 111.768 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 84.6 m -95.66 127.44 41.7 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.451 -1.314 . . . . 1.0 107.451 176.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.82 140.79 47.31 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.338 -179.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 2.2 tt -119.43 147.05 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 N-CA-C 108.435 -0.95 . . . . 1.0 108.435 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.626 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -134.4 145.53 49.01 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 121.12 0.486 . . . . 1.0 110.324 177.314 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.711 ' HZ3' ' NE ' ' A' ' 58' ' ' ARG . 5.5 mmtt -99.61 121.83 41.76 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 104.673 -2.343 . . . . 1.0 104.673 178.394 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -116.09 120.36 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 119.438 -0.905 . . . . 1.0 113.176 -175.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.4 t-160 -110.3 123.18 49.34 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 113.927 -1.488 . . . . 1.0 108.486 178.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.64 113.17 24.79 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 112.384 0.513 . . . . 1.0 112.384 -178.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.4 mp -96.25 -46.98 13.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 115.775 -0.648 . . . . 1.0 111.301 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.95 155.86 42.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.168 0.509 . . . . 1.0 111.574 -178.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.1 t -128.96 142.19 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.706 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.485 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 3.9 tptt -100.66 -152.09 0.42 Allowed 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.712 0.768 . . . . 1.0 110.765 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.485 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -174.89 134.65 0.36 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.487 -1.233 . . . . 1.0 110.985 178.928 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.534 ' OG ' ' N ' ' A' ' 137' ' ' SER . 0.0 OUTLIER -58.1 -72.13 0.1 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.013 -0.994 . . . . 1.0 110.405 179.605 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.534 ' N ' ' OG ' ' A' ' 136' ' ' SER . 33.6 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.184 -0.912 . . . . 1.0 110.877 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.777 ' O3 ' H491 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.598 ' CG ' ' N ' ' A' ' 2' ' ' ASN . 29.6 t80 . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 109.501 -0.555 . . . . 1.0 109.501 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.598 ' N ' ' CG ' ' A' ' 1' ' ' PHE . 49.8 m-20 -70.28 -17.52 63.1 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.425 -0.352 . . . . 1.0 111.208 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.489 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 58.9 pttt -45.36 -43.2 10.77 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.382 -0.527 . . . . 1.0 110.47 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.489 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 3.8 tmtt? -75.16 -42.53 55.85 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 122.058 0.932 . . . . 1.0 109.332 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -50.27 -31.08 13.25 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 114.411 -1.268 . . . . 1.0 110.001 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -62.6 -38.71 91.24 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.17 -0.923 . . . . 1.0 110.251 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -63.48 -51.9 63.65 Favored 'General case' 0 C--O 1.222 -0.372 0 CA-C-O 121.428 0.633 . . . . 1.0 110.867 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 2.3 m-20 -62.74 -35.76 80.83 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.094 -1.076 . . . . 1.0 108.094 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 13' ' ' GLU . 76.8 tttt -65.72 -49.45 68.42 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.42 -1.718 . . . . 1.0 112.095 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.0 t -66.36 -48.67 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 C-N-CA 119.79 -0.764 . . . . 1.0 110.9 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.61 -36.22 82.05 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.799 -1.185 . . . . 1.0 107.799 178.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -73.59 -41.81 42.38 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.836 -1.074 . . . . 1.0 112.213 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.472 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.7 mt-10 -62.79 -31.35 72.3 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 119.464 -0.895 . . . . 1.0 108.634 179.54 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.55 -34.76 53.72 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 115.138 -0.937 . . . . 1.0 109.925 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -60.84 -49.07 78.96 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.499 -1.228 . . . . 1.0 111.11 -178.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.1 mp -70.18 -36.76 74.87 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.195 -0.602 . . . . 1.0 109.495 178.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 96.3 m -61.66 -44.36 97.1 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.593 -0.731 . . . . 1.0 109.715 179.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -76.6 -44.83 32.73 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 114.985 -1.007 . . . . 1.0 112.517 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.3 t30 -60.07 -44.99 94.36 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 113.089 0.774 . . . . 1.0 113.089 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -61.02 -28.5 69.09 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 119.969 -0.693 . . . . 1.0 109.761 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -82.99 -28.08 29.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.571 -0.741 . . . . 1.0 111.235 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.4 mtmt -59.25 139.01 88.45 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 120.834 -0.346 . . . . 1.0 111.478 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_exo -56.5 148.54 62.56 Favored 'Trans proline' 0 N--CA 1.502 2.008 0 C-N-CA 122.167 1.911 . . . . 1.0 113.353 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.415 ' HA2' ' HZ1' ' A' ' 35' ' ' LYS . . . 80.78 -18.84 8.25 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.247 -0.888 . . . . 1.0 111.592 179.209 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.46 137.29 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.444 . . . . 1.0 109.964 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.6 t -122.98 119.62 58.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 108.242 -1.021 . . . . 1.0 108.242 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -94.93 145.44 8.12 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 CA-C-O 121.689 0.757 . . . . 1.0 111.429 -179.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.9 mt -111.92 165.11 13.57 Favored Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 114.189 -1.369 . . . . 1.0 110.481 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -61.21 -29.43 86.63 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.764 1.643 . . . . 1.0 111.048 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -68.34 -16.88 64.1 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 115.678 -0.692 . . . . 1.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.74 -7.0 60.85 Favored Glycine 0 CA--C 1.517 0.196 0 N-CA-C 110.142 -1.183 . . . . 1.0 110.142 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.434 HD23 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.38 134.52 38.42 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 179.528 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.434 ' H ' HD23 ' A' ' 32' ' ' LEU . 26.2 mp0 -121.24 142.91 49.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.454 -0.339 . . . . 1.0 110.641 179.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -136.97 148.13 46.74 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-O 121.56 0.695 . . . . 1.0 110.75 178.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . 0.415 ' HZ1' ' HA2' ' A' ' 24' ' ' GLY . 0.3 OUTLIER -135.27 134.74 40.27 Favored 'General case' 0 N--CA 1.44 -0.948 0 CA-C-N 114.48 -1.236 . . . . 1.0 109.88 -179.174 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 p -93.3 105.34 16.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 122.063 0.935 . . . . 1.0 111.472 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 15.9 mm -70.33 -41.76 78.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.177 -0.92 . . . . 1.0 109.303 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -145.46 119.75 9.57 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.797 -1.092 . . . . 1.0 110.48 -177.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 p -80.32 123.85 28.34 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.264 0.554 . . . . 1.0 110.352 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 -29.24 4.07 Favored Glycine 0 CA--C 1.519 0.286 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.587 ' N ' HD21 ' A' ' 41' ' ' ASN . 1.6 m120 54.73 32.12 16.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.756 -0.722 . . . . 1.0 111.412 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.95 -163.26 38.78 Favored Glycine 0 C--N 1.33 0.247 0 CA-C-O 121.923 0.735 . . . . 1.0 111.548 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.3 m -68.28 -177.77 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 114.154 -1.023 . . . . 1.0 108.615 178.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . 0.425 ' HZ3' ' HB3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.36 154.47 0.39 Allowed Pre-proline 0 C--N 1.317 -0.806 0 N-CA-C 109.454 -0.573 . . . . 1.0 109.454 179.631 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -88.02 159.64 7.28 Favored 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 123.137 2.558 . . . . 1.0 116.355 -174.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.452 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -91.53 175.02 38.69 Favored Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 109.06 -1.616 . . . . 1.0 109.06 176.375 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.534 ' HD3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.47 -23.91 4.48 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.112 -0.544 . . . . 1.0 110.69 -179.691 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.441 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 40.6 m -107.72 -10.09 15.68 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 113.983 1.105 . . . . 1.0 113.983 -177.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.452 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.7 m-20 -84.7 165.51 17.81 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 119.618 -0.833 . . . . 1.0 108.835 179.724 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -103.36 148.93 25.27 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.515 -0.55 . . . . 1.0 109.515 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -125.62 162.44 28.65 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 CA-C-N 115.87 -0.605 . . . . 1.0 112.201 -176.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 87.8 m -130.55 120.37 23.95 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.039 -1.097 . . . . 1.0 108.039 177.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 9.9 m -148.51 164.99 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.004 1.113 . . . . 1.0 114.004 -176.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.4 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 10.4 mt-10 -118.61 152.3 36.3 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 106.425 -1.694 . . . . 1.0 106.425 174.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.473 ' CB ' ' O ' ' A' ' 127' ' ' LYS . 34.1 p90 -162.1 159.57 26.31 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 114.856 1.428 . . . . 1.0 114.856 -177.576 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.5 m -121.24 129.74 53.33 Favored 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.157 -0.929 . . . . 1.0 108.988 176.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.5 133.9 11.78 Favored Glycine 0 N--CA 1.47 0.935 0 N-CA-C 111.185 -0.766 . . . . 1.0 111.185 -178.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -145.54 166.43 25.73 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.69 0.757 . . . . 1.0 112.101 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -87.46 160.08 18.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.578 -1.192 . . . . 1.0 111.272 178.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.444 HD11 ' N ' ' A' ' 60' ' ' ILE . 0.2 OUTLIER -55.12 -26.01 17.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 114.462 -1.244 . . . . 1.0 110.465 177.811 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -96.04 5.63 50.71 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.49 -1.232 . . . . 1.0 111.075 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.73 -9.51 77.47 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.021 -0.536 . . . . 1.0 113.642 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -61.13 97.01 0.06 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 118.331 1.066 . . . . 1.0 110.634 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 98.2 t -68.73 125.69 27.1 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 C-N-CA 119.639 -0.824 . . . . 1.0 108.854 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.597 ' CE2' H431 ' A' ' 138' ' ' RAP . 19.4 p90 -117.38 -15.53 10.33 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.163 -0.926 . . . . 1.0 111.696 -178.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.542 ' CB ' H433 ' A' ' 138' ' ' RAP . 11.8 t70 -154.6 149.87 27.1 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.249 0.547 . . . . 1.0 111.735 178.023 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 84.2 p -155.87 151.32 26.97 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.395 -0.821 . . . . 1.0 111.776 179.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.475 ' O ' ' OG1' ' A' ' 71' ' ' THR . 99.5 m -148.04 -37.8 0.19 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.201 -0.908 . . . . 1.0 110.157 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.43 ' OE2' ' C ' ' A' ' 69' ' ' GLU . 1.1 pp20? -66.62 -27.37 67.65 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 116.14 -0.482 . . . . 1.0 110.04 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -59.4 -43.39 92.99 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 107.744 -1.206 . . . . 1.0 107.744 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 18.5 p -73.01 -32.88 65.42 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 114.876 -1.056 . . . . 1.0 108.523 176.747 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.36 17.68 66.08 Favored Glycine 0 CA--C 1.522 0.484 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.977 178.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.4 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -100.29 114.59 65.76 Favored Pre-proline 0 N--CA 1.471 0.602 0 C-N-CA 120.448 -0.501 . . . . 1.0 111.164 -179.591 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -61.7 152.87 71.25 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.012 1.808 . . . . 1.0 114.097 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.08 145.19 48.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 113.681 -1.599 . . . . 1.0 107.847 178.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.516 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 2.7 t -105.59 136.36 45.32 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.267 0.556 . . . . 1.0 112.482 -178.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.734 ' CE1' ' H42' ' A' ' 138' ' ' RAP . 19.5 m-85 -150.07 151.25 32.92 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.546 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -87.93 128.32 35.37 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 107.652 -1.24 . . . . 1.0 107.652 175.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.5 t -54.86 -32.28 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 120.135 -0.626 . . . . 1.0 110.899 -177.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -72.48 -26.93 61.98 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.8 -0.76 . . . . 1.0 112.063 -177.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.527 ' C ' H482 ' A' ' 138' ' ' RAP . 80.6 mm-40 -98.52 -11.1 22.59 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 112.789 0.662 . . . . 1.0 112.789 -178.08 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.626 ' HA ' H332 ' A' ' 138' ' ' RAP . 0.5 OUTLIER -71.54 169.07 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.798 0.666 . . . . 1.0 112.798 -175.735 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -51.69 145.76 15.19 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 107.134 -1.432 . . . . 1.0 107.134 -178.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -49.73 -44.86 34.32 Favored 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 121.19 1.26 . . . . 1.0 112.654 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.25 91.99 Favored Glycine 0 C--N 1.317 -0.523 0 C-N-CA 120.007 -1.092 . . . . 1.0 111.295 -179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' TRP . . . . . 0.556 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 6.7 m95 -63.76 -31.26 72.38 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 114.028 -1.086 . . . . 1.0 111.523 -179.489 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 99.4 m -56.4 -53.54 56.18 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 121.913 -0.492 . . . . 1.0 111.655 -178.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -71.76 -38.49 70.38 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.284 0.846 . . . . 1.0 113.284 -177.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -64.01 -44.1 93.64 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 114.477 1.288 . . . . 1.0 114.477 -176.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 26.9 mt -58.71 -37.99 77.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.275 0.559 . . . . 1.0 110.778 -177.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -64.92 -24.1 67.42 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.294 -0.866 . . . . 1.0 111.345 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 27.6 mt -102.06 -18.96 15.36 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.173 -0.467 . . . . 1.0 111.212 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.4 ttp -81.34 109.36 13.8 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 112.639 0.607 . . . . 1.0 112.639 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.428 ' O ' ' OG ' ' A' ' 97' ' ' SER . 17.0 Cg_exo -66.39 148.32 84.04 Favored 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 122.679 2.253 . . . . 1.0 113.116 178.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.592 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.91 131.48 46.8 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-O 121.606 0.717 . . . . 1.0 111.811 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.71 -16.51 60.87 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 108.177 -1.969 . . . . 1.0 108.177 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.428 ' OG ' ' O ' ' A' ' 94' ' ' PRO . 5.7 p -88.46 139.13 30.79 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.089 -0.556 . . . . 1.0 110.139 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 50.9 m -110.27 117.43 33.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.12 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -117.49 169.64 9.37 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.95 0.881 . . . . 1.0 110.546 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -130.24 132.65 46.06 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.935 -1.506 . . . . 1.0 106.935 175.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.48 137.13 58.62 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 108.603 -0.888 . . . . 1.0 108.603 179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.64 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.65 102.82 11.85 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 105.83 -1.915 . . . . 1.0 105.83 -177.8 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.6 t -89.94 115.1 63.11 Favored Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 114.516 1.302 . . . . 1.0 114.516 -174.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -51.57 144.33 33.33 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 121.072 1.181 . . . . 1.0 109.696 176.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 87.6 p -49.97 -31.98 13.9 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.377 -0.529 . . . . 1.0 110.959 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.71 -31.78 70.52 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.558 -0.617 . . . . 1.0 111.558 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.09 3.09 43.78 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 110.548 -0.167 . . . . 1.0 110.548 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.481 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.84 -109.06 0.33 Allowed 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 120.736 0.303 . . . . 1.0 111.256 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.584 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 38.6 m-85 -98.32 -4.66 34.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 114.379 1.251 . . . . 1.0 114.379 -176.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.32 172.68 18.95 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 120.497 -0.859 . . . . 1.0 113.174 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.561 ' O ' ' N ' ' A' ' 121' ' ' ASN . 71.9 Cg_endo -73.75 -31.4 8.49 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 123.649 2.899 . . . . 1.0 112.388 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -82.23 170.81 14.98 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.365 0.602 . . . . 1.0 111.435 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.418 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 7.3 m -79.34 88.3 4.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.279 -0.873 . . . . 1.0 109.039 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.3 t -97.88 55.26 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.341 -0.39 . . . . 1.0 111.383 -178.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 173.37 -175.25 46.18 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 120.509 -0.853 . . . . 1.0 112.087 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.34 -103.34 0.01 OUTLIER Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.268 -0.733 . . . . 1.0 111.268 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -62.13 -15.91 47.04 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.478 2.119 . . . . 1.0 110.518 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.502 ' CG2' ' OE2' ' A' ' 122' ' ' GLU . 4.6 mp -66.39 115.03 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.376 -1.342 . . . . 1.0 107.376 178.44 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -97.26 -157.79 30.82 Favored Glycine 0 C--O 1.213 -1.186 0 N-CA-C 110.814 -0.914 . . . . 1.0 110.814 -178.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.48 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 53.4 Cg_endo -71.02 147.58 55.08 Favored 'Trans proline' 0 C--N 1.297 -2.156 0 C-N-CA 121.51 1.474 . . . . 1.0 112.982 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.561 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 39.48 60.97 1.47 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 113.216 0.821 . . . . 1.0 113.216 177.503 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.67 ' H ' ' CD ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -112.69 140.35 47.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.038 0.447 . . . . 1.0 110.611 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 85.5 m -93.93 127.73 39.86 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.1 -1.074 . . . . 1.0 108.1 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -108.85 136.41 48.45 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.516 -0.55 . . . . 1.0 109.516 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ILE . . . . . . . . . . . . . 1.8 tt -117.6 146.87 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 108.706 -0.849 . . . . 1.0 108.706 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 126' ' ' PHE . 4.0 m-85 -135.8 149.49 49.12 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.236 -0.586 . . . . 1.0 111.334 178.137 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.473 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 9.5 mmtt -99.46 124.57 44.73 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 104.948 -2.242 . . . . 1.0 104.948 177.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.9 mt -115.77 118.37 58.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 C-N-CA 119.167 -1.013 . . . . 1.0 111.9 -177.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -110.39 123.05 49.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.655 -1.611 . . . . 1.0 108.484 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.76 112.95 24.55 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 112.544 0.572 . . . . 1.0 112.544 -177.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.405 HD13 ' N ' ' A' ' 131' ' ' ILE . 4.4 mp -94.49 -49.17 12.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 CA-C-N 115.749 -0.66 . . . . 1.0 111.17 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.6 p -145.32 157.39 44.06 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.014 0.435 . . . . 1.0 110.601 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.3 t -130.09 137.56 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.288 -0.414 . . . . 1.0 110.993 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.512 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 15.8 tptt -88.84 -150.15 0.19 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.541 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.512 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER 178.53 138.23 0.09 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.864 0.84 . . . . 1.0 111.493 177.861 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 137' ' ' SER . 1.1 t -63.55 -46.44 85.92 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 114.036 -1.438 . . . . 1.0 110.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.41 ' C ' ' O ' ' A' ' 136' ' ' SER . 94.3 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.887 -1.054 . . . . 1.0 111.462 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' RAP . . . . . 0.734 ' H42' ' CE1' ' A' ' 77' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 . . . . . 0 CA--C 1.517 -0.321 0 CA-C-O 121.861 0.839 . . . . 1.0 110.633 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.611 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 3.7 m-20 -58.55 -38.42 77.79 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 107.528 -1.286 . . . . 1.0 107.528 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -63.93 -50.98 66.55 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 113.125 -1.852 . . . . 1.0 111.806 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 70.7 t -73.82 -48.62 38.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 119.812 -0.755 . . . . 1.0 111.713 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.45 ' O ' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -60.36 -40.63 91.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.827 -1.175 . . . . 1.0 107.827 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.447 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -65.74 -48.07 70.4 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.374 -0.83 . . . . 1.0 112.133 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -61.71 -31.25 71.39 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.01 -0.737 . . . . 1.0 109.01 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.22 -33.79 43.44 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.121 -0.945 . . . . 1.0 109.957 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' O ' ' A' ' 11' ' ' LYS . 64.3 t80 -61.14 -50.78 71.81 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 114.445 -1.252 . . . . 1.0 110.414 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.44 -41.59 80.07 Favored 'General case' 0 CA--C 1.513 -0.452 0 C-N-CA 119.963 -0.695 . . . . 1.0 109.649 178.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.8 m -62.14 -41.31 98.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.569 -0.741 . . . . 1.0 109.474 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -75.74 -45.29 37.38 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.584 -0.734 . . . . 1.0 111.637 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.1 t30 -61.34 -45.03 96.12 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 113.135 0.791 . . . . 1.0 113.135 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -57.68 -31.36 66.27 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 119.305 -0.958 . . . . 1.0 108.833 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -80.74 -31.48 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.72 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 41.2 mtmt -56.97 139.85 78.02 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 120.19 -0.604 . . . . 1.0 110.905 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -56.27 148.49 60.5 Favored 'Trans proline' 0 N--CA 1.502 2.0 0 C-N-CA 122.069 1.846 . . . . 1.0 113.879 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.1 -19.5 10.06 Favored Glycine 0 C--O 1.227 -0.318 0 CA-C-N 114.937 -1.029 . . . . 1.0 111.992 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.404 HG22 ' HB2' ' A' ' 35' ' ' LYS . 43.5 t -83.35 138.17 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.123 0.487 . . . . 1.0 110.929 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.5 t -122.35 122.41 66.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.8 p -96.76 146.22 7.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.653 0 CA-C-O 121.569 0.699 . . . . 1.0 111.847 -178.278 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.7 mt -114.08 166.09 12.23 Favored Pre-proline 0 C--O 1.232 0.146 0 CA-C-N 114.484 -1.235 . . . . 1.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -62.07 -30.46 82.71 Favored 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 121.985 1.79 . . . . 1.0 111.499 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 m -68.84 -13.3 62.33 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.955 -0.566 . . . . 1.0 109.811 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.96 -1.56 68.14 Favored Glycine 0 CA--C 1.517 0.199 0 N-CA-C 109.811 -1.316 . . . . 1.0 109.811 -179.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.459 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.9 tm? -80.95 133.98 35.62 Favored 'General case' 0 CA--C 1.518 -0.258 0 N-CA-C 108.591 -0.892 . . . . 1.0 108.591 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.459 ' H ' HD22 ' A' ' 32' ' ' LEU . 18.9 mp0 -122.42 138.42 54.54 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 116.448 -0.342 . . . . 1.0 111.087 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -133.56 145.5 50.15 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.525 0.679 . . . . 1.0 111.054 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.504 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -127.66 132.82 49.66 Favored 'General case' 0 CA--C 1.505 -0.751 0 CA-C-N 114.552 -1.204 . . . . 1.0 109.499 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.57 104.26 14.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 122.2 1.0 . . . . 1.0 112.122 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.629 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.8 mm -70.24 -41.69 78.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.027 -0.988 . . . . 1.0 108.523 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -143.11 128.34 18.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 114.595 -1.184 . . . . 1.0 109.495 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.0 p -88.12 131.84 34.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.746 0.308 . . . . 1.0 110.239 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.21 -35.44 0.81 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.403 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 6.2 m-20 57.23 30.66 18.77 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.251 -0.474 . . . . 1.0 111.169 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.12 -161.73 37.55 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.828 0.682 . . . . 1.0 111.756 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 25.9 m -69.01 -178.4 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.153 -1.023 . . . . 1.0 109.576 178.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.533 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.62 154.26 0.4 Allowed Pre-proline 0 C--N 1.32 -0.711 0 O-C-N 123.682 0.614 . . . . 1.0 109.523 179.554 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -87.83 157.81 7.46 Favored 'Trans proline' 0 N--CA 1.5 1.894 0 C-N-CA 123.363 2.709 . . . . 1.0 117.242 -174.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.439 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.84 176.17 44.05 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 109.205 -1.558 . . . . 1.0 109.205 176.114 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.468 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.5 -25.46 6.6 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.189 -0.506 . . . . 1.0 112.055 -179.443 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -108.61 -8.42 15.47 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 112.834 0.679 . . . . 1.0 112.834 -177.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.439 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.3 m-20 -82.96 166.47 18.82 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.327 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -105.35 150.59 25.08 Favored 'General case' 0 CA--C 1.511 -0.551 0 CA-C-O 121.334 0.588 . . . . 1.0 110.146 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.0 p -128.94 160.68 39.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.19 -0.914 . . . . 1.0 112.009 -177.07 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.437 HG22 ' HB3' ' A' ' 74' ' ' PRO . 84.8 m -127.69 119.87 26.78 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.125 -1.065 . . . . 1.0 108.125 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.514 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 7.2 m -148.9 164.74 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 114.507 1.299 . . . . 1.0 114.507 -176.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.9 mt-10 -118.22 150.74 38.92 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 106.305 -1.739 . . . . 1.0 106.305 174.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.552 ' O ' ' N ' ' A' ' 68' ' ' THR . 32.5 p90 -163.32 162.9 25.34 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 115.09 1.515 . . . . 1.0 115.09 -177.582 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -126.27 129.47 48.97 Favored 'General case' 0 C--O 1.217 -0.608 0 CA-C-N 115.086 -0.961 . . . . 1.0 108.515 175.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.76 134.61 12.09 Favored Glycine 0 N--CA 1.471 1.011 0 N-CA-C 111.472 -0.651 . . . . 1.0 111.472 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.53 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 8.6 ptp85 -147.03 167.43 24.05 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.701 0.763 . . . . 1.0 112.389 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.5 mp -84.46 165.06 18.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 114.349 -1.296 . . . . 1.0 110.236 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.429 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.79 -26.55 38.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.265 -0.879 . . . . 1.0 110.524 178.445 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -92.0 3.18 55.81 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.044 -1.434 . . . . 1.0 111.701 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.24 -4.09 76.97 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 121.337 -0.458 . . . . 1.0 113.177 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.3 m -68.01 104.06 1.65 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 118.141 0.97 . . . . 1.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.6 t -76.43 120.04 25.79 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.079 0.466 . . . . 1.0 110.153 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.751 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.8 p90 -109.28 -11.79 14.84 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 115.231 -0.895 . . . . 1.0 112.308 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -161.99 153.08 17.99 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.316 -0.554 . . . . 1.0 111.511 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 94.4 p -159.23 154.21 24.97 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.41 0.624 . . . . 1.0 112.558 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.552 ' N ' ' O ' ' A' ' 55' ' ' TYR . 62.3 m -150.15 -40.74 0.13 Allowed 'General case' 0 C--O 1.223 -0.337 0 CA-C-N 115.024 -0.989 . . . . 1.0 110.305 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.41 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.6 pp20? -62.22 -26.62 68.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.241 -0.583 . . . . 1.0 109.637 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.9 mmmt -57.0 -42.91 81.17 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.426 -1.324 . . . . 1.0 107.426 178.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.492 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.4 p -73.28 -33.72 65.39 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.732 -1.122 . . . . 1.0 108.365 176.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.13 17.04 75.27 Favored Glycine 0 C--N 1.334 0.425 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.359 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.6 mttm -101.44 116.7 63.3 Favored Pre-proline 0 N--CA 1.469 0.524 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.693 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.3 Cg_exo -60.08 152.76 63.06 Favored 'Trans proline' 0 N--CA 1.485 0.982 0 C-N-CA 121.786 1.657 . . . . 1.0 114.377 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.412 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -122.29 147.26 46.45 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 113.827 -1.533 . . . . 1.0 107.548 177.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.46 128.12 52.3 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 121.072 0.463 . . . . 1.0 112.014 -179.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -136.06 150.59 49.22 Favored 'General case' 0 CA--C 1.493 -1.24 0 CA-C-O 121.797 0.808 . . . . 1.0 110.844 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 60.5 mt-30 -94.14 123.63 37.65 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 105.828 -1.915 . . . . 1.0 105.828 174.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.3 t -49.44 -25.61 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.795 -0.638 . . . . 1.0 110.663 -176.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 15.3 t -78.11 -24.33 47.53 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 120.308 -0.557 . . . . 1.0 112.189 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -96.6 -10.28 27.48 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.112 0.412 . . . . 1.0 112.112 -179.045 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.68 166.8 2.4 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 N-CA-C 112.59 0.589 . . . . 1.0 112.59 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -57.24 146.7 60.84 Favored Pre-proline 0 CA--C 1.545 0.753 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 -179.672 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -48.88 -46.11 26.05 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.686 1.591 . . . . 1.0 113.03 -178.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.68 -47.56 87.66 Favored Glycine 0 C--N 1.319 -0.398 0 N-CA-C 109.753 -1.339 . . . . 1.0 109.753 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.514 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.3 m95 -64.4 -36.23 83.49 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.147 -1.027 . . . . 1.0 110.199 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.43 ' H ' ' HG1' ' A' ' 87' ' ' THR . 19.5 m -51.17 -54.5 24.87 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.313 -0.403 . . . . 1.0 111.25 -177.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -72.96 -41.62 64.21 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.604 0.594 . . . . 1.0 112.604 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.51 -46.46 83.78 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 113.615 0.969 . . . . 1.0 113.615 -177.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 38.3 mt -58.85 -41.58 87.29 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 109.192 -0.67 . . . . 1.0 109.192 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -62.95 -23.85 67.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 114.938 -1.028 . . . . 1.0 110.696 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.448 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 83.9 mt -103.34 -12.96 16.88 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.255 -0.429 . . . . 1.0 111.327 -179.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.8 ttp -87.6 108.66 21.34 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-O 119.349 -0.358 . . . . 1.0 111.899 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.533 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.44 147.88 83.19 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 122.377 2.051 . . . . 1.0 112.365 178.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -66.46 132.37 48.12 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.519 -0.764 . . . . 1.0 111.438 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 99.52 -18.81 55.73 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 108.567 -1.813 . . . . 1.0 108.567 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.1 p -88.63 136.45 32.99 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 120.959 0.409 . . . . 1.0 110.387 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 90.5 m -108.27 114.39 28.22 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 115.803 -0.635 . . . . 1.0 109.708 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.448 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.1 m0 -115.4 167.6 10.72 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 121.596 0.712 . . . . 1.0 111.228 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.629 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.2 mt-10 -127.37 128.11 45.33 Favored 'General case' 0 CA--C 1.508 -0.639 0 N-CA-C 106.673 -1.603 . . . . 1.0 106.673 175.467 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' A' ' 86' ' ' TRP . 2.6 pt -123.32 138.07 54.5 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.6 0 CA-C-O 121.894 0.855 . . . . 1.0 110.27 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.44 103.9 13.13 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.957 -1.868 . . . . 1.0 105.957 -177.979 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.7 t -90.42 115.4 64.02 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 115.076 1.51 . . . . 1.0 115.076 -174.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -51.15 141.96 36.97 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 121.323 1.348 . . . . 1.0 109.858 175.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.3 p -48.46 -34.28 10.81 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.149 -0.62 . . . . 1.0 110.943 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.87 -32.32 80.72 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.144 -0.782 . . . . 1.0 111.144 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 68.0 mt -98.55 1.67 46.75 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 121.393 -0.123 . . . . 1.0 110.74 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.8 -113.39 0.3 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.052 0.39 . . . . 1.0 112.052 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -98.2 3.77 48.95 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 112.487 0.551 . . . . 1.0 112.487 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 109.49 162.75 19.67 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 121.014 -0.612 . . . . 1.0 112.768 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -74.75 -9.29 21.04 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 123.556 2.837 . . . . 1.0 111.695 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -103.63 166.59 10.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.126 -0.488 . . . . 1.0 109.839 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.57 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -72.3 84.99 1.07 Allowed 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.0 t -100.72 62.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.985 0.422 . . . . 1.0 110.513 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.443 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -179.98 41.09 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 111.502 -0.639 . . . . 1.0 111.502 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.84 -103.98 0.01 OUTLIER Glycine 0 CA--C 1.535 1.322 0 N-CA-C 110.992 -0.843 . . . . 1.0 110.992 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -61.33 -14.78 36.39 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.549 2.166 . . . . 1.0 110.669 -178.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.751 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.1 mp -65.83 113.25 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 106.672 -1.603 . . . . 1.0 106.672 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.31 -172.79 40.14 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.378 -0.828 . . . . 1.0 112.28 -177.431 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.57 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.2 Cg_endo -62.88 138.11 66.58 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 C-N-CA 122.38 2.053 . . . . 1.0 112.405 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.34 51.82 12.4 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 121.039 -0.264 . . . . 1.0 111.061 178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.611 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -98.82 130.06 45.24 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.921 0.712 . . . . 1.0 112.921 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.447 HG21 HD11 ' A' ' 16' ' ' LEU . 43.5 m -96.66 129.13 44.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 106.063 -1.829 . . . . 1.0 106.063 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -110.94 145.15 38.87 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.308 0.575 . . . . 1.0 111.105 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.664 HD12 ' CE2' ' A' ' 102' ' ' TYR . 2.1 tt -124.31 148.55 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 CA-C-N 115.233 -0.894 . . . . 1.0 108.884 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.597 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -140.93 151.17 44.0 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.242 -0.583 . . . . 1.0 111.515 177.536 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.53 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 12.9 mmtt -99.36 125.32 45.01 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 105.46 -2.052 . . . . 1.0 105.46 177.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.02 118.4 56.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.267 -0.973 . . . . 1.0 112.418 -176.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.601 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.6 t60 -109.68 123.88 50.25 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 114.128 -1.397 . . . . 1.0 108.649 178.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.07 111.17 23.02 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 120.246 -0.582 . . . . 1.0 112.39 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.601 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.1 mp -94.29 -42.69 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 115.995 -0.548 . . . . 1.0 111.676 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -153.44 156.0 37.38 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.502 -0.479 . . . . 1.0 110.796 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 44' ' ' LYS . 44.7 t -130.65 138.82 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 116.156 -0.475 . . . . 1.0 111.452 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.4 tptm . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 121.494 0.664 . . . . 1.0 109.564 178.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 . . . . . 0 CA--C 1.515 -0.366 0 CA-C-O 121.655 0.74 . . . . 1.0 110.505 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.4 m-20 -59.67 -35.31 74.19 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.204 -1.035 . . . . 1.0 108.204 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.3 tttt -66.59 -50.5 62.86 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 113.757 -1.565 . . . . 1.0 111.919 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.15 -48.0 82.81 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 C-N-CA 119.813 -0.755 . . . . 1.0 111.253 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.84 -38.1 89.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 178.898 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.15 -44.76 52.9 Favored Glycine 0 CA--C 1.525 0.703 0 CA-C-N 114.847 -1.069 . . . . 1.0 112.366 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -60.44 -31.78 70.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 119.494 -0.882 . . . . 1.0 108.692 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.99 -35.5 57.12 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.809 -1.087 . . . . 1.0 109.87 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.1 t80 -61.39 -51.34 69.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.621 -1.172 . . . . 1.0 110.847 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.408 HD11 HG21 ' A' ' 123' ' ' THR . 5.3 mp -68.12 -38.37 82.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 119.995 -0.682 . . . . 1.0 109.41 179.06 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 99.3 m -62.16 -41.65 98.51 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.553 -0.749 . . . . 1.0 109.296 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -74.62 -46.81 35.96 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.056 -0.975 . . . . 1.0 111.655 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.638 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -55.73 -50.49 70.24 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 112.496 0.554 . . . . 1.0 112.496 -178.783 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.0 ptmt -60.1 -26.74 66.45 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.379 -0.928 . . . . 1.0 109.831 -177.09 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -83.55 -31.23 26.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.377 -0.829 . . . . 1.0 111.186 179.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -58.7 136.45 86.57 Favored Pre-proline 0 CA--C 1.548 0.871 0 CA-C-N 116.52 -0.309 . . . . 1.0 111.576 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -56.75 148.58 64.84 Favored 'Trans proline' 0 N--CA 1.503 2.071 0 C-N-CA 122.138 1.892 . . . . 1.0 113.334 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.14 -19.32 18.11 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.495 -0.775 . . . . 1.0 111.49 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.471 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.1 t -86.42 137.71 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.165 0.507 . . . . 1.0 110.547 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.93 121.78 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 107.582 -1.266 . . . . 1.0 107.582 177.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.19 145.99 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.642 0 CA-C-O 121.361 0.601 . . . . 1.0 111.228 -178.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 92.8 mt -111.94 164.81 14.25 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.85 -1.068 . . . . 1.0 110.462 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -61.54 -30.48 86.28 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.745 1.63 . . . . 1.0 110.91 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -68.83 -14.44 63.03 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.473 -0.785 . . . . 1.0 109.828 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.41 -3.89 66.43 Favored Glycine 0 C--N 1.329 0.157 0 N-CA-C 109.671 -1.371 . . . . 1.0 109.671 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.472 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.16 133.93 36.71 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 108.457 -0.942 . . . . 1.0 108.457 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.472 ' H ' HD22 ' A' ' 32' ' ' LEU . 15.2 mp0 -123.07 143.38 50.0 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 116.286 -0.416 . . . . 1.0 110.887 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.4 p90 -138.21 143.59 40.25 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-O 121.635 0.731 . . . . 1.0 110.757 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.525 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -127.51 131.24 50.14 Favored 'General case' 0 CA--C 1.501 -0.924 0 CA-C-N 114.594 -1.184 . . . . 1.0 109.188 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 p -88.85 104.62 15.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 122.279 1.038 . . . . 1.0 111.688 -178.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.0 mm -69.25 -42.2 81.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.881 -1.054 . . . . 1.0 108.453 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -143.36 124.55 14.54 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.501 -1.227 . . . . 1.0 109.907 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -85.83 129.64 34.77 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.611 -0.436 . . . . 1.0 109.9 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.23 -33.24 1.26 Allowed Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.895 -1.282 . . . . 1.0 109.895 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.406 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 5.1 m-20 57.04 31.67 20.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.477 -0.361 . . . . 1.0 111.157 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.08 -162.18 37.92 Favored Glycine 0 C--N 1.332 0.329 0 CA-C-O 121.819 0.677 . . . . 1.0 111.822 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.4 m -68.17 -177.93 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 114.061 -1.069 . . . . 1.0 109.127 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.695 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.32 154.82 0.39 Allowed Pre-proline 0 C--N 1.317 -0.834 0 N-CA-C 109.338 -0.616 . . . . 1.0 109.338 179.553 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.427 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 56.8 Cg_endo -86.71 158.78 9.09 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 123.11 2.54 . . . . 1.0 115.741 -175.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 177.29 41.72 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 108.766 -1.734 . . . . 1.0 108.766 176.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.48 -23.02 9.07 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.882 -0.327 . . . . 1.0 111.07 -179.713 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 57.9 m -108.05 -9.22 15.67 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 113.629 0.974 . . . . 1.0 113.629 -176.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.7 m-20 -84.74 166.87 16.64 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 119.883 -0.727 . . . . 1.0 109.468 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.5 m -104.56 148.44 26.5 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.612 -0.514 . . . . 1.0 109.612 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.427 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -126.57 161.79 32.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.478 0 CA-C-N 115.857 -0.611 . . . . 1.0 112.278 -176.313 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.421 HG22 ' HB3' ' A' ' 74' ' ' PRO . 86.4 m -130.48 118.18 20.74 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 75' ' ' ALA . 2.5 m -148.14 166.43 4.79 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 112.577 0.584 . . . . 1.0 112.577 -177.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.2 mt-10 -116.39 157.7 24.66 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 106.469 -1.678 . . . . 1.0 106.469 175.078 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.475 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.6 p90 -167.2 160.91 14.15 Favored 'General case' 0 C--N 1.346 0.415 0 N-CA-C 114.846 1.425 . . . . 1.0 114.846 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -124.76 127.81 47.8 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.119 -1.067 . . . . 1.0 108.119 174.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.89 134.03 11.39 Favored Glycine 0 N--CA 1.47 0.955 0 C-N-CA 120.748 -0.739 . . . . 1.0 111.915 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -146.48 166.84 25.22 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.715 0.769 . . . . 1.0 112.169 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.0 162.66 20.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.391 -1.277 . . . . 1.0 110.062 177.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.05 -25.33 29.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.913 0.863 . . . . 1.0 110.206 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -92.22 2.84 56.37 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 113.947 -1.479 . . . . 1.0 111.852 -177.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.96 -4.98 78.86 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 121.016 -0.611 . . . . 1.0 112.781 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.7 m -68.82 105.75 2.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 118.068 0.934 . . . . 1.0 109.63 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 67.7 t -77.69 121.82 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.691 0 CA-C-O 121.229 0.538 . . . . 1.0 110.301 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.6 p90 -110.41 -11.53 14.5 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.089 -0.959 . . . . 1.0 111.688 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -159.84 154.13 23.66 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.192 0.52 . . . . 1.0 111.497 177.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.3 p -159.29 151.43 20.98 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.41 -0.814 . . . . 1.0 111.213 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.475 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.9 m -154.38 -41.78 0.09 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.645 -0.707 . . . . 1.0 110.649 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.426 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -62.38 -26.33 68.41 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.862 -0.608 . . . . 1.0 110.313 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -55.34 -41.88 73.06 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 108.153 -1.054 . . . . 1.0 108.153 179.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.7 p -80.05 -30.82 39.47 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.067 177.365 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.1 16.99 68.19 Favored Glycine 0 C--N 1.336 0.531 0 CA-C-N 115.689 -0.687 . . . . 1.0 111.592 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -97.28 115.73 65.8 Favored Pre-proline 0 N--CA 1.471 0.591 0 C-N-CA 120.716 -0.394 . . . . 1.0 110.342 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 Cg_exo -60.32 156.23 41.93 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.177 1.918 . . . . 1.0 114.687 -178.364 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.67 145.36 49.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 113.908 -1.496 . . . . 1.0 107.595 177.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.513 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 1.4 t -104.0 133.91 48.16 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.395 0.617 . . . . 1.0 112.075 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 76' ' ' THR . 22.6 m-85 -144.18 152.45 40.9 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.837 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -94.52 125.15 38.99 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.878 -1.527 . . . . 1.0 106.878 175.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.95 -30.87 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 C-N-CA 120.04 -0.664 . . . . 1.0 110.57 -177.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -73.42 -24.25 60.24 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.299 -0.561 . . . . 1.0 112.349 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 86.1 mm-40 -99.72 -14.67 18.79 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.888 0.699 . . . . 1.0 112.888 -177.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -73.14 169.43 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 112.434 0.531 . . . . 1.0 112.434 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.435 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -56.09 149.08 37.06 Favored Pre-proline 0 CA--C 1.547 0.831 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 -179.402 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.435 ' HD2' HG22 ' A' ' 83' ' ' ILE . 74.0 Cg_exo -51.49 -45.01 40.18 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 121.359 1.372 . . . . 1.0 112.941 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.93 -46.78 93.13 Favored Glycine 0 N--CA 1.45 -0.428 0 N-CA-C 110.29 -1.124 . . . . 1.0 110.29 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.6 m95 -65.87 -33.5 75.99 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.389 -0.906 . . . . 1.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.7 m -54.91 -54.16 46.18 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.703 -0.399 . . . . 1.0 111.359 -178.372 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -72.74 -42.44 64.07 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 112.771 0.656 . . . . 1.0 112.771 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.73 -46.8 83.95 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.903 1.075 . . . . 1.0 113.903 -177.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.2 mt -58.5 -41.56 85.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.347 0.594 . . . . 1.0 109.811 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -63.74 -23.59 67.43 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.095 -0.957 . . . . 1.0 110.515 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.528 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 81.3 mt -102.59 -10.03 19.63 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 116.032 -0.531 . . . . 1.0 111.422 -179.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.6 ttp -91.89 107.81 25.43 Favored Pre-proline 0 CA--C 1.546 0.823 0 N-CA-C 111.835 0.309 . . . . 1.0 111.835 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.695 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.0 Cg_exo -65.78 147.66 85.76 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 122.488 2.125 . . . . 1.0 112.357 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.74 137.55 58.12 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.666 0.746 . . . . 1.0 111.508 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.73 53.27 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 108.546 -1.822 . . . . 1.0 108.546 -178.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 p -87.18 134.6 33.51 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.009 0.433 . . . . 1.0 110.178 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.9 m -107.59 114.68 28.83 Favored 'General case' 0 CA--C 1.51 -0.582 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.052 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.528 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.6 m0 -115.71 164.38 14.43 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.708 0.766 . . . . 1.0 111.23 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.6 mt-10 -124.96 126.39 45.4 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 106.815 -1.55 . . . . 1.0 106.815 175.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -121.92 138.39 52.32 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.688 0 CA-C-O 121.899 0.857 . . . . 1.0 109.969 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.751 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.64 103.25 12.08 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.646 -1.983 . . . . 1.0 105.646 -178.231 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.2 115.45 64.07 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 114.75 1.389 . . . . 1.0 114.75 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -50.84 143.2 30.75 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 C-N-CA 121.433 1.422 . . . . 1.0 109.783 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 96.5 p -49.1 -35.26 15.75 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.273 -0.571 . . . . 1.0 110.531 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.86 -32.15 81.89 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 111.388 -0.685 . . . . 1.0 111.388 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 53.3 mt -100.59 2.91 42.2 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 121.499 -0.08 . . . . 1.0 110.832 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.66 -107.95 0.33 Allowed 'General case' 0 N--CA 1.457 -0.11 0 CA-C-O 120.923 0.392 . . . . 1.0 111.037 -178.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -100.03 4.89 45.01 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 111.965 0.357 . . . . 1.0 111.965 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.78 160.97 25.76 Favored Glycine 0 CA--C 1.529 0.927 0 C-N-CA 121.395 -0.431 . . . . 1.0 112.925 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.567 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.2 Cg_endo -70.56 -15.94 34.12 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 123.316 2.677 . . . . 1.0 112.676 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.456 ' O ' HG23 ' A' ' 114' ' ' VAL . 2.8 mpt_? -96.75 169.48 9.84 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.22 -0.659 . . . . 1.0 109.22 179.314 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.426 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.3 m -75.76 82.78 2.72 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.352 -0.539 . . . . 1.0 110.096 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.5 t -98.36 60.11 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.771 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 172.68 -172.7 45.16 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.534 -0.841 . . . . 1.0 112.033 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.81 -103.78 0.05 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 111.036 -0.826 . . . . 1.0 111.036 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -59.3 -16.88 36.79 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.219 1.946 . . . . 1.0 110.397 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.645 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.0 mp -67.75 114.7 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 107.889 -1.152 . . . . 1.0 107.889 179.157 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.611 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -94.89 -158.5 33.09 Favored Glycine 0 C--O 1.212 -1.253 0 N-CA-C 110.968 -0.853 . . . . 1.0 110.968 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.511 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 44.6 Cg_endo -70.09 147.45 60.75 Favored 'Trans proline' 0 C--N 1.299 -2.034 0 C-N-CA 121.892 1.728 . . . . 1.0 113.098 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.567 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.6 OUTLIER 39.99 60.74 1.65 Allowed 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.254 0.835 . . . . 1.0 113.254 177.511 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.709 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.03 135.85 53.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.571 0.7 . . . . 1.0 111.355 -179.423 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.408 HG21 HD11 ' A' ' 16' ' ' LEU . 99.2 m -93.69 129.0 40.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.329 178.117 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.51 140.97 42.63 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.142 0.496 . . . . 1.0 110.133 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.751 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -121.11 143.68 32.6 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.729 0 CA-C-N 115.506 -0.77 . . . . 1.0 109.014 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -134.89 150.66 50.46 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.082 0.468 . . . . 1.0 111.08 177.269 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 14.3 mmtt -99.63 126.02 45.56 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 104.85 -2.278 . . . . 1.0 104.85 176.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.8 mt -119.72 119.54 60.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 119.16 -1.016 . . . . 1.0 111.851 -177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.603 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.6 t60 -111.92 120.94 43.63 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 114.091 -1.413 . . . . 1.0 108.816 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.63 112.45 24.41 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 120.236 -0.585 . . . . 1.0 112.326 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.603 HD11 ' CD2' ' A' ' 129' ' ' HIS . 3.9 mp -94.84 -47.49 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.5 p -148.14 157.54 43.56 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.93 0.395 . . . . 1.0 111.246 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.43 HG21 ' HA ' ' A' ' 44' ' ' LYS . 54.7 t -130.07 139.25 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 116.043 -0.526 . . . . 1.0 111.396 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 12.5 tptt . . . . . 0 CA--C 1.536 0.409 0 CA-C-N 115.424 -0.807 . . . . 1.0 110.298 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 . . . . . 0 C--O 1.223 -0.331 0 CA-C-O 121.487 0.661 . . . . 1.0 110.694 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 30.4 m-20 -59.51 -34.0 72.07 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-O 121.964 0.888 . . . . 1.0 108.617 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.8 tttt -64.43 -49.71 70.42 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 114.108 -1.405 . . . . 1.0 111.664 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.31 -47.26 74.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.408 -0.517 . . . . 1.0 112.112 -178.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.443 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.2 -36.91 83.36 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 179.686 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.79 -44.15 39.53 Favored Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.925 -1.034 . . . . 1.0 112.408 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -60.66 -30.97 70.22 Favored 'General case' 0 CA--C 1.514 -0.416 0 C-N-CA 119.701 -0.8 . . . . 1.0 108.883 179.221 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.8 -35.68 51.13 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.129 -0.941 . . . . 1.0 109.849 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 t80 -61.96 -50.8 70.66 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.728 -1.124 . . . . 1.0 110.901 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.45 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -66.82 -38.74 87.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 179.038 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.48 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 99.0 m -61.27 -43.0 99.59 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.498 -0.773 . . . . 1.0 109.584 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -75.32 -46.48 33.08 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.591 -0.731 . . . . 1.0 112.111 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.655 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 51.3 t30 -61.47 -45.12 95.58 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 113.145 0.795 . . . . 1.0 113.145 -177.763 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -58.02 -33.69 69.23 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 119.321 -0.952 . . . . 1.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 17' ' ' THR . 43.6 m-80 -75.46 -33.91 60.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.305 -0.861 . . . . 1.0 111.538 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -58.99 137.41 87.72 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 120.593 -0.443 . . . . 1.0 111.8 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -53.85 149.13 34.77 Favored 'Trans proline' 0 N--CA 1.507 2.302 0 C-N-CA 122.723 2.282 . . . . 1.0 114.757 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.76 -21.91 5.2 Favored Glycine 0 CA--C 1.508 -0.368 0 CA-C-N 114.421 -1.263 . . . . 1.0 111.265 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 54.3 t -80.21 132.0 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 N-CA-C 109.34 -0.615 . . . . 1.0 109.34 -179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.77 120.4 64.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.327 -0.99 . . . . 1.0 108.327 177.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.3 p -95.5 145.91 7.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 CA-C-O 121.471 0.653 . . . . 1.0 111.265 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.0 mt -114.17 165.26 14.07 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.597 -1.183 . . . . 1.0 110.955 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.76 -30.44 90.28 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 C-N-CA 121.828 1.685 . . . . 1.0 111.006 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.5 m -68.4 -15.82 63.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.608 -0.724 . . . . 1.0 109.801 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.95 -2.77 64.26 Favored Glycine 0 C--O 1.229 -0.192 0 N-CA-C 110.016 -1.234 . . . . 1.0 110.016 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.479 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -78.78 134.1 37.04 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.479 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.0 mp0 -123.64 142.93 50.58 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.393 -0.367 . . . . 1.0 111.525 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -140.6 142.26 35.08 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.919 0.866 . . . . 1.0 112.183 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.58 ' HE3' HD13 ' A' ' 37' ' ' ILE . 8.6 ttpt -123.99 126.57 46.52 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.173 -1.376 . . . . 1.0 108.45 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.416 ' H ' HG12 ' A' ' 36' ' ' VAL . 2.9 p -82.61 113.52 21.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.128 -178.301 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.58 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.8 mm -77.27 -42.24 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 CA-C-O 121.541 0.686 . . . . 1.0 109.844 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -144.34 124.01 13.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.725 -1.125 . . . . 1.0 109.917 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -81.84 129.58 34.79 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.539 -0.464 . . . . 1.0 110.527 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.15 -36.13 1.05 Allowed Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.106 -1.198 . . . . 1.0 110.106 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 57.81 31.22 20.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.447 -0.376 . . . . 1.0 111.49 179.225 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.67 -161.8 37.25 Favored Glycine 0 C--N 1.332 0.35 0 CA-C-O 121.984 0.769 . . . . 1.0 111.731 179.438 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.2 m -68.97 -177.86 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.093 -1.053 . . . . 1.0 109.086 178.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.61 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.18 154.23 0.38 Allowed Pre-proline 0 C--N 1.32 -0.676 0 O-C-N 123.757 0.661 . . . . 1.0 109.556 179.734 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.407 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.5 Cg_endo -87.71 158.01 7.63 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 123.336 2.691 . . . . 1.0 116.45 -175.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -90.0 175.57 41.68 Favored Glycine 0 N--CA 1.449 -0.449 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 176.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.498 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.84 -22.31 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.778 -0.369 . . . . 1.0 111.274 -179.383 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 53.5 m -107.88 -9.3 15.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.534 0.939 . . . . 1.0 113.534 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.19 165.43 17.4 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.436 -0.949 . . . . 1.0 108.436 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.7 m -104.72 150.53 24.66 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 109.869 -0.419 . . . . 1.0 109.869 -179.559 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.407 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.4 p -127.09 163.37 30.06 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 112.599 0.592 . . . . 1.0 112.599 -176.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.403 HG22 ' HB3' ' A' ' 74' ' ' PRO . 97.1 m -131.55 120.18 22.55 Favored 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 108.488 -0.93 . . . . 1.0 108.488 178.235 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.583 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 15.8 m -148.75 165.28 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 114.438 1.273 . . . . 1.0 114.438 -176.367 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.427 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 7.0 mt-10 -118.35 147.92 43.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 174.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.499 ' H ' ' HB ' ' A' ' 68' ' ' THR . 37.3 p90 -163.63 162.14 24.11 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 114.68 1.363 . . . . 1.0 114.68 -176.725 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.49 133.11 54.6 Favored 'General case' 0 C--O 1.216 -0.675 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 175.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.83 135.96 11.79 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 120.972 -0.633 . . . . 1.0 111.855 -178.601 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.8 ptp85 -148.61 167.5 25.28 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.745 0.783 . . . . 1.0 112.997 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.69 163.79 18.99 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 114.377 -1.283 . . . . 1.0 110.989 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.58 -25.65 35.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 122.272 1.034 . . . . 1.0 109.589 177.468 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -89.86 0.72 56.87 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 113.378 -1.737 . . . . 1.0 111.688 -177.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.69 81.74 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 121.182 -0.533 . . . . 1.0 112.351 178.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.4 m -68.9 104.13 1.99 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 119.92 -0.712 . . . . 1.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.7 t -77.08 121.13 28.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 CA-C-N 116.059 -0.519 . . . . 1.0 110.062 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.698 ' CD2' HD11 ' A' ' 118' ' ' ILE . 22.0 p90 -110.59 -14.26 14.09 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.184 -0.916 . . . . 1.0 112.056 -178.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -159.58 148.19 17.7 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.156 -0.618 . . . . 1.0 111.511 177.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 89.5 p -153.63 156.25 37.58 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.541 179.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.499 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 55.8 m -155.17 -39.51 0.09 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.984 -0.553 . . . . 1.0 110.78 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -63.12 -26.19 68.71 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.632 -0.427 . . . . 1.0 109.895 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -56.49 -41.3 76.4 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.085 -1.45 . . . . 1.0 107.085 178.288 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 68' ' ' THR . 23.1 p -76.74 -32.66 57.93 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.203 -1.362 . . . . 1.0 109.042 177.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.48 15.18 80.32 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.922 -0.871 . . . . 1.0 110.922 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.427 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 12.9 mttp -96.55 115.26 65.56 Favored Pre-proline 0 N--CA 1.47 0.537 0 C-N-CA 120.827 -0.349 . . . . 1.0 110.962 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.412 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.3 Cg_exo -61.41 151.75 77.46 Favored 'Trans proline' 0 N--CA 1.482 0.827 0 C-N-CA 121.539 1.493 . . . . 1.0 114.405 -178.241 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.8 150.34 46.45 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.089 -1.414 . . . . 1.0 107.78 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -107.53 136.07 47.93 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 112.882 0.697 . . . . 1.0 112.882 -178.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -144.48 151.01 38.55 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 114.858 -1.064 . . . . 1.0 109.032 177.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 70.1 mt-30 -90.14 125.87 35.6 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 106.434 -1.691 . . . . 1.0 106.434 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.0 t -50.6 -31.4 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 C-N-CA 119.926 -0.71 . . . . 1.0 110.545 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.8 t -73.57 -27.37 61.28 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 120.116 -0.634 . . . . 1.0 111.994 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.0 mm100 -101.35 -8.72 21.8 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 113.219 0.822 . . . . 1.0 113.219 -178.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.546 HG22 ' H ' ' A' ' 83' ' ' ILE . 3.5 p -80.32 172.84 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 C-N-CA 119.457 -0.897 . . . . 1.0 110.151 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.546 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.03 145.83 31.97 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 120.165 -0.614 . . . . 1.0 109.976 -176.733 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -51.42 -44.21 44.94 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.081 1.854 . . . . 1.0 112.783 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.05 -47.5 88.76 Favored Glycine 0 C--N 1.319 -0.4 0 N-CA-C 109.343 -1.503 . . . . 1.0 109.343 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.583 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 8.1 m95 -64.9 -35.21 80.4 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.796 -1.202 . . . . 1.0 110.565 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.24 -54.23 27.75 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.822 0.344 . . . . 1.0 111.172 -178.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -72.64 -43.14 63.59 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.745 0.646 . . . . 1.0 112.745 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.53 -45.84 84.56 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 113.957 1.095 . . . . 1.0 113.957 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.51 -41.12 84.7 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.457 0.646 . . . . 1.0 109.625 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -64.59 -23.85 67.4 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.836 -1.075 . . . . 1.0 110.805 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.482 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 80.6 mt -103.81 -10.73 18.03 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 116.207 -0.451 . . . . 1.0 111.41 -178.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 46.7 ttp -92.18 108.4 30.32 Favored Pre-proline 0 CA--C 1.55 0.978 0 CA-C-O 119.445 -0.312 . . . . 1.0 111.345 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.61 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.0 Cg_exo -65.35 148.26 88.12 Favored 'Trans proline' 0 N--CA 1.5 1.881 0 C-N-CA 122.681 2.254 . . . . 1.0 112.777 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.76 136.86 57.77 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.368 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.23 -19.31 53.12 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 108.954 -1.659 . . . . 1.0 108.954 -178.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.7 p -87.88 135.45 33.39 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 120.851 0.358 . . . . 1.0 110.473 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 72.0 m -107.89 114.94 29.24 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 115.952 -0.567 . . . . 1.0 110.142 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.482 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.4 m0 -114.99 164.24 14.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.491 0.662 . . . . 1.0 111.404 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.486 ' HB2' HD11 ' A' ' 37' ' ' ILE . 29.7 mt-10 -124.35 127.78 48.1 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.642 -1.614 . . . . 1.0 106.642 175.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -123.77 138.72 52.58 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.461 0 CA-C-O 121.768 0.794 . . . . 1.0 110.288 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.677 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.23 103.85 12.89 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.864 -1.902 . . . . 1.0 105.864 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.67 115.65 64.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 N-CA-C 115.466 1.654 . . . . 1.0 115.466 -174.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -50.71 143.25 29.7 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 C-N-CA 121.611 1.541 . . . . 1.0 110.017 176.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.5 p -50.09 -34.66 22.57 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.524 -0.47 . . . . 1.0 110.986 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.8 -31.89 76.68 Favored Glycine 0 CA--C 1.52 0.396 0 N-CA-C 110.812 -0.915 . . . . 1.0 110.812 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 54.9 mt -98.97 2.38 46.36 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 121.436 -0.106 . . . . 1.0 110.878 -179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -107.86 0.33 Allowed 'General case' 0 C--N 1.34 0.166 0 CA-C-O 120.503 0.192 . . . . 1.0 111.338 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 38.0 m-85 -99.45 4.64 46.22 Favored 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 113.279 0.844 . . . . 1.0 113.279 -177.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.33 164.52 22.81 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 120.756 -0.735 . . . . 1.0 113.352 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 121' ' ' ASN . 79.5 Cg_endo -73.98 -16.89 22.77 Favored 'Trans proline' 0 N--CA 1.493 1.46 0 C-N-CA 123.531 2.821 . . . . 1.0 110.9 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.439 ' O ' HG23 ' A' ' 114' ' ' VAL . 60.4 ttt180 -96.06 165.12 12.4 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.477 -1.238 . . . . 1.0 109.685 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.522 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 8.1 m -77.02 91.97 3.68 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.565 -0.531 . . . . 1.0 109.565 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.3 t -107.56 60.66 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.113 -0.494 . . . . 1.0 111.199 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.518 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 171.23 178.05 41.45 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 120.201 -0.999 . . . . 1.0 112.145 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.23 -103.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 111.072 -0.811 . . . . 1.0 111.072 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -62.35 -16.04 48.91 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.567 2.178 . . . . 1.0 110.779 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.2 mp -66.67 115.92 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 108.233 -1.025 . . . . 1.0 108.233 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -96.52 -158.96 31.78 Favored Glycine 0 C--O 1.213 -1.194 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.522 ' N ' ' OG ' ' A' ' 113' ' ' SER . 46.9 Cg_endo -70.89 147.39 55.51 Favored 'Trans proline' 0 C--N 1.297 -2.141 0 C-N-CA 121.766 1.644 . . . . 1.0 113.326 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' PRO . 18.0 t-20 41.17 60.6 2.0 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.195 0.813 . . . . 1.0 113.195 177.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.683 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.38 137.71 51.47 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 121.683 0.754 . . . . 1.0 111.225 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.45 HG21 HD11 ' A' ' 16' ' ' LEU . 81.8 m -94.43 130.09 40.91 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.332 -1.304 . . . . 1.0 108.624 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.29 141.3 46.17 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.05 -0.523 . . . . 1.0 109.8 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.677 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.7 tt -119.72 146.05 25.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 N-CA-C 108.368 -0.975 . . . . 1.0 108.368 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.574 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -137.98 151.0 47.5 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.394 -0.522 . . . . 1.0 111.759 177.838 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.469 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 4.1 mmtt -101.16 122.91 44.46 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 105.741 -1.948 . . . . 1.0 105.741 177.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.453 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.0 mt -117.51 119.19 60.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.956 0.884 . . . . 1.0 113.257 -176.27 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.555 ' CD2' HD11 ' A' ' 131' ' ' ILE . 4.5 t60 -109.95 124.03 50.67 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 113.935 -1.484 . . . . 1.0 108.354 178.04 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.93 111.12 23.2 Favored 'General case' 0 N--CA 1.465 0.293 0 C-N-CA 120.162 -0.615 . . . . 1.0 112.369 -178.235 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.555 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.3 mp -94.01 -45.03 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 115.881 -0.599 . . . . 1.0 111.729 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.7 p -150.63 155.82 40.13 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.683 -0.407 . . . . 1.0 110.79 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.426 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.4 t -129.71 137.21 57.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 121.05 0.452 . . . . 1.0 111.772 -177.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 tptt . . . . . 0 N--CA 1.447 -0.581 0 CA-C-N 115.723 -0.671 . . . . 1.0 110.098 178.793 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 121.663 0.744 . . . . 1.0 110.439 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.7 m-20 -58.0 -35.11 70.77 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.255 -1.017 . . . . 1.0 108.255 179.29 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.505 ' O ' ' N ' ' A' ' 13' ' ' GLU . 18.7 tttm -65.22 -51.07 63.26 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.691 178.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.52 -46.67 82.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 119.974 -0.69 . . . . 1.0 111.538 -178.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.51 -37.11 86.04 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.418 -1.327 . . . . 1.0 107.418 178.728 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.466 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -72.71 -41.37 50.44 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 114.758 -1.11 . . . . 1.0 112.213 179.275 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.505 ' N ' ' O ' ' A' ' 9' ' ' LYS . 49.0 mt-10 -62.83 -31.73 72.79 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.719 -0.845 . . . . 1.0 108.719 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.79 -37.08 59.51 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 115.099 -0.955 . . . . 1.0 109.483 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -60.92 -51.01 71.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.199 -1.364 . . . . 1.0 110.789 -179.03 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.466 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.7 mp -69.01 -37.9 78.93 Favored 'General case' 0 CA--C 1.512 -0.497 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.583 178.206 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 93.9 m -61.03 -43.67 98.55 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.757 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -76.34 -45.63 31.25 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.813 -0.63 . . . . 1.0 112.58 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.639 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.4 t30 -60.75 -44.15 97.06 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.309 0.855 . . . . 1.0 113.309 -177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -59.65 -32.46 70.48 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.275 -0.97 . . . . 1.0 109.313 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.2 m-80 -77.96 -29.97 50.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.405 -0.816 . . . . 1.0 111.714 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 26.7 mtmt -60.45 137.69 92.29 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 120.457 -0.497 . . . . 1.0 111.499 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -55.66 149.4 49.49 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 C-N-CA 122.341 2.027 . . . . 1.0 113.726 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.34 -19.26 14.27 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-N 114.811 -1.086 . . . . 1.0 111.302 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.416 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.0 t -87.49 135.06 26.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 121.067 0.461 . . . . 1.0 110.77 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.08 121.79 66.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 107.981 -1.118 . . . . 1.0 107.981 177.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.416 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.5 p -96.74 145.87 8.22 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.622 0 CA-C-O 121.676 0.751 . . . . 1.0 111.872 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 74.7 mt -112.34 163.57 17.45 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 114.327 -1.306 . . . . 1.0 110.719 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.03 -29.91 90.35 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.058 1.839 . . . . 1.0 110.69 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.6 m -67.69 -15.54 63.69 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.284 -0.871 . . . . 1.0 109.456 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.94 -3.74 70.8 Favored Glycine 0 C--N 1.328 0.115 0 N-CA-C 109.815 -1.314 . . . . 1.0 109.815 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.6 133.51 38.43 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.5 139.26 54.08 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.284 -0.417 . . . . 1.0 110.865 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -134.95 145.81 48.52 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-O 121.642 0.734 . . . . 1.0 110.619 178.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.528 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.3 tmtp? -130.84 134.1 46.52 Favored 'General case' 0 N--CA 1.443 -0.804 0 CA-C-N 114.503 -1.226 . . . . 1.0 109.084 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -90.48 105.38 16.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 122.18 0.991 . . . . 1.0 111.54 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.636 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.7 mm -70.55 -42.36 78.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 108.594 -0.891 . . . . 1.0 108.594 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -141.82 128.93 20.88 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.816 -1.084 . . . . 1.0 109.767 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.5 p -87.89 123.06 32.26 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.956 0.408 . . . . 1.0 110.182 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.81 -36.22 1.73 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 57.58 32.46 21.87 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.22 -0.49 . . . . 1.0 111.64 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.24 -161.65 37.41 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.907 0.726 . . . . 1.0 111.408 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.594 ' O ' ' N ' ' A' ' 95' ' ' ALA . 31.2 m -69.48 -177.92 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.17 -1.015 . . . . 1.0 109.374 178.438 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.565 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.75 154.59 0.48 Allowed Pre-proline 0 C--N 1.319 -0.729 0 O-C-N 123.569 0.543 . . . . 1.0 110.11 179.646 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.7 Cg_endo -87.75 154.29 7.44 Favored 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.697 2.932 . . . . 1.0 117.055 -174.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -84.8 175.74 50.59 Favored Glycine 0 C--N 1.334 0.42 0 N-CA-C 109.601 -1.4 . . . . 1.0 109.601 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.884 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.31 -22.34 11.75 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.315 -0.443 . . . . 1.0 111.667 -179.328 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.4 m -109.18 -7.17 15.34 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 112.651 0.612 . . . . 1.0 112.651 -178.183 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.436 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 78.7 m-20 -82.83 167.88 17.67 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.182 -0.303 . . . . 1.0 110.182 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.3 m -107.5 147.75 30.1 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-O 121.06 0.457 . . . . 1.0 109.949 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.45 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.3 p -127.17 163.05 30.91 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 CA-C-N 115.705 -0.679 . . . . 1.0 111.591 -176.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.42 HG22 ' HB3' ' A' ' 74' ' ' PRO . 95.3 m -129.78 120.15 24.57 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 108.077 -1.083 . . . . 1.0 108.077 177.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.485 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.3 m -148.38 165.62 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 114.227 1.195 . . . . 1.0 114.227 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.4 mt-10 -118.69 147.92 43.3 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 105.913 -1.884 . . . . 1.0 105.913 173.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.476 ' H ' ' HB ' ' A' ' 68' ' ' THR . 30.0 p90 -161.48 162.84 30.57 Favored 'General case' 0 C--N 1.343 0.292 0 N-CA-C 114.769 1.396 . . . . 1.0 114.769 -177.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.7 m -126.06 132.9 51.85 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.872 175.597 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.87 134.92 11.77 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 111.302 -0.719 . . . . 1.0 111.302 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.572 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 6.2 ptp85 -143.65 163.61 32.75 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-O 121.553 0.692 . . . . 1.0 111.929 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.0 mp -85.01 162.54 19.31 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.664 -1.153 . . . . 1.0 109.844 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.452 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -57.64 -25.82 25.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.305 -0.861 . . . . 1.0 110.395 178.517 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -93.34 2.98 56.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 114.279 -1.328 . . . . 1.0 111.603 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -6.14 79.18 Favored Glycine 0 CA--C 1.525 0.68 0 C-N-CA 121.069 -0.586 . . . . 1.0 112.832 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.2 m -65.0 105.3 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 119.548 -0.861 . . . . 1.0 109.103 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.3 t -74.08 117.3 17.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 C-N-CA 120.225 -0.59 . . . . 1.0 110.072 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -103.52 -10.47 18.48 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.064 -0.971 . . . . 1.0 112.228 -179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -168.12 155.34 8.03 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 119.838 -0.745 . . . . 1.0 111.636 177.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 60.1 p -157.84 154.8 28.59 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.656 -0.702 . . . . 1.0 111.914 179.058 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.476 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 95.9 m -153.28 -40.7 0.1 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.528 -0.76 . . . . 1.0 110.357 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.404 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.8 pp20? -63.0 -26.27 68.77 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.657 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -52.11 -44.24 64.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 108.279 -1.008 . . . . 1.0 108.279 179.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 68' ' ' THR . 16.5 p -79.64 -27.94 40.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.707 -1.133 . . . . 1.0 109.246 177.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.11 16.2 77.12 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.441 -0.8 . . . . 1.0 111.74 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.42 114.95 64.27 Favored Pre-proline 0 N--CA 1.47 0.545 0 C-N-CA 120.553 -0.459 . . . . 1.0 110.628 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.424 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 36.1 Cg_exo -61.24 152.49 71.81 Favored 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 121.809 1.673 . . . . 1.0 114.601 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.87 152.17 42.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.048 -1.433 . . . . 1.0 107.247 177.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.7 t -110.42 131.2 55.26 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.605 0.717 . . . . 1.0 112.771 -178.434 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -136.58 154.7 50.62 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.824 -1.08 . . . . 1.0 109.652 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -96.32 124.03 40.17 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 105.801 -1.926 . . . . 1.0 105.801 174.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.7 t -47.39 -29.14 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.398 -176.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.9 t -75.86 -24.3 55.72 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 111.974 0.361 . . . . 1.0 111.974 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 92.3 mm-40 -98.23 -12.71 21.35 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.353 0.871 . . . . 1.0 113.353 -177.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.426 HG22 ' H ' ' A' ' 83' ' ' ILE . 4.1 p -83.93 169.12 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.101 -0.64 . . . . 1.0 112.022 -177.392 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.426 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.12 148.72 21.06 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 -177.354 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.63 -43.14 47.18 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.794 1.662 . . . . 1.0 112.833 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.85 -48.69 80.44 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 119.517 -1.325 . . . . 1.0 109.852 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.485 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 8.7 m95 -63.26 -38.14 90.01 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 113.902 -1.149 . . . . 1.0 110.438 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.9 m -51.13 -53.53 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.265 -0.425 . . . . 1.0 111.594 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -72.42 -41.59 66.03 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.642 0.608 . . . . 1.0 112.642 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.64 -48.21 82.56 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.917 1.08 . . . . 1.0 113.917 -177.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.0 mt -56.93 -39.95 75.47 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 121.133 0.492 . . . . 1.0 110.511 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -63.05 -23.24 67.36 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.607 -0.724 . . . . 1.0 110.753 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.432 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 45.5 mt -105.25 -11.4 16.54 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.307 -0.406 . . . . 1.0 110.935 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 33.4 ttm -86.04 106.81 10.83 Favored Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.669 0.606 . . . . 1.0 111.89 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.565 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 14.6 Cg_exo -68.46 145.7 65.72 Favored 'Trans proline' 0 N--CA 1.501 1.964 0 C-N-CA 122.576 2.184 . . . . 1.0 113.008 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.594 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.55 132.96 54.18 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.53 -0.759 . . . . 1.0 111.17 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.95 -17.82 58.61 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 109.147 -1.581 . . . . 1.0 109.147 -179.067 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -88.86 136.46 33.0 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-O 120.838 0.351 . . . . 1.0 110.247 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 57.3 m -107.61 113.76 27.27 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.979 -0.555 . . . . 1.0 109.752 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.432 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.6 m0 -115.51 164.68 13.95 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.728 0.775 . . . . 1.0 110.902 -178.538 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.636 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.7 mt-10 -126.25 126.01 43.31 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 106.943 -1.503 . . . . 1.0 106.943 175.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.4 137.12 56.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.733 0 CA-C-O 121.704 0.764 . . . . 1.0 109.649 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.707 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.53 103.59 12.74 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 105.894 -1.891 . . . . 1.0 105.894 -177.981 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.53 115.54 64.39 Favored Pre-proline 0 C--N 1.326 -0.438 0 N-CA-C 115.077 1.51 . . . . 1.0 115.077 -174.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -51.52 146.72 24.99 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.578 1.519 . . . . 1.0 109.748 176.148 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 58.4 p -51.6 -36.43 45.62 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.192 -0.603 . . . . 1.0 110.901 -178.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.29 -32.52 83.99 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.251 -0.74 . . . . 1.0 111.251 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.0 mt -99.26 1.51 44.75 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.498 -0.186 . . . . 1.0 110.498 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -109.28 -103.34 0.37 Allowed 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 120.352 0.12 . . . . 1.0 110.819 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 -107.6 5.97 27.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 114.915 1.45 . . . . 1.0 114.915 -176.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.15 169.43 22.2 Favored Glycine 0 N--CA 1.473 1.127 0 C-N-CA 120.245 -0.978 . . . . 1.0 114.139 176.086 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 121' ' ' ASN . 57.0 Cg_endo -78.47 -12.76 15.29 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 123.697 2.931 . . . . 1.0 110.645 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 113' ' ' SER . 60.0 ttt180 -104.77 165.55 10.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.75 -1.113 . . . . 1.0 109.403 -179.196 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.56 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 3.5 m -76.28 97.65 4.25 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.171 -0.677 . . . . 1.0 109.171 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -108.74 61.38 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.576 -0.283 . . . . 1.0 110.597 -179.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.532 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 169.22 -170.84 42.8 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 120.455 -0.879 . . . . 1.0 112.188 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -66.09 -105.19 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 N-CA-C 111.842 -0.503 . . . . 1.0 111.842 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.03 -16.08 47.71 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.439 2.093 . . . . 1.0 111.387 -178.246 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.555 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.6 mp -66.97 114.24 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 109.26 -0.645 . . . . 1.0 109.26 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.411 ' N ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.26 -168.14 42.44 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 110.566 -1.014 . . . . 1.0 110.566 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.566 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 39.3 Cg_endo -65.53 142.62 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.257 1.971 . . . . 1.0 113.34 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.471 ' ND2' ' O ' ' A' ' 121' ' ' ASN . 2.1 t30 50.55 53.62 12.62 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.158 -0.474 . . . . 1.0 111.859 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.427 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 54.9 mm-40 -99.76 133.01 44.74 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.146 -0.479 . . . . 1.0 111.527 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.436 HG21 HD11 ' A' ' 16' ' ' LEU . 52.8 m -93.86 128.58 40.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 106.571 -1.641 . . . . 1.0 106.571 175.822 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.4 ' N ' HD22 ' A' ' 124' ' ' LEU . 2.0 mm? -112.13 138.86 48.22 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.394 0.616 . . . . 1.0 111.096 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.707 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -118.6 145.22 24.93 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.679 0 CA-C-N 114.976 -1.011 . . . . 1.0 108.523 178.075 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.561 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -136.89 150.78 48.45 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 120.217 -0.593 . . . . 1.0 111.201 177.129 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.572 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 5.3 mmtt -100.14 122.39 42.9 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 105.031 -2.211 . . . . 1.0 105.031 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.42 118.27 57.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 C-N-CA 119.395 -0.922 . . . . 1.0 112.432 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.445 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.2 t-160 -108.67 123.6 49.22 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 114.121 -1.4 . . . . 1.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.82 111.31 23.32 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 120.478 -0.489 . . . . 1.0 112.197 -177.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.472 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -94.3 -45.05 13.61 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.486 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.1 p -151.07 155.81 39.76 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.305 0.574 . . . . 1.0 111.137 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.451 HG21 ' HA ' ' A' ' 44' ' ' LYS . 45.8 t -128.8 135.91 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.757 -0.656 . . . . 1.0 109.958 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 tptm . . . . . 0 N--CA 1.443 -0.782 0 CA-C-O 121.87 0.843 . . . . 1.0 111.586 -179.233 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 . . . . . 0 CA--C 1.518 -0.27 0 CA-C-O 121.502 0.668 . . . . 1.0 111.12 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 9.5 m-20 -62.85 -37.09 85.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 107.81 -1.182 . . . . 1.0 107.81 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 64.6 tttt -65.95 -51.38 59.04 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 113.297 -1.774 . . . . 1.0 111.485 179.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.2 t -67.31 -46.59 83.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 C-N-CA 120.238 -0.585 . . . . 1.0 111.423 -179.312 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.543 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 1.2 mptp? -62.05 -38.94 90.66 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.649 -1.241 . . . . 1.0 107.649 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.486 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -71.6 -44.55 49.26 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 114.629 -1.169 . . . . 1.0 112.444 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -59.71 -34.1 72.47 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.526 -0.916 . . . . 1.0 108.526 179.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.87 -37.08 62.26 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.892 -1.049 . . . . 1.0 110.111 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.19 -49.33 78.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.753 -1.112 . . . . 1.0 111.198 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.486 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.78 -38.26 79.88 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.14 -0.624 . . . . 1.0 109.385 178.785 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 55.9 m -60.76 -43.47 97.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.352 -0.84 . . . . 1.0 109.688 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -76.9 -44.69 30.86 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.85 -0.614 . . . . 1.0 111.973 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.649 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 54.6 t30 -60.33 -44.78 95.17 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.475 0.917 . . . . 1.0 113.475 -177.165 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -58.26 -31.7 67.69 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 119.441 -0.904 . . . . 1.0 109.613 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -80.98 -27.61 35.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.734 -0.667 . . . . 1.0 111.683 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.1 mtmt -59.47 146.22 80.21 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 120.335 -0.546 . . . . 1.0 111.517 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.45 148.93 59.8 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.543 2.162 . . . . 1.0 114.048 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.65 -18.48 2.96 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 115.167 -0.924 . . . . 1.0 112.576 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -83.75 134.66 26.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.549 -0.46 . . . . 1.0 110.202 -179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.2 121.96 66.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 107.838 -1.171 . . . . 1.0 107.838 177.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.9 p -93.53 146.16 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 CA-C-O 121.637 0.732 . . . . 1.0 111.981 -177.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 97.9 mt -113.03 163.17 18.68 Favored Pre-proline 0 N--CA 1.461 0.119 0 CA-C-N 114.469 -1.242 . . . . 1.0 110.892 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -60.32 -30.71 91.63 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.844 1.696 . . . . 1.0 111.249 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -69.44 -11.16 60.59 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.828 -0.624 . . . . 1.0 109.737 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.02 -2.49 75.77 Favored Glycine 0 C--O 1.229 -0.174 0 N-CA-C 109.949 -1.26 . . . . 1.0 109.949 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.442 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.08 133.7 36.13 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 108.59 -0.893 . . . . 1.0 108.59 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.442 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.6 mp0 -121.82 138.53 54.34 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 116.319 -0.4 . . . . 1.0 111.086 -179.32 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -133.5 146.55 51.19 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-O 121.591 0.71 . . . . 1.0 111.089 178.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.497 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.7 tmtp? -129.86 135.8 48.81 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.495 -1.23 . . . . 1.0 109.233 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.25 104.67 15.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-O 122.153 0.978 . . . . 1.0 112.248 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.0 mm -70.69 -42.36 77.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.249 -0.887 . . . . 1.0 108.848 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -144.07 127.33 16.71 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.845 -1.071 . . . . 1.0 110.634 -178.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.2 p -84.51 126.9 33.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.043 0.449 . . . . 1.0 110.499 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -115.86 -36.78 1.11 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 56.49 30.39 17.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.465 -0.367 . . . . 1.0 111.187 179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.07 -159.68 35.86 Favored Glycine 0 C--N 1.334 0.421 0 CA-C-O 121.87 0.706 . . . . 1.0 111.955 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.603 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.0 m -69.57 -178.73 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.239 -0.981 . . . . 1.0 109.411 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.546 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 155.14 0.38 Allowed Pre-proline 0 C--N 1.319 -0.731 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.785 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.1 Cg_endo -87.76 161.49 7.69 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 123.011 2.474 . . . . 1.0 115.273 -175.457 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.2 171.45 32.5 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 108.049 -2.02 . . . . 1.0 108.049 175.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.613 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -45.75 -24.9 0.42 Allowed 'General case' 0 C--N 1.297 -1.701 0 CA-C-N 114.59 -0.805 . . . . 1.0 111.374 178.452 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.0 m -107.63 -9.64 15.83 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.863 1.06 . . . . 1.0 113.863 -177.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -85.37 166.34 16.5 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 119.39 -0.924 . . . . 1.0 109.136 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.3 m -104.16 146.97 27.99 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.167 -0.679 . . . . 1.0 109.167 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.401 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.1 p -124.39 160.3 29.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 112.554 0.575 . . . . 1.0 112.554 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.4 HG22 ' HB3' ' A' ' 74' ' ' PRO . 87.6 m -127.23 119.51 26.54 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.408 -0.96 . . . . 1.0 108.408 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.453 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 5.3 m -148.84 165.76 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 113.968 1.099 . . . . 1.0 113.968 -176.696 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 9.3 mt-10 -118.53 151.25 38.2 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.356 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 35.2 p90 -164.23 161.88 22.29 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 114.536 1.31 . . . . 1.0 114.536 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -123.51 127.04 47.78 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.201 -0.908 . . . . 1.0 108.691 175.329 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.25 136.38 13.54 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.93 -0.652 . . . . 1.0 111.775 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -147.25 166.49 26.88 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 121.805 0.812 . . . . 1.0 112.395 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.5 mp -83.16 164.07 20.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 114.129 -1.396 . . . . 1.0 110.037 177.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.471 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.38 -24.38 30.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.127 -0.942 . . . . 1.0 110.139 177.889 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -93.1 2.58 56.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 113.855 -1.52 . . . . 1.0 111.741 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.36 -4.69 80.52 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.19 -0.529 . . . . 1.0 112.735 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -69.76 105.06 2.62 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.682 -0.807 . . . . 1.0 110.212 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.5 t -73.66 122.06 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.139 0.495 . . . . 1.0 110.471 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.424 ' HB2' HD11 ' A' ' 118' ' ' ILE . 30.7 p90 -110.76 -15.54 13.8 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 115.145 -0.934 . . . . 1.0 111.75 -179.546 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.503 ' OD2' ' N ' ' A' ' 67' ' ' SER . 55.4 t0 -155.49 147.31 23.25 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 120.704 -0.399 . . . . 1.0 110.883 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.503 ' N ' ' OD2' ' A' ' 66' ' ' ASP . 97.5 p -154.25 152.71 30.63 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.217 -0.447 . . . . 1.0 111.612 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 84.9 m -156.58 -38.05 0.08 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.031 -0.531 . . . . 1.0 111.289 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.412 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 2.0 pp20? -65.99 -26.77 67.7 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.203 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -57.46 -39.7 76.9 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 108.173 -1.047 . . . . 1.0 108.173 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.41 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.9 p -81.76 -27.03 34.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.94 -1.027 . . . . 1.0 108.493 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 76.63 16.99 80.3 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.384 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.429 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.3 mptp? -97.35 114.79 65.34 Favored Pre-proline 0 N--CA 1.471 0.622 0 C-N-CA 120.855 -0.338 . . . . 1.0 110.419 -179.21 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 37.3 Cg_exo -61.99 154.19 63.54 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 121.916 1.744 . . . . 1.0 114.457 -178.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -126.05 150.61 48.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.262 -1.335 . . . . 1.0 108.407 178.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -104.57 134.35 47.9 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 113.006 0.743 . . . . 1.0 113.006 -178.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -142.42 148.76 38.33 Favored 'General case' 0 CA--C 1.495 -1.141 0 CA-C-N 115.009 -0.996 . . . . 1.0 110.602 178.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -90.31 124.5 34.96 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.004 -1.85 . . . . 1.0 106.004 175.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.0 t -52.07 -32.05 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 C-N-CA 119.774 -0.771 . . . . 1.0 110.509 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -74.02 -27.56 61.01 Favored 'General case' 0 CA--C 1.514 -0.413 0 C-N-CA 120.248 -0.581 . . . . 1.0 112.138 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 -101.29 -12.62 18.53 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 113.348 0.87 . . . . 1.0 113.348 -178.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.505 HG22 ' H ' ' A' ' 83' ' ' ILE . 4.5 p -71.04 172.03 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 119.288 -0.965 . . . . 1.0 109.94 -177.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.505 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -53.8 148.36 20.1 Favored Pre-proline 0 CA--C 1.55 0.945 0 N-CA-C 108.812 -0.81 . . . . 1.0 108.812 -178.803 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.493 ' HD2' HG22 ' A' ' 83' ' ' ILE . 85.1 Cg_exo -49.42 -47.51 22.2 Favored 'Trans proline' 0 N--CA 1.503 2.084 0 C-N-CA 122.151 1.9 . . . . 1.0 113.773 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.3 -48.16 77.15 Favored Glycine 0 C--N 1.318 -0.44 0 N-CA-C 110.021 -1.232 . . . . 1.0 110.021 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.453 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.8 m95 -63.78 -34.14 77.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 114.047 -1.076 . . . . 1.0 111.562 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -51.94 -54.1 33.48 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.744 -0.382 . . . . 1.0 110.888 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -74.17 -44.29 54.02 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.177 0.806 . . . . 1.0 113.177 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -55.71 -44.37 77.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 113.796 1.035 . . . . 1.0 113.796 -177.354 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.3 mt -58.47 -41.52 85.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.243 0.544 . . . . 1.0 110.142 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -65.7 -23.09 66.69 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.252 -0.885 . . . . 1.0 111.145 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.485 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 55.1 mt -103.09 -9.94 19.3 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.596 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 5.2 ttt -91.11 107.14 18.99 Favored Pre-proline 0 CA--C 1.549 0.942 0 O-C-N 123.729 0.643 . . . . 1.0 111.638 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.546 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.9 Cg_exo -66.37 149.11 85.01 Favored 'Trans proline' 0 N--CA 1.499 1.846 0 C-N-CA 122.904 2.402 . . . . 1.0 112.656 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.603 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.96 136.16 55.7 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 115.422 -0.808 . . . . 1.0 111.459 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.02 -19.74 51.4 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.415 -1.874 . . . . 1.0 108.415 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -85.99 134.49 33.85 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.053 0.454 . . . . 1.0 110.269 178.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.4 m -108.26 115.01 29.32 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.689 -0.687 . . . . 1.0 109.659 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.485 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.5 m0 -116.12 166.87 11.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.528 0.68 . . . . 1.0 110.79 -179.019 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.4 mt-10 -126.9 128.57 46.68 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 106.683 -1.599 . . . . 1.0 106.683 175.545 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.401 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -123.16 138.2 53.96 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 CA-C-O 121.809 0.814 . . . . 1.0 109.699 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.752 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.31 103.71 12.7 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 105.424 -2.065 . . . . 1.0 105.424 -177.905 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.5 t -90.73 116.12 65.71 Favored Pre-proline 0 C--N 1.327 -0.4 0 N-CA-C 114.674 1.361 . . . . 1.0 114.674 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -51.03 144.67 27.44 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 121.261 1.307 . . . . 1.0 109.79 176.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 55.3 p -50.49 -35.44 29.2 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.338 -0.545 . . . . 1.0 110.561 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.58 -32.78 84.32 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.19 -0.764 . . . . 1.0 111.19 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 82.8 mt -98.92 1.3 45.51 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 121.314 -0.154 . . . . 1.0 110.655 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.18 -106.62 0.34 Allowed 'General case' 0 C--N 1.342 0.264 0 N-CA-C 111.643 0.238 . . . . 1.0 111.643 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -101.97 5.05 40.56 Favored 'General case' 0 C--N 1.341 0.234 0 N-CA-C 113.705 1.002 . . . . 1.0 113.705 -177.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 99.93 167.28 29.36 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 120.645 -0.788 . . . . 1.0 114.043 176.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.513 ' O ' ' N ' ' A' ' 121' ' ' ASN . 73.8 Cg_endo -70.97 -19.99 29.66 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 C-N-CA 123.742 2.962 . . . . 1.0 113.038 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.423 HH11 ' HG2' ' A' ' 111' ' ' PRO . 11.7 mpt_? -93.74 167.15 11.84 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.009 -0.367 . . . . 1.0 110.009 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 5.7 m -74.46 76.32 1.93 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 177.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.0 t -92.21 61.53 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.268 -0.423 . . . . 1.0 110.967 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.97 179.61 42.27 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 120.967 -0.635 . . . . 1.0 111.516 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -60.66 -107.14 0.01 OUTLIER Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.449 -0.66 . . . . 1.0 111.449 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -59.24 -13.15 18.64 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 C-N-CA 122.222 1.948 . . . . 1.0 110.725 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.884 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.3 mp -66.74 113.17 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 N-CA-C 108.185 -1.043 . . . . 1.0 108.185 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -91.66 -166.9 40.25 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 110.548 -1.021 . . . . 1.0 110.548 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.554 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 37.6 Cg_endo -64.09 147.21 91.59 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.14 1.893 . . . . 1.0 112.7 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 111' ' ' PRO . 11.5 t-20 44.82 57.53 4.53 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.96 -0.564 . . . . 1.0 112.072 178.219 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 53.9 mm-40 -102.64 132.06 49.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.28 0.562 . . . . 1.0 112.334 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.474 HG21 HD11 ' A' ' 16' ' ' LEU . 36.2 m -96.34 129.08 43.76 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 106.418 -1.697 . . . . 1.0 106.418 175.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.98 146.17 40.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.387 0.613 . . . . 1.0 111.042 -179.057 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.752 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -123.58 148.28 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.764 0 CA-C-N 115.088 -0.96 . . . . 1.0 108.543 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -139.41 151.43 46.27 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 120.286 -0.566 . . . . 1.0 111.288 177.848 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.519 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 11.4 mmtt -100.15 124.88 46.07 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.162 -2.162 . . . . 1.0 105.162 176.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.7 mt -119.35 119.21 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 119.075 -1.05 . . . . 1.0 111.998 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.488 ' CD2' HD11 ' A' ' 131' ' ' ILE . 4.7 t60 -111.85 125.42 54.0 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.048 -1.433 . . . . 1.0 108.714 179.215 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.02 114.51 26.71 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 112.869 0.692 . . . . 1.0 112.869 -178.557 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.499 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -96.05 -45.42 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 115.992 -0.549 . . . . 1.0 110.88 178.058 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.3 p -151.29 157.78 42.98 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 120.877 0.37 . . . . 1.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.436 HG21 ' HA ' ' A' ' 44' ' ' LYS . 58.1 t -127.37 134.66 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-O 121.325 0.583 . . . . 1.0 111.451 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.533 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 21.6 tptt . . . . . 0 N--CA 1.449 -0.519 0 CA-C-N 115.152 -0.931 . . . . 1.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 . . . . . 0 CA--C 1.513 -0.47 0 CA-C-O 121.886 0.85 . . . . 1.0 110.24 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.571 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.0 m-20 -57.48 -35.64 70.45 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.737 -1.12 . . . . 1.0 108.543 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 45.1 tttt -64.74 -50.64 66.09 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 113.793 -1.549 . . . . 1.0 111.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.7 t -72.31 -47.52 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 119.964 -0.694 . . . . 1.0 112.152 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.463 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.4 OUTLIER -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.305 -0.998 . . . . 1.0 108.305 -179.919 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.95 -46.86 50.01 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 115.188 -0.915 . . . . 1.0 112.546 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -58.68 -34.26 71.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 108.804 -0.813 . . . . 1.0 108.804 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.55 -36.55 63.12 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.183 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -62.35 -49.37 75.85 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.579 -1.191 . . . . 1.0 111.134 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -70.75 -39.61 73.19 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 119.954 -0.698 . . . . 1.0 109.922 178.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.469 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 75.6 m -60.97 -43.35 98.92 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.443 -0.798 . . . . 1.0 109.702 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -76.28 -46.07 29.61 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.91 -0.587 . . . . 1.0 111.816 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.654 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 55.4 t30 -59.88 -44.58 94.1 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.473 0.916 . . . . 1.0 113.473 -177.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.75 -31.61 68.5 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.337 -0.945 . . . . 1.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.469 ' ND2' ' O ' ' A' ' 17' ' ' THR . 50.0 m-80 -77.54 -34.23 53.97 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.514 -0.766 . . . . 1.0 111.653 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -57.94 137.03 83.71 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 120.628 -0.429 . . . . 1.0 111.76 -177.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.13 148.84 57.11 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 122.167 1.911 . . . . 1.0 113.442 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.13 -20.84 14.16 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.972 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.6 t -85.16 135.71 24.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.0 109.789 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.1 t -120.74 121.37 65.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.743 -1.206 . . . . 1.0 107.743 178.261 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.0 p -97.63 144.8 10.39 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.677 0 CA-C-O 121.746 0.784 . . . . 1.0 111.773 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 95.2 mt -111.32 164.28 15.37 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.314 -1.312 . . . . 1.0 110.688 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -60.84 -30.82 90.87 Favored 'Trans proline' 0 N--CA 1.485 0.983 0 C-N-CA 121.72 1.613 . . . . 1.0 110.83 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -67.81 -12.1 59.91 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.568 -0.742 . . . . 1.0 109.346 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.9 -1.59 78.28 Favored Glycine 0 C--O 1.228 -0.269 0 N-CA-C 109.962 -1.255 . . . . 1.0 109.962 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.474 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.1 tm? -78.68 133.66 37.18 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 108.375 -0.972 . . . . 1.0 108.375 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.447 ' HG3' ' HA ' ' A' ' 27' ' ' VAL . 24.3 mp0 -122.23 137.46 54.83 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.681 -0.236 . . . . 1.0 111.289 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -134.23 142.65 47.43 Favored 'General case' 0 CA--C 1.506 -0.725 0 CA-C-O 121.638 0.733 . . . . 1.0 111.116 178.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.529 ' HD3' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -123.9 130.89 53.32 Favored 'General case' 0 CA--C 1.503 -0.831 0 CA-C-N 114.528 -1.215 . . . . 1.0 109.216 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -88.92 104.48 14.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 122.294 1.045 . . . . 1.0 112.025 -178.108 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.604 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.1 mm -69.42 -41.84 80.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 114.766 -1.107 . . . . 1.0 108.471 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -144.26 126.1 15.27 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.522 -1.217 . . . . 1.0 109.752 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.8 p -85.23 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.027 0.441 . . . . 1.0 110.487 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.4 ' H ' ' HB3' ' A' ' 97' ' ' SER . . . -116.11 -37.54 1.02 Allowed Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.247 -1.141 . . . . 1.0 110.247 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.422 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 6.4 m-20 58.02 31.67 20.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.541 -0.329 . . . . 1.0 111.399 179.357 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.83 -159.78 35.64 Favored Glycine 0 C--N 1.333 0.376 0 CA-C-O 122.316 0.953 . . . . 1.0 112.51 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.608 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.9 m -69.68 -177.93 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 113.627 -1.286 . . . . 1.0 108.951 178.238 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.58 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.29 155.25 0.4 Allowed Pre-proline 0 C--N 1.318 -0.784 0 O-C-N 123.619 0.574 . . . . 1.0 109.932 179.459 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.445 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 58.4 Cg_endo -87.7 156.4 7.57 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 123.305 2.67 . . . . 1.0 115.941 -174.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.35 176.59 45.17 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 108.874 -1.691 . . . . 1.0 108.874 176.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.519 ' CE ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.06 -22.38 15.82 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 120.501 -0.48 . . . . 1.0 111.517 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.449 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 35.8 m -106.97 -7.33 17.03 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.874 0.694 . . . . 1.0 112.874 -177.46 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -84.58 170.81 13.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.952 -0.388 . . . . 1.0 109.952 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.3 m -110.76 147.04 35.28 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.285 0.564 . . . . 1.0 109.907 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.445 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.2 p -127.9 163.11 32.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 115.357 -0.838 . . . . 1.0 112.676 -175.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.407 HG22 ' HB3' ' A' ' 74' ' ' PRO . 68.1 m -130.12 121.21 25.9 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.589 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.1 m -149.02 165.76 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 114.635 1.346 . . . . 1.0 114.635 -176.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 3.0 mt-10 -118.08 147.28 43.42 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.991 -1.855 . . . . 1.0 105.991 174.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.1 p90 -164.7 168.89 17.52 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 114.525 1.306 . . . . 1.0 114.525 -176.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -131.78 129.25 40.3 Favored 'General case' 0 C--O 1.217 -0.658 0 CA-C-N 114.771 -1.104 . . . . 1.0 108.267 175.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.65 131.73 9.84 Favored Glycine 0 N--CA 1.473 1.115 0 N-CA-C 111.292 -0.723 . . . . 1.0 111.292 -179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 11.7 ptp180 -146.4 167.3 23.94 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.705 0.764 . . . . 1.0 112.219 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.9 mp -82.48 164.17 21.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.325 -1.307 . . . . 1.0 110.063 177.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.456 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -61.37 -24.44 33.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 122.411 1.1 . . . . 1.0 109.858 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.425 ' H ' HD13 ' A' ' 60' ' ' ILE . 53.6 t0 -89.71 -0.02 57.27 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 113.21 -1.813 . . . . 1.0 111.882 -177.067 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.04 -1.71 78.07 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.904 -0.665 . . . . 1.0 112.317 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -71.82 102.46 2.87 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 119.805 -0.758 . . . . 1.0 110.021 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.2 127.41 36.77 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.519 0.676 . . . . 1.0 110.507 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 29.3 p90 -121.14 -11.07 8.91 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 114.705 -1.134 . . . . 1.0 111.486 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -154.46 143.87 21.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.132 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 20.5 p -157.93 156.12 30.71 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 113.038 0.755 . . . . 1.0 113.038 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 55' ' ' TYR . 65.3 m -159.15 -45.57 0.06 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 114.861 -1.063 . . . . 1.0 110.72 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -58.63 -26.1 63.38 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 116.391 -0.368 . . . . 1.0 110.114 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.8 mmtt -49.51 -41.08 39.91 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.523 -1.288 . . . . 1.0 107.523 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 27.6 p -83.31 -32.26 26.42 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 113.923 -1.489 . . . . 1.0 109.668 177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.64 13.16 81.98 Favored Glycine 0 C--N 1.332 0.338 0 N-CA-C 110.954 -0.858 . . . . 1.0 110.954 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -94.18 116.91 66.99 Favored Pre-proline 0 N--CA 1.466 0.34 0 C-N-CA 121.104 -0.238 . . . . 1.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.413 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 39.6 Cg_exo -61.1 150.7 83.09 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 121.972 1.781 . . . . 1.0 115.112 -177.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -125.65 150.81 47.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 114.107 -1.406 . . . . 1.0 108.301 177.134 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.04 135.42 47.52 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 113.593 0.96 . . . . 1.0 113.593 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -142.24 153.89 44.33 Favored 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.162 -0.926 . . . . 1.0 109.449 177.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -90.75 130.35 36.74 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.912 -1.884 . . . . 1.0 105.912 173.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.7 -29.98 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 C-N-CA 119.734 -0.786 . . . . 1.0 110.506 -177.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.0 t -73.32 -25.21 60.55 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 120.244 -0.582 . . . . 1.0 112.212 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 62.6 mm-40 -98.14 -15.39 19.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.553 0.575 . . . . 1.0 112.553 -178.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 83' ' ' ILE . 2.0 p -78.47 172.71 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 120.021 -0.672 . . . . 1.0 111.147 -176.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.447 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -56.48 151.24 30.19 Favored Pre-proline 0 CA--C 1.55 0.974 0 C-N-CA 119.973 -0.691 . . . . 1.0 110.814 -178.362 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HD2' HG22 ' A' ' 83' ' ' ILE . 54.1 Cg_exo -53.89 -46.26 34.97 Favored 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 122.13 1.887 . . . . 1.0 112.876 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.4 -47.82 80.26 Favored Glycine 0 N--CA 1.451 -0.336 0 N-CA-C 109.132 -1.587 . . . . 1.0 109.132 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.589 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.7 m95 -64.29 -39.0 93.04 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 113.542 -1.329 . . . . 1.0 109.669 178.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 m -51.76 -53.61 37.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 1.0 111.185 -178.392 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -72.4 -40.88 66.84 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.23 -48.17 82.85 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 113.995 1.109 . . . . 1.0 113.995 -177.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 52.1 mt -57.95 -40.85 81.56 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 121.545 0.688 . . . . 1.0 109.814 -178.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -63.89 -24.53 67.77 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.839 -1.073 . . . . 1.0 111.221 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.8 mt -101.86 -15.64 16.82 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.394 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' MET . . . . . 0.507 ' CE ' ' H ' ' A' ' 99' ' ' TRP . 8.2 ttt -83.4 108.48 13.29 Favored Pre-proline 0 C--N 1.321 -0.642 0 O-C-N 123.811 0.694 . . . . 1.0 112.689 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.58 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -68.91 146.38 65.24 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.34 2.026 . . . . 1.0 112.082 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.608 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.89 136.69 57.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.472 -0.785 . . . . 1.0 111.731 -179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.7 57.08 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 108.92 -1.672 . . . . 1.0 108.92 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.4 ' HB3' ' H ' ' A' ' 40' ' ' GLY . 5.0 p -89.5 139.62 30.34 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 120.707 0.289 . . . . 1.0 110.49 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.6 m -110.31 112.48 24.46 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.004 -0.543 . . . . 1.0 109.902 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.507 ' H ' ' CE ' ' A' ' 93' ' ' MET . 40.8 m0 -115.25 161.34 18.6 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.805 0.812 . . . . 1.0 111.566 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.604 ' CD ' HD11 ' A' ' 37' ' ' ILE . 90.7 mt-10 -120.96 124.31 44.59 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 106.713 -1.588 . . . . 1.0 106.713 175.226 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -118.49 137.37 52.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-O 121.882 0.848 . . . . 1.0 110.61 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.675 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.28 103.05 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.722 -1.955 . . . . 1.0 105.722 -178.756 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 t -90.61 115.94 65.3 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 114.921 1.452 . . . . 1.0 114.921 -174.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -51.27 142.11 37.67 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 121.166 1.244 . . . . 1.0 109.868 176.142 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.3 p -48.11 -35.62 11.75 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 120.692 -0.403 . . . . 1.0 110.722 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.66 -33.19 85.42 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.181 -0.767 . . . . 1.0 111.181 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 71.9 mt -99.01 3.39 46.9 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.768 -0.216 . . . . 1.0 111.431 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.96 -114.98 0.28 Allowed 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.526 -0.546 . . . . 1.0 109.526 -179.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -91.25 5.06 50.62 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.821 0.344 . . . . 1.0 111.636 -179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.59 164.19 22.55 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.157 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.511 ' O ' ' N ' ' A' ' 121' ' ' ASN . 86.9 Cg_endo -74.23 -9.35 21.79 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 123.362 2.708 . . . . 1.0 110.247 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -107.7 162.95 13.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.495 -1.229 . . . . 1.0 109.745 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.5 m -72.01 89.94 1.14 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.671 -0.411 . . . . 1.0 109.939 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -104.52 62.23 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 121.118 -0.233 . . . . 1.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 164.62 -175.34 40.63 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 120.309 -0.948 . . . . 1.0 112.705 179.304 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.98 -104.81 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 N-CA-C 111.639 -0.584 . . . . 1.0 111.639 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -63.76 -15.36 48.39 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.545 2.163 . . . . 1.0 111.322 -178.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.674 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.8 mp -67.25 111.8 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.02 0 N-CA-C 108.295 -1.002 . . . . 1.0 108.295 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.425 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.62 -170.72 43.5 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.054 -0.976 . . . . 1.0 111.223 -179.342 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.571 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 28.6 Cg_endo -61.86 143.56 95.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.461 2.108 . . . . 1.0 112.788 179.178 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 121' ' ' ASN . 0.6 OUTLIER 49.07 48.84 20.39 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.792 0.664 . . . . 1.0 112.792 178.392 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.425 ' HG3' ' H ' ' A' ' 119' ' ' GLY . 45.9 mm-40 -93.94 129.27 40.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 113.164 0.802 . . . . 1.0 113.164 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.493 HG21 HD11 ' A' ' 16' ' ' LEU . 17.5 m -95.63 129.1 42.94 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 105.796 -1.927 . . . . 1.0 105.796 174.728 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.417 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.1 mm? -116.0 143.64 45.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.369 0.605 . . . . 1.0 110.69 -179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.675 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -119.54 148.11 22.74 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.649 0 CA-C-N 115.157 -0.928 . . . . 1.0 109.076 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.591 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.96 149.94 45.32 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.478 0.656 . . . . 1.0 111.527 177.356 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 8.6 mmtt -100.12 124.4 45.49 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 105.229 -2.137 . . . . 1.0 105.229 177.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.424 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.4 mt -122.01 127.61 75.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 119.497 -0.881 . . . . 1.0 112.327 -176.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.432 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.7 t-160 -118.97 124.31 46.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.321 -1.309 . . . . 1.0 107.633 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.78 110.39 22.87 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 120.225 -0.59 . . . . 1.0 112.374 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -94.34 -47.22 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.518 -0.765 . . . . 1.0 112.117 -179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.4 p -146.7 156.94 43.56 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.655 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.415 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.5 t -132.48 140.0 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.203 0.525 . . . . 1.0 111.942 -178.14 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.54 0.56 0 CA-C-N 115.703 -0.68 . . . . 1.0 109.613 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 . . . . . 0 CA--C 1.514 -0.433 0 CA-C-O 121.627 0.727 . . . . 1.0 110.864 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.612 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 14.3 m-20 -60.49 -35.75 76.67 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -66.16 -51.38 58.39 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.687 -1.597 . . . . 1.0 111.444 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.61 -48.03 78.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 C-N-CA 120.352 -0.539 . . . . 1.0 111.702 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.426 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.81 -38.73 91.86 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.552 -1.277 . . . . 1.0 107.552 179.119 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.5 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.15 -42.74 66.36 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 114.942 -1.027 . . . . 1.0 111.831 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -62.36 -32.18 72.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.972 -0.751 . . . . 1.0 108.972 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -35.05 49.6 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.261 -0.881 . . . . 1.0 109.878 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -61.17 -50.24 73.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 114.459 -1.246 . . . . 1.0 111.043 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.5 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.4 mp -70.92 -39.8 72.5 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.213 -0.595 . . . . 1.0 109.945 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.69 -42.63 99.19 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.541 -0.754 . . . . 1.0 109.315 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -76.71 -44.53 33.09 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-N 115.485 -0.78 . . . . 1.0 112.019 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.653 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.6 t30 -60.67 -44.77 96.09 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 113.375 0.879 . . . . 1.0 113.375 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.19 -31.93 67.76 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 119.517 -0.873 . . . . 1.0 109.237 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -79.83 -30.35 40.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.151 -0.931 . . . . 1.0 111.647 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 33.0 mtmt -58.18 136.43 84.61 Favored Pre-proline 0 CA--C 1.547 0.857 0 C-N-CA 120.425 -0.51 . . . . 1.0 111.396 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -52.92 148.66 28.76 Favored 'Trans proline' 0 N--CA 1.501 1.965 0 C-N-CA 122.271 1.981 . . . . 1.0 113.547 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -19.51 10.33 Favored Glycine 0 C--O 1.225 -0.413 0 CA-C-N 115.094 -0.957 . . . . 1.0 111.829 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.3 t -86.56 136.56 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.162 0.506 . . . . 1.0 110.896 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.7 t -120.99 123.97 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 N-CA-C 107.952 -1.129 . . . . 1.0 107.952 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.02 145.89 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-O 121.796 0.808 . . . . 1.0 112.008 -178.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.2 mt -113.03 165.18 13.7 Favored Pre-proline 0 C--O 1.231 0.126 0 CA-C-N 114.328 -1.305 . . . . 1.0 111.111 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -61.42 -30.03 86.31 Favored 'Trans proline' 0 C--N 1.32 -0.965 0 C-N-CA 122.167 1.911 . . . . 1.0 111.274 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 m -68.66 -14.97 63.37 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.713 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.5 -3.07 65.56 Favored Glycine 0 C--N 1.329 0.168 0 N-CA-C 109.688 -1.365 . . . . 1.0 109.688 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.47 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.99 133.84 36.2 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.47 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.0 mp0 -121.47 140.13 52.57 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 1.0 110.984 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -135.97 144.52 45.44 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.629 0.728 . . . . 1.0 110.935 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.54 134.8 49.74 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.427 -1.261 . . . . 1.0 109.041 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -92.82 104.04 15.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 122.158 0.98 . . . . 1.0 111.929 -178.273 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.648 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.4 mm -69.41 -41.48 80.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 178.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.4 m120 -143.73 130.01 19.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.676 -1.147 . . . . 1.0 109.697 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -86.15 131.8 34.16 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.025 -0.361 . . . . 1.0 110.025 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.75 -35.34 0.85 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 54.61 30.07 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.659 -0.271 . . . . 1.0 111.104 179.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.21 -161.23 37.12 Favored Glycine 0 C--N 1.331 0.256 0 CA-C-O 121.997 0.776 . . . . 1.0 111.752 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.8 m -68.94 -178.58 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 114.128 -1.036 . . . . 1.0 109.506 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.553 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.26 154.86 0.39 Allowed Pre-proline 0 C--N 1.32 -0.708 0 CA-C-N 115.608 -0.723 . . . . 1.0 109.391 179.536 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -87.72 156.72 7.56 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 123.195 2.597 . . . . 1.0 116.054 -175.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.44 178.37 47.52 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 108.579 -1.808 . . . . 1.0 108.579 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.722 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -56.32 -20.47 19.09 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.409 -0.516 . . . . 1.0 111.153 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.2 m -108.48 -7.84 15.69 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.386 0.884 . . . . 1.0 113.386 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.57 164.59 16.01 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 120.202 -0.599 . . . . 1.0 109.466 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 6.7 m -101.88 150.53 23.09 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.156 0.503 . . . . 1.0 110.114 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.19 160.21 38.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.335 0 CA-C-N 115.374 -0.83 . . . . 1.0 111.925 -177.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.0 m -129.87 120.79 25.48 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.441 -0.948 . . . . 1.0 108.441 178.02 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.538 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 10.9 m -149.19 166.27 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 113.832 1.049 . . . . 1.0 113.832 -176.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.0 mt-10 -118.4 149.6 40.96 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 105.748 -1.945 . . . . 1.0 105.748 173.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.494 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.3 p90 -163.29 162.4 25.18 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 118.285 -1.366 . . . . 1.0 114.338 -177.069 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -124.33 131.78 53.53 Favored 'General case' 0 C--O 1.217 -0.654 0 N-CA-C 108.183 -1.043 . . . . 1.0 108.183 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -117.76 137.83 13.52 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.39 -0.684 . . . . 1.0 111.39 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.84 168.01 23.29 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.769 0.795 . . . . 1.0 112.183 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.1 mp -85.07 164.73 18.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.376 -1.284 . . . . 1.0 109.772 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.13 -26.07 35.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 121.925 0.869 . . . . 1.0 110.061 178.294 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -92.22 2.96 56.29 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 113.808 -1.542 . . . . 1.0 111.764 -177.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.02 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 120.932 -0.651 . . . . 1.0 112.962 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.0 m -70.05 102.44 2.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 118.105 0.952 . . . . 1.0 110.026 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -72.95 120.07 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.819 0 CA-C-O 121.465 0.65 . . . . 1.0 110.354 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.66 ' CD2' HD11 ' A' ' 118' ' ' ILE . 18.8 p90 -114.78 -8.72 12.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.641 -1.163 . . . . 1.0 111.966 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -155.1 146.45 22.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.104 -0.498 . . . . 1.0 110.692 178.184 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 87.9 p -157.49 150.08 22.97 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 115.81 -0.632 . . . . 1.0 111.681 179.058 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.494 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 92.4 m -156.04 -40.46 0.08 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.759 -0.655 . . . . 1.0 110.884 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -63.6 -26.06 68.51 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.222 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -55.93 -43.76 77.7 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.967 -1.124 . . . . 1.0 107.967 178.316 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 68' ' ' THR . 72.9 p -73.79 -34.5 64.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.878 -1.055 . . . . 1.0 108.521 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.93 16.16 70.76 Favored Glycine 0 C--N 1.334 0.453 0 CA-C-N 115.036 -0.984 . . . . 1.0 111.012 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.42 116.31 65.52 Favored Pre-proline 0 N--CA 1.471 0.576 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.592 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.407 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.8 Cg_exo -60.98 153.69 62.1 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 121.723 1.615 . . . . 1.0 114.483 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.4 150.88 45.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.307 -1.315 . . . . 1.0 107.786 178.127 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 t -110.29 133.81 52.89 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -143.01 152.51 42.0 Favored 'General case' 0 CA--C 1.503 -0.832 0 CA-C-N 114.577 -1.192 . . . . 1.0 109.505 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -92.34 125.2 36.9 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 106.334 -1.728 . . . . 1.0 106.334 174.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.6 t -47.02 -32.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 115.773 -0.649 . . . . 1.0 110.609 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.9 t -74.42 -24.41 59.09 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 120.347 -0.541 . . . . 1.0 111.859 -178.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -98.82 -9.2 24.69 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 112.928 0.714 . . . . 1.0 112.928 -178.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.449 HG22 ' H ' ' A' ' 83' ' ' ILE . 3.3 p -88.04 170.71 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 118.196 0.453 . . . . 1.0 111.494 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.449 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -53.46 145.02 29.58 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 120.871 -0.331 . . . . 1.0 110.58 -176.552 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.32 -44.87 36.75 Favored 'Trans proline' 0 N--CA 1.498 1.737 0 C-N-CA 121.952 1.768 . . . . 1.0 112.74 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.39 -47.48 82.64 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 109.281 -1.528 . . . . 1.0 109.281 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.538 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.7 m95 -66.22 -37.02 84.54 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 113.791 -1.205 . . . . 1.0 110.261 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.19 -53.31 36.12 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.856 -0.338 . . . . 1.0 110.942 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tp10 -71.89 -43.98 64.5 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.085 0.402 . . . . 1.0 112.085 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.94 -46.43 85.09 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 114.022 1.119 . . . . 1.0 114.022 -177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.3 -41.58 84.75 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.154 -0.618 . . . . 1.0 109.634 -178.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -65.69 -23.41 66.77 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.187 -0.915 . . . . 1.0 111.197 -179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.422 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 85.4 mt -102.93 -10.34 19.1 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.459 -0.337 . . . . 1.0 110.741 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' MET . . . . . 0.53 ' HE3' ' H ' ' A' ' 99' ' ' TRP . 25.5 ttt -90.62 107.47 20.53 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.734 -0.666 . . . . 1.0 112.032 -178.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.553 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.0 Cg_exo -68.89 148.09 69.9 Favored 'Trans proline' 0 N--CA 1.498 1.77 0 C-N-CA 122.546 2.164 . . . . 1.0 112.361 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.585 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.67 137.67 57.47 Favored 'General case' 0 CA--C 1.509 -0.602 0 CA-C-N 115.546 -0.752 . . . . 1.0 111.664 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.16 -19.19 54.65 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 108.873 -1.691 . . . . 1.0 108.873 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.2 p -88.19 129.98 35.19 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 115.475 -0.362 . . . . 1.0 110.443 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 60.7 m -102.12 115.02 29.67 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 109.438 -0.579 . . . . 1.0 109.438 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.53 ' H ' ' HE3' ' A' ' 93' ' ' MET . 39.4 m0 -116.28 168.31 10.24 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.817 0.818 . . . . 1.0 111.278 -178.144 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.648 ' CD ' HD11 ' A' ' 37' ' ' ILE . 81.5 mt-10 -129.25 129.57 45.12 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 106.63 -1.619 . . . . 1.0 106.63 175.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 pt -125.58 138.45 54.42 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.533 0 CA-C-O 121.771 0.796 . . . . 1.0 109.78 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.743 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.26 103.25 12.18 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 106.021 -1.844 . . . . 1.0 106.021 -178.032 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.1 t -90.01 115.74 64.7 Favored Pre-proline 0 C--N 1.326 -0.442 0 N-CA-C 115.248 1.573 . . . . 1.0 115.248 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -51.44 143.77 34.11 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.188 1.259 . . . . 1.0 109.634 176.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 88.1 p -50.37 -33.76 21.66 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.517 -178.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.5 -32.73 82.58 Favored Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.03 -0.828 . . . . 1.0 111.03 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -99.78 1.73 43.43 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.981 -0.11 . . . . 1.0 110.859 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -111.83 0.3 Allowed 'General case' 0 C--N 1.342 0.264 0 CA-C-O 120.754 0.312 . . . . 1.0 110.816 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 -98.12 5.41 48.62 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 113.567 0.951 . . . . 1.0 113.567 -177.316 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.81 164.07 18.59 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 121.018 -0.61 . . . . 1.0 113.483 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 121' ' ' ASN . 93.9 Cg_endo -77.02 -9.99 17.98 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.571 2.847 . . . . 1.0 111.173 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -106.65 169.29 8.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.252 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.4 m -75.26 97.21 3.49 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.743 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.2 t -110.77 60.08 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 121.059 -0.256 . . . . 1.0 111.125 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.548 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.68 -177.95 42.34 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 120.514 -0.85 . . . . 1.0 111.998 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.04 -103.77 0.01 OUTLIER Glycine 0 CA--C 1.535 1.338 0 N-CA-C 111.141 -0.783 . . . . 1.0 111.141 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -63.21 -14.05 39.48 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.732 2.288 . . . . 1.0 111.159 -178.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.66 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.3 mp -65.86 114.93 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 108.273 -1.01 . . . . 1.0 108.273 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.432 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -95.03 -171.88 37.1 Favored Glycine 0 CA--C 1.52 0.354 0 CA-C-N 115.512 -0.767 . . . . 1.0 111.553 -178.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.529 ' N ' ' OG ' ' A' ' 113' ' ' SER . 26.3 Cg_endo -63.25 138.2 65.2 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.562 2.174 . . . . 1.0 112.535 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.53 ' N ' ' O ' ' A' ' 111' ' ' PRO . 27.8 t-20 53.17 51.41 15.69 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 120.962 -0.295 . . . . 1.0 111.3 178.531 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.612 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -96.74 131.27 43.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.294 -0.412 . . . . 1.0 111.6 -179.608 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.43 HG21 HD11 ' A' ' 16' ' ' LEU . 49.1 m -95.97 128.66 43.05 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.34 138.9 48.41 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.064 0.459 . . . . 1.0 110.998 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.743 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -117.91 147.35 21.42 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.583 0 CA-C-N 115.724 -0.671 . . . . 1.0 109.195 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.584 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.83 150.92 47.58 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.441 -0.504 . . . . 1.0 111.629 177.855 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.424 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.0 mmtt -100.76 123.97 45.72 Favored 'General case' 0 CA--C 1.501 -0.907 0 N-CA-C 105.807 -1.923 . . . . 1.0 105.807 177.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.468 HG23 ' CH2' ' A' ' 86' ' ' TRP . 2.9 mt -117.0 125.61 73.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 119.592 -0.843 . . . . 1.0 112.732 -176.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -118.03 124.58 48.46 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.172 -1.377 . . . . 1.0 108.484 178.388 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.23 114.22 25.98 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 119.746 -0.782 . . . . 1.0 112.808 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.485 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -95.46 -43.01 12.74 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 115.732 -0.667 . . . . 1.0 110.996 178.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -154.21 156.5 37.2 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.604 -0.439 . . . . 1.0 111.265 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.413 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.7 t -129.82 138.43 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.111 -0.495 . . . . 1.0 111.273 -178.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.466 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 8.9 tptm . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 1.0 109.931 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 22.7 mt-10 . . . . . 0 C--O 1.223 -0.302 0 CA-C-O 121.842 0.83 . . . . 1.0 110.104 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -58.75 -34.07 70.99 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 115.002 -0.999 . . . . 1.0 108.409 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 17.7 tttp -66.1 -51.47 57.77 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.073 -1.422 . . . . 1.0 111.493 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.3 t -67.32 -46.88 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 C-N-CA 119.845 -0.742 . . . . 1.0 111.663 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.447 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.59 -37.58 86.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.893 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.459 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.95 -44.66 29.65 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.861 -1.063 . . . . 1.0 112.317 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.435 ' N ' ' O ' ' A' ' 9' ' ' LYS . 58.3 mt-10 -60.73 -34.5 74.51 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.53 -0.915 . . . . 1.0 108.53 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.56 -36.07 65.56 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.016 -0.993 . . . . 1.0 109.826 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -61.14 -50.22 74.08 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.762 -1.108 . . . . 1.0 110.3 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 12' ' ' GLY . 4.7 mp -66.22 -38.43 87.92 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.387 -0.597 . . . . 1.0 109.387 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -61.51 -42.59 99.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.739 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -75.62 -44.61 41.93 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.6 -0.727 . . . . 1.0 111.887 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.628 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -56.98 -49.52 75.48 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -178.486 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.3 ptmt -58.93 -29.47 67.13 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.355 -0.938 . . . . 1.0 110.021 -176.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -81.79 -29.1 32.86 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.311 -0.859 . . . . 1.0 111.482 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 mtmt -60.69 145.63 87.52 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 120.625 -0.43 . . . . 1.0 112.005 -178.099 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.0 149.05 64.52 Favored 'Trans proline' 0 N--CA 1.507 2.296 0 C-N-CA 122.946 2.431 . . . . 1.0 114.708 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.44 -20.53 2.11 Favored Glycine 0 N--CA 1.462 0.41 0 CA-C-N 114.957 -1.02 . . . . 1.0 111.894 178.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.2 t -79.2 131.55 34.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 C-N-CA 120.138 -0.625 . . . . 1.0 109.925 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 67.4 t -116.03 120.33 64.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.103 -1.073 . . . . 1.0 108.103 177.003 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.6 p -93.32 145.94 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 CA-C-O 121.688 0.756 . . . . 1.0 111.366 -178.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.33 163.55 18.0 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-N 114.534 -1.212 . . . . 1.0 110.446 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.4 -30.99 92.1 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 121.668 1.579 . . . . 1.0 111.294 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.3 m -69.34 -13.44 62.38 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.676 -0.693 . . . . 1.0 110.114 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.32 -4.0 64.29 Favored Glycine 0 CA--C 1.518 0.252 0 N-CA-C 110.179 -1.169 . . . . 1.0 110.179 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.498 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.8 tm? -77.45 134.56 38.34 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 108.565 -0.902 . . . . 1.0 108.565 179.573 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.498 ' H ' HD22 ' A' ' 32' ' ' LEU . 14.2 mp0 -125.1 141.68 51.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 116.341 -0.391 . . . . 1.0 111.609 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.1 p90 -137.01 142.58 42.52 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.745 0.783 . . . . 1.0 112.087 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.557 ' HE3' HD13 ' A' ' 37' ' ' ILE . 6.2 ttpt -124.85 124.63 42.5 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 114.282 -1.327 . . . . 1.0 108.296 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.88 113.39 21.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 CA-C-N 115.199 -0.91 . . . . 1.0 111.107 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.557 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.7 mm -77.02 -42.15 31.77 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 CA-C-O 121.808 0.813 . . . . 1.0 109.63 178.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -143.81 128.76 18.49 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.208 -1.36 . . . . 1.0 109.655 -177.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.9 p -90.83 128.57 36.77 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.941 0.401 . . . . 1.0 109.996 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.89 -32.64 1.39 Allowed Glycine 0 CA--C 1.52 0.368 0 N-CA-C 110.045 -1.222 . . . . 1.0 110.045 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 56.6 31.92 20.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.532 -0.334 . . . . 1.0 111.126 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.13 -161.01 37.0 Favored Glycine 0 C--N 1.334 0.445 0 CA-C-O 121.833 0.685 . . . . 1.0 111.553 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.586 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.6 m -68.41 -178.49 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.108 -1.046 . . . . 1.0 109.301 178.575 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.492 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.66 154.59 0.36 Allowed Pre-proline 0 C--N 1.319 -0.741 0 O-C-N 123.84 0.712 . . . . 1.0 109.213 179.529 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.8 Cg_endo -86.99 157.9 8.62 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.933 2.422 . . . . 1.0 115.781 -175.512 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.412 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.31 172.69 38.25 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 108.446 -1.862 . . . . 1.0 108.446 176.098 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.618 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -47.04 -25.27 0.78 Allowed 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 114.83 -0.685 . . . . 1.0 111.62 178.773 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.428 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 20.7 m -108.25 -9.14 15.56 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 113.363 0.875 . . . . 1.0 113.363 -177.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.412 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.7 m-20 -84.72 167.39 16.19 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 119.717 -0.793 . . . . 1.0 109.005 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.8 m -106.14 149.93 26.31 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.096 0.474 . . . . 1.0 109.918 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.431 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.1 p -126.53 162.35 30.93 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.297 0 CA-C-N 115.477 -0.783 . . . . 1.0 112.21 -176.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 77.9 m -130.23 119.96 23.72 Favored 'General case' 0 N--CA 1.464 0.24 0 N-CA-C 108.333 -0.988 . . . . 1.0 108.333 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.559 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.8 m -148.99 166.62 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 114.28 1.215 . . . . 1.0 114.28 -176.631 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 9.4 mt-10 -118.4 152.19 36.34 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 106.386 -1.709 . . . . 1.0 106.386 174.237 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.504 ' H ' ' HB ' ' A' ' 68' ' ' THR . 32.8 p90 -163.63 160.71 23.16 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 118.423 -1.311 . . . . 1.0 114.538 -178.021 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.15 130.29 53.09 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.769 -0.826 . . . . 1.0 108.769 175.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.2 137.08 13.93 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.881 -0.676 . . . . 1.0 112.02 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -147.84 167.28 25.17 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.617 0.722 . . . . 1.0 112.227 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -86.89 166.05 15.46 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.491 -1.231 . . . . 1.0 111.404 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.417 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.01 -26.24 35.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 114.809 -1.087 . . . . 1.0 110.266 178.066 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -93.79 2.38 56.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.173 -1.376 . . . . 1.0 111.416 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -2.25 75.67 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 120.998 -0.62 . . . . 1.0 112.767 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.4 m -69.03 103.44 1.86 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.821 0.81 . . . . 1.0 110.326 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.9 t -74.03 122.7 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 C-N-CA 120.287 -0.565 . . . . 1.0 109.601 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.841 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.3 p90 -116.35 -8.46 11.64 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 115.003 -0.999 . . . . 1.0 111.598 -178.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 33.7 t0 -158.29 152.42 24.09 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.467 -0.493 . . . . 1.0 111.335 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 96.4 p -159.29 153.23 23.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.729 -0.668 . . . . 1.0 111.623 178.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.504 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 66.2 m -155.86 -39.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.643 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.4 pp20? -65.8 -27.15 68.06 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -58.15 -43.83 87.55 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 107.808 -1.182 . . . . 1.0 107.808 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.5 p -73.99 -31.32 62.92 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.865 -1.062 . . . . 1.0 108.797 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.71 18.31 68.42 Favored Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.81 178.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.413 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 0.0 OUTLIER -101.73 115.03 65.43 Favored Pre-proline 0 N--CA 1.47 0.539 0 C-N-CA 120.682 -0.407 . . . . 1.0 110.98 -179.275 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.407 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 30.4 Cg_exo -60.83 152.49 69.67 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.823 1.682 . . . . 1.0 114.366 -178.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.26 152.21 41.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.042 -1.436 . . . . 1.0 107.833 178.165 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 130.9 55.38 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 121.408 0.623 . . . . 1.0 112.511 -178.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -138.82 148.44 43.77 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.0 -1.0 . . . . 1.0 109.853 178.487 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 67.8 mt-30 -90.35 125.39 35.52 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 106.335 -1.728 . . . . 1.0 106.335 174.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.8 t -53.69 -28.85 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 C-N-CA 119.394 -0.922 . . . . 1.0 110.15 -177.326 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.7 t -73.97 -25.59 60.02 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.025 -0.67 . . . . 1.0 111.835 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -100.1 -16.07 17.97 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.717 -0.393 . . . . 1.0 112.022 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -64.99 164.75 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 112.109 0.411 . . . . 1.0 112.109 -177.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.58 148.96 23.19 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.501 -0.925 . . . . 1.0 108.501 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -51.33 -42.62 53.68 Favored 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 121.061 1.174 . . . . 1.0 112.093 -178.485 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.76 -48.09 87.73 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 119.872 -1.156 . . . . 1.0 110.54 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.559 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.5 m95 -65.56 -35.5 81.04 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.301 -0.949 . . . . 1.0 111.144 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.2 m -51.19 -54.38 26.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.987 -0.285 . . . . 1.0 111.637 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.89 -40.8 68.65 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.456 0.539 . . . . 1.0 112.456 -179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.1 -48.1 82.84 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 114.136 1.162 . . . . 1.0 114.136 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.4 mt -58.32 -42.25 86.31 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.299 0.571 . . . . 1.0 109.896 -177.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -63.25 -23.9 67.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.332 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.517 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.7 mt -100.95 -12.45 18.91 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.902 -0.59 . . . . 1.0 111.246 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.5 ttp -90.17 107.45 19.64 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 111.863 0.32 . . . . 1.0 111.863 -178.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.492 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.3 Cg_exo -67.28 148.02 79.38 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.614 2.209 . . . . 1.0 112.426 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.586 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.61 135.6 55.26 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-O 121.546 0.688 . . . . 1.0 110.926 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.46 57.49 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 107.788 -2.125 . . . . 1.0 107.788 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.8 p -90.24 133.51 34.88 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.956 -0.622 . . . . 1.0 110.676 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.0 m -108.8 115.42 30.06 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.581 -0.736 . . . . 1.0 109.426 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.517 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 40.6 m0 -115.43 168.52 9.92 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.777 0.799 . . . . 1.0 111.081 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.426 ' HB2' HD11 ' A' ' 37' ' ' ILE . 25.2 mt-10 -127.89 129.91 47.65 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 106.449 -1.686 . . . . 1.0 106.449 175.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.7 pt -126.33 137.83 56.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.782 0.801 . . . . 1.0 109.707 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.91 103.62 12.71 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 105.866 -1.901 . . . . 1.0 105.866 -178.078 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 t -90.48 115.57 64.43 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 115.162 1.541 . . . . 1.0 115.162 -174.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -51.07 145.6 24.96 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.525 1.483 . . . . 1.0 109.89 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.7 p -51.7 -36.24 45.92 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.241 -0.584 . . . . 1.0 111.046 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.43 -32.48 83.62 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.862 -0.895 . . . . 1.0 110.862 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.6 mt -99.19 2.28 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.856 -0.172 . . . . 1.0 111.001 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.82 -103.81 0.37 Allowed 'General case' 0 C--O 1.219 -0.54 0 N-CA-C 112.197 0.443 . . . . 1.0 112.197 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.401 ' O ' HG21 ' A' ' 114' ' ' VAL . 31.9 m-85 -104.07 3.96 33.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 113.435 0.902 . . . . 1.0 113.435 -177.182 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.78 167.8 17.22 Favored Glycine 0 N--CA 1.47 0.922 0 C-N-CA 120.673 -0.775 . . . . 1.0 113.786 177.107 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.575 ' O ' ' N ' ' A' ' 121' ' ' ASN . 91.0 Cg_endo -76.37 -17.74 16.41 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 124.013 3.142 . . . . 1.0 111.764 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -103.67 169.69 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.848 -0.615 . . . . 1.0 110.066 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.406 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.2 m -74.16 102.95 4.42 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.673 -0.491 . . . . 1.0 109.673 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 109' ' ' TYR . 8.7 t -111.62 61.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-O 120.699 0.285 . . . . 1.0 110.795 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.501 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 162.95 178.32 36.67 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.631 -0.795 . . . . 1.0 111.793 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.46 -103.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.156 0 N-CA-C 111.09 -0.804 . . . . 1.0 111.09 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -61.76 -16.64 50.12 Favored 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.672 2.248 . . . . 1.0 111.734 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.841 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.9 mp -66.46 117.2 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 107.475 -1.305 . . . . 1.0 107.475 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -93.47 -170.15 39.09 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.622 -0.717 . . . . 1.0 111.926 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.406 ' N ' ' OG ' ' A' ' 113' ' ' SER . 30.1 Cg_endo -67.55 145.56 70.84 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 C-N-CA 122.413 2.075 . . . . 1.0 111.614 178.292 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.575 ' N ' ' O ' ' A' ' 111' ' ' PRO . 18.3 t-20 42.99 48.76 5.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.324 0.583 . . . . 1.0 110.415 179.078 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 4.4 tp10 -100.86 128.97 46.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.126 -0.943 . . . . 1.0 111.226 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 16' ' ' LEU . 46.7 m -91.29 131.38 36.83 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.299 -0.864 . . . . 1.0 109.404 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -113.14 147.98 36.27 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.876 0.37 . . . . 1.0 110.28 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -126.39 143.22 40.62 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.595 0 N-CA-C 108.546 -0.909 . . . . 1.0 108.546 178.358 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.565 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.5 m-85 -134.15 149.9 51.08 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.378 -0.529 . . . . 1.0 111.657 177.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.5 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 6.9 mmtt -100.16 124.39 45.52 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 105.728 -1.953 . . . . 1.0 105.728 177.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.2 118.95 59.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.878 0.846 . . . . 1.0 113.031 -176.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.441 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.0 t60 -109.64 127.12 54.32 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 113.98 -1.464 . . . . 1.0 108.536 178.679 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.6 111.61 23.68 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 120.041 -0.664 . . . . 1.0 112.41 -178.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.442 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.2 mp -93.86 -44.79 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 CA-C-N 116.119 -0.492 . . . . 1.0 111.1 179.137 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.5 p -152.39 158.39 42.61 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.89 0.376 . . . . 1.0 110.744 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.4 t -130.88 139.68 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.516 -177.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 7.2 tptt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 121.356 0.598 . . . . 1.0 109.906 178.719 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 . . . . . 0 CA--C 1.516 -0.337 0 CA-C-O 121.599 0.714 . . . . 1.0 110.512 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 28.5 m-20 -59.7 -35.66 74.95 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.171 -0.922 . . . . 1.0 108.657 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttpm? -65.74 -50.83 63.37 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.197 -1.365 . . . . 1.0 111.139 179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -67.21 -48.81 77.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 119.58 -0.848 . . . . 1.0 112.015 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.458 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.16 -38.04 87.53 Favored 'General case' 0 N--CA 1.444 -0.757 0 N-CA-C 107.703 -1.221 . . . . 1.0 107.703 179.212 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.479 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.2 -47.96 41.66 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 114.897 -1.047 . . . . 1.0 112.296 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -59.86 -30.81 69.23 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 119.882 -0.727 . . . . 1.0 109.248 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.4 -35.31 47.29 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.266 -0.879 . . . . 1.0 109.978 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.5 t80 -60.55 -49.43 77.58 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.764 -1.107 . . . . 1.0 110.379 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.479 HD12 ' O ' ' A' ' 12' ' ' GLY . 6.0 mp -66.99 -40.01 87.29 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 109.199 -0.667 . . . . 1.0 109.199 178.243 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 98.0 m -61.96 -41.75 98.35 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.488 -0.778 . . . . 1.0 109.733 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -75.73 -43.38 47.23 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.69 -0.687 . . . . 1.0 111.36 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.666 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 47.4 t30 -61.53 -45.31 94.72 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 112.793 0.664 . . . . 1.0 112.793 -178.257 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -58.89 -30.74 68.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.48 -0.888 . . . . 1.0 108.947 -179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 58.9 m-20 -79.07 -31.65 44.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.261 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 29.4 mtmt -58.55 142.72 82.45 Favored Pre-proline 0 CA--C 1.547 0.865 0 C-N-CA 120.525 -0.47 . . . . 1.0 111.163 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.68 149.06 61.3 Favored 'Trans proline' 0 N--CA 1.503 2.042 0 C-N-CA 122.422 2.081 . . . . 1.0 114.297 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.73 -19.31 5.12 Favored Glycine 0 C--O 1.228 -0.243 0 CA-C-N 115.021 -0.99 . . . . 1.0 112.226 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.54 136.53 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.02 0.438 . . . . 1.0 110.754 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.3 t -121.41 122.91 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 107.963 -1.125 . . . . 1.0 107.963 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.92 146.0 8.1 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.753 0.787 . . . . 1.0 111.896 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.8 mt -114.86 166.5 11.59 Favored Pre-proline 0 C--O 1.231 0.119 0 CA-C-N 114.35 -1.296 . . . . 1.0 111.048 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -61.57 -31.6 87.27 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 122.241 1.961 . . . . 1.0 111.97 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 m -69.94 -10.71 59.53 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.25 0.548 . . . . 1.0 109.855 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.25 0.94 72.89 Favored Glycine 0 CA--C 1.517 0.185 0 N-CA-C 109.952 -1.259 . . . . 1.0 109.952 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.48 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -82.64 133.58 35.17 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 108.555 -0.905 . . . . 1.0 108.555 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.48 ' H ' HD22 ' A' ' 32' ' ' LEU . 16.5 mp0 -121.84 143.46 49.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.413 -0.358 . . . . 1.0 111.164 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 26.7 p90 -137.4 145.27 43.04 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.733 0.778 . . . . 1.0 111.072 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.506 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -128.66 132.63 48.1 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 114.38 -1.282 . . . . 1.0 109.08 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.85 104.63 15.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 122.314 1.055 . . . . 1.0 112.02 -178.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.613 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -69.77 -41.35 79.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.992 -1.004 . . . . 1.0 108.551 179.021 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -143.92 129.38 19.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.661 -1.154 . . . . 1.0 109.73 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.3 p -89.43 128.81 35.98 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.734 -0.469 . . . . 1.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.48 -35.15 1.22 Allowed Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 58.07 29.9 18.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 1.0 111.138 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.93 -161.99 37.84 Favored Glycine 0 C--N 1.331 0.259 0 CA-C-O 121.888 0.716 . . . . 1.0 111.713 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.9 m -68.61 -177.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.061 -1.07 . . . . 1.0 108.841 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' HG21 ' A' ' 133' ' ' VAL . 0.0 OUTLIER 177.67 155.4 0.49 Allowed Pre-proline 0 C--N 1.317 -0.836 0 O-C-N 123.628 0.58 . . . . 1.0 109.516 179.797 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -83.84 165.23 13.64 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 123.241 2.627 . . . . 1.0 116.292 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.443 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -98.08 175.02 29.37 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 108.633 -1.787 . . . . 1.0 108.633 176.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.84 -23.53 18.8 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.618 -0.433 . . . . 1.0 111.492 -179.086 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 36.4 m -107.02 -6.31 17.55 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 112.9 0.704 . . . . 1.0 112.9 -177.437 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.727 ' OD1' ' N ' ' A' ' 50' ' ' THR . 67.2 t0 -82.33 170.68 15.07 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.282 0.563 . . . . 1.0 110.595 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.727 ' N ' ' OD1' ' A' ' 49' ' ' ASP . 8.9 m -112.38 144.06 42.44 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.697 -0.853 . . . . 1.0 108.697 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' THR . 9.0 p -125.39 160.34 31.52 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 CA-C-N 115.182 -0.917 . . . . 1.0 111.974 -175.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.444 HG22 ' HB3' ' A' ' 74' ' ' PRO . 99.3 m -125.5 119.74 29.03 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.602 -0.888 . . . . 1.0 108.602 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.433 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.5 m -148.48 166.93 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 114.341 1.237 . . . . 1.0 114.341 -177.191 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -119.36 147.68 44.06 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 106.283 -1.747 . . . . 1.0 106.283 173.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.4 p90 -162.19 163.4 28.36 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 115.083 1.512 . . . . 1.0 115.083 -176.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -127.45 127.5 44.18 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 115.254 -0.884 . . . . 1.0 109.332 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.74 136.07 13.19 Favored Glycine 0 N--CA 1.471 1.001 0 C-N-CA 121.094 -0.574 . . . . 1.0 112.355 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 58' ' ' ARG . 5.3 ptp180 -147.4 168.55 21.57 Favored 'General case' 0 C--N 1.341 0.199 0 CA-C-O 121.498 0.666 . . . . 1.0 112.266 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.2 mp -84.93 164.7 18.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.519 -1.219 . . . . 1.0 110.761 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.43 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.57 -25.49 34.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 114.883 -1.053 . . . . 1.0 110.018 177.792 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -92.65 3.02 56.36 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.926 -1.488 . . . . 1.0 111.622 -177.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.27 -2.03 80.56 Favored Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.822 -0.704 . . . . 1.0 112.668 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.4 m -71.37 104.49 3.21 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 119.722 -0.791 . . . . 1.0 109.785 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.1 t -75.46 126.34 36.11 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.81 0 CA-C-O 121.202 0.525 . . . . 1.0 110.332 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 30.2 p90 -115.0 -11.68 12.1 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.032 -0.986 . . . . 1.0 111.425 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -162.5 153.35 17.3 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.838 -0.745 . . . . 1.0 112.158 178.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 93.3 p -160.44 154.88 23.6 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 115.706 -0.679 . . . . 1.0 112.124 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.505 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 90.4 m -152.26 -43.51 0.1 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.688 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.413 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.8 pp20? -59.04 -25.98 64.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.152 -0.476 . . . . 1.0 110.427 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -54.98 -42.55 72.56 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.674 -1.232 . . . . 1.0 107.674 178.892 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 71.9 p -77.06 -34.83 57.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.525 -1.216 . . . . 1.0 109.193 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 85.05 16.75 64.37 Favored Glycine 0 C--N 1.333 0.362 0 CA-C-N 115.452 -0.795 . . . . 1.0 111.57 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.5 116.14 65.15 Favored Pre-proline 0 N--CA 1.472 0.672 0 C-N-CA 120.488 -0.485 . . . . 1.0 110.874 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HB3' HG22 ' A' ' 52' ' ' THR . 34.7 Cg_exo -59.7 151.65 68.71 Favored 'Trans proline' 0 N--CA 1.481 0.752 0 C-N-CA 121.458 1.438 . . . . 1.0 114.438 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.36 149.52 46.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.027 -1.442 . . . . 1.0 107.257 177.487 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -103.34 136.99 42.07 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.358 0.599 . . . . 1.0 112.493 -178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -140.23 148.3 41.31 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 114.933 -1.031 . . . . 1.0 110.767 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -92.0 125.19 36.6 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.752 -1.944 . . . . 1.0 105.752 174.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.6 t -56.45 -29.98 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 C-N-CA 118.704 -1.198 . . . . 1.0 110.126 -176.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LYS . 3.1 t -73.53 -25.78 60.57 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 120.074 -0.65 . . . . 1.0 112.577 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.5 mm100 -101.37 -15.9 17.07 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 111.885 0.328 . . . . 1.0 111.885 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.481 HG22 ' H ' ' A' ' 83' ' ' ILE . 1.6 p -69.94 170.52 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 119.42 -0.912 . . . . 1.0 111.886 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.481 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.08 146.99 27.34 Favored Pre-proline 0 CA--C 1.548 0.875 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 -178.069 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -52.13 -43.64 51.6 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.814 1.676 . . . . 1.0 113.105 -178.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.65 -47.15 92.36 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 109.574 -1.41 . . . . 1.0 109.574 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.433 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 6.7 m95 -63.03 -35.31 79.8 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.153 -1.024 . . . . 1.0 110.387 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 24.8 m -51.56 -53.54 36.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.063 0.458 . . . . 1.0 111.063 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -71.9 -44.91 62.92 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.617 -0.72 . . . . 1.0 112.687 -179.141 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -58.81 -46.8 86.75 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 114.509 1.3 . . . . 1.0 114.509 -177.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 19.4 mt -57.84 -42.88 85.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.362 0.601 . . . . 1.0 109.478 -178.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -62.95 -20.08 64.89 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.942 -1.026 . . . . 1.0 110.434 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.537 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 96.2 mt -105.93 -11.05 16.33 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.968 -0.56 . . . . 1.0 111.352 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 54.2 ttp -92.52 107.18 21.93 Favored Pre-proline 0 CA--C 1.547 0.842 0 O-C-N 123.273 0.358 . . . . 1.0 111.376 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.43 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 23.8 Cg_exo -64.43 147.7 90.65 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.398 2.065 . . . . 1.0 112.936 178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.599 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -61.87 132.66 53.77 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 115.482 -0.781 . . . . 1.0 111.579 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.49 -19.26 55.09 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 108.492 -1.843 . . . . 1.0 108.492 -178.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -84.61 131.83 34.56 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.038 0.447 . . . . 1.0 109.994 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.5 m -105.24 113.67 27.4 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 115.923 -0.58 . . . . 1.0 109.604 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.9 m0 -115.65 165.69 12.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.871 0.843 . . . . 1.0 111.258 -178.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.613 ' CD ' HD11 ' A' ' 37' ' ' ILE . 83.7 mt-10 -125.84 132.88 52.13 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 106.277 -1.749 . . . . 1.0 106.277 175.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.425 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.7 pt -128.66 139.71 51.17 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-O 121.84 0.829 . . . . 1.0 109.925 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.697 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.88 103.07 11.8 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 105.742 -1.947 . . . . 1.0 105.742 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 t -90.64 116.23 65.94 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 115.614 1.709 . . . . 1.0 115.614 -174.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.81 144.56 26.38 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.66 1.574 . . . . 1.0 109.766 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.5 p -50.45 -36.24 32.42 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 120.434 -0.506 . . . . 1.0 111.363 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.98 -32.2 80.2 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.977 -0.849 . . . . 1.0 110.977 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.4 mt -98.4 2.32 47.75 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 121.364 -0.134 . . . . 1.0 110.746 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.446 ' O ' HG22 ' A' ' 83' ' ' ILE . . . -107.95 -103.22 0.36 Allowed 'General case' 0 C--O 1.216 -0.665 0 N-CA-C 110.069 -0.345 . . . . 1.0 110.069 -179.097 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -105.29 5.17 31.74 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 113.397 0.888 . . . . 1.0 113.397 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 105.46 166.7 23.69 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 120.814 -0.707 . . . . 1.0 113.075 177.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 121' ' ' ASN . 72.6 Cg_endo -72.64 -18.46 25.38 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 123.454 2.769 . . . . 1.0 112.45 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -98.03 169.3 9.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.303 -0.408 . . . . 1.0 109.947 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.7 m -76.33 85.82 3.11 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.7 t -98.04 59.23 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.51 -0.314 . . . . 1.0 110.923 -179.114 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.75 179.9 41.76 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 120.629 -0.796 . . . . 1.0 112.088 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.01 -105.87 0.01 OUTLIER Glycine 0 CA--C 1.537 1.418 0 N-CA-C 111.747 -0.541 . . . . 1.0 111.747 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -61.15 -13.72 29.68 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 C-N-CA 122.399 2.066 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.841 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.1 mp -68.24 112.22 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 108.334 -0.987 . . . . 1.0 108.334 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.412 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -91.21 -167.11 40.9 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.691 -0.964 . . . . 1.0 110.691 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.503 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 38.0 Cg_endo -64.76 146.65 88.81 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 122.242 1.961 . . . . 1.0 112.973 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.468 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 46.16 49.87 12.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.67 -0.695 . . . . 1.0 111.925 178.353 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.437 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 49.1 mm-40 -93.21 132.69 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.093 0.473 . . . . 1.0 111.978 179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.465 HG21 HD11 ' A' ' 16' ' ' LEU . 63.4 m -96.2 127.82 42.55 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.243 -1.762 . . . . 1.0 106.243 175.31 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.423 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.97 143.16 45.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.517 0.675 . . . . 1.0 110.747 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.697 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.7 tt -119.28 146.38 24.04 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.659 0 CA-C-N 115.078 -0.965 . . . . 1.0 108.508 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.562 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.84 152.27 48.92 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.314 -0.554 . . . . 1.0 111.376 177.63 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.476 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 3.4 mmtt -100.47 124.03 45.46 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 105.697 -1.964 . . . . 1.0 105.697 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -118.61 119.05 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 119.41 -0.916 . . . . 1.0 112.394 -176.685 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.59 ' CD2' HD11 ' A' ' 131' ' ' ILE . 4.2 t60 -110.81 122.66 48.38 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 114.096 -1.411 . . . . 1.0 108.654 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.49 112.13 23.89 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 120.364 -0.534 . . . . 1.0 112.378 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.59 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.3 mp -95.55 -45.04 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 116.015 -0.539 . . . . 1.0 111.412 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -151.05 157.82 43.31 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.827 0.346 . . . . 1.0 110.691 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.471 HG21 ' HA ' ' A' ' 44' ' ' LYS . 60.5 t -128.79 140.67 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 121.039 0.447 . . . . 1.0 111.51 -177.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.7 tptt . . . . . 0 CA--C 1.534 0.33 0 CA-C-O 121.942 0.877 . . . . 1.0 111.22 179.911 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 . . . . . 0 CA--C 1.515 -0.378 0 CA-C-O 122.023 0.916 . . . . 1.0 110.646 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.562 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.8 m-20 -59.59 -37.47 78.63 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 114.608 -1.178 . . . . 1.0 108.221 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -67.46 -52.14 42.97 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.183 -1.371 . . . . 1.0 111.495 179.541 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.92 -48.37 75.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 119.736 -0.786 . . . . 1.0 112.058 -177.188 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.449 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -63.36 -35.54 80.73 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.015 -1.106 . . . . 1.0 108.015 178.982 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.475 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -74.54 -43.57 29.61 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 114.754 -1.112 . . . . 1.0 112.054 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.3 mt-10 -61.72 -31.25 71.39 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.907 -0.775 . . . . 1.0 108.907 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.39 -32.08 48.67 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.441 -0.8 . . . . 1.0 110.04 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -62.44 -49.12 76.7 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.579 -1.191 . . . . 1.0 110.762 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.73 -40.1 76.4 Favored 'General case' 0 C--N 1.32 -0.686 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.892 178.439 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.4 m -61.04 -41.7 97.09 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.814 -0.63 . . . . 1.0 109.481 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -75.48 -46.52 31.94 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.31 -0.859 . . . . 1.0 111.575 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.9 t30 -60.37 -44.91 95.17 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 113.016 0.747 . . . . 1.0 113.016 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -60.42 -28.84 68.58 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 119.47 -0.892 . . . . 1.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-20 -80.25 -30.02 38.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.191 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -59.4 142.95 86.35 Favored Pre-proline 0 CA--C 1.55 0.951 0 N-CA-C 112.268 0.47 . . . . 1.0 112.268 -177.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.06 149.05 65.08 Favored 'Trans proline' 0 N--CA 1.505 2.195 0 C-N-CA 122.499 2.132 . . . . 1.0 113.362 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.72 -19.37 5.08 Favored Glycine 0 C--O 1.225 -0.412 0 CA-C-N 115.601 -0.727 . . . . 1.0 112.189 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.5 t -85.11 136.28 23.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.148 0.499 . . . . 1.0 110.833 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.91 124.24 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 107.854 -1.165 . . . . 1.0 107.854 177.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.4 p -97.24 146.32 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-O 121.71 0.767 . . . . 1.0 111.811 -178.354 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.29 165.05 14.11 Favored Pre-proline 0 C--O 1.232 0.14 0 CA-C-N 114.355 -1.293 . . . . 1.0 110.856 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -61.37 -30.24 87.01 Favored 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 121.983 1.789 . . . . 1.0 111.379 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -68.51 -14.47 63.03 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.591 -0.731 . . . . 1.0 109.387 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.93 -2.1 68.88 Favored Glycine 0 C--O 1.229 -0.158 0 N-CA-C 109.734 -1.346 . . . . 1.0 109.734 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.437 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.54 132.78 35.71 Favored 'General case' 0 CA--C 1.519 -0.25 0 N-CA-C 108.411 -0.959 . . . . 1.0 108.411 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.437 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.7 mp0 -119.62 140.96 49.77 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-N 116.196 -0.456 . . . . 1.0 110.869 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -136.37 147.85 47.56 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 121.6 0.714 . . . . 1.0 111.143 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.538 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -130.64 132.54 45.51 Favored 'General case' 0 CA--C 1.501 -0.932 0 CA-C-N 114.479 -1.237 . . . . 1.0 109.317 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.16 104.85 15.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.281 1.038 . . . . 1.0 112.356 -178.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.63 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.3 mm -70.7 -41.64 77.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.039 -0.982 . . . . 1.0 108.72 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -143.6 131.52 21.59 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 114.639 -1.164 . . . . 1.0 109.792 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.8 p -90.3 129.1 36.57 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.857 -0.423 . . . . 1.0 109.857 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.74 -33.2 1.32 Allowed Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 54.32 30.83 13.22 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.287 -0.457 . . . . 1.0 110.577 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.33 -162.22 37.78 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-O 121.789 0.66 . . . . 1.0 111.669 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 23.4 m -68.28 -177.54 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.266 -0.967 . . . . 1.0 109.375 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.606 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.56 154.58 0.35 Allowed Pre-proline 0 C--N 1.317 -0.832 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 179.54 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.436 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.9 Cg_endo -88.21 160.4 7.03 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.162 2.575 . . . . 1.0 116.189 -175.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.422 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 174.22 39.06 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 108.096 -2.001 . . . . 1.0 108.096 175.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.607 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -49.26 -25.81 2.58 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.99 -0.605 . . . . 1.0 111.439 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.438 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 9.4 m -107.24 -9.21 16.15 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -177.595 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.6 m-20 -84.18 165.92 18.01 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 119.708 -0.797 . . . . 1.0 108.975 179.222 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.415 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.2 m -103.24 151.86 22.17 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-O 121.224 0.535 . . . . 1.0 109.948 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.8 p -129.66 161.82 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.389 0 CA-C-N 115.292 -0.867 . . . . 1.0 112.114 -176.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -132.12 118.17 19.26 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 108.67 -0.863 . . . . 1.0 108.67 177.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.418 ' HB ' ' O ' ' A' ' 129' ' ' HIS . 2.5 m -148.1 166.98 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.883 0.697 . . . . 1.0 112.883 -177.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.1 mt-10 -116.93 154.04 31.53 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 106.909 -1.515 . . . . 1.0 106.909 175.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.521 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.1 p90 -165.07 163.55 20.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 114.82 1.415 . . . . 1.0 114.82 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -126.24 128.97 48.03 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 107.895 -1.15 . . . . 1.0 107.895 174.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.68 12.25 Favored Glycine 0 N--CA 1.47 0.905 0 C-N-CA 120.687 -0.768 . . . . 1.0 111.757 -178.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.3 ptp180 -146.23 167.02 24.52 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.95 0.881 . . . . 1.0 112.632 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.483 HD11 HD13 ' A' ' 118' ' ' ILE . 3.0 mp -81.76 163.79 22.16 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.065 -1.425 . . . . 1.0 110.147 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.19 -24.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 114.942 -1.026 . . . . 1.0 109.77 177.749 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -96.25 4.69 52.19 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 113.648 -1.615 . . . . 1.0 111.791 -177.267 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.05 80.51 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.788 -0.72 . . . . 1.0 113.316 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 m -72.83 111.51 8.03 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.112 -1.035 . . . . 1.0 109.422 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.02 120.17 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-O 121.543 0.687 . . . . 1.0 111.171 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.591 ' CG ' HD11 ' A' ' 118' ' ' ILE . 23.3 p90 -108.47 -9.81 15.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.884 -1.053 . . . . 1.0 111.613 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.578 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 4.1 p-10 -161.62 149.24 14.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.977 -0.556 . . . . 1.0 110.829 178.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 68.9 p -156.15 149.44 24.51 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.61 -0.723 . . . . 1.0 111.108 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.521 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 46.1 m -155.98 -42.0 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.602 -0.726 . . . . 1.0 110.967 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.413 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.8 pp20? -63.18 -26.95 69.04 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.742 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.7 mmtp -54.37 -43.15 71.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.699 -1.223 . . . . 1.0 107.699 178.265 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 28.5 p -76.3 -34.85 59.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.096 -1.411 . . . . 1.0 109.102 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.6 15.5 70.78 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.357 -0.838 . . . . 1.0 111.144 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -97.97 115.27 65.77 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 120.402 -0.519 . . . . 1.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.408 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 33.8 Cg_exo -59.83 153.24 58.11 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 122.022 1.814 . . . . 1.0 114.114 -178.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.97 150.73 46.36 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.059 -1.428 . . . . 1.0 108.069 178.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.29 129.65 55.7 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.014 0.746 . . . . 1.0 113.014 -178.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -140.98 153.02 45.4 Favored 'General case' 0 CA--C 1.502 -0.88 0 CA-C-N 114.678 -1.146 . . . . 1.0 108.795 177.463 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -90.44 127.18 36.14 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 106.359 -1.719 . . . . 1.0 106.359 174.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.4 t -46.79 -34.45 2.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.351 -0.539 . . . . 1.0 110.471 -178.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -73.56 -24.34 60.09 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 120.467 -0.493 . . . . 1.0 112.323 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -100.13 -12.0 20.0 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 113.618 0.969 . . . . 1.0 113.618 -177.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 83' ' ' ILE . 5.4 p -84.44 177.93 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 119.656 -0.818 . . . . 1.0 110.455 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.644 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.95 146.51 37.76 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.595 -177.198 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -51.54 -44.55 43.2 Favored 'Trans proline' 0 N--CA 1.499 1.817 0 C-N-CA 121.896 1.73 . . . . 1.0 112.527 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.48 -47.4 90.06 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.549 -1.42 . . . . 1.0 109.549 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.1 m95 -63.83 -36.06 82.68 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.287 -0.956 . . . . 1.0 110.04 179.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.2 m -52.23 -52.95 49.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.674 -0.411 . . . . 1.0 110.904 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -72.32 -45.35 60.34 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.891 -0.595 . . . . 1.0 112.444 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.34 -48.46 76.72 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 113.925 1.083 . . . . 1.0 113.925 -177.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 32.7 mt -57.93 -42.66 85.31 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-O 121.084 0.469 . . . . 1.0 109.959 -177.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -62.65 -23.27 67.01 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 115.615 -0.721 . . . . 1.0 110.289 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.6 mt -101.79 -14.4 17.31 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.876 -0.602 . . . . 1.0 111.266 -179.131 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.2 ttp -88.98 108.18 22.25 Favored Pre-proline 0 CA--C 1.547 0.833 0 N-CA-C 111.991 0.367 . . . . 1.0 111.991 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.606 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.2 Cg_exo -66.06 148.08 85.07 Favored 'Trans proline' 0 N--CA 1.499 1.842 0 C-N-CA 122.438 2.092 . . . . 1.0 112.162 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.96 137.53 58.05 Favored 'General case' 0 CA--C 1.507 -0.695 0 CA-C-O 121.493 0.663 . . . . 1.0 111.331 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.16 -18.57 55.91 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.252 -1.939 . . . . 1.0 108.252 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.4 p -89.39 128.41 35.92 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 121.263 0.554 . . . . 1.0 110.735 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 89.9 m -103.56 114.24 28.36 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 115.392 -0.822 . . . . 1.0 109.944 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.483 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.6 m0 -116.04 164.9 13.77 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 121.442 0.639 . . . . 1.0 110.882 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.63 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.8 mt-10 -123.59 129.14 50.71 Favored 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 106.394 -1.706 . . . . 1.0 106.394 175.774 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -125.93 138.9 53.07 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.665 0 CA-C-O 121.926 0.869 . . . . 1.0 110.376 -179.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.749 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.27 104.12 13.2 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.928 -1.878 . . . . 1.0 105.928 -178.16 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.6 t -90.4 115.95 65.28 Favored Pre-proline 0 C--N 1.326 -0.415 0 N-CA-C 114.879 1.437 . . . . 1.0 114.879 -174.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -51.21 143.49 32.86 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 121.276 1.317 . . . . 1.0 110.021 175.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 92.4 p -49.26 -35.17 16.99 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.426 -0.51 . . . . 1.0 110.423 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.0 81.51 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 111.174 -0.77 . . . . 1.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -101.25 3.24 40.67 Favored 'General case' 0 C--O 1.225 -0.189 0 CA-C-O 119.771 -0.157 . . . . 1.0 110.872 -179.148 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.23 -112.33 0.29 Allowed 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.487 0.184 . . . . 1.0 110.554 -178.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -98.32 4.85 48.66 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 113.405 0.891 . . . . 1.0 113.405 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 115.14 162.97 13.87 Favored Glycine 0 N--CA 1.47 0.911 0 C-N-CA 120.996 -0.621 . . . . 1.0 112.969 177.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 121' ' ' ASN . 96.3 Cg_endo -76.16 -9.4 19.15 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 123.626 2.884 . . . . 1.0 111.0 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -109.19 168.9 9.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.498 -0.774 . . . . 1.0 109.446 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.1 m -73.86 96.37 2.58 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.0 t -111.91 60.25 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-N 116.244 -0.434 . . . . 1.0 110.444 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.55 172.46 36.19 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.35 -0.7 . . . . 1.0 111.35 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.59 -103.19 0.01 OUTLIER Glycine 0 CA--C 1.535 1.337 0 N-CA-C 111.226 -0.75 . . . . 1.0 111.226 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -58.04 -11.42 10.03 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.754 2.303 . . . . 1.0 111.628 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.591 HD11 ' CG ' ' A' ' 65' ' ' PHE . 14.9 mm -66.96 125.55 24.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-N 114.716 -1.129 . . . . 1.0 109.138 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -102.63 -175.86 27.12 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.321 -0.854 . . . . 1.0 111.249 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.562 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 21.6 Cg_endo -62.38 142.23 90.09 Favored 'Trans proline' 0 C--N 1.295 -2.25 0 C-N-CA 122.384 2.056 . . . . 1.0 111.756 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.531 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 45.79 55.39 6.93 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 120.796 -0.362 . . . . 1.0 111.103 178.11 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.521 ' OE2' ' ND2' ' A' ' 8' ' ' ASN . 3.3 tp10 -102.34 130.03 48.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.987 -0.552 . . . . 1.0 111.412 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.426 HG21 HD11 ' A' ' 16' ' ' LEU . 46.4 m -95.36 129.79 42.38 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.007 -1.109 . . . . 1.0 108.007 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.449 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.64 148.8 33.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.423 0.63 . . . . 1.0 111.114 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.749 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -124.58 149.29 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.041 -0.981 . . . . 1.0 108.485 178.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.6 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -140.52 149.82 42.94 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 120.479 -0.488 . . . . 1.0 111.522 178.033 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 13.9 mmtt -99.42 127.07 45.44 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 104.768 -2.308 . . . . 1.0 104.768 176.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -121.18 121.13 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 119.259 -0.976 . . . . 1.0 112.138 -177.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.55 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.1 t60 -113.75 120.71 41.73 Favored 'General case' 0 C--O 1.223 -0.327 0 CA-C-N 114.157 -1.383 . . . . 1.0 108.612 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.35 111.89 23.63 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 120.014 -0.675 . . . . 1.0 112.519 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.55 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.1 mp -94.14 -45.14 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-N 116.222 -0.444 . . . . 1.0 111.12 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -150.74 155.58 39.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.85 0.357 . . . . 1.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.424 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.7 t -128.7 139.09 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.285 -0.416 . . . . 1.0 111.326 -178.756 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.415 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.6 tptm . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 121.599 0.714 . . . . 1.0 110.057 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 121.785 0.803 . . . . 1.0 110.54 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.608 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 12.9 m-20 -61.49 -35.33 77.36 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.004 -1.11 . . . . 1.0 108.004 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.405 ' O ' ' N ' ' A' ' 13' ' ' GLU . 55.6 tttt -66.76 -51.02 60.68 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.385 -1.734 . . . . 1.0 111.571 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.8 t -66.87 -48.85 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.276 0 C-N-CA 119.979 -0.688 . . . . 1.0 111.393 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.445 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -62.84 -38.64 91.59 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.639 -1.245 . . . . 1.0 107.639 179.034 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.492 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.54 -42.77 71.51 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 114.868 -1.06 . . . . 1.0 111.875 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.405 ' N ' ' O ' ' A' ' 9' ' ' LYS . 33.8 mt-10 -62.67 -33.27 74.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.438 -0.949 . . . . 1.0 108.438 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.3 -34.25 59.05 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 114.791 -1.095 . . . . 1.0 109.798 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -61.89 -51.11 69.5 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 114.492 -1.231 . . . . 1.0 110.762 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.66 -40.18 76.6 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.061 -0.656 . . . . 1.0 109.733 178.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.441 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 97.7 m -61.07 -42.06 97.78 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.505 -0.771 . . . . 1.0 109.13 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -75.74 -47.35 26.35 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.006 -0.997 . . . . 1.0 111.9 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.661 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 49.5 t30 -58.7 -45.4 89.6 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -177.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.5 -29.35 67.79 Favored 'General case' 0 C--N 1.315 -0.909 0 C-N-CA 119.303 -0.959 . . . . 1.0 109.154 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.441 ' ND2' ' O ' ' A' ' 17' ' ' THR . 7.4 m-80 -82.0 -29.69 31.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.372 -0.831 . . . . 1.0 111.591 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -59.74 146.08 81.92 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 120.48 -0.488 . . . . 1.0 111.371 -178.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.14 148.47 69.35 Favored 'Trans proline' 0 N--CA 1.504 2.094 0 C-N-CA 122.525 2.15 . . . . 1.0 113.791 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.89 -18.61 5.88 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.492 -0.776 . . . . 1.0 112.625 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.2 136.95 21.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.219 0.533 . . . . 1.0 111.286 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -121.66 126.03 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 107.64 -1.244 . . . . 1.0 107.64 177.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -100.73 145.62 10.81 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 CA-C-O 121.828 0.823 . . . . 1.0 112.266 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.1 mt -112.31 166.17 11.52 Favored Pre-proline 0 CA--C 1.529 0.155 0 CA-C-N 114.1 -1.409 . . . . 1.0 111.357 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.87 -30.7 84.4 Favored 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.188 1.926 . . . . 1.0 111.358 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.1 m -68.52 -14.42 62.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.839 -0.618 . . . . 1.0 109.8 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.14 -0.96 66.94 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 109.593 -1.403 . . . . 1.0 109.593 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.449 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -81.21 133.39 35.44 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.511 -0.922 . . . . 1.0 108.511 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.449 ' H ' HD22 ' A' ' 32' ' ' LEU . 21.2 mp0 -120.94 143.38 49.01 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.91 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -138.2 143.86 40.4 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 121.712 0.767 . . . . 1.0 110.734 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.513 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.53 132.83 49.86 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-N 114.504 -1.225 . . . . 1.0 109.106 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 p -90.82 104.9 15.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 122.148 0.975 . . . . 1.0 111.86 -178.156 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.6 mm -70.09 -42.34 79.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.222 -0.899 . . . . 1.0 108.671 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -140.27 128.04 21.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 114.619 -1.173 . . . . 1.0 109.627 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 p -88.57 127.22 35.54 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.736 -0.468 . . . . 1.0 109.736 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.36 -34.53 1.19 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 110.683 -0.967 . . . . 1.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 56.02 32.01 19.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.99 0.424 . . . . 1.0 110.737 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.41 -161.0 36.84 Favored Glycine 0 C--N 1.333 0.37 0 CA-C-O 121.924 0.736 . . . . 1.0 111.769 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.596 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.3 m -69.69 -178.09 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 114.084 -1.058 . . . . 1.0 109.289 178.208 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.424 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 154.84 0.37 Allowed Pre-proline 0 C--N 1.32 -0.694 0 O-C-N 123.829 0.705 . . . . 1.0 109.549 179.387 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -87.15 156.17 8.3 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 123.091 2.528 . . . . 1.0 115.993 -175.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.29 175.12 44.22 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 108.778 -1.729 . . . . 1.0 108.778 176.187 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.558 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.68 -22.44 5.14 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 120.82 -0.352 . . . . 1.0 111.14 -179.402 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.8 m -107.41 -9.9 15.88 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.245 0.831 . . . . 1.0 113.245 -177.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -84.58 168.99 14.85 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 119.867 -0.733 . . . . 1.0 109.028 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.406 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -107.66 152.1 24.76 Favored 'General case' 0 CA--C 1.513 -0.466 0 N-CA-C 109.618 -0.512 . . . . 1.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -128.31 160.1 38.83 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.405 0 CA-C-N 115.741 -0.663 . . . . 1.0 112.285 -176.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 74' ' ' PRO . 85.9 m -126.3 120.19 29.3 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 107.729 -1.212 . . . . 1.0 107.729 177.482 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.609 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 27.0 m -148.98 163.32 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 N-CA-C 114.291 1.219 . . . . 1.0 114.291 -175.79 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -118.44 150.67 39.18 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 106.41 -1.7 . . . . 1.0 106.41 174.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.5 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.9 p90 -163.75 163.53 24.03 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 118.393 -1.323 . . . . 1.0 114.506 -177.567 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -125.11 130.05 51.44 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 115.261 -0.881 . . . . 1.0 108.848 175.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.38 136.56 13.6 Favored Glycine 0 N--CA 1.468 0.787 0 C-N-CA 121.005 -0.617 . . . . 1.0 111.602 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -148.72 166.88 27.07 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.674 0.749 . . . . 1.0 112.533 179.385 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -84.28 164.38 19.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 114.456 -1.247 . . . . 1.0 110.502 178.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.45 -24.88 32.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.918 -1.037 . . . . 1.0 110.528 178.149 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.67 4.5 53.76 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.566 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.95 -5.23 81.95 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.016 178.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.6 m -67.14 103.39 1.2 Allowed 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.569 -0.853 . . . . 1.0 110.067 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.4 t -74.93 125.99 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.853 0 C-N-CA 120.347 -0.541 . . . . 1.0 109.702 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.589 ' CD2' HD11 ' A' ' 118' ' ' ILE . 28.0 p90 -117.48 -10.81 10.59 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 114.993 -1.003 . . . . 1.0 111.471 -179.215 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t0 -157.41 150.76 23.79 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.401 -0.52 . . . . 1.0 111.65 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -159.59 151.79 20.89 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.632 -0.713 . . . . 1.0 111.817 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.5 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.3 m -151.25 -42.1 0.12 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.342 -0.845 . . . . 1.0 110.183 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.45 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -62.09 -27.93 69.26 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-N 116.018 -0.537 . . . . 1.0 109.672 179.379 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -56.73 -43.3 80.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 107.741 -1.207 . . . . 1.0 107.741 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -75.14 -33.4 61.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.632 -1.167 . . . . 1.0 107.974 176.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.12 18.39 67.28 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 115.639 -0.71 . . . . 1.0 111.957 178.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -101.18 115.87 64.61 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 120.882 -0.327 . . . . 1.0 110.629 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.448 ' HB3' HG22 ' A' ' 52' ' ' THR . 37.2 Cg_exo -60.61 152.5 68.23 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 121.754 1.636 . . . . 1.0 114.282 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.35 150.99 42.97 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.094 -1.412 . . . . 1.0 107.926 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.99 125.31 50.84 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.589 0.588 . . . . 1.0 112.589 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -132.93 147.8 52.29 Favored 'General case' 0 CA--C 1.502 -0.892 0 CA-C-N 115.367 -0.833 . . . . 1.0 109.222 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -90.63 127.93 36.45 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.268 -1.752 . . . . 1.0 106.268 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.1 t -52.75 -33.5 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 C-N-CA 119.6 -0.84 . . . . 1.0 110.149 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 3.3 t -74.06 -26.66 60.52 Favored 'General case' 0 CA--C 1.515 -0.401 0 C-N-CA 120.21 -0.596 . . . . 1.0 111.651 -178.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 21.6 mm100 -100.29 -3.76 30.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.312 -0.404 . . . . 1.0 111.873 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -84.3 166.58 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 CA-C-N 118.233 0.469 . . . . 1.0 111.406 -178.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.8 147.28 15.94 Favored Pre-proline 0 N--CA 1.474 0.756 0 N-CA-C 109.093 -0.706 . . . . 1.0 109.093 -177.701 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -50.9 -43.55 46.59 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.747 1.631 . . . . 1.0 112.701 -178.125 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.19 92.29 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 119.57 -1.3 . . . . 1.0 110.018 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.609 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.4 m95 -64.32 -35.91 82.41 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.369 -0.916 . . . . 1.0 110.398 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 25.1 m -51.0 -53.11 36.22 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.721 0.296 . . . . 1.0 111.67 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 20.5 tp10 -72.39 -41.62 66.11 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.738 0.644 . . . . 1.0 112.738 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.66 -45.45 91.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 114.036 1.125 . . . . 1.0 114.036 -177.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.04 -41.91 88.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.263 0.554 . . . . 1.0 109.761 -177.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.0 mt-30 -64.66 -24.61 67.64 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.705 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.496 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 59.8 mt -101.9 -10.67 19.62 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.182 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.7 ttp -91.78 107.39 22.08 Favored Pre-proline 0 CA--C 1.546 0.789 0 O-C-N 123.154 0.283 . . . . 1.0 111.639 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.424 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -66.93 147.69 80.8 Favored 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.508 2.139 . . . . 1.0 111.98 178.542 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.596 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.59 139.55 58.78 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-O 121.686 0.755 . . . . 1.0 111.429 -179.022 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.78 -18.76 54.81 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.123 -1.991 . . . . 1.0 108.123 -178.241 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.4 p -89.88 129.6 36.22 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.037 0.446 . . . . 1.0 110.621 179.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 85.1 m -103.44 114.22 28.33 Favored 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 115.659 -0.701 . . . . 1.0 109.855 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.496 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -115.98 161.94 18.11 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.742 0.782 . . . . 1.0 111.487 -178.611 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.4 mt-10 -121.57 125.61 47.16 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.162 -1.421 . . . . 1.0 107.162 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -120.9 138.03 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.564 0 CA-C-O 121.8 0.81 . . . . 1.0 109.838 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.724 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.0 103.4 12.42 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -177.983 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.27 116.25 65.94 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 115.022 1.49 . . . . 1.0 115.022 -174.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -51.39 142.58 37.44 Favored 'Trans proline' 0 C--N 1.315 -1.191 0 C-N-CA 121.361 1.374 . . . . 1.0 109.81 176.47 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 97.6 p -48.61 -35.28 13.25 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.31 -0.556 . . . . 1.0 111.185 -178.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.75 -32.77 82.22 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.153 -0.779 . . . . 1.0 111.153 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.5 mt -98.46 2.49 47.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.957 -0.121 . . . . 1.0 110.91 -179.067 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.45 -110.77 0.31 Allowed 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 112.029 0.381 . . . . 1.0 112.029 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.439 ' O ' HG21 ' A' ' 114' ' ' VAL . 44.4 m-85 -96.88 4.31 51.7 Favored 'General case' 0 C--N 1.342 0.249 0 N-CA-C 112.288 0.477 . . . . 1.0 112.288 -177.853 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.11 162.87 17.93 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 121.172 -0.537 . . . . 1.0 112.831 177.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 121' ' ' ASN . 83.3 Cg_endo -76.9 -10.23 18.17 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 123.423 2.749 . . . . 1.0 111.4 179.229 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 5.9 ttm-85 -105.15 168.45 9.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.252 -0.885 . . . . 1.0 109.51 -179.545 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.518 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -74.18 100.04 3.56 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.3 -0.629 . . . . 1.0 109.3 178.746 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 109' ' ' TYR . 14.0 t -110.9 61.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.76 0.314 . . . . 1.0 110.831 -179.337 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 159.15 175.73 30.41 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 120.472 -0.87 . . . . 1.0 112.44 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.42 -103.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.328 0 CA-C-N 114.963 -0.619 . . . . 1.0 111.87 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -61.87 -16.95 52.62 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 122.613 2.208 . . . . 1.0 111.773 -177.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.691 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.3 mp -67.4 114.56 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 108.343 -0.984 . . . . 1.0 108.343 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.416 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.98 -171.02 38.53 Favored Glycine 0 N--CA 1.452 -0.258 0 N-CA-C 110.949 -0.86 . . . . 1.0 110.949 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.518 ' N ' ' OG ' ' A' ' 113' ' ' SER . 34.1 Cg_endo -64.01 139.55 67.97 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.318 2.012 . . . . 1.0 112.627 179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.588 ' O ' ' ND2' ' A' ' 121' ' ' ASN . 0.5 OUTLIER 52.59 48.85 21.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.439 -0.346 . . . . 1.0 111.371 178.132 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.608 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -93.14 132.58 37.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.541 -0.3 . . . . 1.0 110.716 179.843 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.422 HG21 HD11 ' A' ' 16' ' ' LEU . 52.1 m -96.2 127.77 42.5 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.405 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.5 mm? -111.28 145.33 38.97 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.128 0.489 . . . . 1.0 110.468 -179.162 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.724 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -122.63 146.14 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.476 -0.783 . . . . 1.0 108.937 178.853 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.622 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.6 m-85 -136.33 149.65 48.49 Favored 'General case' 0 CA--C 1.517 -0.319 0 C-N-CA 120.26 -0.576 . . . . 1.0 111.509 178.005 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 12.6 mmtt -99.5 123.57 43.89 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 105.423 -2.065 . . . . 1.0 105.423 177.686 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.7 mt -118.94 118.1 56.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 119.112 -1.035 . . . . 1.0 112.879 -176.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.559 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.6 t60 -108.65 126.22 52.73 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 113.572 -1.649 . . . . 1.0 108.278 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 111.3 23.42 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 119.871 -0.732 . . . . 1.0 112.271 -178.124 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.559 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.2 mp -93.71 -45.93 13.76 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.852 -0.613 . . . . 1.0 111.676 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.6 p -150.84 156.03 40.41 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.575 -0.45 . . . . 1.0 110.84 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.402 HG21 ' HA ' ' A' ' 44' ' ' LYS . 56.9 t -128.0 141.45 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.969 -0.559 . . . . 1.0 111.395 -178.118 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.406 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.2 tptm . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.638 -0.71 . . . . 1.0 110.33 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.687 0.756 . . . . 1.0 110.419 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.4 m-20 -58.02 -34.01 69.57 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.501 -0.926 . . . . 1.0 108.501 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -66.21 -51.08 61.1 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.406 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.99 -48.22 82.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 119.942 -0.703 . . . . 1.0 111.614 -178.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.453 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.8 -38.95 92.74 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.785 -1.191 . . . . 1.0 107.785 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.413 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.08 -46.27 52.11 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-N 114.779 -1.101 . . . . 1.0 112.631 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -59.53 -34.97 73.32 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.288 -0.965 . . . . 1.0 108.492 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.58 -36.14 65.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.94 -1.027 . . . . 1.0 110.401 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -61.31 -50.4 73.12 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.879 -1.055 . . . . 1.0 110.628 -179.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.416 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -67.1 -39.81 86.78 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 119.783 -0.767 . . . . 1.0 109.461 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.499 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 19.9 m -61.86 -42.16 98.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.743 -0.662 . . . . 1.0 109.657 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -75.24 -45.46 39.98 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.661 -0.699 . . . . 1.0 111.845 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.647 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.8 t30 -61.65 -44.65 96.57 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 113.18 0.807 . . . . 1.0 113.18 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -59.74 -34.9 73.55 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.27 -0.972 . . . . 1.0 108.578 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 17' ' ' THR . 77.5 m-20 -71.51 -36.29 71.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.158 -0.928 . . . . 1.0 111.991 178.789 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 mtmt -55.78 135.66 72.24 Favored Pre-proline 0 CA--C 1.546 0.808 0 CA-C-N 116.412 -0.358 . . . . 1.0 111.588 -178.071 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.76 148.37 66.33 Favored 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.202 1.935 . . . . 1.0 113.627 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.06 -19.71 20.4 Favored Glycine 0 C--O 1.226 -0.394 0 CA-C-N 115.136 -0.938 . . . . 1.0 111.004 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.5 t -85.17 136.0 23.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.161 0.505 . . . . 1.0 110.155 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.07 121.46 65.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 107.767 -1.197 . . . . 1.0 107.767 178.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 p -95.93 145.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.648 0.737 . . . . 1.0 111.703 -177.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.55 164.15 16.06 Favored Pre-proline 0 C--N 1.334 -0.106 0 CA-C-N 114.455 -1.248 . . . . 1.0 110.437 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.57 -30.81 86.6 Favored 'Trans proline' 0 C--N 1.318 -1.059 0 C-N-CA 121.634 1.556 . . . . 1.0 111.339 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 m -69.33 -10.73 59.23 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.925 -0.579 . . . . 1.0 109.912 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.35 -2.8 71.5 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 110.232 -1.147 . . . . 1.0 110.232 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.482 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -79.17 133.27 36.72 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 108.628 -0.879 . . . . 1.0 108.628 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.482 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.4 mp0 -122.8 139.54 53.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.395 -0.366 . . . . 1.0 110.983 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -135.5 143.13 45.63 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.675 0.75 . . . . 1.0 110.913 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.534 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.2 tmtp? -126.58 132.9 51.19 Favored 'General case' 0 CA--C 1.503 -0.86 0 CA-C-N 114.645 -1.161 . . . . 1.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.78 104.66 15.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.167 0.984 . . . . 1.0 111.906 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.621 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.5 mm -69.58 -41.86 80.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 108.007 -1.108 . . . . 1.0 108.007 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -142.36 129.64 21.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.573 -1.194 . . . . 1.0 109.804 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.7 p -88.49 131.35 34.93 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.764 -0.458 . . . . 1.0 109.764 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.0 -33.25 1.08 Allowed Glycine 0 C--N 1.331 0.291 0 N-CA-C 110.051 -1.219 . . . . 1.0 110.051 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.402 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 5.5 m-20 54.7 30.93 14.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.375 -0.413 . . . . 1.0 110.958 179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.31 -162.3 37.85 Favored Glycine 0 C--N 1.331 0.281 0 CA-C-O 121.905 0.725 . . . . 1.0 111.957 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.5 m -68.81 -178.63 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 113.905 -1.148 . . . . 1.0 109.125 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.674 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.49 154.77 0.4 Allowed Pre-proline 0 C--N 1.321 -0.631 0 O-C-N 123.705 0.628 . . . . 1.0 109.948 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.404 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.0 Cg_endo -87.33 154.43 8.0 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 123.439 2.759 . . . . 1.0 116.971 -174.486 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.45 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.55 177.2 48.47 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 109.141 -1.584 . . . . 1.0 109.141 175.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.504 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.37 -25.43 15.43 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.963 -0.295 . . . . 1.0 111.507 -179.722 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.6 m -108.03 -5.11 17.23 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.815 0.672 . . . . 1.0 112.815 -176.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.45 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 66.6 m-20 -83.49 165.36 19.2 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.4 m -106.52 150.31 26.25 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 109.636 -0.505 . . . . 1.0 109.636 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -129.39 162.94 35.9 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.465 0 CA-C-N 116.126 -0.488 . . . . 1.0 111.982 -176.399 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 51' ' ' VAL . 98.5 m -130.15 119.63 23.3 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 108.52 -0.918 . . . . 1.0 108.52 177.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.501 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.7 m -148.18 165.17 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 114.885 1.439 . . . . 1.0 114.885 -177.006 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.416 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.2 mt-10 -118.89 145.07 46.02 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 106.568 -1.642 . . . . 1.0 106.568 174.189 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.525 ' O ' ' N ' ' A' ' 68' ' ' THR . 38.8 p90 -161.11 164.07 30.94 Favored 'General case' 0 C--N 1.344 0.357 0 N-CA-C 114.825 1.417 . . . . 1.0 114.825 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -127.13 127.86 45.26 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 115.158 -0.928 . . . . 1.0 108.792 175.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.8 134.1 11.61 Favored Glycine 0 N--CA 1.473 1.114 0 C-N-CA 120.933 -0.651 . . . . 1.0 111.92 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.7 ptp85 -147.86 170.31 17.92 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.866 0.841 . . . . 1.0 113.071 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -83.58 164.08 19.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 114.126 -1.397 . . . . 1.0 110.795 178.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.449 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.3 -25.86 35.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.017 -0.992 . . . . 1.0 110.769 178.329 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -95.25 6.01 50.18 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.564 -1.198 . . . . 1.0 111.857 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.39 -3.46 75.69 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 121.01 -0.614 . . . . 1.0 113.313 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 m -71.78 106.58 4.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 118.157 0.978 . . . . 1.0 110.228 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 54.5 t -76.33 130.41 36.25 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.232 0.539 . . . . 1.0 110.575 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -120.37 -14.45 8.73 Favored 'General case' 0 CA--C 1.522 -0.112 0 CA-C-N 115.11 -0.95 . . . . 1.0 111.208 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 67' ' ' SER . 30.4 t0 -155.38 151.83 28.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.379 -0.373 . . . . 1.0 111.098 178.373 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 87.8 p -160.84 154.61 22.41 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 112.723 0.638 . . . . 1.0 112.723 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 55' ' ' TYR . 85.3 m -155.3 -42.01 0.08 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.143 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.405 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 2.0 pp20? -61.32 -26.19 67.63 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.602 -0.439 . . . . 1.0 110.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -53.83 -42.73 68.8 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.212 -1.033 . . . . 1.0 108.212 178.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' A' ' 68' ' ' THR . 21.6 p -78.36 -30.61 48.08 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.957 -1.019 . . . . 1.0 108.956 177.213 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.75 17.16 73.56 Favored Glycine 0 C--N 1.337 0.593 0 N-CA-C 111.363 -0.695 . . . . 1.0 111.363 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 7.2 mptt -99.89 115.94 65.12 Favored Pre-proline 0 N--CA 1.469 0.492 0 C-N-CA 120.987 -0.285 . . . . 1.0 110.498 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.416 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 37.2 Cg_exo -61.13 152.49 71.33 Favored 'Trans proline' 0 N--CA 1.483 0.867 0 C-N-CA 121.646 1.564 . . . . 1.0 113.964 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.31 149.53 46.44 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.335 -1.302 . . . . 1.0 107.612 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -103.58 131.76 50.43 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.226 0.536 . . . . 1.0 112.219 -178.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -137.71 150.05 47.0 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 115.29 -0.868 . . . . 1.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -93.47 124.65 37.6 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.162 -1.792 . . . . 1.0 106.162 174.571 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.4 t -51.46 -27.1 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 C-N-CA 119.778 -0.769 . . . . 1.0 110.608 -176.815 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 42.4 t -76.32 -24.58 54.31 Favored 'General case' 0 CA--C 1.519 -0.224 0 C-N-CA 120.344 -0.542 . . . . 1.0 112.287 -179.159 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -98.56 -8.27 26.8 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 112.233 0.457 . . . . 1.0 112.233 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.4 p -83.08 168.8 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 119.961 -0.696 . . . . 1.0 111.852 -177.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.483 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -55.19 153.32 13.05 Favored Pre-proline 0 CA--C 1.548 0.867 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 -177.953 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.483 ' HD2' HG22 ' A' ' 83' ' ' ILE . 50.8 Cg_exo -53.28 -45.65 39.5 Favored 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.633 1.556 . . . . 1.0 112.948 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.11 -48.09 85.16 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.501 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 8.1 m95 -64.07 -35.74 81.74 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.101 -1.05 . . . . 1.0 110.108 179.267 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.4 m -52.17 -54.0 36.2 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.649 -0.42 . . . . 1.0 111.294 -178.2 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -72.71 -42.73 63.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.976 -0.557 . . . . 1.0 112.338 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.57 -47.36 79.69 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 113.848 1.055 . . . . 1.0 113.848 -177.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.2 mt -58.25 -41.76 84.9 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.365 0.603 . . . . 1.0 109.799 -178.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.5 mt-30 -63.24 -24.78 68.02 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.952 -1.022 . . . . 1.0 110.904 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.42 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 70.1 mt -101.65 -13.27 17.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.252 -0.431 . . . . 1.0 111.29 -179.209 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 36.5 ttp -88.04 108.99 24.31 Favored Pre-proline 0 CA--C 1.547 0.847 0 N-CA-C 112.249 0.463 . . . . 1.0 112.249 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.674 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.8 Cg_exo -66.37 147.77 83.33 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.274 1.983 . . . . 1.0 112.289 178.7 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.78 136.85 57.75 Favored 'General case' 0 CA--C 1.509 -0.627 0 CA-C-O 121.492 0.663 . . . . 1.0 111.503 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.08 -18.48 56.06 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 109.001 -1.64 . . . . 1.0 109.001 -178.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -86.99 133.67 33.56 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 120.894 0.378 . . . . 1.0 110.165 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 84.4 m -106.06 112.96 26.22 Favored 'General case' 0 CA--C 1.511 -0.557 0 CA-C-N 115.986 -0.552 . . . . 1.0 109.938 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.42 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.3 m0 -115.1 163.75 15.18 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.677 0.751 . . . . 1.0 111.544 -178.53 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.621 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.1 mt-10 -124.02 124.56 42.82 Favored 'General case' 0 CA--C 1.51 -0.566 0 N-CA-C 107.101 -1.444 . . . . 1.0 107.101 175.588 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -119.0 137.84 51.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.866 0.841 . . . . 1.0 110.086 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.714 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.84 103.42 12.21 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 105.707 -1.96 . . . . 1.0 105.707 -178.303 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 t -90.63 116.12 65.7 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 115.529 1.678 . . . . 1.0 115.529 -174.042 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -50.75 143.32 29.77 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 121.611 1.54 . . . . 1.0 110.23 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 79.9 p -49.76 -35.43 22.39 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.282 -0.567 . . . . 1.0 110.524 -178.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.02 -32.39 82.37 Favored Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.985 -0.846 . . . . 1.0 110.985 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 42.9 mt -100.87 2.64 41.17 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.877 -0.162 . . . . 1.0 110.898 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 83' ' ' ILE . . . -107.37 -104.53 0.34 Allowed 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 117.693 0.224 . . . . 1.0 110.511 -178.683 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.438 ' O ' HG21 ' A' ' 114' ' ' VAL . 53.5 m-85 -104.99 5.39 32.61 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 113.564 0.95 . . . . 1.0 113.564 -178.24 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 108.54 164.68 20.88 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.924 -0.655 . . . . 1.0 113.506 176.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.475 ' O ' ' N ' ' A' ' 121' ' ' ASN . 89.9 Cg_endo -75.11 -14.75 20.8 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 C-N-CA 123.618 2.878 . . . . 1.0 111.404 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.441 ' O ' HG23 ' A' ' 114' ' ' VAL . 58.1 mtm180 -101.28 165.98 11.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.115 -0.948 . . . . 1.0 109.586 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.448 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -75.21 97.71 3.58 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.411 -0.516 . . . . 1.0 109.844 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 112' ' ' ARG . 3.2 t -110.34 59.0 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.858 -179.181 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 167.81 -178.29 41.73 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 120.117 -1.04 . . . . 1.0 112.247 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -58.35 -106.4 0.01 OUTLIER Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.972 -0.451 . . . . 1.0 111.972 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -14.87 38.9 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 122.028 1.819 . . . . 1.0 111.011 -178.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.895 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -67.03 115.89 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 107.922 -1.14 . . . . 1.0 107.922 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.598 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -93.88 -160.72 34.98 Favored Glycine 0 C--O 1.215 -1.047 0 N-CA-C 110.398 -1.081 . . . . 1.0 110.398 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.448 ' N ' ' OG ' ' A' ' 113' ' ' SER . 74.2 Cg_endo -73.35 145.39 38.29 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 122.112 1.874 . . . . 1.0 112.756 178.22 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 111' ' ' PRO . 1.1 t30 45.24 59.92 3.28 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.782 0.66 . . . . 1.0 112.782 177.726 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.688 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -115.06 138.44 50.88 Favored 'General case' 0 N--CA 1.473 0.702 0 CA-C-O 121.62 0.724 . . . . 1.0 111.185 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.416 HG21 HD11 ' A' ' 16' ' ' LEU . 97.5 m -94.57 129.53 41.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.658 -1.155 . . . . 1.0 108.71 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.416 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.8 mm? -111.96 143.57 42.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.248 0.547 . . . . 1.0 110.076 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.714 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -122.44 148.15 26.25 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 108.659 -0.867 . . . . 1.0 108.659 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.34 150.94 47.08 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.051 0.453 . . . . 1.0 111.166 177.435 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.5 mmtt -100.25 123.33 44.35 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 105.721 -1.955 . . . . 1.0 105.721 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.423 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.8 119.0 58.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 119.143 -1.023 . . . . 1.0 113.056 -176.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.551 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.2 t60 -109.96 123.25 49.3 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 113.885 -1.507 . . . . 1.0 108.682 178.438 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.49 111.29 23.22 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 120.346 -0.542 . . . . 1.0 112.186 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.551 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.1 mp -93.46 -44.69 13.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.33 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -152.12 156.55 40.08 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.068 0.461 . . . . 1.0 111.03 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.439 HG21 ' HA ' ' A' ' 44' ' ' LYS . 49.1 t -129.82 134.71 62.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.969 -0.56 . . . . 1.0 110.446 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.9 tptm . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 122.011 0.91 . . . . 1.0 110.452 179.471 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 . . . . . 0 CA--C 1.511 -0.543 0 CA-C-O 121.929 0.871 . . . . 1.0 110.29 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.545 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 9.6 m-20 -57.28 -35.75 70.16 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.549 -1.205 . . . . 1.0 108.462 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 tttm -65.96 -51.9 54.36 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 113.651 -1.613 . . . . 1.0 111.602 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.5 t -69.96 -48.41 63.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 C-N-CA 119.881 -0.728 . . . . 1.0 112.162 -178.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.448 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.18 -39.77 93.79 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 108.113 -1.069 . . . . 1.0 108.113 179.56 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.14 73.53 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-N 115.148 -0.933 . . . . 1.0 111.913 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.419 ' O ' ' OG1' ' A' ' 17' ' ' THR . 88.9 mt-10 -61.35 -31.6 71.48 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.974 -0.75 . . . . 1.0 108.974 178.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -34.08 50.2 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.135 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -63.12 -50.45 70.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.388 -1.278 . . . . 1.0 110.774 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.466 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -73.41 -39.73 64.83 Favored 'General case' 0 CA--C 1.509 -0.618 0 C-N-CA 119.912 -0.715 . . . . 1.0 110.225 178.627 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.419 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 91.1 m -62.0 -42.84 99.59 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.347 -179.243 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -75.85 -46.79 28.46 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.859 -0.609 . . . . 1.0 112.243 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 59.8 t30 -60.89 -44.63 96.83 Favored 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 113.573 0.953 . . . . 1.0 113.573 -177.765 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -59.2 -35.08 72.96 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 119.706 -0.798 . . . . 1.0 109.7 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -73.75 -33.99 64.53 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.221 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -60.37 125.51 82.07 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-N 115.956 -0.565 . . . . 1.0 112.066 -178.124 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.27 149.92 15.64 Favored 'Trans proline' 0 N--CA 1.5 1.854 0 C-N-CA 122.168 1.912 . . . . 1.0 112.847 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.77 -20.14 33.53 Favored Glycine 0 C--O 1.224 -0.523 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 -179.302 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 35' ' ' LYS . 48.9 t -93.36 133.01 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 1.0 109.614 179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.1 t -117.41 120.83 66.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 108.528 -0.916 . . . . 1.0 108.528 177.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.1 p -96.34 146.08 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.623 0 CA-C-O 121.676 0.75 . . . . 1.0 111.393 -178.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 62.5 mt -113.56 164.22 16.42 Favored Pre-proline 0 C--N 1.332 -0.167 0 CA-C-N 114.438 -1.255 . . . . 1.0 110.958 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.07 -30.35 93.04 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.894 1.73 . . . . 1.0 110.913 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.5 m -67.93 -15.17 63.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.785 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.66 68.57 Favored Glycine 0 C--O 1.23 -0.139 0 N-CA-C 110.089 -1.205 . . . . 1.0 110.089 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.474 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.74 133.97 38.18 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 109.056 -0.72 . . . . 1.0 109.056 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.474 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.0 mp0 -123.12 137.77 54.83 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.1 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -133.73 143.16 48.31 Favored 'General case' 0 CA--C 1.504 -0.797 0 CA-C-O 121.739 0.78 . . . . 1.0 110.927 178.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -126.96 131.84 50.97 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 114.432 -1.258 . . . . 1.0 109.562 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -88.39 105.12 15.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 122.045 0.926 . . . . 1.0 111.922 -178.273 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.1 mm -69.44 -42.34 80.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.036 -0.984 . . . . 1.0 108.447 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.419 ' O ' ' OG ' ' A' ' 97' ' ' SER . 14.1 m120 -141.96 127.19 18.61 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.524 -1.216 . . . . 1.0 109.72 -179.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -86.73 130.96 34.27 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.803 0.335 . . . . 1.0 110.399 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.528 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -121.33 -36.01 0.77 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 109.914 -1.275 . . . . 1.0 109.914 179.597 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.414 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 6.3 m-20 58.48 32.81 22.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 1.0 111.593 179.058 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.9 -161.67 37.58 Favored Glycine 0 C--N 1.331 0.255 0 CA-C-O 121.861 0.7 . . . . 1.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 26.4 m -69.6 -178.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.07 -1.065 . . . . 1.0 109.494 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.719 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.47 154.43 0.45 Allowed Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 109.61 -0.515 . . . . 1.0 109.61 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HB2' ' HB2' ' A' ' 49' ' ' ASP . 60.1 Cg_endo -88.02 157.47 7.18 Favored 'Trans proline' 0 N--CA 1.503 2.077 0 C-N-CA 123.72 2.946 . . . . 1.0 117.454 -174.657 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.443 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.45 177.6 48.75 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 109.725 -1.35 . . . . 1.0 109.725 175.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.478 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.05 -25.54 31.42 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.216 -0.492 . . . . 1.0 111.904 -179.612 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.7 m -108.94 -4.84 16.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.551 0.574 . . . . 1.0 112.551 -177.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.443 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 89.5 m-20 -82.18 169.56 16.46 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.046 -0.724 . . . . 1.0 109.046 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.6 m -111.4 151.46 28.47 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.699 -0.482 . . . . 1.0 109.699 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.444 HG11 HD13 ' A' ' 90' ' ' LEU . 5.4 p -129.96 162.56 37.46 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 CA-C-N 115.754 -0.657 . . . . 1.0 111.716 -176.668 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 73.6 m -129.67 120.16 24.72 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.288 -1.004 . . . . 1.0 108.288 177.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.57 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.5 m -149.06 164.86 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 N-CA-C 114.379 1.252 . . . . 1.0 114.379 -176.08 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.411 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 2.6 mt-10 -118.72 146.26 44.88 Favored 'General case' 0 N--CA 1.486 1.352 0 N-CA-C 106.056 -1.831 . . . . 1.0 106.056 174.191 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.508 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.1 p90 -162.98 164.61 25.63 Favored 'General case' 0 C--N 1.342 0.275 0 N-CA-C 114.971 1.471 . . . . 1.0 114.971 -176.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -125.97 130.45 51.24 Favored 'General case' 0 C--O 1.216 -0.679 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.706 175.526 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.48 132.86 10.72 Favored Glycine 0 N--CA 1.473 1.113 0 N-CA-C 111.356 -0.698 . . . . 1.0 111.356 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 -147.06 167.54 23.82 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.788 0.804 . . . . 1.0 112.658 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.6 mp -81.9 164.83 21.28 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 114.252 -1.34 . . . . 1.0 110.274 178.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.425 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.82 -26.27 37.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 114.794 -1.094 . . . . 1.0 110.243 178.173 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.415 ' O ' ' OD2' ' A' ' 61' ' ' ASP . 7.0 t70 -94.04 5.26 52.27 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.019 -1.446 . . . . 1.0 111.919 -176.709 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.56 -4.53 79.7 Favored Glycine 0 CA--C 1.528 0.883 0 C-N-CA 121.0 -0.619 . . . . 1.0 113.227 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -70.29 103.88 2.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 118.073 0.937 . . . . 1.0 110.028 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -75.55 128.3 37.18 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.727 0 C-N-CA 120.642 -0.423 . . . . 1.0 110.059 179.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.761 ' CD2' HD11 ' A' ' 118' ' ' ILE . 9.2 p90 -116.08 -10.34 11.55 Favored 'General case' 0 CA--C 1.521 -0.165 0 CA-C-N 115.439 -0.8 . . . . 1.0 111.116 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -164.24 153.32 13.55 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.443 -0.503 . . . . 1.0 111.677 177.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.7 p -159.41 158.08 31.46 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 115.763 -0.653 . . . . 1.0 111.869 179.214 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 67.2 m -152.78 -40.61 0.1 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.358 -0.837 . . . . 1.0 110.254 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.435 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.3 pp20? -59.86 -27.59 66.8 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.373 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -55.45 -40.23 71.33 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.641 -1.244 . . . . 1.0 107.641 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.8 -34.94 57.92 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.029 -1.442 . . . . 1.0 108.642 178.179 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.54 17.87 69.9 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 110.69 -0.964 . . . . 1.0 110.69 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -105.07 116.26 60.94 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 121.155 -0.218 . . . . 1.0 110.754 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 32.3 Cg_exo -60.36 149.93 83.31 Favored 'Trans proline' 0 N--CA 1.479 0.67 0 C-N-CA 121.255 1.303 . . . . 1.0 113.358 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -122.83 151.27 41.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 114.483 -1.235 . . . . 1.0 108.204 178.425 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.1 t -106.41 127.44 53.29 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 113.13 0.789 . . . . 1.0 113.13 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 54.6 m-85 -133.97 150.02 51.26 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-N 115.148 -0.933 . . . . 1.0 108.973 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 68.0 mt-30 -90.38 125.05 35.41 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 106.353 -1.721 . . . . 1.0 106.353 174.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.5 t -48.48 -30.43 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 120.06 -0.656 . . . . 1.0 110.199 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.9 t -75.13 -25.12 58.17 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.27 -0.572 . . . . 1.0 111.681 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -98.87 -8.2 26.08 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 113.518 0.933 . . . . 1.0 113.518 -177.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.472 HG22 ' H ' ' A' ' 83' ' ' ILE . 3.9 p -88.22 170.49 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 118.907 0.776 . . . . 1.0 111.974 -178.34 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.472 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -52.98 148.51 13.85 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 120.256 -0.578 . . . . 1.0 109.623 -176.684 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.75 -44.34 41.48 Favored 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 122.25 1.967 . . . . 1.0 113.143 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.63 -47.43 90.19 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.818 -1.313 . . . . 1.0 109.818 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.57 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.2 m95 -63.79 -36.97 85.63 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.747 -1.227 . . . . 1.0 110.128 178.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 20.9 m -50.89 -54.19 26.1 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 116.258 -0.428 . . . . 1.0 111.041 -177.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.0 tp10 -72.84 -42.6 63.58 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.541 0.571 . . . . 1.0 112.541 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.52 -47.21 79.83 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 113.552 0.945 . . . . 1.0 113.552 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.444 HD13 HG11 ' A' ' 51' ' ' VAL . 79.3 mt -57.84 -41.28 82.01 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.406 0.622 . . . . 1.0 109.995 -178.384 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 21.4 mt-30 -64.57 -23.74 67.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.26 -0.882 . . . . 1.0 111.126 -179.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.8 mt -105.3 -12.23 16.15 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.505 -0.316 . . . . 1.0 111.075 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 17.6 ttm -88.77 108.4 23.08 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 116.014 -0.539 . . . . 1.0 111.925 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.719 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.2 Cg_exo -65.54 149.14 87.9 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.853 2.369 . . . . 1.0 113.318 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.86 133.43 51.88 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-N 115.591 -0.731 . . . . 1.0 111.359 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.4 -19.06 54.8 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 109.67 -1.372 . . . . 1.0 109.67 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.528 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 23.8 t -84.08 125.96 32.62 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.967 0.413 . . . . 1.0 109.946 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 44.1 m -96.94 111.86 23.88 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 116.151 -0.477 . . . . 1.0 110.044 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.431 ' NE1' ' OG ' ' A' ' 97' ' ' SER . 39.8 m0 -114.95 164.47 14.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.863 0.84 . . . . 1.0 111.476 -178.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.6 mt-10 -125.81 126.52 44.65 Favored 'General case' 0 CA--C 1.508 -0.636 0 N-CA-C 106.582 -1.636 . . . . 1.0 106.582 175.676 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.0 pt -120.4 137.15 55.13 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.767 0.794 . . . . 1.0 109.792 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.35 103.27 12.39 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 105.77 -1.937 . . . . 1.0 105.77 -178.13 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.95 115.09 63.57 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 114.969 1.47 . . . . 1.0 114.969 -174.51 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -51.32 144.53 30.45 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.121 1.214 . . . . 1.0 109.768 175.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.4 p -49.0 -36.67 18.21 Favored 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 120.653 -0.419 . . . . 1.0 110.961 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.18 -32.29 81.8 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.377 -0.689 . . . . 1.0 111.377 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 59.1 mt -98.58 2.07 47.06 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 122.926 -0.161 . . . . 1.0 110.645 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.37 -111.26 0.31 Allowed 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 110.035 -0.358 . . . . 1.0 110.035 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -98.88 4.21 47.42 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 112.327 0.492 . . . . 1.0 112.327 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.85 157.9 15.36 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 121.387 -0.435 . . . . 1.0 112.592 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.445 ' O ' ' N ' ' A' ' 121' ' ' ASN . 88.4 Cg_endo -74.12 -11.72 23.28 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 123.506 2.804 . . . . 1.0 110.562 179.222 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ARG . . . . . 0.437 ' O ' HG23 ' A' ' 114' ' ' VAL . 70.2 ttt180 -100.85 165.12 11.51 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.8 -1.091 . . . . 1.0 108.946 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.51 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.1 m -72.28 97.17 1.95 Allowed 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 119.989 -0.684 . . . . 1.0 109.173 178.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 112' ' ' ARG . 4.4 t -112.08 60.9 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 121.049 -0.261 . . . . 1.0 111.322 -179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 163.19 169.39 26.56 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.333 -0.937 . . . . 1.0 111.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.21 -103.47 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.191 -0.764 . . . . 1.0 111.191 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -60.81 -19.39 61.44 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 122.46 2.107 . . . . 1.0 111.608 -178.141 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.761 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.4 mp -68.05 118.7 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 107.54 -1.282 . . . . 1.0 107.54 178.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -101.31 -168.0 27.87 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 115.225 -0.898 . . . . 1.0 113.796 -176.591 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 19.5 Cg_endo -63.6 144.71 90.48 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.859 2.373 . . . . 1.0 112.289 178.313 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.445 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 43.25 50.93 5.84 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.717 0.294 . . . . 1.0 111.004 179.108 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.545 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 3.9 tp10 -106.15 127.51 53.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.623 0.725 . . . . 1.0 112.627 -177.604 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.466 HG21 HD11 ' A' ' 16' ' ' LEU . 25.7 m -95.61 135.24 37.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.649 -1.16 . . . . 1.0 108.52 178.205 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.0 mm? -115.32 142.16 47.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.232 0.539 . . . . 1.0 110.862 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.53 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.5 tt -120.84 149.37 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 115.468 -0.787 . . . . 1.0 108.951 178.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.581 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -139.62 149.84 44.26 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.507 -0.477 . . . . 1.0 111.046 177.019 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.9 mmtt -100.5 122.35 43.08 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 105.577 -2.008 . . . . 1.0 105.577 178.091 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.458 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.18 119.37 60.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 C-N-CA 119.311 -0.956 . . . . 1.0 113.564 -175.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' HIS . . . . . 0.42 ' ND1' HD11 ' A' ' 131' ' ' ILE . 10.4 t-160 -108.53 122.58 47.34 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 113.912 -1.495 . . . . 1.0 108.451 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.7 110.58 22.69 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.173 0.511 . . . . 1.0 111.64 -178.483 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.451 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -93.69 -46.86 13.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.212 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.3 p -150.99 158.45 44.15 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.237 0.542 . . . . 1.0 111.188 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.44 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -129.05 141.99 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 115.492 -0.776 . . . . 1.0 110.001 -178.015 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.3 tptm . . . . . 0 N--CA 1.449 -0.503 0 CA-C-O 121.45 0.643 . . . . 1.0 111.929 -178.847 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.4 ' O ' ' HD2' ' A' ' 11' ' ' LYS . 48.1 mt-10 . . . . . 0 CA--C 1.508 -0.647 0 CA-C-O 121.571 0.7 . . . . 1.0 110.709 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.549 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 4.0 m-20 -59.6 -36.98 77.35 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.145 -1.057 . . . . 1.0 108.145 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.3 ttpm? -66.74 -50.54 62.43 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 113.762 -1.563 . . . . 1.0 111.867 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.4 t -65.14 -48.67 82.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 119.614 -0.834 . . . . 1.0 110.993 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.462 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.83 -38.32 90.66 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.028 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.424 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.35 -46.97 46.22 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 115.094 -0.957 . . . . 1.0 112.199 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.431 ' O ' ' OG1' ' A' ' 17' ' ' THR . 91.9 mt-10 -57.69 -34.81 69.81 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 108.645 -0.872 . . . . 1.0 108.645 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.05 -31.01 44.38 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.853 -1.067 . . . . 1.0 110.364 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -61.68 -49.23 77.32 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.147 -179.347 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.424 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.2 mp -66.57 -38.23 86.63 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 119.69 -0.804 . . . . 1.0 109.304 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.8 m -61.85 -42.97 99.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.549 0.69 . . . . 1.0 109.275 178.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -74.21 -44.29 53.8 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-N 115.334 -0.848 . . . . 1.0 111.609 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -56.83 -50.16 73.24 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.111 0.481 . . . . 1.0 111.883 -178.874 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 9.5 ptmt -60.01 -28.63 67.88 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.221 -0.992 . . . . 1.0 109.545 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -81.87 -29.57 32.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.33 -0.85 . . . . 1.0 111.442 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -58.95 136.35 87.52 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 120.848 -0.341 . . . . 1.0 111.177 -179.152 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -55.75 148.47 55.29 Favored 'Trans proline' 0 N--CA 1.506 2.234 0 C-N-CA 122.48 2.12 . . . . 1.0 114.179 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.76 -18.59 11.56 Favored Glycine 0 N--CA 1.462 0.428 0 CA-C-N 115.097 -0.956 . . . . 1.0 111.397 178.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.4 t -85.08 136.27 23.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.04 0.448 . . . . 1.0 111.074 -179.293 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.5 t -120.47 122.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 N-CA-C 107.716 -1.216 . . . . 1.0 107.716 176.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.27 147.0 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 121.414 0.626 . . . . 1.0 111.812 -178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 54.6 mt -115.79 163.77 19.86 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.758 -1.11 . . . . 1.0 110.779 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.22 -31.91 93.67 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.584 1.523 . . . . 1.0 111.974 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.4 m -68.14 -12.23 60.54 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 109.294 -0.632 . . . . 1.0 109.294 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.0 -1.57 68.05 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 109.365 -1.494 . . . . 1.0 109.365 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.489 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -79.98 134.39 36.25 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.434 -0.95 . . . . 1.0 108.434 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.489 ' H ' HD22 ' A' ' 32' ' ' LEU . 13.0 mp0 -124.84 145.54 49.73 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-N 115.891 -0.595 . . . . 1.0 110.929 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -139.39 150.11 44.9 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.521 0.677 . . . . 1.0 110.733 178.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.5 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -135.13 134.94 40.73 Favored 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 114.563 -1.199 . . . . 1.0 109.119 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -92.33 103.75 14.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 122.211 1.005 . . . . 1.0 111.742 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.618 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.3 mm -69.02 -41.74 81.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.039 -0.982 . . . . 1.0 109.197 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -142.04 128.0 19.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.109 -0.95 . . . . 1.0 109.942 -178.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.9 p -87.55 124.46 33.51 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.858 0.361 . . . . 1.0 110.101 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.468 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.19 -32.77 2.1 Favored Glycine 0 CA--C 1.517 0.218 0 N-CA-C 109.539 -1.424 . . . . 1.0 109.539 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 56.49 32.43 20.75 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.3 -0.45 . . . . 1.0 110.995 179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.75 -163.01 38.66 Favored Glycine 0 C--N 1.329 0.167 0 CA-C-O 121.977 0.765 . . . . 1.0 111.536 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.602 ' O ' ' N ' ' A' ' 95' ' ' ALA . 29.2 m -69.43 -177.94 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.009 -1.095 . . . . 1.0 108.42 177.78 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.604 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.25 154.27 0.38 Allowed Pre-proline 0 C--N 1.316 -0.852 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.6 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.486 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 70.3 Cg_endo -87.79 152.78 7.36 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.827 2.351 . . . . 1.0 115.265 -175.325 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.53 178.98 51.54 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.612 -1.795 . . . . 1.0 108.612 176.275 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.648 ' NZ ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.95 -21.48 11.86 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.445 -0.502 . . . . 1.0 110.847 -179.666 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.4 m -107.64 -11.03 15.52 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 113.587 0.958 . . . . 1.0 113.587 -177.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -85.69 166.1 16.42 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 119.632 -0.827 . . . . 1.0 109.331 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.469 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 4.8 m -103.79 151.01 23.57 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.23 0.538 . . . . 1.0 110.43 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.486 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.3 p -128.06 157.56 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.421 0 CA-C-N 115.278 -0.874 . . . . 1.0 112.343 -176.338 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.447 HG22 ' HB3' ' A' ' 74' ' ' PRO . 98.1 m -124.07 120.54 32.68 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 107.923 -1.14 . . . . 1.0 107.923 177.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.618 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.7 m -149.23 163.18 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 114.698 1.37 . . . . 1.0 114.698 -175.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.4 152.61 35.52 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 106.384 -1.71 . . . . 1.0 106.384 173.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.554 ' H ' ' HB ' ' A' ' 68' ' ' THR . 33.6 p90 -164.09 160.73 21.89 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.528 1.307 . . . . 1.0 114.528 -177.573 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -123.37 128.46 49.91 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.953 -0.758 . . . . 1.0 108.953 175.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.8 137.69 14.45 Favored Glycine 0 N--CA 1.467 0.716 0 C-N-CA 120.925 -0.655 . . . . 1.0 112.138 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -146.18 165.91 27.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.714 0.769 . . . . 1.0 112.574 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.2 mp -82.91 163.28 21.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 114.276 -1.329 . . . . 1.0 110.052 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.33 -26.2 36.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.155 -0.929 . . . . 1.0 110.276 178.08 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -93.82 7.76 43.69 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.376 -1.284 . . . . 1.0 111.78 -177.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.83 -7.27 81.46 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 121.241 -0.504 . . . . 1.0 113.31 178.057 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -68.19 105.79 2.22 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 119.444 -0.902 . . . . 1.0 110.565 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 99.2 t -76.84 118.98 24.34 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.82 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -106.34 -20.22 13.45 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.016 -0.993 . . . . 1.0 111.897 -178.125 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.414 ' OD2' ' N ' ' A' ' 67' ' ' SER . 10.2 t70 -154.82 155.4 34.35 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.228 0.537 . . . . 1.0 111.972 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 92.9 p -157.4 159.8 37.75 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.341 -0.845 . . . . 1.0 111.57 178.622 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.554 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 89.9 m -155.25 -38.51 0.09 Allowed 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 115.567 -0.742 . . . . 1.0 110.01 -179.309 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -65.29 -25.37 67.61 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.638 -1.245 . . . . 1.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.6 mmtt -59.53 -45.63 91.2 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 176.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.8 OUTLIER -73.05 -33.36 65.64 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.505 -1.225 . . . . 1.0 108.194 177.423 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.55 18.93 67.27 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 111.497 -0.641 . . . . 1.0 111.497 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.9 115.37 60.4 Favored Pre-proline 0 N--CA 1.47 0.549 0 C-N-CA 120.936 -0.306 . . . . 1.0 110.919 -179.023 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.447 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.0 Cg_exo -59.9 151.26 72.75 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 121.826 1.684 . . . . 1.0 114.185 -179.249 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -120.68 148.63 43.67 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 113.915 -1.493 . . . . 1.0 107.498 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.15 124.57 49.89 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.335 0.588 . . . . 1.0 112.378 -178.245 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -133.32 149.34 51.9 Favored 'General case' 0 CA--C 1.493 -1.221 0 CA-C-N 115.286 -0.87 . . . . 1.0 109.707 178.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 49.3 mt-30 -90.75 130.36 36.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 105.09 -2.189 . . . . 1.0 105.09 174.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 87' ' ' THR . 38.2 t -57.23 -31.61 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 119.099 -1.04 . . . . 1.0 110.108 -176.511 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.1 t -73.67 -25.99 60.52 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.424 -0.51 . . . . 1.0 112.038 -178.27 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 11.9 mm100 -102.26 -6.64 22.91 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 112.959 0.726 . . . . 1.0 112.959 -177.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.2 p -78.91 168.58 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 121.046 -0.262 . . . . 1.0 111.242 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -52.56 146.81 16.22 Favored Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 107.903 -1.147 . . . . 1.0 107.903 -178.133 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.53 -43.29 45.78 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 121.433 1.422 . . . . 1.0 112.648 -177.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.11 -47.34 91.25 Favored Glycine 0 C--N 1.317 -0.479 0 C-N-CA 119.747 -1.216 . . . . 1.0 110.946 -178.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.618 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.8 m95 -66.68 -32.3 73.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 113.973 -1.113 . . . . 1.0 110.748 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.46 HG23 ' O ' ' A' ' 79' ' ' VAL . 29.5 m -51.37 -54.48 26.06 Favored 'General case' 0 C--N 1.322 -0.603 0 O-C-N 122.029 -0.42 . . . . 1.0 111.812 -178.567 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -72.7 -40.27 66.33 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.7 -44.06 97.0 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 114.432 1.271 . . . . 1.0 114.432 -176.546 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.4 mt -58.6 -41.56 86.11 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.147 0.499 . . . . 1.0 110.323 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -64.55 -23.89 67.42 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.368 -0.833 . . . . 1.0 110.401 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.524 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 88.6 mt -99.61 -14.84 18.81 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.964 -0.562 . . . . 1.0 111.718 -178.7 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 48.7 ttp -91.2 108.68 30.23 Favored Pre-proline 0 CA--C 1.548 0.892 0 O-C-N 123.224 0.327 . . . . 1.0 111.826 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.604 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 24.0 Cg_exo -63.79 149.1 91.51 Favored 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.586 2.191 . . . . 1.0 113.052 178.115 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.602 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.99 133.4 54.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.436 0.636 . . . . 1.0 110.76 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.61 -13.79 66.53 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 108.744 -1.742 . . . . 1.0 108.744 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.468 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 7.7 t -90.83 122.66 33.74 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.012 0.434 . . . . 1.0 109.839 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.8 m -97.07 115.07 26.82 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.402 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 31.7 m0 -115.76 167.95 10.48 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.657 0.741 . . . . 1.0 110.996 -178.59 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.618 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.5 mt-10 -128.44 134.74 48.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 106.453 -1.684 . . . . 1.0 106.453 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.414 HD13 HG21 ' A' ' 101' ' ' ILE . 3.5 pt -130.91 139.03 52.14 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.654 0 CA-C-O 121.724 0.773 . . . . 1.0 109.601 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.703 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.3 OUTLIER -109.39 102.9 11.76 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.995 -1.854 . . . . 1.0 105.995 -177.408 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 t -90.33 116.23 65.9 Favored Pre-proline 0 N--CA 1.453 -0.302 0 N-CA-C 115.093 1.516 . . . . 1.0 115.093 -174.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.33 143.56 26.26 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.519 1.479 . . . . 1.0 109.601 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.7 p -53.7 -27.97 31.16 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.411 -0.515 . . . . 1.0 110.929 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.61 -29.48 65.6 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 110.194 -1.163 . . . . 1.0 110.194 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.9 mt -101.03 2.28 40.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.301 -0.45 . . . . 1.0 111.173 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -110.43 -108.34 0.35 Allowed 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.852 0.316 . . . . 1.0 111.852 -178.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -99.24 3.39 46.26 Favored 'General case' 0 C--N 1.339 0.118 0 N-CA-C 112.136 0.421 . . . . 1.0 112.136 -178.072 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.03 163.98 22.13 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.23 -0.509 . . . . 1.0 112.396 178.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.551 ' O ' ' N ' ' A' ' 121' ' ' ASN . 84.9 Cg_endo -75.77 -11.55 20.1 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 123.404 2.736 . . . . 1.0 111.955 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -98.62 167.17 10.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.065 -0.516 . . . . 1.0 109.729 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.572 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.8 m -74.05 78.18 1.71 Allowed 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.301 -0.56 . . . . 1.0 109.842 178.672 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.1 t -93.68 60.44 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.084 -0.507 . . . . 1.0 109.949 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.59 177.09 40.42 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 120.224 -0.988 . . . . 1.0 112.295 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.97 -106.74 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 N-CA-C 111.293 -0.723 . . . . 1.0 111.293 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.31 -13.72 17.47 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 121.905 1.737 . . . . 1.0 110.522 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.865 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.5 mp -67.26 111.84 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 107.383 -1.34 . . . . 1.0 107.383 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.43 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -93.16 -167.1 38.54 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.473 -1.051 . . . . 1.0 110.473 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.572 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.5 Cg_endo -62.91 144.99 94.35 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.227 1.951 . . . . 1.0 112.7 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 111' ' ' PRO . 28.0 t-20 47.33 56.78 6.5 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.221 0.452 . . . . 1.0 112.221 177.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.43 ' HG3' ' H ' ' A' ' 119' ' ' GLY . 52.1 mm-40 -103.1 128.47 50.0 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 112.308 0.484 . . . . 1.0 112.308 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.8 m -93.94 128.4 40.23 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.191 -1.411 . . . . 1.0 107.191 176.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.403 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.6 mm? -109.41 147.95 31.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 121.482 0.658 . . . . 1.0 111.156 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.703 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -126.79 144.21 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.64 0 N-CA-C 108.477 -0.935 . . . . 1.0 108.477 178.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.543 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.9 OUTLIER -135.0 151.95 51.28 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 120.499 -0.48 . . . . 1.0 111.305 177.81 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.479 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.7 mmtt -100.18 125.12 46.28 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.044 -2.206 . . . . 1.0 105.044 176.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.469 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.3 mt -118.61 118.49 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 119.153 -1.019 . . . . 1.0 112.331 -176.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -109.77 121.7 45.81 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 113.569 -1.65 . . . . 1.0 108.232 178.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.33 112.16 24.01 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 120.235 -0.586 . . . . 1.0 112.064 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -91.57 -47.1 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.68 -0.691 . . . . 1.0 110.974 179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.9 t -150.02 158.12 43.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.833 0.349 . . . . 1.0 111.013 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.449 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -130.26 136.91 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 116.192 -0.458 . . . . 1.0 111.609 -178.243 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.469 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 20.3 tptt . . . . . 0 CA--C 1.533 0.318 0 CA-C-O 121.661 0.743 . . . . 1.0 110.075 178.49 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 CA--C 1.517 -0.3 0 CA-C-O 121.682 0.753 . . . . 1.0 110.593 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.567 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 7.0 m-20 -60.13 -34.44 73.53 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.223 -0.899 . . . . 1.0 108.599 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -66.93 -51.23 57.76 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.164 -1.38 . . . . 1.0 111.649 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.1 t -67.41 -46.83 82.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.082 -0.647 . . . . 1.0 111.887 -177.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.67 -38.22 90.29 Favored 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 107.442 -1.318 . . . . 1.0 107.442 178.567 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.544 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.04 -44.35 61.37 Favored Glycine 0 CA--C 1.528 0.905 0 CA-C-N 114.845 -1.071 . . . . 1.0 112.44 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -61.98 -32.06 72.48 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 119.342 -0.943 . . . . 1.0 108.72 179.297 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.17 -35.3 64.01 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.133 -0.94 . . . . 1.0 109.682 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -63.83 -50.3 69.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.213 -179.384 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.544 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -71.11 -37.87 72.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 109.178 -0.675 . . . . 1.0 109.178 178.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.2 m -62.03 -43.08 99.59 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.791 -0.641 . . . . 1.0 109.482 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -75.02 -45.78 39.52 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.655 -0.702 . . . . 1.0 112.154 -179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 46.0 t30 -61.62 -44.62 96.66 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 113.126 0.787 . . . . 1.0 113.126 -177.545 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.68 -30.36 68.72 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 119.406 -0.917 . . . . 1.0 109.505 -179.455 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 26.2 m-80 -81.15 -29.49 34.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.667 -0.697 . . . . 1.0 111.782 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 18.7 mtmt -59.55 136.52 89.36 Favored Pre-proline 0 CA--C 1.545 0.774 0 C-N-CA 120.687 -0.405 . . . . 1.0 111.188 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.75 147.49 60.61 Favored 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 121.719 1.612 . . . . 1.0 112.807 178.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.76 -20.23 25.14 Favored Glycine 0 C--O 1.225 -0.417 0 CA-C-N 115.27 -0.877 . . . . 1.0 111.486 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 35' ' ' LYS . 42.9 t -88.13 134.38 28.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.05 0.453 . . . . 1.0 110.751 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 83.8 t -118.67 122.26 69.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 108.062 -1.088 . . . . 1.0 108.062 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.428 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.3 p -94.79 146.06 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.721 0.772 . . . . 1.0 111.789 -178.701 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.6 mt -114.77 162.29 24.53 Favored Pre-proline 0 N--CA 1.465 0.316 0 CA-C-N 114.418 -1.264 . . . . 1.0 110.612 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.16 -30.92 94.39 Favored 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 121.681 1.588 . . . . 1.0 111.277 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 m -66.99 -15.04 63.47 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.509 -0.769 . . . . 1.0 109.389 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.28 -0.72 66.39 Favored Glycine 0 CA--C 1.51 -0.221 0 N-CA-C 109.432 -1.467 . . . . 1.0 109.432 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -80.56 134.21 35.89 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.355 -0.98 . . . . 1.0 108.355 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.2 mp0 -122.82 138.8 54.54 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.965 -0.561 . . . . 1.0 110.564 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -133.54 147.16 51.56 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.878 0.847 . . . . 1.0 111.0 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.523 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.8 tmtp? -134.1 136.48 43.93 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-N 114.174 -1.375 . . . . 1.0 109.724 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -92.79 105.73 17.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 122.366 1.079 . . . . 1.0 111.589 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.642 HD11 ' CD ' ' A' ' 100' ' ' GLU . 17.7 mm -70.54 -42.25 78.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.082 -0.963 . . . . 1.0 109.124 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.403 ' O ' ' OG ' ' A' ' 97' ' ' SER . 22.1 m120 -143.07 124.48 14.72 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 113.998 -1.456 . . . . 1.0 109.09 -178.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.1 p -88.61 125.58 34.88 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.596 -0.52 . . . . 1.0 109.596 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.508 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.11 -33.76 1.93 Allowed Glycine 0 CA--C 1.516 0.129 0 N-CA-C 110.345 -1.102 . . . . 1.0 110.345 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 57.98 32.97 22.68 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 123.679 0.281 . . . . 1.0 111.441 179.065 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.37 -161.08 36.92 Favored Glycine 0 C--N 1.335 0.502 0 CA-C-O 121.763 0.646 . . . . 1.0 111.929 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.584 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.8 m -68.74 -179.75 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 114.309 -0.945 . . . . 1.0 109.025 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.626 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 178.0 155.84 0.52 Allowed Pre-proline 0 N--CA 1.476 0.831 0 CA-C-O 120.953 0.406 . . . . 1.0 110.886 179.234 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HB2' ' HB3' ' A' ' 49' ' ' ASP . 32.6 Cg_endo -85.02 167.03 11.09 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 123.433 2.756 . . . . 1.0 117.521 -173.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.502 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -102.91 165.62 16.29 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 113.571 -1.649 . . . . 1.0 109.566 177.021 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.612 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -44.97 -25.86 0.36 Allowed 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.657 -0.771 . . . . 1.0 111.886 -179.636 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 66.5 m -108.32 -5.57 16.7 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 112.759 0.651 . . . . 1.0 112.759 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.706 ' OD2' ' N ' ' A' ' 50' ' ' THR . 66.4 t0 -82.29 169.08 16.93 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.151 0.501 . . . . 1.0 110.841 -179.473 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.706 ' N ' ' OD2' ' A' ' 49' ' ' ASP . 7.6 m -110.91 142.7 42.63 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.656 -0.868 . . . . 1.0 108.656 177.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.12 160.34 30.82 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.534 0 CA-C-N 114.994 -1.003 . . . . 1.0 112.252 -175.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.494 HG22 ' HB3' ' A' ' 74' ' ' PRO . 91.1 m -124.69 120.3 31.43 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.873 -0.788 . . . . 1.0 108.873 178.173 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.585 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 11.4 m -148.75 165.44 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 114.636 1.347 . . . . 1.0 114.636 -176.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -119.32 151.99 37.5 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 173.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.52 ' O ' ' N ' ' A' ' 68' ' ' THR . 33.6 p90 -164.96 164.83 20.6 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 118.425 -1.31 . . . . 1.0 113.973 -177.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.3 m -123.88 130.82 53.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 108.021 -1.103 . . . . 1.0 108.021 175.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.6 131.44 9.98 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.093 -1.203 . . . . 1.0 110.093 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.711 ' CZ ' ' HZ1' ' A' ' 127' ' ' LYS . 5.1 ptp180 -145.77 169.29 18.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.977 0.894 . . . . 1.0 112.762 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.7 mp -84.59 165.89 17.61 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 113.912 -1.495 . . . . 1.0 109.941 177.614 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.06 -25.62 30.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.431 178.889 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -100.22 10.17 41.65 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.134 -0.939 . . . . 1.0 112.026 -177.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.94 -6.62 81.81 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 120.403 -0.903 . . . . 1.0 113.771 178.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.7 m -65.18 102.02 0.6 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 118.727 1.263 . . . . 1.0 109.182 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 88.4 t -74.86 117.4 18.99 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.408 0.623 . . . . 1.0 111.1 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CD2' HD11 ' A' ' 118' ' ' ILE . 27.4 p90 -103.76 -15.63 15.67 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 114.903 -1.044 . . . . 1.0 112.092 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -159.24 153.91 24.47 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.27 -0.572 . . . . 1.0 110.375 177.811 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.0 p -157.19 158.55 36.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.826 -0.625 . . . . 1.0 111.802 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.2 m -153.07 -43.89 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.171 -0.922 . . . . 1.0 109.799 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.437 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -61.07 -28.02 68.78 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-N 115.888 -0.597 . . . . 1.0 109.66 179.42 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -57.24 -42.9 82.37 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 107.434 -1.321 . . . . 1.0 107.434 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.8 -33.47 60.13 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.299 -1.319 . . . . 1.0 107.558 176.251 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.02 17.75 73.87 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.314 -0.857 . . . . 1.0 112.118 178.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -98.13 116.35 65.61 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 121.265 -0.174 . . . . 1.0 110.557 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.494 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.4 Cg_exo -58.54 150.52 68.44 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 121.501 1.467 . . . . 1.0 114.204 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.77 145.82 48.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.354 -1.293 . . . . 1.0 108.472 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.3 t -103.8 131.3 51.12 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-O 121.453 0.644 . . . . 1.0 112.452 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -139.8 149.6 43.71 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.994 -1.003 . . . . 1.0 110.42 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -90.81 127.54 36.39 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 105.766 -1.938 . . . . 1.0 105.766 174.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.1 t -51.64 -29.2 9.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 C-N-CA 118.981 -1.088 . . . . 1.0 110.512 -176.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 48.3 t -77.68 -23.17 49.65 Favored 'General case' 0 CA--C 1.521 -0.171 0 C-N-CA 120.306 -0.558 . . . . 1.0 111.835 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -98.56 -6.6 29.77 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 113.728 1.01 . . . . 1.0 113.728 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -87.59 172.36 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 119.775 -0.77 . . . . 1.0 110.924 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.466 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -53.48 152.31 9.12 Favored Pre-proline 0 N--CA 1.478 0.954 0 N-CA-C 109.301 -0.629 . . . . 1.0 109.301 -176.956 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.466 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -52.26 -45.14 41.35 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.098 1.866 . . . . 1.0 112.061 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.77 -46.86 91.81 Favored Glycine 0 CA--C 1.522 0.512 0 C-N-CA 119.957 -1.116 . . . . 1.0 110.876 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.585 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.1 m95 -64.58 -35.44 80.98 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.342 -0.929 . . . . 1.0 111.495 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 30.7 m -50.78 -55.29 17.48 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.55 -0.46 . . . . 1.0 112.14 -177.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -73.27 -40.42 64.6 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 112.365 0.506 . . . . 1.0 112.365 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.47 -45.76 84.45 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 114.154 1.168 . . . . 1.0 114.154 -178.526 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.1 mt -57.84 -41.59 82.66 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.197 0.522 . . . . 1.0 110.629 -177.696 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.9 mt-30 -65.43 -19.1 65.79 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.277 -0.874 . . . . 1.0 111.346 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.502 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 57.5 mt -106.01 -13.4 15.48 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.116 -0.493 . . . . 1.0 110.7 -178.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.0 ttp -88.91 109.13 28.02 Favored Pre-proline 0 CA--C 1.553 1.063 0 N-CA-C 112.101 0.408 . . . . 1.0 112.101 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.626 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 22.3 Cg_exo -64.58 149.53 89.72 Favored 'Trans proline' 0 N--CA 1.504 2.11 0 C-N-CA 122.979 2.453 . . . . 1.0 113.296 178.346 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.584 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.33 132.58 50.58 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.495 0.664 . . . . 1.0 111.154 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.76 -18.21 57.65 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 108.505 -1.838 . . . . 1.0 108.505 -178.833 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.508 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 9.3 t -86.02 128.64 34.9 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 109.944 -0.391 . . . . 1.0 109.944 179.092 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.7 m -103.33 114.8 29.36 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 115.594 -0.73 . . . . 1.0 109.696 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' TRP . . . . . 0.502 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -114.14 167.96 10.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.781 0.8 . . . . 1.0 111.336 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.642 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.7 mt-10 -128.46 124.5 36.33 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.171 -1.418 . . . . 1.0 107.171 175.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.435 HD13 HG21 ' A' ' 101' ' ' ILE . 3.6 pt -120.68 135.49 60.72 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.868 0 N-CA-C 108.735 -0.839 . . . . 1.0 108.735 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.72 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -107.12 104.0 13.53 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.725 -1.954 . . . . 1.0 105.725 -177.258 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 t -90.51 115.53 64.36 Favored Pre-proline 0 C--N 1.32 -0.675 0 N-CA-C 115.256 1.576 . . . . 1.0 115.256 -173.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -51.35 146.03 25.91 Favored 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 121.941 1.761 . . . . 1.0 110.569 176.294 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.0 p -53.58 -24.51 13.95 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.456 -178.291 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -78.56 -29.5 52.31 Favored Glycine 0 N--CA 1.46 0.268 0 N-CA-C 110.697 -0.961 . . . . 1.0 110.697 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.2 mt -102.16 2.77 37.71 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.523 -0.338 . . . . 1.0 110.49 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.26 -102.43 0.35 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 110.11 -0.33 . . . . 1.0 110.11 -178.102 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -108.96 5.46 24.33 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.753 1.02 . . . . 1.0 113.753 -177.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.57 163.05 17.4 Favored Glycine 0 N--CA 1.473 1.128 0 C-N-CA 121.285 -0.483 . . . . 1.0 113.209 177.186 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.553 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.1 Cg_endo -71.13 -18.67 30.55 Favored 'Trans proline' 0 N--CA 1.494 1.527 0 C-N-CA 123.535 2.823 . . . . 1.0 112.37 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -104.01 171.56 7.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.229 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.465 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.0 m -73.64 97.28 2.63 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.926 -0.579 . . . . 1.0 110.171 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.6 t -109.55 61.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.596 -0.274 . . . . 1.0 110.873 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.502 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -168.53 40.98 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 120.892 -0.671 . . . . 1.0 111.715 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.12 -104.9 0.04 OUTLIER Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.457 -0.657 . . . . 1.0 111.457 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -58.9 -19.05 45.5 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.237 1.958 . . . . 1.0 111.621 -178.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.613 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -66.56 112.83 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 119.901 -0.72 . . . . 1.0 109.166 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.4 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.65 -164.84 39.93 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.679 -0.968 . . . . 1.0 110.679 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.567 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 23.5 Cg_endo -63.22 152.05 81.74 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.359 2.039 . . . . 1.0 113.272 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.553 ' N ' ' O ' ' A' ' 111' ' ' PRO . 4.5 t-20 37.17 53.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.807 177.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.423 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 41.7 mm-40 -97.36 132.29 43.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.29 0.567 . . . . 1.0 111.768 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.464 HG21 HD11 ' A' ' 16' ' ' LEU . 84.6 m -95.66 127.44 41.7 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.451 -1.314 . . . . 1.0 107.451 176.197 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.82 140.79 47.31 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.338 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.72 HD12 ' CD2' ' A' ' 102' ' ' TYR . 2.2 tt -119.43 147.05 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 N-CA-C 108.435 -0.95 . . . . 1.0 108.435 178.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.626 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -134.4 145.53 49.01 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 121.12 0.486 . . . . 1.0 110.324 177.314 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.711 ' HZ1' ' CZ ' ' A' ' 58' ' ' ARG . 5.5 mmtt -99.61 121.83 41.76 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 104.673 -2.343 . . . . 1.0 104.673 178.394 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.411 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.5 mt -116.09 120.36 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 119.438 -0.905 . . . . 1.0 113.176 -175.22 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.4 t-160 -110.3 123.18 49.34 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 113.927 -1.488 . . . . 1.0 108.486 178.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.64 113.17 24.79 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 112.384 0.513 . . . . 1.0 112.384 -178.154 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -96.25 -46.98 13.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 115.775 -0.648 . . . . 1.0 111.301 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.95 155.86 42.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.168 0.509 . . . . 1.0 111.574 -178.651 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 44' ' ' LYS . 50.1 t -128.96 142.19 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.706 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.401 ' C ' ' OD2' ' A' ' 49' ' ' ASP . 3.9 tptt . . . . . 0 N--CA 1.453 -0.294 0 CA-C-O 121.712 0.768 . . . . 1.0 110.765 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 . . . . . 0 C--O 1.222 -0.372 0 CA-C-O 121.428 0.633 . . . . 1.0 110.867 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 2.3 m-20 -62.74 -35.76 80.83 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.094 -1.076 . . . . 1.0 108.094 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 13' ' ' GLU . 76.8 tttt -65.72 -49.45 68.42 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.42 -1.718 . . . . 1.0 112.095 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.0 t -66.36 -48.67 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 C-N-CA 119.79 -0.764 . . . . 1.0 110.9 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.0 OUTLIER -62.61 -36.22 82.05 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.799 -1.185 . . . . 1.0 107.799 178.9 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.456 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.59 -41.81 42.38 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.836 -1.074 . . . . 1.0 112.213 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.472 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.7 mt-10 -62.79 -31.35 72.3 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 119.464 -0.895 . . . . 1.0 108.634 179.54 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.55 -34.76 53.72 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 115.138 -0.937 . . . . 1.0 109.925 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -60.84 -49.07 78.96 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.499 -1.228 . . . . 1.0 111.11 -178.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.456 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.1 mp -70.18 -36.76 74.87 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.195 -0.602 . . . . 1.0 109.495 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.66 -44.36 97.1 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.593 -0.731 . . . . 1.0 109.715 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -76.6 -44.83 32.73 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 114.985 -1.007 . . . . 1.0 112.517 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.3 t30 -60.07 -44.99 94.36 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 113.089 0.774 . . . . 1.0 113.089 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -61.02 -28.5 69.09 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 119.969 -0.693 . . . . 1.0 109.761 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -82.99 -28.08 29.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.571 -0.741 . . . . 1.0 111.235 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.4 mtmt -59.25 139.01 88.45 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 120.834 -0.346 . . . . 1.0 111.478 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_exo -56.5 148.54 62.56 Favored 'Trans proline' 0 N--CA 1.502 2.008 0 C-N-CA 122.167 1.911 . . . . 1.0 113.353 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA3' ' HZ2' ' A' ' 35' ' ' LYS . . . 80.78 -18.84 8.25 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.247 -0.888 . . . . 1.0 111.592 179.209 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.46 137.29 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.444 . . . . 1.0 109.964 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.6 t -122.98 119.62 58.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 108.242 -1.021 . . . . 1.0 108.242 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.426 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.2 p -94.93 145.44 8.12 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 CA-C-O 121.689 0.757 . . . . 1.0 111.429 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.9 mt -111.92 165.11 13.57 Favored Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 114.189 -1.369 . . . . 1.0 110.481 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -61.21 -29.43 86.63 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.764 1.643 . . . . 1.0 111.048 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -68.34 -16.88 64.1 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 115.678 -0.692 . . . . 1.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.74 -7.0 60.85 Favored Glycine 0 CA--C 1.517 0.196 0 N-CA-C 110.142 -1.183 . . . . 1.0 110.142 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.475 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.38 134.52 38.42 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 179.528 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.475 ' H ' HD22 ' A' ' 32' ' ' LEU . 26.2 mp0 -121.24 142.91 49.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.454 -0.339 . . . . 1.0 110.641 179.203 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -136.97 148.13 46.74 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-O 121.56 0.695 . . . . 1.0 110.75 178.452 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LYS . . . . . 0.593 ' CD ' HD13 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -135.27 134.74 40.27 Favored 'General case' 0 N--CA 1.44 -0.948 0 CA-C-N 114.48 -1.236 . . . . 1.0 109.88 -179.174 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 p -93.3 105.34 16.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 122.063 0.935 . . . . 1.0 111.472 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.631 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -70.33 -41.76 78.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.177 -0.92 . . . . 1.0 109.303 179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -145.46 119.75 9.57 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.797 -1.092 . . . . 1.0 110.48 -177.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 p -80.32 123.85 28.34 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.264 0.554 . . . . 1.0 110.352 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.449 ' H ' ' CB ' ' A' ' 97' ' ' SER . . . -109.22 -29.24 4.07 Favored Glycine 0 CA--C 1.519 0.286 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 179.352 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 54.73 32.12 16.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.756 -0.722 . . . . 1.0 111.412 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.95 -163.26 38.78 Favored Glycine 0 C--N 1.33 0.247 0 CA-C-O 121.923 0.735 . . . . 1.0 111.548 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.3 m -68.28 -177.77 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 114.154 -1.023 . . . . 1.0 108.615 178.097 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.522 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.36 154.47 0.39 Allowed Pre-proline 0 C--N 1.317 -0.806 0 N-CA-C 109.454 -0.573 . . . . 1.0 109.454 179.631 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -88.02 159.64 7.28 Favored 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 123.137 2.558 . . . . 1.0 116.355 -174.294 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -91.53 175.02 38.69 Favored Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 109.06 -1.616 . . . . 1.0 109.06 176.375 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.628 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.47 -23.91 4.48 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.112 -0.544 . . . . 1.0 110.69 -179.691 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.466 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 40.6 m -107.72 -10.09 15.68 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 113.983 1.105 . . . . 1.0 113.983 -177.302 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.7 m-20 -84.7 165.51 17.81 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 119.618 -0.833 . . . . 1.0 108.835 179.724 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -103.36 148.93 25.27 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.515 -0.55 . . . . 1.0 109.515 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.7 p -125.62 162.44 28.65 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 CA-C-N 115.87 -0.605 . . . . 1.0 112.201 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.423 HG22 ' CB ' ' A' ' 74' ' ' PRO . 87.8 m -130.55 120.37 23.95 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.039 -1.097 . . . . 1.0 108.039 177.462 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.459 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 9.9 m -148.51 164.99 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.004 1.113 . . . . 1.0 114.004 -176.309 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.465 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 10.4 mt-10 -118.61 152.3 36.3 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 106.425 -1.694 . . . . 1.0 106.425 174.32 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.1 p90 -162.1 159.57 26.31 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 114.856 1.428 . . . . 1.0 114.856 -177.576 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -121.24 129.74 53.33 Favored 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.157 -0.929 . . . . 1.0 108.988 176.019 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.5 133.9 11.78 Favored Glycine 0 N--CA 1.47 0.935 0 N-CA-C 111.185 -0.766 . . . . 1.0 111.185 -178.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -145.54 166.43 25.73 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.69 0.757 . . . . 1.0 112.101 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -87.46 160.08 18.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.578 -1.192 . . . . 1.0 111.272 178.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -55.12 -26.01 17.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 114.462 -1.244 . . . . 1.0 110.465 177.811 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -96.04 5.63 50.71 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.49 -1.232 . . . . 1.0 111.075 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.73 -9.51 77.47 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.021 -0.536 . . . . 1.0 113.642 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -61.13 97.01 0.06 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 118.331 1.066 . . . . 1.0 110.634 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 98.2 t -68.73 125.69 27.1 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 C-N-CA 119.639 -0.824 . . . . 1.0 108.854 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.908 ' CD2' HD11 ' A' ' 118' ' ' ILE . 19.4 p90 -117.38 -15.53 10.33 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.163 -0.926 . . . . 1.0 111.696 -178.615 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -154.6 149.87 27.1 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.249 0.547 . . . . 1.0 111.735 178.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -155.87 151.32 26.97 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.395 -0.821 . . . . 1.0 111.776 179.137 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 99.5 m -148.04 -37.8 0.19 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.201 -0.908 . . . . 1.0 110.157 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.465 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.1 pp20? -66.62 -27.37 67.65 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 116.14 -0.482 . . . . 1.0 110.04 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -59.4 -43.39 92.99 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 107.744 -1.206 . . . . 1.0 107.744 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 18.5 p -73.01 -32.88 65.42 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 114.876 -1.056 . . . . 1.0 108.523 176.747 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.36 17.68 66.08 Favored Glycine 0 CA--C 1.522 0.484 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.977 178.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.439 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -100.29 114.59 65.76 Favored Pre-proline 0 N--CA 1.471 0.602 0 C-N-CA 120.448 -0.501 . . . . 1.0 111.164 -179.591 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' CB ' HG22 ' A' ' 52' ' ' THR . 38.5 Cg_exo -61.7 152.87 71.25 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.012 1.808 . . . . 1.0 114.097 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.416 ' HB1' ' CZ ' ' A' ' 77' ' ' PHE . . . -123.08 145.19 48.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 113.681 -1.599 . . . . 1.0 107.847 178.623 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.516 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 2.7 t -105.59 136.36 45.32 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.267 0.556 . . . . 1.0 112.482 -178.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.516 ' CD2' ' O ' ' A' ' 76' ' ' THR . 19.5 m-85 -150.07 151.25 32.92 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.546 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -87.93 128.32 35.37 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 107.652 -1.24 . . . . 1.0 107.652 175.699 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.5 t -54.86 -32.28 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 120.135 -0.626 . . . . 1.0 110.899 -177.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -72.48 -26.93 61.98 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.8 -0.76 . . . . 1.0 112.063 -177.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 20.4 mm100 -98.52 -11.1 22.59 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 112.789 0.662 . . . . 1.0 112.789 -178.08 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -71.54 169.07 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.798 0.666 . . . . 1.0 112.798 -175.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.425 HD13 HG21 ' A' ' 83' ' ' ILE . 0.1 OUTLIER -51.69 145.76 15.19 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 107.134 -1.432 . . . . 1.0 107.134 -178.785 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.412 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -49.73 -44.86 34.32 Favored 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 121.19 1.26 . . . . 1.0 112.654 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.25 91.99 Favored Glycine 0 C--N 1.317 -0.523 0 C-N-CA 120.007 -1.092 . . . . 1.0 111.295 -179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' TRP . . . . . 0.459 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 6.7 m95 -63.76 -31.26 72.38 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 114.028 -1.086 . . . . 1.0 111.523 -179.489 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 99.4 m -56.4 -53.54 56.18 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 121.913 -0.492 . . . . 1.0 111.655 -178.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -71.76 -38.49 70.38 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.284 0.846 . . . . 1.0 113.284 -177.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -64.01 -44.1 93.64 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 114.477 1.288 . . . . 1.0 114.477 -176.445 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 26.9 mt -58.71 -37.99 77.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.275 0.559 . . . . 1.0 110.778 -177.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -64.92 -24.1 67.42 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.294 -0.866 . . . . 1.0 111.345 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 27.6 mt -102.06 -18.96 15.36 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.173 -0.467 . . . . 1.0 111.212 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.4 ttp -81.34 109.36 13.8 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 112.639 0.607 . . . . 1.0 112.639 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.522 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.39 148.32 84.04 Favored 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 122.679 2.253 . . . . 1.0 113.116 178.636 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.592 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.91 131.48 46.8 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-O 121.606 0.717 . . . . 1.0 111.811 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.71 -16.51 60.87 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 108.177 -1.969 . . . . 1.0 108.177 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.449 ' CB ' ' H ' ' A' ' 40' ' ' GLY . 5.7 p -88.46 139.13 30.79 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.089 -0.556 . . . . 1.0 110.139 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 50.9 m -110.27 117.43 33.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.12 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -117.49 169.64 9.37 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.95 0.881 . . . . 1.0 110.546 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.631 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.8 mt-10 -130.24 132.65 46.06 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.935 -1.506 . . . . 1.0 106.935 175.76 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.41 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -127.48 137.13 58.62 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 108.603 -0.888 . . . . 1.0 108.603 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.65 102.82 11.85 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 105.83 -1.915 . . . . 1.0 105.83 -177.8 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.6 t -89.94 115.1 63.11 Favored Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 114.516 1.302 . . . . 1.0 114.516 -174.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -51.57 144.33 33.33 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 121.072 1.181 . . . . 1.0 109.696 176.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 87.6 p -49.97 -31.98 13.9 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.377 -0.529 . . . . 1.0 110.959 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.71 -31.78 70.52 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.558 -0.617 . . . . 1.0 111.558 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.09 3.09 43.78 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 110.548 -0.167 . . . . 1.0 110.548 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.84 -109.06 0.33 Allowed 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 120.736 0.303 . . . . 1.0 111.256 -178.349 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.404 ' O ' HG21 ' A' ' 114' ' ' VAL . 38.6 m-85 -98.32 -4.66 34.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 114.379 1.251 . . . . 1.0 114.379 -176.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.32 172.68 18.95 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 120.497 -0.859 . . . . 1.0 113.174 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 121' ' ' ASN . 71.9 Cg_endo -73.75 -31.4 8.49 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 123.649 2.899 . . . . 1.0 112.388 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -82.23 170.81 14.98 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.365 0.602 . . . . 1.0 111.435 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.418 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 7.3 m -79.34 88.3 4.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.279 -0.873 . . . . 1.0 109.039 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.404 HG21 ' O ' ' A' ' 109' ' ' TYR . 3.3 t -97.88 55.26 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.341 -0.39 . . . . 1.0 111.383 -178.462 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 173.37 -175.25 46.18 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 120.509 -0.853 . . . . 1.0 112.087 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.34 -103.34 0.01 OUTLIER Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.268 -0.733 . . . . 1.0 111.268 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -62.13 -15.91 47.04 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.478 2.119 . . . . 1.0 110.518 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.908 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.6 mp -66.39 115.03 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.376 -1.342 . . . . 1.0 107.376 178.44 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -97.26 -157.79 30.82 Favored Glycine 0 C--O 1.213 -1.186 0 N-CA-C 110.814 -0.914 . . . . 1.0 110.814 -178.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.48 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 53.4 Cg_endo -71.02 147.58 55.08 Favored 'Trans proline' 0 C--N 1.297 -2.156 0 C-N-CA 121.51 1.474 . . . . 1.0 112.982 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.545 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 39.48 60.97 1.47 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 113.216 0.821 . . . . 1.0 113.216 177.503 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.744 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -112.69 140.35 47.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.038 0.447 . . . . 1.0 110.611 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 85.5 m -93.93 127.73 39.86 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.1 -1.074 . . . . 1.0 108.1 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -108.85 136.41 48.45 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.516 -0.55 . . . . 1.0 109.516 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -117.6 146.87 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 108.706 -0.849 . . . . 1.0 108.706 178.463 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 126' ' ' PHE . 4.0 m-85 -135.8 149.49 49.12 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.236 -0.586 . . . . 1.0 111.334 178.137 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.473 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 9.5 mmtt -99.46 124.57 44.73 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 104.948 -2.242 . . . . 1.0 104.948 177.427 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.9 mt -115.77 118.37 58.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 C-N-CA 119.167 -1.013 . . . . 1.0 111.9 -177.498 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -110.39 123.05 49.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.655 -1.611 . . . . 1.0 108.484 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.76 112.95 24.55 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 112.544 0.572 . . . . 1.0 112.544 -177.618 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.486 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -94.49 -49.17 12.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 CA-C-N 115.749 -0.66 . . . . 1.0 111.17 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.6 p -145.32 157.39 44.06 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.014 0.435 . . . . 1.0 110.601 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.461 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.3 t -130.09 137.56 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.288 -0.414 . . . . 1.0 110.993 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 tptt . . . . . 0 N--CA 1.449 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.541 178.64 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.121 -0.696 . . . . 1.0 109.121 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 66.0 m-80 -61.92 -18.49 60.45 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.131 -0.692 . . . . 1.0 109.131 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -49.57 -41.05 40.59 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.361 -0.978 . . . . 1.0 108.361 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.556 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 0.3 OUTLIER -64.68 -35.94 82.67 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.239 -179.38 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -52.62 -38.02 59.44 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 116.191 -0.459 . . . . 1.0 110.384 179.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -65.08 -37.48 87.64 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.603 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -66.9 -51.4 55.87 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.861 0.839 . . . . 1.0 110.633 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.611 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 3.7 m-20 -58.55 -38.42 77.79 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 107.528 -1.286 . . . . 1.0 107.528 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -63.93 -50.98 66.55 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 113.125 -1.852 . . . . 1.0 111.806 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 70.7 t -73.82 -48.62 38.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 119.812 -0.755 . . . . 1.0 111.713 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.45 ' O ' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -60.36 -40.63 91.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.827 -1.175 . . . . 1.0 107.827 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.447 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -65.74 -48.07 70.4 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.374 -0.83 . . . . 1.0 112.133 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -61.71 -31.25 71.39 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.01 -0.737 . . . . 1.0 109.01 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.22 -33.79 43.44 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.121 -0.945 . . . . 1.0 109.957 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' O ' ' A' ' 11' ' ' LYS . 64.3 t80 -61.14 -50.78 71.81 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 114.445 -1.252 . . . . 1.0 110.414 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.44 -41.59 80.07 Favored 'General case' 0 CA--C 1.513 -0.452 0 C-N-CA 119.963 -0.695 . . . . 1.0 109.649 178.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.8 m -62.14 -41.31 98.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.569 -0.741 . . . . 1.0 109.474 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -75.74 -45.29 37.38 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.584 -0.734 . . . . 1.0 111.637 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.1 t30 -61.34 -45.03 96.12 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 113.135 0.791 . . . . 1.0 113.135 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -57.68 -31.36 66.27 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 119.305 -0.958 . . . . 1.0 108.833 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -80.74 -31.48 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.72 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 41.2 mtmt -56.97 139.85 78.02 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 120.19 -0.604 . . . . 1.0 110.905 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -56.27 148.49 60.5 Favored 'Trans proline' 0 N--CA 1.502 2.0 0 C-N-CA 122.069 1.846 . . . . 1.0 113.879 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.1 -19.5 10.06 Favored Glycine 0 C--O 1.227 -0.318 0 CA-C-N 114.937 -1.029 . . . . 1.0 111.992 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.404 HG22 ' HB2' ' A' ' 35' ' ' LYS . 43.5 t -83.35 138.17 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.123 0.487 . . . . 1.0 110.929 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.5 t -122.35 122.41 66.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.8 p -96.76 146.22 7.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.653 0 CA-C-O 121.569 0.699 . . . . 1.0 111.847 -178.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.7 mt -114.08 166.09 12.23 Favored Pre-proline 0 C--O 1.232 0.146 0 CA-C-N 114.484 -1.235 . . . . 1.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -62.07 -30.46 82.71 Favored 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 121.985 1.79 . . . . 1.0 111.499 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 m -68.84 -13.3 62.33 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.955 -0.566 . . . . 1.0 109.811 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.96 -1.56 68.14 Favored Glycine 0 CA--C 1.517 0.199 0 N-CA-C 109.811 -1.316 . . . . 1.0 109.811 -179.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.459 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.9 tm? -80.95 133.98 35.62 Favored 'General case' 0 CA--C 1.518 -0.258 0 N-CA-C 108.591 -0.892 . . . . 1.0 108.591 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.459 ' H ' HD22 ' A' ' 32' ' ' LEU . 18.9 mp0 -122.42 138.42 54.54 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 116.448 -0.342 . . . . 1.0 111.087 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -133.56 145.5 50.15 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.525 0.679 . . . . 1.0 111.054 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.504 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -127.66 132.82 49.66 Favored 'General case' 0 CA--C 1.505 -0.751 0 CA-C-N 114.552 -1.204 . . . . 1.0 109.499 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.57 104.26 14.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 122.2 1.0 . . . . 1.0 112.122 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.629 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.8 mm -70.24 -41.69 78.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.027 -0.988 . . . . 1.0 108.523 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -143.11 128.34 18.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 114.595 -1.184 . . . . 1.0 109.495 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.0 p -88.12 131.84 34.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.746 0.308 . . . . 1.0 110.239 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.21 -35.44 0.81 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.403 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 6.2 m-20 57.23 30.66 18.77 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.251 -0.474 . . . . 1.0 111.169 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.12 -161.73 37.55 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.828 0.682 . . . . 1.0 111.756 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 25.9 m -69.01 -178.4 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.153 -1.023 . . . . 1.0 109.576 178.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.533 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.62 154.26 0.4 Allowed Pre-proline 0 C--N 1.32 -0.711 0 O-C-N 123.682 0.614 . . . . 1.0 109.523 179.554 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -87.83 157.81 7.46 Favored 'Trans proline' 0 N--CA 1.5 1.894 0 C-N-CA 123.363 2.709 . . . . 1.0 117.242 -174.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.439 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.84 176.17 44.05 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 109.205 -1.558 . . . . 1.0 109.205 176.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.468 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.5 -25.46 6.6 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.189 -0.506 . . . . 1.0 112.055 -179.443 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -108.61 -8.42 15.47 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 112.834 0.679 . . . . 1.0 112.834 -177.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.439 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.3 m-20 -82.96 166.47 18.82 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.327 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -105.35 150.59 25.08 Favored 'General case' 0 CA--C 1.511 -0.551 0 CA-C-O 121.334 0.588 . . . . 1.0 110.146 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.0 p -128.94 160.68 39.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.19 -0.914 . . . . 1.0 112.009 -177.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.437 HG22 ' HB3' ' A' ' 74' ' ' PRO . 84.8 m -127.69 119.87 26.78 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.125 -1.065 . . . . 1.0 108.125 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.514 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 7.2 m -148.9 164.74 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 114.507 1.299 . . . . 1.0 114.507 -176.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.9 mt-10 -118.22 150.74 38.92 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 106.305 -1.739 . . . . 1.0 106.305 174.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.552 ' O ' ' N ' ' A' ' 68' ' ' THR . 32.5 p90 -163.32 162.9 25.34 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 115.09 1.515 . . . . 1.0 115.09 -177.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -126.27 129.47 48.97 Favored 'General case' 0 C--O 1.217 -0.608 0 CA-C-N 115.086 -0.961 . . . . 1.0 108.515 175.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.76 134.61 12.09 Favored Glycine 0 N--CA 1.471 1.011 0 N-CA-C 111.472 -0.651 . . . . 1.0 111.472 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.53 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 8.6 ptp85 -147.03 167.43 24.05 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.701 0.763 . . . . 1.0 112.389 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.5 mp -84.46 165.06 18.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 114.349 -1.296 . . . . 1.0 110.236 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.429 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.79 -26.55 38.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.265 -0.879 . . . . 1.0 110.524 178.445 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -92.0 3.18 55.81 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.044 -1.434 . . . . 1.0 111.701 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.24 -4.09 76.97 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 121.337 -0.458 . . . . 1.0 113.177 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.3 m -68.01 104.06 1.65 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 118.141 0.97 . . . . 1.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.6 t -76.43 120.04 25.79 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.079 0.466 . . . . 1.0 110.153 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.751 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.8 p90 -109.28 -11.79 14.84 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 115.231 -0.895 . . . . 1.0 112.308 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.503 ' CB ' H433 ' A' ' 138' ' ' RAP . 11.5 t70 -161.99 153.08 17.99 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.316 -0.554 . . . . 1.0 111.511 178.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 94.4 p -159.23 154.21 24.97 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.41 0.624 . . . . 1.0 112.558 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.552 ' N ' ' O ' ' A' ' 55' ' ' TYR . 62.3 m -150.15 -40.74 0.13 Allowed 'General case' 0 C--O 1.223 -0.337 0 CA-C-N 115.024 -0.989 . . . . 1.0 110.305 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.41 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.6 pp20? -62.22 -26.62 68.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.241 -0.583 . . . . 1.0 109.637 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.9 mmmt -57.0 -42.91 81.17 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.426 -1.324 . . . . 1.0 107.426 178.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.492 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.4 p -73.28 -33.72 65.39 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.732 -1.122 . . . . 1.0 108.365 176.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.13 17.04 75.27 Favored Glycine 0 C--N 1.334 0.425 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.359 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.6 mttm -101.44 116.7 63.3 Favored Pre-proline 0 N--CA 1.469 0.524 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.693 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.3 Cg_exo -60.08 152.76 63.06 Favored 'Trans proline' 0 N--CA 1.485 0.982 0 C-N-CA 121.786 1.657 . . . . 1.0 114.377 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.412 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -122.29 147.26 46.45 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 113.827 -1.533 . . . . 1.0 107.548 177.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.46 128.12 52.3 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 121.072 0.463 . . . . 1.0 112.014 -179.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.505 ' CD2' ' H31' ' A' ' 138' ' ' RAP . 25.5 m-85 -136.06 150.59 49.22 Favored 'General case' 0 CA--C 1.493 -1.24 0 CA-C-O 121.797 0.808 . . . . 1.0 110.844 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 60.5 mt-30 -94.14 123.63 37.65 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 105.828 -1.915 . . . . 1.0 105.828 174.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.3 t -49.44 -25.61 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.795 -0.638 . . . . 1.0 110.663 -176.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 15.3 t -78.11 -24.33 47.53 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 120.308 -0.557 . . . . 1.0 112.189 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.495 ' O ' ' H34' ' A' ' 138' ' ' RAP . 92.7 mm-40 -96.6 -10.28 27.48 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.112 0.412 . . . . 1.0 112.112 -179.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.615 HG23 H31A ' A' ' 138' ' ' RAP . 0.5 OUTLIER -79.68 166.8 2.4 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 N-CA-C 112.59 0.589 . . . . 1.0 112.59 -176.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -57.24 146.7 60.84 Favored Pre-proline 0 CA--C 1.545 0.753 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 -179.672 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -48.88 -46.11 26.05 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.686 1.591 . . . . 1.0 113.03 -178.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.68 -47.56 87.66 Favored Glycine 0 C--N 1.319 -0.398 0 N-CA-C 109.753 -1.339 . . . . 1.0 109.753 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.604 ' CD2' ' H41' ' A' ' 138' ' ' RAP . 7.3 m95 -64.4 -36.23 83.49 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.147 -1.027 . . . . 1.0 110.199 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.43 ' H ' ' HG1' ' A' ' 87' ' ' THR . 19.5 m -51.17 -54.5 24.87 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.313 -0.403 . . . . 1.0 111.25 -177.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -72.96 -41.62 64.21 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.604 0.594 . . . . 1.0 112.604 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.51 -46.46 83.78 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 113.615 0.969 . . . . 1.0 113.615 -177.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 38.3 mt -58.85 -41.58 87.29 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 109.192 -0.67 . . . . 1.0 109.192 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 25.3 mt-30 -62.95 -23.85 67.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 114.938 -1.028 . . . . 1.0 110.696 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.448 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 83.9 mt -103.34 -12.96 16.88 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.255 -0.429 . . . . 1.0 111.327 -179.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.8 ttp -87.6 108.66 21.34 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-O 119.349 -0.358 . . . . 1.0 111.899 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.533 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.44 147.88 83.19 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 122.377 2.051 . . . . 1.0 112.365 178.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -66.46 132.37 48.12 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.519 -0.764 . . . . 1.0 111.438 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 99.52 -18.81 55.73 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 108.567 -1.813 . . . . 1.0 108.567 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.1 p -88.63 136.45 32.99 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 120.959 0.409 . . . . 1.0 110.387 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 90.5 m -108.27 114.39 28.22 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 115.803 -0.635 . . . . 1.0 109.708 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.448 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.1 m0 -115.4 167.6 10.72 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 121.596 0.712 . . . . 1.0 111.228 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.629 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.2 mt-10 -127.37 128.11 45.33 Favored 'General case' 0 CA--C 1.508 -0.639 0 N-CA-C 106.673 -1.603 . . . . 1.0 106.673 175.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' A' ' 86' ' ' TRP . 2.6 pt -123.32 138.07 54.5 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.6 0 CA-C-O 121.894 0.855 . . . . 1.0 110.27 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.44 103.9 13.13 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.957 -1.868 . . . . 1.0 105.957 -177.979 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.7 t -90.42 115.4 64.02 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 115.076 1.51 . . . . 1.0 115.076 -174.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -51.15 141.96 36.97 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 121.323 1.348 . . . . 1.0 109.858 175.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.3 p -48.46 -34.28 10.81 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.149 -0.62 . . . . 1.0 110.943 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.87 -32.32 80.72 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.144 -0.782 . . . . 1.0 111.144 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 68.0 mt -98.55 1.67 46.75 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 121.393 -0.123 . . . . 1.0 110.74 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.8 -113.39 0.3 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.052 0.39 . . . . 1.0 112.052 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.655 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 58.4 m-85 -98.2 3.77 48.95 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 112.487 0.551 . . . . 1.0 112.487 -177.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 109.49 162.75 19.67 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 121.014 -0.612 . . . . 1.0 112.768 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -74.75 -9.29 21.04 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 123.556 2.837 . . . . 1.0 111.695 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -103.63 166.59 10.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.126 -0.488 . . . . 1.0 109.839 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.57 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -72.3 84.99 1.07 Allowed 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.0 t -100.72 62.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.985 0.422 . . . . 1.0 110.513 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.443 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -179.98 41.09 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 111.502 -0.639 . . . . 1.0 111.502 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.84 -103.98 0.01 OUTLIER Glycine 0 CA--C 1.535 1.322 0 N-CA-C 110.992 -0.843 . . . . 1.0 110.992 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -61.33 -14.78 36.39 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.549 2.166 . . . . 1.0 110.669 -178.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.751 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.1 mp -65.83 113.25 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 106.672 -1.603 . . . . 1.0 106.672 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.31 -172.79 40.14 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.378 -0.828 . . . . 1.0 112.28 -177.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.57 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.2 Cg_endo -62.88 138.11 66.58 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 C-N-CA 122.38 2.053 . . . . 1.0 112.405 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.34 51.82 12.4 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 121.039 -0.264 . . . . 1.0 111.061 178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.611 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -98.82 130.06 45.24 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.921 0.712 . . . . 1.0 112.921 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.447 HG21 HD11 ' A' ' 16' ' ' LEU . 43.5 m -96.66 129.13 44.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 106.063 -1.829 . . . . 1.0 106.063 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -110.94 145.15 38.87 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.308 0.575 . . . . 1.0 111.105 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.664 HD12 ' CE2' ' A' ' 102' ' ' TYR . 2.1 tt -124.31 148.55 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 CA-C-N 115.233 -0.894 . . . . 1.0 108.884 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.597 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -140.93 151.17 44.0 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.242 -0.583 . . . . 1.0 111.515 177.536 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.53 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 12.9 mmtt -99.36 125.32 45.01 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 105.46 -2.052 . . . . 1.0 105.46 177.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.02 118.4 56.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.267 -0.973 . . . . 1.0 112.418 -176.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.601 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.6 t60 -109.68 123.88 50.25 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 114.128 -1.397 . . . . 1.0 108.649 178.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.07 111.17 23.02 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 120.246 -0.582 . . . . 1.0 112.39 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.601 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.1 mp -94.29 -42.69 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 115.995 -0.548 . . . . 1.0 111.676 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -153.44 156.0 37.38 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.502 -0.479 . . . . 1.0 110.796 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 44' ' ' LYS . 44.7 t -130.65 138.82 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 116.156 -0.475 . . . . 1.0 111.452 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.4 tptm -99.65 -151.9 0.4 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 121.494 0.664 . . . . 1.0 109.564 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.414 ' H ' ' HG3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -172.17 137.47 0.91 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.198 -0.91 . . . . 1.0 110.486 178.333 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.499 ' OG ' ' N ' ' A' ' 137' ' ' SER . 5.3 p -68.16 -57.81 5.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 1.0 111.043 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.499 ' N ' ' OG ' ' A' ' 136' ' ' SER . 1.2 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.929 -1.034 . . . . 1.0 110.134 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.725 ' O2 ' ' O3 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 26.4 m-85 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.456 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 96.8 m-20 -65.17 -36.46 84.3 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.883 -0.327 . . . . 1.0 110.813 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.516 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 58.6 pttt -46.29 -43.6 15.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.12 0.486 . . . . 1.0 110.276 -178.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.516 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 6.6 tmtt? -70.37 -38.8 74.81 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.866 0.841 . . . . 1.0 109.589 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.84 -35.07 43.37 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 114.908 -1.042 . . . . 1.0 110.165 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -65.12 -37.68 88.23 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.395 -0.82 . . . . 1.0 110.889 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -65.79 -51.89 55.34 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.655 0.74 . . . . 1.0 110.505 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.4 m-20 -59.67 -35.31 74.19 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.204 -1.035 . . . . 1.0 108.204 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.3 tttt -66.59 -50.5 62.86 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 113.757 -1.565 . . . . 1.0 111.919 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.15 -48.0 82.81 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 C-N-CA 119.813 -0.755 . . . . 1.0 111.253 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.84 -38.1 89.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 178.898 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.15 -44.76 52.9 Favored Glycine 0 CA--C 1.525 0.703 0 CA-C-N 114.847 -1.069 . . . . 1.0 112.366 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -60.44 -31.78 70.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 119.494 -0.882 . . . . 1.0 108.692 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.99 -35.5 57.12 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.809 -1.087 . . . . 1.0 109.87 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.1 t80 -61.39 -51.34 69.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.621 -1.172 . . . . 1.0 110.847 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.408 HD11 HG21 ' A' ' 123' ' ' THR . 5.3 mp -68.12 -38.37 82.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 119.995 -0.682 . . . . 1.0 109.41 179.06 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 99.3 m -62.16 -41.65 98.51 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.553 -0.749 . . . . 1.0 109.296 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -74.62 -46.81 35.96 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.056 -0.975 . . . . 1.0 111.655 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.638 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -55.73 -50.49 70.24 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 112.496 0.554 . . . . 1.0 112.496 -178.783 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.0 ptmt -60.1 -26.74 66.45 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.379 -0.928 . . . . 1.0 109.831 -177.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -83.55 -31.23 26.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.377 -0.829 . . . . 1.0 111.186 179.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -58.7 136.45 86.57 Favored Pre-proline 0 CA--C 1.548 0.871 0 CA-C-N 116.52 -0.309 . . . . 1.0 111.576 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -56.75 148.58 64.84 Favored 'Trans proline' 0 N--CA 1.503 2.071 0 C-N-CA 122.138 1.892 . . . . 1.0 113.334 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.14 -19.32 18.11 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.495 -0.775 . . . . 1.0 111.49 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.471 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.1 t -86.42 137.71 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.165 0.507 . . . . 1.0 110.547 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.93 121.78 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 107.582 -1.266 . . . . 1.0 107.582 177.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.19 145.99 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.642 0 CA-C-O 121.361 0.601 . . . . 1.0 111.228 -178.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 92.8 mt -111.94 164.81 14.25 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.85 -1.068 . . . . 1.0 110.462 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -61.54 -30.48 86.28 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.745 1.63 . . . . 1.0 110.91 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -68.83 -14.44 63.03 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.473 -0.785 . . . . 1.0 109.828 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.41 -3.89 66.43 Favored Glycine 0 C--N 1.329 0.157 0 N-CA-C 109.671 -1.371 . . . . 1.0 109.671 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.472 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.16 133.93 36.71 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 108.457 -0.942 . . . . 1.0 108.457 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.472 ' H ' HD22 ' A' ' 32' ' ' LEU . 15.2 mp0 -123.07 143.38 50.0 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 116.286 -0.416 . . . . 1.0 110.887 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.4 p90 -138.21 143.59 40.25 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-O 121.635 0.731 . . . . 1.0 110.757 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.525 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -127.51 131.24 50.14 Favored 'General case' 0 CA--C 1.501 -0.924 0 CA-C-N 114.594 -1.184 . . . . 1.0 109.188 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 p -88.85 104.62 15.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 122.279 1.038 . . . . 1.0 111.688 -178.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.0 mm -69.25 -42.2 81.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.881 -1.054 . . . . 1.0 108.453 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -143.36 124.55 14.54 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.501 -1.227 . . . . 1.0 109.907 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -85.83 129.64 34.77 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.611 -0.436 . . . . 1.0 109.9 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.23 -33.24 1.26 Allowed Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.895 -1.282 . . . . 1.0 109.895 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.406 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 5.1 m-20 57.04 31.67 20.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.477 -0.361 . . . . 1.0 111.157 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.08 -162.18 37.92 Favored Glycine 0 C--N 1.332 0.329 0 CA-C-O 121.819 0.677 . . . . 1.0 111.822 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.4 m -68.17 -177.93 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 114.061 -1.069 . . . . 1.0 109.127 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.695 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.32 154.82 0.39 Allowed Pre-proline 0 C--N 1.317 -0.834 0 N-CA-C 109.338 -0.616 . . . . 1.0 109.338 179.553 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.427 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 56.8 Cg_endo -86.71 158.78 9.09 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 123.11 2.54 . . . . 1.0 115.741 -175.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 177.29 41.72 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 108.766 -1.734 . . . . 1.0 108.766 176.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.48 -23.02 9.07 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.882 -0.327 . . . . 1.0 111.07 -179.713 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 57.9 m -108.05 -9.22 15.67 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 113.629 0.974 . . . . 1.0 113.629 -176.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.7 m-20 -84.74 166.87 16.64 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 119.883 -0.727 . . . . 1.0 109.468 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.5 m -104.56 148.44 26.5 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.612 -0.514 . . . . 1.0 109.612 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.427 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -126.57 161.79 32.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.478 0 CA-C-N 115.857 -0.611 . . . . 1.0 112.278 -176.313 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.421 HG22 ' HB3' ' A' ' 74' ' ' PRO . 86.4 m -130.48 118.18 20.74 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 75' ' ' ALA . 2.5 m -148.14 166.43 4.79 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 112.577 0.584 . . . . 1.0 112.577 -177.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.2 mt-10 -116.39 157.7 24.66 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 106.469 -1.678 . . . . 1.0 106.469 175.078 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.475 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.6 p90 -167.2 160.91 14.15 Favored 'General case' 0 C--N 1.346 0.415 0 N-CA-C 114.846 1.425 . . . . 1.0 114.846 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -124.76 127.81 47.8 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.119 -1.067 . . . . 1.0 108.119 174.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.89 134.03 11.39 Favored Glycine 0 N--CA 1.47 0.955 0 C-N-CA 120.748 -0.739 . . . . 1.0 111.915 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -146.48 166.84 25.22 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.715 0.769 . . . . 1.0 112.169 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.0 162.66 20.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.391 -1.277 . . . . 1.0 110.062 177.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.05 -25.33 29.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.913 0.863 . . . . 1.0 110.206 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -92.22 2.84 56.37 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 113.947 -1.479 . . . . 1.0 111.852 -177.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.96 -4.98 78.86 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 121.016 -0.611 . . . . 1.0 112.781 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.7 m -68.82 105.75 2.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 118.068 0.934 . . . . 1.0 109.63 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 67.7 t -77.69 121.82 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.691 0 CA-C-O 121.229 0.538 . . . . 1.0 110.301 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.6 p90 -110.41 -11.53 14.5 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.089 -0.959 . . . . 1.0 111.688 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -159.84 154.13 23.66 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.192 0.52 . . . . 1.0 111.497 177.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.3 p -159.29 151.43 20.98 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.41 -0.814 . . . . 1.0 111.213 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.475 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.9 m -154.38 -41.78 0.09 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.645 -0.707 . . . . 1.0 110.649 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.426 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -62.38 -26.33 68.41 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.862 -0.608 . . . . 1.0 110.313 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -55.34 -41.88 73.06 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 108.153 -1.054 . . . . 1.0 108.153 179.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.7 p -80.05 -30.82 39.47 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.067 177.365 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.1 16.99 68.19 Favored Glycine 0 C--N 1.336 0.531 0 CA-C-N 115.689 -0.687 . . . . 1.0 111.592 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -97.28 115.73 65.8 Favored Pre-proline 0 N--CA 1.471 0.591 0 C-N-CA 120.716 -0.394 . . . . 1.0 110.342 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 Cg_exo -60.32 156.23 41.93 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.177 1.918 . . . . 1.0 114.687 -178.364 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.67 145.36 49.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 113.908 -1.496 . . . . 1.0 107.595 177.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.513 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 1.4 t -104.0 133.91 48.16 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.395 0.617 . . . . 1.0 112.075 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.689 ' CZ ' ' H52' ' A' ' 138' ' ' RAP . 22.6 m-85 -144.18 152.45 40.9 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.837 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -94.52 125.15 38.99 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.878 -1.527 . . . . 1.0 106.878 175.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.95 -30.87 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 C-N-CA 120.04 -0.664 . . . . 1.0 110.57 -177.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -73.42 -24.25 60.24 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.299 -0.561 . . . . 1.0 112.349 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.534 ' O ' ' H34' ' A' ' 138' ' ' RAP . 86.1 mm-40 -99.72 -14.67 18.79 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.888 0.699 . . . . 1.0 112.888 -177.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.717 HG23 H31A ' A' ' 138' ' ' RAP . 0.8 OUTLIER -73.14 169.43 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 112.434 0.531 . . . . 1.0 112.434 -176.745 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.523 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -56.09 149.08 37.06 Favored Pre-proline 0 CA--C 1.547 0.831 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 -179.402 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.435 ' HD2' HG22 ' A' ' 83' ' ' ILE . 74.0 Cg_exo -51.49 -45.01 40.18 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 121.359 1.372 . . . . 1.0 112.941 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.93 -46.78 93.13 Favored Glycine 0 N--CA 1.45 -0.428 0 N-CA-C 110.29 -1.124 . . . . 1.0 110.29 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.6 m95 -65.87 -33.5 75.99 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.389 -0.906 . . . . 1.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.7 m -54.91 -54.16 46.18 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.703 -0.399 . . . . 1.0 111.359 -178.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -72.74 -42.44 64.07 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 112.771 0.656 . . . . 1.0 112.771 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.73 -46.8 83.95 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.903 1.075 . . . . 1.0 113.903 -177.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.2 mt -58.5 -41.56 85.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.347 0.594 . . . . 1.0 109.811 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -63.74 -23.59 67.43 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.095 -0.957 . . . . 1.0 110.515 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.528 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 81.3 mt -102.59 -10.03 19.63 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 116.032 -0.531 . . . . 1.0 111.422 -179.36 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.6 ttp -91.89 107.81 25.43 Favored Pre-proline 0 CA--C 1.546 0.823 0 N-CA-C 111.835 0.309 . . . . 1.0 111.835 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.695 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.0 Cg_exo -65.78 147.66 85.76 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 122.488 2.125 . . . . 1.0 112.357 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.74 137.55 58.12 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.666 0.746 . . . . 1.0 111.508 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.73 53.27 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 108.546 -1.822 . . . . 1.0 108.546 -178.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 p -87.18 134.6 33.51 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.009 0.433 . . . . 1.0 110.178 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.9 m -107.59 114.68 28.83 Favored 'General case' 0 CA--C 1.51 -0.582 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.052 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.528 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.6 m0 -115.71 164.38 14.43 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.708 0.766 . . . . 1.0 111.23 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.6 mt-10 -124.96 126.39 45.4 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 106.815 -1.55 . . . . 1.0 106.815 175.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -121.92 138.39 52.32 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.688 0 CA-C-O 121.899 0.857 . . . . 1.0 109.969 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.751 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.64 103.25 12.08 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.646 -1.983 . . . . 1.0 105.646 -178.231 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.2 115.45 64.07 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 114.75 1.389 . . . . 1.0 114.75 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -50.84 143.2 30.75 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 C-N-CA 121.433 1.422 . . . . 1.0 109.783 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 96.5 p -49.1 -35.26 15.75 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.273 -0.571 . . . . 1.0 110.531 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.86 -32.15 81.89 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 111.388 -0.685 . . . . 1.0 111.388 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 53.3 mt -100.59 2.91 42.2 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 121.499 -0.08 . . . . 1.0 110.832 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.66 -107.95 0.33 Allowed 'General case' 0 N--CA 1.457 -0.11 0 CA-C-O 120.923 0.392 . . . . 1.0 111.037 -178.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.64 ' CZ ' H121 ' A' ' 138' ' ' RAP . 52.7 m-85 -100.03 4.89 45.01 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 111.965 0.357 . . . . 1.0 111.965 -178.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.78 160.97 25.76 Favored Glycine 0 CA--C 1.529 0.927 0 C-N-CA 121.395 -0.431 . . . . 1.0 112.925 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.567 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.2 Cg_endo -70.56 -15.94 34.12 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 123.316 2.677 . . . . 1.0 112.676 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.456 ' O ' HG23 ' A' ' 114' ' ' VAL . 2.8 mpt_? -96.75 169.48 9.84 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.22 -0.659 . . . . 1.0 109.22 179.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.426 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.3 m -75.76 82.78 2.72 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.352 -0.539 . . . . 1.0 110.096 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.5 t -98.36 60.11 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.771 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 172.68 -172.7 45.16 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.534 -0.841 . . . . 1.0 112.033 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.81 -103.78 0.05 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 111.036 -0.826 . . . . 1.0 111.036 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -59.3 -16.88 36.79 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.219 1.946 . . . . 1.0 110.397 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.645 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.0 mp -67.75 114.7 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 107.889 -1.152 . . . . 1.0 107.889 179.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.611 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -94.89 -158.5 33.09 Favored Glycine 0 C--O 1.212 -1.253 0 N-CA-C 110.968 -0.853 . . . . 1.0 110.968 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.511 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 44.6 Cg_endo -70.09 147.45 60.75 Favored 'Trans proline' 0 C--N 1.299 -2.034 0 C-N-CA 121.892 1.728 . . . . 1.0 113.098 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.567 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.6 OUTLIER 39.99 60.74 1.65 Allowed 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.254 0.835 . . . . 1.0 113.254 177.511 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.709 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.03 135.85 53.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.571 0.7 . . . . 1.0 111.355 -179.423 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.408 HG21 HD11 ' A' ' 16' ' ' LEU . 99.2 m -93.69 129.0 40.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.329 178.117 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.51 140.97 42.63 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.142 0.496 . . . . 1.0 110.133 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.751 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -121.11 143.68 32.6 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.729 0 CA-C-N 115.506 -0.77 . . . . 1.0 109.014 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -134.89 150.66 50.46 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.082 0.468 . . . . 1.0 111.08 177.269 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 14.3 mmtt -99.63 126.02 45.56 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 104.85 -2.278 . . . . 1.0 104.85 176.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.8 mt -119.72 119.54 60.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 119.16 -1.016 . . . . 1.0 111.851 -177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.603 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.6 t60 -111.92 120.94 43.63 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 114.091 -1.413 . . . . 1.0 108.816 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.63 112.45 24.41 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 120.236 -0.585 . . . . 1.0 112.326 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.603 HD11 ' CD2' ' A' ' 129' ' ' HIS . 3.9 mp -94.84 -47.49 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.5 p -148.14 157.54 43.56 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.93 0.395 . . . . 1.0 111.246 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.43 HG21 ' HA ' ' A' ' 44' ' ' LYS . 54.7 t -130.07 139.25 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 116.043 -0.526 . . . . 1.0 111.396 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.543 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 12.5 tptt -94.98 -142.83 0.25 Allowed 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 115.424 -0.807 . . . . 1.0 110.298 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.543 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -171.77 149.9 2.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 114.685 -1.143 . . . . 1.0 109.751 177.877 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.423 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 87.7 p -40.51 -26.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.324 -0.853 . . . . 1.0 111.304 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 135' ' ' LYS . 97.7 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.686 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.769 H331 ' O2 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.504 ' CG ' ' N ' ' A' ' 2' ' ' ASN . 49.4 t80 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 108.935 -0.765 . . . . 1.0 108.935 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.504 ' N ' ' CG ' ' A' ' 1' ' ' PHE . 87.8 m-20 -71.08 -19.38 62.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.633 -0.258 . . . . 1.0 111.344 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 62.5 pttt -46.69 -41.58 15.19 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.578 -0.449 . . . . 1.0 110.482 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.513 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 4.4 tmtt? -69.21 -36.76 77.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.957 0.884 . . . . 1.0 109.951 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -51.34 -33.88 31.38 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 114.796 -1.093 . . . . 1.0 110.66 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -64.24 -36.85 85.43 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.197 -0.911 . . . . 1.0 110.804 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -66.79 -52.69 41.1 Favored 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 119.933 -0.707 . . . . 1.0 110.694 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 30.4 m-20 -59.51 -34.0 72.07 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-O 121.964 0.888 . . . . 1.0 108.617 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.8 tttt -64.43 -49.71 70.42 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 114.108 -1.405 . . . . 1.0 111.664 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.31 -47.26 74.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.408 -0.517 . . . . 1.0 112.112 -178.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.443 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.2 -36.91 83.36 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 179.686 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.79 -44.15 39.53 Favored Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.925 -1.034 . . . . 1.0 112.408 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -60.66 -30.97 70.22 Favored 'General case' 0 CA--C 1.514 -0.416 0 C-N-CA 119.701 -0.8 . . . . 1.0 108.883 179.221 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.8 -35.68 51.13 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.129 -0.941 . . . . 1.0 109.849 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 t80 -61.96 -50.8 70.66 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.728 -1.124 . . . . 1.0 110.901 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.45 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -66.82 -38.74 87.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 179.038 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.48 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 99.0 m -61.27 -43.0 99.59 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.498 -0.773 . . . . 1.0 109.584 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -75.32 -46.48 33.08 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.591 -0.731 . . . . 1.0 112.111 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.655 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 51.3 t30 -61.47 -45.12 95.58 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 113.145 0.795 . . . . 1.0 113.145 -177.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -58.02 -33.69 69.23 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 119.321 -0.952 . . . . 1.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 17' ' ' THR . 43.6 m-80 -75.46 -33.91 60.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.305 -0.861 . . . . 1.0 111.538 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -58.99 137.41 87.72 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 120.593 -0.443 . . . . 1.0 111.8 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -53.85 149.13 34.77 Favored 'Trans proline' 0 N--CA 1.507 2.302 0 C-N-CA 122.723 2.282 . . . . 1.0 114.757 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.76 -21.91 5.2 Favored Glycine 0 CA--C 1.508 -0.368 0 CA-C-N 114.421 -1.263 . . . . 1.0 111.265 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 54.3 t -80.21 132.0 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 N-CA-C 109.34 -0.615 . . . . 1.0 109.34 -179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.77 120.4 64.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.327 -0.99 . . . . 1.0 108.327 177.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.3 p -95.5 145.91 7.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 CA-C-O 121.471 0.653 . . . . 1.0 111.265 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.0 mt -114.17 165.26 14.07 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.597 -1.183 . . . . 1.0 110.955 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.76 -30.44 90.28 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 C-N-CA 121.828 1.685 . . . . 1.0 111.006 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.5 m -68.4 -15.82 63.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.608 -0.724 . . . . 1.0 109.801 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.95 -2.77 64.26 Favored Glycine 0 C--O 1.229 -0.192 0 N-CA-C 110.016 -1.234 . . . . 1.0 110.016 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.479 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -78.78 134.1 37.04 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.479 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.0 mp0 -123.64 142.93 50.58 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.393 -0.367 . . . . 1.0 111.525 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -140.6 142.26 35.08 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.919 0.866 . . . . 1.0 112.183 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.58 ' HE3' HD13 ' A' ' 37' ' ' ILE . 8.6 ttpt -123.99 126.57 46.52 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.173 -1.376 . . . . 1.0 108.45 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.416 ' H ' HG12 ' A' ' 36' ' ' VAL . 2.9 p -82.61 113.52 21.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.128 -178.301 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.58 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.8 mm -77.27 -42.24 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 CA-C-O 121.541 0.686 . . . . 1.0 109.844 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -144.34 124.01 13.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.725 -1.125 . . . . 1.0 109.917 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -81.84 129.58 34.79 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.539 -0.464 . . . . 1.0 110.527 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.15 -36.13 1.05 Allowed Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.106 -1.198 . . . . 1.0 110.106 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 57.81 31.22 20.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.447 -0.376 . . . . 1.0 111.49 179.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.67 -161.8 37.25 Favored Glycine 0 C--N 1.332 0.35 0 CA-C-O 121.984 0.769 . . . . 1.0 111.731 179.438 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.2 m -68.97 -177.86 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.093 -1.053 . . . . 1.0 109.086 178.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.61 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.18 154.23 0.38 Allowed Pre-proline 0 C--N 1.32 -0.676 0 O-C-N 123.757 0.661 . . . . 1.0 109.556 179.734 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.407 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.5 Cg_endo -87.71 158.01 7.63 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 123.336 2.691 . . . . 1.0 116.45 -175.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -90.0 175.57 41.68 Favored Glycine 0 N--CA 1.449 -0.449 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 176.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.498 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.84 -22.31 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.778 -0.369 . . . . 1.0 111.274 -179.383 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 53.5 m -107.88 -9.3 15.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.534 0.939 . . . . 1.0 113.534 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.19 165.43 17.4 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.436 -0.949 . . . . 1.0 108.436 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.7 m -104.72 150.53 24.66 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 109.869 -0.419 . . . . 1.0 109.869 -179.559 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.407 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.4 p -127.09 163.37 30.06 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 112.599 0.592 . . . . 1.0 112.599 -176.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.403 HG22 ' HB3' ' A' ' 74' ' ' PRO . 97.1 m -131.55 120.18 22.55 Favored 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 108.488 -0.93 . . . . 1.0 108.488 178.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.583 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 15.8 m -148.75 165.28 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 114.438 1.273 . . . . 1.0 114.438 -176.367 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.427 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 7.0 mt-10 -118.35 147.92 43.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 174.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.583 ' CE2' ' H51' ' A' ' 138' ' ' RAP . 37.3 p90 -163.63 162.14 24.11 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 114.68 1.363 . . . . 1.0 114.68 -176.725 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.49 133.11 54.6 Favored 'General case' 0 C--O 1.216 -0.675 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 175.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.83 135.96 11.79 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 120.972 -0.633 . . . . 1.0 111.855 -178.601 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.8 ptp85 -148.61 167.5 25.28 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.745 0.783 . . . . 1.0 112.997 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.69 163.79 18.99 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 114.377 -1.283 . . . . 1.0 110.989 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.58 -25.65 35.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 122.272 1.034 . . . . 1.0 109.589 177.468 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -89.86 0.72 56.87 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 113.378 -1.737 . . . . 1.0 111.688 -177.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.69 81.74 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 121.182 -0.533 . . . . 1.0 112.351 178.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.4 m -68.9 104.13 1.99 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 119.92 -0.712 . . . . 1.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.7 t -77.08 121.13 28.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 CA-C-N 116.059 -0.519 . . . . 1.0 110.062 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.698 ' CD2' HD11 ' A' ' 118' ' ' ILE . 22.0 p90 -110.59 -14.26 14.09 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.184 -0.916 . . . . 1.0 112.056 -178.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.523 ' OD2' H433 ' A' ' 138' ' ' RAP . 38.7 t0 -159.58 148.19 17.7 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.156 -0.618 . . . . 1.0 111.511 177.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 89.5 p -153.63 156.25 37.58 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.541 179.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.499 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 55.8 m -155.17 -39.51 0.09 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.984 -0.553 . . . . 1.0 110.78 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -63.12 -26.19 68.71 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.632 -0.427 . . . . 1.0 109.895 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -56.49 -41.3 76.4 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.085 -1.45 . . . . 1.0 107.085 178.288 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 68' ' ' THR . 23.1 p -76.74 -32.66 57.93 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.203 -1.362 . . . . 1.0 109.042 177.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.48 15.18 80.32 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.922 -0.871 . . . . 1.0 110.922 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.427 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 12.9 mttp -96.55 115.26 65.56 Favored Pre-proline 0 N--CA 1.47 0.537 0 C-N-CA 120.827 -0.349 . . . . 1.0 110.962 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.412 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.3 Cg_exo -61.41 151.75 77.46 Favored 'Trans proline' 0 N--CA 1.482 0.827 0 C-N-CA 121.539 1.493 . . . . 1.0 114.405 -178.241 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.8 150.34 46.45 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.089 -1.414 . . . . 1.0 107.78 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -107.53 136.07 47.93 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 112.882 0.697 . . . . 1.0 112.882 -178.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.606 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 48.0 m-85 -144.48 151.01 38.55 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 114.858 -1.064 . . . . 1.0 109.032 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 70.1 mt-30 -90.14 125.87 35.6 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 106.434 -1.691 . . . . 1.0 106.434 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.0 t -50.6 -31.4 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 C-N-CA 119.926 -0.71 . . . . 1.0 110.545 -177.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.8 t -73.57 -27.37 61.28 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 120.116 -0.634 . . . . 1.0 111.994 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.493 ' OE1' ' C46' ' A' ' 138' ' ' RAP . 43.9 mm-40 -101.35 -8.72 21.8 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 113.219 0.822 . . . . 1.0 113.219 -178.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.747 ' CG2' H31A ' A' ' 138' ' ' RAP . 3.5 p -80.32 172.84 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 C-N-CA 119.457 -0.897 . . . . 1.0 110.151 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.546 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.03 145.83 31.97 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 120.165 -0.614 . . . . 1.0 109.976 -176.733 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -51.42 -44.21 44.94 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.081 1.854 . . . . 1.0 112.783 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.05 -47.5 88.76 Favored Glycine 0 C--N 1.319 -0.4 0 N-CA-C 109.343 -1.503 . . . . 1.0 109.343 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.824 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 8.1 m95 -64.9 -35.21 80.4 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.796 -1.202 . . . . 1.0 110.565 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.24 -54.23 27.75 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.822 0.344 . . . . 1.0 111.172 -178.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -72.64 -43.14 63.59 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.745 0.646 . . . . 1.0 112.745 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.53 -45.84 84.56 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 113.957 1.095 . . . . 1.0 113.957 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.51 -41.12 84.7 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.457 0.646 . . . . 1.0 109.625 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -64.59 -23.85 67.4 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.836 -1.075 . . . . 1.0 110.805 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.482 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 80.6 mt -103.81 -10.73 18.03 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 116.207 -0.451 . . . . 1.0 111.41 -178.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 46.7 ttp -92.18 108.4 30.32 Favored Pre-proline 0 CA--C 1.55 0.978 0 CA-C-O 119.445 -0.312 . . . . 1.0 111.345 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.61 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.0 Cg_exo -65.35 148.26 88.12 Favored 'Trans proline' 0 N--CA 1.5 1.881 0 C-N-CA 122.681 2.254 . . . . 1.0 112.777 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.76 136.86 57.77 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.368 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.23 -19.31 53.12 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 108.954 -1.659 . . . . 1.0 108.954 -178.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.7 p -87.88 135.45 33.39 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 120.851 0.358 . . . . 1.0 110.473 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 72.0 m -107.89 114.94 29.24 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 115.952 -0.567 . . . . 1.0 110.142 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.482 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.4 m0 -114.99 164.24 14.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.491 0.662 . . . . 1.0 111.404 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.486 ' HB2' HD11 ' A' ' 37' ' ' ILE . 29.7 mt-10 -124.35 127.78 48.1 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.642 -1.614 . . . . 1.0 106.642 175.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -123.77 138.72 52.58 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.461 0 CA-C-O 121.768 0.794 . . . . 1.0 110.288 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.677 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.23 103.85 12.89 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.864 -1.902 . . . . 1.0 105.864 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.67 115.65 64.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 N-CA-C 115.466 1.654 . . . . 1.0 115.466 -174.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -50.71 143.25 29.7 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 C-N-CA 121.611 1.541 . . . . 1.0 110.017 176.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.5 p -50.09 -34.66 22.57 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.524 -0.47 . . . . 1.0 110.986 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.8 -31.89 76.68 Favored Glycine 0 CA--C 1.52 0.396 0 N-CA-C 110.812 -0.915 . . . . 1.0 110.812 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 54.9 mt -98.97 2.38 46.36 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 121.436 -0.106 . . . . 1.0 110.878 -179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -107.86 0.33 Allowed 'General case' 0 C--N 1.34 0.166 0 CA-C-O 120.503 0.192 . . . . 1.0 111.338 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.713 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 38.0 m-85 -99.45 4.64 46.22 Favored 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 113.279 0.844 . . . . 1.0 113.279 -177.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.33 164.52 22.81 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 120.756 -0.735 . . . . 1.0 113.352 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 121' ' ' ASN . 79.5 Cg_endo -73.98 -16.89 22.77 Favored 'Trans proline' 0 N--CA 1.493 1.46 0 C-N-CA 123.531 2.821 . . . . 1.0 110.9 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.439 ' O ' HG23 ' A' ' 114' ' ' VAL . 60.4 ttt180 -96.06 165.12 12.4 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.477 -1.238 . . . . 1.0 109.685 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.522 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 8.1 m -77.02 91.97 3.68 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.565 -0.531 . . . . 1.0 109.565 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.3 t -107.56 60.66 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.113 -0.494 . . . . 1.0 111.199 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.518 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 171.23 178.05 41.45 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 120.201 -0.999 . . . . 1.0 112.145 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.23 -103.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 111.072 -0.811 . . . . 1.0 111.072 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -62.35 -16.04 48.91 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.567 2.178 . . . . 1.0 110.779 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.2 mp -66.67 115.92 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 108.233 -1.025 . . . . 1.0 108.233 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -96.52 -158.96 31.78 Favored Glycine 0 C--O 1.213 -1.194 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.522 ' N ' ' OG ' ' A' ' 113' ' ' SER . 46.9 Cg_endo -70.89 147.39 55.51 Favored 'Trans proline' 0 C--N 1.297 -2.141 0 C-N-CA 121.766 1.644 . . . . 1.0 113.326 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' PRO . 18.0 t-20 41.17 60.6 2.0 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.195 0.813 . . . . 1.0 113.195 177.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.683 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.38 137.71 51.47 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 121.683 0.754 . . . . 1.0 111.225 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.45 HG21 HD11 ' A' ' 16' ' ' LEU . 81.8 m -94.43 130.09 40.91 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.332 -1.304 . . . . 1.0 108.624 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.29 141.3 46.17 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.05 -0.523 . . . . 1.0 109.8 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.677 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.7 tt -119.72 146.05 25.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 N-CA-C 108.368 -0.975 . . . . 1.0 108.368 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.574 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -137.98 151.0 47.5 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.394 -0.522 . . . . 1.0 111.759 177.838 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.469 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 4.1 mmtt -101.16 122.91 44.46 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 105.741 -1.948 . . . . 1.0 105.741 177.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.453 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.0 mt -117.51 119.19 60.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.956 0.884 . . . . 1.0 113.257 -176.27 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.555 ' CD2' HD11 ' A' ' 131' ' ' ILE . 4.5 t60 -109.95 124.03 50.67 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 113.935 -1.484 . . . . 1.0 108.354 178.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.93 111.12 23.2 Favored 'General case' 0 N--CA 1.465 0.293 0 C-N-CA 120.162 -0.615 . . . . 1.0 112.369 -178.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.555 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.3 mp -94.01 -45.03 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 115.881 -0.599 . . . . 1.0 111.729 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.7 p -150.63 155.82 40.13 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.683 -0.407 . . . . 1.0 110.79 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.426 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.4 t -129.71 137.21 57.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 121.05 0.452 . . . . 1.0 111.772 -177.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.449 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 17.5 tptt -88.62 -151.28 0.2 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.723 -0.671 . . . . 1.0 110.098 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.449 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -178.07 131.48 0.14 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.653 0.74 . . . . 1.0 111.716 179.178 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.8 t -65.08 -47.05 78.62 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.376 -1.283 . . . . 1.0 110.96 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.408 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 1.7 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 117.99 -1.005 . . . . 1.0 109.937 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.892 H491 H381 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 71.0 m-20 -62.12 -34.33 76.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.051 -0.522 . . . . 1.0 110.461 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -46.79 -32.58 3.77 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? -68.3 -35.04 77.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 122.134 0.969 . . . . 1.0 108.935 178.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.582 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.21 -36.6 42.35 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 114.592 -1.185 . . . . 1.0 110.794 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.44 -35.65 78.19 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.087 -179.199 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -66.11 -52.58 47.28 Favored 'General case' 0 C--O 1.222 -0.346 0 CA-C-O 121.663 0.744 . . . . 1.0 110.439 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.7 m-20 -58.0 -35.11 70.77 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.255 -1.017 . . . . 1.0 108.255 179.29 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.505 ' O ' ' N ' ' A' ' 13' ' ' GLU . 18.7 tttm -65.22 -51.07 63.26 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.691 178.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.52 -46.67 82.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 119.974 -0.69 . . . . 1.0 111.538 -178.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.51 -37.11 86.04 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.418 -1.327 . . . . 1.0 107.418 178.728 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.466 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -72.71 -41.37 50.44 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 114.758 -1.11 . . . . 1.0 112.213 179.275 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.505 ' N ' ' O ' ' A' ' 9' ' ' LYS . 49.0 mt-10 -62.83 -31.73 72.79 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.719 -0.845 . . . . 1.0 108.719 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.79 -37.08 59.51 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 115.099 -0.955 . . . . 1.0 109.483 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -60.92 -51.01 71.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.199 -1.364 . . . . 1.0 110.789 -179.03 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.466 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.7 mp -69.01 -37.9 78.93 Favored 'General case' 0 CA--C 1.512 -0.497 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.583 178.206 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 93.9 m -61.03 -43.67 98.55 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.757 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -76.34 -45.63 31.25 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.813 -0.63 . . . . 1.0 112.58 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.639 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.4 t30 -60.75 -44.15 97.06 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.309 0.855 . . . . 1.0 113.309 -177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -59.65 -32.46 70.48 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.275 -0.97 . . . . 1.0 109.313 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.2 m-80 -77.96 -29.97 50.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.405 -0.816 . . . . 1.0 111.714 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 26.7 mtmt -60.45 137.69 92.29 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 120.457 -0.497 . . . . 1.0 111.499 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -55.66 149.4 49.49 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 C-N-CA 122.341 2.027 . . . . 1.0 113.726 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.34 -19.26 14.27 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-N 114.811 -1.086 . . . . 1.0 111.302 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.416 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.0 t -87.49 135.06 26.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 121.067 0.461 . . . . 1.0 110.77 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.08 121.79 66.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 107.981 -1.118 . . . . 1.0 107.981 177.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.416 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.5 p -96.74 145.87 8.22 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.622 0 CA-C-O 121.676 0.751 . . . . 1.0 111.872 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 74.7 mt -112.34 163.57 17.45 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 114.327 -1.306 . . . . 1.0 110.719 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.03 -29.91 90.35 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.058 1.839 . . . . 1.0 110.69 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.6 m -67.69 -15.54 63.69 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.284 -0.871 . . . . 1.0 109.456 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.94 -3.74 70.8 Favored Glycine 0 C--N 1.328 0.115 0 N-CA-C 109.815 -1.314 . . . . 1.0 109.815 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.6 133.51 38.43 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.5 139.26 54.08 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.284 -0.417 . . . . 1.0 110.865 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -134.95 145.81 48.52 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-O 121.642 0.734 . . . . 1.0 110.619 178.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.528 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.3 tmtp? -130.84 134.1 46.52 Favored 'General case' 0 N--CA 1.443 -0.804 0 CA-C-N 114.503 -1.226 . . . . 1.0 109.084 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -90.48 105.38 16.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 122.18 0.991 . . . . 1.0 111.54 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.636 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.7 mm -70.55 -42.36 78.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 108.594 -0.891 . . . . 1.0 108.594 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -141.82 128.93 20.88 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.816 -1.084 . . . . 1.0 109.767 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.5 p -87.89 123.06 32.26 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.956 0.408 . . . . 1.0 110.182 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.81 -36.22 1.73 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 57.58 32.46 21.87 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.22 -0.49 . . . . 1.0 111.64 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.24 -161.65 37.41 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.907 0.726 . . . . 1.0 111.408 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.594 ' O ' ' N ' ' A' ' 95' ' ' ALA . 31.2 m -69.48 -177.92 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.17 -1.015 . . . . 1.0 109.374 178.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.565 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.75 154.59 0.48 Allowed Pre-proline 0 C--N 1.319 -0.729 0 O-C-N 123.569 0.543 . . . . 1.0 110.11 179.646 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.7 Cg_endo -87.75 154.29 7.44 Favored 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.697 2.932 . . . . 1.0 117.055 -174.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -84.8 175.74 50.59 Favored Glycine 0 C--N 1.334 0.42 0 N-CA-C 109.601 -1.4 . . . . 1.0 109.601 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.884 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.31 -22.34 11.75 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.315 -0.443 . . . . 1.0 111.667 -179.328 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.4 m -109.18 -7.17 15.34 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 112.651 0.612 . . . . 1.0 112.651 -178.183 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.436 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 78.7 m-20 -82.83 167.88 17.67 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.182 -0.303 . . . . 1.0 110.182 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.3 m -107.5 147.75 30.1 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-O 121.06 0.457 . . . . 1.0 109.949 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.45 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.3 p -127.17 163.05 30.91 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 CA-C-N 115.705 -0.679 . . . . 1.0 111.591 -176.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.42 HG22 ' HB3' ' A' ' 74' ' ' PRO . 95.3 m -129.78 120.15 24.57 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 108.077 -1.083 . . . . 1.0 108.077 177.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.485 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.3 m -148.38 165.62 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 114.227 1.195 . . . . 1.0 114.227 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.4 mt-10 -118.69 147.92 43.3 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 105.913 -1.884 . . . . 1.0 105.913 173.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.508 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 30.0 p90 -161.48 162.84 30.57 Favored 'General case' 0 C--N 1.343 0.292 0 N-CA-C 114.769 1.396 . . . . 1.0 114.769 -177.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.7 m -126.06 132.9 51.85 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.872 175.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.87 134.92 11.77 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 111.302 -0.719 . . . . 1.0 111.302 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.572 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 6.2 ptp85 -143.65 163.61 32.75 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-O 121.553 0.692 . . . . 1.0 111.929 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.0 mp -85.01 162.54 19.31 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.664 -1.153 . . . . 1.0 109.844 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.452 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -57.64 -25.82 25.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.305 -0.861 . . . . 1.0 110.395 178.517 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -93.34 2.98 56.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 114.279 -1.328 . . . . 1.0 111.603 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -6.14 79.18 Favored Glycine 0 CA--C 1.525 0.68 0 C-N-CA 121.069 -0.586 . . . . 1.0 112.832 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.2 m -65.0 105.3 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 119.548 -0.861 . . . . 1.0 109.103 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.3 t -74.08 117.3 17.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 C-N-CA 120.225 -0.59 . . . . 1.0 110.072 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.456 ' CE2' H431 ' A' ' 138' ' ' RAP . 13.9 p90 -103.52 -10.47 18.48 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.064 -0.971 . . . . 1.0 112.228 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.523 ' CB ' H433 ' A' ' 138' ' ' RAP . 1.0 OUTLIER -168.12 155.34 8.03 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 119.838 -0.745 . . . . 1.0 111.636 177.847 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 60.1 p -157.84 154.8 28.59 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.656 -0.702 . . . . 1.0 111.914 179.058 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.476 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 95.9 m -153.28 -40.7 0.1 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.528 -0.76 . . . . 1.0 110.357 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.404 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.8 pp20? -63.0 -26.27 68.77 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.657 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -52.11 -44.24 64.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 108.279 -1.008 . . . . 1.0 108.279 179.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 68' ' ' THR . 16.5 p -79.64 -27.94 40.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.707 -1.133 . . . . 1.0 109.246 177.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.11 16.2 77.12 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.441 -0.8 . . . . 1.0 111.74 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.42 114.95 64.27 Favored Pre-proline 0 N--CA 1.47 0.545 0 C-N-CA 120.553 -0.459 . . . . 1.0 110.628 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.424 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 36.1 Cg_exo -61.24 152.49 71.81 Favored 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 121.809 1.673 . . . . 1.0 114.601 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.87 152.17 42.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.048 -1.433 . . . . 1.0 107.247 177.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.7 t -110.42 131.2 55.26 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.605 0.717 . . . . 1.0 112.771 -178.434 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.553 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 32.2 m-85 -136.58 154.7 50.62 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.824 -1.08 . . . . 1.0 109.652 178.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 58.8 mt-30 -96.32 124.03 40.17 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 105.801 -1.926 . . . . 1.0 105.801 174.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.7 t -47.39 -29.14 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.398 -176.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.9 t -75.86 -24.3 55.72 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 111.974 0.361 . . . . 1.0 111.974 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.491 ' OE1' H461 ' A' ' 138' ' ' RAP . 92.3 mm-40 -98.23 -12.71 21.35 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.353 0.871 . . . . 1.0 113.353 -177.477 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.564 ' CG2' ' H32' ' A' ' 138' ' ' RAP . 4.1 p -83.93 169.12 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.101 -0.64 . . . . 1.0 112.022 -177.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.426 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.12 148.72 21.06 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 -177.354 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.63 -43.14 47.18 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.794 1.662 . . . . 1.0 112.833 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.85 -48.69 80.44 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 119.517 -1.325 . . . . 1.0 109.852 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.535 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 8.7 m95 -63.26 -38.14 90.01 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 113.902 -1.149 . . . . 1.0 110.438 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.9 m -51.13 -53.53 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.265 -0.425 . . . . 1.0 111.594 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -72.42 -41.59 66.03 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.642 0.608 . . . . 1.0 112.642 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.64 -48.21 82.56 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.917 1.08 . . . . 1.0 113.917 -177.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.0 mt -56.93 -39.95 75.47 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 121.133 0.492 . . . . 1.0 110.511 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -63.05 -23.24 67.36 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.607 -0.724 . . . . 1.0 110.753 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.432 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 45.5 mt -105.25 -11.4 16.54 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.307 -0.406 . . . . 1.0 110.935 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 33.4 ttm -86.04 106.81 10.83 Favored Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.669 0.606 . . . . 1.0 111.89 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.565 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 14.6 Cg_exo -68.46 145.7 65.72 Favored 'Trans proline' 0 N--CA 1.501 1.964 0 C-N-CA 122.576 2.184 . . . . 1.0 113.008 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.594 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.55 132.96 54.18 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.53 -0.759 . . . . 1.0 111.17 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.95 -17.82 58.61 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 109.147 -1.581 . . . . 1.0 109.147 -179.067 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -88.86 136.46 33.0 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-O 120.838 0.351 . . . . 1.0 110.247 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 57.3 m -107.61 113.76 27.27 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.979 -0.555 . . . . 1.0 109.752 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.432 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.6 m0 -115.51 164.68 13.95 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.728 0.775 . . . . 1.0 110.902 -178.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.636 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.7 mt-10 -126.25 126.01 43.31 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 106.943 -1.503 . . . . 1.0 106.943 175.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.4 137.12 56.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.733 0 CA-C-O 121.704 0.764 . . . . 1.0 109.649 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.707 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.53 103.59 12.74 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 105.894 -1.891 . . . . 1.0 105.894 -177.981 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.53 115.54 64.39 Favored Pre-proline 0 C--N 1.326 -0.438 0 N-CA-C 115.077 1.51 . . . . 1.0 115.077 -174.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -51.52 146.72 24.99 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.578 1.519 . . . . 1.0 109.748 176.148 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 58.4 p -51.6 -36.43 45.62 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.192 -0.603 . . . . 1.0 110.901 -178.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.29 -32.52 83.99 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.251 -0.74 . . . . 1.0 111.251 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.0 mt -99.26 1.51 44.75 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.498 -0.186 . . . . 1.0 110.498 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.521 ' O ' H521 ' A' ' 138' ' ' RAP . . . -109.28 -103.34 0.37 Allowed 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 120.352 0.12 . . . . 1.0 110.819 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.597 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 44.2 m-85 -107.6 5.97 27.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 114.915 1.45 . . . . 1.0 114.915 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.15 169.43 22.2 Favored Glycine 0 N--CA 1.473 1.127 0 C-N-CA 120.245 -0.978 . . . . 1.0 114.139 176.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 121' ' ' ASN . 57.0 Cg_endo -78.47 -12.76 15.29 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 123.697 2.931 . . . . 1.0 110.645 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 113' ' ' SER . 60.0 ttt180 -104.77 165.55 10.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.75 -1.113 . . . . 1.0 109.403 -179.196 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.56 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 3.5 m -76.28 97.65 4.25 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.171 -0.677 . . . . 1.0 109.171 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -108.74 61.38 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.576 -0.283 . . . . 1.0 110.597 -179.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.532 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 169.22 -170.84 42.8 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 120.455 -0.879 . . . . 1.0 112.188 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -66.09 -105.19 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 N-CA-C 111.842 -0.503 . . . . 1.0 111.842 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.03 -16.08 47.71 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.439 2.093 . . . . 1.0 111.387 -178.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.555 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.6 mp -66.97 114.24 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 109.26 -0.645 . . . . 1.0 109.26 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.411 ' N ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.26 -168.14 42.44 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 110.566 -1.014 . . . . 1.0 110.566 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.566 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 39.3 Cg_endo -65.53 142.62 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.257 1.971 . . . . 1.0 113.34 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.471 ' ND2' ' O ' ' A' ' 121' ' ' ASN . 2.1 t30 50.55 53.62 12.62 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.158 -0.474 . . . . 1.0 111.859 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.427 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 54.9 mm-40 -99.76 133.01 44.74 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.146 -0.479 . . . . 1.0 111.527 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.436 HG21 HD11 ' A' ' 16' ' ' LEU . 52.8 m -93.86 128.58 40.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 106.571 -1.641 . . . . 1.0 106.571 175.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.4 ' N ' HD22 ' A' ' 124' ' ' LEU . 2.0 mm? -112.13 138.86 48.22 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.394 0.616 . . . . 1.0 111.096 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.707 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -118.6 145.22 24.93 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.679 0 CA-C-N 114.976 -1.011 . . . . 1.0 108.523 178.075 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.561 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -136.89 150.78 48.45 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 120.217 -0.593 . . . . 1.0 111.201 177.129 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.572 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 5.3 mmtt -100.14 122.39 42.9 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 105.031 -2.211 . . . . 1.0 105.031 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.42 118.27 57.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 C-N-CA 119.395 -0.922 . . . . 1.0 112.432 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.445 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.2 t-160 -108.67 123.6 49.22 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 114.121 -1.4 . . . . 1.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.82 111.31 23.32 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 120.478 -0.489 . . . . 1.0 112.197 -177.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.472 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -94.3 -45.05 13.61 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.486 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.1 p -151.07 155.81 39.76 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.305 0.574 . . . . 1.0 111.137 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.451 HG21 ' HA ' ' A' ' 44' ' ' LYS . 45.8 t -128.8 135.91 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.757 -0.656 . . . . 1.0 109.958 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.42 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 14.6 tptm -77.72 -84.03 0.08 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.87 0.843 . . . . 1.0 111.586 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.496 ' C ' ' H ' ' A' ' 137' ' ' SER . 0.0 OUTLIER 85.45 127.93 0.04 OUTLIER 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 113.777 -1.556 . . . . 1.0 110.47 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -47.47 -7.29 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 113.84 -1.527 . . . . 1.0 112.151 -178.22 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.496 ' H ' ' C ' ' A' ' 135' ' ' LYS . 16.1 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.002 -0.999 . . . . 1.0 111.135 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.922 H491 H381 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.505 -0.554 . . . . 1.0 109.505 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.5 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 20.1 m120 -65.05 -31.95 73.42 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 112.366 0.506 . . . . 1.0 112.366 -179.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.401 ' HG3' ' H ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -46.38 -41.46 13.58 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.323 -0.551 . . . . 1.0 111.078 -178.392 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.506 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 6.1 tmtt? -69.99 -35.93 74.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.596 0.712 . . . . 1.0 109.806 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -52.59 -34.5 51.07 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 115.47 -0.786 . . . . 1.0 110.753 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -61.33 -39.4 90.37 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.142 -0.935 . . . . 1.0 110.401 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -64.84 -48.63 73.64 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.502 0.668 . . . . 1.0 111.12 -179.417 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 9.5 m-20 -62.85 -37.09 85.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 107.81 -1.182 . . . . 1.0 107.81 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 64.6 tttt -65.95 -51.38 59.04 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 113.297 -1.774 . . . . 1.0 111.485 179.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.2 t -67.31 -46.59 83.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 C-N-CA 120.238 -0.585 . . . . 1.0 111.423 -179.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.543 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 1.2 mptp? -62.05 -38.94 90.66 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.649 -1.241 . . . . 1.0 107.649 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.486 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -71.6 -44.55 49.26 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 114.629 -1.169 . . . . 1.0 112.444 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -59.71 -34.1 72.47 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.526 -0.916 . . . . 1.0 108.526 179.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.87 -37.08 62.26 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.892 -1.049 . . . . 1.0 110.111 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.19 -49.33 78.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.753 -1.112 . . . . 1.0 111.198 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.486 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.78 -38.26 79.88 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.14 -0.624 . . . . 1.0 109.385 178.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 55.9 m -60.76 -43.47 97.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.352 -0.84 . . . . 1.0 109.688 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -76.9 -44.69 30.86 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.85 -0.614 . . . . 1.0 111.973 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.649 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 54.6 t30 -60.33 -44.78 95.17 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.475 0.917 . . . . 1.0 113.475 -177.165 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -58.26 -31.7 67.69 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 119.441 -0.904 . . . . 1.0 109.613 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -80.98 -27.61 35.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.734 -0.667 . . . . 1.0 111.683 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.1 mtmt -59.47 146.22 80.21 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 120.335 -0.546 . . . . 1.0 111.517 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.45 148.93 59.8 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.543 2.162 . . . . 1.0 114.048 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.65 -18.48 2.96 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 115.167 -0.924 . . . . 1.0 112.576 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -83.75 134.66 26.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.549 -0.46 . . . . 1.0 110.202 -179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.2 121.96 66.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 107.838 -1.171 . . . . 1.0 107.838 177.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.9 p -93.53 146.16 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 CA-C-O 121.637 0.732 . . . . 1.0 111.981 -177.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 97.9 mt -113.03 163.17 18.68 Favored Pre-proline 0 N--CA 1.461 0.119 0 CA-C-N 114.469 -1.242 . . . . 1.0 110.892 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -60.32 -30.71 91.63 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.844 1.696 . . . . 1.0 111.249 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -69.44 -11.16 60.59 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.828 -0.624 . . . . 1.0 109.737 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.02 -2.49 75.77 Favored Glycine 0 C--O 1.229 -0.174 0 N-CA-C 109.949 -1.26 . . . . 1.0 109.949 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.442 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.08 133.7 36.13 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 108.59 -0.893 . . . . 1.0 108.59 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.442 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.6 mp0 -121.82 138.53 54.34 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 116.319 -0.4 . . . . 1.0 111.086 -179.32 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -133.5 146.55 51.19 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-O 121.591 0.71 . . . . 1.0 111.089 178.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.497 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.7 tmtp? -129.86 135.8 48.81 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.495 -1.23 . . . . 1.0 109.233 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.25 104.67 15.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-O 122.153 0.978 . . . . 1.0 112.248 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.0 mm -70.69 -42.36 77.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.249 -0.887 . . . . 1.0 108.848 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -144.07 127.33 16.71 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.845 -1.071 . . . . 1.0 110.634 -178.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.2 p -84.51 126.9 33.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.043 0.449 . . . . 1.0 110.499 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -115.86 -36.78 1.11 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 56.49 30.39 17.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.465 -0.367 . . . . 1.0 111.187 179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.07 -159.68 35.86 Favored Glycine 0 C--N 1.334 0.421 0 CA-C-O 121.87 0.706 . . . . 1.0 111.955 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.603 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.0 m -69.57 -178.73 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.239 -0.981 . . . . 1.0 109.411 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.546 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 155.14 0.38 Allowed Pre-proline 0 C--N 1.319 -0.731 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.785 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.1 Cg_endo -87.76 161.49 7.69 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 123.011 2.474 . . . . 1.0 115.273 -175.457 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.2 171.45 32.5 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 108.049 -2.02 . . . . 1.0 108.049 175.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.613 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -45.75 -24.9 0.42 Allowed 'General case' 0 C--N 1.297 -1.701 0 CA-C-N 114.59 -0.805 . . . . 1.0 111.374 178.452 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.0 m -107.63 -9.64 15.83 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.863 1.06 . . . . 1.0 113.863 -177.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -85.37 166.34 16.5 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 119.39 -0.924 . . . . 1.0 109.136 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.3 m -104.16 146.97 27.99 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.167 -0.679 . . . . 1.0 109.167 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.401 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.1 p -124.39 160.3 29.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 112.554 0.575 . . . . 1.0 112.554 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.4 HG22 ' HB3' ' A' ' 74' ' ' PRO . 87.6 m -127.23 119.51 26.54 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.408 -0.96 . . . . 1.0 108.408 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.453 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 5.3 m -148.84 165.76 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 113.968 1.099 . . . . 1.0 113.968 -176.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 9.3 mt-10 -118.53 151.25 38.2 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.356 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 35.2 p90 -164.23 161.88 22.29 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 114.536 1.31 . . . . 1.0 114.536 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -123.51 127.04 47.78 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.201 -0.908 . . . . 1.0 108.691 175.329 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.25 136.38 13.54 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.93 -0.652 . . . . 1.0 111.775 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -147.25 166.49 26.88 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 121.805 0.812 . . . . 1.0 112.395 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.5 mp -83.16 164.07 20.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 114.129 -1.396 . . . . 1.0 110.037 177.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.471 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.38 -24.38 30.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.127 -0.942 . . . . 1.0 110.139 177.889 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -93.1 2.58 56.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 113.855 -1.52 . . . . 1.0 111.741 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.36 -4.69 80.52 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.19 -0.529 . . . . 1.0 112.735 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -69.76 105.06 2.62 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.682 -0.807 . . . . 1.0 110.212 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.5 t -73.66 122.06 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.139 0.495 . . . . 1.0 110.471 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.424 ' HB2' HD11 ' A' ' 118' ' ' ILE . 30.7 p90 -110.76 -15.54 13.8 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 115.145 -0.934 . . . . 1.0 111.75 -179.546 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.503 ' OD2' ' N ' ' A' ' 67' ' ' SER . 55.4 t0 -155.49 147.31 23.25 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 120.704 -0.399 . . . . 1.0 110.883 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.503 ' N ' ' OD2' ' A' ' 66' ' ' ASP . 97.5 p -154.25 152.71 30.63 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.217 -0.447 . . . . 1.0 111.612 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 84.9 m -156.58 -38.05 0.08 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.031 -0.531 . . . . 1.0 111.289 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.412 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 2.0 pp20? -65.99 -26.77 67.7 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.203 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -57.46 -39.7 76.9 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 108.173 -1.047 . . . . 1.0 108.173 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.41 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.9 p -81.76 -27.03 34.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.94 -1.027 . . . . 1.0 108.493 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 76.63 16.99 80.3 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.384 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.429 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.3 mptp? -97.35 114.79 65.34 Favored Pre-proline 0 N--CA 1.471 0.622 0 C-N-CA 120.855 -0.338 . . . . 1.0 110.419 -179.21 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 37.3 Cg_exo -61.99 154.19 63.54 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 121.916 1.744 . . . . 1.0 114.457 -178.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -126.05 150.61 48.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.262 -1.335 . . . . 1.0 108.407 178.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -104.57 134.35 47.9 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 113.006 0.743 . . . . 1.0 113.006 -178.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.649 ' HB3' H481 ' A' ' 138' ' ' RAP . 55.1 m-85 -142.42 148.76 38.33 Favored 'General case' 0 CA--C 1.495 -1.141 0 CA-C-N 115.009 -0.996 . . . . 1.0 110.602 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -90.31 124.5 34.96 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.004 -1.85 . . . . 1.0 106.004 175.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.0 t -52.07 -32.05 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 C-N-CA 119.774 -0.771 . . . . 1.0 110.509 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -74.02 -27.56 61.01 Favored 'General case' 0 CA--C 1.514 -0.413 0 C-N-CA 120.248 -0.581 . . . . 1.0 112.138 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.506 ' HB3' ' H27' ' A' ' 138' ' ' RAP . 15.9 mm100 -101.29 -12.62 18.53 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 113.348 0.87 . . . . 1.0 113.348 -178.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.657 ' CG2' H31A ' A' ' 138' ' ' RAP . 4.5 p -71.04 172.03 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 119.288 -0.965 . . . . 1.0 109.94 -177.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.505 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -53.8 148.36 20.1 Favored Pre-proline 0 CA--C 1.55 0.945 0 N-CA-C 108.812 -0.81 . . . . 1.0 108.812 -178.803 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.493 ' HD2' HG22 ' A' ' 83' ' ' ILE . 85.1 Cg_exo -49.42 -47.51 22.2 Favored 'Trans proline' 0 N--CA 1.503 2.084 0 C-N-CA 122.151 1.9 . . . . 1.0 113.773 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.3 -48.16 77.15 Favored Glycine 0 C--N 1.318 -0.44 0 N-CA-C 110.021 -1.232 . . . . 1.0 110.021 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.638 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 7.8 m95 -63.78 -34.14 77.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 114.047 -1.076 . . . . 1.0 111.562 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -51.94 -54.1 33.48 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.744 -0.382 . . . . 1.0 110.888 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -74.17 -44.29 54.02 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.177 0.806 . . . . 1.0 113.177 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -55.71 -44.37 77.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 113.796 1.035 . . . . 1.0 113.796 -177.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.3 mt -58.47 -41.52 85.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.243 0.544 . . . . 1.0 110.142 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -65.7 -23.09 66.69 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.252 -0.885 . . . . 1.0 111.145 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.485 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 55.1 mt -103.09 -9.94 19.3 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.596 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 5.2 ttt -91.11 107.14 18.99 Favored Pre-proline 0 CA--C 1.549 0.942 0 O-C-N 123.729 0.643 . . . . 1.0 111.638 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.546 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.9 Cg_exo -66.37 149.11 85.01 Favored 'Trans proline' 0 N--CA 1.499 1.846 0 C-N-CA 122.904 2.402 . . . . 1.0 112.656 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.603 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.96 136.16 55.7 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 115.422 -0.808 . . . . 1.0 111.459 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.02 -19.74 51.4 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.415 -1.874 . . . . 1.0 108.415 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -85.99 134.49 33.85 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.053 0.454 . . . . 1.0 110.269 178.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.4 m -108.26 115.01 29.32 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.689 -0.687 . . . . 1.0 109.659 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.485 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.5 m0 -116.12 166.87 11.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.528 0.68 . . . . 1.0 110.79 -179.019 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.4 mt-10 -126.9 128.57 46.68 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 106.683 -1.599 . . . . 1.0 106.683 175.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.401 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -123.16 138.2 53.96 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 CA-C-O 121.809 0.814 . . . . 1.0 109.699 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.752 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.31 103.71 12.7 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 105.424 -2.065 . . . . 1.0 105.424 -177.905 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.5 t -90.73 116.12 65.71 Favored Pre-proline 0 C--N 1.327 -0.4 0 N-CA-C 114.674 1.361 . . . . 1.0 114.674 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -51.03 144.67 27.44 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 121.261 1.307 . . . . 1.0 109.79 176.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 55.3 p -50.49 -35.44 29.2 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.338 -0.545 . . . . 1.0 110.561 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.58 -32.78 84.32 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.19 -0.764 . . . . 1.0 111.19 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 82.8 mt -98.92 1.3 45.51 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 121.314 -0.154 . . . . 1.0 110.655 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.18 -106.62 0.34 Allowed 'General case' 0 C--N 1.342 0.264 0 N-CA-C 111.643 0.238 . . . . 1.0 111.643 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.607 ' HH ' H121 ' A' ' 138' ' ' RAP . 48.1 m-85 -101.97 5.05 40.56 Favored 'General case' 0 C--N 1.341 0.234 0 N-CA-C 113.705 1.002 . . . . 1.0 113.705 -177.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 99.93 167.28 29.36 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 120.645 -0.788 . . . . 1.0 114.043 176.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.513 ' O ' ' N ' ' A' ' 121' ' ' ASN . 73.8 Cg_endo -70.97 -19.99 29.66 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 C-N-CA 123.742 2.962 . . . . 1.0 113.038 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.423 HH11 ' HG2' ' A' ' 111' ' ' PRO . 11.7 mpt_? -93.74 167.15 11.84 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.009 -0.367 . . . . 1.0 110.009 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 5.7 m -74.46 76.32 1.93 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 177.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.0 t -92.21 61.53 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.268 -0.423 . . . . 1.0 110.967 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.97 179.61 42.27 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 120.967 -0.635 . . . . 1.0 111.516 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -60.66 -107.14 0.01 OUTLIER Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.449 -0.66 . . . . 1.0 111.449 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -59.24 -13.15 18.64 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 C-N-CA 122.222 1.948 . . . . 1.0 110.725 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.884 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.3 mp -66.74 113.17 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 N-CA-C 108.185 -1.043 . . . . 1.0 108.185 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -91.66 -166.9 40.25 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 110.548 -1.021 . . . . 1.0 110.548 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.554 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 37.6 Cg_endo -64.09 147.21 91.59 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.14 1.893 . . . . 1.0 112.7 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 111' ' ' PRO . 11.5 t-20 44.82 57.53 4.53 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.96 -0.564 . . . . 1.0 112.072 178.219 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 53.9 mm-40 -102.64 132.06 49.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.28 0.562 . . . . 1.0 112.334 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.474 HG21 HD11 ' A' ' 16' ' ' LEU . 36.2 m -96.34 129.08 43.76 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 106.418 -1.697 . . . . 1.0 106.418 175.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.98 146.17 40.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.387 0.613 . . . . 1.0 111.042 -179.057 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.752 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -123.58 148.28 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.764 0 CA-C-N 115.088 -0.96 . . . . 1.0 108.543 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -139.41 151.43 46.27 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 120.286 -0.566 . . . . 1.0 111.288 177.848 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.519 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 11.4 mmtt -100.15 124.88 46.07 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.162 -2.162 . . . . 1.0 105.162 176.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.7 mt -119.35 119.21 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 119.075 -1.05 . . . . 1.0 111.998 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.488 ' CD2' HD11 ' A' ' 131' ' ' ILE . 4.7 t60 -111.85 125.42 54.0 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.048 -1.433 . . . . 1.0 108.714 179.215 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.02 114.51 26.71 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 112.869 0.692 . . . . 1.0 112.869 -178.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.499 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -96.05 -45.42 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 115.992 -0.549 . . . . 1.0 110.88 178.058 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.3 p -151.29 157.78 42.98 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 120.877 0.37 . . . . 1.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.436 HG21 ' HA ' ' A' ' 44' ' ' LYS . 58.1 t -127.37 134.66 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-O 121.325 0.583 . . . . 1.0 111.451 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.533 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 21.6 tptt -93.89 -143.71 0.24 Allowed 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.152 -0.931 . . . . 1.0 111.115 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.52 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -160.26 156.04 25.81 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.455 -1.248 . . . . 1.0 109.606 178.18 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.444 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 90.3 p -45.72 -33.17 2.84 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.465 -0.789 . . . . 1.0 111.139 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 34.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.381 179.507 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.795 H331 ' O2 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 1.5 m-20 -66.08 -30.88 71.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.186 -0.461 . . . . 1.0 111.159 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.516 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 62.9 pttt -47.79 -40.43 20.9 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 119.896 -0.722 . . . . 1.0 109.513 -179.496 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.697 ' NZ ' HD21 ' A' ' 8' ' ' ASN . 4.9 tmtt? -66.33 -38.25 87.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.646 -0.707 . . . . 1.0 109.444 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.472 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -54.78 -35.26 63.64 Favored 'General case' 0 CA--C 1.509 -0.625 0 CA-C-N 115.181 -0.918 . . . . 1.0 109.801 179.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -69.32 -35.03 75.54 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.25 -0.886 . . . . 1.0 110.527 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -66.7 -54.49 22.54 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 121.886 0.85 . . . . 1.0 110.24 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.697 HD21 ' NZ ' ' A' ' 4' ' ' LYS . 16.0 m-20 -57.48 -35.64 70.45 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.737 -1.12 . . . . 1.0 108.543 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 45.1 tttt -64.74 -50.64 66.09 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 113.793 -1.549 . . . . 1.0 111.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.7 t -72.31 -47.52 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 119.964 -0.694 . . . . 1.0 112.152 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.463 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.4 OUTLIER -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.305 -0.998 . . . . 1.0 108.305 -179.919 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.95 -46.86 50.01 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 115.188 -0.915 . . . . 1.0 112.546 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -58.68 -34.26 71.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 108.804 -0.813 . . . . 1.0 108.804 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.55 -36.55 63.12 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.183 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -62.35 -49.37 75.85 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.579 -1.191 . . . . 1.0 111.134 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -70.75 -39.61 73.19 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 119.954 -0.698 . . . . 1.0 109.922 178.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.469 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 75.6 m -60.97 -43.35 98.92 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.443 -0.798 . . . . 1.0 109.702 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -76.28 -46.07 29.61 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.91 -0.587 . . . . 1.0 111.816 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.654 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 55.4 t30 -59.88 -44.58 94.1 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.473 0.916 . . . . 1.0 113.473 -177.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.75 -31.61 68.5 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.337 -0.945 . . . . 1.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.469 ' ND2' ' O ' ' A' ' 17' ' ' THR . 50.0 m-80 -77.54 -34.23 53.97 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.514 -0.766 . . . . 1.0 111.653 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -57.94 137.03 83.71 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 120.628 -0.429 . . . . 1.0 111.76 -177.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.13 148.84 57.11 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 122.167 1.911 . . . . 1.0 113.442 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.13 -20.84 14.16 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.972 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.6 t -85.16 135.71 24.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.0 109.789 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.1 t -120.74 121.37 65.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.743 -1.206 . . . . 1.0 107.743 178.261 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.0 p -97.63 144.8 10.39 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.677 0 CA-C-O 121.746 0.784 . . . . 1.0 111.773 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 95.2 mt -111.32 164.28 15.37 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.314 -1.312 . . . . 1.0 110.688 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -60.84 -30.82 90.87 Favored 'Trans proline' 0 N--CA 1.485 0.983 0 C-N-CA 121.72 1.613 . . . . 1.0 110.83 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -67.81 -12.1 59.91 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.568 -0.742 . . . . 1.0 109.346 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.9 -1.59 78.28 Favored Glycine 0 C--O 1.228 -0.269 0 N-CA-C 109.962 -1.255 . . . . 1.0 109.962 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.474 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.1 tm? -78.68 133.66 37.18 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 108.375 -0.972 . . . . 1.0 108.375 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.447 ' HG3' ' HA ' ' A' ' 27' ' ' VAL . 24.3 mp0 -122.23 137.46 54.83 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.681 -0.236 . . . . 1.0 111.289 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -134.23 142.65 47.43 Favored 'General case' 0 CA--C 1.506 -0.725 0 CA-C-O 121.638 0.733 . . . . 1.0 111.116 178.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.529 ' HD3' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -123.9 130.89 53.32 Favored 'General case' 0 CA--C 1.503 -0.831 0 CA-C-N 114.528 -1.215 . . . . 1.0 109.216 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -88.92 104.48 14.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 122.294 1.045 . . . . 1.0 112.025 -178.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.604 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.1 mm -69.42 -41.84 80.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 114.766 -1.107 . . . . 1.0 108.471 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -144.26 126.1 15.27 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.522 -1.217 . . . . 1.0 109.752 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.8 p -85.23 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.027 0.441 . . . . 1.0 110.487 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.4 ' H ' ' HB3' ' A' ' 97' ' ' SER . . . -116.11 -37.54 1.02 Allowed Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.247 -1.141 . . . . 1.0 110.247 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.422 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 6.4 m-20 58.02 31.67 20.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.541 -0.329 . . . . 1.0 111.399 179.357 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.83 -159.78 35.64 Favored Glycine 0 C--N 1.333 0.376 0 CA-C-O 122.316 0.953 . . . . 1.0 112.51 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.608 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.9 m -69.68 -177.93 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 113.627 -1.286 . . . . 1.0 108.951 178.238 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.58 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.29 155.25 0.4 Allowed Pre-proline 0 C--N 1.318 -0.784 0 O-C-N 123.619 0.574 . . . . 1.0 109.932 179.459 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.445 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 58.4 Cg_endo -87.7 156.4 7.57 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 123.305 2.67 . . . . 1.0 115.941 -174.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.35 176.59 45.17 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 108.874 -1.691 . . . . 1.0 108.874 176.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.519 ' CE ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.06 -22.38 15.82 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 120.501 -0.48 . . . . 1.0 111.517 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.449 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 35.8 m -106.97 -7.33 17.03 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.874 0.694 . . . . 1.0 112.874 -177.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -84.58 170.81 13.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.952 -0.388 . . . . 1.0 109.952 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.3 m -110.76 147.04 35.28 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.285 0.564 . . . . 1.0 109.907 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.445 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.2 p -127.9 163.11 32.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 115.357 -0.838 . . . . 1.0 112.676 -175.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.407 HG22 ' HB3' ' A' ' 74' ' ' PRO . 68.1 m -130.12 121.21 25.9 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.589 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.1 m -149.02 165.76 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 114.635 1.346 . . . . 1.0 114.635 -176.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 3.0 mt-10 -118.08 147.28 43.42 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.991 -1.855 . . . . 1.0 105.991 174.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.1 p90 -164.7 168.89 17.52 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 114.525 1.306 . . . . 1.0 114.525 -176.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -131.78 129.25 40.3 Favored 'General case' 0 C--O 1.217 -0.658 0 CA-C-N 114.771 -1.104 . . . . 1.0 108.267 175.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.65 131.73 9.84 Favored Glycine 0 N--CA 1.473 1.115 0 N-CA-C 111.292 -0.723 . . . . 1.0 111.292 -179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 11.7 ptp180 -146.4 167.3 23.94 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.705 0.764 . . . . 1.0 112.219 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.9 mp -82.48 164.17 21.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.325 -1.307 . . . . 1.0 110.063 177.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.456 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -61.37 -24.44 33.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 122.411 1.1 . . . . 1.0 109.858 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.425 ' H ' HD13 ' A' ' 60' ' ' ILE . 53.6 t0 -89.71 -0.02 57.27 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 113.21 -1.813 . . . . 1.0 111.882 -177.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.04 -1.71 78.07 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.904 -0.665 . . . . 1.0 112.317 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -71.82 102.46 2.87 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 119.805 -0.758 . . . . 1.0 110.021 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.2 127.41 36.77 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.519 0.676 . . . . 1.0 110.507 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 29.3 p90 -121.14 -11.07 8.91 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 114.705 -1.134 . . . . 1.0 111.486 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -154.46 143.87 21.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.132 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 20.5 p -157.93 156.12 30.71 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 113.038 0.755 . . . . 1.0 113.038 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 55' ' ' TYR . 65.3 m -159.15 -45.57 0.06 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 114.861 -1.063 . . . . 1.0 110.72 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -58.63 -26.1 63.38 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 116.391 -0.368 . . . . 1.0 110.114 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.8 mmtt -49.51 -41.08 39.91 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.523 -1.288 . . . . 1.0 107.523 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 27.6 p -83.31 -32.26 26.42 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 113.923 -1.489 . . . . 1.0 109.668 177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.64 13.16 81.98 Favored Glycine 0 C--N 1.332 0.338 0 N-CA-C 110.954 -0.858 . . . . 1.0 110.954 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -94.18 116.91 66.99 Favored Pre-proline 0 N--CA 1.466 0.34 0 C-N-CA 121.104 -0.238 . . . . 1.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.413 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 39.6 Cg_exo -61.1 150.7 83.09 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 121.972 1.781 . . . . 1.0 115.112 -177.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -125.65 150.81 47.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 114.107 -1.406 . . . . 1.0 108.301 177.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.04 135.42 47.52 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 113.593 0.96 . . . . 1.0 113.593 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.562 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 60.4 m-85 -142.24 153.89 44.33 Favored 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.162 -0.926 . . . . 1.0 109.449 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -90.75 130.35 36.74 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.912 -1.884 . . . . 1.0 105.912 173.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.7 -29.98 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 C-N-CA 119.734 -0.786 . . . . 1.0 110.506 -177.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.0 t -73.32 -25.21 60.55 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 120.244 -0.582 . . . . 1.0 112.212 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.531 ' C ' H482 ' A' ' 138' ' ' RAP . 62.6 mm-40 -98.14 -15.39 19.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.553 0.575 . . . . 1.0 112.553 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.572 ' CG2' H31A ' A' ' 138' ' ' RAP . 2.0 p -78.47 172.71 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 120.021 -0.672 . . . . 1.0 111.147 -176.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.5 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -56.48 151.24 30.19 Favored Pre-proline 0 CA--C 1.55 0.974 0 C-N-CA 119.973 -0.691 . . . . 1.0 110.814 -178.362 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HD2' HG22 ' A' ' 83' ' ' ILE . 54.1 Cg_exo -53.89 -46.26 34.97 Favored 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 122.13 1.887 . . . . 1.0 112.876 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.4 -47.82 80.26 Favored Glycine 0 N--CA 1.451 -0.336 0 N-CA-C 109.132 -1.587 . . . . 1.0 109.132 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.673 ' CH2' ' H42' ' A' ' 138' ' ' RAP . 7.7 m95 -64.29 -39.0 93.04 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 113.542 -1.329 . . . . 1.0 109.669 178.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 m -51.76 -53.61 37.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 1.0 111.185 -178.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -72.4 -40.88 66.84 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.23 -48.17 82.85 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 113.995 1.109 . . . . 1.0 113.995 -177.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 52.1 mt -57.95 -40.85 81.56 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 121.545 0.688 . . . . 1.0 109.814 -178.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -63.89 -24.53 67.77 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.839 -1.073 . . . . 1.0 111.221 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.8 mt -101.86 -15.64 16.82 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.394 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' MET . . . . . 0.507 ' CE ' ' H ' ' A' ' 99' ' ' TRP . 8.2 ttt -83.4 108.48 13.29 Favored Pre-proline 0 C--N 1.321 -0.642 0 O-C-N 123.811 0.694 . . . . 1.0 112.689 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.58 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -68.91 146.38 65.24 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.34 2.026 . . . . 1.0 112.082 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.608 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.89 136.69 57.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.472 -0.785 . . . . 1.0 111.731 -179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.7 57.08 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 108.92 -1.672 . . . . 1.0 108.92 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.4 ' HB3' ' H ' ' A' ' 40' ' ' GLY . 5.0 p -89.5 139.62 30.34 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 120.707 0.289 . . . . 1.0 110.49 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.6 m -110.31 112.48 24.46 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.004 -0.543 . . . . 1.0 109.902 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.507 ' H ' ' CE ' ' A' ' 93' ' ' MET . 40.8 m0 -115.25 161.34 18.6 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.805 0.812 . . . . 1.0 111.566 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.604 ' CD ' HD11 ' A' ' 37' ' ' ILE . 90.7 mt-10 -120.96 124.31 44.59 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 106.713 -1.588 . . . . 1.0 106.713 175.226 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -118.49 137.37 52.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-O 121.882 0.848 . . . . 1.0 110.61 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.675 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.28 103.05 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.722 -1.955 . . . . 1.0 105.722 -178.756 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 t -90.61 115.94 65.3 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 114.921 1.452 . . . . 1.0 114.921 -174.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -51.27 142.11 37.67 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 121.166 1.244 . . . . 1.0 109.868 176.142 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.3 p -48.11 -35.62 11.75 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 120.692 -0.403 . . . . 1.0 110.722 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.66 -33.19 85.42 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.181 -0.767 . . . . 1.0 111.181 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 71.9 mt -99.01 3.39 46.9 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.768 -0.216 . . . . 1.0 111.431 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.96 -114.98 0.28 Allowed 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.526 -0.546 . . . . 1.0 109.526 -179.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.588 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 62.3 m-85 -91.25 5.06 50.62 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.821 0.344 . . . . 1.0 111.636 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.59 164.19 22.55 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.157 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.511 ' O ' ' N ' ' A' ' 121' ' ' ASN . 86.9 Cg_endo -74.23 -9.35 21.79 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 123.362 2.708 . . . . 1.0 110.247 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -107.7 162.95 13.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.495 -1.229 . . . . 1.0 109.745 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.5 m -72.01 89.94 1.14 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.671 -0.411 . . . . 1.0 109.939 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -104.52 62.23 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 121.118 -0.233 . . . . 1.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 164.62 -175.34 40.63 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 120.309 -0.948 . . . . 1.0 112.705 179.304 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.98 -104.81 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 N-CA-C 111.639 -0.584 . . . . 1.0 111.639 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -63.76 -15.36 48.39 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.545 2.163 . . . . 1.0 111.322 -178.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.674 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.8 mp -67.25 111.8 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.02 0 N-CA-C 108.295 -1.002 . . . . 1.0 108.295 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.425 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.62 -170.72 43.5 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.054 -0.976 . . . . 1.0 111.223 -179.342 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.571 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 28.6 Cg_endo -61.86 143.56 95.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.461 2.108 . . . . 1.0 112.788 179.178 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 121' ' ' ASN . 0.6 OUTLIER 49.07 48.84 20.39 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.792 0.664 . . . . 1.0 112.792 178.392 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.538 ' OE1' ' NZ ' ' A' ' 4' ' ' LYS . 45.9 mm-40 -93.94 129.27 40.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 113.164 0.802 . . . . 1.0 113.164 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.493 HG21 HD11 ' A' ' 16' ' ' LEU . 17.5 m -95.63 129.1 42.94 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 105.796 -1.927 . . . . 1.0 105.796 174.728 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.417 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.1 mm? -116.0 143.64 45.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.369 0.605 . . . . 1.0 110.69 -179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.675 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -119.54 148.11 22.74 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.649 0 CA-C-N 115.157 -0.928 . . . . 1.0 109.076 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.591 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.96 149.94 45.32 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.478 0.656 . . . . 1.0 111.527 177.356 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 8.6 mmtt -100.12 124.4 45.49 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 105.229 -2.137 . . . . 1.0 105.229 177.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.424 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.4 mt -122.01 127.61 75.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 119.497 -0.881 . . . . 1.0 112.327 -176.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.432 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.7 t-160 -118.97 124.31 46.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.321 -1.309 . . . . 1.0 107.633 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.78 110.39 22.87 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 120.225 -0.59 . . . . 1.0 112.374 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -94.34 -47.22 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.518 -0.765 . . . . 1.0 112.117 -179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.4 p -146.7 156.94 43.56 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.655 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.415 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.5 t -132.48 140.0 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.203 0.525 . . . . 1.0 111.942 -178.14 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.703 ' HG3' ' H ' ' A' ' 135' ' ' LYS . 0.1 OUTLIER -97.46 -145.7 0.3 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.703 -0.68 . . . . 1.0 109.613 178.177 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.703 ' H ' ' HG3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -174.08 142.2 0.82 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.777 178.676 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 10.7 t -52.47 -39.7 61.47 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.801 -1.09 . . . . 1.0 111.443 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 13.1 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.02 -0.991 . . . . 1.0 110.513 179.899 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.739 ' O3 ' H492 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.057 -0.72 . . . . 1.0 109.057 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.434 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 19.6 m120 -67.17 -18.33 65.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.841 -0.618 . . . . 1.0 110.401 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.2 pttt -45.2 -37.57 4.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.612 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 3.7 tmtm? -73.65 -38.74 64.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.756 0.789 . . . . 1.0 109.532 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.01 -33.82 26.65 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.397 -0.82 . . . . 1.0 110.237 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -65.98 -39.65 90.54 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.229 -0.896 . . . . 1.0 111.457 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -64.94 -50.11 67.72 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 121.627 0.727 . . . . 1.0 110.864 -178.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.612 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 14.3 m-20 -60.49 -35.75 76.67 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -66.16 -51.38 58.39 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.687 -1.597 . . . . 1.0 111.444 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.61 -48.03 78.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 C-N-CA 120.352 -0.539 . . . . 1.0 111.702 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.426 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.81 -38.73 91.86 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.552 -1.277 . . . . 1.0 107.552 179.119 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.5 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.15 -42.74 66.36 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 114.942 -1.027 . . . . 1.0 111.831 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -62.36 -32.18 72.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.972 -0.751 . . . . 1.0 108.972 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -35.05 49.6 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.261 -0.881 . . . . 1.0 109.878 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -61.17 -50.24 73.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 114.459 -1.246 . . . . 1.0 111.043 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.5 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.4 mp -70.92 -39.8 72.5 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.213 -0.595 . . . . 1.0 109.945 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.69 -42.63 99.19 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.541 -0.754 . . . . 1.0 109.315 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -76.71 -44.53 33.09 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-N 115.485 -0.78 . . . . 1.0 112.019 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.653 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.6 t30 -60.67 -44.77 96.09 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 113.375 0.879 . . . . 1.0 113.375 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.19 -31.93 67.76 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 119.517 -0.873 . . . . 1.0 109.237 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -79.83 -30.35 40.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.151 -0.931 . . . . 1.0 111.647 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 33.0 mtmt -58.18 136.43 84.61 Favored Pre-proline 0 CA--C 1.547 0.857 0 C-N-CA 120.425 -0.51 . . . . 1.0 111.396 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -52.92 148.66 28.76 Favored 'Trans proline' 0 N--CA 1.501 1.965 0 C-N-CA 122.271 1.981 . . . . 1.0 113.547 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -19.51 10.33 Favored Glycine 0 C--O 1.225 -0.413 0 CA-C-N 115.094 -0.957 . . . . 1.0 111.829 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.3 t -86.56 136.56 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.162 0.506 . . . . 1.0 110.896 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.7 t -120.99 123.97 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 N-CA-C 107.952 -1.129 . . . . 1.0 107.952 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.02 145.89 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-O 121.796 0.808 . . . . 1.0 112.008 -178.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.2 mt -113.03 165.18 13.7 Favored Pre-proline 0 C--O 1.231 0.126 0 CA-C-N 114.328 -1.305 . . . . 1.0 111.111 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -61.42 -30.03 86.31 Favored 'Trans proline' 0 C--N 1.32 -0.965 0 C-N-CA 122.167 1.911 . . . . 1.0 111.274 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 m -68.66 -14.97 63.37 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.713 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.5 -3.07 65.56 Favored Glycine 0 C--N 1.329 0.168 0 N-CA-C 109.688 -1.365 . . . . 1.0 109.688 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.47 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.99 133.84 36.2 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.47 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.0 mp0 -121.47 140.13 52.57 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 1.0 110.984 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -135.97 144.52 45.44 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.629 0.728 . . . . 1.0 110.935 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.54 134.8 49.74 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.427 -1.261 . . . . 1.0 109.041 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -92.82 104.04 15.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 122.158 0.98 . . . . 1.0 111.929 -178.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.648 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.4 mm -69.41 -41.48 80.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 178.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.4 m120 -143.73 130.01 19.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.676 -1.147 . . . . 1.0 109.697 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -86.15 131.8 34.16 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.025 -0.361 . . . . 1.0 110.025 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.75 -35.34 0.85 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 54.61 30.07 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.659 -0.271 . . . . 1.0 111.104 179.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.21 -161.23 37.12 Favored Glycine 0 C--N 1.331 0.256 0 CA-C-O 121.997 0.776 . . . . 1.0 111.752 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.8 m -68.94 -178.58 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 114.128 -1.036 . . . . 1.0 109.506 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.553 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.26 154.86 0.39 Allowed Pre-proline 0 C--N 1.32 -0.708 0 CA-C-N 115.608 -0.723 . . . . 1.0 109.391 179.536 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -87.72 156.72 7.56 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 123.195 2.597 . . . . 1.0 116.054 -175.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.44 178.37 47.52 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 108.579 -1.808 . . . . 1.0 108.579 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.722 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -56.32 -20.47 19.09 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.409 -0.516 . . . . 1.0 111.153 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.2 m -108.48 -7.84 15.69 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.386 0.884 . . . . 1.0 113.386 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.57 164.59 16.01 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 120.202 -0.599 . . . . 1.0 109.466 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 6.7 m -101.88 150.53 23.09 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.156 0.503 . . . . 1.0 110.114 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.19 160.21 38.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.335 0 CA-C-N 115.374 -0.83 . . . . 1.0 111.925 -177.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.0 m -129.87 120.79 25.48 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.441 -0.948 . . . . 1.0 108.441 178.02 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.538 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 10.9 m -149.19 166.27 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 113.832 1.049 . . . . 1.0 113.832 -176.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.0 mt-10 -118.4 149.6 40.96 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 105.748 -1.945 . . . . 1.0 105.748 173.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.579 ' CZ ' ' C5 ' ' A' ' 138' ' ' RAP . 41.3 p90 -163.29 162.4 25.18 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 118.285 -1.366 . . . . 1.0 114.338 -177.069 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -124.33 131.78 53.53 Favored 'General case' 0 C--O 1.217 -0.654 0 N-CA-C 108.183 -1.043 . . . . 1.0 108.183 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -117.76 137.83 13.52 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.39 -0.684 . . . . 1.0 111.39 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.84 168.01 23.29 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.769 0.795 . . . . 1.0 112.183 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.1 mp -85.07 164.73 18.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.376 -1.284 . . . . 1.0 109.772 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.13 -26.07 35.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 121.925 0.869 . . . . 1.0 110.061 178.294 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -92.22 2.96 56.29 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 113.808 -1.542 . . . . 1.0 111.764 -177.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.02 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 120.932 -0.651 . . . . 1.0 112.962 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.0 m -70.05 102.44 2.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 118.105 0.952 . . . . 1.0 110.026 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -72.95 120.07 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.819 0 CA-C-O 121.465 0.65 . . . . 1.0 110.354 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.66 ' CD2' HD11 ' A' ' 118' ' ' ILE . 18.8 p90 -114.78 -8.72 12.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.641 -1.163 . . . . 1.0 111.966 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -155.1 146.45 22.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.104 -0.498 . . . . 1.0 110.692 178.184 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 87.9 p -157.49 150.08 22.97 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 115.81 -0.632 . . . . 1.0 111.681 179.058 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.494 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 92.4 m -156.04 -40.46 0.08 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.759 -0.655 . . . . 1.0 110.884 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -63.6 -26.06 68.51 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.222 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -55.93 -43.76 77.7 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.967 -1.124 . . . . 1.0 107.967 178.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 68' ' ' THR . 72.9 p -73.79 -34.5 64.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.878 -1.055 . . . . 1.0 108.521 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.93 16.16 70.76 Favored Glycine 0 C--N 1.334 0.453 0 CA-C-N 115.036 -0.984 . . . . 1.0 111.012 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.42 116.31 65.52 Favored Pre-proline 0 N--CA 1.471 0.576 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.592 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.407 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.8 Cg_exo -60.98 153.69 62.1 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 121.723 1.615 . . . . 1.0 114.483 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.4 150.88 45.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.307 -1.315 . . . . 1.0 107.786 178.127 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 t -110.29 133.81 52.89 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.543 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 58.9 m-85 -143.01 152.51 42.0 Favored 'General case' 0 CA--C 1.503 -0.832 0 CA-C-N 114.577 -1.192 . . . . 1.0 109.505 178.384 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 -92.34 125.2 36.9 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 106.334 -1.728 . . . . 1.0 106.334 174.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.6 t -47.02 -32.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 115.773 -0.649 . . . . 1.0 110.609 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.9 t -74.42 -24.41 59.09 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 120.347 -0.541 . . . . 1.0 111.859 -178.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.539 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 25.8 mm100 -98.82 -9.2 24.69 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 112.928 0.714 . . . . 1.0 112.928 -178.25 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.657 ' CG2' H31A ' A' ' 138' ' ' RAP . 3.3 p -88.04 170.71 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 118.196 0.453 . . . . 1.0 111.494 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.497 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -53.46 145.02 29.58 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 120.871 -0.331 . . . . 1.0 110.58 -176.552 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.32 -44.87 36.75 Favored 'Trans proline' 0 N--CA 1.498 1.737 0 C-N-CA 121.952 1.768 . . . . 1.0 112.74 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.39 -47.48 82.64 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 109.281 -1.528 . . . . 1.0 109.281 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.768 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 9.7 m95 -66.22 -37.02 84.54 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 113.791 -1.205 . . . . 1.0 110.261 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.19 -53.31 36.12 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.856 -0.338 . . . . 1.0 110.942 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tp10 -71.89 -43.98 64.5 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.085 0.402 . . . . 1.0 112.085 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.94 -46.43 85.09 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 114.022 1.119 . . . . 1.0 114.022 -177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.3 -41.58 84.75 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.154 -0.618 . . . . 1.0 109.634 -178.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -65.69 -23.41 66.77 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.187 -0.915 . . . . 1.0 111.197 -179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.422 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 85.4 mt -102.93 -10.34 19.1 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.459 -0.337 . . . . 1.0 110.741 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' MET . . . . . 0.53 ' HE3' ' H ' ' A' ' 99' ' ' TRP . 25.5 ttt -90.62 107.47 20.53 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.734 -0.666 . . . . 1.0 112.032 -178.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.553 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.0 Cg_exo -68.89 148.09 69.9 Favored 'Trans proline' 0 N--CA 1.498 1.77 0 C-N-CA 122.546 2.164 . . . . 1.0 112.361 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.585 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.67 137.67 57.47 Favored 'General case' 0 CA--C 1.509 -0.602 0 CA-C-N 115.546 -0.752 . . . . 1.0 111.664 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.16 -19.19 54.65 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 108.873 -1.691 . . . . 1.0 108.873 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.2 p -88.19 129.98 35.19 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 115.475 -0.362 . . . . 1.0 110.443 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 60.7 m -102.12 115.02 29.67 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 109.438 -0.579 . . . . 1.0 109.438 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.53 ' H ' ' HE3' ' A' ' 93' ' ' MET . 39.4 m0 -116.28 168.31 10.24 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.817 0.818 . . . . 1.0 111.278 -178.144 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.648 ' CD ' HD11 ' A' ' 37' ' ' ILE . 81.5 mt-10 -129.25 129.57 45.12 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 106.63 -1.619 . . . . 1.0 106.63 175.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 pt -125.58 138.45 54.42 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.533 0 CA-C-O 121.771 0.796 . . . . 1.0 109.78 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.743 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.26 103.25 12.18 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 106.021 -1.844 . . . . 1.0 106.021 -178.032 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.1 t -90.01 115.74 64.7 Favored Pre-proline 0 C--N 1.326 -0.442 0 N-CA-C 115.248 1.573 . . . . 1.0 115.248 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -51.44 143.77 34.11 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.188 1.259 . . . . 1.0 109.634 176.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 88.1 p -50.37 -33.76 21.66 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.517 -178.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.5 -32.73 82.58 Favored Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.03 -0.828 . . . . 1.0 111.03 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -99.78 1.73 43.43 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.981 -0.11 . . . . 1.0 110.859 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -111.83 0.3 Allowed 'General case' 0 C--N 1.342 0.264 0 CA-C-O 120.754 0.312 . . . . 1.0 110.816 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.493 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 53.3 m-85 -98.12 5.41 48.62 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 113.567 0.951 . . . . 1.0 113.567 -177.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.81 164.07 18.59 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 121.018 -0.61 . . . . 1.0 113.483 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 121' ' ' ASN . 93.9 Cg_endo -77.02 -9.99 17.98 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.571 2.847 . . . . 1.0 111.173 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -106.65 169.29 8.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.252 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.4 m -75.26 97.21 3.49 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.743 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.2 t -110.77 60.08 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 121.059 -0.256 . . . . 1.0 111.125 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.548 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.68 -177.95 42.34 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 120.514 -0.85 . . . . 1.0 111.998 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.04 -103.77 0.01 OUTLIER Glycine 0 CA--C 1.535 1.338 0 N-CA-C 111.141 -0.783 . . . . 1.0 111.141 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -63.21 -14.05 39.48 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.732 2.288 . . . . 1.0 111.159 -178.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.66 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.3 mp -65.86 114.93 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 108.273 -1.01 . . . . 1.0 108.273 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.432 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -95.03 -171.88 37.1 Favored Glycine 0 CA--C 1.52 0.354 0 CA-C-N 115.512 -0.767 . . . . 1.0 111.553 -178.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.529 ' N ' ' OG ' ' A' ' 113' ' ' SER . 26.3 Cg_endo -63.25 138.2 65.2 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.562 2.174 . . . . 1.0 112.535 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.53 ' N ' ' O ' ' A' ' 111' ' ' PRO . 27.8 t-20 53.17 51.41 15.69 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 120.962 -0.295 . . . . 1.0 111.3 178.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.612 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -96.74 131.27 43.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.294 -0.412 . . . . 1.0 111.6 -179.608 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.43 HG21 HD11 ' A' ' 16' ' ' LEU . 49.1 m -95.97 128.66 43.05 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.34 138.9 48.41 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.064 0.459 . . . . 1.0 110.998 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.743 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -117.91 147.35 21.42 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.583 0 CA-C-N 115.724 -0.671 . . . . 1.0 109.195 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.584 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.83 150.92 47.58 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.441 -0.504 . . . . 1.0 111.629 177.855 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.424 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.0 mmtt -100.76 123.97 45.72 Favored 'General case' 0 CA--C 1.501 -0.907 0 N-CA-C 105.807 -1.923 . . . . 1.0 105.807 177.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.468 HG23 ' CH2' ' A' ' 86' ' ' TRP . 2.9 mt -117.0 125.61 73.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 119.592 -0.843 . . . . 1.0 112.732 -176.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -118.03 124.58 48.46 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.172 -1.377 . . . . 1.0 108.484 178.388 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.23 114.22 25.98 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 119.746 -0.782 . . . . 1.0 112.808 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.485 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -95.46 -43.01 12.74 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 115.732 -0.667 . . . . 1.0 110.996 178.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -154.21 156.5 37.2 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.604 -0.439 . . . . 1.0 111.265 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.413 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.7 t -129.82 138.43 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.111 -0.495 . . . . 1.0 111.273 -178.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.466 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 8.9 tptm -97.16 -148.93 0.32 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 1.0 109.931 178.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.462 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER -167.54 146.26 4.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.28 178.024 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 96.4 p -59.15 -35.15 73.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.011 -0.995 . . . . 1.0 110.947 -179.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' A' ' 137' ' ' SER . 1.0 OUTLIER . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.963 -1.018 . . . . 1.0 110.043 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.949 H472 ' C20' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 . . . . . 0 N--CA 1.492 1.64 0 N-CA-C 109.773 -0.454 . . . . 1.0 109.773 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.466 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 27.2 m120 -64.36 -17.7 63.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.797 -0.638 . . . . 1.0 111.685 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -50.04 -43.58 51.0 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.99 0.424 . . . . 1.0 109.888 -178.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.535 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 4.9 tmtt? -68.91 -37.05 78.7 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-O 121.612 0.72 . . . . 1.0 109.971 179.12 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.484 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -51.3 -33.35 28.55 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.482 -0.781 . . . . 1.0 110.8 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -62.73 -36.92 84.57 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.32 -0.855 . . . . 1.0 110.751 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.415 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 22.7 mt-10 -66.68 -52.38 45.45 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-O 121.842 0.83 . . . . 1.0 110.104 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.535 ' OD1' ' NZ ' ' A' ' 4' ' ' LYS . 88.5 m-20 -58.75 -34.07 70.99 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 115.002 -0.999 . . . . 1.0 108.409 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 17.7 tttp -66.1 -51.47 57.77 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.073 -1.422 . . . . 1.0 111.493 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.3 t -67.32 -46.88 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 C-N-CA 119.845 -0.742 . . . . 1.0 111.663 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.447 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.59 -37.58 86.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.893 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.459 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.95 -44.66 29.65 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.861 -1.063 . . . . 1.0 112.317 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.435 ' N ' ' O ' ' A' ' 9' ' ' LYS . 58.3 mt-10 -60.73 -34.5 74.51 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.53 -0.915 . . . . 1.0 108.53 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.56 -36.07 65.56 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.016 -0.993 . . . . 1.0 109.826 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -61.14 -50.22 74.08 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.762 -1.108 . . . . 1.0 110.3 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 12' ' ' GLY . 4.7 mp -66.22 -38.43 87.92 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.387 -0.597 . . . . 1.0 109.387 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -61.51 -42.59 99.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.739 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -75.62 -44.61 41.93 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.6 -0.727 . . . . 1.0 111.887 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.628 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -56.98 -49.52 75.48 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -178.486 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.3 ptmt -58.93 -29.47 67.13 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.355 -0.938 . . . . 1.0 110.021 -176.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -81.79 -29.1 32.86 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.311 -0.859 . . . . 1.0 111.482 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 mtmt -60.69 145.63 87.52 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 120.625 -0.43 . . . . 1.0 112.005 -178.099 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.0 149.05 64.52 Favored 'Trans proline' 0 N--CA 1.507 2.296 0 C-N-CA 122.946 2.431 . . . . 1.0 114.708 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.44 -20.53 2.11 Favored Glycine 0 N--CA 1.462 0.41 0 CA-C-N 114.957 -1.02 . . . . 1.0 111.894 178.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.2 t -79.2 131.55 34.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 C-N-CA 120.138 -0.625 . . . . 1.0 109.925 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 67.4 t -116.03 120.33 64.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.103 -1.073 . . . . 1.0 108.103 177.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.6 p -93.32 145.94 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 CA-C-O 121.688 0.756 . . . . 1.0 111.366 -178.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.33 163.55 18.0 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-N 114.534 -1.212 . . . . 1.0 110.446 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.4 -30.99 92.1 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 121.668 1.579 . . . . 1.0 111.294 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.3 m -69.34 -13.44 62.38 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.676 -0.693 . . . . 1.0 110.114 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.32 -4.0 64.29 Favored Glycine 0 CA--C 1.518 0.252 0 N-CA-C 110.179 -1.169 . . . . 1.0 110.179 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.498 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.8 tm? -77.45 134.56 38.34 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 108.565 -0.902 . . . . 1.0 108.565 179.573 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.498 ' H ' HD22 ' A' ' 32' ' ' LEU . 14.2 mp0 -125.1 141.68 51.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 116.341 -0.391 . . . . 1.0 111.609 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.1 p90 -137.01 142.58 42.52 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.745 0.783 . . . . 1.0 112.087 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.557 ' HE3' HD13 ' A' ' 37' ' ' ILE . 6.2 ttpt -124.85 124.63 42.5 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 114.282 -1.327 . . . . 1.0 108.296 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.88 113.39 21.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 CA-C-N 115.199 -0.91 . . . . 1.0 111.107 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.557 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.7 mm -77.02 -42.15 31.77 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 CA-C-O 121.808 0.813 . . . . 1.0 109.63 178.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -143.81 128.76 18.49 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.208 -1.36 . . . . 1.0 109.655 -177.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.9 p -90.83 128.57 36.77 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.941 0.401 . . . . 1.0 109.996 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.89 -32.64 1.39 Allowed Glycine 0 CA--C 1.52 0.368 0 N-CA-C 110.045 -1.222 . . . . 1.0 110.045 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 56.6 31.92 20.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.532 -0.334 . . . . 1.0 111.126 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.13 -161.01 37.0 Favored Glycine 0 C--N 1.334 0.445 0 CA-C-O 121.833 0.685 . . . . 1.0 111.553 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.586 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.6 m -68.41 -178.49 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.108 -1.046 . . . . 1.0 109.301 178.575 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.492 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.66 154.59 0.36 Allowed Pre-proline 0 C--N 1.319 -0.741 0 O-C-N 123.84 0.712 . . . . 1.0 109.213 179.529 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.8 Cg_endo -86.99 157.9 8.62 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.933 2.422 . . . . 1.0 115.781 -175.512 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.412 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.31 172.69 38.25 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 108.446 -1.862 . . . . 1.0 108.446 176.098 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.618 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -47.04 -25.27 0.78 Allowed 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 114.83 -0.685 . . . . 1.0 111.62 178.773 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.428 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 20.7 m -108.25 -9.14 15.56 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 113.363 0.875 . . . . 1.0 113.363 -177.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.412 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.7 m-20 -84.72 167.39 16.19 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 119.717 -0.793 . . . . 1.0 109.005 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.8 m -106.14 149.93 26.31 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.096 0.474 . . . . 1.0 109.918 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.431 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.1 p -126.53 162.35 30.93 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.297 0 CA-C-N 115.477 -0.783 . . . . 1.0 112.21 -176.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 77.9 m -130.23 119.96 23.72 Favored 'General case' 0 N--CA 1.464 0.24 0 N-CA-C 108.333 -0.988 . . . . 1.0 108.333 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.559 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.8 m -148.99 166.62 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 114.28 1.215 . . . . 1.0 114.28 -176.631 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 9.4 mt-10 -118.4 152.19 36.34 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 106.386 -1.709 . . . . 1.0 106.386 174.237 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.504 ' H ' ' HB ' ' A' ' 68' ' ' THR . 32.8 p90 -163.63 160.71 23.16 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 118.423 -1.311 . . . . 1.0 114.538 -178.021 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.15 130.29 53.09 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.769 -0.826 . . . . 1.0 108.769 175.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.2 137.08 13.93 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.881 -0.676 . . . . 1.0 112.02 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -147.84 167.28 25.17 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.617 0.722 . . . . 1.0 112.227 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -86.89 166.05 15.46 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.491 -1.231 . . . . 1.0 111.404 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.417 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.01 -26.24 35.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 114.809 -1.087 . . . . 1.0 110.266 178.066 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -93.79 2.38 56.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.173 -1.376 . . . . 1.0 111.416 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -2.25 75.67 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 120.998 -0.62 . . . . 1.0 112.767 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.4 m -69.03 103.44 1.86 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.821 0.81 . . . . 1.0 110.326 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.9 t -74.03 122.7 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 C-N-CA 120.287 -0.565 . . . . 1.0 109.601 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.841 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.3 p90 -116.35 -8.46 11.64 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 115.003 -0.999 . . . . 1.0 111.598 -178.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.519 ' OD1' H433 ' A' ' 138' ' ' RAP . 33.7 t0 -158.29 152.42 24.09 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.467 -0.493 . . . . 1.0 111.335 178.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 96.4 p -159.29 153.23 23.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.729 -0.668 . . . . 1.0 111.623 178.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.504 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 66.2 m -155.86 -39.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.643 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.4 pp20? -65.8 -27.15 68.06 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -58.15 -43.83 87.55 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 107.808 -1.182 . . . . 1.0 107.808 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.5 p -73.99 -31.32 62.92 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.865 -1.062 . . . . 1.0 108.797 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.71 18.31 68.42 Favored Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.81 178.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.413 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 0.0 OUTLIER -101.73 115.03 65.43 Favored Pre-proline 0 N--CA 1.47 0.539 0 C-N-CA 120.682 -0.407 . . . . 1.0 110.98 -179.275 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.407 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 30.4 Cg_exo -60.83 152.49 69.67 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.823 1.682 . . . . 1.0 114.366 -178.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.26 152.21 41.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.042 -1.436 . . . . 1.0 107.833 178.165 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 130.9 55.38 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 121.408 0.623 . . . . 1.0 112.511 -178.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.591 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 42.3 m-85 -138.82 148.44 43.77 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.0 -1.0 . . . . 1.0 109.853 178.487 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 67.8 mt-30 -90.35 125.39 35.52 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 106.335 -1.728 . . . . 1.0 106.335 174.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.8 t -53.69 -28.85 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 C-N-CA 119.394 -0.922 . . . . 1.0 110.15 -177.326 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.7 t -73.97 -25.59 60.02 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.025 -0.67 . . . . 1.0 111.835 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.566 ' NE2' H462 ' A' ' 138' ' ' RAP . 24.9 mm100 -100.1 -16.07 17.97 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.717 -0.393 . . . . 1.0 112.022 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.923 ' HA ' H332 ' A' ' 138' ' ' RAP . 0.4 OUTLIER -64.99 164.75 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 112.109 0.411 . . . . 1.0 112.109 -177.637 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.518 HG12 H492 ' A' ' 138' ' ' RAP . 0.0 OUTLIER -54.58 148.96 23.19 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.501 -0.925 . . . . 1.0 108.501 -178.394 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -51.33 -42.62 53.68 Favored 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 121.061 1.174 . . . . 1.0 112.093 -178.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.76 -48.09 87.73 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 119.872 -1.156 . . . . 1.0 110.54 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.684 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 9.5 m95 -65.56 -35.5 81.04 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.301 -0.949 . . . . 1.0 111.144 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.2 m -51.19 -54.38 26.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.987 -0.285 . . . . 1.0 111.637 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.89 -40.8 68.65 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.456 0.539 . . . . 1.0 112.456 -179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.1 -48.1 82.84 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 114.136 1.162 . . . . 1.0 114.136 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.4 mt -58.32 -42.25 86.31 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.299 0.571 . . . . 1.0 109.896 -177.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -63.25 -23.9 67.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.332 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.517 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.7 mt -100.95 -12.45 18.91 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.902 -0.59 . . . . 1.0 111.246 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.5 ttp -90.17 107.45 19.64 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 111.863 0.32 . . . . 1.0 111.863 -178.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.492 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.3 Cg_exo -67.28 148.02 79.38 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.614 2.209 . . . . 1.0 112.426 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.586 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.61 135.6 55.26 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-O 121.546 0.688 . . . . 1.0 110.926 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.46 57.49 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 107.788 -2.125 . . . . 1.0 107.788 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.8 p -90.24 133.51 34.88 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.956 -0.622 . . . . 1.0 110.676 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.0 m -108.8 115.42 30.06 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.581 -0.736 . . . . 1.0 109.426 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.517 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 40.6 m0 -115.43 168.52 9.92 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.777 0.799 . . . . 1.0 111.081 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.426 ' HB2' HD11 ' A' ' 37' ' ' ILE . 25.2 mt-10 -127.89 129.91 47.65 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 106.449 -1.686 . . . . 1.0 106.449 175.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.7 pt -126.33 137.83 56.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.782 0.801 . . . . 1.0 109.707 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.91 103.62 12.71 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 105.866 -1.901 . . . . 1.0 105.866 -178.078 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 t -90.48 115.57 64.43 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 115.162 1.541 . . . . 1.0 115.162 -174.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -51.07 145.6 24.96 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.525 1.483 . . . . 1.0 109.89 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.7 p -51.7 -36.24 45.92 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.241 -0.584 . . . . 1.0 111.046 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.43 -32.48 83.62 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.862 -0.895 . . . . 1.0 110.862 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.6 mt -99.19 2.28 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.856 -0.172 . . . . 1.0 111.001 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.53 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.82 -103.81 0.37 Allowed 'General case' 0 C--O 1.219 -0.54 0 N-CA-C 112.197 0.443 . . . . 1.0 112.197 -177.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.688 ' CE2' H491 ' A' ' 138' ' ' RAP . 31.9 m-85 -104.07 3.96 33.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 113.435 0.902 . . . . 1.0 113.435 -177.182 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.78 167.8 17.22 Favored Glycine 0 N--CA 1.47 0.922 0 C-N-CA 120.673 -0.775 . . . . 1.0 113.786 177.107 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.575 ' O ' ' N ' ' A' ' 121' ' ' ASN . 91.0 Cg_endo -76.37 -17.74 16.41 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 124.013 3.142 . . . . 1.0 111.764 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -103.67 169.69 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.848 -0.615 . . . . 1.0 110.066 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.406 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.2 m -74.16 102.95 4.42 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.673 -0.491 . . . . 1.0 109.673 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 109' ' ' TYR . 8.7 t -111.62 61.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-O 120.699 0.285 . . . . 1.0 110.795 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.501 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 162.95 178.32 36.67 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.631 -0.795 . . . . 1.0 111.793 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.46 -103.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.156 0 N-CA-C 111.09 -0.804 . . . . 1.0 111.09 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -61.76 -16.64 50.12 Favored 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.672 2.248 . . . . 1.0 111.734 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.841 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.9 mp -66.46 117.2 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 107.475 -1.305 . . . . 1.0 107.475 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -93.47 -170.15 39.09 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.622 -0.717 . . . . 1.0 111.926 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.484 ' HB2' ' HB2' ' A' ' 5' ' ' ALA . 30.1 Cg_endo -67.55 145.56 70.84 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 C-N-CA 122.413 2.075 . . . . 1.0 111.614 178.292 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.575 ' N ' ' O ' ' A' ' 111' ' ' PRO . 18.3 t-20 42.99 48.76 5.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.324 0.583 . . . . 1.0 110.415 179.078 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 4.4 tp10 -100.86 128.97 46.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.126 -0.943 . . . . 1.0 111.226 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 16' ' ' LEU . 46.7 m -91.29 131.38 36.83 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.299 -0.864 . . . . 1.0 109.404 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -113.14 147.98 36.27 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.876 0.37 . . . . 1.0 110.28 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -126.39 143.22 40.62 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.595 0 N-CA-C 108.546 -0.909 . . . . 1.0 108.546 178.358 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.565 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.5 m-85 -134.15 149.9 51.08 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.378 -0.529 . . . . 1.0 111.657 177.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.5 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 6.9 mmtt -100.16 124.39 45.52 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 105.728 -1.953 . . . . 1.0 105.728 177.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.2 118.95 59.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.878 0.846 . . . . 1.0 113.031 -176.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.441 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.0 t60 -109.64 127.12 54.32 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 113.98 -1.464 . . . . 1.0 108.536 178.679 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.6 111.61 23.68 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 120.041 -0.664 . . . . 1.0 112.41 -178.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.442 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.2 mp -93.86 -44.79 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 CA-C-N 116.119 -0.492 . . . . 1.0 111.1 179.137 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.5 p -152.39 158.39 42.61 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.89 0.376 . . . . 1.0 110.744 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.4 t -130.88 139.68 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.516 -177.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.501 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 7.2 tptt -93.6 -148.56 0.26 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.356 0.598 . . . . 1.0 109.906 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.501 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -176.58 137.4 0.27 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.646 178.234 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.4 t -86.79 -71.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.844 -1.071 . . . . 1.0 110.881 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.6 t . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.449 -179.668 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.923 H332 ' HA ' ' A' ' 82' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 34.7 p90 . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.565 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 81.0 m-20 -69.94 -24.09 63.3 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.758 -0.377 . . . . 1.0 110.982 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 59.7 pttt -45.31 -42.59 9.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.135 0.493 . . . . 1.0 110.404 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.498 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 3.1 tmtt? -67.51 -35.81 79.83 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.959 0.885 . . . . 1.0 109.502 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.78 -33.66 36.32 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 114.83 -1.077 . . . . 1.0 111.039 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.505 ' OD2' ' NZ ' ' A' ' 9' ' ' LYS . 52.7 m-20 -62.73 -39.39 93.95 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 115.456 -0.793 . . . . 1.0 109.982 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -63.03 -52.87 61.19 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.599 0.714 . . . . 1.0 110.512 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 28.5 m-20 -59.7 -35.66 74.95 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.171 -0.922 . . . . 1.0 108.657 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.505 ' NZ ' ' OD2' ' A' ' 6' ' ' ASP . 1.9 ttpm? -65.74 -50.83 63.37 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.197 -1.365 . . . . 1.0 111.139 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -67.21 -48.81 77.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 119.58 -0.848 . . . . 1.0 112.015 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.458 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.16 -38.04 87.53 Favored 'General case' 0 N--CA 1.444 -0.757 0 N-CA-C 107.703 -1.221 . . . . 1.0 107.703 179.212 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.479 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.2 -47.96 41.66 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 114.897 -1.047 . . . . 1.0 112.296 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -59.86 -30.81 69.23 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 119.882 -0.727 . . . . 1.0 109.248 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.4 -35.31 47.29 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.266 -0.879 . . . . 1.0 109.978 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.5 t80 -60.55 -49.43 77.58 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.764 -1.107 . . . . 1.0 110.379 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.479 HD12 ' O ' ' A' ' 12' ' ' GLY . 6.0 mp -66.99 -40.01 87.29 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 109.199 -0.667 . . . . 1.0 109.199 178.243 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 98.0 m -61.96 -41.75 98.35 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.488 -0.778 . . . . 1.0 109.733 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -75.73 -43.38 47.23 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.69 -0.687 . . . . 1.0 111.36 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.666 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 47.4 t30 -61.53 -45.31 94.72 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 112.793 0.664 . . . . 1.0 112.793 -178.257 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -58.89 -30.74 68.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.48 -0.888 . . . . 1.0 108.947 -179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 58.9 m-20 -79.07 -31.65 44.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.261 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 29.4 mtmt -58.55 142.72 82.45 Favored Pre-proline 0 CA--C 1.547 0.865 0 C-N-CA 120.525 -0.47 . . . . 1.0 111.163 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.68 149.06 61.3 Favored 'Trans proline' 0 N--CA 1.503 2.042 0 C-N-CA 122.422 2.081 . . . . 1.0 114.297 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.73 -19.31 5.12 Favored Glycine 0 C--O 1.228 -0.243 0 CA-C-N 115.021 -0.99 . . . . 1.0 112.226 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.54 136.53 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.02 0.438 . . . . 1.0 110.754 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.3 t -121.41 122.91 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 107.963 -1.125 . . . . 1.0 107.963 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.92 146.0 8.1 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.753 0.787 . . . . 1.0 111.896 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.8 mt -114.86 166.5 11.59 Favored Pre-proline 0 C--O 1.231 0.119 0 CA-C-N 114.35 -1.296 . . . . 1.0 111.048 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -61.57 -31.6 87.27 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 122.241 1.961 . . . . 1.0 111.97 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 m -69.94 -10.71 59.53 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.25 0.548 . . . . 1.0 109.855 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.25 0.94 72.89 Favored Glycine 0 CA--C 1.517 0.185 0 N-CA-C 109.952 -1.259 . . . . 1.0 109.952 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.48 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -82.64 133.58 35.17 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 108.555 -0.905 . . . . 1.0 108.555 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.48 ' H ' HD22 ' A' ' 32' ' ' LEU . 16.5 mp0 -121.84 143.46 49.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.413 -0.358 . . . . 1.0 111.164 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 26.7 p90 -137.4 145.27 43.04 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.733 0.778 . . . . 1.0 111.072 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.506 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -128.66 132.63 48.1 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 114.38 -1.282 . . . . 1.0 109.08 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.85 104.63 15.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 122.314 1.055 . . . . 1.0 112.02 -178.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.613 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -69.77 -41.35 79.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.992 -1.004 . . . . 1.0 108.551 179.021 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -143.92 129.38 19.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.661 -1.154 . . . . 1.0 109.73 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.3 p -89.43 128.81 35.98 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.734 -0.469 . . . . 1.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.48 -35.15 1.22 Allowed Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 58.07 29.9 18.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 1.0 111.138 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.93 -161.99 37.84 Favored Glycine 0 C--N 1.331 0.259 0 CA-C-O 121.888 0.716 . . . . 1.0 111.713 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.9 m -68.61 -177.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.061 -1.07 . . . . 1.0 108.841 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' HG21 ' A' ' 133' ' ' VAL . 0.0 OUTLIER 177.67 155.4 0.49 Allowed Pre-proline 0 C--N 1.317 -0.836 0 O-C-N 123.628 0.58 . . . . 1.0 109.516 179.797 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -83.84 165.23 13.64 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 123.241 2.627 . . . . 1.0 116.292 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.443 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -98.08 175.02 29.37 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 108.633 -1.787 . . . . 1.0 108.633 176.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.84 -23.53 18.8 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.618 -0.433 . . . . 1.0 111.492 -179.086 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 36.4 m -107.02 -6.31 17.55 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 112.9 0.704 . . . . 1.0 112.9 -177.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.727 ' OD1' ' N ' ' A' ' 50' ' ' THR . 67.2 t0 -82.33 170.68 15.07 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.282 0.563 . . . . 1.0 110.595 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.727 ' N ' ' OD1' ' A' ' 49' ' ' ASP . 8.9 m -112.38 144.06 42.44 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.697 -0.853 . . . . 1.0 108.697 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' THR . 9.0 p -125.39 160.34 31.52 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 CA-C-N 115.182 -0.917 . . . . 1.0 111.974 -175.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.444 HG22 ' HB3' ' A' ' 74' ' ' PRO . 99.3 m -125.5 119.74 29.03 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.602 -0.888 . . . . 1.0 108.602 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.433 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.5 m -148.48 166.93 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 114.341 1.237 . . . . 1.0 114.341 -177.191 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -119.36 147.68 44.06 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 106.283 -1.747 . . . . 1.0 106.283 173.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.4 p90 -162.19 163.4 28.36 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 115.083 1.512 . . . . 1.0 115.083 -176.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -127.45 127.5 44.18 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 115.254 -0.884 . . . . 1.0 109.332 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.74 136.07 13.19 Favored Glycine 0 N--CA 1.471 1.001 0 C-N-CA 121.094 -0.574 . . . . 1.0 112.355 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 58' ' ' ARG . 5.3 ptp180 -147.4 168.55 21.57 Favored 'General case' 0 C--N 1.341 0.199 0 CA-C-O 121.498 0.666 . . . . 1.0 112.266 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.2 mp -84.93 164.7 18.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.519 -1.219 . . . . 1.0 110.761 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.43 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.57 -25.49 34.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 114.883 -1.053 . . . . 1.0 110.018 177.792 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -92.65 3.02 56.36 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.926 -1.488 . . . . 1.0 111.622 -177.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.27 -2.03 80.56 Favored Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.822 -0.704 . . . . 1.0 112.668 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.4 m -71.37 104.49 3.21 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 119.722 -0.791 . . . . 1.0 109.785 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.1 t -75.46 126.34 36.11 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.81 0 CA-C-O 121.202 0.525 . . . . 1.0 110.332 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 30.2 p90 -115.0 -11.68 12.1 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.032 -0.986 . . . . 1.0 111.425 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.424 ' CB ' ' C43' ' A' ' 138' ' ' RAP . 21.1 t0 -162.5 153.35 17.3 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.838 -0.745 . . . . 1.0 112.158 178.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 93.3 p -160.44 154.88 23.6 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 115.706 -0.679 . . . . 1.0 112.124 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.505 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 90.4 m -152.26 -43.51 0.1 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.688 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.413 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.8 pp20? -59.04 -25.98 64.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.152 -0.476 . . . . 1.0 110.427 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -54.98 -42.55 72.56 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.674 -1.232 . . . . 1.0 107.674 178.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 71.9 p -77.06 -34.83 57.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.525 -1.216 . . . . 1.0 109.193 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 85.05 16.75 64.37 Favored Glycine 0 C--N 1.333 0.362 0 CA-C-N 115.452 -0.795 . . . . 1.0 111.57 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.5 116.14 65.15 Favored Pre-proline 0 N--CA 1.472 0.672 0 C-N-CA 120.488 -0.485 . . . . 1.0 110.874 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HB3' HG22 ' A' ' 52' ' ' THR . 34.7 Cg_exo -59.7 151.65 68.71 Favored 'Trans proline' 0 N--CA 1.481 0.752 0 C-N-CA 121.458 1.438 . . . . 1.0 114.438 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.36 149.52 46.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.027 -1.442 . . . . 1.0 107.257 177.487 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -103.34 136.99 42.07 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.358 0.599 . . . . 1.0 112.493 -178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.55 ' CE1' ' H42' ' A' ' 138' ' ' RAP . 38.7 m-85 -140.23 148.3 41.31 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 114.933 -1.031 . . . . 1.0 110.767 179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.469 ' H ' H483 ' A' ' 138' ' ' RAP . 64.7 mt-30 -92.0 125.19 36.6 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.752 -1.944 . . . . 1.0 105.752 174.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.6 t -56.45 -29.98 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 C-N-CA 118.704 -1.198 . . . . 1.0 110.126 -176.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LYS . 3.1 t -73.53 -25.78 60.57 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 120.074 -0.65 . . . . 1.0 112.577 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.631 ' O ' ' O11' ' A' ' 138' ' ' RAP . 26.5 mm100 -101.37 -15.9 17.07 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 111.885 0.328 . . . . 1.0 111.885 -179.099 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.73 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.6 p -69.94 170.52 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 119.42 -0.912 . . . . 1.0 111.886 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.481 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.08 146.99 27.34 Favored Pre-proline 0 CA--C 1.548 0.875 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 -178.069 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -52.13 -43.64 51.6 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.814 1.676 . . . . 1.0 113.105 -178.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.65 -47.15 92.36 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 109.574 -1.41 . . . . 1.0 109.574 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.615 ' CD2' ' H41' ' A' ' 138' ' ' RAP . 6.7 m95 -63.03 -35.31 79.8 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.153 -1.024 . . . . 1.0 110.387 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 24.8 m -51.56 -53.54 36.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.063 0.458 . . . . 1.0 111.063 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -71.9 -44.91 62.92 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.617 -0.72 . . . . 1.0 112.687 -179.141 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -58.81 -46.8 86.75 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 114.509 1.3 . . . . 1.0 114.509 -177.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 19.4 mt -57.84 -42.88 85.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.362 0.601 . . . . 1.0 109.478 -178.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -62.95 -20.08 64.89 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.942 -1.026 . . . . 1.0 110.434 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.537 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 96.2 mt -105.93 -11.05 16.33 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.968 -0.56 . . . . 1.0 111.352 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 54.2 ttp -92.52 107.18 21.93 Favored Pre-proline 0 CA--C 1.547 0.842 0 O-C-N 123.273 0.358 . . . . 1.0 111.376 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.43 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 23.8 Cg_exo -64.43 147.7 90.65 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.398 2.065 . . . . 1.0 112.936 178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.599 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -61.87 132.66 53.77 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 115.482 -0.781 . . . . 1.0 111.579 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.49 -19.26 55.09 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 108.492 -1.843 . . . . 1.0 108.492 -178.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -84.61 131.83 34.56 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.038 0.447 . . . . 1.0 109.994 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.5 m -105.24 113.67 27.4 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 115.923 -0.58 . . . . 1.0 109.604 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.9 m0 -115.65 165.69 12.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.871 0.843 . . . . 1.0 111.258 -178.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.613 ' CD ' HD11 ' A' ' 37' ' ' ILE . 83.7 mt-10 -125.84 132.88 52.13 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 106.277 -1.749 . . . . 1.0 106.277 175.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.425 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.7 pt -128.66 139.71 51.17 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-O 121.84 0.829 . . . . 1.0 109.925 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.697 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.88 103.07 11.8 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 105.742 -1.947 . . . . 1.0 105.742 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 t -90.64 116.23 65.94 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 115.614 1.709 . . . . 1.0 115.614 -174.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.81 144.56 26.38 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.66 1.574 . . . . 1.0 109.766 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.5 p -50.45 -36.24 32.42 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 120.434 -0.506 . . . . 1.0 111.363 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.98 -32.2 80.2 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.977 -0.849 . . . . 1.0 110.977 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.4 mt -98.4 2.32 47.75 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 121.364 -0.134 . . . . 1.0 110.746 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.619 ' O ' H521 ' A' ' 138' ' ' RAP . . . -107.95 -103.22 0.36 Allowed 'General case' 0 C--O 1.216 -0.665 0 N-CA-C 110.069 -0.345 . . . . 1.0 110.069 -179.097 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.532 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 35.7 m-85 -105.29 5.17 31.74 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 113.397 0.888 . . . . 1.0 113.397 -178.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 105.46 166.7 23.69 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 120.814 -0.707 . . . . 1.0 113.075 177.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 121' ' ' ASN . 72.6 Cg_endo -72.64 -18.46 25.38 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 123.454 2.769 . . . . 1.0 112.45 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -98.03 169.3 9.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.303 -0.408 . . . . 1.0 109.947 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.7 m -76.33 85.82 3.11 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.7 t -98.04 59.23 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.51 -0.314 . . . . 1.0 110.923 -179.114 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.75 179.9 41.76 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 120.629 -0.796 . . . . 1.0 112.088 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.01 -105.87 0.01 OUTLIER Glycine 0 CA--C 1.537 1.418 0 N-CA-C 111.747 -0.541 . . . . 1.0 111.747 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -61.15 -13.72 29.68 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 C-N-CA 122.399 2.066 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.841 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.1 mp -68.24 112.22 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 108.334 -0.987 . . . . 1.0 108.334 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.412 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -91.21 -167.11 40.9 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.691 -0.964 . . . . 1.0 110.691 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.519 ' HB2' ' HB2' ' A' ' 5' ' ' ALA . 38.0 Cg_endo -64.76 146.65 88.81 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 122.242 1.961 . . . . 1.0 112.973 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.468 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 46.16 49.87 12.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.67 -0.695 . . . . 1.0 111.925 178.353 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.437 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 49.1 mm-40 -93.21 132.69 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.093 0.473 . . . . 1.0 111.978 179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.465 HG21 HD11 ' A' ' 16' ' ' LEU . 63.4 m -96.2 127.82 42.55 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.243 -1.762 . . . . 1.0 106.243 175.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.423 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.97 143.16 45.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.517 0.675 . . . . 1.0 110.747 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.697 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.7 tt -119.28 146.38 24.04 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.659 0 CA-C-N 115.078 -0.965 . . . . 1.0 108.508 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.562 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.84 152.27 48.92 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.314 -0.554 . . . . 1.0 111.376 177.63 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.476 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 3.4 mmtt -100.47 124.03 45.46 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 105.697 -1.964 . . . . 1.0 105.697 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -118.61 119.05 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 119.41 -0.916 . . . . 1.0 112.394 -176.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.59 ' CD2' HD11 ' A' ' 131' ' ' ILE . 4.2 t60 -110.81 122.66 48.38 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 114.096 -1.411 . . . . 1.0 108.654 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.49 112.13 23.89 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 120.364 -0.534 . . . . 1.0 112.378 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.59 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.3 mp -95.55 -45.04 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 116.015 -0.539 . . . . 1.0 111.412 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -151.05 157.82 43.31 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.827 0.346 . . . . 1.0 110.691 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.471 HG21 ' HA ' ' A' ' 44' ' ' LYS . 60.5 t -128.79 140.67 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 121.039 0.447 . . . . 1.0 111.51 -177.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.519 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 14.7 tptt -97.5 -151.47 0.37 Allowed 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.942 0.877 . . . . 1.0 111.22 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.519 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.4 OUTLIER -174.18 126.42 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 114.056 -1.429 . . . . 1.0 110.533 177.811 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -70.63 -47.1 61.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 113.869 -1.514 . . . . 1.0 111.98 -178.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.135 -0.936 . . . . 1.0 110.301 -179.594 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.73 H31A ' CG2' ' A' ' 82' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.095 -0.706 . . . . 1.0 109.095 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -65.67 -27.3 68.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 120.155 -0.618 . . . . 1.0 110.718 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.535 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 40.2 pttt -55.26 -40.52 71.07 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.558 -0.457 . . . . 1.0 109.982 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.535 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 6.7 tmtt? -73.45 -39.39 65.0 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 121.854 0.835 . . . . 1.0 109.154 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -50.75 -33.41 23.06 Favored 'General case' 0 CA--C 1.505 -0.77 0 CA-C-N 114.834 -1.075 . . . . 1.0 110.424 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -62.09 -44.08 97.43 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.666 -0.697 . . . . 1.0 110.294 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -59.61 -52.08 67.05 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 122.023 0.916 . . . . 1.0 110.646 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.562 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.8 m-20 -59.59 -37.47 78.63 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 114.608 -1.178 . . . . 1.0 108.221 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -67.46 -52.14 42.97 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.183 -1.371 . . . . 1.0 111.495 179.541 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.92 -48.37 75.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 119.736 -0.786 . . . . 1.0 112.058 -177.188 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.449 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -63.36 -35.54 80.73 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.015 -1.106 . . . . 1.0 108.015 178.982 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.475 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -74.54 -43.57 29.61 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 114.754 -1.112 . . . . 1.0 112.054 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.3 mt-10 -61.72 -31.25 71.39 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.907 -0.775 . . . . 1.0 108.907 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.39 -32.08 48.67 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.441 -0.8 . . . . 1.0 110.04 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -62.44 -49.12 76.7 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.579 -1.191 . . . . 1.0 110.762 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.73 -40.1 76.4 Favored 'General case' 0 C--N 1.32 -0.686 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.892 178.439 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.4 m -61.04 -41.7 97.09 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.814 -0.63 . . . . 1.0 109.481 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -75.48 -46.52 31.94 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.31 -0.859 . . . . 1.0 111.575 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.9 t30 -60.37 -44.91 95.17 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 113.016 0.747 . . . . 1.0 113.016 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -60.42 -28.84 68.58 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 119.47 -0.892 . . . . 1.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-20 -80.25 -30.02 38.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.191 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -59.4 142.95 86.35 Favored Pre-proline 0 CA--C 1.55 0.951 0 N-CA-C 112.268 0.47 . . . . 1.0 112.268 -177.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.06 149.05 65.08 Favored 'Trans proline' 0 N--CA 1.505 2.195 0 C-N-CA 122.499 2.132 . . . . 1.0 113.362 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.72 -19.37 5.08 Favored Glycine 0 C--O 1.225 -0.412 0 CA-C-N 115.601 -0.727 . . . . 1.0 112.189 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.5 t -85.11 136.28 23.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.148 0.499 . . . . 1.0 110.833 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.91 124.24 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 107.854 -1.165 . . . . 1.0 107.854 177.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.4 p -97.24 146.32 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-O 121.71 0.767 . . . . 1.0 111.811 -178.354 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.29 165.05 14.11 Favored Pre-proline 0 C--O 1.232 0.14 0 CA-C-N 114.355 -1.293 . . . . 1.0 110.856 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -61.37 -30.24 87.01 Favored 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 121.983 1.789 . . . . 1.0 111.379 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -68.51 -14.47 63.03 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.591 -0.731 . . . . 1.0 109.387 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.93 -2.1 68.88 Favored Glycine 0 C--O 1.229 -0.158 0 N-CA-C 109.734 -1.346 . . . . 1.0 109.734 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.437 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.54 132.78 35.71 Favored 'General case' 0 CA--C 1.519 -0.25 0 N-CA-C 108.411 -0.959 . . . . 1.0 108.411 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.437 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.7 mp0 -119.62 140.96 49.77 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-N 116.196 -0.456 . . . . 1.0 110.869 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -136.37 147.85 47.56 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 121.6 0.714 . . . . 1.0 111.143 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.538 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -130.64 132.54 45.51 Favored 'General case' 0 CA--C 1.501 -0.932 0 CA-C-N 114.479 -1.237 . . . . 1.0 109.317 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.16 104.85 15.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.281 1.038 . . . . 1.0 112.356 -178.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.63 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.3 mm -70.7 -41.64 77.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.039 -0.982 . . . . 1.0 108.72 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -143.6 131.52 21.59 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 114.639 -1.164 . . . . 1.0 109.792 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.8 p -90.3 129.1 36.57 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.857 -0.423 . . . . 1.0 109.857 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.74 -33.2 1.32 Allowed Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 54.32 30.83 13.22 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.287 -0.457 . . . . 1.0 110.577 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.33 -162.22 37.78 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-O 121.789 0.66 . . . . 1.0 111.669 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 23.4 m -68.28 -177.54 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.266 -0.967 . . . . 1.0 109.375 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.606 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.56 154.58 0.35 Allowed Pre-proline 0 C--N 1.317 -0.832 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 179.54 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.436 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.9 Cg_endo -88.21 160.4 7.03 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.162 2.575 . . . . 1.0 116.189 -175.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.422 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 174.22 39.06 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 108.096 -2.001 . . . . 1.0 108.096 175.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.607 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -49.26 -25.81 2.58 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.99 -0.605 . . . . 1.0 111.439 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.438 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 9.4 m -107.24 -9.21 16.15 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -177.595 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.6 m-20 -84.18 165.92 18.01 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 119.708 -0.797 . . . . 1.0 108.975 179.222 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.415 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.2 m -103.24 151.86 22.17 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-O 121.224 0.535 . . . . 1.0 109.948 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.8 p -129.66 161.82 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.389 0 CA-C-N 115.292 -0.867 . . . . 1.0 112.114 -176.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -132.12 118.17 19.26 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 108.67 -0.863 . . . . 1.0 108.67 177.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.418 ' HB ' ' O ' ' A' ' 129' ' ' HIS . 2.5 m -148.1 166.98 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.883 0.697 . . . . 1.0 112.883 -177.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.1 mt-10 -116.93 154.04 31.53 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 106.909 -1.515 . . . . 1.0 106.909 175.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.521 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.1 p90 -165.07 163.55 20.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 114.82 1.415 . . . . 1.0 114.82 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -126.24 128.97 48.03 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 107.895 -1.15 . . . . 1.0 107.895 174.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.68 12.25 Favored Glycine 0 N--CA 1.47 0.905 0 C-N-CA 120.687 -0.768 . . . . 1.0 111.757 -178.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.3 ptp180 -146.23 167.02 24.52 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.95 0.881 . . . . 1.0 112.632 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.483 HD11 HD13 ' A' ' 118' ' ' ILE . 3.0 mp -81.76 163.79 22.16 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.065 -1.425 . . . . 1.0 110.147 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.19 -24.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 114.942 -1.026 . . . . 1.0 109.77 177.749 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -96.25 4.69 52.19 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 113.648 -1.615 . . . . 1.0 111.791 -177.267 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.05 80.51 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.788 -0.72 . . . . 1.0 113.316 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 m -72.83 111.51 8.03 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.112 -1.035 . . . . 1.0 109.422 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.02 120.17 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-O 121.543 0.687 . . . . 1.0 111.171 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.591 ' CG ' HD11 ' A' ' 118' ' ' ILE . 23.3 p90 -108.47 -9.81 15.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.884 -1.053 . . . . 1.0 111.613 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.578 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 4.1 p-10 -161.62 149.24 14.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.977 -0.556 . . . . 1.0 110.829 178.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 68.9 p -156.15 149.44 24.51 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.61 -0.723 . . . . 1.0 111.108 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.521 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 46.1 m -155.98 -42.0 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.602 -0.726 . . . . 1.0 110.967 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.413 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.8 pp20? -63.18 -26.95 69.04 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.742 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.7 mmtp -54.37 -43.15 71.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.699 -1.223 . . . . 1.0 107.699 178.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 28.5 p -76.3 -34.85 59.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.096 -1.411 . . . . 1.0 109.102 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.6 15.5 70.78 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.357 -0.838 . . . . 1.0 111.144 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -97.97 115.27 65.77 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 120.402 -0.519 . . . . 1.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.408 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 33.8 Cg_exo -59.83 153.24 58.11 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 122.022 1.814 . . . . 1.0 114.114 -178.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.97 150.73 46.36 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.059 -1.428 . . . . 1.0 108.069 178.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.29 129.65 55.7 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.014 0.746 . . . . 1.0 113.014 -178.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.512 ' CE1' ' C4 ' ' A' ' 138' ' ' RAP . 36.0 m-85 -140.98 153.02 45.4 Favored 'General case' 0 CA--C 1.502 -0.88 0 CA-C-N 114.678 -1.146 . . . . 1.0 108.795 177.463 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -90.44 127.18 36.14 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 106.359 -1.719 . . . . 1.0 106.359 174.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.4 t -46.79 -34.45 2.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.351 -0.539 . . . . 1.0 110.471 -178.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -73.56 -24.34 60.09 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 120.467 -0.493 . . . . 1.0 112.323 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.524 ' OE1' H242 ' A' ' 138' ' ' RAP . 82.8 mm-40 -100.13 -12.0 20.0 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 113.618 0.969 . . . . 1.0 113.618 -177.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 83' ' ' ILE . 5.4 p -84.44 177.93 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 119.656 -0.818 . . . . 1.0 110.455 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.65 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -54.95 146.51 37.76 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.595 -177.198 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -51.54 -44.55 43.2 Favored 'Trans proline' 0 N--CA 1.499 1.817 0 C-N-CA 121.896 1.73 . . . . 1.0 112.527 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.48 -47.4 90.06 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.549 -1.42 . . . . 1.0 109.549 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.724 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 6.1 m95 -63.83 -36.06 82.68 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.287 -0.956 . . . . 1.0 110.04 179.052 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.2 m -52.23 -52.95 49.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.674 -0.411 . . . . 1.0 110.904 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -72.32 -45.35 60.34 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.891 -0.595 . . . . 1.0 112.444 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.34 -48.46 76.72 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 113.925 1.083 . . . . 1.0 113.925 -177.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 32.7 mt -57.93 -42.66 85.31 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-O 121.084 0.469 . . . . 1.0 109.959 -177.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -62.65 -23.27 67.01 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 115.615 -0.721 . . . . 1.0 110.289 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.6 mt -101.79 -14.4 17.31 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.876 -0.602 . . . . 1.0 111.266 -179.131 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.2 ttp -88.98 108.18 22.25 Favored Pre-proline 0 CA--C 1.547 0.833 0 N-CA-C 111.991 0.367 . . . . 1.0 111.991 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.606 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.2 Cg_exo -66.06 148.08 85.07 Favored 'Trans proline' 0 N--CA 1.499 1.842 0 C-N-CA 122.438 2.092 . . . . 1.0 112.162 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.96 137.53 58.05 Favored 'General case' 0 CA--C 1.507 -0.695 0 CA-C-O 121.493 0.663 . . . . 1.0 111.331 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.16 -18.57 55.91 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.252 -1.939 . . . . 1.0 108.252 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.4 p -89.39 128.41 35.92 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 121.263 0.554 . . . . 1.0 110.735 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 89.9 m -103.56 114.24 28.36 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 115.392 -0.822 . . . . 1.0 109.944 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.483 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.6 m0 -116.04 164.9 13.77 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 121.442 0.639 . . . . 1.0 110.882 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.63 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.8 mt-10 -123.59 129.14 50.71 Favored 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 106.394 -1.706 . . . . 1.0 106.394 175.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -125.93 138.9 53.07 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.665 0 CA-C-O 121.926 0.869 . . . . 1.0 110.376 -179.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.749 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.27 104.12 13.2 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.928 -1.878 . . . . 1.0 105.928 -178.16 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.6 t -90.4 115.95 65.28 Favored Pre-proline 0 C--N 1.326 -0.415 0 N-CA-C 114.879 1.437 . . . . 1.0 114.879 -174.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -51.21 143.49 32.86 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 121.276 1.317 . . . . 1.0 110.021 175.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 92.4 p -49.26 -35.17 16.99 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.426 -0.51 . . . . 1.0 110.423 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.0 81.51 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 111.174 -0.77 . . . . 1.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -101.25 3.24 40.67 Favored 'General case' 0 C--O 1.225 -0.189 0 CA-C-O 119.771 -0.157 . . . . 1.0 110.872 -179.148 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.23 -112.33 0.29 Allowed 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.487 0.184 . . . . 1.0 110.554 -178.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.626 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 68.1 m-85 -98.32 4.85 48.66 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 113.405 0.891 . . . . 1.0 113.405 -178.39 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 115.14 162.97 13.87 Favored Glycine 0 N--CA 1.47 0.911 0 C-N-CA 120.996 -0.621 . . . . 1.0 112.969 177.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 121' ' ' ASN . 96.3 Cg_endo -76.16 -9.4 19.15 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 123.626 2.884 . . . . 1.0 111.0 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -109.19 168.9 9.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.498 -0.774 . . . . 1.0 109.446 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.1 m -73.86 96.37 2.58 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.0 t -111.91 60.25 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-N 116.244 -0.434 . . . . 1.0 110.444 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.55 172.46 36.19 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.35 -0.7 . . . . 1.0 111.35 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.59 -103.19 0.01 OUTLIER Glycine 0 CA--C 1.535 1.337 0 N-CA-C 111.226 -0.75 . . . . 1.0 111.226 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -58.04 -11.42 10.03 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.754 2.303 . . . . 1.0 111.628 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.591 HD11 ' CG ' ' A' ' 65' ' ' PHE . 14.9 mm -66.96 125.55 24.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-N 114.716 -1.129 . . . . 1.0 109.138 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -102.63 -175.86 27.12 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.321 -0.854 . . . . 1.0 111.249 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.562 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 21.6 Cg_endo -62.38 142.23 90.09 Favored 'Trans proline' 0 C--N 1.295 -2.25 0 C-N-CA 122.384 2.056 . . . . 1.0 111.756 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.531 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 45.79 55.39 6.93 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 120.796 -0.362 . . . . 1.0 111.103 178.11 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.521 ' OE2' ' ND2' ' A' ' 8' ' ' ASN . 3.3 tp10 -102.34 130.03 48.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.987 -0.552 . . . . 1.0 111.412 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.426 HG21 HD11 ' A' ' 16' ' ' LEU . 46.4 m -95.36 129.79 42.38 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.007 -1.109 . . . . 1.0 108.007 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.449 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.64 148.8 33.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.423 0.63 . . . . 1.0 111.114 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.749 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -124.58 149.29 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.041 -0.981 . . . . 1.0 108.485 178.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.6 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -140.52 149.82 42.94 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 120.479 -0.488 . . . . 1.0 111.522 178.033 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 13.9 mmtt -99.42 127.07 45.44 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 104.768 -2.308 . . . . 1.0 104.768 176.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -121.18 121.13 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 119.259 -0.976 . . . . 1.0 112.138 -177.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.55 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.1 t60 -113.75 120.71 41.73 Favored 'General case' 0 C--O 1.223 -0.327 0 CA-C-N 114.157 -1.383 . . . . 1.0 108.612 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.35 111.89 23.63 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 120.014 -0.675 . . . . 1.0 112.519 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.55 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.1 mp -94.14 -45.14 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-N 116.222 -0.444 . . . . 1.0 111.12 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -150.74 155.58 39.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.85 0.357 . . . . 1.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.424 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.7 t -128.7 139.09 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.285 -0.416 . . . . 1.0 111.326 -178.756 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.415 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.6 tptm -95.74 -150.16 0.32 Allowed 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.599 0.714 . . . . 1.0 110.057 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.41 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -173.41 143.42 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.849 -1.069 . . . . 1.0 110.865 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.409 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 15.3 t -113.25 -49.18 2.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.511 -1.222 . . . . 1.0 109.977 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 117.943 -1.027 . . . . 1.0 110.351 -179.633 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.724 ' H41' ' CZ3' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.842 -0.799 . . . . 1.0 108.842 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.477 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 69.7 m-80 -65.64 -31.15 72.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.949 -0.569 . . . . 1.0 111.233 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -41.91 9.92 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.305 -0.407 . . . . 1.0 111.054 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 5.2 tmtt? -71.8 -38.83 70.18 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 121.994 0.902 . . . . 1.0 109.772 179.428 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -50.67 -33.86 24.21 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 114.889 -1.05 . . . . 1.0 110.538 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.63 -38.13 89.06 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.153 -0.93 . . . . 1.0 111.144 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -67.02 -48.83 67.17 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.785 0.803 . . . . 1.0 110.54 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.608 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 12.9 m-20 -61.49 -35.33 77.36 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.004 -1.11 . . . . 1.0 108.004 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.405 ' O ' ' N ' ' A' ' 13' ' ' GLU . 55.6 tttt -66.76 -51.02 60.68 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.385 -1.734 . . . . 1.0 111.571 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.8 t -66.87 -48.85 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.276 0 C-N-CA 119.979 -0.688 . . . . 1.0 111.393 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.445 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -62.84 -38.64 91.59 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.639 -1.245 . . . . 1.0 107.639 179.034 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.492 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.54 -42.77 71.51 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 114.868 -1.06 . . . . 1.0 111.875 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.405 ' N ' ' O ' ' A' ' 9' ' ' LYS . 33.8 mt-10 -62.67 -33.27 74.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.438 -0.949 . . . . 1.0 108.438 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.3 -34.25 59.05 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 114.791 -1.095 . . . . 1.0 109.798 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -61.89 -51.11 69.5 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 114.492 -1.231 . . . . 1.0 110.762 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.66 -40.18 76.6 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.061 -0.656 . . . . 1.0 109.733 178.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.441 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 97.7 m -61.07 -42.06 97.78 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.505 -0.771 . . . . 1.0 109.13 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -75.74 -47.35 26.35 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.006 -0.997 . . . . 1.0 111.9 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.661 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 49.5 t30 -58.7 -45.4 89.6 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -177.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.5 -29.35 67.79 Favored 'General case' 0 C--N 1.315 -0.909 0 C-N-CA 119.303 -0.959 . . . . 1.0 109.154 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.441 ' ND2' ' O ' ' A' ' 17' ' ' THR . 7.4 m-80 -82.0 -29.69 31.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.372 -0.831 . . . . 1.0 111.591 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -59.74 146.08 81.92 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 120.48 -0.488 . . . . 1.0 111.371 -178.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.14 148.47 69.35 Favored 'Trans proline' 0 N--CA 1.504 2.094 0 C-N-CA 122.525 2.15 . . . . 1.0 113.791 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.89 -18.61 5.88 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.492 -0.776 . . . . 1.0 112.625 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.2 136.95 21.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.219 0.533 . . . . 1.0 111.286 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -121.66 126.03 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 107.64 -1.244 . . . . 1.0 107.64 177.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -100.73 145.62 10.81 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 CA-C-O 121.828 0.823 . . . . 1.0 112.266 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.1 mt -112.31 166.17 11.52 Favored Pre-proline 0 CA--C 1.529 0.155 0 CA-C-N 114.1 -1.409 . . . . 1.0 111.357 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.87 -30.7 84.4 Favored 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.188 1.926 . . . . 1.0 111.358 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.1 m -68.52 -14.42 62.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.839 -0.618 . . . . 1.0 109.8 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.14 -0.96 66.94 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 109.593 -1.403 . . . . 1.0 109.593 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.449 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -81.21 133.39 35.44 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.511 -0.922 . . . . 1.0 108.511 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.449 ' H ' HD22 ' A' ' 32' ' ' LEU . 21.2 mp0 -120.94 143.38 49.01 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.91 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -138.2 143.86 40.4 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 121.712 0.767 . . . . 1.0 110.734 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.513 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.53 132.83 49.86 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-N 114.504 -1.225 . . . . 1.0 109.106 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 p -90.82 104.9 15.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 122.148 0.975 . . . . 1.0 111.86 -178.156 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.6 mm -70.09 -42.34 79.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.222 -0.899 . . . . 1.0 108.671 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -140.27 128.04 21.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 114.619 -1.173 . . . . 1.0 109.627 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 p -88.57 127.22 35.54 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.736 -0.468 . . . . 1.0 109.736 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.36 -34.53 1.19 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 110.683 -0.967 . . . . 1.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 56.02 32.01 19.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.99 0.424 . . . . 1.0 110.737 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.41 -161.0 36.84 Favored Glycine 0 C--N 1.333 0.37 0 CA-C-O 121.924 0.736 . . . . 1.0 111.769 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.596 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.3 m -69.69 -178.09 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 114.084 -1.058 . . . . 1.0 109.289 178.208 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.424 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 154.84 0.37 Allowed Pre-proline 0 C--N 1.32 -0.694 0 O-C-N 123.829 0.705 . . . . 1.0 109.549 179.387 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -87.15 156.17 8.3 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 123.091 2.528 . . . . 1.0 115.993 -175.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.29 175.12 44.22 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 108.778 -1.729 . . . . 1.0 108.778 176.187 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.558 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.68 -22.44 5.14 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 120.82 -0.352 . . . . 1.0 111.14 -179.402 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.8 m -107.41 -9.9 15.88 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.245 0.831 . . . . 1.0 113.245 -177.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -84.58 168.99 14.85 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 119.867 -0.733 . . . . 1.0 109.028 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.406 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -107.66 152.1 24.76 Favored 'General case' 0 CA--C 1.513 -0.466 0 N-CA-C 109.618 -0.512 . . . . 1.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -128.31 160.1 38.83 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.405 0 CA-C-N 115.741 -0.663 . . . . 1.0 112.285 -176.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 74' ' ' PRO . 85.9 m -126.3 120.19 29.3 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 107.729 -1.212 . . . . 1.0 107.729 177.482 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.609 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 27.0 m -148.98 163.32 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 N-CA-C 114.291 1.219 . . . . 1.0 114.291 -175.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -118.44 150.67 39.18 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 106.41 -1.7 . . . . 1.0 106.41 174.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.5 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.9 p90 -163.75 163.53 24.03 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 118.393 -1.323 . . . . 1.0 114.506 -177.567 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -125.11 130.05 51.44 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 115.261 -0.881 . . . . 1.0 108.848 175.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.38 136.56 13.6 Favored Glycine 0 N--CA 1.468 0.787 0 C-N-CA 121.005 -0.617 . . . . 1.0 111.602 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -148.72 166.88 27.07 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.674 0.749 . . . . 1.0 112.533 179.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -84.28 164.38 19.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 114.456 -1.247 . . . . 1.0 110.502 178.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.45 -24.88 32.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.918 -1.037 . . . . 1.0 110.528 178.149 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.67 4.5 53.76 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.566 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.95 -5.23 81.95 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.016 178.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.6 m -67.14 103.39 1.2 Allowed 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.569 -0.853 . . . . 1.0 110.067 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.4 t -74.93 125.99 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.853 0 C-N-CA 120.347 -0.541 . . . . 1.0 109.702 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.589 ' CD2' HD11 ' A' ' 118' ' ' ILE . 28.0 p90 -117.48 -10.81 10.59 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 114.993 -1.003 . . . . 1.0 111.471 -179.215 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.481 ' OD1' ' O4 ' ' A' ' 138' ' ' RAP . 32.7 t0 -157.41 150.76 23.79 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.401 -0.52 . . . . 1.0 111.65 179.261 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -159.59 151.79 20.89 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.632 -0.713 . . . . 1.0 111.817 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.5 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.3 m -151.25 -42.1 0.12 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.342 -0.845 . . . . 1.0 110.183 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.45 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -62.09 -27.93 69.26 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-N 116.018 -0.537 . . . . 1.0 109.672 179.379 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -56.73 -43.3 80.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 107.741 -1.207 . . . . 1.0 107.741 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -75.14 -33.4 61.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.632 -1.167 . . . . 1.0 107.974 176.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.12 18.39 67.28 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 115.639 -0.71 . . . . 1.0 111.957 178.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -101.18 115.87 64.61 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 120.882 -0.327 . . . . 1.0 110.629 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.448 ' HB3' HG22 ' A' ' 52' ' ' THR . 37.2 Cg_exo -60.61 152.5 68.23 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 121.754 1.636 . . . . 1.0 114.282 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.35 150.99 42.97 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.094 -1.412 . . . . 1.0 107.926 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.99 125.31 50.84 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.589 0.588 . . . . 1.0 112.589 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.556 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 35.3 m-85 -132.93 147.8 52.29 Favored 'General case' 0 CA--C 1.502 -0.892 0 CA-C-N 115.367 -0.833 . . . . 1.0 109.222 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -90.63 127.93 36.45 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.268 -1.752 . . . . 1.0 106.268 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.1 t -52.75 -33.5 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 C-N-CA 119.6 -0.84 . . . . 1.0 110.149 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 3.3 t -74.06 -26.66 60.52 Favored 'General case' 0 CA--C 1.515 -0.401 0 C-N-CA 120.21 -0.596 . . . . 1.0 111.651 -178.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.552 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 21.6 mm100 -100.29 -3.76 30.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.312 -0.404 . . . . 1.0 111.873 -178.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.708 HG23 H31A ' A' ' 138' ' ' RAP . 1.0 OUTLIER -84.3 166.58 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 CA-C-N 118.233 0.469 . . . . 1.0 111.406 -178.943 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.411 ' CD1' H492 ' A' ' 138' ' ' RAP . 0.0 OUTLIER -52.8 147.28 15.94 Favored Pre-proline 0 N--CA 1.474 0.756 0 N-CA-C 109.093 -0.706 . . . . 1.0 109.093 -177.701 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -50.9 -43.55 46.59 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.747 1.631 . . . . 1.0 112.701 -178.125 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.19 92.29 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 119.57 -1.3 . . . . 1.0 110.018 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.609 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.4 m95 -64.32 -35.91 82.41 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.369 -0.916 . . . . 1.0 110.398 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 25.1 m -51.0 -53.11 36.22 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.721 0.296 . . . . 1.0 111.67 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 20.5 tp10 -72.39 -41.62 66.11 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.738 0.644 . . . . 1.0 112.738 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.66 -45.45 91.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 114.036 1.125 . . . . 1.0 114.036 -177.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.04 -41.91 88.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.263 0.554 . . . . 1.0 109.761 -177.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.0 mt-30 -64.66 -24.61 67.64 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.705 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.496 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 59.8 mt -101.9 -10.67 19.62 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.182 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.7 ttp -91.78 107.39 22.08 Favored Pre-proline 0 CA--C 1.546 0.789 0 O-C-N 123.154 0.283 . . . . 1.0 111.639 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.424 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -66.93 147.69 80.8 Favored 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.508 2.139 . . . . 1.0 111.98 178.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.596 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.59 139.55 58.78 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-O 121.686 0.755 . . . . 1.0 111.429 -179.022 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.78 -18.76 54.81 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.123 -1.991 . . . . 1.0 108.123 -178.241 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.4 p -89.88 129.6 36.22 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.037 0.446 . . . . 1.0 110.621 179.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 85.1 m -103.44 114.22 28.33 Favored 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 115.659 -0.701 . . . . 1.0 109.855 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.496 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -115.98 161.94 18.11 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.742 0.782 . . . . 1.0 111.487 -178.611 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.4 mt-10 -121.57 125.61 47.16 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.162 -1.421 . . . . 1.0 107.162 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -120.9 138.03 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.564 0 CA-C-O 121.8 0.81 . . . . 1.0 109.838 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.724 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.0 103.4 12.42 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -177.983 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.27 116.25 65.94 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 115.022 1.49 . . . . 1.0 115.022 -174.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -51.39 142.58 37.44 Favored 'Trans proline' 0 C--N 1.315 -1.191 0 C-N-CA 121.361 1.374 . . . . 1.0 109.81 176.47 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 97.6 p -48.61 -35.28 13.25 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.31 -0.556 . . . . 1.0 111.185 -178.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.75 -32.77 82.22 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.153 -0.779 . . . . 1.0 111.153 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.5 mt -98.46 2.49 47.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.957 -0.121 . . . . 1.0 110.91 -179.067 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.45 -110.77 0.31 Allowed 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 112.029 0.381 . . . . 1.0 112.029 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.742 ' CE2' H491 ' A' ' 138' ' ' RAP . 44.4 m-85 -96.88 4.31 51.7 Favored 'General case' 0 C--N 1.342 0.249 0 N-CA-C 112.288 0.477 . . . . 1.0 112.288 -177.853 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.11 162.87 17.93 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 121.172 -0.537 . . . . 1.0 112.831 177.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 121' ' ' ASN . 83.3 Cg_endo -76.9 -10.23 18.17 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 123.423 2.749 . . . . 1.0 111.4 179.229 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 5.9 ttm-85 -105.15 168.45 9.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.252 -0.885 . . . . 1.0 109.51 -179.545 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.518 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -74.18 100.04 3.56 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.3 -0.629 . . . . 1.0 109.3 178.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 109' ' ' TYR . 14.0 t -110.9 61.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.76 0.314 . . . . 1.0 110.831 -179.337 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 159.15 175.73 30.41 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 120.472 -0.87 . . . . 1.0 112.44 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.42 -103.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.328 0 CA-C-N 114.963 -0.619 . . . . 1.0 111.87 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -61.87 -16.95 52.62 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 122.613 2.208 . . . . 1.0 111.773 -177.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.691 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.3 mp -67.4 114.56 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 108.343 -0.984 . . . . 1.0 108.343 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.416 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.98 -171.02 38.53 Favored Glycine 0 N--CA 1.452 -0.258 0 N-CA-C 110.949 -0.86 . . . . 1.0 110.949 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.518 ' N ' ' OG ' ' A' ' 113' ' ' SER . 34.1 Cg_endo -64.01 139.55 67.97 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.318 2.012 . . . . 1.0 112.627 179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.588 ' O ' ' ND2' ' A' ' 121' ' ' ASN . 0.5 OUTLIER 52.59 48.85 21.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.439 -0.346 . . . . 1.0 111.371 178.132 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.608 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -93.14 132.58 37.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.541 -0.3 . . . . 1.0 110.716 179.843 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.422 HG21 HD11 ' A' ' 16' ' ' LEU . 52.1 m -96.2 127.77 42.5 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.405 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.5 mm? -111.28 145.33 38.97 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.128 0.489 . . . . 1.0 110.468 -179.162 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.724 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -122.63 146.14 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.476 -0.783 . . . . 1.0 108.937 178.853 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.622 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.6 m-85 -136.33 149.65 48.49 Favored 'General case' 0 CA--C 1.517 -0.319 0 C-N-CA 120.26 -0.576 . . . . 1.0 111.509 178.005 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 12.6 mmtt -99.5 123.57 43.89 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 105.423 -2.065 . . . . 1.0 105.423 177.686 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.7 mt -118.94 118.1 56.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 119.112 -1.035 . . . . 1.0 112.879 -176.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.559 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.6 t60 -108.65 126.22 52.73 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 113.572 -1.649 . . . . 1.0 108.278 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 111.3 23.42 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 119.871 -0.732 . . . . 1.0 112.271 -178.124 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.559 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.2 mp -93.71 -45.93 13.76 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.852 -0.613 . . . . 1.0 111.676 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.6 p -150.84 156.03 40.41 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.575 -0.45 . . . . 1.0 110.84 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.402 HG21 ' HA ' ' A' ' 44' ' ' LYS . 56.9 t -128.0 141.45 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.969 -0.559 . . . . 1.0 111.395 -178.118 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.458 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 9.2 tptm -100.13 -147.86 0.35 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.638 -0.71 . . . . 1.0 110.33 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.458 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER -164.47 143.15 7.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.72 -1.127 . . . . 1.0 110.477 178.016 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.401 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 96.1 p -59.48 -33.3 71.14 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.803 -1.09 . . . . 1.0 111.232 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 34.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.384 -179.751 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.742 H491 ' CE2' ' A' ' 109' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 65.7 t80 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 108.963 -0.754 . . . . 1.0 108.963 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.566 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 76.7 m-20 -69.47 -24.32 63.77 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.637 -0.425 . . . . 1.0 110.722 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.466 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 63.3 pttt -47.56 -40.82 20.04 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 109.283 -0.636 . . . . 1.0 109.283 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.466 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 5.9 tmtm? -64.16 -37.05 86.05 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.221 -0.899 . . . . 1.0 109.274 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.566 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -51.4 -35.95 41.34 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-N 115.048 -0.978 . . . . 1.0 110.799 -179.63 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.46 -37.38 87.06 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.241 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -66.15 -53.1 41.78 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.687 0.756 . . . . 1.0 110.419 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.4 m-20 -58.02 -34.01 69.57 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.501 -0.926 . . . . 1.0 108.501 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -66.21 -51.08 61.1 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.406 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.99 -48.22 82.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 119.942 -0.703 . . . . 1.0 111.614 -178.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.453 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.8 -38.95 92.74 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.785 -1.191 . . . . 1.0 107.785 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.413 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.08 -46.27 52.11 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-N 114.779 -1.101 . . . . 1.0 112.631 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -59.53 -34.97 73.32 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.288 -0.965 . . . . 1.0 108.492 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.58 -36.14 65.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.94 -1.027 . . . . 1.0 110.401 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -61.31 -50.4 73.12 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.879 -1.055 . . . . 1.0 110.628 -179.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.416 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -67.1 -39.81 86.78 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 119.783 -0.767 . . . . 1.0 109.461 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.499 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 19.9 m -61.86 -42.16 98.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.743 -0.662 . . . . 1.0 109.657 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -75.24 -45.46 39.98 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.661 -0.699 . . . . 1.0 111.845 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.647 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.8 t30 -61.65 -44.65 96.57 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 113.18 0.807 . . . . 1.0 113.18 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -59.74 -34.9 73.55 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.27 -0.972 . . . . 1.0 108.578 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 17' ' ' THR . 77.5 m-20 -71.51 -36.29 71.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.158 -0.928 . . . . 1.0 111.991 178.789 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 mtmt -55.78 135.66 72.24 Favored Pre-proline 0 CA--C 1.546 0.808 0 CA-C-N 116.412 -0.358 . . . . 1.0 111.588 -178.071 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.76 148.37 66.33 Favored 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.202 1.935 . . . . 1.0 113.627 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.06 -19.71 20.4 Favored Glycine 0 C--O 1.226 -0.394 0 CA-C-N 115.136 -0.938 . . . . 1.0 111.004 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.5 t -85.17 136.0 23.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.161 0.505 . . . . 1.0 110.155 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.07 121.46 65.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 107.767 -1.197 . . . . 1.0 107.767 178.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 p -95.93 145.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.648 0.737 . . . . 1.0 111.703 -177.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.55 164.15 16.06 Favored Pre-proline 0 C--N 1.334 -0.106 0 CA-C-N 114.455 -1.248 . . . . 1.0 110.437 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.57 -30.81 86.6 Favored 'Trans proline' 0 C--N 1.318 -1.059 0 C-N-CA 121.634 1.556 . . . . 1.0 111.339 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 m -69.33 -10.73 59.23 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.925 -0.579 . . . . 1.0 109.912 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.35 -2.8 71.5 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 110.232 -1.147 . . . . 1.0 110.232 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.482 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -79.17 133.27 36.72 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 108.628 -0.879 . . . . 1.0 108.628 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.482 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.4 mp0 -122.8 139.54 53.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.395 -0.366 . . . . 1.0 110.983 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -135.5 143.13 45.63 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.675 0.75 . . . . 1.0 110.913 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.534 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.2 tmtp? -126.58 132.9 51.19 Favored 'General case' 0 CA--C 1.503 -0.86 0 CA-C-N 114.645 -1.161 . . . . 1.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.78 104.66 15.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.167 0.984 . . . . 1.0 111.906 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.621 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.5 mm -69.58 -41.86 80.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 108.007 -1.108 . . . . 1.0 108.007 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -142.36 129.64 21.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.573 -1.194 . . . . 1.0 109.804 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.7 p -88.49 131.35 34.93 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.764 -0.458 . . . . 1.0 109.764 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.0 -33.25 1.08 Allowed Glycine 0 C--N 1.331 0.291 0 N-CA-C 110.051 -1.219 . . . . 1.0 110.051 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.402 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 5.5 m-20 54.7 30.93 14.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.375 -0.413 . . . . 1.0 110.958 179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.31 -162.3 37.85 Favored Glycine 0 C--N 1.331 0.281 0 CA-C-O 121.905 0.725 . . . . 1.0 111.957 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.5 m -68.81 -178.63 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 113.905 -1.148 . . . . 1.0 109.125 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.674 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.49 154.77 0.4 Allowed Pre-proline 0 C--N 1.321 -0.631 0 O-C-N 123.705 0.628 . . . . 1.0 109.948 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.404 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.0 Cg_endo -87.33 154.43 8.0 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 123.439 2.759 . . . . 1.0 116.971 -174.486 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.45 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.55 177.2 48.47 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 109.141 -1.584 . . . . 1.0 109.141 175.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.504 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.37 -25.43 15.43 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.963 -0.295 . . . . 1.0 111.507 -179.722 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.6 m -108.03 -5.11 17.23 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.815 0.672 . . . . 1.0 112.815 -176.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.45 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 66.6 m-20 -83.49 165.36 19.2 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.4 m -106.52 150.31 26.25 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 109.636 -0.505 . . . . 1.0 109.636 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -129.39 162.94 35.9 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.465 0 CA-C-N 116.126 -0.488 . . . . 1.0 111.982 -176.399 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 51' ' ' VAL . 98.5 m -130.15 119.63 23.3 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 108.52 -0.918 . . . . 1.0 108.52 177.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.501 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.7 m -148.18 165.17 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 114.885 1.439 . . . . 1.0 114.885 -177.006 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.416 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.2 mt-10 -118.89 145.07 46.02 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 106.568 -1.642 . . . . 1.0 106.568 174.189 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.568 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 38.8 p90 -161.11 164.07 30.94 Favored 'General case' 0 C--N 1.344 0.357 0 N-CA-C 114.825 1.417 . . . . 1.0 114.825 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -127.13 127.86 45.26 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 115.158 -0.928 . . . . 1.0 108.792 175.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.8 134.1 11.61 Favored Glycine 0 N--CA 1.473 1.114 0 C-N-CA 120.933 -0.651 . . . . 1.0 111.92 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.7 ptp85 -147.86 170.31 17.92 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.866 0.841 . . . . 1.0 113.071 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -83.58 164.08 19.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 114.126 -1.397 . . . . 1.0 110.795 178.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.449 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.3 -25.86 35.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.017 -0.992 . . . . 1.0 110.769 178.329 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -95.25 6.01 50.18 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.564 -1.198 . . . . 1.0 111.857 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.39 -3.46 75.69 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 121.01 -0.614 . . . . 1.0 113.313 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 m -71.78 106.58 4.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 118.157 0.978 . . . . 1.0 110.228 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 54.5 t -76.33 130.41 36.25 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.232 0.539 . . . . 1.0 110.575 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -120.37 -14.45 8.73 Favored 'General case' 0 CA--C 1.522 -0.112 0 CA-C-N 115.11 -0.95 . . . . 1.0 111.208 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 67' ' ' SER . 30.4 t0 -155.38 151.83 28.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.379 -0.373 . . . . 1.0 111.098 178.373 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 87.8 p -160.84 154.61 22.41 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 112.723 0.638 . . . . 1.0 112.723 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 55' ' ' TYR . 85.3 m -155.3 -42.01 0.08 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.143 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.405 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 2.0 pp20? -61.32 -26.19 67.63 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.602 -0.439 . . . . 1.0 110.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -53.83 -42.73 68.8 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.212 -1.033 . . . . 1.0 108.212 178.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' A' ' 68' ' ' THR . 21.6 p -78.36 -30.61 48.08 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.957 -1.019 . . . . 1.0 108.956 177.213 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.75 17.16 73.56 Favored Glycine 0 C--N 1.337 0.593 0 N-CA-C 111.363 -0.695 . . . . 1.0 111.363 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 7.2 mptt -99.89 115.94 65.12 Favored Pre-proline 0 N--CA 1.469 0.492 0 C-N-CA 120.987 -0.285 . . . . 1.0 110.498 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.416 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 37.2 Cg_exo -61.13 152.49 71.33 Favored 'Trans proline' 0 N--CA 1.483 0.867 0 C-N-CA 121.646 1.564 . . . . 1.0 113.964 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.31 149.53 46.44 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.335 -1.302 . . . . 1.0 107.612 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -103.58 131.76 50.43 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.226 0.536 . . . . 1.0 112.219 -178.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.516 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 20.3 m-85 -137.71 150.05 47.0 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 115.29 -0.868 . . . . 1.0 110.482 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -93.47 124.65 37.6 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.162 -1.792 . . . . 1.0 106.162 174.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.4 t -51.46 -27.1 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 C-N-CA 119.778 -0.769 . . . . 1.0 110.608 -176.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 42.4 t -76.32 -24.58 54.31 Favored 'General case' 0 CA--C 1.519 -0.224 0 C-N-CA 120.344 -0.542 . . . . 1.0 112.287 -179.159 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.46 ' OE1' ' C46' ' A' ' 138' ' ' RAP . 88.4 mm-40 -98.56 -8.27 26.8 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 112.233 0.457 . . . . 1.0 112.233 -178.52 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.731 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.4 p -83.08 168.8 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 119.961 -0.696 . . . . 1.0 111.852 -177.512 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.508 HG12 ' O2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -55.19 153.32 13.05 Favored Pre-proline 0 CA--C 1.548 0.867 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 -177.953 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.483 ' HD2' HG22 ' A' ' 83' ' ' ILE . 50.8 Cg_exo -53.28 -45.65 39.5 Favored 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.633 1.556 . . . . 1.0 112.948 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.11 -48.09 85.16 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.706 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 8.1 m95 -64.07 -35.74 81.74 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.101 -1.05 . . . . 1.0 110.108 179.267 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.4 m -52.17 -54.0 36.2 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.649 -0.42 . . . . 1.0 111.294 -178.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -72.71 -42.73 63.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.976 -0.557 . . . . 1.0 112.338 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.57 -47.36 79.69 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 113.848 1.055 . . . . 1.0 113.848 -177.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.2 mt -58.25 -41.76 84.9 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.365 0.603 . . . . 1.0 109.799 -178.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.5 mt-30 -63.24 -24.78 68.02 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.952 -1.022 . . . . 1.0 110.904 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.42 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 70.1 mt -101.65 -13.27 17.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.252 -0.431 . . . . 1.0 111.29 -179.209 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 36.5 ttp -88.04 108.99 24.31 Favored Pre-proline 0 CA--C 1.547 0.847 0 N-CA-C 112.249 0.463 . . . . 1.0 112.249 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.674 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.8 Cg_exo -66.37 147.77 83.33 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.274 1.983 . . . . 1.0 112.289 178.7 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.78 136.85 57.75 Favored 'General case' 0 CA--C 1.509 -0.627 0 CA-C-O 121.492 0.663 . . . . 1.0 111.503 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.08 -18.48 56.06 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 109.001 -1.64 . . . . 1.0 109.001 -178.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -86.99 133.67 33.56 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 120.894 0.378 . . . . 1.0 110.165 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 84.4 m -106.06 112.96 26.22 Favored 'General case' 0 CA--C 1.511 -0.557 0 CA-C-N 115.986 -0.552 . . . . 1.0 109.938 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.42 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.3 m0 -115.1 163.75 15.18 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.677 0.751 . . . . 1.0 111.544 -178.53 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.621 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.1 mt-10 -124.02 124.56 42.82 Favored 'General case' 0 CA--C 1.51 -0.566 0 N-CA-C 107.101 -1.444 . . . . 1.0 107.101 175.588 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -119.0 137.84 51.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.866 0.841 . . . . 1.0 110.086 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.714 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.84 103.42 12.21 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 105.707 -1.96 . . . . 1.0 105.707 -178.303 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 t -90.63 116.12 65.7 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 115.529 1.678 . . . . 1.0 115.529 -174.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -50.75 143.32 29.77 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 121.611 1.54 . . . . 1.0 110.23 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 79.9 p -49.76 -35.43 22.39 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.282 -0.567 . . . . 1.0 110.524 -178.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.02 -32.39 82.37 Favored Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.985 -0.846 . . . . 1.0 110.985 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 42.9 mt -100.87 2.64 41.17 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.877 -0.162 . . . . 1.0 110.898 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 83' ' ' ILE . . . -107.37 -104.53 0.34 Allowed 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 117.693 0.224 . . . . 1.0 110.511 -178.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.617 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 53.5 m-85 -104.99 5.39 32.61 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 113.564 0.95 . . . . 1.0 113.564 -178.24 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 108.54 164.68 20.88 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.924 -0.655 . . . . 1.0 113.506 176.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.475 ' O ' ' N ' ' A' ' 121' ' ' ASN . 89.9 Cg_endo -75.11 -14.75 20.8 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 C-N-CA 123.618 2.878 . . . . 1.0 111.404 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.441 ' O ' HG23 ' A' ' 114' ' ' VAL . 58.1 mtm180 -101.28 165.98 11.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.115 -0.948 . . . . 1.0 109.586 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.448 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -75.21 97.71 3.58 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.411 -0.516 . . . . 1.0 109.844 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 112' ' ' ARG . 3.2 t -110.34 59.0 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.858 -179.181 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 167.81 -178.29 41.73 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 120.117 -1.04 . . . . 1.0 112.247 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -58.35 -106.4 0.01 OUTLIER Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.972 -0.451 . . . . 1.0 111.972 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -14.87 38.9 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 122.028 1.819 . . . . 1.0 111.011 -178.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.895 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -67.03 115.89 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 107.922 -1.14 . . . . 1.0 107.922 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.598 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -93.88 -160.72 34.98 Favored Glycine 0 C--O 1.215 -1.047 0 N-CA-C 110.398 -1.081 . . . . 1.0 110.398 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.566 ' HB2' ' HB2' ' A' ' 5' ' ' ALA . 74.2 Cg_endo -73.35 145.39 38.29 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 122.112 1.874 . . . . 1.0 112.756 178.22 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 111' ' ' PRO . 1.1 t30 45.24 59.92 3.28 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.782 0.66 . . . . 1.0 112.782 177.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.688 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -115.06 138.44 50.88 Favored 'General case' 0 N--CA 1.473 0.702 0 CA-C-O 121.62 0.724 . . . . 1.0 111.185 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.416 HG21 HD11 ' A' ' 16' ' ' LEU . 97.5 m -94.57 129.53 41.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.658 -1.155 . . . . 1.0 108.71 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.416 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.8 mm? -111.96 143.57 42.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.248 0.547 . . . . 1.0 110.076 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.714 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -122.44 148.15 26.25 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 108.659 -0.867 . . . . 1.0 108.659 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.34 150.94 47.08 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.051 0.453 . . . . 1.0 111.166 177.435 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.5 mmtt -100.25 123.33 44.35 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 105.721 -1.955 . . . . 1.0 105.721 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.423 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.8 119.0 58.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 119.143 -1.023 . . . . 1.0 113.056 -176.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.551 ' CD2' HD11 ' A' ' 131' ' ' ILE . 3.2 t60 -109.96 123.25 49.3 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 113.885 -1.507 . . . . 1.0 108.682 178.438 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.49 111.29 23.22 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 120.346 -0.542 . . . . 1.0 112.186 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.551 HD11 ' CD2' ' A' ' 129' ' ' HIS . 4.1 mp -93.46 -44.69 13.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.33 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -152.12 156.55 40.08 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.068 0.461 . . . . 1.0 111.03 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.439 HG21 ' HA ' ' A' ' 44' ' ' LYS . 49.1 t -129.82 134.71 62.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.969 -0.56 . . . . 1.0 110.446 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.449 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 16.9 tptm -72.77 -82.86 0.05 OUTLIER 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 122.011 0.91 . . . . 1.0 110.452 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.467 ' HD2' ' N ' ' A' ' 136' ' ' SER . 0.0 OUTLIER 88.31 124.69 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 113.609 -1.632 . . . . 1.0 111.705 179.216 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.467 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 3.4 t -122.89 -43.48 2.24 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 113.963 -1.472 . . . . 1.0 111.099 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 48.1 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.044 -0.979 . . . . 1.0 110.547 -178.71 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.907 ' O11' H471 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 73.1 t80 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.181 -0.674 . . . . 1.0 109.181 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 17.0 m-20 -66.79 -26.79 67.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.003 -0.544 . . . . 1.0 110.391 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.457 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 59.4 pttt -46.13 -41.78 12.89 Favored 'General case' 0 C--O 1.224 -0.283 0 C-N-CA 120.356 -0.538 . . . . 1.0 110.396 -178.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.562 ' HZ3' ' CG ' ' A' ' 8' ' ' ASN . 5.6 tmtt? -62.29 -41.21 98.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 120.167 -0.613 . . . . 1.0 109.358 -178.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.416 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -54.57 -36.36 64.29 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 115.713 -0.676 . . . . 1.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -67.9 -37.21 81.44 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.399 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -65.77 -52.57 49.9 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-O 121.929 0.871 . . . . 1.0 110.29 -179.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.562 ' CG ' ' HZ3' ' A' ' 4' ' ' LYS . 9.6 m-20 -57.28 -35.75 70.16 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.549 -1.205 . . . . 1.0 108.462 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 tttm -65.96 -51.9 54.36 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 113.651 -1.613 . . . . 1.0 111.602 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.5 t -69.96 -48.41 63.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 C-N-CA 119.881 -0.728 . . . . 1.0 112.162 -178.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.448 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.18 -39.77 93.79 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 108.113 -1.069 . . . . 1.0 108.113 179.56 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.14 73.53 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-N 115.148 -0.933 . . . . 1.0 111.913 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.419 ' O ' ' OG1' ' A' ' 17' ' ' THR . 88.9 mt-10 -61.35 -31.6 71.48 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.974 -0.75 . . . . 1.0 108.974 178.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -34.08 50.2 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.135 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -63.12 -50.45 70.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.388 -1.278 . . . . 1.0 110.774 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.466 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -73.41 -39.73 64.83 Favored 'General case' 0 CA--C 1.509 -0.618 0 C-N-CA 119.912 -0.715 . . . . 1.0 110.225 178.627 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.419 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 91.1 m -62.0 -42.84 99.59 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.347 -179.243 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -75.85 -46.79 28.46 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.859 -0.609 . . . . 1.0 112.243 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 59.8 t30 -60.89 -44.63 96.83 Favored 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 113.573 0.953 . . . . 1.0 113.573 -177.765 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -59.2 -35.08 72.96 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 119.706 -0.798 . . . . 1.0 109.7 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -73.75 -33.99 64.53 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.221 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -60.37 125.51 82.07 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-N 115.956 -0.565 . . . . 1.0 112.066 -178.124 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.27 149.92 15.64 Favored 'Trans proline' 0 N--CA 1.5 1.854 0 C-N-CA 122.168 1.912 . . . . 1.0 112.847 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.77 -20.14 33.53 Favored Glycine 0 C--O 1.224 -0.523 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 -179.302 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 35' ' ' LYS . 48.9 t -93.36 133.01 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 1.0 109.614 179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.1 t -117.41 120.83 66.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 108.528 -0.916 . . . . 1.0 108.528 177.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.1 p -96.34 146.08 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.623 0 CA-C-O 121.676 0.75 . . . . 1.0 111.393 -178.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 62.5 mt -113.56 164.22 16.42 Favored Pre-proline 0 C--N 1.332 -0.167 0 CA-C-N 114.438 -1.255 . . . . 1.0 110.958 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.07 -30.35 93.04 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.894 1.73 . . . . 1.0 110.913 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.5 m -67.93 -15.17 63.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.785 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.66 68.57 Favored Glycine 0 C--O 1.23 -0.139 0 N-CA-C 110.089 -1.205 . . . . 1.0 110.089 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.474 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.74 133.97 38.18 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 109.056 -0.72 . . . . 1.0 109.056 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.474 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.0 mp0 -123.12 137.77 54.83 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.1 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -133.73 143.16 48.31 Favored 'General case' 0 CA--C 1.504 -0.797 0 CA-C-O 121.739 0.78 . . . . 1.0 110.927 178.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -126.96 131.84 50.97 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 114.432 -1.258 . . . . 1.0 109.562 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -88.39 105.12 15.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 122.045 0.926 . . . . 1.0 111.922 -178.273 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.1 mm -69.44 -42.34 80.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.036 -0.984 . . . . 1.0 108.447 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.419 ' O ' ' OG ' ' A' ' 97' ' ' SER . 14.1 m120 -141.96 127.19 18.61 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.524 -1.216 . . . . 1.0 109.72 -179.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -86.73 130.96 34.27 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.803 0.335 . . . . 1.0 110.399 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.528 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -121.33 -36.01 0.77 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 109.914 -1.275 . . . . 1.0 109.914 179.597 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.414 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 6.3 m-20 58.48 32.81 22.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 1.0 111.593 179.058 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.9 -161.67 37.58 Favored Glycine 0 C--N 1.331 0.255 0 CA-C-O 121.861 0.7 . . . . 1.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 26.4 m -69.6 -178.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.07 -1.065 . . . . 1.0 109.494 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.719 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.47 154.43 0.45 Allowed Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 109.61 -0.515 . . . . 1.0 109.61 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HB2' ' HB2' ' A' ' 49' ' ' ASP . 60.1 Cg_endo -88.02 157.47 7.18 Favored 'Trans proline' 0 N--CA 1.503 2.077 0 C-N-CA 123.72 2.946 . . . . 1.0 117.454 -174.657 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.443 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.45 177.6 48.75 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 109.725 -1.35 . . . . 1.0 109.725 175.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.478 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.05 -25.54 31.42 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.216 -0.492 . . . . 1.0 111.904 -179.612 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.7 m -108.94 -4.84 16.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.551 0.574 . . . . 1.0 112.551 -177.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.443 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 89.5 m-20 -82.18 169.56 16.46 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.046 -0.724 . . . . 1.0 109.046 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.6 m -111.4 151.46 28.47 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.699 -0.482 . . . . 1.0 109.699 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.444 HG11 HD13 ' A' ' 90' ' ' LEU . 5.4 p -129.96 162.56 37.46 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 CA-C-N 115.754 -0.657 . . . . 1.0 111.716 -176.668 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 73.6 m -129.67 120.16 24.72 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.288 -1.004 . . . . 1.0 108.288 177.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.57 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.5 m -149.06 164.86 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 N-CA-C 114.379 1.252 . . . . 1.0 114.379 -176.08 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.411 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 2.6 mt-10 -118.72 146.26 44.88 Favored 'General case' 0 N--CA 1.486 1.352 0 N-CA-C 106.056 -1.831 . . . . 1.0 106.056 174.191 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.613 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 41.1 p90 -162.98 164.61 25.63 Favored 'General case' 0 C--N 1.342 0.275 0 N-CA-C 114.971 1.471 . . . . 1.0 114.971 -176.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -125.97 130.45 51.24 Favored 'General case' 0 C--O 1.216 -0.679 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.706 175.526 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.48 132.86 10.72 Favored Glycine 0 N--CA 1.473 1.113 0 N-CA-C 111.356 -0.698 . . . . 1.0 111.356 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 -147.06 167.54 23.82 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.788 0.804 . . . . 1.0 112.658 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.6 mp -81.9 164.83 21.28 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 114.252 -1.34 . . . . 1.0 110.274 178.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.425 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.82 -26.27 37.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 114.794 -1.094 . . . . 1.0 110.243 178.173 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.415 ' O ' ' OD2' ' A' ' 61' ' ' ASP . 7.0 t70 -94.04 5.26 52.27 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.019 -1.446 . . . . 1.0 111.919 -176.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.56 -4.53 79.7 Favored Glycine 0 CA--C 1.528 0.883 0 C-N-CA 121.0 -0.619 . . . . 1.0 113.227 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -70.29 103.88 2.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 118.073 0.937 . . . . 1.0 110.028 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -75.55 128.3 37.18 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.727 0 C-N-CA 120.642 -0.423 . . . . 1.0 110.059 179.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.761 ' CD2' HD11 ' A' ' 118' ' ' ILE . 9.2 p90 -116.08 -10.34 11.55 Favored 'General case' 0 CA--C 1.521 -0.165 0 CA-C-N 115.439 -0.8 . . . . 1.0 111.116 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -164.24 153.32 13.55 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.443 -0.503 . . . . 1.0 111.677 177.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.7 p -159.41 158.08 31.46 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 115.763 -0.653 . . . . 1.0 111.869 179.214 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 67.2 m -152.78 -40.61 0.1 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.358 -0.837 . . . . 1.0 110.254 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.435 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.3 pp20? -59.86 -27.59 66.8 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.373 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -55.45 -40.23 71.33 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.641 -1.244 . . . . 1.0 107.641 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.8 -34.94 57.92 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.029 -1.442 . . . . 1.0 108.642 178.179 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.54 17.87 69.9 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 110.69 -0.964 . . . . 1.0 110.69 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -105.07 116.26 60.94 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 121.155 -0.218 . . . . 1.0 110.754 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 32.3 Cg_exo -60.36 149.93 83.31 Favored 'Trans proline' 0 N--CA 1.479 0.67 0 C-N-CA 121.255 1.303 . . . . 1.0 113.358 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -122.83 151.27 41.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 114.483 -1.235 . . . . 1.0 108.204 178.425 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.1 t -106.41 127.44 53.29 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 113.13 0.789 . . . . 1.0 113.13 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.479 ' CZ ' ' H62' ' A' ' 138' ' ' RAP . 54.6 m-85 -133.97 150.02 51.26 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-N 115.148 -0.933 . . . . 1.0 108.973 177.087 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 68.0 mt-30 -90.38 125.05 35.41 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 106.353 -1.721 . . . . 1.0 106.353 174.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.5 t -48.48 -30.43 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 120.06 -0.656 . . . . 1.0 110.199 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.9 t -75.13 -25.12 58.17 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.27 -0.572 . . . . 1.0 111.681 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.504 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 94.4 mm-40 -98.87 -8.2 26.08 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 113.518 0.933 . . . . 1.0 113.518 -177.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.685 ' HA ' H482 ' A' ' 138' ' ' RAP . 3.9 p -88.22 170.49 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 118.907 0.776 . . . . 1.0 111.974 -178.34 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.537 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -52.98 148.51 13.85 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 120.256 -0.578 . . . . 1.0 109.623 -176.684 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.75 -44.34 41.48 Favored 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 122.25 1.967 . . . . 1.0 113.143 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.63 -47.43 90.19 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.818 -1.313 . . . . 1.0 109.818 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.682 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 9.2 m95 -63.79 -36.97 85.63 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.747 -1.227 . . . . 1.0 110.128 178.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 20.9 m -50.89 -54.19 26.1 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 116.258 -0.428 . . . . 1.0 111.041 -177.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.0 tp10 -72.84 -42.6 63.58 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.541 0.571 . . . . 1.0 112.541 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.52 -47.21 79.83 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 113.552 0.945 . . . . 1.0 113.552 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.444 HD13 HG11 ' A' ' 51' ' ' VAL . 79.3 mt -57.84 -41.28 82.01 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.406 0.622 . . . . 1.0 109.995 -178.384 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 21.4 mt-30 -64.57 -23.74 67.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.26 -0.882 . . . . 1.0 111.126 -179.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.8 mt -105.3 -12.23 16.15 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.505 -0.316 . . . . 1.0 111.075 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 17.6 ttm -88.77 108.4 23.08 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 116.014 -0.539 . . . . 1.0 111.925 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.719 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.2 Cg_exo -65.54 149.14 87.9 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.853 2.369 . . . . 1.0 113.318 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.86 133.43 51.88 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-N 115.591 -0.731 . . . . 1.0 111.359 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.4 -19.06 54.8 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 109.67 -1.372 . . . . 1.0 109.67 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.528 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 23.8 t -84.08 125.96 32.62 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.967 0.413 . . . . 1.0 109.946 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 44.1 m -96.94 111.86 23.88 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 116.151 -0.477 . . . . 1.0 110.044 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.431 ' NE1' ' OG ' ' A' ' 97' ' ' SER . 39.8 m0 -114.95 164.47 14.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.863 0.84 . . . . 1.0 111.476 -178.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.6 mt-10 -125.81 126.52 44.65 Favored 'General case' 0 CA--C 1.508 -0.636 0 N-CA-C 106.582 -1.636 . . . . 1.0 106.582 175.676 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.0 pt -120.4 137.15 55.13 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.767 0.794 . . . . 1.0 109.792 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.35 103.27 12.39 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 105.77 -1.937 . . . . 1.0 105.77 -178.13 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.95 115.09 63.57 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 114.969 1.47 . . . . 1.0 114.969 -174.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -51.32 144.53 30.45 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.121 1.214 . . . . 1.0 109.768 175.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.4 p -49.0 -36.67 18.21 Favored 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 120.653 -0.419 . . . . 1.0 110.961 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.18 -32.29 81.8 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.377 -0.689 . . . . 1.0 111.377 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 59.1 mt -98.58 2.07 47.06 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 122.926 -0.161 . . . . 1.0 110.645 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.495 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.37 -111.26 0.31 Allowed 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 110.035 -0.358 . . . . 1.0 110.035 -179.276 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.598 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 52.3 m-85 -98.88 4.21 47.42 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 112.327 0.492 . . . . 1.0 112.327 -178.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.85 157.9 15.36 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 121.387 -0.435 . . . . 1.0 112.592 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.445 ' O ' ' N ' ' A' ' 121' ' ' ASN . 88.4 Cg_endo -74.12 -11.72 23.28 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 123.506 2.804 . . . . 1.0 110.562 179.222 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ARG . . . . . 0.437 ' O ' HG23 ' A' ' 114' ' ' VAL . 70.2 ttt180 -100.85 165.12 11.51 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.8 -1.091 . . . . 1.0 108.946 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.51 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.1 m -72.28 97.17 1.95 Allowed 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 119.989 -0.684 . . . . 1.0 109.173 178.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 112' ' ' ARG . 4.4 t -112.08 60.9 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 121.049 -0.261 . . . . 1.0 111.322 -179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 163.19 169.39 26.56 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.333 -0.937 . . . . 1.0 111.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.21 -103.47 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.191 -0.764 . . . . 1.0 111.191 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -60.81 -19.39 61.44 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 122.46 2.107 . . . . 1.0 111.608 -178.141 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.761 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.4 mp -68.05 118.7 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 107.54 -1.282 . . . . 1.0 107.54 178.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -101.31 -168.0 27.87 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 115.225 -0.898 . . . . 1.0 113.796 -176.591 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 19.5 Cg_endo -63.6 144.71 90.48 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.859 2.373 . . . . 1.0 112.289 178.313 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.445 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 43.25 50.93 5.84 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.717 0.294 . . . . 1.0 111.004 179.108 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.545 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 3.9 tp10 -106.15 127.51 53.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.623 0.725 . . . . 1.0 112.627 -177.604 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.466 HG21 HD11 ' A' ' 16' ' ' LEU . 25.7 m -95.61 135.24 37.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.649 -1.16 . . . . 1.0 108.52 178.205 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.0 mm? -115.32 142.16 47.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.232 0.539 . . . . 1.0 110.862 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.53 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.5 tt -120.84 149.37 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 115.468 -0.787 . . . . 1.0 108.951 178.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.581 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -139.62 149.84 44.26 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.507 -0.477 . . . . 1.0 111.046 177.019 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.9 mmtt -100.5 122.35 43.08 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 105.577 -2.008 . . . . 1.0 105.577 178.091 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.458 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.18 119.37 60.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 C-N-CA 119.311 -0.956 . . . . 1.0 113.564 -175.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' HIS . . . . . 0.42 ' ND1' HD11 ' A' ' 131' ' ' ILE . 10.4 t-160 -108.53 122.58 47.34 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 113.912 -1.495 . . . . 1.0 108.451 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.7 110.58 22.69 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.173 0.511 . . . . 1.0 111.64 -178.483 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.451 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -93.69 -46.86 13.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.212 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.3 p -150.99 158.45 44.15 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.237 0.542 . . . . 1.0 111.188 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.44 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -129.05 141.99 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 115.492 -0.776 . . . . 1.0 110.001 -178.015 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.452 ' O ' ' CB ' ' A' ' 135' ' ' LYS . 12.3 tptm -84.6 -83.98 0.15 Allowed 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.45 0.643 . . . . 1.0 111.929 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.452 ' CB ' ' O ' ' A' ' 134' ' ' LYS . 1.5 tmtt? 94.78 128.0 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 113.99 -1.459 . . . . 1.0 110.342 -178.367 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.429 ' H ' ' HD3' ' A' ' 135' ' ' LYS . 28.8 t -72.54 35.46 0.07 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 113.719 -1.582 . . . . 1.0 111.795 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.415 ' H ' ' C ' ' A' ' 135' ' ' LYS . 13.9 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.861 -1.066 . . . . 1.0 110.435 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.816 H491 H381 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 110.431 -0.211 . . . . 1.0 110.431 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -64.36 -30.87 71.91 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 119.941 -0.704 . . . . 1.0 110.51 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.9 ttpt -51.23 -43.52 61.47 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.098 -0.641 . . . . 1.0 110.095 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.495 ' HZ2' HD21 ' A' ' 8' ' ' ASN . 6.4 tmtt? -68.81 -43.23 76.01 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 108.776 -0.824 . . . . 1.0 108.776 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.15 -34.49 45.06 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 114.816 -1.084 . . . . 1.0 110.339 179.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.517 ' OD2' ' NZ ' ' A' ' 9' ' ' LYS . 60.6 m-20 -64.57 -40.2 95.13 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.406 -0.815 . . . . 1.0 110.163 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.4 ' O ' ' HD2' ' A' ' 11' ' ' LYS . 48.1 mt-10 -60.89 -54.74 41.36 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-O 121.571 0.7 . . . . 1.0 110.709 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.549 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 4.0 m-20 -59.6 -36.98 77.35 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.145 -1.057 . . . . 1.0 108.145 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.517 ' NZ ' ' OD2' ' A' ' 6' ' ' ASP . 4.3 ttpm? -66.74 -50.54 62.43 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 113.762 -1.563 . . . . 1.0 111.867 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.4 t -65.14 -48.67 82.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 119.614 -0.834 . . . . 1.0 110.993 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.462 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.83 -38.32 90.66 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.028 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.424 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.35 -46.97 46.22 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 115.094 -0.957 . . . . 1.0 112.199 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.431 ' O ' ' OG1' ' A' ' 17' ' ' THR . 91.9 mt-10 -57.69 -34.81 69.81 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 108.645 -0.872 . . . . 1.0 108.645 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.05 -31.01 44.38 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.853 -1.067 . . . . 1.0 110.364 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -61.68 -49.23 77.32 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.147 -179.347 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.424 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.2 mp -66.57 -38.23 86.63 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 119.69 -0.804 . . . . 1.0 109.304 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.8 m -61.85 -42.97 99.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.549 0.69 . . . . 1.0 109.275 178.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -74.21 -44.29 53.8 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-N 115.334 -0.848 . . . . 1.0 111.609 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -56.83 -50.16 73.24 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.111 0.481 . . . . 1.0 111.883 -178.874 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 9.5 ptmt -60.01 -28.63 67.88 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.221 -0.992 . . . . 1.0 109.545 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -81.87 -29.57 32.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.33 -0.85 . . . . 1.0 111.442 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -58.95 136.35 87.52 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 120.848 -0.341 . . . . 1.0 111.177 -179.152 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -55.75 148.47 55.29 Favored 'Trans proline' 0 N--CA 1.506 2.234 0 C-N-CA 122.48 2.12 . . . . 1.0 114.179 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.76 -18.59 11.56 Favored Glycine 0 N--CA 1.462 0.428 0 CA-C-N 115.097 -0.956 . . . . 1.0 111.397 178.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.4 t -85.08 136.27 23.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.04 0.448 . . . . 1.0 111.074 -179.293 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.5 t -120.47 122.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 N-CA-C 107.716 -1.216 . . . . 1.0 107.716 176.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.27 147.0 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 121.414 0.626 . . . . 1.0 111.812 -178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 54.6 mt -115.79 163.77 19.86 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.758 -1.11 . . . . 1.0 110.779 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.22 -31.91 93.67 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.584 1.523 . . . . 1.0 111.974 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.4 m -68.14 -12.23 60.54 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 109.294 -0.632 . . . . 1.0 109.294 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.0 -1.57 68.05 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 109.365 -1.494 . . . . 1.0 109.365 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.489 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -79.98 134.39 36.25 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.434 -0.95 . . . . 1.0 108.434 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.489 ' H ' HD22 ' A' ' 32' ' ' LEU . 13.0 mp0 -124.84 145.54 49.73 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-N 115.891 -0.595 . . . . 1.0 110.929 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -139.39 150.11 44.9 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.521 0.677 . . . . 1.0 110.733 178.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.5 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -135.13 134.94 40.73 Favored 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 114.563 -1.199 . . . . 1.0 109.119 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -92.33 103.75 14.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 122.211 1.005 . . . . 1.0 111.742 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.618 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.3 mm -69.02 -41.74 81.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.039 -0.982 . . . . 1.0 109.197 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -142.04 128.0 19.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.109 -0.95 . . . . 1.0 109.942 -178.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.9 p -87.55 124.46 33.51 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.858 0.361 . . . . 1.0 110.101 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.468 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.19 -32.77 2.1 Favored Glycine 0 CA--C 1.517 0.218 0 N-CA-C 109.539 -1.424 . . . . 1.0 109.539 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 56.49 32.43 20.75 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.3 -0.45 . . . . 1.0 110.995 179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.75 -163.01 38.66 Favored Glycine 0 C--N 1.329 0.167 0 CA-C-O 121.977 0.765 . . . . 1.0 111.536 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.602 ' O ' ' N ' ' A' ' 95' ' ' ALA . 29.2 m -69.43 -177.94 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.009 -1.095 . . . . 1.0 108.42 177.78 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.604 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.25 154.27 0.38 Allowed Pre-proline 0 C--N 1.316 -0.852 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.6 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.486 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 70.3 Cg_endo -87.79 152.78 7.36 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.827 2.351 . . . . 1.0 115.265 -175.325 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.53 178.98 51.54 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.612 -1.795 . . . . 1.0 108.612 176.275 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.648 ' NZ ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.95 -21.48 11.86 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.445 -0.502 . . . . 1.0 110.847 -179.666 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.4 m -107.64 -11.03 15.52 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 113.587 0.958 . . . . 1.0 113.587 -177.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -85.69 166.1 16.42 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 119.632 -0.827 . . . . 1.0 109.331 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.469 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 4.8 m -103.79 151.01 23.57 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.23 0.538 . . . . 1.0 110.43 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.486 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.3 p -128.06 157.56 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.421 0 CA-C-N 115.278 -0.874 . . . . 1.0 112.343 -176.338 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.447 HG22 ' HB3' ' A' ' 74' ' ' PRO . 98.1 m -124.07 120.54 32.68 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 107.923 -1.14 . . . . 1.0 107.923 177.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.618 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.7 m -149.23 163.18 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 114.698 1.37 . . . . 1.0 114.698 -175.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.4 152.61 35.52 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 106.384 -1.71 . . . . 1.0 106.384 173.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.554 ' H ' ' HB ' ' A' ' 68' ' ' THR . 33.6 p90 -164.09 160.73 21.89 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.528 1.307 . . . . 1.0 114.528 -177.573 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -123.37 128.46 49.91 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.953 -0.758 . . . . 1.0 108.953 175.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.8 137.69 14.45 Favored Glycine 0 N--CA 1.467 0.716 0 C-N-CA 120.925 -0.655 . . . . 1.0 112.138 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -146.18 165.91 27.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.714 0.769 . . . . 1.0 112.574 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.2 mp -82.91 163.28 21.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 114.276 -1.329 . . . . 1.0 110.052 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.33 -26.2 36.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.155 -0.929 . . . . 1.0 110.276 178.08 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -93.82 7.76 43.69 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.376 -1.284 . . . . 1.0 111.78 -177.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.83 -7.27 81.46 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 121.241 -0.504 . . . . 1.0 113.31 178.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -68.19 105.79 2.22 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 119.444 -0.902 . . . . 1.0 110.565 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 99.2 t -76.84 118.98 24.34 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.82 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -106.34 -20.22 13.45 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.016 -0.993 . . . . 1.0 111.897 -178.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.466 ' OD1' ' O6 ' ' A' ' 138' ' ' RAP . 10.2 t70 -154.82 155.4 34.35 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.228 0.537 . . . . 1.0 111.972 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 92.9 p -157.4 159.8 37.75 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.341 -0.845 . . . . 1.0 111.57 178.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.554 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 89.9 m -155.25 -38.51 0.09 Allowed 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 115.567 -0.742 . . . . 1.0 110.01 -179.309 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -65.29 -25.37 67.61 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.638 -1.245 . . . . 1.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.6 mmtt -59.53 -45.63 91.2 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 176.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.8 OUTLIER -73.05 -33.36 65.64 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.505 -1.225 . . . . 1.0 108.194 177.423 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.55 18.93 67.27 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 111.497 -0.641 . . . . 1.0 111.497 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.9 115.37 60.4 Favored Pre-proline 0 N--CA 1.47 0.549 0 C-N-CA 120.936 -0.306 . . . . 1.0 110.919 -179.023 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.447 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.0 Cg_exo -59.9 151.26 72.75 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 121.826 1.684 . . . . 1.0 114.185 -179.249 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -120.68 148.63 43.67 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 113.915 -1.493 . . . . 1.0 107.498 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.15 124.57 49.89 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.335 0.588 . . . . 1.0 112.378 -178.245 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.575 ' HB3' H481 ' A' ' 138' ' ' RAP . 47.3 m-85 -133.32 149.34 51.9 Favored 'General case' 0 CA--C 1.493 -1.221 0 CA-C-N 115.286 -0.87 . . . . 1.0 109.707 178.59 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 49.3 mt-30 -90.75 130.36 36.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 105.09 -2.189 . . . . 1.0 105.09 174.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 87' ' ' THR . 38.2 t -57.23 -31.61 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 119.099 -1.04 . . . . 1.0 110.108 -176.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.1 t -73.67 -25.99 60.52 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.424 -0.51 . . . . 1.0 112.038 -178.27 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.514 ' CB ' ' H30' ' A' ' 138' ' ' RAP . 11.9 mm100 -102.26 -6.64 22.91 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 112.959 0.726 . . . . 1.0 112.959 -177.707 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.669 HG23 H31A ' A' ' 138' ' ' RAP . 1.2 p -78.91 168.58 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 121.046 -0.262 . . . . 1.0 111.242 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.411 HG12 H492 ' A' ' 138' ' ' RAP . 0.0 OUTLIER -52.56 146.81 16.22 Favored Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 107.903 -1.147 . . . . 1.0 107.903 -178.133 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.53 -43.29 45.78 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 121.433 1.422 . . . . 1.0 112.648 -177.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.11 -47.34 91.25 Favored Glycine 0 C--N 1.317 -0.479 0 C-N-CA 119.747 -1.216 . . . . 1.0 110.946 -178.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.703 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 7.8 m95 -66.68 -32.3 73.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 113.973 -1.113 . . . . 1.0 110.748 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.46 HG23 ' O ' ' A' ' 79' ' ' VAL . 29.5 m -51.37 -54.48 26.06 Favored 'General case' 0 C--N 1.322 -0.603 0 O-C-N 122.029 -0.42 . . . . 1.0 111.812 -178.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -72.7 -40.27 66.33 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.7 -44.06 97.0 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 114.432 1.271 . . . . 1.0 114.432 -176.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.4 mt -58.6 -41.56 86.11 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.147 0.499 . . . . 1.0 110.323 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -64.55 -23.89 67.42 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.368 -0.833 . . . . 1.0 110.401 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.524 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 88.6 mt -99.61 -14.84 18.81 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.964 -0.562 . . . . 1.0 111.718 -178.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 48.7 ttp -91.2 108.68 30.23 Favored Pre-proline 0 CA--C 1.548 0.892 0 O-C-N 123.224 0.327 . . . . 1.0 111.826 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.604 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 24.0 Cg_exo -63.79 149.1 91.51 Favored 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.586 2.191 . . . . 1.0 113.052 178.115 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.602 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.99 133.4 54.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.436 0.636 . . . . 1.0 110.76 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.61 -13.79 66.53 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 108.744 -1.742 . . . . 1.0 108.744 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.468 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 7.7 t -90.83 122.66 33.74 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.012 0.434 . . . . 1.0 109.839 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.8 m -97.07 115.07 26.82 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.402 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 31.7 m0 -115.76 167.95 10.48 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.657 0.741 . . . . 1.0 110.996 -178.59 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.618 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.5 mt-10 -128.44 134.74 48.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 106.453 -1.684 . . . . 1.0 106.453 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.414 HD13 HG21 ' A' ' 101' ' ' ILE . 3.5 pt -130.91 139.03 52.14 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.654 0 CA-C-O 121.724 0.773 . . . . 1.0 109.601 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.703 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.3 OUTLIER -109.39 102.9 11.76 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.995 -1.854 . . . . 1.0 105.995 -177.408 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 t -90.33 116.23 65.9 Favored Pre-proline 0 N--CA 1.453 -0.302 0 N-CA-C 115.093 1.516 . . . . 1.0 115.093 -174.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.33 143.56 26.26 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.519 1.479 . . . . 1.0 109.601 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.7 p -53.7 -27.97 31.16 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.411 -0.515 . . . . 1.0 110.929 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.61 -29.48 65.6 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 110.194 -1.163 . . . . 1.0 110.194 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.9 mt -101.03 2.28 40.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.301 -0.45 . . . . 1.0 111.173 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.533 ' O ' H521 ' A' ' 138' ' ' RAP . . . -110.43 -108.34 0.35 Allowed 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.852 0.316 . . . . 1.0 111.852 -178.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.631 ' CE2' H491 ' A' ' 138' ' ' RAP . 42.4 m-85 -99.24 3.39 46.26 Favored 'General case' 0 C--N 1.339 0.118 0 N-CA-C 112.136 0.421 . . . . 1.0 112.136 -178.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.03 163.98 22.13 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.23 -0.509 . . . . 1.0 112.396 178.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.551 ' O ' ' N ' ' A' ' 121' ' ' ASN . 84.9 Cg_endo -75.77 -11.55 20.1 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 123.404 2.736 . . . . 1.0 111.955 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -98.62 167.17 10.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.065 -0.516 . . . . 1.0 109.729 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.572 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.8 m -74.05 78.18 1.71 Allowed 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.301 -0.56 . . . . 1.0 109.842 178.672 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.1 t -93.68 60.44 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.084 -0.507 . . . . 1.0 109.949 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.59 177.09 40.42 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 120.224 -0.988 . . . . 1.0 112.295 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.97 -106.74 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 N-CA-C 111.293 -0.723 . . . . 1.0 111.293 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.31 -13.72 17.47 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 121.905 1.737 . . . . 1.0 110.522 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.865 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.5 mp -67.26 111.84 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 107.383 -1.34 . . . . 1.0 107.383 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.43 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -93.16 -167.1 38.54 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.473 -1.051 . . . . 1.0 110.473 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.572 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.5 Cg_endo -62.91 144.99 94.35 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.227 1.951 . . . . 1.0 112.7 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 111' ' ' PRO . 28.0 t-20 47.33 56.78 6.5 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.221 0.452 . . . . 1.0 112.221 177.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.43 ' HG3' ' H ' ' A' ' 119' ' ' GLY . 52.1 mm-40 -103.1 128.47 50.0 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 112.308 0.484 . . . . 1.0 112.308 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.8 m -93.94 128.4 40.23 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.191 -1.411 . . . . 1.0 107.191 176.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.403 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.6 mm? -109.41 147.95 31.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 121.482 0.658 . . . . 1.0 111.156 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.703 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -126.79 144.21 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.64 0 N-CA-C 108.477 -0.935 . . . . 1.0 108.477 178.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.543 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.9 OUTLIER -135.0 151.95 51.28 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 120.499 -0.48 . . . . 1.0 111.305 177.81 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.479 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.7 mmtt -100.18 125.12 46.28 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.044 -2.206 . . . . 1.0 105.044 176.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.469 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.3 mt -118.61 118.49 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 119.153 -1.019 . . . . 1.0 112.331 -176.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -109.77 121.7 45.81 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 113.569 -1.65 . . . . 1.0 108.232 178.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.33 112.16 24.01 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 120.235 -0.586 . . . . 1.0 112.064 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -91.57 -47.1 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.68 -0.691 . . . . 1.0 110.974 179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.9 t -150.02 158.12 43.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.833 0.349 . . . . 1.0 111.013 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.449 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -130.26 136.91 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 116.192 -0.458 . . . . 1.0 111.609 -178.243 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.553 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 20.3 tptt -92.83 -148.4 0.24 Allowed 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.661 0.743 . . . . 1.0 110.075 178.49 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.553 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -172.37 137.62 0.88 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 114.841 -1.072 . . . . 1.0 110.006 178.42 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.41 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 6.5 t -95.85 -63.59 1.14 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.371 -0.831 . . . . 1.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 117.918 -1.039 . . . . 1.0 110.57 -179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.703 ' H51' ' CZ2' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.819 -0.808 . . . . 1.0 108.819 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.417 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 19.0 m120 -64.95 -37.23 86.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.271 -0.422 . . . . 1.0 110.788 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.66 -38.52 6.83 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.474 -0.491 . . . . 1.0 110.339 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 3.1 tmtt? -72.34 -40.54 67.32 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 121.49 0.662 . . . . 1.0 109.61 178.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.51 -32.57 28.13 Favored 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 115.003 -0.998 . . . . 1.0 110.537 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -61.8 -39.79 92.96 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.537 -0.756 . . . . 1.0 110.109 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -62.2 -53.38 56.04 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 121.682 0.753 . . . . 1.0 110.593 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.567 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 7.0 m-20 -60.13 -34.44 73.53 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.223 -0.899 . . . . 1.0 108.599 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -66.93 -51.23 57.76 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.164 -1.38 . . . . 1.0 111.649 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.1 t -67.41 -46.83 82.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.082 -0.647 . . . . 1.0 111.887 -177.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.67 -38.22 90.29 Favored 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 107.442 -1.318 . . . . 1.0 107.442 178.567 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.544 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.04 -44.35 61.37 Favored Glycine 0 CA--C 1.528 0.905 0 CA-C-N 114.845 -1.071 . . . . 1.0 112.44 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -61.98 -32.06 72.48 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 119.342 -0.943 . . . . 1.0 108.72 179.297 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.17 -35.3 64.01 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.133 -0.94 . . . . 1.0 109.682 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -63.83 -50.3 69.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.213 -179.384 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.544 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -71.11 -37.87 72.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 109.178 -0.675 . . . . 1.0 109.178 178.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.2 m -62.03 -43.08 99.59 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.791 -0.641 . . . . 1.0 109.482 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -75.02 -45.78 39.52 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.655 -0.702 . . . . 1.0 112.154 -179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 46.0 t30 -61.62 -44.62 96.66 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 113.126 0.787 . . . . 1.0 113.126 -177.545 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.68 -30.36 68.72 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 119.406 -0.917 . . . . 1.0 109.505 -179.455 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 26.2 m-80 -81.15 -29.49 34.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.667 -0.697 . . . . 1.0 111.782 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 18.7 mtmt -59.55 136.52 89.36 Favored Pre-proline 0 CA--C 1.545 0.774 0 C-N-CA 120.687 -0.405 . . . . 1.0 111.188 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.75 147.49 60.61 Favored 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 121.719 1.612 . . . . 1.0 112.807 178.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.76 -20.23 25.14 Favored Glycine 0 C--O 1.225 -0.417 0 CA-C-N 115.27 -0.877 . . . . 1.0 111.486 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 35' ' ' LYS . 42.9 t -88.13 134.38 28.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.05 0.453 . . . . 1.0 110.751 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 83.8 t -118.67 122.26 69.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 108.062 -1.088 . . . . 1.0 108.062 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.428 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.3 p -94.79 146.06 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.721 0.772 . . . . 1.0 111.789 -178.701 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.6 mt -114.77 162.29 24.53 Favored Pre-proline 0 N--CA 1.465 0.316 0 CA-C-N 114.418 -1.264 . . . . 1.0 110.612 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.16 -30.92 94.39 Favored 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 121.681 1.588 . . . . 1.0 111.277 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 m -66.99 -15.04 63.47 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.509 -0.769 . . . . 1.0 109.389 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.28 -0.72 66.39 Favored Glycine 0 CA--C 1.51 -0.221 0 N-CA-C 109.432 -1.467 . . . . 1.0 109.432 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -80.56 134.21 35.89 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.355 -0.98 . . . . 1.0 108.355 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.2 mp0 -122.82 138.8 54.54 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.965 -0.561 . . . . 1.0 110.564 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -133.54 147.16 51.56 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.878 0.847 . . . . 1.0 111.0 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.523 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.8 tmtp? -134.1 136.48 43.93 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-N 114.174 -1.375 . . . . 1.0 109.724 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -92.79 105.73 17.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 122.366 1.079 . . . . 1.0 111.589 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.642 HD11 ' CD ' ' A' ' 100' ' ' GLU . 17.7 mm -70.54 -42.25 78.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.082 -0.963 . . . . 1.0 109.124 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.403 ' O ' ' OG ' ' A' ' 97' ' ' SER . 22.1 m120 -143.07 124.48 14.72 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 113.998 -1.456 . . . . 1.0 109.09 -178.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.1 p -88.61 125.58 34.88 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.596 -0.52 . . . . 1.0 109.596 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.508 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.11 -33.76 1.93 Allowed Glycine 0 CA--C 1.516 0.129 0 N-CA-C 110.345 -1.102 . . . . 1.0 110.345 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 57.98 32.97 22.68 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 123.679 0.281 . . . . 1.0 111.441 179.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.37 -161.08 36.92 Favored Glycine 0 C--N 1.335 0.502 0 CA-C-O 121.763 0.646 . . . . 1.0 111.929 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.584 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.8 m -68.74 -179.75 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 114.309 -0.945 . . . . 1.0 109.025 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.626 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 178.0 155.84 0.52 Allowed Pre-proline 0 N--CA 1.476 0.831 0 CA-C-O 120.953 0.406 . . . . 1.0 110.886 179.234 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HB2' ' HB3' ' A' ' 49' ' ' ASP . 32.6 Cg_endo -85.02 167.03 11.09 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 123.433 2.756 . . . . 1.0 117.521 -173.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.502 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -102.91 165.62 16.29 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 113.571 -1.649 . . . . 1.0 109.566 177.021 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.612 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -44.97 -25.86 0.36 Allowed 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.657 -0.771 . . . . 1.0 111.886 -179.636 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 66.5 m -108.32 -5.57 16.7 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 112.759 0.651 . . . . 1.0 112.759 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.706 ' OD2' ' N ' ' A' ' 50' ' ' THR . 66.4 t0 -82.29 169.08 16.93 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.151 0.501 . . . . 1.0 110.841 -179.473 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.706 ' N ' ' OD2' ' A' ' 49' ' ' ASP . 7.6 m -110.91 142.7 42.63 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.656 -0.868 . . . . 1.0 108.656 177.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.12 160.34 30.82 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.534 0 CA-C-N 114.994 -1.003 . . . . 1.0 112.252 -175.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.494 HG22 ' HB3' ' A' ' 74' ' ' PRO . 91.1 m -124.69 120.3 31.43 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.873 -0.788 . . . . 1.0 108.873 178.173 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.585 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 11.4 m -148.75 165.44 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 114.636 1.347 . . . . 1.0 114.636 -176.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -119.32 151.99 37.5 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 173.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.52 ' O ' ' N ' ' A' ' 68' ' ' THR . 33.6 p90 -164.96 164.83 20.6 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 118.425 -1.31 . . . . 1.0 113.973 -177.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.3 m -123.88 130.82 53.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 108.021 -1.103 . . . . 1.0 108.021 175.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.6 131.44 9.98 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.093 -1.203 . . . . 1.0 110.093 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.711 ' CZ ' ' HZ1' ' A' ' 127' ' ' LYS . 5.1 ptp180 -145.77 169.29 18.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.977 0.894 . . . . 1.0 112.762 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.7 mp -84.59 165.89 17.61 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 113.912 -1.495 . . . . 1.0 109.941 177.614 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.06 -25.62 30.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.431 178.889 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -100.22 10.17 41.65 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.134 -0.939 . . . . 1.0 112.026 -177.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.94 -6.62 81.81 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 120.403 -0.903 . . . . 1.0 113.771 178.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.7 m -65.18 102.02 0.6 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 118.727 1.263 . . . . 1.0 109.182 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 88.4 t -74.86 117.4 18.99 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.408 0.623 . . . . 1.0 111.1 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CD2' HD11 ' A' ' 118' ' ' ILE . 27.4 p90 -103.76 -15.63 15.67 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 114.903 -1.044 . . . . 1.0 112.092 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.413 ' OD2' H432 ' A' ' 138' ' ' RAP . 0.2 OUTLIER -159.24 153.91 24.47 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.27 -0.572 . . . . 1.0 110.375 177.811 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.0 p -157.19 158.55 36.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.826 -0.625 . . . . 1.0 111.802 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.2 m -153.07 -43.89 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.171 -0.922 . . . . 1.0 109.799 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.437 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -61.07 -28.02 68.78 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-N 115.888 -0.597 . . . . 1.0 109.66 179.42 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -57.24 -42.9 82.37 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 107.434 -1.321 . . . . 1.0 107.434 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.8 -33.47 60.13 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.299 -1.319 . . . . 1.0 107.558 176.251 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.02 17.75 73.87 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.314 -0.857 . . . . 1.0 112.118 178.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -98.13 116.35 65.61 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 121.265 -0.174 . . . . 1.0 110.557 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.494 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.4 Cg_exo -58.54 150.52 68.44 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 121.501 1.467 . . . . 1.0 114.204 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.77 145.82 48.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.354 -1.293 . . . . 1.0 108.472 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.3 t -103.8 131.3 51.12 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-O 121.453 0.644 . . . . 1.0 112.452 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.652 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 36.0 m-85 -139.8 149.6 43.71 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.994 -1.003 . . . . 1.0 110.42 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -90.81 127.54 36.39 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 105.766 -1.938 . . . . 1.0 105.766 174.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.1 t -51.64 -29.2 9.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 C-N-CA 118.981 -1.088 . . . . 1.0 110.512 -176.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 48.3 t -77.68 -23.17 49.65 Favored 'General case' 0 CA--C 1.521 -0.171 0 C-N-CA 120.306 -0.558 . . . . 1.0 111.835 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.504 ' HB3' H513 ' A' ' 138' ' ' RAP . 97.3 mm-40 -98.56 -6.6 29.77 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 113.728 1.01 . . . . 1.0 113.728 -178.11 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.578 HG22 ' H32' ' A' ' 138' ' ' RAP . 4.6 p -87.59 172.36 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 119.775 -0.77 . . . . 1.0 110.924 -178.205 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.524 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -53.48 152.31 9.12 Favored Pre-proline 0 N--CA 1.478 0.954 0 N-CA-C 109.301 -0.629 . . . . 1.0 109.301 -176.956 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.466 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -52.26 -45.14 41.35 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.098 1.866 . . . . 1.0 112.061 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.77 -46.86 91.81 Favored Glycine 0 CA--C 1.522 0.512 0 C-N-CA 119.957 -1.116 . . . . 1.0 110.876 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.585 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.1 m95 -64.58 -35.44 80.98 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.342 -0.929 . . . . 1.0 111.495 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 30.7 m -50.78 -55.29 17.48 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.55 -0.46 . . . . 1.0 112.14 -177.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -73.27 -40.42 64.6 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 112.365 0.506 . . . . 1.0 112.365 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.47 -45.76 84.45 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 114.154 1.168 . . . . 1.0 114.154 -178.526 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.1 mt -57.84 -41.59 82.66 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.197 0.522 . . . . 1.0 110.629 -177.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.9 mt-30 -65.43 -19.1 65.79 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.277 -0.874 . . . . 1.0 111.346 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.502 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 57.5 mt -106.01 -13.4 15.48 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.116 -0.493 . . . . 1.0 110.7 -178.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.0 ttp -88.91 109.13 28.02 Favored Pre-proline 0 CA--C 1.553 1.063 0 N-CA-C 112.101 0.408 . . . . 1.0 112.101 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.626 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 22.3 Cg_exo -64.58 149.53 89.72 Favored 'Trans proline' 0 N--CA 1.504 2.11 0 C-N-CA 122.979 2.453 . . . . 1.0 113.296 178.346 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.584 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.33 132.58 50.58 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.495 0.664 . . . . 1.0 111.154 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.76 -18.21 57.65 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 108.505 -1.838 . . . . 1.0 108.505 -178.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.508 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 9.3 t -86.02 128.64 34.9 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 109.944 -0.391 . . . . 1.0 109.944 179.092 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.7 m -103.33 114.8 29.36 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 115.594 -0.73 . . . . 1.0 109.696 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' TRP . . . . . 0.502 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -114.14 167.96 10.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.781 0.8 . . . . 1.0 111.336 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.642 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.7 mt-10 -128.46 124.5 36.33 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.171 -1.418 . . . . 1.0 107.171 175.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.435 HD13 HG21 ' A' ' 101' ' ' ILE . 3.6 pt -120.68 135.49 60.72 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.868 0 N-CA-C 108.735 -0.839 . . . . 1.0 108.735 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.72 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -107.12 104.0 13.53 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.725 -1.954 . . . . 1.0 105.725 -177.258 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 t -90.51 115.53 64.36 Favored Pre-proline 0 C--N 1.32 -0.675 0 N-CA-C 115.256 1.576 . . . . 1.0 115.256 -173.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -51.35 146.03 25.91 Favored 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 121.941 1.761 . . . . 1.0 110.569 176.294 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.0 p -53.58 -24.51 13.95 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.456 -178.291 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -78.56 -29.5 52.31 Favored Glycine 0 N--CA 1.46 0.268 0 N-CA-C 110.697 -0.961 . . . . 1.0 110.697 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.2 mt -102.16 2.77 37.71 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.523 -0.338 . . . . 1.0 110.49 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.26 -102.43 0.35 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 110.11 -0.33 . . . . 1.0 110.11 -178.102 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.641 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 47.6 m-85 -108.96 5.46 24.33 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.753 1.02 . . . . 1.0 113.753 -177.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.57 163.05 17.4 Favored Glycine 0 N--CA 1.473 1.128 0 C-N-CA 121.285 -0.483 . . . . 1.0 113.209 177.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.553 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.1 Cg_endo -71.13 -18.67 30.55 Favored 'Trans proline' 0 N--CA 1.494 1.527 0 C-N-CA 123.535 2.823 . . . . 1.0 112.37 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -104.01 171.56 7.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.229 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.465 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.0 m -73.64 97.28 2.63 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.926 -0.579 . . . . 1.0 110.171 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.6 t -109.55 61.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.596 -0.274 . . . . 1.0 110.873 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.502 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -168.53 40.98 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 120.892 -0.671 . . . . 1.0 111.715 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.12 -104.9 0.04 OUTLIER Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.457 -0.657 . . . . 1.0 111.457 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -58.9 -19.05 45.5 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.237 1.958 . . . . 1.0 111.621 -178.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.613 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -66.56 112.83 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 119.901 -0.72 . . . . 1.0 109.166 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.4 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.65 -164.84 39.93 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.679 -0.968 . . . . 1.0 110.679 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.567 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 23.5 Cg_endo -63.22 152.05 81.74 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.359 2.039 . . . . 1.0 113.272 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.553 ' N ' ' O ' ' A' ' 111' ' ' PRO . 4.5 t-20 37.17 53.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.807 177.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.423 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 41.7 mm-40 -97.36 132.29 43.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.29 0.567 . . . . 1.0 111.768 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.464 HG21 HD11 ' A' ' 16' ' ' LEU . 84.6 m -95.66 127.44 41.7 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.451 -1.314 . . . . 1.0 107.451 176.197 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.82 140.79 47.31 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.338 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.72 HD12 ' CD2' ' A' ' 102' ' ' TYR . 2.2 tt -119.43 147.05 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 N-CA-C 108.435 -0.95 . . . . 1.0 108.435 178.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.626 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -134.4 145.53 49.01 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 121.12 0.486 . . . . 1.0 110.324 177.314 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.711 ' HZ1' ' CZ ' ' A' ' 58' ' ' ARG . 5.5 mmtt -99.61 121.83 41.76 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 104.673 -2.343 . . . . 1.0 104.673 178.394 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.411 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.5 mt -116.09 120.36 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 119.438 -0.905 . . . . 1.0 113.176 -175.22 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.4 t-160 -110.3 123.18 49.34 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 113.927 -1.488 . . . . 1.0 108.486 178.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.64 113.17 24.79 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 112.384 0.513 . . . . 1.0 112.384 -178.154 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -96.25 -46.98 13.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 115.775 -0.648 . . . . 1.0 111.301 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.95 155.86 42.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.168 0.509 . . . . 1.0 111.574 -178.651 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 44' ' ' LYS . 50.1 t -128.96 142.19 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.706 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.448 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 3.9 tptt -100.66 -152.09 0.42 Allowed 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.712 0.768 . . . . 1.0 110.765 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.448 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -174.89 134.65 0.36 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.487 -1.233 . . . . 1.0 110.985 178.928 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.534 ' OG ' ' N ' ' A' ' 137' ' ' SER . 0.0 OUTLIER -58.1 -72.13 0.1 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.013 -0.994 . . . . 1.0 110.405 179.605 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.534 ' N ' ' OG ' ' A' ' 136' ' ' SER . 33.6 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.184 -0.912 . . . . 1.0 110.877 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.893 ' O3 ' H492 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.598 ' CG ' ' N ' ' A' ' 2' ' ' ASN . 29.6 t80 . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 109.501 -0.555 . . . . 1.0 109.501 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.598 ' N ' ' CG ' ' A' ' 1' ' ' PHE . 49.8 m-20 -70.28 -17.52 63.1 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.425 -0.352 . . . . 1.0 111.208 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.489 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 58.9 pttt -45.36 -43.2 10.77 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.382 -0.527 . . . . 1.0 110.47 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.489 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 3.8 tmtt? -75.16 -42.53 55.85 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 122.058 0.932 . . . . 1.0 109.332 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.456 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -50.27 -31.08 13.25 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 114.411 -1.268 . . . . 1.0 110.001 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.433 ' HA ' ' HB3' ' A' ' 9' ' ' LYS . 95.3 m-20 -62.6 -38.71 91.24 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.17 -0.923 . . . . 1.0 110.251 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -63.48 -51.9 63.65 Favored 'General case' 0 C--O 1.222 -0.372 0 CA-C-O 121.428 0.633 . . . . 1.0 110.867 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 2.3 m-20 -62.74 -35.76 80.83 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.094 -1.076 . . . . 1.0 108.094 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 13' ' ' GLU . 76.8 tttt -65.72 -49.45 68.42 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.42 -1.718 . . . . 1.0 112.095 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.0 t -66.36 -48.67 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 C-N-CA 119.79 -0.764 . . . . 1.0 110.9 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.0 OUTLIER -62.61 -36.22 82.05 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.799 -1.185 . . . . 1.0 107.799 178.9 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.456 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.59 -41.81 42.38 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.836 -1.074 . . . . 1.0 112.213 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.472 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.7 mt-10 -62.79 -31.35 72.3 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 119.464 -0.895 . . . . 1.0 108.634 179.54 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.55 -34.76 53.72 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 115.138 -0.937 . . . . 1.0 109.925 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -60.84 -49.07 78.96 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.499 -1.228 . . . . 1.0 111.11 -178.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.456 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.1 mp -70.18 -36.76 74.87 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.195 -0.602 . . . . 1.0 109.495 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.66 -44.36 97.1 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.593 -0.731 . . . . 1.0 109.715 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -76.6 -44.83 32.73 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 114.985 -1.007 . . . . 1.0 112.517 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.3 t30 -60.07 -44.99 94.36 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 113.089 0.774 . . . . 1.0 113.089 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -61.02 -28.5 69.09 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 119.969 -0.693 . . . . 1.0 109.761 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -82.99 -28.08 29.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.571 -0.741 . . . . 1.0 111.235 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.4 mtmt -59.25 139.01 88.45 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 120.834 -0.346 . . . . 1.0 111.478 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_exo -56.5 148.54 62.56 Favored 'Trans proline' 0 N--CA 1.502 2.008 0 C-N-CA 122.167 1.911 . . . . 1.0 113.353 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA3' ' HZ2' ' A' ' 35' ' ' LYS . . . 80.78 -18.84 8.25 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.247 -0.888 . . . . 1.0 111.592 179.209 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.46 137.29 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.444 . . . . 1.0 109.964 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.6 t -122.98 119.62 58.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 108.242 -1.021 . . . . 1.0 108.242 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.426 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.2 p -94.93 145.44 8.12 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 CA-C-O 121.689 0.757 . . . . 1.0 111.429 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.9 mt -111.92 165.11 13.57 Favored Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 114.189 -1.369 . . . . 1.0 110.481 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -61.21 -29.43 86.63 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.764 1.643 . . . . 1.0 111.048 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -68.34 -16.88 64.1 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 115.678 -0.692 . . . . 1.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.74 -7.0 60.85 Favored Glycine 0 CA--C 1.517 0.196 0 N-CA-C 110.142 -1.183 . . . . 1.0 110.142 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.475 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.38 134.52 38.42 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 179.528 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.475 ' H ' HD22 ' A' ' 32' ' ' LEU . 26.2 mp0 -121.24 142.91 49.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.454 -0.339 . . . . 1.0 110.641 179.203 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -136.97 148.13 46.74 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-O 121.56 0.695 . . . . 1.0 110.75 178.452 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LYS . . . . . 0.593 ' CD ' HD13 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -135.27 134.74 40.27 Favored 'General case' 0 N--CA 1.44 -0.948 0 CA-C-N 114.48 -1.236 . . . . 1.0 109.88 -179.174 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 p -93.3 105.34 16.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 122.063 0.935 . . . . 1.0 111.472 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.631 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -70.33 -41.76 78.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.177 -0.92 . . . . 1.0 109.303 179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -145.46 119.75 9.57 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.797 -1.092 . . . . 1.0 110.48 -177.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 p -80.32 123.85 28.34 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.264 0.554 . . . . 1.0 110.352 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.449 ' H ' ' CB ' ' A' ' 97' ' ' SER . . . -109.22 -29.24 4.07 Favored Glycine 0 CA--C 1.519 0.286 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 179.352 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 m-20 54.73 32.12 16.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.756 -0.722 . . . . 1.0 111.412 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.95 -163.26 38.78 Favored Glycine 0 C--N 1.33 0.247 0 CA-C-O 121.923 0.735 . . . . 1.0 111.548 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.3 m -68.28 -177.77 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 114.154 -1.023 . . . . 1.0 108.615 178.097 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.522 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.36 154.47 0.39 Allowed Pre-proline 0 C--N 1.317 -0.806 0 N-CA-C 109.454 -0.573 . . . . 1.0 109.454 179.631 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -88.02 159.64 7.28 Favored 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 123.137 2.558 . . . . 1.0 116.355 -174.294 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -91.53 175.02 38.69 Favored Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 109.06 -1.616 . . . . 1.0 109.06 176.375 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.628 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.47 -23.91 4.48 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.112 -0.544 . . . . 1.0 110.69 -179.691 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.466 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 40.6 m -107.72 -10.09 15.68 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 113.983 1.105 . . . . 1.0 113.983 -177.302 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.7 m-20 -84.7 165.51 17.81 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 119.618 -0.833 . . . . 1.0 108.835 179.724 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -103.36 148.93 25.27 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.515 -0.55 . . . . 1.0 109.515 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.7 p -125.62 162.44 28.65 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 CA-C-N 115.87 -0.605 . . . . 1.0 112.201 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.423 HG22 ' CB ' ' A' ' 74' ' ' PRO . 87.8 m -130.55 120.37 23.95 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.039 -1.097 . . . . 1.0 108.039 177.462 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.459 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 9.9 m -148.51 164.99 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.004 1.113 . . . . 1.0 114.004 -176.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.465 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 10.4 mt-10 -118.61 152.3 36.3 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 106.425 -1.694 . . . . 1.0 106.425 174.32 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.1 p90 -162.1 159.57 26.31 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 114.856 1.428 . . . . 1.0 114.856 -177.576 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -121.24 129.74 53.33 Favored 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.157 -0.929 . . . . 1.0 108.988 176.019 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.5 133.9 11.78 Favored Glycine 0 N--CA 1.47 0.935 0 N-CA-C 111.185 -0.766 . . . . 1.0 111.185 -178.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -145.54 166.43 25.73 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.69 0.757 . . . . 1.0 112.101 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -87.46 160.08 18.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.578 -1.192 . . . . 1.0 111.272 178.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -55.12 -26.01 17.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 114.462 -1.244 . . . . 1.0 110.465 177.811 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -96.04 5.63 50.71 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.49 -1.232 . . . . 1.0 111.075 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.73 -9.51 77.47 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.021 -0.536 . . . . 1.0 113.642 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -61.13 97.01 0.06 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 118.331 1.066 . . . . 1.0 110.634 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 98.2 t -68.73 125.69 27.1 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 C-N-CA 119.639 -0.824 . . . . 1.0 108.854 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.908 ' CD2' HD11 ' A' ' 118' ' ' ILE . 19.4 p90 -117.38 -15.53 10.33 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.163 -0.926 . . . . 1.0 111.696 -178.615 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.542 ' CB ' H433 ' A' ' 138' ' ' RAP . 11.8 t70 -154.6 149.87 27.1 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.249 0.547 . . . . 1.0 111.735 178.023 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -155.87 151.32 26.97 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.395 -0.821 . . . . 1.0 111.776 179.137 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 99.5 m -148.04 -37.8 0.19 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.201 -0.908 . . . . 1.0 110.157 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.465 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.1 pp20? -66.62 -27.37 67.65 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 116.14 -0.482 . . . . 1.0 110.04 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -59.4 -43.39 92.99 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 107.744 -1.206 . . . . 1.0 107.744 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 18.5 p -73.01 -32.88 65.42 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 114.876 -1.056 . . . . 1.0 108.523 176.747 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.36 17.68 66.08 Favored Glycine 0 CA--C 1.522 0.484 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.977 178.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.439 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -100.29 114.59 65.76 Favored Pre-proline 0 N--CA 1.471 0.602 0 C-N-CA 120.448 -0.501 . . . . 1.0 111.164 -179.591 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.423 ' CB ' HG22 ' A' ' 52' ' ' THR . 38.5 Cg_exo -61.7 152.87 71.25 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.012 1.808 . . . . 1.0 114.097 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.416 ' HB1' ' CZ ' ' A' ' 77' ' ' PHE . . . -123.08 145.19 48.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 113.681 -1.599 . . . . 1.0 107.847 178.623 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.516 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 2.7 t -105.59 136.36 45.32 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.267 0.556 . . . . 1.0 112.482 -178.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.754 ' CE1' ' H42' ' A' ' 138' ' ' RAP . 19.5 m-85 -150.07 151.25 32.92 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.546 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -87.93 128.32 35.37 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 107.652 -1.24 . . . . 1.0 107.652 175.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.5 t -54.86 -32.28 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 120.135 -0.626 . . . . 1.0 110.899 -177.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -72.48 -26.93 61.98 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.8 -0.76 . . . . 1.0 112.063 -177.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.539 ' C ' H482 ' A' ' 138' ' ' RAP . 80.6 mm-40 -98.52 -11.1 22.59 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 112.789 0.662 . . . . 1.0 112.789 -178.08 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.725 ' HA ' H332 ' A' ' 138' ' ' RAP . 0.5 OUTLIER -71.54 169.07 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.798 0.666 . . . . 1.0 112.798 -175.735 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.425 HD13 HG21 ' A' ' 83' ' ' ILE . 0.1 OUTLIER -51.69 145.76 15.19 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 107.134 -1.432 . . . . 1.0 107.134 -178.785 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.412 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -49.73 -44.86 34.32 Favored 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 121.19 1.26 . . . . 1.0 112.654 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.25 91.99 Favored Glycine 0 C--N 1.317 -0.523 0 C-N-CA 120.007 -1.092 . . . . 1.0 111.295 -179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' TRP . . . . . 0.573 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 6.7 m95 -63.76 -31.26 72.38 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 114.028 -1.086 . . . . 1.0 111.523 -179.489 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 99.4 m -56.4 -53.54 56.18 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 121.913 -0.492 . . . . 1.0 111.655 -178.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -71.76 -38.49 70.38 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.284 0.846 . . . . 1.0 113.284 -177.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -64.01 -44.1 93.64 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 114.477 1.288 . . . . 1.0 114.477 -176.445 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 26.9 mt -58.71 -37.99 77.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.275 0.559 . . . . 1.0 110.778 -177.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 30.1 mt-30 -64.92 -24.1 67.42 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.294 -0.866 . . . . 1.0 111.345 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 27.6 mt -102.06 -18.96 15.36 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.173 -0.467 . . . . 1.0 111.212 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.4 ttp -81.34 109.36 13.8 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 112.639 0.607 . . . . 1.0 112.639 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.522 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.39 148.32 84.04 Favored 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 122.679 2.253 . . . . 1.0 113.116 178.636 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.592 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.91 131.48 46.8 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-O 121.606 0.717 . . . . 1.0 111.811 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.71 -16.51 60.87 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 108.177 -1.969 . . . . 1.0 108.177 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.449 ' CB ' ' H ' ' A' ' 40' ' ' GLY . 5.7 p -88.46 139.13 30.79 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.089 -0.556 . . . . 1.0 110.139 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 50.9 m -110.27 117.43 33.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.12 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -117.49 169.64 9.37 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.95 0.881 . . . . 1.0 110.546 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.631 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.8 mt-10 -130.24 132.65 46.06 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.935 -1.506 . . . . 1.0 106.935 175.76 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.41 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -127.48 137.13 58.62 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 108.603 -0.888 . . . . 1.0 108.603 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.65 102.82 11.85 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 105.83 -1.915 . . . . 1.0 105.83 -177.8 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.6 t -89.94 115.1 63.11 Favored Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 114.516 1.302 . . . . 1.0 114.516 -174.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -51.57 144.33 33.33 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 121.072 1.181 . . . . 1.0 109.696 176.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 87.6 p -49.97 -31.98 13.9 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.377 -0.529 . . . . 1.0 110.959 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.71 -31.78 70.52 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.558 -0.617 . . . . 1.0 111.558 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.09 3.09 43.78 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 110.548 -0.167 . . . . 1.0 110.548 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.527 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.84 -109.06 0.33 Allowed 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 120.736 0.303 . . . . 1.0 111.256 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.584 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 38.6 m-85 -98.32 -4.66 34.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 114.379 1.251 . . . . 1.0 114.379 -176.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.32 172.68 18.95 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 120.497 -0.859 . . . . 1.0 113.174 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 121' ' ' ASN . 71.9 Cg_endo -73.75 -31.4 8.49 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 123.649 2.899 . . . . 1.0 112.388 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -82.23 170.81 14.98 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.365 0.602 . . . . 1.0 111.435 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.418 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 7.3 m -79.34 88.3 4.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.279 -0.873 . . . . 1.0 109.039 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.404 HG21 ' O ' ' A' ' 109' ' ' TYR . 3.3 t -97.88 55.26 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.341 -0.39 . . . . 1.0 111.383 -178.462 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 173.37 -175.25 46.18 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 120.509 -0.853 . . . . 1.0 112.087 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.34 -103.34 0.01 OUTLIER Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.268 -0.733 . . . . 1.0 111.268 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -62.13 -15.91 47.04 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.478 2.119 . . . . 1.0 110.518 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.908 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.6 mp -66.39 115.03 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.376 -1.342 . . . . 1.0 107.376 178.44 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -97.26 -157.79 30.82 Favored Glycine 0 C--O 1.213 -1.186 0 N-CA-C 110.814 -0.914 . . . . 1.0 110.814 -178.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.48 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 53.4 Cg_endo -71.02 147.58 55.08 Favored 'Trans proline' 0 C--N 1.297 -2.156 0 C-N-CA 121.51 1.474 . . . . 1.0 112.982 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.545 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 39.48 60.97 1.47 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 113.216 0.821 . . . . 1.0 113.216 177.503 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.744 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -112.69 140.35 47.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.038 0.447 . . . . 1.0 110.611 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 85.5 m -93.93 127.73 39.86 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.1 -1.074 . . . . 1.0 108.1 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -108.85 136.41 48.45 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.516 -0.55 . . . . 1.0 109.516 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -117.6 146.87 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 108.706 -0.849 . . . . 1.0 108.706 178.463 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 126' ' ' PHE . 4.0 m-85 -135.8 149.49 49.12 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.236 -0.586 . . . . 1.0 111.334 178.137 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.473 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 9.5 mmtt -99.46 124.57 44.73 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 104.948 -2.242 . . . . 1.0 104.948 177.427 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.9 mt -115.77 118.37 58.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 C-N-CA 119.167 -1.013 . . . . 1.0 111.9 -177.498 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -110.39 123.05 49.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.655 -1.611 . . . . 1.0 108.484 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.76 112.95 24.55 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 112.544 0.572 . . . . 1.0 112.544 -177.618 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.486 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -94.49 -49.17 12.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 CA-C-N 115.749 -0.66 . . . . 1.0 111.17 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.6 p -145.32 157.39 44.06 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.014 0.435 . . . . 1.0 110.601 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.461 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.3 t -130.09 137.56 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.288 -0.414 . . . . 1.0 110.993 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.491 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 15.8 tptt -88.84 -150.15 0.19 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.541 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.491 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER 178.53 138.23 0.09 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.864 0.84 . . . . 1.0 111.493 177.861 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 137' ' ' SER . 1.1 t -63.55 -46.44 85.92 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 114.036 -1.438 . . . . 1.0 110.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.41 ' C ' ' O ' ' A' ' 136' ' ' SER . 94.3 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.887 -1.054 . . . . 1.0 111.462 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' RAP . . . . . 0.889 H512 H472 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 . . . . . 0 CA--C 1.517 -0.321 0 CA-C-O 121.861 0.839 . . . . 1.0 110.633 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.611 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 3.7 m-20 -58.55 -38.42 77.79 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 107.528 -1.286 . . . . 1.0 107.528 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -63.93 -50.98 66.55 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 113.125 -1.852 . . . . 1.0 111.806 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 70.7 t -73.82 -48.62 38.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 119.812 -0.755 . . . . 1.0 111.713 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.45 ' O ' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -60.36 -40.63 91.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.827 -1.175 . . . . 1.0 107.827 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.447 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -65.74 -48.07 70.4 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.374 -0.83 . . . . 1.0 112.133 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -61.71 -31.25 71.39 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.01 -0.737 . . . . 1.0 109.01 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.22 -33.79 43.44 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.121 -0.945 . . . . 1.0 109.957 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' O ' ' A' ' 11' ' ' LYS . 64.3 t80 -61.14 -50.78 71.81 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 114.445 -1.252 . . . . 1.0 110.414 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.44 -41.59 80.07 Favored 'General case' 0 CA--C 1.513 -0.452 0 C-N-CA 119.963 -0.695 . . . . 1.0 109.649 178.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.8 m -62.14 -41.31 98.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.569 -0.741 . . . . 1.0 109.474 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -75.74 -45.29 37.38 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.584 -0.734 . . . . 1.0 111.637 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.1 t30 -61.34 -45.03 96.12 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 113.135 0.791 . . . . 1.0 113.135 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -57.68 -31.36 66.27 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 119.305 -0.958 . . . . 1.0 108.833 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -80.74 -31.48 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.72 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 41.2 mtmt -56.97 139.85 78.02 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 120.19 -0.604 . . . . 1.0 110.905 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -56.27 148.49 60.5 Favored 'Trans proline' 0 N--CA 1.502 2.0 0 C-N-CA 122.069 1.846 . . . . 1.0 113.879 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.1 -19.5 10.06 Favored Glycine 0 C--O 1.227 -0.318 0 CA-C-N 114.937 -1.029 . . . . 1.0 111.992 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.404 HG22 ' HB2' ' A' ' 35' ' ' LYS . 43.5 t -83.35 138.17 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.123 0.487 . . . . 1.0 110.929 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.5 t -122.35 122.41 66.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.8 p -96.76 146.22 7.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.653 0 CA-C-O 121.569 0.699 . . . . 1.0 111.847 -178.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.7 mt -114.08 166.09 12.23 Favored Pre-proline 0 C--O 1.232 0.146 0 CA-C-N 114.484 -1.235 . . . . 1.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -62.07 -30.46 82.71 Favored 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 121.985 1.79 . . . . 1.0 111.499 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 m -68.84 -13.3 62.33 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.955 -0.566 . . . . 1.0 109.811 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.96 -1.56 68.14 Favored Glycine 0 CA--C 1.517 0.199 0 N-CA-C 109.811 -1.316 . . . . 1.0 109.811 -179.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.459 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.9 tm? -80.95 133.98 35.62 Favored 'General case' 0 CA--C 1.518 -0.258 0 N-CA-C 108.591 -0.892 . . . . 1.0 108.591 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.459 ' H ' HD22 ' A' ' 32' ' ' LEU . 18.9 mp0 -122.42 138.42 54.54 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 116.448 -0.342 . . . . 1.0 111.087 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -133.56 145.5 50.15 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.525 0.679 . . . . 1.0 111.054 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.504 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -127.66 132.82 49.66 Favored 'General case' 0 CA--C 1.505 -0.751 0 CA-C-N 114.552 -1.204 . . . . 1.0 109.499 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.57 104.26 14.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 122.2 1.0 . . . . 1.0 112.122 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.629 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.8 mm -70.24 -41.69 78.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.027 -0.988 . . . . 1.0 108.523 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.423 HD22 ' HB ' ' A' ' 98' ' ' THR . 9.9 m-80 -143.11 128.34 18.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 114.595 -1.184 . . . . 1.0 109.495 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.0 p -88.12 131.84 34.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.746 0.308 . . . . 1.0 110.239 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.21 -35.44 0.81 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.639 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 57.23 30.66 18.77 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.251 -0.474 . . . . 1.0 111.169 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.12 -161.73 37.55 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.828 0.682 . . . . 1.0 111.756 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 25.9 m -69.01 -178.4 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.153 -1.023 . . . . 1.0 109.576 178.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.533 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.62 154.26 0.4 Allowed Pre-proline 0 C--N 1.32 -0.711 0 O-C-N 123.682 0.614 . . . . 1.0 109.523 179.554 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -87.83 157.81 7.46 Favored 'Trans proline' 0 N--CA 1.5 1.894 0 C-N-CA 123.363 2.709 . . . . 1.0 117.242 -174.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.439 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.84 176.17 44.05 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 109.205 -1.558 . . . . 1.0 109.205 176.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.468 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.5 -25.46 6.6 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.189 -0.506 . . . . 1.0 112.055 -179.443 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -108.61 -8.42 15.47 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 112.834 0.679 . . . . 1.0 112.834 -177.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.439 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.3 m-20 -82.96 166.47 18.82 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.327 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -105.35 150.59 25.08 Favored 'General case' 0 CA--C 1.511 -0.551 0 CA-C-O 121.334 0.588 . . . . 1.0 110.146 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.0 p -128.94 160.68 39.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.19 -0.914 . . . . 1.0 112.009 -177.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.437 HG22 ' HB3' ' A' ' 74' ' ' PRO . 84.8 m -127.69 119.87 26.78 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.125 -1.065 . . . . 1.0 108.125 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.514 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 7.2 m -148.9 164.74 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 114.507 1.299 . . . . 1.0 114.507 -176.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.9 mt-10 -118.22 150.74 38.92 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 106.305 -1.739 . . . . 1.0 106.305 174.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.552 ' O ' ' N ' ' A' ' 68' ' ' THR . 32.5 p90 -163.32 162.9 25.34 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 115.09 1.515 . . . . 1.0 115.09 -177.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -126.27 129.47 48.97 Favored 'General case' 0 C--O 1.217 -0.608 0 CA-C-N 115.086 -0.961 . . . . 1.0 108.515 175.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.76 134.61 12.09 Favored Glycine 0 N--CA 1.471 1.011 0 N-CA-C 111.472 -0.651 . . . . 1.0 111.472 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.53 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 8.6 ptp85 -147.03 167.43 24.05 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.701 0.763 . . . . 1.0 112.389 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.5 mp -84.46 165.06 18.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 114.349 -1.296 . . . . 1.0 110.236 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.429 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.79 -26.55 38.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.265 -0.879 . . . . 1.0 110.524 178.445 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -92.0 3.18 55.81 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.044 -1.434 . . . . 1.0 111.701 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.24 -4.09 76.97 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 121.337 -0.458 . . . . 1.0 113.177 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.3 m -68.01 104.06 1.65 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 118.141 0.97 . . . . 1.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.6 t -76.43 120.04 25.79 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.079 0.466 . . . . 1.0 110.153 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.751 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.8 p90 -109.28 -11.79 14.84 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 115.231 -0.895 . . . . 1.0 112.308 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -161.99 153.08 17.99 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.316 -0.554 . . . . 1.0 111.511 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 94.4 p -159.23 154.21 24.97 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.41 0.624 . . . . 1.0 112.558 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.552 ' N ' ' O ' ' A' ' 55' ' ' TYR . 62.3 m -150.15 -40.74 0.13 Allowed 'General case' 0 C--O 1.223 -0.337 0 CA-C-N 115.024 -0.989 . . . . 1.0 110.305 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.41 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.6 pp20? -62.22 -26.62 68.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.241 -0.583 . . . . 1.0 109.637 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.9 mmmt -57.0 -42.91 81.17 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.426 -1.324 . . . . 1.0 107.426 178.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.492 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.4 p -73.28 -33.72 65.39 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.732 -1.122 . . . . 1.0 108.365 176.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.13 17.04 75.27 Favored Glycine 0 C--N 1.334 0.425 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.359 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.6 mttm -101.44 116.7 63.3 Favored Pre-proline 0 N--CA 1.469 0.524 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.693 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.3 Cg_exo -60.08 152.76 63.06 Favored 'Trans proline' 0 N--CA 1.485 0.982 0 C-N-CA 121.786 1.657 . . . . 1.0 114.377 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.412 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -122.29 147.26 46.45 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 113.827 -1.533 . . . . 1.0 107.548 177.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.46 128.12 52.3 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 121.072 0.463 . . . . 1.0 112.014 -179.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -136.06 150.59 49.22 Favored 'General case' 0 CA--C 1.493 -1.24 0 CA-C-O 121.797 0.808 . . . . 1.0 110.844 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -94.14 123.63 37.65 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 105.828 -1.915 . . . . 1.0 105.828 174.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.459 HG11 HE21 ' A' ' 91' ' ' GLN . 25.3 t -49.44 -25.61 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.795 -0.638 . . . . 1.0 110.663 -176.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 15.3 t -78.11 -24.33 47.53 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 120.308 -0.557 . . . . 1.0 112.189 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 92.7 mm-40 -96.6 -10.28 27.48 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.112 0.412 . . . . 1.0 112.112 -179.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -79.68 166.8 2.4 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 N-CA-C 112.59 0.589 . . . . 1.0 112.59 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -57.24 146.7 60.84 Favored Pre-proline 0 CA--C 1.545 0.753 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 -179.672 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -48.88 -46.11 26.05 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.686 1.591 . . . . 1.0 113.03 -178.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.68 -47.56 87.66 Favored Glycine 0 C--N 1.319 -0.398 0 N-CA-C 109.753 -1.339 . . . . 1.0 109.753 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.514 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.3 m95 -64.4 -36.23 83.49 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.147 -1.027 . . . . 1.0 110.199 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.43 ' H ' ' HG1' ' A' ' 87' ' ' THR . 19.5 m -51.17 -54.5 24.87 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.313 -0.403 . . . . 1.0 111.25 -177.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -72.96 -41.62 64.21 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.604 0.594 . . . . 1.0 112.604 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.51 -46.46 83.78 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 113.615 0.969 . . . . 1.0 113.615 -177.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 38.3 mt -58.85 -41.58 87.29 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 109.192 -0.67 . . . . 1.0 109.192 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.459 HE21 HG11 ' A' ' 79' ' ' VAL . 74.6 mt-30 -62.95 -23.85 67.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 114.938 -1.028 . . . . 1.0 110.696 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.448 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 83.9 mt -103.34 -12.96 16.88 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.255 -0.429 . . . . 1.0 111.327 -179.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.8 ttp -87.6 108.66 21.34 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-O 119.349 -0.358 . . . . 1.0 111.899 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.533 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.44 147.88 83.19 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 122.377 2.051 . . . . 1.0 112.365 178.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -66.46 132.37 48.12 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.519 -0.764 . . . . 1.0 111.438 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 99.52 -18.81 55.73 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 108.567 -1.813 . . . . 1.0 108.567 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.1 p -88.63 136.45 32.99 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 120.959 0.409 . . . . 1.0 110.387 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.423 ' HB ' HD22 ' A' ' 38' ' ' ASN . 90.5 m -108.27 114.39 28.22 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 115.803 -0.635 . . . . 1.0 109.708 178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.448 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.1 m0 -115.4 167.6 10.72 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 121.596 0.712 . . . . 1.0 111.228 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.629 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.2 mt-10 -127.37 128.11 45.33 Favored 'General case' 0 CA--C 1.508 -0.639 0 N-CA-C 106.673 -1.603 . . . . 1.0 106.673 175.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' A' ' 86' ' ' TRP . 2.6 pt -123.32 138.07 54.5 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.6 0 CA-C-O 121.894 0.855 . . . . 1.0 110.27 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.44 103.9 13.13 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.957 -1.868 . . . . 1.0 105.957 -177.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.7 t -90.42 115.4 64.02 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 115.076 1.51 . . . . 1.0 115.076 -174.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -51.15 141.96 36.97 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 121.323 1.348 . . . . 1.0 109.858 175.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.3 p -48.46 -34.28 10.81 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.149 -0.62 . . . . 1.0 110.943 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.87 -32.32 80.72 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.144 -0.782 . . . . 1.0 111.144 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 68.0 mt -98.55 1.67 46.75 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 121.393 -0.123 . . . . 1.0 110.74 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.8 -113.39 0.3 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.052 0.39 . . . . 1.0 112.052 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -98.2 3.77 48.95 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 112.487 0.551 . . . . 1.0 112.487 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 109.49 162.75 19.67 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 121.014 -0.612 . . . . 1.0 112.768 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -74.75 -9.29 21.04 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 123.556 2.837 . . . . 1.0 111.695 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -103.63 166.59 10.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.126 -0.488 . . . . 1.0 109.839 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.57 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -72.3 84.99 1.07 Allowed 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.0 t -100.72 62.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.985 0.422 . . . . 1.0 110.513 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.443 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -179.98 41.09 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 111.502 -0.639 . . . . 1.0 111.502 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.84 -103.98 0.01 OUTLIER Glycine 0 CA--C 1.535 1.322 0 N-CA-C 110.992 -0.843 . . . . 1.0 110.992 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -61.33 -14.78 36.39 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.549 2.166 . . . . 1.0 110.669 -178.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.751 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.1 mp -65.83 113.25 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 106.672 -1.603 . . . . 1.0 106.672 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.31 -172.79 40.14 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.378 -0.828 . . . . 1.0 112.28 -177.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.57 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.2 Cg_endo -62.88 138.11 66.58 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 C-N-CA 122.38 2.053 . . . . 1.0 112.405 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.34 51.82 12.4 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 121.039 -0.264 . . . . 1.0 111.061 178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.611 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -98.82 130.06 45.24 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.921 0.712 . . . . 1.0 112.921 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.447 HG21 HD11 ' A' ' 16' ' ' LEU . 43.5 m -96.66 129.13 44.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 106.063 -1.829 . . . . 1.0 106.063 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -110.94 145.15 38.87 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.308 0.575 . . . . 1.0 111.105 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.664 HD12 ' CE2' ' A' ' 102' ' ' TYR . 2.1 tt -124.31 148.55 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 CA-C-N 115.233 -0.894 . . . . 1.0 108.884 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.597 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -140.93 151.17 44.0 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.242 -0.583 . . . . 1.0 111.515 177.536 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.53 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 12.9 mmtt -99.36 125.32 45.01 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 105.46 -2.052 . . . . 1.0 105.46 177.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.02 118.4 56.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.267 -0.973 . . . . 1.0 112.418 -176.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.401 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.5 t-160 -109.68 123.88 50.25 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 114.128 -1.397 . . . . 1.0 108.649 178.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.07 111.17 23.02 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 120.246 -0.582 . . . . 1.0 112.39 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -94.29 -42.69 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 115.995 -0.548 . . . . 1.0 111.676 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -153.44 156.0 37.38 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.502 -0.479 . . . . 1.0 110.796 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 44' ' ' LYS . 44.7 t -130.65 138.82 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 116.156 -0.475 . . . . 1.0 111.452 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.4 tptm . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 121.494 0.664 . . . . 1.0 109.564 178.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 . . . . . 0 CA--C 1.515 -0.366 0 CA-C-O 121.655 0.74 . . . . 1.0 110.505 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.4 m-20 -59.67 -35.31 74.19 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.204 -1.035 . . . . 1.0 108.204 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.3 tttt -66.59 -50.5 62.86 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 113.757 -1.565 . . . . 1.0 111.919 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.15 -48.0 82.81 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 C-N-CA 119.813 -0.755 . . . . 1.0 111.253 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.84 -38.1 89.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 178.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.15 -44.76 52.9 Favored Glycine 0 CA--C 1.525 0.703 0 CA-C-N 114.847 -1.069 . . . . 1.0 112.366 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -60.44 -31.78 70.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 119.494 -0.882 . . . . 1.0 108.692 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.99 -35.5 57.12 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.809 -1.087 . . . . 1.0 109.87 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.1 t80 -61.39 -51.34 69.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.621 -1.172 . . . . 1.0 110.847 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.408 HD11 HG21 ' A' ' 123' ' ' THR . 5.3 mp -68.12 -38.37 82.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 119.995 -0.682 . . . . 1.0 109.41 179.06 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 99.3 m -62.16 -41.65 98.51 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.553 -0.749 . . . . 1.0 109.296 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -74.62 -46.81 35.96 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.056 -0.975 . . . . 1.0 111.655 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.638 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -55.73 -50.49 70.24 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 112.496 0.554 . . . . 1.0 112.496 -178.783 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.0 ptmt -60.1 -26.74 66.45 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.379 -0.928 . . . . 1.0 109.831 -177.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -83.55 -31.23 26.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.377 -0.829 . . . . 1.0 111.186 179.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -58.7 136.45 86.57 Favored Pre-proline 0 CA--C 1.548 0.871 0 CA-C-N 116.52 -0.309 . . . . 1.0 111.576 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -56.75 148.58 64.84 Favored 'Trans proline' 0 N--CA 1.503 2.071 0 C-N-CA 122.138 1.892 . . . . 1.0 113.334 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.14 -19.32 18.11 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.495 -0.775 . . . . 1.0 111.49 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.471 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.1 t -86.42 137.71 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.165 0.507 . . . . 1.0 110.547 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.93 121.78 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 107.582 -1.266 . . . . 1.0 107.582 177.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.19 145.99 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.642 0 CA-C-O 121.361 0.601 . . . . 1.0 111.228 -178.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 92.8 mt -111.94 164.81 14.25 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.85 -1.068 . . . . 1.0 110.462 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -61.54 -30.48 86.28 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.745 1.63 . . . . 1.0 110.91 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -68.83 -14.44 63.03 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.473 -0.785 . . . . 1.0 109.828 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.41 -3.89 66.43 Favored Glycine 0 C--N 1.329 0.157 0 N-CA-C 109.671 -1.371 . . . . 1.0 109.671 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.472 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.16 133.93 36.71 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 108.457 -0.942 . . . . 1.0 108.457 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.472 ' H ' HD22 ' A' ' 32' ' ' LEU . 15.2 mp0 -123.07 143.38 50.0 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 116.286 -0.416 . . . . 1.0 110.887 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.4 p90 -138.21 143.59 40.25 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-O 121.635 0.731 . . . . 1.0 110.757 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.525 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -127.51 131.24 50.14 Favored 'General case' 0 CA--C 1.501 -0.924 0 CA-C-N 114.594 -1.184 . . . . 1.0 109.188 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 p -88.85 104.62 15.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 122.279 1.038 . . . . 1.0 111.688 -178.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.0 mm -69.25 -42.2 81.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.881 -1.054 . . . . 1.0 108.453 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -143.36 124.55 14.54 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.501 -1.227 . . . . 1.0 109.907 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -85.83 129.64 34.77 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.611 -0.436 . . . . 1.0 109.9 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.23 -33.24 1.26 Allowed Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.895 -1.282 . . . . 1.0 109.895 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.666 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 57.04 31.67 20.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.477 -0.361 . . . . 1.0 111.157 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.08 -162.18 37.92 Favored Glycine 0 C--N 1.332 0.329 0 CA-C-O 121.819 0.677 . . . . 1.0 111.822 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.4 m -68.17 -177.93 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 114.061 -1.069 . . . . 1.0 109.127 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.695 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.32 154.82 0.39 Allowed Pre-proline 0 C--N 1.317 -0.834 0 N-CA-C 109.338 -0.616 . . . . 1.0 109.338 179.553 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.427 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 56.8 Cg_endo -86.71 158.78 9.09 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 123.11 2.54 . . . . 1.0 115.741 -175.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 177.29 41.72 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 108.766 -1.734 . . . . 1.0 108.766 176.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.48 -23.02 9.07 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.882 -0.327 . . . . 1.0 111.07 -179.713 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 57.9 m -108.05 -9.22 15.67 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 113.629 0.974 . . . . 1.0 113.629 -176.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.7 m-20 -84.74 166.87 16.64 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 119.883 -0.727 . . . . 1.0 109.468 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.5 m -104.56 148.44 26.5 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.612 -0.514 . . . . 1.0 109.612 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.427 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -126.57 161.79 32.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.478 0 CA-C-N 115.857 -0.611 . . . . 1.0 112.278 -176.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.421 HG22 ' HB3' ' A' ' 74' ' ' PRO . 86.4 m -130.48 118.18 20.74 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 75' ' ' ALA . 2.5 m -148.14 166.43 4.79 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 112.577 0.584 . . . . 1.0 112.577 -177.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.2 mt-10 -116.39 157.7 24.66 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 106.469 -1.678 . . . . 1.0 106.469 175.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.475 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.6 p90 -167.2 160.91 14.15 Favored 'General case' 0 C--N 1.346 0.415 0 N-CA-C 114.846 1.425 . . . . 1.0 114.846 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -124.76 127.81 47.8 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.119 -1.067 . . . . 1.0 108.119 174.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.89 134.03 11.39 Favored Glycine 0 N--CA 1.47 0.955 0 C-N-CA 120.748 -0.739 . . . . 1.0 111.915 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -146.48 166.84 25.22 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.715 0.769 . . . . 1.0 112.169 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.0 162.66 20.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.391 -1.277 . . . . 1.0 110.062 177.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.05 -25.33 29.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.913 0.863 . . . . 1.0 110.206 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -92.22 2.84 56.37 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 113.947 -1.479 . . . . 1.0 111.852 -177.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.96 -4.98 78.86 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 121.016 -0.611 . . . . 1.0 112.781 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.7 m -68.82 105.75 2.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 118.068 0.934 . . . . 1.0 109.63 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 67.7 t -77.69 121.82 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.691 0 CA-C-O 121.229 0.538 . . . . 1.0 110.301 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.6 p90 -110.41 -11.53 14.5 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.089 -0.959 . . . . 1.0 111.688 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -159.84 154.13 23.66 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.192 0.52 . . . . 1.0 111.497 177.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.3 p -159.29 151.43 20.98 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.41 -0.814 . . . . 1.0 111.213 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.475 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.9 m -154.38 -41.78 0.09 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.645 -0.707 . . . . 1.0 110.649 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.426 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -62.38 -26.33 68.41 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.862 -0.608 . . . . 1.0 110.313 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -55.34 -41.88 73.06 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 108.153 -1.054 . . . . 1.0 108.153 179.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.7 p -80.05 -30.82 39.47 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.067 177.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.1 16.99 68.19 Favored Glycine 0 C--N 1.336 0.531 0 CA-C-N 115.689 -0.687 . . . . 1.0 111.592 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -97.28 115.73 65.8 Favored Pre-proline 0 N--CA 1.471 0.591 0 C-N-CA 120.716 -0.394 . . . . 1.0 110.342 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 Cg_exo -60.32 156.23 41.93 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.177 1.918 . . . . 1.0 114.687 -178.364 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.67 145.36 49.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 113.908 -1.496 . . . . 1.0 107.595 177.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.513 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 1.4 t -104.0 133.91 48.16 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.395 0.617 . . . . 1.0 112.075 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 76' ' ' THR . 22.6 m-85 -144.18 152.45 40.9 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.837 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -94.52 125.15 38.99 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.878 -1.527 . . . . 1.0 106.878 175.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.95 -30.87 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 C-N-CA 120.04 -0.664 . . . . 1.0 110.57 -177.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -73.42 -24.25 60.24 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.299 -0.561 . . . . 1.0 112.349 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 86.1 mm-40 -99.72 -14.67 18.79 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.888 0.699 . . . . 1.0 112.888 -177.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -73.14 169.43 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 112.434 0.531 . . . . 1.0 112.434 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.435 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -56.09 149.08 37.06 Favored Pre-proline 0 CA--C 1.547 0.831 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 -179.402 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.435 ' HD2' HG22 ' A' ' 83' ' ' ILE . 74.0 Cg_exo -51.49 -45.01 40.18 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 121.359 1.372 . . . . 1.0 112.941 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.93 -46.78 93.13 Favored Glycine 0 N--CA 1.45 -0.428 0 N-CA-C 110.29 -1.124 . . . . 1.0 110.29 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.6 m95 -65.87 -33.5 75.99 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.389 -0.906 . . . . 1.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.7 m -54.91 -54.16 46.18 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.703 -0.399 . . . . 1.0 111.359 -178.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -72.74 -42.44 64.07 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 112.771 0.656 . . . . 1.0 112.771 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.73 -46.8 83.95 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.903 1.075 . . . . 1.0 113.903 -177.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.2 mt -58.5 -41.56 85.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.347 0.594 . . . . 1.0 109.811 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -63.74 -23.59 67.43 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.095 -0.957 . . . . 1.0 110.515 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.528 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 81.3 mt -102.59 -10.03 19.63 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 116.032 -0.531 . . . . 1.0 111.422 -179.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.6 ttp -91.89 107.81 25.43 Favored Pre-proline 0 CA--C 1.546 0.823 0 N-CA-C 111.835 0.309 . . . . 1.0 111.835 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.695 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.0 Cg_exo -65.78 147.66 85.76 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 122.488 2.125 . . . . 1.0 112.357 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.74 137.55 58.12 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.666 0.746 . . . . 1.0 111.508 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.73 53.27 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 108.546 -1.822 . . . . 1.0 108.546 -178.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 p -87.18 134.6 33.51 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.009 0.433 . . . . 1.0 110.178 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.9 m -107.59 114.68 28.83 Favored 'General case' 0 CA--C 1.51 -0.582 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.052 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.528 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.6 m0 -115.71 164.38 14.43 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.708 0.766 . . . . 1.0 111.23 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.6 mt-10 -124.96 126.39 45.4 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 106.815 -1.55 . . . . 1.0 106.815 175.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -121.92 138.39 52.32 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.688 0 CA-C-O 121.899 0.857 . . . . 1.0 109.969 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.751 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.64 103.25 12.08 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.646 -1.983 . . . . 1.0 105.646 -178.231 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.2 115.45 64.07 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 114.75 1.389 . . . . 1.0 114.75 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -50.84 143.2 30.75 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 C-N-CA 121.433 1.422 . . . . 1.0 109.783 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 96.5 p -49.1 -35.26 15.75 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.273 -0.571 . . . . 1.0 110.531 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.86 -32.15 81.89 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 111.388 -0.685 . . . . 1.0 111.388 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 53.3 mt -100.59 2.91 42.2 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 121.499 -0.08 . . . . 1.0 110.832 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.66 -107.95 0.33 Allowed 'General case' 0 N--CA 1.457 -0.11 0 CA-C-O 120.923 0.392 . . . . 1.0 111.037 -178.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -100.03 4.89 45.01 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 111.965 0.357 . . . . 1.0 111.965 -178.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.78 160.97 25.76 Favored Glycine 0 CA--C 1.529 0.927 0 C-N-CA 121.395 -0.431 . . . . 1.0 112.925 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.567 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.2 Cg_endo -70.56 -15.94 34.12 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 123.316 2.677 . . . . 1.0 112.676 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.456 ' O ' HG23 ' A' ' 114' ' ' VAL . 2.8 mpt_? -96.75 169.48 9.84 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.22 -0.659 . . . . 1.0 109.22 179.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.426 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.3 m -75.76 82.78 2.72 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.352 -0.539 . . . . 1.0 110.096 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.5 t -98.36 60.11 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.771 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 172.68 -172.7 45.16 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.534 -0.841 . . . . 1.0 112.033 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.81 -103.78 0.05 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 111.036 -0.826 . . . . 1.0 111.036 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -59.3 -16.88 36.79 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.219 1.946 . . . . 1.0 110.397 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.645 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.0 mp -67.75 114.7 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 107.889 -1.152 . . . . 1.0 107.889 179.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.611 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -94.89 -158.5 33.09 Favored Glycine 0 C--O 1.212 -1.253 0 N-CA-C 110.968 -0.853 . . . . 1.0 110.968 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.511 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 44.6 Cg_endo -70.09 147.45 60.75 Favored 'Trans proline' 0 C--N 1.299 -2.034 0 C-N-CA 121.892 1.728 . . . . 1.0 113.098 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.567 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.5 t-20 39.99 60.74 1.65 Allowed 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.254 0.835 . . . . 1.0 113.254 177.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.709 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.03 135.85 53.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.571 0.7 . . . . 1.0 111.355 -179.423 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.408 HG21 HD11 ' A' ' 16' ' ' LEU . 99.2 m -93.69 129.0 40.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.329 178.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.51 140.97 42.63 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.142 0.496 . . . . 1.0 110.133 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.751 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -121.11 143.68 32.6 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.729 0 CA-C-N 115.506 -0.77 . . . . 1.0 109.014 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -134.89 150.66 50.46 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.082 0.468 . . . . 1.0 111.08 177.269 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 14.3 mmtt -99.63 126.02 45.56 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 104.85 -2.278 . . . . 1.0 104.85 176.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.8 mt -119.72 119.54 60.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 119.16 -1.016 . . . . 1.0 111.851 -177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.403 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.1 t-160 -111.92 120.94 43.63 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 114.091 -1.413 . . . . 1.0 108.816 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.63 112.45 24.41 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 120.236 -0.585 . . . . 1.0 112.326 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.491 ' N ' HD12 ' A' ' 131' ' ' ILE . 3.9 mp -94.84 -47.49 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.5 p -148.14 157.54 43.56 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.93 0.395 . . . . 1.0 111.246 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.43 HG21 ' HA ' ' A' ' 44' ' ' LYS . 54.7 t -130.07 139.25 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 116.043 -0.526 . . . . 1.0 111.396 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 12.5 tptt . . . . . 0 CA--C 1.536 0.409 0 CA-C-N 115.424 -0.807 . . . . 1.0 110.298 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 . . . . . 0 C--O 1.223 -0.331 0 CA-C-O 121.487 0.661 . . . . 1.0 110.694 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 30.4 m-20 -59.51 -34.0 72.07 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-O 121.964 0.888 . . . . 1.0 108.617 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.8 tttt -64.43 -49.71 70.42 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 114.108 -1.405 . . . . 1.0 111.664 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.31 -47.26 74.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.408 -0.517 . . . . 1.0 112.112 -178.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.443 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.2 -36.91 83.36 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 179.686 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.79 -44.15 39.53 Favored Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.925 -1.034 . . . . 1.0 112.408 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -60.66 -30.97 70.22 Favored 'General case' 0 CA--C 1.514 -0.416 0 C-N-CA 119.701 -0.8 . . . . 1.0 108.883 179.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.8 -35.68 51.13 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.129 -0.941 . . . . 1.0 109.849 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 t80 -61.96 -50.8 70.66 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.728 -1.124 . . . . 1.0 110.901 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.45 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -66.82 -38.74 87.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 179.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.48 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 99.0 m -61.27 -43.0 99.59 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.498 -0.773 . . . . 1.0 109.584 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -75.32 -46.48 33.08 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.591 -0.731 . . . . 1.0 112.111 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.655 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 51.3 t30 -61.47 -45.12 95.58 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 113.145 0.795 . . . . 1.0 113.145 -177.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -58.02 -33.69 69.23 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 119.321 -0.952 . . . . 1.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 17' ' ' THR . 43.6 m-80 -75.46 -33.91 60.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.305 -0.861 . . . . 1.0 111.538 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -58.99 137.41 87.72 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 120.593 -0.443 . . . . 1.0 111.8 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -53.85 149.13 34.77 Favored 'Trans proline' 0 N--CA 1.507 2.302 0 C-N-CA 122.723 2.282 . . . . 1.0 114.757 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.76 -21.91 5.2 Favored Glycine 0 CA--C 1.508 -0.368 0 CA-C-N 114.421 -1.263 . . . . 1.0 111.265 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 54.3 t -80.21 132.0 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 N-CA-C 109.34 -0.615 . . . . 1.0 109.34 -179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.77 120.4 64.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.327 -0.99 . . . . 1.0 108.327 177.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.3 p -95.5 145.91 7.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 CA-C-O 121.471 0.653 . . . . 1.0 111.265 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.0 mt -114.17 165.26 14.07 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.597 -1.183 . . . . 1.0 110.955 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.76 -30.44 90.28 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 C-N-CA 121.828 1.685 . . . . 1.0 111.006 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.5 m -68.4 -15.82 63.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.608 -0.724 . . . . 1.0 109.801 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.95 -2.77 64.26 Favored Glycine 0 C--O 1.229 -0.192 0 N-CA-C 110.016 -1.234 . . . . 1.0 110.016 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.479 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -78.78 134.1 37.04 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.479 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.0 mp0 -123.64 142.93 50.58 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.393 -0.367 . . . . 1.0 111.525 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -140.6 142.26 35.08 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.919 0.866 . . . . 1.0 112.183 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.58 ' HE3' HD13 ' A' ' 37' ' ' ILE . 8.6 ttpt -123.99 126.57 46.52 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.173 -1.376 . . . . 1.0 108.45 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.416 ' H ' HG12 ' A' ' 36' ' ' VAL . 2.9 p -82.61 113.52 21.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.128 -178.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.58 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.8 mm -77.27 -42.24 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 CA-C-O 121.541 0.686 . . . . 1.0 109.844 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.503 HD22 ' HB ' ' A' ' 37' ' ' ILE . 27.0 m-80 -144.34 124.01 13.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.725 -1.125 . . . . 1.0 109.917 -177.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -81.84 129.58 34.79 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.539 -0.464 . . . . 1.0 110.527 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.15 -36.13 1.05 Allowed Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.106 -1.198 . . . . 1.0 110.106 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.619 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 57.81 31.22 20.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.447 -0.376 . . . . 1.0 111.49 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.67 -161.8 37.25 Favored Glycine 0 C--N 1.332 0.35 0 CA-C-O 121.984 0.769 . . . . 1.0 111.731 179.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.2 m -68.97 -177.86 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.093 -1.053 . . . . 1.0 109.086 178.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.61 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.18 154.23 0.38 Allowed Pre-proline 0 C--N 1.32 -0.676 0 O-C-N 123.757 0.661 . . . . 1.0 109.556 179.734 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.407 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.5 Cg_endo -87.71 158.01 7.63 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 123.336 2.691 . . . . 1.0 116.45 -175.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -90.0 175.57 41.68 Favored Glycine 0 N--CA 1.449 -0.449 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 176.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.498 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.84 -22.31 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.778 -0.369 . . . . 1.0 111.274 -179.383 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 53.5 m -107.88 -9.3 15.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.534 0.939 . . . . 1.0 113.534 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.19 165.43 17.4 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.436 -0.949 . . . . 1.0 108.436 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.7 m -104.72 150.53 24.66 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 109.869 -0.419 . . . . 1.0 109.869 -179.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.407 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.4 p -127.09 163.37 30.06 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 112.599 0.592 . . . . 1.0 112.599 -176.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.403 HG22 ' HB3' ' A' ' 74' ' ' PRO . 97.1 m -131.55 120.18 22.55 Favored 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 108.488 -0.93 . . . . 1.0 108.488 178.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.583 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 15.8 m -148.75 165.28 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 114.438 1.273 . . . . 1.0 114.438 -176.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.427 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 7.0 mt-10 -118.35 147.92 43.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 174.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.499 ' H ' ' HB ' ' A' ' 68' ' ' THR . 37.3 p90 -163.63 162.14 24.11 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 114.68 1.363 . . . . 1.0 114.68 -176.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.49 133.11 54.6 Favored 'General case' 0 C--O 1.216 -0.675 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 175.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.83 135.96 11.79 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 120.972 -0.633 . . . . 1.0 111.855 -178.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.8 ptp85 -148.61 167.5 25.28 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.745 0.783 . . . . 1.0 112.997 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.69 163.79 18.99 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 114.377 -1.283 . . . . 1.0 110.989 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.58 -25.65 35.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 122.272 1.034 . . . . 1.0 109.589 177.468 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -89.86 0.72 56.87 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 113.378 -1.737 . . . . 1.0 111.688 -177.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.69 81.74 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 121.182 -0.533 . . . . 1.0 112.351 178.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.4 m -68.9 104.13 1.99 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 119.92 -0.712 . . . . 1.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.7 t -77.08 121.13 28.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 CA-C-N 116.059 -0.519 . . . . 1.0 110.062 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.698 ' CD2' HD11 ' A' ' 118' ' ' ILE . 22.0 p90 -110.59 -14.26 14.09 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.184 -0.916 . . . . 1.0 112.056 -178.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.7 t0 -159.58 148.19 17.7 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.156 -0.618 . . . . 1.0 111.511 177.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 89.5 p -153.63 156.25 37.58 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.541 179.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.499 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 55.8 m -155.17 -39.51 0.09 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.984 -0.553 . . . . 1.0 110.78 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -63.12 -26.19 68.71 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.632 -0.427 . . . . 1.0 109.895 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -56.49 -41.3 76.4 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.085 -1.45 . . . . 1.0 107.085 178.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 68' ' ' THR . 23.1 p -76.74 -32.66 57.93 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.203 -1.362 . . . . 1.0 109.042 177.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.48 15.18 80.32 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.922 -0.871 . . . . 1.0 110.922 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.427 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 12.9 mttp -96.55 115.26 65.56 Favored Pre-proline 0 N--CA 1.47 0.537 0 C-N-CA 120.827 -0.349 . . . . 1.0 110.962 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.412 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.3 Cg_exo -61.41 151.75 77.46 Favored 'Trans proline' 0 N--CA 1.482 0.827 0 C-N-CA 121.539 1.493 . . . . 1.0 114.405 -178.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.8 150.34 46.45 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.089 -1.414 . . . . 1.0 107.78 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -107.53 136.07 47.93 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 112.882 0.697 . . . . 1.0 112.882 -178.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -144.48 151.01 38.55 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 114.858 -1.064 . . . . 1.0 109.032 177.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -90.14 125.87 35.6 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 106.434 -1.691 . . . . 1.0 106.434 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.429 HG11 HE21 ' A' ' 91' ' ' GLN . 23.0 t -50.6 -31.4 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 C-N-CA 119.926 -0.71 . . . . 1.0 110.545 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.8 t -73.57 -27.37 61.28 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 120.116 -0.634 . . . . 1.0 111.994 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 43.9 mm-40 -101.35 -8.72 21.8 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 113.219 0.822 . . . . 1.0 113.219 -178.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.546 HG22 ' H ' ' A' ' 83' ' ' ILE . 3.5 p -80.32 172.84 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 C-N-CA 119.457 -0.897 . . . . 1.0 110.151 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.546 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.03 145.83 31.97 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 120.165 -0.614 . . . . 1.0 109.976 -176.733 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -51.42 -44.21 44.94 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.081 1.854 . . . . 1.0 112.783 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.05 -47.5 88.76 Favored Glycine 0 C--N 1.319 -0.4 0 N-CA-C 109.343 -1.503 . . . . 1.0 109.343 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.583 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 8.1 m95 -64.9 -35.21 80.4 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.796 -1.202 . . . . 1.0 110.565 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.24 -54.23 27.75 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.822 0.344 . . . . 1.0 111.172 -178.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -72.64 -43.14 63.59 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.745 0.646 . . . . 1.0 112.745 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.53 -45.84 84.56 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 113.957 1.095 . . . . 1.0 113.957 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.51 -41.12 84.7 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.457 0.646 . . . . 1.0 109.625 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.429 HE21 HG11 ' A' ' 79' ' ' VAL . 69.6 mt-30 -64.59 -23.85 67.4 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.836 -1.075 . . . . 1.0 110.805 -178.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.482 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 80.6 mt -103.81 -10.73 18.03 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 116.207 -0.451 . . . . 1.0 111.41 -178.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 46.7 ttp -92.18 108.4 30.32 Favored Pre-proline 0 CA--C 1.55 0.978 0 CA-C-O 119.445 -0.312 . . . . 1.0 111.345 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.61 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.0 Cg_exo -65.35 148.26 88.12 Favored 'Trans proline' 0 N--CA 1.5 1.881 0 C-N-CA 122.681 2.254 . . . . 1.0 112.777 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.76 136.86 57.77 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.368 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.23 -19.31 53.12 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 108.954 -1.659 . . . . 1.0 108.954 -178.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.7 p -87.88 135.45 33.39 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 120.851 0.358 . . . . 1.0 110.473 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.4 ' HB ' HD22 ' A' ' 38' ' ' ASN . 72.0 m -107.89 114.94 29.24 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 115.952 -0.567 . . . . 1.0 110.142 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.482 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.4 m0 -114.99 164.24 14.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.491 0.662 . . . . 1.0 111.404 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.486 ' HB2' HD11 ' A' ' 37' ' ' ILE . 29.7 mt-10 -124.35 127.78 48.1 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.642 -1.614 . . . . 1.0 106.642 175.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -123.77 138.72 52.58 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.461 0 CA-C-O 121.768 0.794 . . . . 1.0 110.288 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.677 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.23 103.85 12.89 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.864 -1.902 . . . . 1.0 105.864 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.67 115.65 64.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 N-CA-C 115.466 1.654 . . . . 1.0 115.466 -174.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -50.71 143.25 29.7 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 C-N-CA 121.611 1.541 . . . . 1.0 110.017 176.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.5 p -50.09 -34.66 22.57 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.524 -0.47 . . . . 1.0 110.986 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.8 -31.89 76.68 Favored Glycine 0 CA--C 1.52 0.396 0 N-CA-C 110.812 -0.915 . . . . 1.0 110.812 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 54.9 mt -98.97 2.38 46.36 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 121.436 -0.106 . . . . 1.0 110.878 -179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -107.86 0.33 Allowed 'General case' 0 C--N 1.34 0.166 0 CA-C-O 120.503 0.192 . . . . 1.0 111.338 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 38.0 m-85 -99.45 4.64 46.22 Favored 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 113.279 0.844 . . . . 1.0 113.279 -177.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.33 164.52 22.81 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 120.756 -0.735 . . . . 1.0 113.352 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 121' ' ' ASN . 79.5 Cg_endo -73.98 -16.89 22.77 Favored 'Trans proline' 0 N--CA 1.493 1.46 0 C-N-CA 123.531 2.821 . . . . 1.0 110.9 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.439 ' O ' HG23 ' A' ' 114' ' ' VAL . 60.4 ttt180 -96.06 165.12 12.4 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.477 -1.238 . . . . 1.0 109.685 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.522 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 8.1 m -77.02 91.97 3.68 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.565 -0.531 . . . . 1.0 109.565 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.3 t -107.56 60.66 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.113 -0.494 . . . . 1.0 111.199 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.518 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 171.23 178.05 41.45 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 120.201 -0.999 . . . . 1.0 112.145 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.23 -103.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 111.072 -0.811 . . . . 1.0 111.072 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -62.35 -16.04 48.91 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.567 2.178 . . . . 1.0 110.779 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.2 mp -66.67 115.92 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 108.233 -1.025 . . . . 1.0 108.233 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -96.52 -158.96 31.78 Favored Glycine 0 C--O 1.213 -1.194 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.522 ' N ' ' OG ' ' A' ' 113' ' ' SER . 46.9 Cg_endo -70.89 147.39 55.51 Favored 'Trans proline' 0 C--N 1.297 -2.141 0 C-N-CA 121.766 1.644 . . . . 1.0 113.326 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.507 ' C ' HD22 ' A' ' 121' ' ' ASN . 0.1 OUTLIER 41.17 60.6 2.0 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.195 0.813 . . . . 1.0 113.195 177.515 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.683 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.38 137.71 51.47 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 121.683 0.754 . . . . 1.0 111.225 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.45 HG21 HD11 ' A' ' 16' ' ' LEU . 81.8 m -94.43 130.09 40.91 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.332 -1.304 . . . . 1.0 108.624 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.29 141.3 46.17 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.05 -0.523 . . . . 1.0 109.8 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.677 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.7 tt -119.72 146.05 25.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 N-CA-C 108.368 -0.975 . . . . 1.0 108.368 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.574 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -137.98 151.0 47.5 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.394 -0.522 . . . . 1.0 111.759 177.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.469 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 4.1 mmtt -101.16 122.91 44.46 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 105.741 -1.948 . . . . 1.0 105.741 177.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.453 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.0 mt -117.51 119.19 60.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.956 0.884 . . . . 1.0 113.257 -176.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -109.95 124.03 50.67 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 113.935 -1.484 . . . . 1.0 108.354 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.93 111.12 23.2 Favored 'General case' 0 N--CA 1.465 0.293 0 C-N-CA 120.162 -0.615 . . . . 1.0 112.369 -178.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.477 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -94.01 -45.03 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 115.881 -0.599 . . . . 1.0 111.729 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.7 p -150.63 155.82 40.13 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.683 -0.407 . . . . 1.0 110.79 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.426 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.4 t -129.71 137.21 57.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 121.05 0.452 . . . . 1.0 111.772 -177.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 tptt . . . . . 0 N--CA 1.447 -0.581 0 CA-C-N 115.723 -0.671 . . . . 1.0 110.098 178.793 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 121.663 0.744 . . . . 1.0 110.439 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.7 m-20 -58.0 -35.11 70.77 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.255 -1.017 . . . . 1.0 108.255 179.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.505 ' O ' ' N ' ' A' ' 13' ' ' GLU . 18.7 tttm -65.22 -51.07 63.26 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.691 178.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.52 -46.67 82.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 119.974 -0.69 . . . . 1.0 111.538 -178.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.51 -37.11 86.04 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.418 -1.327 . . . . 1.0 107.418 178.728 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.466 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -72.71 -41.37 50.44 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 114.758 -1.11 . . . . 1.0 112.213 179.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.505 ' N ' ' O ' ' A' ' 9' ' ' LYS . 49.0 mt-10 -62.83 -31.73 72.79 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.719 -0.845 . . . . 1.0 108.719 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.79 -37.08 59.51 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 115.099 -0.955 . . . . 1.0 109.483 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -60.92 -51.01 71.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.199 -1.364 . . . . 1.0 110.789 -179.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.466 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.7 mp -69.01 -37.9 78.93 Favored 'General case' 0 CA--C 1.512 -0.497 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.583 178.206 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 93.9 m -61.03 -43.67 98.55 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.757 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -76.34 -45.63 31.25 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.813 -0.63 . . . . 1.0 112.58 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.639 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.4 t30 -60.75 -44.15 97.06 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.309 0.855 . . . . 1.0 113.309 -177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -59.65 -32.46 70.48 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.275 -0.97 . . . . 1.0 109.313 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.2 m-80 -77.96 -29.97 50.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.405 -0.816 . . . . 1.0 111.714 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 26.7 mtmt -60.45 137.69 92.29 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 120.457 -0.497 . . . . 1.0 111.499 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -55.66 149.4 49.49 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 C-N-CA 122.341 2.027 . . . . 1.0 113.726 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.34 -19.26 14.27 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-N 114.811 -1.086 . . . . 1.0 111.302 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.416 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.0 t -87.49 135.06 26.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 121.067 0.461 . . . . 1.0 110.77 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.08 121.79 66.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 107.981 -1.118 . . . . 1.0 107.981 177.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.416 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.5 p -96.74 145.87 8.22 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.622 0 CA-C-O 121.676 0.751 . . . . 1.0 111.872 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 74.7 mt -112.34 163.57 17.45 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 114.327 -1.306 . . . . 1.0 110.719 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.03 -29.91 90.35 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.058 1.839 . . . . 1.0 110.69 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.6 m -67.69 -15.54 63.69 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.284 -0.871 . . . . 1.0 109.456 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.94 -3.74 70.8 Favored Glycine 0 C--N 1.328 0.115 0 N-CA-C 109.815 -1.314 . . . . 1.0 109.815 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.6 133.51 38.43 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.5 139.26 54.08 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.284 -0.417 . . . . 1.0 110.865 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -134.95 145.81 48.52 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-O 121.642 0.734 . . . . 1.0 110.619 178.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.528 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.3 tmtp? -130.84 134.1 46.52 Favored 'General case' 0 N--CA 1.443 -0.804 0 CA-C-N 114.503 -1.226 . . . . 1.0 109.084 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -90.48 105.38 16.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 122.18 0.991 . . . . 1.0 111.54 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.636 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.7 mm -70.55 -42.36 78.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 108.594 -0.891 . . . . 1.0 108.594 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -141.82 128.93 20.88 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.816 -1.084 . . . . 1.0 109.767 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.5 p -87.89 123.06 32.26 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.956 0.408 . . . . 1.0 110.182 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.81 -36.22 1.73 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.602 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.7 m120 57.58 32.46 21.87 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.22 -0.49 . . . . 1.0 111.64 179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.24 -161.65 37.41 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.907 0.726 . . . . 1.0 111.408 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.594 ' O ' ' N ' ' A' ' 95' ' ' ALA . 31.2 m -69.48 -177.92 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.17 -1.015 . . . . 1.0 109.374 178.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.565 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.75 154.59 0.48 Allowed Pre-proline 0 C--N 1.319 -0.729 0 O-C-N 123.569 0.543 . . . . 1.0 110.11 179.646 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.7 Cg_endo -87.75 154.29 7.44 Favored 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.697 2.932 . . . . 1.0 117.055 -174.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -84.8 175.74 50.59 Favored Glycine 0 C--N 1.334 0.42 0 N-CA-C 109.601 -1.4 . . . . 1.0 109.601 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.884 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.31 -22.34 11.75 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.315 -0.443 . . . . 1.0 111.667 -179.328 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.4 m -109.18 -7.17 15.34 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 112.651 0.612 . . . . 1.0 112.651 -178.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.436 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 78.7 m-20 -82.83 167.88 17.67 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.182 -0.303 . . . . 1.0 110.182 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.3 m -107.5 147.75 30.1 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-O 121.06 0.457 . . . . 1.0 109.949 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.45 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.3 p -127.17 163.05 30.91 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 CA-C-N 115.705 -0.679 . . . . 1.0 111.591 -176.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.42 HG22 ' HB3' ' A' ' 74' ' ' PRO . 95.3 m -129.78 120.15 24.57 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 108.077 -1.083 . . . . 1.0 108.077 177.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.485 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.3 m -148.38 165.62 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 114.227 1.195 . . . . 1.0 114.227 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.4 mt-10 -118.69 147.92 43.3 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 105.913 -1.884 . . . . 1.0 105.913 173.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.476 ' H ' ' HB ' ' A' ' 68' ' ' THR . 30.0 p90 -161.48 162.84 30.57 Favored 'General case' 0 C--N 1.343 0.292 0 N-CA-C 114.769 1.396 . . . . 1.0 114.769 -177.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.7 m -126.06 132.9 51.85 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.872 175.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.87 134.92 11.77 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 111.302 -0.719 . . . . 1.0 111.302 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.572 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 6.2 ptp85 -143.65 163.61 32.75 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-O 121.553 0.692 . . . . 1.0 111.929 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.0 mp -85.01 162.54 19.31 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.664 -1.153 . . . . 1.0 109.844 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.452 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -57.64 -25.82 25.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.305 -0.861 . . . . 1.0 110.395 178.517 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -93.34 2.98 56.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 114.279 -1.328 . . . . 1.0 111.603 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -6.14 79.18 Favored Glycine 0 CA--C 1.525 0.68 0 C-N-CA 121.069 -0.586 . . . . 1.0 112.832 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.2 m -65.0 105.3 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 119.548 -0.861 . . . . 1.0 109.103 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.3 t -74.08 117.3 17.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 C-N-CA 120.225 -0.59 . . . . 1.0 110.072 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -103.52 -10.47 18.48 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.064 -0.971 . . . . 1.0 112.228 -179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -168.12 155.34 8.03 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 119.838 -0.745 . . . . 1.0 111.636 177.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 60.1 p -157.84 154.8 28.59 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.656 -0.702 . . . . 1.0 111.914 179.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.476 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 95.9 m -153.28 -40.7 0.1 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.528 -0.76 . . . . 1.0 110.357 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.404 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.8 pp20? -63.0 -26.27 68.77 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.657 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -52.11 -44.24 64.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 108.279 -1.008 . . . . 1.0 108.279 179.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 68' ' ' THR . 16.5 p -79.64 -27.94 40.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.707 -1.133 . . . . 1.0 109.246 177.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.11 16.2 77.12 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.441 -0.8 . . . . 1.0 111.74 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.42 114.95 64.27 Favored Pre-proline 0 N--CA 1.47 0.545 0 C-N-CA 120.553 -0.459 . . . . 1.0 110.628 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.424 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 36.1 Cg_exo -61.24 152.49 71.81 Favored 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 121.809 1.673 . . . . 1.0 114.601 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.87 152.17 42.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.048 -1.433 . . . . 1.0 107.247 177.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.7 t -110.42 131.2 55.26 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.605 0.717 . . . . 1.0 112.771 -178.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -136.58 154.7 50.62 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.824 -1.08 . . . . 1.0 109.652 178.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -96.32 124.03 40.17 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 105.801 -1.926 . . . . 1.0 105.801 174.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.7 t -47.39 -29.14 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.398 -176.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.9 t -75.86 -24.3 55.72 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 111.974 0.361 . . . . 1.0 111.974 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 92.3 mm-40 -98.23 -12.71 21.35 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.353 0.871 . . . . 1.0 113.353 -177.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.426 HG22 ' H ' ' A' ' 83' ' ' ILE . 4.1 p -83.93 169.12 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.101 -0.64 . . . . 1.0 112.022 -177.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.426 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.12 148.72 21.06 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 -177.354 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.63 -43.14 47.18 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.794 1.662 . . . . 1.0 112.833 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.85 -48.69 80.44 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 119.517 -1.325 . . . . 1.0 109.852 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.485 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 8.7 m95 -63.26 -38.14 90.01 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 113.902 -1.149 . . . . 1.0 110.438 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.9 m -51.13 -53.53 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.265 -0.425 . . . . 1.0 111.594 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -72.42 -41.59 66.03 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.642 0.608 . . . . 1.0 112.642 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.64 -48.21 82.56 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.917 1.08 . . . . 1.0 113.917 -177.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.0 mt -56.93 -39.95 75.47 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 121.133 0.492 . . . . 1.0 110.511 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -63.05 -23.24 67.36 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.607 -0.724 . . . . 1.0 110.753 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.432 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 45.5 mt -105.25 -11.4 16.54 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.307 -0.406 . . . . 1.0 110.935 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 33.4 ttm -86.04 106.81 10.83 Favored Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.669 0.606 . . . . 1.0 111.89 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.565 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 14.6 Cg_exo -68.46 145.7 65.72 Favored 'Trans proline' 0 N--CA 1.501 1.964 0 C-N-CA 122.576 2.184 . . . . 1.0 113.008 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.594 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.55 132.96 54.18 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.53 -0.759 . . . . 1.0 111.17 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.95 -17.82 58.61 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 109.147 -1.581 . . . . 1.0 109.147 -179.067 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -88.86 136.46 33.0 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-O 120.838 0.351 . . . . 1.0 110.247 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 57.3 m -107.61 113.76 27.27 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.979 -0.555 . . . . 1.0 109.752 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.432 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.6 m0 -115.51 164.68 13.95 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.728 0.775 . . . . 1.0 110.902 -178.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.636 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.7 mt-10 -126.25 126.01 43.31 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 106.943 -1.503 . . . . 1.0 106.943 175.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.4 137.12 56.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.733 0 CA-C-O 121.704 0.764 . . . . 1.0 109.649 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.707 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.53 103.59 12.74 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 105.894 -1.891 . . . . 1.0 105.894 -177.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.53 115.54 64.39 Favored Pre-proline 0 C--N 1.326 -0.438 0 N-CA-C 115.077 1.51 . . . . 1.0 115.077 -174.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -51.52 146.72 24.99 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.578 1.519 . . . . 1.0 109.748 176.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 58.4 p -51.6 -36.43 45.62 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.192 -0.603 . . . . 1.0 110.901 -178.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.29 -32.52 83.99 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.251 -0.74 . . . . 1.0 111.251 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.0 mt -99.26 1.51 44.75 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.498 -0.186 . . . . 1.0 110.498 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -109.28 -103.34 0.37 Allowed 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 120.352 0.12 . . . . 1.0 110.819 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 -107.6 5.97 27.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 114.915 1.45 . . . . 1.0 114.915 -176.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.15 169.43 22.2 Favored Glycine 0 N--CA 1.473 1.127 0 C-N-CA 120.245 -0.978 . . . . 1.0 114.139 176.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 121' ' ' ASN . 57.0 Cg_endo -78.47 -12.76 15.29 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 123.697 2.931 . . . . 1.0 110.645 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 113' ' ' SER . 60.0 ttt180 -104.77 165.55 10.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.75 -1.113 . . . . 1.0 109.403 -179.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.56 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 3.5 m -76.28 97.65 4.25 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.171 -0.677 . . . . 1.0 109.171 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -108.74 61.38 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.576 -0.283 . . . . 1.0 110.597 -179.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.532 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 169.22 -170.84 42.8 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 120.455 -0.879 . . . . 1.0 112.188 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -66.09 -105.19 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 N-CA-C 111.842 -0.503 . . . . 1.0 111.842 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.03 -16.08 47.71 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.439 2.093 . . . . 1.0 111.387 -178.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.555 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.6 mp -66.97 114.24 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 109.26 -0.645 . . . . 1.0 109.26 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.411 ' N ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.26 -168.14 42.44 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 110.566 -1.014 . . . . 1.0 110.566 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.566 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 39.3 Cg_endo -65.53 142.62 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.257 1.971 . . . . 1.0 113.34 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.471 ' ND2' ' O ' ' A' ' 121' ' ' ASN . 2.1 t30 50.55 53.62 12.62 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.158 -0.474 . . . . 1.0 111.859 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.427 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 54.9 mm-40 -99.76 133.01 44.74 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.146 -0.479 . . . . 1.0 111.527 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.436 HG21 HD11 ' A' ' 16' ' ' LEU . 52.8 m -93.86 128.58 40.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 106.571 -1.641 . . . . 1.0 106.571 175.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.4 ' N ' HD22 ' A' ' 124' ' ' LEU . 2.0 mm? -112.13 138.86 48.22 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.394 0.616 . . . . 1.0 111.096 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.707 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -118.6 145.22 24.93 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.679 0 CA-C-N 114.976 -1.011 . . . . 1.0 108.523 178.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.561 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -136.89 150.78 48.45 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 120.217 -0.593 . . . . 1.0 111.201 177.129 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.572 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 5.3 mmtt -100.14 122.39 42.9 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 105.031 -2.211 . . . . 1.0 105.031 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.42 118.27 57.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 C-N-CA 119.395 -0.922 . . . . 1.0 112.432 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.445 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.2 t-160 -108.67 123.6 49.22 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 114.121 -1.4 . . . . 1.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.82 111.31 23.32 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 120.478 -0.489 . . . . 1.0 112.197 -177.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.472 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -94.3 -45.05 13.61 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.486 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.1 p -151.07 155.81 39.76 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.305 0.574 . . . . 1.0 111.137 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.451 HG21 ' HA ' ' A' ' 44' ' ' LYS . 45.8 t -128.8 135.91 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.757 -0.656 . . . . 1.0 109.958 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.6 tptm . . . . . 0 N--CA 1.443 -0.782 0 CA-C-O 121.87 0.843 . . . . 1.0 111.586 -179.233 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 . . . . . 0 CA--C 1.518 -0.27 0 CA-C-O 121.502 0.668 . . . . 1.0 111.12 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 9.5 m-20 -62.85 -37.09 85.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 107.81 -1.182 . . . . 1.0 107.81 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 64.6 tttt -65.95 -51.38 59.04 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 113.297 -1.774 . . . . 1.0 111.485 179.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.2 t -67.31 -46.59 83.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 C-N-CA 120.238 -0.585 . . . . 1.0 111.423 -179.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.543 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 1.2 mptp? -62.05 -38.94 90.66 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.649 -1.241 . . . . 1.0 107.649 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.486 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -71.6 -44.55 49.26 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 114.629 -1.169 . . . . 1.0 112.444 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -59.71 -34.1 72.47 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.526 -0.916 . . . . 1.0 108.526 179.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.87 -37.08 62.26 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.892 -1.049 . . . . 1.0 110.111 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.19 -49.33 78.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.753 -1.112 . . . . 1.0 111.198 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.486 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.78 -38.26 79.88 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.14 -0.624 . . . . 1.0 109.385 178.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 55.9 m -60.76 -43.47 97.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.352 -0.84 . . . . 1.0 109.688 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -76.9 -44.69 30.86 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.85 -0.614 . . . . 1.0 111.973 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.649 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 54.6 t30 -60.33 -44.78 95.17 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.475 0.917 . . . . 1.0 113.475 -177.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -58.26 -31.7 67.69 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 119.441 -0.904 . . . . 1.0 109.613 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -80.98 -27.61 35.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.734 -0.667 . . . . 1.0 111.683 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.1 mtmt -59.47 146.22 80.21 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 120.335 -0.546 . . . . 1.0 111.517 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.45 148.93 59.8 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.543 2.162 . . . . 1.0 114.048 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.65 -18.48 2.96 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 115.167 -0.924 . . . . 1.0 112.576 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -83.75 134.66 26.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.549 -0.46 . . . . 1.0 110.202 -179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.2 121.96 66.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 107.838 -1.171 . . . . 1.0 107.838 177.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.9 p -93.53 146.16 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 CA-C-O 121.637 0.732 . . . . 1.0 111.981 -177.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 97.9 mt -113.03 163.17 18.68 Favored Pre-proline 0 N--CA 1.461 0.119 0 CA-C-N 114.469 -1.242 . . . . 1.0 110.892 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -60.32 -30.71 91.63 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.844 1.696 . . . . 1.0 111.249 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -69.44 -11.16 60.59 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.828 -0.624 . . . . 1.0 109.737 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.02 -2.49 75.77 Favored Glycine 0 C--O 1.229 -0.174 0 N-CA-C 109.949 -1.26 . . . . 1.0 109.949 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.442 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.08 133.7 36.13 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 108.59 -0.893 . . . . 1.0 108.59 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.442 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.6 mp0 -121.82 138.53 54.34 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 116.319 -0.4 . . . . 1.0 111.086 -179.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -133.5 146.55 51.19 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-O 121.591 0.71 . . . . 1.0 111.089 178.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.497 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.7 tmtp? -129.86 135.8 48.81 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.495 -1.23 . . . . 1.0 109.233 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.25 104.67 15.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-O 122.153 0.978 . . . . 1.0 112.248 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.0 mm -70.69 -42.36 77.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.249 -0.887 . . . . 1.0 108.848 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -144.07 127.33 16.71 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.845 -1.071 . . . . 1.0 110.634 -178.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.2 p -84.51 126.9 33.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.043 0.449 . . . . 1.0 110.499 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -115.86 -36.78 1.11 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.663 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 56.49 30.39 17.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.465 -0.367 . . . . 1.0 111.187 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.07 -159.68 35.86 Favored Glycine 0 C--N 1.334 0.421 0 CA-C-O 121.87 0.706 . . . . 1.0 111.955 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.603 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.0 m -69.57 -178.73 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.239 -0.981 . . . . 1.0 109.411 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.546 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 155.14 0.38 Allowed Pre-proline 0 C--N 1.319 -0.731 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.785 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.1 Cg_endo -87.76 161.49 7.69 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 123.011 2.474 . . . . 1.0 115.273 -175.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.2 171.45 32.5 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 108.049 -2.02 . . . . 1.0 108.049 175.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.613 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -45.75 -24.9 0.42 Allowed 'General case' 0 C--N 1.297 -1.701 0 CA-C-N 114.59 -0.805 . . . . 1.0 111.374 178.452 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.0 m -107.63 -9.64 15.83 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.863 1.06 . . . . 1.0 113.863 -177.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -85.37 166.34 16.5 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 119.39 -0.924 . . . . 1.0 109.136 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.3 m -104.16 146.97 27.99 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.167 -0.679 . . . . 1.0 109.167 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.401 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.1 p -124.39 160.3 29.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 112.554 0.575 . . . . 1.0 112.554 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.4 HG22 ' HB3' ' A' ' 74' ' ' PRO . 87.6 m -127.23 119.51 26.54 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.408 -0.96 . . . . 1.0 108.408 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.453 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 5.3 m -148.84 165.76 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 113.968 1.099 . . . . 1.0 113.968 -176.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 9.3 mt-10 -118.53 151.25 38.2 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 35.2 p90 -164.23 161.88 22.29 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 114.536 1.31 . . . . 1.0 114.536 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -123.51 127.04 47.78 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.201 -0.908 . . . . 1.0 108.691 175.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.25 136.38 13.54 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.93 -0.652 . . . . 1.0 111.775 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -147.25 166.49 26.88 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 121.805 0.812 . . . . 1.0 112.395 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.5 mp -83.16 164.07 20.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 114.129 -1.396 . . . . 1.0 110.037 177.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.471 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.38 -24.38 30.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.127 -0.942 . . . . 1.0 110.139 177.889 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -93.1 2.58 56.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 113.855 -1.52 . . . . 1.0 111.741 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.36 -4.69 80.52 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.19 -0.529 . . . . 1.0 112.735 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -69.76 105.06 2.62 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.682 -0.807 . . . . 1.0 110.212 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.5 t -73.66 122.06 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.139 0.495 . . . . 1.0 110.471 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.424 ' HB2' HD11 ' A' ' 118' ' ' ILE . 30.7 p90 -110.76 -15.54 13.8 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 115.145 -0.934 . . . . 1.0 111.75 -179.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.503 ' OD2' ' N ' ' A' ' 67' ' ' SER . 55.4 t0 -155.49 147.31 23.25 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 120.704 -0.399 . . . . 1.0 110.883 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.503 ' N ' ' OD2' ' A' ' 66' ' ' ASP . 97.5 p -154.25 152.71 30.63 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.217 -0.447 . . . . 1.0 111.612 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 84.9 m -156.58 -38.05 0.08 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.031 -0.531 . . . . 1.0 111.289 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.412 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 2.0 pp20? -65.99 -26.77 67.7 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.203 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -57.46 -39.7 76.9 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 108.173 -1.047 . . . . 1.0 108.173 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.41 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.9 p -81.76 -27.03 34.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.94 -1.027 . . . . 1.0 108.493 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 76.63 16.99 80.3 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.384 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.429 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.3 mptp? -97.35 114.79 65.34 Favored Pre-proline 0 N--CA 1.471 0.622 0 C-N-CA 120.855 -0.338 . . . . 1.0 110.419 -179.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 37.3 Cg_exo -61.99 154.19 63.54 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 121.916 1.744 . . . . 1.0 114.457 -178.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -126.05 150.61 48.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.262 -1.335 . . . . 1.0 108.407 178.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -104.57 134.35 47.9 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 113.006 0.743 . . . . 1.0 113.006 -178.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -142.42 148.76 38.33 Favored 'General case' 0 CA--C 1.495 -1.141 0 CA-C-N 115.009 -0.996 . . . . 1.0 110.602 178.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 -90.31 124.5 34.96 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.004 -1.85 . . . . 1.0 106.004 175.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.0 t -52.07 -32.05 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 C-N-CA 119.774 -0.771 . . . . 1.0 110.509 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -74.02 -27.56 61.01 Favored 'General case' 0 CA--C 1.514 -0.413 0 C-N-CA 120.248 -0.581 . . . . 1.0 112.138 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 70.9 mm-40 -101.29 -12.62 18.53 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 113.348 0.87 . . . . 1.0 113.348 -178.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.505 HG22 ' H ' ' A' ' 83' ' ' ILE . 4.5 p -71.04 172.03 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 119.288 -0.965 . . . . 1.0 109.94 -177.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.505 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -53.8 148.36 20.1 Favored Pre-proline 0 CA--C 1.55 0.945 0 N-CA-C 108.812 -0.81 . . . . 1.0 108.812 -178.803 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.493 ' HD2' HG22 ' A' ' 83' ' ' ILE . 85.1 Cg_exo -49.42 -47.51 22.2 Favored 'Trans proline' 0 N--CA 1.503 2.084 0 C-N-CA 122.151 1.9 . . . . 1.0 113.773 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.3 -48.16 77.15 Favored Glycine 0 C--N 1.318 -0.44 0 N-CA-C 110.021 -1.232 . . . . 1.0 110.021 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.453 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.8 m95 -63.78 -34.14 77.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 114.047 -1.076 . . . . 1.0 111.562 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -51.94 -54.1 33.48 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.744 -0.382 . . . . 1.0 110.888 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -74.17 -44.29 54.02 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.177 0.806 . . . . 1.0 113.177 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -55.71 -44.37 77.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 113.796 1.035 . . . . 1.0 113.796 -177.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.3 mt -58.47 -41.52 85.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.243 0.544 . . . . 1.0 110.142 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -65.7 -23.09 66.69 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.252 -0.885 . . . . 1.0 111.145 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.485 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 55.1 mt -103.09 -9.94 19.3 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.596 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 5.2 ttt -91.11 107.14 18.99 Favored Pre-proline 0 CA--C 1.549 0.942 0 O-C-N 123.729 0.643 . . . . 1.0 111.638 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.546 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.9 Cg_exo -66.37 149.11 85.01 Favored 'Trans proline' 0 N--CA 1.499 1.846 0 C-N-CA 122.904 2.402 . . . . 1.0 112.656 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.603 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.96 136.16 55.7 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 115.422 -0.808 . . . . 1.0 111.459 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.02 -19.74 51.4 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.415 -1.874 . . . . 1.0 108.415 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -85.99 134.49 33.85 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.053 0.454 . . . . 1.0 110.269 178.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.4 m -108.26 115.01 29.32 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.689 -0.687 . . . . 1.0 109.659 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.485 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.5 m0 -116.12 166.87 11.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.528 0.68 . . . . 1.0 110.79 -179.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.4 mt-10 -126.9 128.57 46.68 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 106.683 -1.599 . . . . 1.0 106.683 175.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.401 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -123.16 138.2 53.96 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 CA-C-O 121.809 0.814 . . . . 1.0 109.699 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.752 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.31 103.71 12.7 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 105.424 -2.065 . . . . 1.0 105.424 -177.905 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.5 t -90.73 116.12 65.71 Favored Pre-proline 0 C--N 1.327 -0.4 0 N-CA-C 114.674 1.361 . . . . 1.0 114.674 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -51.03 144.67 27.44 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 121.261 1.307 . . . . 1.0 109.79 176.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 55.3 p -50.49 -35.44 29.2 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.338 -0.545 . . . . 1.0 110.561 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.58 -32.78 84.32 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.19 -0.764 . . . . 1.0 111.19 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 82.8 mt -98.92 1.3 45.51 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 121.314 -0.154 . . . . 1.0 110.655 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.18 -106.62 0.34 Allowed 'General case' 0 C--N 1.342 0.264 0 N-CA-C 111.643 0.238 . . . . 1.0 111.643 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -101.97 5.05 40.56 Favored 'General case' 0 C--N 1.341 0.234 0 N-CA-C 113.705 1.002 . . . . 1.0 113.705 -177.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 99.93 167.28 29.36 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 120.645 -0.788 . . . . 1.0 114.043 176.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.513 ' O ' ' N ' ' A' ' 121' ' ' ASN . 73.8 Cg_endo -70.97 -19.99 29.66 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 C-N-CA 123.742 2.962 . . . . 1.0 113.038 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.423 HH11 ' HG2' ' A' ' 111' ' ' PRO . 11.7 mpt_? -93.74 167.15 11.84 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.009 -0.367 . . . . 1.0 110.009 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 5.7 m -74.46 76.32 1.93 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 177.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.0 t -92.21 61.53 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.268 -0.423 . . . . 1.0 110.967 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.97 179.61 42.27 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 120.967 -0.635 . . . . 1.0 111.516 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -60.66 -107.14 0.01 OUTLIER Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.449 -0.66 . . . . 1.0 111.449 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -59.24 -13.15 18.64 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 C-N-CA 122.222 1.948 . . . . 1.0 110.725 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.884 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.3 mp -66.74 113.17 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 N-CA-C 108.185 -1.043 . . . . 1.0 108.185 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -91.66 -166.9 40.25 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 110.548 -1.021 . . . . 1.0 110.548 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.554 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 37.6 Cg_endo -64.09 147.21 91.59 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.14 1.893 . . . . 1.0 112.7 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 44.82 57.53 4.53 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.96 -0.564 . . . . 1.0 112.072 178.219 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 53.9 mm-40 -102.64 132.06 49.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.28 0.562 . . . . 1.0 112.334 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.474 HG21 HD11 ' A' ' 16' ' ' LEU . 36.2 m -96.34 129.08 43.76 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 106.418 -1.697 . . . . 1.0 106.418 175.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.98 146.17 40.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.387 0.613 . . . . 1.0 111.042 -179.057 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.752 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -123.58 148.28 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.764 0 CA-C-N 115.088 -0.96 . . . . 1.0 108.543 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -139.41 151.43 46.27 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 120.286 -0.566 . . . . 1.0 111.288 177.848 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.519 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 11.4 mmtt -100.15 124.88 46.07 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.162 -2.162 . . . . 1.0 105.162 176.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.7 mt -119.35 119.21 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 119.075 -1.05 . . . . 1.0 111.998 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -111.85 125.42 54.0 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.048 -1.433 . . . . 1.0 108.714 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.02 114.51 26.71 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 112.869 0.692 . . . . 1.0 112.869 -178.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.499 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -96.05 -45.42 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 115.992 -0.549 . . . . 1.0 110.88 178.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.3 p -151.29 157.78 42.98 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 120.877 0.37 . . . . 1.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.436 HG21 ' HA ' ' A' ' 44' ' ' LYS . 58.1 t -127.37 134.66 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-O 121.325 0.583 . . . . 1.0 111.451 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.533 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 21.6 tptt . . . . . 0 N--CA 1.449 -0.519 0 CA-C-N 115.152 -0.931 . . . . 1.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 . . . . . 0 CA--C 1.513 -0.47 0 CA-C-O 121.886 0.85 . . . . 1.0 110.24 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.571 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.0 m-20 -57.48 -35.64 70.45 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.737 -1.12 . . . . 1.0 108.543 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 45.1 tttt -64.74 -50.64 66.09 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 113.793 -1.549 . . . . 1.0 111.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.7 t -72.31 -47.52 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 119.964 -0.694 . . . . 1.0 112.152 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.463 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.4 OUTLIER -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.305 -0.998 . . . . 1.0 108.305 -179.919 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.95 -46.86 50.01 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 115.188 -0.915 . . . . 1.0 112.546 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -58.68 -34.26 71.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 108.804 -0.813 . . . . 1.0 108.804 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.55 -36.55 63.12 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.183 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -62.35 -49.37 75.85 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.579 -1.191 . . . . 1.0 111.134 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -70.75 -39.61 73.19 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 119.954 -0.698 . . . . 1.0 109.922 178.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.469 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 75.6 m -60.97 -43.35 98.92 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.443 -0.798 . . . . 1.0 109.702 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -76.28 -46.07 29.61 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.91 -0.587 . . . . 1.0 111.816 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.654 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 55.4 t30 -59.88 -44.58 94.1 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.473 0.916 . . . . 1.0 113.473 -177.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.75 -31.61 68.5 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.337 -0.945 . . . . 1.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.469 ' ND2' ' O ' ' A' ' 17' ' ' THR . 50.0 m-80 -77.54 -34.23 53.97 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.514 -0.766 . . . . 1.0 111.653 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -57.94 137.03 83.71 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 120.628 -0.429 . . . . 1.0 111.76 -177.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.13 148.84 57.11 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 122.167 1.911 . . . . 1.0 113.442 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.13 -20.84 14.16 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.972 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.6 t -85.16 135.71 24.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.0 109.789 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.1 t -120.74 121.37 65.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.743 -1.206 . . . . 1.0 107.743 178.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.0 p -97.63 144.8 10.39 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.677 0 CA-C-O 121.746 0.784 . . . . 1.0 111.773 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 95.2 mt -111.32 164.28 15.37 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.314 -1.312 . . . . 1.0 110.688 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -60.84 -30.82 90.87 Favored 'Trans proline' 0 N--CA 1.485 0.983 0 C-N-CA 121.72 1.613 . . . . 1.0 110.83 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -67.81 -12.1 59.91 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.568 -0.742 . . . . 1.0 109.346 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.9 -1.59 78.28 Favored Glycine 0 C--O 1.228 -0.269 0 N-CA-C 109.962 -1.255 . . . . 1.0 109.962 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.474 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.1 tm? -78.68 133.66 37.18 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 108.375 -0.972 . . . . 1.0 108.375 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.447 ' HG3' ' HA ' ' A' ' 27' ' ' VAL . 24.3 mp0 -122.23 137.46 54.83 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.681 -0.236 . . . . 1.0 111.289 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -134.23 142.65 47.43 Favored 'General case' 0 CA--C 1.506 -0.725 0 CA-C-O 121.638 0.733 . . . . 1.0 111.116 178.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.529 ' HD3' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -123.9 130.89 53.32 Favored 'General case' 0 CA--C 1.503 -0.831 0 CA-C-N 114.528 -1.215 . . . . 1.0 109.216 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -88.92 104.48 14.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 122.294 1.045 . . . . 1.0 112.025 -178.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.604 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.1 mm -69.42 -41.84 80.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 114.766 -1.107 . . . . 1.0 108.471 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -144.26 126.1 15.27 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.522 -1.217 . . . . 1.0 109.752 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.8 p -85.23 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.027 0.441 . . . . 1.0 110.487 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.4 ' H ' ' HB3' ' A' ' 97' ' ' SER . . . -116.11 -37.54 1.02 Allowed Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.247 -1.141 . . . . 1.0 110.247 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.651 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 58.02 31.67 20.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.541 -0.329 . . . . 1.0 111.399 179.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.83 -159.78 35.64 Favored Glycine 0 C--N 1.333 0.376 0 CA-C-O 122.316 0.953 . . . . 1.0 112.51 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.608 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.9 m -69.68 -177.93 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 113.627 -1.286 . . . . 1.0 108.951 178.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.58 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.29 155.25 0.4 Allowed Pre-proline 0 C--N 1.318 -0.784 0 O-C-N 123.619 0.574 . . . . 1.0 109.932 179.459 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.445 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 58.4 Cg_endo -87.7 156.4 7.57 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 123.305 2.67 . . . . 1.0 115.941 -174.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.35 176.59 45.17 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 108.874 -1.691 . . . . 1.0 108.874 176.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.519 ' CE ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.06 -22.38 15.82 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 120.501 -0.48 . . . . 1.0 111.517 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.449 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 35.8 m -106.97 -7.33 17.03 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.874 0.694 . . . . 1.0 112.874 -177.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -84.58 170.81 13.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.952 -0.388 . . . . 1.0 109.952 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.3 m -110.76 147.04 35.28 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.285 0.564 . . . . 1.0 109.907 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.445 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.2 p -127.9 163.11 32.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 115.357 -0.838 . . . . 1.0 112.676 -175.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.407 HG22 ' HB3' ' A' ' 74' ' ' PRO . 68.1 m -130.12 121.21 25.9 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.589 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.1 m -149.02 165.76 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 114.635 1.346 . . . . 1.0 114.635 -176.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 3.0 mt-10 -118.08 147.28 43.42 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.991 -1.855 . . . . 1.0 105.991 174.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.1 p90 -164.7 168.89 17.52 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 114.525 1.306 . . . . 1.0 114.525 -176.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -131.78 129.25 40.3 Favored 'General case' 0 C--O 1.217 -0.658 0 CA-C-N 114.771 -1.104 . . . . 1.0 108.267 175.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.65 131.73 9.84 Favored Glycine 0 N--CA 1.473 1.115 0 N-CA-C 111.292 -0.723 . . . . 1.0 111.292 -179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 11.7 ptp180 -146.4 167.3 23.94 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.705 0.764 . . . . 1.0 112.219 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.9 mp -82.48 164.17 21.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.325 -1.307 . . . . 1.0 110.063 177.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.456 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -61.37 -24.44 33.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 122.411 1.1 . . . . 1.0 109.858 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.425 ' H ' HD13 ' A' ' 60' ' ' ILE . 53.6 t0 -89.71 -0.02 57.27 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 113.21 -1.813 . . . . 1.0 111.882 -177.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.04 -1.71 78.07 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.904 -0.665 . . . . 1.0 112.317 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -71.82 102.46 2.87 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 119.805 -0.758 . . . . 1.0 110.021 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.2 127.41 36.77 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.519 0.676 . . . . 1.0 110.507 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 29.3 p90 -121.14 -11.07 8.91 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 114.705 -1.134 . . . . 1.0 111.486 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -154.46 143.87 21.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.132 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 20.5 p -157.93 156.12 30.71 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 113.038 0.755 . . . . 1.0 113.038 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 55' ' ' TYR . 65.3 m -159.15 -45.57 0.06 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 114.861 -1.063 . . . . 1.0 110.72 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -58.63 -26.1 63.38 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 116.391 -0.368 . . . . 1.0 110.114 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.8 mmtt -49.51 -41.08 39.91 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.523 -1.288 . . . . 1.0 107.523 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 27.6 p -83.31 -32.26 26.42 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 113.923 -1.489 . . . . 1.0 109.668 177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.64 13.16 81.98 Favored Glycine 0 C--N 1.332 0.338 0 N-CA-C 110.954 -0.858 . . . . 1.0 110.954 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -94.18 116.91 66.99 Favored Pre-proline 0 N--CA 1.466 0.34 0 C-N-CA 121.104 -0.238 . . . . 1.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.413 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 39.6 Cg_exo -61.1 150.7 83.09 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 121.972 1.781 . . . . 1.0 115.112 -177.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -125.65 150.81 47.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 114.107 -1.406 . . . . 1.0 108.301 177.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.04 135.42 47.52 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 113.593 0.96 . . . . 1.0 113.593 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -142.24 153.89 44.33 Favored 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.162 -0.926 . . . . 1.0 109.449 177.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -90.75 130.35 36.74 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.912 -1.884 . . . . 1.0 105.912 173.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.7 -29.98 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 C-N-CA 119.734 -0.786 . . . . 1.0 110.506 -177.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.0 t -73.32 -25.21 60.55 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 120.244 -0.582 . . . . 1.0 112.212 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 62.6 mm-40 -98.14 -15.39 19.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.553 0.575 . . . . 1.0 112.553 -178.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.414 HG22 ' H ' ' A' ' 83' ' ' ILE . 2.0 p -78.47 172.71 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 120.021 -0.672 . . . . 1.0 111.147 -176.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.447 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -56.48 151.24 30.19 Favored Pre-proline 0 CA--C 1.55 0.974 0 C-N-CA 119.973 -0.691 . . . . 1.0 110.814 -178.362 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HD2' HG22 ' A' ' 83' ' ' ILE . 54.1 Cg_exo -53.89 -46.26 34.97 Favored 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 122.13 1.887 . . . . 1.0 112.876 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.4 -47.82 80.26 Favored Glycine 0 N--CA 1.451 -0.336 0 N-CA-C 109.132 -1.587 . . . . 1.0 109.132 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.589 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.7 m95 -64.29 -39.0 93.04 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 113.542 -1.329 . . . . 1.0 109.669 178.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 m -51.76 -53.61 37.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 1.0 111.185 -178.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -72.4 -40.88 66.84 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.23 -48.17 82.85 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 113.995 1.109 . . . . 1.0 113.995 -177.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 52.1 mt -57.95 -40.85 81.56 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 121.545 0.688 . . . . 1.0 109.814 -178.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -63.89 -24.53 67.77 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.839 -1.073 . . . . 1.0 111.221 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.8 mt -101.86 -15.64 16.82 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.394 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . 0.507 ' CE ' ' H ' ' A' ' 99' ' ' TRP . 8.2 ttt -83.4 108.48 13.29 Favored Pre-proline 0 C--N 1.321 -0.642 0 O-C-N 123.811 0.694 . . . . 1.0 112.689 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.58 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -68.91 146.38 65.24 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.34 2.026 . . . . 1.0 112.082 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.608 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.89 136.69 57.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.472 -0.785 . . . . 1.0 111.731 -179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.7 57.08 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 108.92 -1.672 . . . . 1.0 108.92 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.4 ' HB3' ' H ' ' A' ' 40' ' ' GLY . 5.0 p -89.5 139.62 30.34 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 120.707 0.289 . . . . 1.0 110.49 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.6 m -110.31 112.48 24.46 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.004 -0.543 . . . . 1.0 109.902 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.507 ' H ' ' CE ' ' A' ' 93' ' ' MET . 40.8 m0 -115.25 161.34 18.6 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.805 0.812 . . . . 1.0 111.566 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.604 ' CD ' HD11 ' A' ' 37' ' ' ILE . 90.7 mt-10 -120.96 124.31 44.59 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 106.713 -1.588 . . . . 1.0 106.713 175.226 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -118.49 137.37 52.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-O 121.882 0.848 . . . . 1.0 110.61 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.675 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.28 103.05 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.722 -1.955 . . . . 1.0 105.722 -178.756 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 t -90.61 115.94 65.3 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 114.921 1.452 . . . . 1.0 114.921 -174.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -51.27 142.11 37.67 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 121.166 1.244 . . . . 1.0 109.868 176.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.3 p -48.11 -35.62 11.75 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 120.692 -0.403 . . . . 1.0 110.722 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.66 -33.19 85.42 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.181 -0.767 . . . . 1.0 111.181 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 71.9 mt -99.01 3.39 46.9 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.768 -0.216 . . . . 1.0 111.431 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.96 -114.98 0.28 Allowed 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.526 -0.546 . . . . 1.0 109.526 -179.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -91.25 5.06 50.62 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.821 0.344 . . . . 1.0 111.636 -179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.59 164.19 22.55 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.157 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.511 ' O ' ' N ' ' A' ' 121' ' ' ASN . 86.9 Cg_endo -74.23 -9.35 21.79 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 123.362 2.708 . . . . 1.0 110.247 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -107.7 162.95 13.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.495 -1.229 . . . . 1.0 109.745 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.5 m -72.01 89.94 1.14 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.671 -0.411 . . . . 1.0 109.939 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -104.52 62.23 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 121.118 -0.233 . . . . 1.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 164.62 -175.34 40.63 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 120.309 -0.948 . . . . 1.0 112.705 179.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.98 -104.81 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 N-CA-C 111.639 -0.584 . . . . 1.0 111.639 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -63.76 -15.36 48.39 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.545 2.163 . . . . 1.0 111.322 -178.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.674 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.8 mp -67.25 111.8 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.02 0 N-CA-C 108.295 -1.002 . . . . 1.0 108.295 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.425 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.62 -170.72 43.5 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.054 -0.976 . . . . 1.0 111.223 -179.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.571 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 28.6 Cg_endo -61.86 143.56 95.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.461 2.108 . . . . 1.0 112.788 179.178 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.8 t-20 49.07 48.84 20.39 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.792 0.664 . . . . 1.0 112.792 178.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.425 ' HG3' ' H ' ' A' ' 119' ' ' GLY . 45.9 mm-40 -93.94 129.27 40.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 113.164 0.802 . . . . 1.0 113.164 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.493 HG21 HD11 ' A' ' 16' ' ' LEU . 17.5 m -95.63 129.1 42.94 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 105.796 -1.927 . . . . 1.0 105.796 174.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.417 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.1 mm? -116.0 143.64 45.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.369 0.605 . . . . 1.0 110.69 -179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.675 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -119.54 148.11 22.74 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.649 0 CA-C-N 115.157 -0.928 . . . . 1.0 109.076 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.591 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.96 149.94 45.32 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.478 0.656 . . . . 1.0 111.527 177.356 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 8.6 mmtt -100.12 124.4 45.49 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 105.229 -2.137 . . . . 1.0 105.229 177.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.424 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.4 mt -122.01 127.61 75.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 119.497 -0.881 . . . . 1.0 112.327 -176.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.432 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.7 t-160 -118.97 124.31 46.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.321 -1.309 . . . . 1.0 107.633 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.78 110.39 22.87 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 120.225 -0.59 . . . . 1.0 112.374 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -94.34 -47.22 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.518 -0.765 . . . . 1.0 112.117 -179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.4 p -146.7 156.94 43.56 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.655 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.415 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.5 t -132.48 140.0 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.203 0.525 . . . . 1.0 111.942 -178.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.54 0.56 0 CA-C-N 115.703 -0.68 . . . . 1.0 109.613 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 . . . . . 0 CA--C 1.514 -0.433 0 CA-C-O 121.627 0.727 . . . . 1.0 110.864 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.612 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 14.3 m-20 -60.49 -35.75 76.67 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -66.16 -51.38 58.39 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.687 -1.597 . . . . 1.0 111.444 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.61 -48.03 78.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 C-N-CA 120.352 -0.539 . . . . 1.0 111.702 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.426 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.81 -38.73 91.86 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.552 -1.277 . . . . 1.0 107.552 179.119 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.5 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.15 -42.74 66.36 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 114.942 -1.027 . . . . 1.0 111.831 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -62.36 -32.18 72.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.972 -0.751 . . . . 1.0 108.972 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -35.05 49.6 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.261 -0.881 . . . . 1.0 109.878 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -61.17 -50.24 73.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 114.459 -1.246 . . . . 1.0 111.043 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.5 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.4 mp -70.92 -39.8 72.5 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.213 -0.595 . . . . 1.0 109.945 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.69 -42.63 99.19 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.541 -0.754 . . . . 1.0 109.315 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -76.71 -44.53 33.09 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-N 115.485 -0.78 . . . . 1.0 112.019 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.653 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.6 t30 -60.67 -44.77 96.09 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 113.375 0.879 . . . . 1.0 113.375 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.19 -31.93 67.76 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 119.517 -0.873 . . . . 1.0 109.237 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -79.83 -30.35 40.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.151 -0.931 . . . . 1.0 111.647 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 33.0 mtmt -58.18 136.43 84.61 Favored Pre-proline 0 CA--C 1.547 0.857 0 C-N-CA 120.425 -0.51 . . . . 1.0 111.396 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -52.92 148.66 28.76 Favored 'Trans proline' 0 N--CA 1.501 1.965 0 C-N-CA 122.271 1.981 . . . . 1.0 113.547 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -19.51 10.33 Favored Glycine 0 C--O 1.225 -0.413 0 CA-C-N 115.094 -0.957 . . . . 1.0 111.829 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.3 t -86.56 136.56 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.162 0.506 . . . . 1.0 110.896 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.7 t -120.99 123.97 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 N-CA-C 107.952 -1.129 . . . . 1.0 107.952 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.02 145.89 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-O 121.796 0.808 . . . . 1.0 112.008 -178.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.2 mt -113.03 165.18 13.7 Favored Pre-proline 0 C--O 1.231 0.126 0 CA-C-N 114.328 -1.305 . . . . 1.0 111.111 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -61.42 -30.03 86.31 Favored 'Trans proline' 0 C--N 1.32 -0.965 0 C-N-CA 122.167 1.911 . . . . 1.0 111.274 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 m -68.66 -14.97 63.37 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.713 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.5 -3.07 65.56 Favored Glycine 0 C--N 1.329 0.168 0 N-CA-C 109.688 -1.365 . . . . 1.0 109.688 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.47 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.99 133.84 36.2 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.47 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.0 mp0 -121.47 140.13 52.57 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 1.0 110.984 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -135.97 144.52 45.44 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.629 0.728 . . . . 1.0 110.935 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.54 134.8 49.74 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.427 -1.261 . . . . 1.0 109.041 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -92.82 104.04 15.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 122.158 0.98 . . . . 1.0 111.929 -178.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.648 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.4 mm -69.41 -41.48 80.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 178.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -143.73 130.01 19.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.676 -1.147 . . . . 1.0 109.697 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -86.15 131.8 34.16 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.025 -0.361 . . . . 1.0 110.025 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.75 -35.34 0.85 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.658 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 54.61 30.07 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.659 -0.271 . . . . 1.0 111.104 179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.21 -161.23 37.12 Favored Glycine 0 C--N 1.331 0.256 0 CA-C-O 121.997 0.776 . . . . 1.0 111.752 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.8 m -68.94 -178.58 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 114.128 -1.036 . . . . 1.0 109.506 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.553 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.26 154.86 0.39 Allowed Pre-proline 0 C--N 1.32 -0.708 0 CA-C-N 115.608 -0.723 . . . . 1.0 109.391 179.536 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -87.72 156.72 7.56 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 123.195 2.597 . . . . 1.0 116.054 -175.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.44 178.37 47.52 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 108.579 -1.808 . . . . 1.0 108.579 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.722 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -56.32 -20.47 19.09 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.409 -0.516 . . . . 1.0 111.153 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.2 m -108.48 -7.84 15.69 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.386 0.884 . . . . 1.0 113.386 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.57 164.59 16.01 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 120.202 -0.599 . . . . 1.0 109.466 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 6.7 m -101.88 150.53 23.09 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.156 0.503 . . . . 1.0 110.114 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.19 160.21 38.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.335 0 CA-C-N 115.374 -0.83 . . . . 1.0 111.925 -177.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.0 m -129.87 120.79 25.48 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.441 -0.948 . . . . 1.0 108.441 178.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.538 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 10.9 m -149.19 166.27 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 113.832 1.049 . . . . 1.0 113.832 -176.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.0 mt-10 -118.4 149.6 40.96 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 105.748 -1.945 . . . . 1.0 105.748 173.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.494 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.3 p90 -163.29 162.4 25.18 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 118.285 -1.366 . . . . 1.0 114.338 -177.069 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -124.33 131.78 53.53 Favored 'General case' 0 C--O 1.217 -0.654 0 N-CA-C 108.183 -1.043 . . . . 1.0 108.183 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -117.76 137.83 13.52 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.39 -0.684 . . . . 1.0 111.39 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.84 168.01 23.29 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.769 0.795 . . . . 1.0 112.183 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.1 mp -85.07 164.73 18.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.376 -1.284 . . . . 1.0 109.772 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.13 -26.07 35.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 121.925 0.869 . . . . 1.0 110.061 178.294 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -92.22 2.96 56.29 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 113.808 -1.542 . . . . 1.0 111.764 -177.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.02 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 120.932 -0.651 . . . . 1.0 112.962 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.0 m -70.05 102.44 2.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 118.105 0.952 . . . . 1.0 110.026 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -72.95 120.07 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.819 0 CA-C-O 121.465 0.65 . . . . 1.0 110.354 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.66 ' CD2' HD11 ' A' ' 118' ' ' ILE . 18.8 p90 -114.78 -8.72 12.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.641 -1.163 . . . . 1.0 111.966 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -155.1 146.45 22.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.104 -0.498 . . . . 1.0 110.692 178.184 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 87.9 p -157.49 150.08 22.97 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 115.81 -0.632 . . . . 1.0 111.681 179.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.494 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 92.4 m -156.04 -40.46 0.08 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.759 -0.655 . . . . 1.0 110.884 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -63.6 -26.06 68.51 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.222 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -55.93 -43.76 77.7 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.967 -1.124 . . . . 1.0 107.967 178.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 68' ' ' THR . 72.9 p -73.79 -34.5 64.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.878 -1.055 . . . . 1.0 108.521 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.93 16.16 70.76 Favored Glycine 0 C--N 1.334 0.453 0 CA-C-N 115.036 -0.984 . . . . 1.0 111.012 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.42 116.31 65.52 Favored Pre-proline 0 N--CA 1.471 0.576 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.592 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.407 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.8 Cg_exo -60.98 153.69 62.1 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 121.723 1.615 . . . . 1.0 114.483 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.4 150.88 45.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.307 -1.315 . . . . 1.0 107.786 178.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 t -110.29 133.81 52.89 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -143.01 152.51 42.0 Favored 'General case' 0 CA--C 1.503 -0.832 0 CA-C-N 114.577 -1.192 . . . . 1.0 109.505 178.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -92.34 125.2 36.9 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 106.334 -1.728 . . . . 1.0 106.334 174.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.6 t -47.02 -32.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 115.773 -0.649 . . . . 1.0 110.609 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.9 t -74.42 -24.41 59.09 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 120.347 -0.541 . . . . 1.0 111.859 -178.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 89.1 mm-40 -98.82 -9.2 24.69 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 112.928 0.714 . . . . 1.0 112.928 -178.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.449 HG22 ' H ' ' A' ' 83' ' ' ILE . 3.3 p -88.04 170.71 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 118.196 0.453 . . . . 1.0 111.494 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.449 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -53.46 145.02 29.58 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 120.871 -0.331 . . . . 1.0 110.58 -176.552 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.32 -44.87 36.75 Favored 'Trans proline' 0 N--CA 1.498 1.737 0 C-N-CA 121.952 1.768 . . . . 1.0 112.74 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.39 -47.48 82.64 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 109.281 -1.528 . . . . 1.0 109.281 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.538 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.7 m95 -66.22 -37.02 84.54 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 113.791 -1.205 . . . . 1.0 110.261 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.19 -53.31 36.12 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.856 -0.338 . . . . 1.0 110.942 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tp10 -71.89 -43.98 64.5 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.085 0.402 . . . . 1.0 112.085 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.94 -46.43 85.09 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 114.022 1.119 . . . . 1.0 114.022 -177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.3 -41.58 84.75 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.154 -0.618 . . . . 1.0 109.634 -178.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -65.69 -23.41 66.77 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.187 -0.915 . . . . 1.0 111.197 -179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.422 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 85.4 mt -102.93 -10.34 19.1 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.459 -0.337 . . . . 1.0 110.741 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . 0.53 ' HE3' ' H ' ' A' ' 99' ' ' TRP . 25.5 ttt -90.62 107.47 20.53 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.734 -0.666 . . . . 1.0 112.032 -178.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.553 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.0 Cg_exo -68.89 148.09 69.9 Favored 'Trans proline' 0 N--CA 1.498 1.77 0 C-N-CA 122.546 2.164 . . . . 1.0 112.361 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.585 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.67 137.67 57.47 Favored 'General case' 0 CA--C 1.509 -0.602 0 CA-C-N 115.546 -0.752 . . . . 1.0 111.664 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.16 -19.19 54.65 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 108.873 -1.691 . . . . 1.0 108.873 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.2 p -88.19 129.98 35.19 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 115.475 -0.362 . . . . 1.0 110.443 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 60.7 m -102.12 115.02 29.67 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 109.438 -0.579 . . . . 1.0 109.438 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.53 ' H ' ' HE3' ' A' ' 93' ' ' MET . 39.4 m0 -116.28 168.31 10.24 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.817 0.818 . . . . 1.0 111.278 -178.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.648 ' CD ' HD11 ' A' ' 37' ' ' ILE . 81.5 mt-10 -129.25 129.57 45.12 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 106.63 -1.619 . . . . 1.0 106.63 175.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 pt -125.58 138.45 54.42 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.533 0 CA-C-O 121.771 0.796 . . . . 1.0 109.78 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.743 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.26 103.25 12.18 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 106.021 -1.844 . . . . 1.0 106.021 -178.032 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.1 t -90.01 115.74 64.7 Favored Pre-proline 0 C--N 1.326 -0.442 0 N-CA-C 115.248 1.573 . . . . 1.0 115.248 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -51.44 143.77 34.11 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.188 1.259 . . . . 1.0 109.634 176.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 88.1 p -50.37 -33.76 21.66 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.517 -178.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.5 -32.73 82.58 Favored Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.03 -0.828 . . . . 1.0 111.03 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -99.78 1.73 43.43 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.981 -0.11 . . . . 1.0 110.859 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -111.83 0.3 Allowed 'General case' 0 C--N 1.342 0.264 0 CA-C-O 120.754 0.312 . . . . 1.0 110.816 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 -98.12 5.41 48.62 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 113.567 0.951 . . . . 1.0 113.567 -177.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.81 164.07 18.59 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 121.018 -0.61 . . . . 1.0 113.483 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 121' ' ' ASN . 93.9 Cg_endo -77.02 -9.99 17.98 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.571 2.847 . . . . 1.0 111.173 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -106.65 169.29 8.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.252 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.4 m -75.26 97.21 3.49 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.743 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.2 t -110.77 60.08 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 121.059 -0.256 . . . . 1.0 111.125 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.548 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.68 -177.95 42.34 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 120.514 -0.85 . . . . 1.0 111.998 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.04 -103.77 0.01 OUTLIER Glycine 0 CA--C 1.535 1.338 0 N-CA-C 111.141 -0.783 . . . . 1.0 111.141 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -63.21 -14.05 39.48 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.732 2.288 . . . . 1.0 111.159 -178.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.66 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.3 mp -65.86 114.93 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 108.273 -1.01 . . . . 1.0 108.273 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.432 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -95.03 -171.88 37.1 Favored Glycine 0 CA--C 1.52 0.354 0 CA-C-N 115.512 -0.767 . . . . 1.0 111.553 -178.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.529 ' N ' ' OG ' ' A' ' 113' ' ' SER . 26.3 Cg_endo -63.25 138.2 65.2 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.562 2.174 . . . . 1.0 112.535 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.539 ' C ' HD22 ' A' ' 121' ' ' ASN . 0.2 OUTLIER 53.17 51.41 15.69 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 120.962 -0.295 . . . . 1.0 111.3 178.531 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.612 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -96.74 131.27 43.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.294 -0.412 . . . . 1.0 111.6 -179.608 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.43 HG21 HD11 ' A' ' 16' ' ' LEU . 49.1 m -95.97 128.66 43.05 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.34 138.9 48.41 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.064 0.459 . . . . 1.0 110.998 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.743 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -117.91 147.35 21.42 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.583 0 CA-C-N 115.724 -0.671 . . . . 1.0 109.195 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.584 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.83 150.92 47.58 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.441 -0.504 . . . . 1.0 111.629 177.855 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.424 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.0 mmtt -100.76 123.97 45.72 Favored 'General case' 0 CA--C 1.501 -0.907 0 N-CA-C 105.807 -1.923 . . . . 1.0 105.807 177.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.468 HG23 ' CH2' ' A' ' 86' ' ' TRP . 2.9 mt -117.0 125.61 73.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 119.592 -0.843 . . . . 1.0 112.732 -176.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -118.03 124.58 48.46 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.172 -1.377 . . . . 1.0 108.484 178.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.23 114.22 25.98 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 119.746 -0.782 . . . . 1.0 112.808 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.485 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -95.46 -43.01 12.74 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 115.732 -0.667 . . . . 1.0 110.996 178.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -154.21 156.5 37.2 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.604 -0.439 . . . . 1.0 111.265 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.413 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.7 t -129.82 138.43 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.111 -0.495 . . . . 1.0 111.273 -178.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.466 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 8.9 tptm . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 1.0 109.931 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 22.7 mt-10 . . . . . 0 C--O 1.223 -0.302 0 CA-C-O 121.842 0.83 . . . . 1.0 110.104 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -58.75 -34.07 70.99 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 115.002 -0.999 . . . . 1.0 108.409 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 17.7 tttp -66.1 -51.47 57.77 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.073 -1.422 . . . . 1.0 111.493 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.3 t -67.32 -46.88 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 C-N-CA 119.845 -0.742 . . . . 1.0 111.663 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.447 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.59 -37.58 86.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.459 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.95 -44.66 29.65 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.861 -1.063 . . . . 1.0 112.317 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.435 ' N ' ' O ' ' A' ' 9' ' ' LYS . 58.3 mt-10 -60.73 -34.5 74.51 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.53 -0.915 . . . . 1.0 108.53 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.56 -36.07 65.56 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.016 -0.993 . . . . 1.0 109.826 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -61.14 -50.22 74.08 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.762 -1.108 . . . . 1.0 110.3 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 12' ' ' GLY . 4.7 mp -66.22 -38.43 87.92 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.387 -0.597 . . . . 1.0 109.387 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -61.51 -42.59 99.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.739 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -75.62 -44.61 41.93 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.6 -0.727 . . . . 1.0 111.887 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.628 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -56.98 -49.52 75.48 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -178.486 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.3 ptmt -58.93 -29.47 67.13 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.355 -0.938 . . . . 1.0 110.021 -176.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -81.79 -29.1 32.86 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.311 -0.859 . . . . 1.0 111.482 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 mtmt -60.69 145.63 87.52 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 120.625 -0.43 . . . . 1.0 112.005 -178.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.0 149.05 64.52 Favored 'Trans proline' 0 N--CA 1.507 2.296 0 C-N-CA 122.946 2.431 . . . . 1.0 114.708 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.44 -20.53 2.11 Favored Glycine 0 N--CA 1.462 0.41 0 CA-C-N 114.957 -1.02 . . . . 1.0 111.894 178.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.2 t -79.2 131.55 34.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 C-N-CA 120.138 -0.625 . . . . 1.0 109.925 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 67.4 t -116.03 120.33 64.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.103 -1.073 . . . . 1.0 108.103 177.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.6 p -93.32 145.94 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 CA-C-O 121.688 0.756 . . . . 1.0 111.366 -178.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.33 163.55 18.0 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-N 114.534 -1.212 . . . . 1.0 110.446 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.4 -30.99 92.1 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 121.668 1.579 . . . . 1.0 111.294 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.3 m -69.34 -13.44 62.38 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.676 -0.693 . . . . 1.0 110.114 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.32 -4.0 64.29 Favored Glycine 0 CA--C 1.518 0.252 0 N-CA-C 110.179 -1.169 . . . . 1.0 110.179 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.498 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.8 tm? -77.45 134.56 38.34 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 108.565 -0.902 . . . . 1.0 108.565 179.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.498 ' H ' HD22 ' A' ' 32' ' ' LEU . 14.2 mp0 -125.1 141.68 51.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 116.341 -0.391 . . . . 1.0 111.609 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.1 p90 -137.01 142.58 42.52 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.745 0.783 . . . . 1.0 112.087 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.557 ' HE3' HD13 ' A' ' 37' ' ' ILE . 6.2 ttpt -124.85 124.63 42.5 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 114.282 -1.327 . . . . 1.0 108.296 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.88 113.39 21.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 CA-C-N 115.199 -0.91 . . . . 1.0 111.107 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.557 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.7 mm -77.02 -42.15 31.77 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 CA-C-O 121.808 0.813 . . . . 1.0 109.63 178.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.533 HD22 ' HB ' ' A' ' 37' ' ' ILE . 24.8 m-80 -143.81 128.76 18.49 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.208 -1.36 . . . . 1.0 109.655 -177.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.9 p -90.83 128.57 36.77 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.941 0.401 . . . . 1.0 109.996 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.89 -32.64 1.39 Allowed Glycine 0 CA--C 1.52 0.368 0 N-CA-C 110.045 -1.222 . . . . 1.0 110.045 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.661 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 56.6 31.92 20.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.532 -0.334 . . . . 1.0 111.126 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.13 -161.01 37.0 Favored Glycine 0 C--N 1.334 0.445 0 CA-C-O 121.833 0.685 . . . . 1.0 111.553 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.586 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.6 m -68.41 -178.49 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.108 -1.046 . . . . 1.0 109.301 178.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.492 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.66 154.59 0.36 Allowed Pre-proline 0 C--N 1.319 -0.741 0 O-C-N 123.84 0.712 . . . . 1.0 109.213 179.529 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.8 Cg_endo -86.99 157.9 8.62 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.933 2.422 . . . . 1.0 115.781 -175.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.412 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.31 172.69 38.25 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 108.446 -1.862 . . . . 1.0 108.446 176.098 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.618 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -47.04 -25.27 0.78 Allowed 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 114.83 -0.685 . . . . 1.0 111.62 178.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.428 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 20.7 m -108.25 -9.14 15.56 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 113.363 0.875 . . . . 1.0 113.363 -177.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.412 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.7 m-20 -84.72 167.39 16.19 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 119.717 -0.793 . . . . 1.0 109.005 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.8 m -106.14 149.93 26.31 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.096 0.474 . . . . 1.0 109.918 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.431 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.1 p -126.53 162.35 30.93 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.297 0 CA-C-N 115.477 -0.783 . . . . 1.0 112.21 -176.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 77.9 m -130.23 119.96 23.72 Favored 'General case' 0 N--CA 1.464 0.24 0 N-CA-C 108.333 -0.988 . . . . 1.0 108.333 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.559 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.8 m -148.99 166.62 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 114.28 1.215 . . . . 1.0 114.28 -176.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 9.4 mt-10 -118.4 152.19 36.34 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 106.386 -1.709 . . . . 1.0 106.386 174.237 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.504 ' H ' ' HB ' ' A' ' 68' ' ' THR . 32.8 p90 -163.63 160.71 23.16 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 118.423 -1.311 . . . . 1.0 114.538 -178.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.15 130.29 53.09 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.769 -0.826 . . . . 1.0 108.769 175.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.2 137.08 13.93 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.881 -0.676 . . . . 1.0 112.02 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -147.84 167.28 25.17 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.617 0.722 . . . . 1.0 112.227 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -86.89 166.05 15.46 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.491 -1.231 . . . . 1.0 111.404 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.417 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.01 -26.24 35.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 114.809 -1.087 . . . . 1.0 110.266 178.066 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -93.79 2.38 56.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.173 -1.376 . . . . 1.0 111.416 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -2.25 75.67 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 120.998 -0.62 . . . . 1.0 112.767 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.4 m -69.03 103.44 1.86 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.821 0.81 . . . . 1.0 110.326 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.9 t -74.03 122.7 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 C-N-CA 120.287 -0.565 . . . . 1.0 109.601 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.841 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.3 p90 -116.35 -8.46 11.64 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 115.003 -0.999 . . . . 1.0 111.598 -178.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 33.7 t0 -158.29 152.42 24.09 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.467 -0.493 . . . . 1.0 111.335 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 96.4 p -159.29 153.23 23.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.729 -0.668 . . . . 1.0 111.623 178.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.504 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 66.2 m -155.86 -39.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.643 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.4 pp20? -65.8 -27.15 68.06 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -58.15 -43.83 87.55 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 107.808 -1.182 . . . . 1.0 107.808 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.5 p -73.99 -31.32 62.92 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.865 -1.062 . . . . 1.0 108.797 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.71 18.31 68.42 Favored Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.81 178.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.413 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 0.0 OUTLIER -101.73 115.03 65.43 Favored Pre-proline 0 N--CA 1.47 0.539 0 C-N-CA 120.682 -0.407 . . . . 1.0 110.98 -179.275 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.407 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 30.4 Cg_exo -60.83 152.49 69.67 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.823 1.682 . . . . 1.0 114.366 -178.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.26 152.21 41.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.042 -1.436 . . . . 1.0 107.833 178.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 130.9 55.38 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 121.408 0.623 . . . . 1.0 112.511 -178.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -138.82 148.44 43.77 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.0 -1.0 . . . . 1.0 109.853 178.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.3 mt-30 -90.35 125.39 35.52 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 106.335 -1.728 . . . . 1.0 106.335 174.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.8 t -53.69 -28.85 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 C-N-CA 119.394 -0.922 . . . . 1.0 110.15 -177.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.7 t -73.97 -25.59 60.02 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.025 -0.67 . . . . 1.0 111.835 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 84.5 mm-40 -100.1 -16.07 17.97 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.717 -0.393 . . . . 1.0 112.022 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -64.99 164.75 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 112.109 0.411 . . . . 1.0 112.109 -177.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.58 148.96 23.19 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.501 -0.925 . . . . 1.0 108.501 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -51.33 -42.62 53.68 Favored 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 121.061 1.174 . . . . 1.0 112.093 -178.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.76 -48.09 87.73 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 119.872 -1.156 . . . . 1.0 110.54 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.559 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.5 m95 -65.56 -35.5 81.04 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.301 -0.949 . . . . 1.0 111.144 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.2 m -51.19 -54.38 26.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.987 -0.285 . . . . 1.0 111.637 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.89 -40.8 68.65 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.456 0.539 . . . . 1.0 112.456 -179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.1 -48.1 82.84 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 114.136 1.162 . . . . 1.0 114.136 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.4 mt -58.32 -42.25 86.31 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.299 0.571 . . . . 1.0 109.896 -177.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -63.25 -23.9 67.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.332 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.517 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.7 mt -100.95 -12.45 18.91 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.902 -0.59 . . . . 1.0 111.246 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.5 ttp -90.17 107.45 19.64 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 111.863 0.32 . . . . 1.0 111.863 -178.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.492 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.3 Cg_exo -67.28 148.02 79.38 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.614 2.209 . . . . 1.0 112.426 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.586 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.61 135.6 55.26 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-O 121.546 0.688 . . . . 1.0 110.926 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.46 57.49 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 107.788 -2.125 . . . . 1.0 107.788 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.8 p -90.24 133.51 34.88 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.956 -0.622 . . . . 1.0 110.676 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.419 ' HB ' HD22 ' A' ' 38' ' ' ASN . 86.0 m -108.8 115.42 30.06 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.581 -0.736 . . . . 1.0 109.426 179.09 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.517 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 40.6 m0 -115.43 168.52 9.92 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.777 0.799 . . . . 1.0 111.081 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.426 ' HB2' HD11 ' A' ' 37' ' ' ILE . 25.2 mt-10 -127.89 129.91 47.65 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 106.449 -1.686 . . . . 1.0 106.449 175.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.7 pt -126.33 137.83 56.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.782 0.801 . . . . 1.0 109.707 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.91 103.62 12.71 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 105.866 -1.901 . . . . 1.0 105.866 -178.078 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 t -90.48 115.57 64.43 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 115.162 1.541 . . . . 1.0 115.162 -174.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -51.07 145.6 24.96 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.525 1.483 . . . . 1.0 109.89 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.7 p -51.7 -36.24 45.92 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.241 -0.584 . . . . 1.0 111.046 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.43 -32.48 83.62 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.862 -0.895 . . . . 1.0 110.862 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.6 mt -99.19 2.28 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.856 -0.172 . . . . 1.0 111.001 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.82 -103.81 0.37 Allowed 'General case' 0 C--O 1.219 -0.54 0 N-CA-C 112.197 0.443 . . . . 1.0 112.197 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.401 ' O ' HG21 ' A' ' 114' ' ' VAL . 31.9 m-85 -104.07 3.96 33.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 113.435 0.902 . . . . 1.0 113.435 -177.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.78 167.8 17.22 Favored Glycine 0 N--CA 1.47 0.922 0 C-N-CA 120.673 -0.775 . . . . 1.0 113.786 177.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.575 ' O ' ' N ' ' A' ' 121' ' ' ASN . 91.0 Cg_endo -76.37 -17.74 16.41 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 124.013 3.142 . . . . 1.0 111.764 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -103.67 169.69 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.848 -0.615 . . . . 1.0 110.066 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.406 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.2 m -74.16 102.95 4.42 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.673 -0.491 . . . . 1.0 109.673 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 109' ' ' TYR . 8.7 t -111.62 61.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-O 120.699 0.285 . . . . 1.0 110.795 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.501 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 162.95 178.32 36.67 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.631 -0.795 . . . . 1.0 111.793 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.46 -103.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.156 0 N-CA-C 111.09 -0.804 . . . . 1.0 111.09 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -61.76 -16.64 50.12 Favored 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.672 2.248 . . . . 1.0 111.734 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.841 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.9 mp -66.46 117.2 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 107.475 -1.305 . . . . 1.0 107.475 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -93.47 -170.15 39.09 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.622 -0.717 . . . . 1.0 111.926 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.406 ' N ' ' OG ' ' A' ' 113' ' ' SER . 30.1 Cg_endo -67.55 145.56 70.84 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 C-N-CA 122.413 2.075 . . . . 1.0 111.614 178.292 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.575 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 42.99 48.76 5.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.324 0.583 . . . . 1.0 110.415 179.078 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 4.4 tp10 -100.86 128.97 46.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.126 -0.943 . . . . 1.0 111.226 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 16' ' ' LEU . 46.7 m -91.29 131.38 36.83 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.299 -0.864 . . . . 1.0 109.404 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -113.14 147.98 36.27 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.876 0.37 . . . . 1.0 110.28 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -126.39 143.22 40.62 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.595 0 N-CA-C 108.546 -0.909 . . . . 1.0 108.546 178.358 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.565 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.5 m-85 -134.15 149.9 51.08 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.378 -0.529 . . . . 1.0 111.657 177.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.5 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 6.9 mmtt -100.16 124.39 45.52 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 105.728 -1.953 . . . . 1.0 105.728 177.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.2 118.95 59.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.878 0.846 . . . . 1.0 113.031 -176.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 -109.64 127.12 54.32 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 113.98 -1.464 . . . . 1.0 108.536 178.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.6 111.61 23.68 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 120.041 -0.664 . . . . 1.0 112.41 -178.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.442 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.2 mp -93.86 -44.79 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 CA-C-N 116.119 -0.492 . . . . 1.0 111.1 179.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.5 p -152.39 158.39 42.61 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.89 0.376 . . . . 1.0 110.744 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.4 t -130.88 139.68 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.516 -177.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 7.2 tptt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 121.356 0.598 . . . . 1.0 109.906 178.719 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 . . . . . 0 CA--C 1.516 -0.337 0 CA-C-O 121.599 0.714 . . . . 1.0 110.512 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 28.5 m-20 -59.7 -35.66 74.95 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.171 -0.922 . . . . 1.0 108.657 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 ttpm? -65.74 -50.83 63.37 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.197 -1.365 . . . . 1.0 111.139 179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -67.21 -48.81 77.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 119.58 -0.848 . . . . 1.0 112.015 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.458 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.16 -38.04 87.53 Favored 'General case' 0 N--CA 1.444 -0.757 0 N-CA-C 107.703 -1.221 . . . . 1.0 107.703 179.212 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.479 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.2 -47.96 41.66 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 114.897 -1.047 . . . . 1.0 112.296 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -59.86 -30.81 69.23 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 119.882 -0.727 . . . . 1.0 109.248 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.4 -35.31 47.29 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.266 -0.879 . . . . 1.0 109.978 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.5 t80 -60.55 -49.43 77.58 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.764 -1.107 . . . . 1.0 110.379 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.479 HD12 ' O ' ' A' ' 12' ' ' GLY . 6.0 mp -66.99 -40.01 87.29 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 109.199 -0.667 . . . . 1.0 109.199 178.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 98.0 m -61.96 -41.75 98.35 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.488 -0.778 . . . . 1.0 109.733 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -75.73 -43.38 47.23 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.69 -0.687 . . . . 1.0 111.36 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.666 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 47.4 t30 -61.53 -45.31 94.72 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 112.793 0.664 . . . . 1.0 112.793 -178.257 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -58.89 -30.74 68.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.48 -0.888 . . . . 1.0 108.947 -179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -79.07 -31.65 44.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.261 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 29.4 mtmt -58.55 142.72 82.45 Favored Pre-proline 0 CA--C 1.547 0.865 0 C-N-CA 120.525 -0.47 . . . . 1.0 111.163 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.68 149.06 61.3 Favored 'Trans proline' 0 N--CA 1.503 2.042 0 C-N-CA 122.422 2.081 . . . . 1.0 114.297 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.73 -19.31 5.12 Favored Glycine 0 C--O 1.228 -0.243 0 CA-C-N 115.021 -0.99 . . . . 1.0 112.226 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.54 136.53 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.02 0.438 . . . . 1.0 110.754 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.3 t -121.41 122.91 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 107.963 -1.125 . . . . 1.0 107.963 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.92 146.0 8.1 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.753 0.787 . . . . 1.0 111.896 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.8 mt -114.86 166.5 11.59 Favored Pre-proline 0 C--O 1.231 0.119 0 CA-C-N 114.35 -1.296 . . . . 1.0 111.048 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -61.57 -31.6 87.27 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 122.241 1.961 . . . . 1.0 111.97 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 m -69.94 -10.71 59.53 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.25 0.548 . . . . 1.0 109.855 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.25 0.94 72.89 Favored Glycine 0 CA--C 1.517 0.185 0 N-CA-C 109.952 -1.259 . . . . 1.0 109.952 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.48 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -82.64 133.58 35.17 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 108.555 -0.905 . . . . 1.0 108.555 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.48 ' H ' HD22 ' A' ' 32' ' ' LEU . 16.5 mp0 -121.84 143.46 49.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.413 -0.358 . . . . 1.0 111.164 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 26.7 p90 -137.4 145.27 43.04 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.733 0.778 . . . . 1.0 111.072 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.506 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -128.66 132.63 48.1 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 114.38 -1.282 . . . . 1.0 109.08 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.85 104.63 15.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 122.314 1.055 . . . . 1.0 112.02 -178.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.613 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -69.77 -41.35 79.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.992 -1.004 . . . . 1.0 108.551 179.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -143.92 129.38 19.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.661 -1.154 . . . . 1.0 109.73 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.3 p -89.43 128.81 35.98 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.734 -0.469 . . . . 1.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.48 -35.15 1.22 Allowed Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.626 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.2 m120 58.07 29.9 18.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 1.0 111.138 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.93 -161.99 37.84 Favored Glycine 0 C--N 1.331 0.259 0 CA-C-O 121.888 0.716 . . . . 1.0 111.713 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.9 m -68.61 -177.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.061 -1.07 . . . . 1.0 108.841 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' HG21 ' A' ' 133' ' ' VAL . 0.0 OUTLIER 177.67 155.4 0.49 Allowed Pre-proline 0 C--N 1.317 -0.836 0 O-C-N 123.628 0.58 . . . . 1.0 109.516 179.797 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -83.84 165.23 13.64 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 123.241 2.627 . . . . 1.0 116.292 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.443 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -98.08 175.02 29.37 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 108.633 -1.787 . . . . 1.0 108.633 176.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.84 -23.53 18.8 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.618 -0.433 . . . . 1.0 111.492 -179.086 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 36.4 m -107.02 -6.31 17.55 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 112.9 0.704 . . . . 1.0 112.9 -177.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.727 ' OD1' ' N ' ' A' ' 50' ' ' THR . 67.2 t0 -82.33 170.68 15.07 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.282 0.563 . . . . 1.0 110.595 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.727 ' N ' ' OD1' ' A' ' 49' ' ' ASP . 8.9 m -112.38 144.06 42.44 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.697 -0.853 . . . . 1.0 108.697 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' THR . 9.0 p -125.39 160.34 31.52 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 CA-C-N 115.182 -0.917 . . . . 1.0 111.974 -175.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.444 HG22 ' HB3' ' A' ' 74' ' ' PRO . 99.3 m -125.5 119.74 29.03 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.602 -0.888 . . . . 1.0 108.602 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.433 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.5 m -148.48 166.93 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 114.341 1.237 . . . . 1.0 114.341 -177.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -119.36 147.68 44.06 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 106.283 -1.747 . . . . 1.0 106.283 173.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.4 p90 -162.19 163.4 28.36 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 115.083 1.512 . . . . 1.0 115.083 -176.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -127.45 127.5 44.18 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 115.254 -0.884 . . . . 1.0 109.332 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.74 136.07 13.19 Favored Glycine 0 N--CA 1.471 1.001 0 C-N-CA 121.094 -0.574 . . . . 1.0 112.355 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 58' ' ' ARG . 5.3 ptp180 -147.4 168.55 21.57 Favored 'General case' 0 C--N 1.341 0.199 0 CA-C-O 121.498 0.666 . . . . 1.0 112.266 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.2 mp -84.93 164.7 18.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.519 -1.219 . . . . 1.0 110.761 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.43 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.57 -25.49 34.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 114.883 -1.053 . . . . 1.0 110.018 177.792 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -92.65 3.02 56.36 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.926 -1.488 . . . . 1.0 111.622 -177.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.27 -2.03 80.56 Favored Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.822 -0.704 . . . . 1.0 112.668 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.4 m -71.37 104.49 3.21 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 119.722 -0.791 . . . . 1.0 109.785 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.1 t -75.46 126.34 36.11 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.81 0 CA-C-O 121.202 0.525 . . . . 1.0 110.332 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 30.2 p90 -115.0 -11.68 12.1 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.032 -0.986 . . . . 1.0 111.425 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -162.5 153.35 17.3 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.838 -0.745 . . . . 1.0 112.158 178.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 93.3 p -160.44 154.88 23.6 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 115.706 -0.679 . . . . 1.0 112.124 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.505 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 90.4 m -152.26 -43.51 0.1 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.688 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.413 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.8 pp20? -59.04 -25.98 64.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.152 -0.476 . . . . 1.0 110.427 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -54.98 -42.55 72.56 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.674 -1.232 . . . . 1.0 107.674 178.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 71.9 p -77.06 -34.83 57.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.525 -1.216 . . . . 1.0 109.193 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 85.05 16.75 64.37 Favored Glycine 0 C--N 1.333 0.362 0 CA-C-N 115.452 -0.795 . . . . 1.0 111.57 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.5 116.14 65.15 Favored Pre-proline 0 N--CA 1.472 0.672 0 C-N-CA 120.488 -0.485 . . . . 1.0 110.874 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HB3' HG22 ' A' ' 52' ' ' THR . 34.7 Cg_exo -59.7 151.65 68.71 Favored 'Trans proline' 0 N--CA 1.481 0.752 0 C-N-CA 121.458 1.438 . . . . 1.0 114.438 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.36 149.52 46.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.027 -1.442 . . . . 1.0 107.257 177.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -103.34 136.99 42.07 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.358 0.599 . . . . 1.0 112.493 -178.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -140.23 148.3 41.31 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 114.933 -1.031 . . . . 1.0 110.767 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.5 mt-30 -92.0 125.19 36.6 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.752 -1.944 . . . . 1.0 105.752 174.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.6 t -56.45 -29.98 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 C-N-CA 118.704 -1.198 . . . . 1.0 110.126 -176.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LYS . 3.1 t -73.53 -25.78 60.57 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 120.074 -0.65 . . . . 1.0 112.577 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 87.0 mm-40 -101.37 -15.9 17.07 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 111.885 0.328 . . . . 1.0 111.885 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.481 HG22 ' H ' ' A' ' 83' ' ' ILE . 1.6 p -69.94 170.52 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 119.42 -0.912 . . . . 1.0 111.886 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.481 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.08 146.99 27.34 Favored Pre-proline 0 CA--C 1.548 0.875 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 -178.069 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -52.13 -43.64 51.6 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.814 1.676 . . . . 1.0 113.105 -178.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.65 -47.15 92.36 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 109.574 -1.41 . . . . 1.0 109.574 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.433 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 6.7 m95 -63.03 -35.31 79.8 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.153 -1.024 . . . . 1.0 110.387 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 24.8 m -51.56 -53.54 36.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.063 0.458 . . . . 1.0 111.063 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -71.9 -44.91 62.92 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.617 -0.72 . . . . 1.0 112.687 -179.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -58.81 -46.8 86.75 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 114.509 1.3 . . . . 1.0 114.509 -177.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 19.4 mt -57.84 -42.88 85.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.362 0.601 . . . . 1.0 109.478 -178.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -62.95 -20.08 64.89 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.942 -1.026 . . . . 1.0 110.434 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.537 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 96.2 mt -105.93 -11.05 16.33 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.968 -0.56 . . . . 1.0 111.352 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 54.2 ttp -92.52 107.18 21.93 Favored Pre-proline 0 CA--C 1.547 0.842 0 O-C-N 123.273 0.358 . . . . 1.0 111.376 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.43 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 23.8 Cg_exo -64.43 147.7 90.65 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.398 2.065 . . . . 1.0 112.936 178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.599 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -61.87 132.66 53.77 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 115.482 -0.781 . . . . 1.0 111.579 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.49 -19.26 55.09 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 108.492 -1.843 . . . . 1.0 108.492 -178.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -84.61 131.83 34.56 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.038 0.447 . . . . 1.0 109.994 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.5 m -105.24 113.67 27.4 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 115.923 -0.58 . . . . 1.0 109.604 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.9 m0 -115.65 165.69 12.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.871 0.843 . . . . 1.0 111.258 -178.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.613 ' CD ' HD11 ' A' ' 37' ' ' ILE . 83.7 mt-10 -125.84 132.88 52.13 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 106.277 -1.749 . . . . 1.0 106.277 175.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.425 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.7 pt -128.66 139.71 51.17 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-O 121.84 0.829 . . . . 1.0 109.925 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.697 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.88 103.07 11.8 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 105.742 -1.947 . . . . 1.0 105.742 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 t -90.64 116.23 65.94 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 115.614 1.709 . . . . 1.0 115.614 -174.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.81 144.56 26.38 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.66 1.574 . . . . 1.0 109.766 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.5 p -50.45 -36.24 32.42 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 120.434 -0.506 . . . . 1.0 111.363 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.98 -32.2 80.2 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.977 -0.849 . . . . 1.0 110.977 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.4 mt -98.4 2.32 47.75 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 121.364 -0.134 . . . . 1.0 110.746 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.446 ' O ' HG22 ' A' ' 83' ' ' ILE . . . -107.95 -103.22 0.36 Allowed 'General case' 0 C--O 1.216 -0.665 0 N-CA-C 110.069 -0.345 . . . . 1.0 110.069 -179.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -105.29 5.17 31.74 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 113.397 0.888 . . . . 1.0 113.397 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 105.46 166.7 23.69 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 120.814 -0.707 . . . . 1.0 113.075 177.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 121' ' ' ASN . 72.6 Cg_endo -72.64 -18.46 25.38 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 123.454 2.769 . . . . 1.0 112.45 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -98.03 169.3 9.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.303 -0.408 . . . . 1.0 109.947 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.7 m -76.33 85.82 3.11 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.7 t -98.04 59.23 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.51 -0.314 . . . . 1.0 110.923 -179.114 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.75 179.9 41.76 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 120.629 -0.796 . . . . 1.0 112.088 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.01 -105.87 0.01 OUTLIER Glycine 0 CA--C 1.537 1.418 0 N-CA-C 111.747 -0.541 . . . . 1.0 111.747 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -61.15 -13.72 29.68 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 C-N-CA 122.399 2.066 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.841 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.1 mp -68.24 112.22 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 108.334 -0.987 . . . . 1.0 108.334 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.412 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -91.21 -167.11 40.9 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.691 -0.964 . . . . 1.0 110.691 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.503 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 38.0 Cg_endo -64.76 146.65 88.81 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 122.242 1.961 . . . . 1.0 112.973 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.468 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 46.16 49.87 12.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.67 -0.695 . . . . 1.0 111.925 178.353 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.437 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 49.1 mm-40 -93.21 132.69 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.093 0.473 . . . . 1.0 111.978 179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.465 HG21 HD11 ' A' ' 16' ' ' LEU . 63.4 m -96.2 127.82 42.55 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.243 -1.762 . . . . 1.0 106.243 175.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.423 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.97 143.16 45.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.517 0.675 . . . . 1.0 110.747 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.697 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.7 tt -119.28 146.38 24.04 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.659 0 CA-C-N 115.078 -0.965 . . . . 1.0 108.508 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.562 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.84 152.27 48.92 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.314 -0.554 . . . . 1.0 111.376 177.63 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.476 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 3.4 mmtt -100.47 124.03 45.46 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 105.697 -1.964 . . . . 1.0 105.697 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -118.61 119.05 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 119.41 -0.916 . . . . 1.0 112.394 -176.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.6 t-160 -110.81 122.66 48.38 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 114.096 -1.411 . . . . 1.0 108.654 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.49 112.13 23.89 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 120.364 -0.534 . . . . 1.0 112.378 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.449 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -95.55 -45.04 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 116.015 -0.539 . . . . 1.0 111.412 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -151.05 157.82 43.31 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.827 0.346 . . . . 1.0 110.691 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.471 HG21 ' HA ' ' A' ' 44' ' ' LYS . 60.5 t -128.79 140.67 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 121.039 0.447 . . . . 1.0 111.51 -177.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.7 tptt . . . . . 0 CA--C 1.534 0.33 0 CA-C-O 121.942 0.877 . . . . 1.0 111.22 179.911 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 . . . . . 0 CA--C 1.515 -0.378 0 CA-C-O 122.023 0.916 . . . . 1.0 110.646 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.562 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.8 m-20 -59.59 -37.47 78.63 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 114.608 -1.178 . . . . 1.0 108.221 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -67.46 -52.14 42.97 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.183 -1.371 . . . . 1.0 111.495 179.541 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.92 -48.37 75.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 119.736 -0.786 . . . . 1.0 112.058 -177.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.449 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -63.36 -35.54 80.73 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.015 -1.106 . . . . 1.0 108.015 178.982 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.475 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -74.54 -43.57 29.61 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 114.754 -1.112 . . . . 1.0 112.054 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.3 mt-10 -61.72 -31.25 71.39 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.907 -0.775 . . . . 1.0 108.907 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.39 -32.08 48.67 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.441 -0.8 . . . . 1.0 110.04 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -62.44 -49.12 76.7 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.579 -1.191 . . . . 1.0 110.762 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.73 -40.1 76.4 Favored 'General case' 0 C--N 1.32 -0.686 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.892 178.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.4 m -61.04 -41.7 97.09 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.814 -0.63 . . . . 1.0 109.481 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -75.48 -46.52 31.94 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.31 -0.859 . . . . 1.0 111.575 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.9 t30 -60.37 -44.91 95.17 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 113.016 0.747 . . . . 1.0 113.016 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -60.42 -28.84 68.58 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 119.47 -0.892 . . . . 1.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -80.25 -30.02 38.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.191 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -59.4 142.95 86.35 Favored Pre-proline 0 CA--C 1.55 0.951 0 N-CA-C 112.268 0.47 . . . . 1.0 112.268 -177.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.06 149.05 65.08 Favored 'Trans proline' 0 N--CA 1.505 2.195 0 C-N-CA 122.499 2.132 . . . . 1.0 113.362 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.72 -19.37 5.08 Favored Glycine 0 C--O 1.225 -0.412 0 CA-C-N 115.601 -0.727 . . . . 1.0 112.189 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.5 t -85.11 136.28 23.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.148 0.499 . . . . 1.0 110.833 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.91 124.24 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 107.854 -1.165 . . . . 1.0 107.854 177.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.4 p -97.24 146.32 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-O 121.71 0.767 . . . . 1.0 111.811 -178.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.29 165.05 14.11 Favored Pre-proline 0 C--O 1.232 0.14 0 CA-C-N 114.355 -1.293 . . . . 1.0 110.856 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -61.37 -30.24 87.01 Favored 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 121.983 1.789 . . . . 1.0 111.379 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -68.51 -14.47 63.03 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.591 -0.731 . . . . 1.0 109.387 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.93 -2.1 68.88 Favored Glycine 0 C--O 1.229 -0.158 0 N-CA-C 109.734 -1.346 . . . . 1.0 109.734 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.437 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.54 132.78 35.71 Favored 'General case' 0 CA--C 1.519 -0.25 0 N-CA-C 108.411 -0.959 . . . . 1.0 108.411 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.437 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.7 mp0 -119.62 140.96 49.77 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-N 116.196 -0.456 . . . . 1.0 110.869 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -136.37 147.85 47.56 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 121.6 0.714 . . . . 1.0 111.143 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.538 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -130.64 132.54 45.51 Favored 'General case' 0 CA--C 1.501 -0.932 0 CA-C-N 114.479 -1.237 . . . . 1.0 109.317 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.16 104.85 15.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.281 1.038 . . . . 1.0 112.356 -178.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.63 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.3 mm -70.7 -41.64 77.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.039 -0.982 . . . . 1.0 108.72 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -143.6 131.52 21.59 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 114.639 -1.164 . . . . 1.0 109.792 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.8 p -90.3 129.1 36.57 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.857 -0.423 . . . . 1.0 109.857 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.74 -33.2 1.32 Allowed Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.619 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 54.32 30.83 13.22 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.287 -0.457 . . . . 1.0 110.577 179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.33 -162.22 37.78 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-O 121.789 0.66 . . . . 1.0 111.669 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 23.4 m -68.28 -177.54 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.266 -0.967 . . . . 1.0 109.375 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.606 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.56 154.58 0.35 Allowed Pre-proline 0 C--N 1.317 -0.832 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 179.54 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.436 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.9 Cg_endo -88.21 160.4 7.03 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.162 2.575 . . . . 1.0 116.189 -175.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.422 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 174.22 39.06 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 108.096 -2.001 . . . . 1.0 108.096 175.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.607 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -49.26 -25.81 2.58 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.99 -0.605 . . . . 1.0 111.439 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.438 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 9.4 m -107.24 -9.21 16.15 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -177.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.6 m-20 -84.18 165.92 18.01 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 119.708 -0.797 . . . . 1.0 108.975 179.222 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.415 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.2 m -103.24 151.86 22.17 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-O 121.224 0.535 . . . . 1.0 109.948 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.8 p -129.66 161.82 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.389 0 CA-C-N 115.292 -0.867 . . . . 1.0 112.114 -176.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -132.12 118.17 19.26 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 108.67 -0.863 . . . . 1.0 108.67 177.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.418 ' HB ' ' O ' ' A' ' 129' ' ' HIS . 2.5 m -148.1 166.98 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.883 0.697 . . . . 1.0 112.883 -177.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.1 mt-10 -116.93 154.04 31.53 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 106.909 -1.515 . . . . 1.0 106.909 175.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.521 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.1 p90 -165.07 163.55 20.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 114.82 1.415 . . . . 1.0 114.82 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -126.24 128.97 48.03 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 107.895 -1.15 . . . . 1.0 107.895 174.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.68 12.25 Favored Glycine 0 N--CA 1.47 0.905 0 C-N-CA 120.687 -0.768 . . . . 1.0 111.757 -178.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.3 ptp180 -146.23 167.02 24.52 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.95 0.881 . . . . 1.0 112.632 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.483 HD11 HD13 ' A' ' 118' ' ' ILE . 3.0 mp -81.76 163.79 22.16 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.065 -1.425 . . . . 1.0 110.147 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.19 -24.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 114.942 -1.026 . . . . 1.0 109.77 177.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -96.25 4.69 52.19 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 113.648 -1.615 . . . . 1.0 111.791 -177.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.05 80.51 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.788 -0.72 . . . . 1.0 113.316 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 m -72.83 111.51 8.03 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.112 -1.035 . . . . 1.0 109.422 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.02 120.17 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-O 121.543 0.687 . . . . 1.0 111.171 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.591 ' CG ' HD11 ' A' ' 118' ' ' ILE . 23.3 p90 -108.47 -9.81 15.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.884 -1.053 . . . . 1.0 111.613 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.578 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 4.1 p-10 -161.62 149.24 14.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.977 -0.556 . . . . 1.0 110.829 178.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 68.9 p -156.15 149.44 24.51 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.61 -0.723 . . . . 1.0 111.108 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.521 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 46.1 m -155.98 -42.0 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.602 -0.726 . . . . 1.0 110.967 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.413 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.8 pp20? -63.18 -26.95 69.04 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.742 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.7 mmtp -54.37 -43.15 71.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.699 -1.223 . . . . 1.0 107.699 178.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 28.5 p -76.3 -34.85 59.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.096 -1.411 . . . . 1.0 109.102 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.6 15.5 70.78 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.357 -0.838 . . . . 1.0 111.144 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -97.97 115.27 65.77 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 120.402 -0.519 . . . . 1.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.408 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 33.8 Cg_exo -59.83 153.24 58.11 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 122.022 1.814 . . . . 1.0 114.114 -178.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.97 150.73 46.36 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.059 -1.428 . . . . 1.0 108.069 178.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.29 129.65 55.7 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.014 0.746 . . . . 1.0 113.014 -178.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -140.98 153.02 45.4 Favored 'General case' 0 CA--C 1.502 -0.88 0 CA-C-N 114.678 -1.146 . . . . 1.0 108.795 177.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.5 mt-30 -90.44 127.18 36.14 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 106.359 -1.719 . . . . 1.0 106.359 174.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.4 t -46.79 -34.45 2.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.351 -0.539 . . . . 1.0 110.471 -178.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -73.56 -24.34 60.09 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 120.467 -0.493 . . . . 1.0 112.323 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 82.8 mm-40 -100.13 -12.0 20.0 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 113.618 0.969 . . . . 1.0 113.618 -177.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 83' ' ' ILE . 5.4 p -84.44 177.93 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 119.656 -0.818 . . . . 1.0 110.455 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.644 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.95 146.51 37.76 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.595 -177.198 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -51.54 -44.55 43.2 Favored 'Trans proline' 0 N--CA 1.499 1.817 0 C-N-CA 121.896 1.73 . . . . 1.0 112.527 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.48 -47.4 90.06 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.549 -1.42 . . . . 1.0 109.549 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.1 m95 -63.83 -36.06 82.68 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.287 -0.956 . . . . 1.0 110.04 179.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.2 m -52.23 -52.95 49.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.674 -0.411 . . . . 1.0 110.904 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -72.32 -45.35 60.34 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.891 -0.595 . . . . 1.0 112.444 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.34 -48.46 76.72 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 113.925 1.083 . . . . 1.0 113.925 -177.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 32.7 mt -57.93 -42.66 85.31 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-O 121.084 0.469 . . . . 1.0 109.959 -177.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -62.65 -23.27 67.01 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 115.615 -0.721 . . . . 1.0 110.289 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.6 mt -101.79 -14.4 17.31 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.876 -0.602 . . . . 1.0 111.266 -179.131 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.2 ttp -88.98 108.18 22.25 Favored Pre-proline 0 CA--C 1.547 0.833 0 N-CA-C 111.991 0.367 . . . . 1.0 111.991 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.606 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.2 Cg_exo -66.06 148.08 85.07 Favored 'Trans proline' 0 N--CA 1.499 1.842 0 C-N-CA 122.438 2.092 . . . . 1.0 112.162 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.96 137.53 58.05 Favored 'General case' 0 CA--C 1.507 -0.695 0 CA-C-O 121.493 0.663 . . . . 1.0 111.331 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.16 -18.57 55.91 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.252 -1.939 . . . . 1.0 108.252 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.4 p -89.39 128.41 35.92 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 121.263 0.554 . . . . 1.0 110.735 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 89.9 m -103.56 114.24 28.36 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 115.392 -0.822 . . . . 1.0 109.944 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.483 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.6 m0 -116.04 164.9 13.77 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 121.442 0.639 . . . . 1.0 110.882 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.63 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.8 mt-10 -123.59 129.14 50.71 Favored 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 106.394 -1.706 . . . . 1.0 106.394 175.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -125.93 138.9 53.07 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.665 0 CA-C-O 121.926 0.869 . . . . 1.0 110.376 -179.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.749 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.27 104.12 13.2 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.928 -1.878 . . . . 1.0 105.928 -178.16 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.6 t -90.4 115.95 65.28 Favored Pre-proline 0 C--N 1.326 -0.415 0 N-CA-C 114.879 1.437 . . . . 1.0 114.879 -174.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -51.21 143.49 32.86 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 121.276 1.317 . . . . 1.0 110.021 175.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 92.4 p -49.26 -35.17 16.99 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.426 -0.51 . . . . 1.0 110.423 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.0 81.51 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 111.174 -0.77 . . . . 1.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -101.25 3.24 40.67 Favored 'General case' 0 C--O 1.225 -0.189 0 CA-C-O 119.771 -0.157 . . . . 1.0 110.872 -179.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.23 -112.33 0.29 Allowed 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.487 0.184 . . . . 1.0 110.554 -178.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -98.32 4.85 48.66 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 113.405 0.891 . . . . 1.0 113.405 -178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 115.14 162.97 13.87 Favored Glycine 0 N--CA 1.47 0.911 0 C-N-CA 120.996 -0.621 . . . . 1.0 112.969 177.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 121' ' ' ASN . 96.3 Cg_endo -76.16 -9.4 19.15 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 123.626 2.884 . . . . 1.0 111.0 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -109.19 168.9 9.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.498 -0.774 . . . . 1.0 109.446 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.1 m -73.86 96.37 2.58 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.0 t -111.91 60.25 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-N 116.244 -0.434 . . . . 1.0 110.444 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.55 172.46 36.19 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.35 -0.7 . . . . 1.0 111.35 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.59 -103.19 0.01 OUTLIER Glycine 0 CA--C 1.535 1.337 0 N-CA-C 111.226 -0.75 . . . . 1.0 111.226 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -58.04 -11.42 10.03 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.754 2.303 . . . . 1.0 111.628 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.591 HD11 ' CG ' ' A' ' 65' ' ' PHE . 14.9 mm -66.96 125.55 24.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-N 114.716 -1.129 . . . . 1.0 109.138 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -102.63 -175.86 27.12 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.321 -0.854 . . . . 1.0 111.249 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.562 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 21.6 Cg_endo -62.38 142.23 90.09 Favored 'Trans proline' 0 C--N 1.295 -2.25 0 C-N-CA 122.384 2.056 . . . . 1.0 111.756 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.531 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 45.79 55.39 6.93 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 120.796 -0.362 . . . . 1.0 111.103 178.11 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.521 ' OE2' ' ND2' ' A' ' 8' ' ' ASN . 3.3 tp10 -102.34 130.03 48.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.987 -0.552 . . . . 1.0 111.412 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.426 HG21 HD11 ' A' ' 16' ' ' LEU . 46.4 m -95.36 129.79 42.38 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.007 -1.109 . . . . 1.0 108.007 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.449 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.64 148.8 33.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.423 0.63 . . . . 1.0 111.114 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.749 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -124.58 149.29 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.041 -0.981 . . . . 1.0 108.485 178.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.6 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -140.52 149.82 42.94 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 120.479 -0.488 . . . . 1.0 111.522 178.033 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 13.9 mmtt -99.42 127.07 45.44 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 104.768 -2.308 . . . . 1.0 104.768 176.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -121.18 121.13 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 119.259 -0.976 . . . . 1.0 112.138 -177.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.418 ' O ' ' HB ' ' A' ' 53' ' ' VAL . 9.1 t-160 -113.75 120.71 41.73 Favored 'General case' 0 C--O 1.223 -0.327 0 CA-C-N 114.157 -1.383 . . . . 1.0 108.612 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.35 111.89 23.63 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 120.014 -0.675 . . . . 1.0 112.519 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.466 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -94.14 -45.14 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-N 116.222 -0.444 . . . . 1.0 111.12 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -150.74 155.58 39.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.85 0.357 . . . . 1.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.424 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.7 t -128.7 139.09 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.285 -0.416 . . . . 1.0 111.326 -178.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.415 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.6 tptm . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 121.599 0.714 . . . . 1.0 110.057 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 121.785 0.803 . . . . 1.0 110.54 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.608 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 12.9 m-20 -61.49 -35.33 77.36 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.004 -1.11 . . . . 1.0 108.004 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.405 ' O ' ' N ' ' A' ' 13' ' ' GLU . 55.6 tttt -66.76 -51.02 60.68 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.385 -1.734 . . . . 1.0 111.571 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.8 t -66.87 -48.85 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.276 0 C-N-CA 119.979 -0.688 . . . . 1.0 111.393 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.445 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -62.84 -38.64 91.59 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.639 -1.245 . . . . 1.0 107.639 179.034 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.492 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.54 -42.77 71.51 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 114.868 -1.06 . . . . 1.0 111.875 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.405 ' N ' ' O ' ' A' ' 9' ' ' LYS . 33.8 mt-10 -62.67 -33.27 74.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.438 -0.949 . . . . 1.0 108.438 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.3 -34.25 59.05 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 114.791 -1.095 . . . . 1.0 109.798 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -61.89 -51.11 69.5 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 114.492 -1.231 . . . . 1.0 110.762 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.66 -40.18 76.6 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.061 -0.656 . . . . 1.0 109.733 178.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.441 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 97.7 m -61.07 -42.06 97.78 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.505 -0.771 . . . . 1.0 109.13 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -75.74 -47.35 26.35 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.006 -0.997 . . . . 1.0 111.9 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.661 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 49.5 t30 -58.7 -45.4 89.6 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -177.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.5 -29.35 67.79 Favored 'General case' 0 C--N 1.315 -0.909 0 C-N-CA 119.303 -0.959 . . . . 1.0 109.154 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.441 ' ND2' ' O ' ' A' ' 17' ' ' THR . 7.4 m-80 -82.0 -29.69 31.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.372 -0.831 . . . . 1.0 111.591 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -59.74 146.08 81.92 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 120.48 -0.488 . . . . 1.0 111.371 -178.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.14 148.47 69.35 Favored 'Trans proline' 0 N--CA 1.504 2.094 0 C-N-CA 122.525 2.15 . . . . 1.0 113.791 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.89 -18.61 5.88 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.492 -0.776 . . . . 1.0 112.625 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.2 136.95 21.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.219 0.533 . . . . 1.0 111.286 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -121.66 126.03 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 107.64 -1.244 . . . . 1.0 107.64 177.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -100.73 145.62 10.81 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 CA-C-O 121.828 0.823 . . . . 1.0 112.266 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.1 mt -112.31 166.17 11.52 Favored Pre-proline 0 CA--C 1.529 0.155 0 CA-C-N 114.1 -1.409 . . . . 1.0 111.357 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.87 -30.7 84.4 Favored 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.188 1.926 . . . . 1.0 111.358 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.1 m -68.52 -14.42 62.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.839 -0.618 . . . . 1.0 109.8 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.14 -0.96 66.94 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 109.593 -1.403 . . . . 1.0 109.593 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.449 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -81.21 133.39 35.44 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.511 -0.922 . . . . 1.0 108.511 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.449 ' H ' HD22 ' A' ' 32' ' ' LEU . 21.2 mp0 -120.94 143.38 49.01 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.91 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -138.2 143.86 40.4 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 121.712 0.767 . . . . 1.0 110.734 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.513 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.53 132.83 49.86 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-N 114.504 -1.225 . . . . 1.0 109.106 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 p -90.82 104.9 15.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 122.148 0.975 . . . . 1.0 111.86 -178.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.6 mm -70.09 -42.34 79.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.222 -0.899 . . . . 1.0 108.671 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.6 m-80 -140.27 128.04 21.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 114.619 -1.173 . . . . 1.0 109.627 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 p -88.57 127.22 35.54 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.736 -0.468 . . . . 1.0 109.736 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.36 -34.53 1.19 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 110.683 -0.967 . . . . 1.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.648 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.6 m120 56.02 32.01 19.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.99 0.424 . . . . 1.0 110.737 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.41 -161.0 36.84 Favored Glycine 0 C--N 1.333 0.37 0 CA-C-O 121.924 0.736 . . . . 1.0 111.769 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.596 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.3 m -69.69 -178.09 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 114.084 -1.058 . . . . 1.0 109.289 178.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.424 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 154.84 0.37 Allowed Pre-proline 0 C--N 1.32 -0.694 0 O-C-N 123.829 0.705 . . . . 1.0 109.549 179.387 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -87.15 156.17 8.3 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 123.091 2.528 . . . . 1.0 115.993 -175.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.29 175.12 44.22 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 108.778 -1.729 . . . . 1.0 108.778 176.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.558 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.68 -22.44 5.14 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 120.82 -0.352 . . . . 1.0 111.14 -179.402 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.8 m -107.41 -9.9 15.88 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.245 0.831 . . . . 1.0 113.245 -177.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -84.58 168.99 14.85 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 119.867 -0.733 . . . . 1.0 109.028 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.406 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -107.66 152.1 24.76 Favored 'General case' 0 CA--C 1.513 -0.466 0 N-CA-C 109.618 -0.512 . . . . 1.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -128.31 160.1 38.83 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.405 0 CA-C-N 115.741 -0.663 . . . . 1.0 112.285 -176.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 74' ' ' PRO . 85.9 m -126.3 120.19 29.3 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 107.729 -1.212 . . . . 1.0 107.729 177.482 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.609 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 27.0 m -148.98 163.32 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 N-CA-C 114.291 1.219 . . . . 1.0 114.291 -175.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -118.44 150.67 39.18 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 106.41 -1.7 . . . . 1.0 106.41 174.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.5 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.9 p90 -163.75 163.53 24.03 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 118.393 -1.323 . . . . 1.0 114.506 -177.567 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -125.11 130.05 51.44 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 115.261 -0.881 . . . . 1.0 108.848 175.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.38 136.56 13.6 Favored Glycine 0 N--CA 1.468 0.787 0 C-N-CA 121.005 -0.617 . . . . 1.0 111.602 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -148.72 166.88 27.07 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.674 0.749 . . . . 1.0 112.533 179.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -84.28 164.38 19.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 114.456 -1.247 . . . . 1.0 110.502 178.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.45 -24.88 32.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.918 -1.037 . . . . 1.0 110.528 178.149 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.67 4.5 53.76 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.566 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.95 -5.23 81.95 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.016 178.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.6 m -67.14 103.39 1.2 Allowed 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.569 -0.853 . . . . 1.0 110.067 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.4 t -74.93 125.99 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.853 0 C-N-CA 120.347 -0.541 . . . . 1.0 109.702 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.589 ' CD2' HD11 ' A' ' 118' ' ' ILE . 28.0 p90 -117.48 -10.81 10.59 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 114.993 -1.003 . . . . 1.0 111.471 -179.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.7 t0 -157.41 150.76 23.79 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.401 -0.52 . . . . 1.0 111.65 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -159.59 151.79 20.89 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.632 -0.713 . . . . 1.0 111.817 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.5 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.3 m -151.25 -42.1 0.12 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.342 -0.845 . . . . 1.0 110.183 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.45 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -62.09 -27.93 69.26 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-N 116.018 -0.537 . . . . 1.0 109.672 179.379 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -56.73 -43.3 80.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 107.741 -1.207 . . . . 1.0 107.741 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -75.14 -33.4 61.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.632 -1.167 . . . . 1.0 107.974 176.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.12 18.39 67.28 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 115.639 -0.71 . . . . 1.0 111.957 178.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -101.18 115.87 64.61 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 120.882 -0.327 . . . . 1.0 110.629 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.448 ' HB3' HG22 ' A' ' 52' ' ' THR . 37.2 Cg_exo -60.61 152.5 68.23 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 121.754 1.636 . . . . 1.0 114.282 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.35 150.99 42.97 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.094 -1.412 . . . . 1.0 107.926 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.99 125.31 50.84 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.589 0.588 . . . . 1.0 112.589 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -132.93 147.8 52.29 Favored 'General case' 0 CA--C 1.502 -0.892 0 CA-C-N 115.367 -0.833 . . . . 1.0 109.222 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -90.63 127.93 36.45 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.268 -1.752 . . . . 1.0 106.268 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.1 t -52.75 -33.5 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 C-N-CA 119.6 -0.84 . . . . 1.0 110.149 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 3.3 t -74.06 -26.66 60.52 Favored 'General case' 0 CA--C 1.515 -0.401 0 C-N-CA 120.21 -0.596 . . . . 1.0 111.651 -178.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -100.29 -3.76 30.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.312 -0.404 . . . . 1.0 111.873 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -84.3 166.58 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 CA-C-N 118.233 0.469 . . . . 1.0 111.406 -178.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -52.8 147.28 15.94 Favored Pre-proline 0 N--CA 1.474 0.756 0 N-CA-C 109.093 -0.706 . . . . 1.0 109.093 -177.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -50.9 -43.55 46.59 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.747 1.631 . . . . 1.0 112.701 -178.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.19 92.29 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 119.57 -1.3 . . . . 1.0 110.018 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.609 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.4 m95 -64.32 -35.91 82.41 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.369 -0.916 . . . . 1.0 110.398 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 25.1 m -51.0 -53.11 36.22 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.721 0.296 . . . . 1.0 111.67 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 20.5 tp10 -72.39 -41.62 66.11 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.738 0.644 . . . . 1.0 112.738 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.66 -45.45 91.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 114.036 1.125 . . . . 1.0 114.036 -177.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.04 -41.91 88.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.263 0.554 . . . . 1.0 109.761 -177.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.0 mt-30 -64.66 -24.61 67.64 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.705 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.496 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 59.8 mt -101.9 -10.67 19.62 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.182 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.7 ttp -91.78 107.39 22.08 Favored Pre-proline 0 CA--C 1.546 0.789 0 O-C-N 123.154 0.283 . . . . 1.0 111.639 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.424 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -66.93 147.69 80.8 Favored 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.508 2.139 . . . . 1.0 111.98 178.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.596 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.59 139.55 58.78 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-O 121.686 0.755 . . . . 1.0 111.429 -179.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.78 -18.76 54.81 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.123 -1.991 . . . . 1.0 108.123 -178.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.4 p -89.88 129.6 36.22 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.037 0.446 . . . . 1.0 110.621 179.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 85.1 m -103.44 114.22 28.33 Favored 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 115.659 -0.701 . . . . 1.0 109.855 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.496 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -115.98 161.94 18.11 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.742 0.782 . . . . 1.0 111.487 -178.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.4 mt-10 -121.57 125.61 47.16 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.162 -1.421 . . . . 1.0 107.162 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -120.9 138.03 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.564 0 CA-C-O 121.8 0.81 . . . . 1.0 109.838 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.724 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.0 103.4 12.42 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -177.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.27 116.25 65.94 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 115.022 1.49 . . . . 1.0 115.022 -174.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -51.39 142.58 37.44 Favored 'Trans proline' 0 C--N 1.315 -1.191 0 C-N-CA 121.361 1.374 . . . . 1.0 109.81 176.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 97.6 p -48.61 -35.28 13.25 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.31 -0.556 . . . . 1.0 111.185 -178.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.75 -32.77 82.22 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.153 -0.779 . . . . 1.0 111.153 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.5 mt -98.46 2.49 47.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.957 -0.121 . . . . 1.0 110.91 -179.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.45 -110.77 0.31 Allowed 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 112.029 0.381 . . . . 1.0 112.029 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.439 ' O ' HG21 ' A' ' 114' ' ' VAL . 44.4 m-85 -96.88 4.31 51.7 Favored 'General case' 0 C--N 1.342 0.249 0 N-CA-C 112.288 0.477 . . . . 1.0 112.288 -177.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.11 162.87 17.93 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 121.172 -0.537 . . . . 1.0 112.831 177.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 121' ' ' ASN . 83.3 Cg_endo -76.9 -10.23 18.17 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 123.423 2.749 . . . . 1.0 111.4 179.229 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 5.9 ttm-85 -105.15 168.45 9.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.252 -0.885 . . . . 1.0 109.51 -179.545 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.518 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -74.18 100.04 3.56 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.3 -0.629 . . . . 1.0 109.3 178.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 109' ' ' TYR . 14.0 t -110.9 61.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.76 0.314 . . . . 1.0 110.831 -179.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 159.15 175.73 30.41 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 120.472 -0.87 . . . . 1.0 112.44 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.42 -103.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.328 0 CA-C-N 114.963 -0.619 . . . . 1.0 111.87 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -61.87 -16.95 52.62 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 122.613 2.208 . . . . 1.0 111.773 -177.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.691 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.3 mp -67.4 114.56 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 108.343 -0.984 . . . . 1.0 108.343 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.416 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.98 -171.02 38.53 Favored Glycine 0 N--CA 1.452 -0.258 0 N-CA-C 110.949 -0.86 . . . . 1.0 110.949 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.518 ' N ' ' OG ' ' A' ' 113' ' ' SER . 34.1 Cg_endo -64.01 139.55 67.97 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.318 2.012 . . . . 1.0 112.627 179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.529 ' N ' ' O ' ' A' ' 111' ' ' PRO . 17.1 t-20 52.59 48.85 21.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.439 -0.346 . . . . 1.0 111.371 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.608 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -93.14 132.58 37.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.541 -0.3 . . . . 1.0 110.716 179.843 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.422 HG21 HD11 ' A' ' 16' ' ' LEU . 52.1 m -96.2 127.77 42.5 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.405 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.5 mm? -111.28 145.33 38.97 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.128 0.489 . . . . 1.0 110.468 -179.162 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.724 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -122.63 146.14 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.476 -0.783 . . . . 1.0 108.937 178.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.622 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.6 m-85 -136.33 149.65 48.49 Favored 'General case' 0 CA--C 1.517 -0.319 0 C-N-CA 120.26 -0.576 . . . . 1.0 111.509 178.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 12.6 mmtt -99.5 123.57 43.89 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 105.423 -2.065 . . . . 1.0 105.423 177.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.7 mt -118.94 118.1 56.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 119.112 -1.035 . . . . 1.0 112.879 -176.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -108.65 126.22 52.73 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 113.572 -1.649 . . . . 1.0 108.278 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 111.3 23.42 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 119.871 -0.732 . . . . 1.0 112.271 -178.124 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.2 mp -93.71 -45.93 13.76 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.852 -0.613 . . . . 1.0 111.676 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.6 p -150.84 156.03 40.41 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.575 -0.45 . . . . 1.0 110.84 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.402 HG21 ' HA ' ' A' ' 44' ' ' LYS . 56.9 t -128.0 141.45 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.969 -0.559 . . . . 1.0 111.395 -178.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.406 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.2 tptm . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.638 -0.71 . . . . 1.0 110.33 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 CA--C 1.516 -0.342 0 CA-C-O 121.687 0.756 . . . . 1.0 110.419 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.4 m-20 -58.02 -34.01 69.57 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.501 -0.926 . . . . 1.0 108.501 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -66.21 -51.08 61.1 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.406 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.99 -48.22 82.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 119.942 -0.703 . . . . 1.0 111.614 -178.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.453 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.8 -38.95 92.74 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.785 -1.191 . . . . 1.0 107.785 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.413 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.08 -46.27 52.11 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-N 114.779 -1.101 . . . . 1.0 112.631 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -59.53 -34.97 73.32 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.288 -0.965 . . . . 1.0 108.492 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.58 -36.14 65.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.94 -1.027 . . . . 1.0 110.401 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -61.31 -50.4 73.12 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.879 -1.055 . . . . 1.0 110.628 -179.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.416 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -67.1 -39.81 86.78 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 119.783 -0.767 . . . . 1.0 109.461 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.9 m -61.86 -42.16 98.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.743 -0.662 . . . . 1.0 109.657 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -75.24 -45.46 39.98 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.661 -0.699 . . . . 1.0 111.845 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.647 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.8 t30 -61.65 -44.65 96.57 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 113.18 0.807 . . . . 1.0 113.18 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -59.74 -34.9 73.55 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.27 -0.972 . . . . 1.0 108.578 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -71.51 -36.29 71.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.158 -0.928 . . . . 1.0 111.991 178.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 mtmt -55.78 135.66 72.24 Favored Pre-proline 0 CA--C 1.546 0.808 0 CA-C-N 116.412 -0.358 . . . . 1.0 111.588 -178.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.76 148.37 66.33 Favored 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.202 1.935 . . . . 1.0 113.627 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.06 -19.71 20.4 Favored Glycine 0 C--O 1.226 -0.394 0 CA-C-N 115.136 -0.938 . . . . 1.0 111.004 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.5 t -85.17 136.0 23.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.161 0.505 . . . . 1.0 110.155 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.07 121.46 65.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 107.767 -1.197 . . . . 1.0 107.767 178.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 p -95.93 145.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.648 0.737 . . . . 1.0 111.703 -177.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.55 164.15 16.06 Favored Pre-proline 0 C--N 1.334 -0.106 0 CA-C-N 114.455 -1.248 . . . . 1.0 110.437 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.57 -30.81 86.6 Favored 'Trans proline' 0 C--N 1.318 -1.059 0 C-N-CA 121.634 1.556 . . . . 1.0 111.339 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 m -69.33 -10.73 59.23 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.925 -0.579 . . . . 1.0 109.912 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.35 -2.8 71.5 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 110.232 -1.147 . . . . 1.0 110.232 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.482 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -79.17 133.27 36.72 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 108.628 -0.879 . . . . 1.0 108.628 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.482 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.4 mp0 -122.8 139.54 53.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.395 -0.366 . . . . 1.0 110.983 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -135.5 143.13 45.63 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.675 0.75 . . . . 1.0 110.913 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.534 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.2 tmtp? -126.58 132.9 51.19 Favored 'General case' 0 CA--C 1.503 -0.86 0 CA-C-N 114.645 -1.161 . . . . 1.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.78 104.66 15.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.167 0.984 . . . . 1.0 111.906 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.621 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.5 mm -69.58 -41.86 80.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 108.007 -1.108 . . . . 1.0 108.007 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -142.36 129.64 21.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.573 -1.194 . . . . 1.0 109.804 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.7 p -88.49 131.35 34.93 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.764 -0.458 . . . . 1.0 109.764 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.0 -33.25 1.08 Allowed Glycine 0 C--N 1.331 0.291 0 N-CA-C 110.051 -1.219 . . . . 1.0 110.051 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.66 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 54.7 30.93 14.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.375 -0.413 . . . . 1.0 110.958 179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.31 -162.3 37.85 Favored Glycine 0 C--N 1.331 0.281 0 CA-C-O 121.905 0.725 . . . . 1.0 111.957 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.5 m -68.81 -178.63 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 113.905 -1.148 . . . . 1.0 109.125 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.674 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.49 154.77 0.4 Allowed Pre-proline 0 C--N 1.321 -0.631 0 O-C-N 123.705 0.628 . . . . 1.0 109.948 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.404 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.0 Cg_endo -87.33 154.43 8.0 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 123.439 2.759 . . . . 1.0 116.971 -174.486 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.45 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.55 177.2 48.47 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 109.141 -1.584 . . . . 1.0 109.141 175.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.504 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.37 -25.43 15.43 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.963 -0.295 . . . . 1.0 111.507 -179.722 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.6 m -108.03 -5.11 17.23 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.815 0.672 . . . . 1.0 112.815 -176.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.45 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 66.6 m-20 -83.49 165.36 19.2 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.4 m -106.52 150.31 26.25 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 109.636 -0.505 . . . . 1.0 109.636 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -129.39 162.94 35.9 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.465 0 CA-C-N 116.126 -0.488 . . . . 1.0 111.982 -176.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 51' ' ' VAL . 98.5 m -130.15 119.63 23.3 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 108.52 -0.918 . . . . 1.0 108.52 177.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.501 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.7 m -148.18 165.17 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 114.885 1.439 . . . . 1.0 114.885 -177.006 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.416 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.2 mt-10 -118.89 145.07 46.02 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 106.568 -1.642 . . . . 1.0 106.568 174.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.525 ' O ' ' N ' ' A' ' 68' ' ' THR . 38.8 p90 -161.11 164.07 30.94 Favored 'General case' 0 C--N 1.344 0.357 0 N-CA-C 114.825 1.417 . . . . 1.0 114.825 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -127.13 127.86 45.26 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 115.158 -0.928 . . . . 1.0 108.792 175.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.8 134.1 11.61 Favored Glycine 0 N--CA 1.473 1.114 0 C-N-CA 120.933 -0.651 . . . . 1.0 111.92 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.7 ptp85 -147.86 170.31 17.92 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.866 0.841 . . . . 1.0 113.071 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -83.58 164.08 19.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 114.126 -1.397 . . . . 1.0 110.795 178.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.449 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.3 -25.86 35.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.017 -0.992 . . . . 1.0 110.769 178.329 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -95.25 6.01 50.18 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.564 -1.198 . . . . 1.0 111.857 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.39 -3.46 75.69 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 121.01 -0.614 . . . . 1.0 113.313 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 m -71.78 106.58 4.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 118.157 0.978 . . . . 1.0 110.228 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 54.5 t -76.33 130.41 36.25 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.232 0.539 . . . . 1.0 110.575 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -120.37 -14.45 8.73 Favored 'General case' 0 CA--C 1.522 -0.112 0 CA-C-N 115.11 -0.95 . . . . 1.0 111.208 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 67' ' ' SER . 30.4 t0 -155.38 151.83 28.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.379 -0.373 . . . . 1.0 111.098 178.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 87.8 p -160.84 154.61 22.41 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 112.723 0.638 . . . . 1.0 112.723 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 55' ' ' TYR . 85.3 m -155.3 -42.01 0.08 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.143 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.405 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 2.0 pp20? -61.32 -26.19 67.63 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.602 -0.439 . . . . 1.0 110.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -53.83 -42.73 68.8 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.212 -1.033 . . . . 1.0 108.212 178.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' A' ' 68' ' ' THR . 21.6 p -78.36 -30.61 48.08 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.957 -1.019 . . . . 1.0 108.956 177.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.75 17.16 73.56 Favored Glycine 0 C--N 1.337 0.593 0 N-CA-C 111.363 -0.695 . . . . 1.0 111.363 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 7.2 mptt -99.89 115.94 65.12 Favored Pre-proline 0 N--CA 1.469 0.492 0 C-N-CA 120.987 -0.285 . . . . 1.0 110.498 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.416 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 37.2 Cg_exo -61.13 152.49 71.33 Favored 'Trans proline' 0 N--CA 1.483 0.867 0 C-N-CA 121.646 1.564 . . . . 1.0 113.964 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.31 149.53 46.44 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.335 -1.302 . . . . 1.0 107.612 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -103.58 131.76 50.43 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.226 0.536 . . . . 1.0 112.219 -178.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -137.71 150.05 47.0 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 115.29 -0.868 . . . . 1.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -93.47 124.65 37.6 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.162 -1.792 . . . . 1.0 106.162 174.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.4 t -51.46 -27.1 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 C-N-CA 119.778 -0.769 . . . . 1.0 110.608 -176.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 42.4 t -76.32 -24.58 54.31 Favored 'General case' 0 CA--C 1.519 -0.224 0 C-N-CA 120.344 -0.542 . . . . 1.0 112.287 -179.159 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 88.4 mm-40 -98.56 -8.27 26.8 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 112.233 0.457 . . . . 1.0 112.233 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.4 p -83.08 168.8 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 119.961 -0.696 . . . . 1.0 111.852 -177.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.483 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -55.19 153.32 13.05 Favored Pre-proline 0 CA--C 1.548 0.867 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 -177.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.483 ' HD2' HG22 ' A' ' 83' ' ' ILE . 50.8 Cg_exo -53.28 -45.65 39.5 Favored 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.633 1.556 . . . . 1.0 112.948 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.11 -48.09 85.16 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.501 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 8.1 m95 -64.07 -35.74 81.74 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.101 -1.05 . . . . 1.0 110.108 179.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.4 m -52.17 -54.0 36.2 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.649 -0.42 . . . . 1.0 111.294 -178.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -72.71 -42.73 63.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.976 -0.557 . . . . 1.0 112.338 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.57 -47.36 79.69 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 113.848 1.055 . . . . 1.0 113.848 -177.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.2 mt -58.25 -41.76 84.9 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.365 0.603 . . . . 1.0 109.799 -178.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.5 mt-30 -63.24 -24.78 68.02 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.952 -1.022 . . . . 1.0 110.904 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.42 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 70.1 mt -101.65 -13.27 17.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.252 -0.431 . . . . 1.0 111.29 -179.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 36.5 ttp -88.04 108.99 24.31 Favored Pre-proline 0 CA--C 1.547 0.847 0 N-CA-C 112.249 0.463 . . . . 1.0 112.249 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.674 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.8 Cg_exo -66.37 147.77 83.33 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.274 1.983 . . . . 1.0 112.289 178.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.78 136.85 57.75 Favored 'General case' 0 CA--C 1.509 -0.627 0 CA-C-O 121.492 0.663 . . . . 1.0 111.503 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.08 -18.48 56.06 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 109.001 -1.64 . . . . 1.0 109.001 -178.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -86.99 133.67 33.56 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 120.894 0.378 . . . . 1.0 110.165 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 84.4 m -106.06 112.96 26.22 Favored 'General case' 0 CA--C 1.511 -0.557 0 CA-C-N 115.986 -0.552 . . . . 1.0 109.938 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.42 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.3 m0 -115.1 163.75 15.18 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.677 0.751 . . . . 1.0 111.544 -178.53 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.621 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.1 mt-10 -124.02 124.56 42.82 Favored 'General case' 0 CA--C 1.51 -0.566 0 N-CA-C 107.101 -1.444 . . . . 1.0 107.101 175.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -119.0 137.84 51.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.866 0.841 . . . . 1.0 110.086 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.714 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.84 103.42 12.21 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 105.707 -1.96 . . . . 1.0 105.707 -178.303 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 t -90.63 116.12 65.7 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 115.529 1.678 . . . . 1.0 115.529 -174.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -50.75 143.32 29.77 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 121.611 1.54 . . . . 1.0 110.23 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 79.9 p -49.76 -35.43 22.39 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.282 -0.567 . . . . 1.0 110.524 -178.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.02 -32.39 82.37 Favored Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.985 -0.846 . . . . 1.0 110.985 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 42.9 mt -100.87 2.64 41.17 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.877 -0.162 . . . . 1.0 110.898 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 83' ' ' ILE . . . -107.37 -104.53 0.34 Allowed 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 117.693 0.224 . . . . 1.0 110.511 -178.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.438 ' O ' HG21 ' A' ' 114' ' ' VAL . 53.5 m-85 -104.99 5.39 32.61 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 113.564 0.95 . . . . 1.0 113.564 -178.24 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 108.54 164.68 20.88 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.924 -0.655 . . . . 1.0 113.506 176.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.475 ' O ' ' N ' ' A' ' 121' ' ' ASN . 89.9 Cg_endo -75.11 -14.75 20.8 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 C-N-CA 123.618 2.878 . . . . 1.0 111.404 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.441 ' O ' HG23 ' A' ' 114' ' ' VAL . 58.1 mtm180 -101.28 165.98 11.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.115 -0.948 . . . . 1.0 109.586 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.448 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -75.21 97.71 3.58 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.411 -0.516 . . . . 1.0 109.844 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 112' ' ' ARG . 3.2 t -110.34 59.0 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.858 -179.181 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 167.81 -178.29 41.73 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 120.117 -1.04 . . . . 1.0 112.247 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -58.35 -106.4 0.01 OUTLIER Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.972 -0.451 . . . . 1.0 111.972 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -14.87 38.9 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 122.028 1.819 . . . . 1.0 111.011 -178.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.895 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -67.03 115.89 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 107.922 -1.14 . . . . 1.0 107.922 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.598 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -93.88 -160.72 34.98 Favored Glycine 0 C--O 1.215 -1.047 0 N-CA-C 110.398 -1.081 . . . . 1.0 110.398 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.448 ' N ' ' OG ' ' A' ' 113' ' ' SER . 74.2 Cg_endo -73.35 145.39 38.29 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 122.112 1.874 . . . . 1.0 112.756 178.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 111' ' ' PRO . 1.1 t30 45.24 59.92 3.28 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.782 0.66 . . . . 1.0 112.782 177.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.688 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -115.06 138.44 50.88 Favored 'General case' 0 N--CA 1.473 0.702 0 CA-C-O 121.62 0.724 . . . . 1.0 111.185 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.416 HG21 HD11 ' A' ' 16' ' ' LEU . 97.5 m -94.57 129.53 41.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.658 -1.155 . . . . 1.0 108.71 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.416 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.8 mm? -111.96 143.57 42.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.248 0.547 . . . . 1.0 110.076 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.714 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -122.44 148.15 26.25 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 108.659 -0.867 . . . . 1.0 108.659 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.34 150.94 47.08 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.051 0.453 . . . . 1.0 111.166 177.435 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.5 mmtt -100.25 123.33 44.35 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 105.721 -1.955 . . . . 1.0 105.721 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.423 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.8 119.0 58.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 119.143 -1.023 . . . . 1.0 113.056 -176.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.403 ' CE1' HG13 ' A' ' 131' ' ' ILE . 10.1 t-160 -109.96 123.25 49.3 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 113.885 -1.507 . . . . 1.0 108.682 178.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.49 111.29 23.22 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 120.346 -0.542 . . . . 1.0 112.186 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.447 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -93.46 -44.69 13.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.33 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -152.12 156.55 40.08 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.068 0.461 . . . . 1.0 111.03 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.439 HG21 ' HA ' ' A' ' 44' ' ' LYS . 49.1 t -129.82 134.71 62.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.969 -0.56 . . . . 1.0 110.446 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.9 tptm . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 122.011 0.91 . . . . 1.0 110.452 179.471 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 . . . . . 0 CA--C 1.511 -0.543 0 CA-C-O 121.929 0.871 . . . . 1.0 110.29 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.545 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 9.6 m-20 -57.28 -35.75 70.16 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.549 -1.205 . . . . 1.0 108.462 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 tttm -65.96 -51.9 54.36 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 113.651 -1.613 . . . . 1.0 111.602 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.5 t -69.96 -48.41 63.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 C-N-CA 119.881 -0.728 . . . . 1.0 112.162 -178.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.448 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.18 -39.77 93.79 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 108.113 -1.069 . . . . 1.0 108.113 179.56 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.14 73.53 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-N 115.148 -0.933 . . . . 1.0 111.913 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.419 ' O ' ' OG1' ' A' ' 17' ' ' THR . 88.9 mt-10 -61.35 -31.6 71.48 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.974 -0.75 . . . . 1.0 108.974 178.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -34.08 50.2 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.135 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -63.12 -50.45 70.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.388 -1.278 . . . . 1.0 110.774 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.466 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -73.41 -39.73 64.83 Favored 'General case' 0 CA--C 1.509 -0.618 0 C-N-CA 119.912 -0.715 . . . . 1.0 110.225 178.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.419 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 91.1 m -62.0 -42.84 99.59 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.347 -179.243 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -75.85 -46.79 28.46 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.859 -0.609 . . . . 1.0 112.243 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 59.8 t30 -60.89 -44.63 96.83 Favored 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 113.573 0.953 . . . . 1.0 113.573 -177.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -59.2 -35.08 72.96 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 119.706 -0.798 . . . . 1.0 109.7 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -73.75 -33.99 64.53 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.221 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -60.37 125.51 82.07 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-N 115.956 -0.565 . . . . 1.0 112.066 -178.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.27 149.92 15.64 Favored 'Trans proline' 0 N--CA 1.5 1.854 0 C-N-CA 122.168 1.912 . . . . 1.0 112.847 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.77 -20.14 33.53 Favored Glycine 0 C--O 1.224 -0.523 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 -179.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 35' ' ' LYS . 48.9 t -93.36 133.01 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 1.0 109.614 179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.1 t -117.41 120.83 66.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 108.528 -0.916 . . . . 1.0 108.528 177.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.1 p -96.34 146.08 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.623 0 CA-C-O 121.676 0.75 . . . . 1.0 111.393 -178.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 62.5 mt -113.56 164.22 16.42 Favored Pre-proline 0 C--N 1.332 -0.167 0 CA-C-N 114.438 -1.255 . . . . 1.0 110.958 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.07 -30.35 93.04 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.894 1.73 . . . . 1.0 110.913 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.5 m -67.93 -15.17 63.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.785 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.66 68.57 Favored Glycine 0 C--O 1.23 -0.139 0 N-CA-C 110.089 -1.205 . . . . 1.0 110.089 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.474 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.74 133.97 38.18 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 109.056 -0.72 . . . . 1.0 109.056 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.474 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.0 mp0 -123.12 137.77 54.83 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.1 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -133.73 143.16 48.31 Favored 'General case' 0 CA--C 1.504 -0.797 0 CA-C-O 121.739 0.78 . . . . 1.0 110.927 178.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -126.96 131.84 50.97 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 114.432 -1.258 . . . . 1.0 109.562 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -88.39 105.12 15.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 122.045 0.926 . . . . 1.0 111.922 -178.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.1 mm -69.44 -42.34 80.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.036 -0.984 . . . . 1.0 108.447 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.442 HD22 ' HB ' ' A' ' 98' ' ' THR . 23.0 m-80 -141.96 127.19 18.61 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.524 -1.216 . . . . 1.0 109.72 -179.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -86.73 130.96 34.27 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.803 0.335 . . . . 1.0 110.399 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.528 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -121.33 -36.01 0.77 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 109.914 -1.275 . . . . 1.0 109.914 179.597 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.64 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 58.48 32.81 22.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 1.0 111.593 179.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.9 -161.67 37.58 Favored Glycine 0 C--N 1.331 0.255 0 CA-C-O 121.861 0.7 . . . . 1.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 26.4 m -69.6 -178.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.07 -1.065 . . . . 1.0 109.494 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.719 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.47 154.43 0.45 Allowed Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 109.61 -0.515 . . . . 1.0 109.61 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HB2' ' HB2' ' A' ' 49' ' ' ASP . 60.1 Cg_endo -88.02 157.47 7.18 Favored 'Trans proline' 0 N--CA 1.503 2.077 0 C-N-CA 123.72 2.946 . . . . 1.0 117.454 -174.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.443 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.45 177.6 48.75 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 109.725 -1.35 . . . . 1.0 109.725 175.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.478 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.05 -25.54 31.42 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.216 -0.492 . . . . 1.0 111.904 -179.612 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.7 m -108.94 -4.84 16.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.551 0.574 . . . . 1.0 112.551 -177.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.443 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 89.5 m-20 -82.18 169.56 16.46 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.046 -0.724 . . . . 1.0 109.046 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.6 m -111.4 151.46 28.47 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.699 -0.482 . . . . 1.0 109.699 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.444 HG11 HD13 ' A' ' 90' ' ' LEU . 5.4 p -129.96 162.56 37.46 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 CA-C-N 115.754 -0.657 . . . . 1.0 111.716 -176.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 73.6 m -129.67 120.16 24.72 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.288 -1.004 . . . . 1.0 108.288 177.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.57 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.5 m -149.06 164.86 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 N-CA-C 114.379 1.252 . . . . 1.0 114.379 -176.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.411 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 2.6 mt-10 -118.72 146.26 44.88 Favored 'General case' 0 N--CA 1.486 1.352 0 N-CA-C 106.056 -1.831 . . . . 1.0 106.056 174.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.508 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.1 p90 -162.98 164.61 25.63 Favored 'General case' 0 C--N 1.342 0.275 0 N-CA-C 114.971 1.471 . . . . 1.0 114.971 -176.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -125.97 130.45 51.24 Favored 'General case' 0 C--O 1.216 -0.679 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.706 175.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.48 132.86 10.72 Favored Glycine 0 N--CA 1.473 1.113 0 N-CA-C 111.356 -0.698 . . . . 1.0 111.356 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 -147.06 167.54 23.82 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.788 0.804 . . . . 1.0 112.658 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.6 mp -81.9 164.83 21.28 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 114.252 -1.34 . . . . 1.0 110.274 178.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.425 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.82 -26.27 37.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 114.794 -1.094 . . . . 1.0 110.243 178.173 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.415 ' O ' ' OD2' ' A' ' 61' ' ' ASP . 7.0 t70 -94.04 5.26 52.27 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.019 -1.446 . . . . 1.0 111.919 -176.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.56 -4.53 79.7 Favored Glycine 0 CA--C 1.528 0.883 0 C-N-CA 121.0 -0.619 . . . . 1.0 113.227 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -70.29 103.88 2.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 118.073 0.937 . . . . 1.0 110.028 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -75.55 128.3 37.18 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.727 0 C-N-CA 120.642 -0.423 . . . . 1.0 110.059 179.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.761 ' CD2' HD11 ' A' ' 118' ' ' ILE . 9.2 p90 -116.08 -10.34 11.55 Favored 'General case' 0 CA--C 1.521 -0.165 0 CA-C-N 115.439 -0.8 . . . . 1.0 111.116 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -164.24 153.32 13.55 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.443 -0.503 . . . . 1.0 111.677 177.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.7 p -159.41 158.08 31.46 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 115.763 -0.653 . . . . 1.0 111.869 179.214 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 67.2 m -152.78 -40.61 0.1 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.358 -0.837 . . . . 1.0 110.254 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.435 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.3 pp20? -59.86 -27.59 66.8 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.373 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -55.45 -40.23 71.33 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.641 -1.244 . . . . 1.0 107.641 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.8 -34.94 57.92 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.029 -1.442 . . . . 1.0 108.642 178.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.54 17.87 69.9 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 110.69 -0.964 . . . . 1.0 110.69 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -105.07 116.26 60.94 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 121.155 -0.218 . . . . 1.0 110.754 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 32.3 Cg_exo -60.36 149.93 83.31 Favored 'Trans proline' 0 N--CA 1.479 0.67 0 C-N-CA 121.255 1.303 . . . . 1.0 113.358 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -122.83 151.27 41.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 114.483 -1.235 . . . . 1.0 108.204 178.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.1 t -106.41 127.44 53.29 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 113.13 0.789 . . . . 1.0 113.13 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 54.6 m-85 -133.97 150.02 51.26 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-N 115.148 -0.933 . . . . 1.0 108.973 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -90.38 125.05 35.41 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 106.353 -1.721 . . . . 1.0 106.353 174.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.431 HG11 HE21 ' A' ' 91' ' ' GLN . 25.5 t -48.48 -30.43 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 120.06 -0.656 . . . . 1.0 110.199 -177.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.9 t -75.13 -25.12 58.17 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.27 -0.572 . . . . 1.0 111.681 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -98.87 -8.2 26.08 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 113.518 0.933 . . . . 1.0 113.518 -177.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.472 HG22 ' H ' ' A' ' 83' ' ' ILE . 3.9 p -88.22 170.49 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 118.907 0.776 . . . . 1.0 111.974 -178.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.472 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -52.98 148.51 13.85 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 120.256 -0.578 . . . . 1.0 109.623 -176.684 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.75 -44.34 41.48 Favored 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 122.25 1.967 . . . . 1.0 113.143 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.63 -47.43 90.19 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.818 -1.313 . . . . 1.0 109.818 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.57 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.2 m95 -63.79 -36.97 85.63 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.747 -1.227 . . . . 1.0 110.128 178.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 20.9 m -50.89 -54.19 26.1 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 116.258 -0.428 . . . . 1.0 111.041 -177.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.0 tp10 -72.84 -42.6 63.58 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.541 0.571 . . . . 1.0 112.541 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.52 -47.21 79.83 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 113.552 0.945 . . . . 1.0 113.552 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.444 HD13 HG11 ' A' ' 51' ' ' VAL . 79.3 mt -57.84 -41.28 82.01 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.406 0.622 . . . . 1.0 109.995 -178.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.431 HE21 HG11 ' A' ' 79' ' ' VAL . 67.9 mt-30 -64.57 -23.74 67.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.26 -0.882 . . . . 1.0 111.126 -179.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.8 mt -105.3 -12.23 16.15 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.505 -0.316 . . . . 1.0 111.075 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 17.6 ttm -88.77 108.4 23.08 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 116.014 -0.539 . . . . 1.0 111.925 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.719 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.2 Cg_exo -65.54 149.14 87.9 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.853 2.369 . . . . 1.0 113.318 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.86 133.43 51.88 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-N 115.591 -0.731 . . . . 1.0 111.359 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.4 -19.06 54.8 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 109.67 -1.372 . . . . 1.0 109.67 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.528 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 23.8 t -84.08 125.96 32.62 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.967 0.413 . . . . 1.0 109.946 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.442 ' HB ' HD22 ' A' ' 38' ' ' ASN . 44.1 m -96.94 111.86 23.88 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 116.151 -0.477 . . . . 1.0 110.044 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.431 ' NE1' ' OG ' ' A' ' 97' ' ' SER . 39.8 m0 -114.95 164.47 14.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.863 0.84 . . . . 1.0 111.476 -178.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.6 mt-10 -125.81 126.52 44.65 Favored 'General case' 0 CA--C 1.508 -0.636 0 N-CA-C 106.582 -1.636 . . . . 1.0 106.582 175.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.0 pt -120.4 137.15 55.13 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.767 0.794 . . . . 1.0 109.792 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.35 103.27 12.39 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 105.77 -1.937 . . . . 1.0 105.77 -178.13 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.95 115.09 63.57 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 114.969 1.47 . . . . 1.0 114.969 -174.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -51.32 144.53 30.45 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.121 1.214 . . . . 1.0 109.768 175.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.4 p -49.0 -36.67 18.21 Favored 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 120.653 -0.419 . . . . 1.0 110.961 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.18 -32.29 81.8 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.377 -0.689 . . . . 1.0 111.377 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 59.1 mt -98.58 2.07 47.06 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 122.926 -0.161 . . . . 1.0 110.645 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.37 -111.26 0.31 Allowed 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 110.035 -0.358 . . . . 1.0 110.035 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.3 m-85 -98.88 4.21 47.42 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 112.327 0.492 . . . . 1.0 112.327 -178.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.85 157.9 15.36 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 121.387 -0.435 . . . . 1.0 112.592 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.445 ' O ' ' N ' ' A' ' 121' ' ' ASN . 88.4 Cg_endo -74.12 -11.72 23.28 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 123.506 2.804 . . . . 1.0 110.562 179.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . 0.437 ' O ' HG23 ' A' ' 114' ' ' VAL . 70.2 ttt180 -100.85 165.12 11.51 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.8 -1.091 . . . . 1.0 108.946 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.51 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.1 m -72.28 97.17 1.95 Allowed 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 119.989 -0.684 . . . . 1.0 109.173 178.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 112' ' ' ARG . 4.4 t -112.08 60.9 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 121.049 -0.261 . . . . 1.0 111.322 -179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 163.19 169.39 26.56 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.333 -0.937 . . . . 1.0 111.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.21 -103.47 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.191 -0.764 . . . . 1.0 111.191 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -60.81 -19.39 61.44 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 122.46 2.107 . . . . 1.0 111.608 -178.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.761 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.4 mp -68.05 118.7 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 107.54 -1.282 . . . . 1.0 107.54 178.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -101.31 -168.0 27.87 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 115.225 -0.898 . . . . 1.0 113.796 -176.591 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 19.5 Cg_endo -63.6 144.71 90.48 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.859 2.373 . . . . 1.0 112.289 178.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.445 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 43.25 50.93 5.84 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.717 0.294 . . . . 1.0 111.004 179.108 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.545 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 3.9 tp10 -106.15 127.51 53.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.623 0.725 . . . . 1.0 112.627 -177.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.466 HG21 HD11 ' A' ' 16' ' ' LEU . 25.7 m -95.61 135.24 37.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.649 -1.16 . . . . 1.0 108.52 178.205 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.0 mm? -115.32 142.16 47.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.232 0.539 . . . . 1.0 110.862 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.53 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.5 tt -120.84 149.37 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 115.468 -0.787 . . . . 1.0 108.951 178.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.581 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -139.62 149.84 44.26 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.507 -0.477 . . . . 1.0 111.046 177.019 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.9 mmtt -100.5 122.35 43.08 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 105.577 -2.008 . . . . 1.0 105.577 178.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.458 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.18 119.37 60.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 C-N-CA 119.311 -0.956 . . . . 1.0 113.564 -175.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . 0.42 ' ND1' HD11 ' A' ' 131' ' ' ILE . 10.4 t-160 -108.53 122.58 47.34 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 113.912 -1.495 . . . . 1.0 108.451 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.7 110.58 22.69 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.173 0.511 . . . . 1.0 111.64 -178.483 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.451 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -93.69 -46.86 13.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.212 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.3 p -150.99 158.45 44.15 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.237 0.542 . . . . 1.0 111.188 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.44 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -129.05 141.99 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 115.492 -0.776 . . . . 1.0 110.001 -178.015 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.3 tptm . . . . . 0 N--CA 1.449 -0.503 0 CA-C-O 121.45 0.643 . . . . 1.0 111.929 -178.847 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.4 ' O ' ' HD2' ' A' ' 11' ' ' LYS . 48.1 mt-10 . . . . . 0 CA--C 1.508 -0.647 0 CA-C-O 121.571 0.7 . . . . 1.0 110.709 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.549 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 4.0 m-20 -59.6 -36.98 77.35 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.145 -1.057 . . . . 1.0 108.145 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.3 ttpm? -66.74 -50.54 62.43 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 113.762 -1.563 . . . . 1.0 111.867 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.4 t -65.14 -48.67 82.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 119.614 -0.834 . . . . 1.0 110.993 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.462 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.83 -38.32 90.66 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.028 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.424 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.35 -46.97 46.22 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 115.094 -0.957 . . . . 1.0 112.199 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.431 ' O ' ' OG1' ' A' ' 17' ' ' THR . 91.9 mt-10 -57.69 -34.81 69.81 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 108.645 -0.872 . . . . 1.0 108.645 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.05 -31.01 44.38 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.853 -1.067 . . . . 1.0 110.364 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -61.68 -49.23 77.32 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.147 -179.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.424 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.2 mp -66.57 -38.23 86.63 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 119.69 -0.804 . . . . 1.0 109.304 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.8 m -61.85 -42.97 99.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.549 0.69 . . . . 1.0 109.275 178.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -74.21 -44.29 53.8 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-N 115.334 -0.848 . . . . 1.0 111.609 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -56.83 -50.16 73.24 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.111 0.481 . . . . 1.0 111.883 -178.874 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 9.5 ptmt -60.01 -28.63 67.88 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.221 -0.992 . . . . 1.0 109.545 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -81.87 -29.57 32.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.33 -0.85 . . . . 1.0 111.442 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -58.95 136.35 87.52 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 120.848 -0.341 . . . . 1.0 111.177 -179.152 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -55.75 148.47 55.29 Favored 'Trans proline' 0 N--CA 1.506 2.234 0 C-N-CA 122.48 2.12 . . . . 1.0 114.179 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.76 -18.59 11.56 Favored Glycine 0 N--CA 1.462 0.428 0 CA-C-N 115.097 -0.956 . . . . 1.0 111.397 178.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.4 t -85.08 136.27 23.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.04 0.448 . . . . 1.0 111.074 -179.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.5 t -120.47 122.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 N-CA-C 107.716 -1.216 . . . . 1.0 107.716 176.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.27 147.0 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 121.414 0.626 . . . . 1.0 111.812 -178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 54.6 mt -115.79 163.77 19.86 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.758 -1.11 . . . . 1.0 110.779 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.22 -31.91 93.67 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.584 1.523 . . . . 1.0 111.974 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.4 m -68.14 -12.23 60.54 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 109.294 -0.632 . . . . 1.0 109.294 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.0 -1.57 68.05 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 109.365 -1.494 . . . . 1.0 109.365 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.489 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -79.98 134.39 36.25 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.434 -0.95 . . . . 1.0 108.434 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.489 ' H ' HD22 ' A' ' 32' ' ' LEU . 13.0 mp0 -124.84 145.54 49.73 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-N 115.891 -0.595 . . . . 1.0 110.929 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -139.39 150.11 44.9 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.521 0.677 . . . . 1.0 110.733 178.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.5 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -135.13 134.94 40.73 Favored 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 114.563 -1.199 . . . . 1.0 109.119 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -92.33 103.75 14.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 122.211 1.005 . . . . 1.0 111.742 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.618 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.3 mm -69.02 -41.74 81.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.039 -0.982 . . . . 1.0 109.197 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.406 HD22 ' HB ' ' A' ' 98' ' ' THR . 16.0 m-80 -142.04 128.0 19.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.109 -0.95 . . . . 1.0 109.942 -178.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.9 p -87.55 124.46 33.51 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.858 0.361 . . . . 1.0 110.101 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.468 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.19 -32.77 2.1 Favored Glycine 0 CA--C 1.517 0.218 0 N-CA-C 109.539 -1.424 . . . . 1.0 109.539 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.619 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 56.49 32.43 20.75 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.3 -0.45 . . . . 1.0 110.995 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.75 -163.01 38.66 Favored Glycine 0 C--N 1.329 0.167 0 CA-C-O 121.977 0.765 . . . . 1.0 111.536 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.602 ' O ' ' N ' ' A' ' 95' ' ' ALA . 29.2 m -69.43 -177.94 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.009 -1.095 . . . . 1.0 108.42 177.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.604 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.25 154.27 0.38 Allowed Pre-proline 0 C--N 1.316 -0.852 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.6 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.486 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 70.3 Cg_endo -87.79 152.78 7.36 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.827 2.351 . . . . 1.0 115.265 -175.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.53 178.98 51.54 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.612 -1.795 . . . . 1.0 108.612 176.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.648 ' NZ ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.95 -21.48 11.86 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.445 -0.502 . . . . 1.0 110.847 -179.666 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.4 m -107.64 -11.03 15.52 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 113.587 0.958 . . . . 1.0 113.587 -177.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -85.69 166.1 16.42 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 119.632 -0.827 . . . . 1.0 109.331 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.469 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 4.8 m -103.79 151.01 23.57 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.23 0.538 . . . . 1.0 110.43 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.486 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.3 p -128.06 157.56 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.421 0 CA-C-N 115.278 -0.874 . . . . 1.0 112.343 -176.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.447 HG22 ' HB3' ' A' ' 74' ' ' PRO . 98.1 m -124.07 120.54 32.68 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 107.923 -1.14 . . . . 1.0 107.923 177.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.618 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.7 m -149.23 163.18 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 114.698 1.37 . . . . 1.0 114.698 -175.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.4 152.61 35.52 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 106.384 -1.71 . . . . 1.0 106.384 173.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.554 ' H ' ' HB ' ' A' ' 68' ' ' THR . 33.6 p90 -164.09 160.73 21.89 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.528 1.307 . . . . 1.0 114.528 -177.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -123.37 128.46 49.91 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.953 -0.758 . . . . 1.0 108.953 175.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.8 137.69 14.45 Favored Glycine 0 N--CA 1.467 0.716 0 C-N-CA 120.925 -0.655 . . . . 1.0 112.138 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -146.18 165.91 27.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.714 0.769 . . . . 1.0 112.574 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.2 mp -82.91 163.28 21.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 114.276 -1.329 . . . . 1.0 110.052 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.33 -26.2 36.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.155 -0.929 . . . . 1.0 110.276 178.08 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -93.82 7.76 43.69 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.376 -1.284 . . . . 1.0 111.78 -177.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.83 -7.27 81.46 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 121.241 -0.504 . . . . 1.0 113.31 178.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -68.19 105.79 2.22 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 119.444 -0.902 . . . . 1.0 110.565 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 99.2 t -76.84 118.98 24.34 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.82 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -106.34 -20.22 13.45 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.016 -0.993 . . . . 1.0 111.897 -178.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.414 ' OD2' ' N ' ' A' ' 67' ' ' SER . 10.2 t70 -154.82 155.4 34.35 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.228 0.537 . . . . 1.0 111.972 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 92.9 p -157.4 159.8 37.75 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.341 -0.845 . . . . 1.0 111.57 178.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.554 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 89.9 m -155.25 -38.51 0.09 Allowed 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 115.567 -0.742 . . . . 1.0 110.01 -179.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -65.29 -25.37 67.61 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.638 -1.245 . . . . 1.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.6 mmtt -59.53 -45.63 91.2 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 176.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.8 OUTLIER -73.05 -33.36 65.64 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.505 -1.225 . . . . 1.0 108.194 177.423 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.55 18.93 67.27 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 111.497 -0.641 . . . . 1.0 111.497 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.9 115.37 60.4 Favored Pre-proline 0 N--CA 1.47 0.549 0 C-N-CA 120.936 -0.306 . . . . 1.0 110.919 -179.023 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.447 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.0 Cg_exo -59.9 151.26 72.75 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 121.826 1.684 . . . . 1.0 114.185 -179.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -120.68 148.63 43.67 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 113.915 -1.493 . . . . 1.0 107.498 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.15 124.57 49.89 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.335 0.588 . . . . 1.0 112.378 -178.245 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -133.32 149.34 51.9 Favored 'General case' 0 CA--C 1.493 -1.221 0 CA-C-N 115.286 -0.87 . . . . 1.0 109.707 178.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -90.75 130.36 36.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 105.09 -2.189 . . . . 1.0 105.09 174.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 87' ' ' THR . 38.2 t -57.23 -31.61 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 119.099 -1.04 . . . . 1.0 110.108 -176.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.1 t -73.67 -25.99 60.52 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.424 -0.51 . . . . 1.0 112.038 -178.27 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 56.2 mm-40 -102.26 -6.64 22.91 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 112.959 0.726 . . . . 1.0 112.959 -177.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.2 p -78.91 168.58 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 121.046 -0.262 . . . . 1.0 111.242 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -52.56 146.81 16.22 Favored Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 107.903 -1.147 . . . . 1.0 107.903 -178.133 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.53 -43.29 45.78 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 121.433 1.422 . . . . 1.0 112.648 -177.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.11 -47.34 91.25 Favored Glycine 0 C--N 1.317 -0.479 0 C-N-CA 119.747 -1.216 . . . . 1.0 110.946 -178.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.618 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.8 m95 -66.68 -32.3 73.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 113.973 -1.113 . . . . 1.0 110.748 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.46 HG23 ' O ' ' A' ' 79' ' ' VAL . 29.5 m -51.37 -54.48 26.06 Favored 'General case' 0 C--N 1.322 -0.603 0 O-C-N 122.029 -0.42 . . . . 1.0 111.812 -178.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -72.7 -40.27 66.33 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.7 -44.06 97.0 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 114.432 1.271 . . . . 1.0 114.432 -176.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.4 mt -58.6 -41.56 86.11 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.147 0.499 . . . . 1.0 110.323 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -64.55 -23.89 67.42 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.368 -0.833 . . . . 1.0 110.401 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.524 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 88.6 mt -99.61 -14.84 18.81 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.964 -0.562 . . . . 1.0 111.718 -178.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 48.7 ttp -91.2 108.68 30.23 Favored Pre-proline 0 CA--C 1.548 0.892 0 O-C-N 123.224 0.327 . . . . 1.0 111.826 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.604 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 24.0 Cg_exo -63.79 149.1 91.51 Favored 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.586 2.191 . . . . 1.0 113.052 178.115 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.602 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.99 133.4 54.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.436 0.636 . . . . 1.0 110.76 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.61 -13.79 66.53 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 108.744 -1.742 . . . . 1.0 108.744 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.468 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 7.7 t -90.83 122.66 33.74 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.012 0.434 . . . . 1.0 109.839 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.406 ' HB ' HD22 ' A' ' 38' ' ' ASN . 63.8 m -97.07 115.07 26.82 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.402 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 31.7 m0 -115.76 167.95 10.48 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.657 0.741 . . . . 1.0 110.996 -178.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.618 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.5 mt-10 -128.44 134.74 48.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 106.453 -1.684 . . . . 1.0 106.453 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.414 HD13 HG21 ' A' ' 101' ' ' ILE . 3.5 pt -130.91 139.03 52.14 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.654 0 CA-C-O 121.724 0.773 . . . . 1.0 109.601 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.703 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.3 OUTLIER -109.39 102.9 11.76 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.995 -1.854 . . . . 1.0 105.995 -177.408 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 t -90.33 116.23 65.9 Favored Pre-proline 0 N--CA 1.453 -0.302 0 N-CA-C 115.093 1.516 . . . . 1.0 115.093 -174.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.33 143.56 26.26 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.519 1.479 . . . . 1.0 109.601 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.7 p -53.7 -27.97 31.16 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.411 -0.515 . . . . 1.0 110.929 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.61 -29.48 65.6 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 110.194 -1.163 . . . . 1.0 110.194 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.9 mt -101.03 2.28 40.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.301 -0.45 . . . . 1.0 111.173 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -110.43 -108.34 0.35 Allowed 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.852 0.316 . . . . 1.0 111.852 -178.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -99.24 3.39 46.26 Favored 'General case' 0 C--N 1.339 0.118 0 N-CA-C 112.136 0.421 . . . . 1.0 112.136 -178.072 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.03 163.98 22.13 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.23 -0.509 . . . . 1.0 112.396 178.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.551 ' O ' ' N ' ' A' ' 121' ' ' ASN . 84.9 Cg_endo -75.77 -11.55 20.1 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 123.404 2.736 . . . . 1.0 111.955 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -98.62 167.17 10.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.065 -0.516 . . . . 1.0 109.729 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.572 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.8 m -74.05 78.18 1.71 Allowed 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.301 -0.56 . . . . 1.0 109.842 178.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.1 t -93.68 60.44 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.084 -0.507 . . . . 1.0 109.949 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.59 177.09 40.42 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 120.224 -0.988 . . . . 1.0 112.295 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.97 -106.74 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 N-CA-C 111.293 -0.723 . . . . 1.0 111.293 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.31 -13.72 17.47 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 121.905 1.737 . . . . 1.0 110.522 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.865 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.5 mp -67.26 111.84 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 107.383 -1.34 . . . . 1.0 107.383 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.43 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -93.16 -167.1 38.54 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.473 -1.051 . . . . 1.0 110.473 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.572 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.5 Cg_endo -62.91 144.99 94.35 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.227 1.951 . . . . 1.0 112.7 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 47.33 56.78 6.5 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.221 0.452 . . . . 1.0 112.221 177.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.43 ' HG3' ' H ' ' A' ' 119' ' ' GLY . 52.1 mm-40 -103.1 128.47 50.0 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 112.308 0.484 . . . . 1.0 112.308 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.8 m -93.94 128.4 40.23 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.191 -1.411 . . . . 1.0 107.191 176.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.403 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.6 mm? -109.41 147.95 31.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 121.482 0.658 . . . . 1.0 111.156 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.703 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -126.79 144.21 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.64 0 N-CA-C 108.477 -0.935 . . . . 1.0 108.477 178.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.543 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.9 OUTLIER -135.0 151.95 51.28 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 120.499 -0.48 . . . . 1.0 111.305 177.81 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.479 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.7 mmtt -100.18 125.12 46.28 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.044 -2.206 . . . . 1.0 105.044 176.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.469 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.3 mt -118.61 118.49 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 119.153 -1.019 . . . . 1.0 112.331 -176.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -109.77 121.7 45.81 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 113.569 -1.65 . . . . 1.0 108.232 178.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.33 112.16 24.01 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 120.235 -0.586 . . . . 1.0 112.064 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -91.57 -47.1 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.68 -0.691 . . . . 1.0 110.974 179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.9 t -150.02 158.12 43.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.833 0.349 . . . . 1.0 111.013 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.449 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -130.26 136.91 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 116.192 -0.458 . . . . 1.0 111.609 -178.243 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.469 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 20.3 tptt . . . . . 0 CA--C 1.533 0.318 0 CA-C-O 121.661 0.743 . . . . 1.0 110.075 178.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 CA--C 1.517 -0.3 0 CA-C-O 121.682 0.753 . . . . 1.0 110.593 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.567 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 7.0 m-20 -60.13 -34.44 73.53 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.223 -0.899 . . . . 1.0 108.599 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -66.93 -51.23 57.76 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.164 -1.38 . . . . 1.0 111.649 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.1 t -67.41 -46.83 82.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.082 -0.647 . . . . 1.0 111.887 -177.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.67 -38.22 90.29 Favored 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 107.442 -1.318 . . . . 1.0 107.442 178.567 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.544 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.04 -44.35 61.37 Favored Glycine 0 CA--C 1.528 0.905 0 CA-C-N 114.845 -1.071 . . . . 1.0 112.44 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -61.98 -32.06 72.48 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 119.342 -0.943 . . . . 1.0 108.72 179.297 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.17 -35.3 64.01 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.133 -0.94 . . . . 1.0 109.682 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -63.83 -50.3 69.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.213 -179.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.544 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -71.11 -37.87 72.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 109.178 -0.675 . . . . 1.0 109.178 178.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.2 m -62.03 -43.08 99.59 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.791 -0.641 . . . . 1.0 109.482 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -75.02 -45.78 39.52 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.655 -0.702 . . . . 1.0 112.154 -179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 46.0 t30 -61.62 -44.62 96.66 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 113.126 0.787 . . . . 1.0 113.126 -177.545 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.68 -30.36 68.72 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 119.406 -0.917 . . . . 1.0 109.505 -179.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 26.2 m-80 -81.15 -29.49 34.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.667 -0.697 . . . . 1.0 111.782 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 18.7 mtmt -59.55 136.52 89.36 Favored Pre-proline 0 CA--C 1.545 0.774 0 C-N-CA 120.687 -0.405 . . . . 1.0 111.188 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.75 147.49 60.61 Favored 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 121.719 1.612 . . . . 1.0 112.807 178.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.76 -20.23 25.14 Favored Glycine 0 C--O 1.225 -0.417 0 CA-C-N 115.27 -0.877 . . . . 1.0 111.486 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 35' ' ' LYS . 42.9 t -88.13 134.38 28.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.05 0.453 . . . . 1.0 110.751 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 83.8 t -118.67 122.26 69.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 108.062 -1.088 . . . . 1.0 108.062 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.428 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.3 p -94.79 146.06 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.721 0.772 . . . . 1.0 111.789 -178.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.6 mt -114.77 162.29 24.53 Favored Pre-proline 0 N--CA 1.465 0.316 0 CA-C-N 114.418 -1.264 . . . . 1.0 110.612 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.16 -30.92 94.39 Favored 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 121.681 1.588 . . . . 1.0 111.277 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 m -66.99 -15.04 63.47 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.509 -0.769 . . . . 1.0 109.389 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.28 -0.72 66.39 Favored Glycine 0 CA--C 1.51 -0.221 0 N-CA-C 109.432 -1.467 . . . . 1.0 109.432 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -80.56 134.21 35.89 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.355 -0.98 . . . . 1.0 108.355 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.2 mp0 -122.82 138.8 54.54 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.965 -0.561 . . . . 1.0 110.564 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -133.54 147.16 51.56 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.878 0.847 . . . . 1.0 111.0 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.523 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.8 tmtp? -134.1 136.48 43.93 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-N 114.174 -1.375 . . . . 1.0 109.724 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -92.79 105.73 17.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 122.366 1.079 . . . . 1.0 111.589 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.642 HD11 ' CD ' ' A' ' 100' ' ' GLU . 17.7 mm -70.54 -42.25 78.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.082 -0.963 . . . . 1.0 109.124 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.403 ' O ' ' OG ' ' A' ' 97' ' ' SER . 56.6 m-80 -143.07 124.48 14.72 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 113.998 -1.456 . . . . 1.0 109.09 -178.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.1 p -88.61 125.58 34.88 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.596 -0.52 . . . . 1.0 109.596 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.508 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.11 -33.76 1.93 Allowed Glycine 0 CA--C 1.516 0.129 0 N-CA-C 110.345 -1.102 . . . . 1.0 110.345 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.621 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 57.98 32.97 22.68 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 123.679 0.281 . . . . 1.0 111.441 179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.37 -161.08 36.92 Favored Glycine 0 C--N 1.335 0.502 0 CA-C-O 121.763 0.646 . . . . 1.0 111.929 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.584 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.8 m -68.74 -179.75 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 114.309 -0.945 . . . . 1.0 109.025 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.626 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 178.0 155.84 0.52 Allowed Pre-proline 0 N--CA 1.476 0.831 0 CA-C-O 120.953 0.406 . . . . 1.0 110.886 179.234 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HB2' ' HB3' ' A' ' 49' ' ' ASP . 32.6 Cg_endo -85.02 167.03 11.09 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 123.433 2.756 . . . . 1.0 117.521 -173.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.502 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -102.91 165.62 16.29 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 113.571 -1.649 . . . . 1.0 109.566 177.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.612 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -44.97 -25.86 0.36 Allowed 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.657 -0.771 . . . . 1.0 111.886 -179.636 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 66.5 m -108.32 -5.57 16.7 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 112.759 0.651 . . . . 1.0 112.759 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.706 ' OD2' ' N ' ' A' ' 50' ' ' THR . 66.4 t0 -82.29 169.08 16.93 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.151 0.501 . . . . 1.0 110.841 -179.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.706 ' N ' ' OD2' ' A' ' 49' ' ' ASP . 7.6 m -110.91 142.7 42.63 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.656 -0.868 . . . . 1.0 108.656 177.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.12 160.34 30.82 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.534 0 CA-C-N 114.994 -1.003 . . . . 1.0 112.252 -175.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.494 HG22 ' HB3' ' A' ' 74' ' ' PRO . 91.1 m -124.69 120.3 31.43 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.873 -0.788 . . . . 1.0 108.873 178.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.585 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 11.4 m -148.75 165.44 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 114.636 1.347 . . . . 1.0 114.636 -176.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -119.32 151.99 37.5 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 173.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.52 ' O ' ' N ' ' A' ' 68' ' ' THR . 33.6 p90 -164.96 164.83 20.6 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 118.425 -1.31 . . . . 1.0 113.973 -177.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.3 m -123.88 130.82 53.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 108.021 -1.103 . . . . 1.0 108.021 175.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.6 131.44 9.98 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.093 -1.203 . . . . 1.0 110.093 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.711 ' CZ ' ' HZ1' ' A' ' 127' ' ' LYS . 5.1 ptp180 -145.77 169.29 18.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.977 0.894 . . . . 1.0 112.762 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.7 mp -84.59 165.89 17.61 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 113.912 -1.495 . . . . 1.0 109.941 177.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.06 -25.62 30.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.431 178.889 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -100.22 10.17 41.65 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.134 -0.939 . . . . 1.0 112.026 -177.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.94 -6.62 81.81 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 120.403 -0.903 . . . . 1.0 113.771 178.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.7 m -65.18 102.02 0.6 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 118.727 1.263 . . . . 1.0 109.182 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 88.4 t -74.86 117.4 18.99 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.408 0.623 . . . . 1.0 111.1 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CD2' HD11 ' A' ' 118' ' ' ILE . 27.4 p90 -103.76 -15.63 15.67 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 114.903 -1.044 . . . . 1.0 112.092 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -159.24 153.91 24.47 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.27 -0.572 . . . . 1.0 110.375 177.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.0 p -157.19 158.55 36.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.826 -0.625 . . . . 1.0 111.802 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.2 m -153.07 -43.89 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.171 -0.922 . . . . 1.0 109.799 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.437 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -61.07 -28.02 68.78 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-N 115.888 -0.597 . . . . 1.0 109.66 179.42 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -57.24 -42.9 82.37 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 107.434 -1.321 . . . . 1.0 107.434 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.8 -33.47 60.13 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.299 -1.319 . . . . 1.0 107.558 176.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.02 17.75 73.87 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.314 -0.857 . . . . 1.0 112.118 178.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -98.13 116.35 65.61 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 121.265 -0.174 . . . . 1.0 110.557 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.494 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.4 Cg_exo -58.54 150.52 68.44 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 121.501 1.467 . . . . 1.0 114.204 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.77 145.82 48.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.354 -1.293 . . . . 1.0 108.472 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.3 t -103.8 131.3 51.12 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-O 121.453 0.644 . . . . 1.0 112.452 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -139.8 149.6 43.71 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.994 -1.003 . . . . 1.0 110.42 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -90.81 127.54 36.39 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 105.766 -1.938 . . . . 1.0 105.766 174.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.1 t -51.64 -29.2 9.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 C-N-CA 118.981 -1.088 . . . . 1.0 110.512 -176.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 48.3 t -77.68 -23.17 49.65 Favored 'General case' 0 CA--C 1.521 -0.171 0 C-N-CA 120.306 -0.558 . . . . 1.0 111.835 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -98.56 -6.6 29.77 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 113.728 1.01 . . . . 1.0 113.728 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.6 p -87.59 172.36 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 119.775 -0.77 . . . . 1.0 110.924 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.466 HG22 ' HD2' ' A' ' 84' ' ' PRO . 0.0 OUTLIER -53.48 152.31 9.12 Favored Pre-proline 0 N--CA 1.478 0.954 0 N-CA-C 109.301 -0.629 . . . . 1.0 109.301 -176.956 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.466 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -52.26 -45.14 41.35 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.098 1.866 . . . . 1.0 112.061 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.77 -46.86 91.81 Favored Glycine 0 CA--C 1.522 0.512 0 C-N-CA 119.957 -1.116 . . . . 1.0 110.876 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.585 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.1 m95 -64.58 -35.44 80.98 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.342 -0.929 . . . . 1.0 111.495 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 30.7 m -50.78 -55.29 17.48 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.55 -0.46 . . . . 1.0 112.14 -177.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -73.27 -40.42 64.6 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 112.365 0.506 . . . . 1.0 112.365 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.47 -45.76 84.45 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 114.154 1.168 . . . . 1.0 114.154 -178.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.1 mt -57.84 -41.59 82.66 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.197 0.522 . . . . 1.0 110.629 -177.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.9 mt-30 -65.43 -19.1 65.79 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.277 -0.874 . . . . 1.0 111.346 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.502 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 57.5 mt -106.01 -13.4 15.48 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.116 -0.493 . . . . 1.0 110.7 -178.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.0 ttp -88.91 109.13 28.02 Favored Pre-proline 0 CA--C 1.553 1.063 0 N-CA-C 112.101 0.408 . . . . 1.0 112.101 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.626 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 22.3 Cg_exo -64.58 149.53 89.72 Favored 'Trans proline' 0 N--CA 1.504 2.11 0 C-N-CA 122.979 2.453 . . . . 1.0 113.296 178.346 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.584 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.33 132.58 50.58 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.495 0.664 . . . . 1.0 111.154 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.76 -18.21 57.65 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 108.505 -1.838 . . . . 1.0 108.505 -178.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.508 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 9.3 t -86.02 128.64 34.9 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 109.944 -0.391 . . . . 1.0 109.944 179.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.7 m -103.33 114.8 29.36 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 115.594 -0.73 . . . . 1.0 109.696 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . 0.502 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -114.14 167.96 10.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.781 0.8 . . . . 1.0 111.336 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.642 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.7 mt-10 -128.46 124.5 36.33 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.171 -1.418 . . . . 1.0 107.171 175.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.435 HD13 HG21 ' A' ' 101' ' ' ILE . 3.6 pt -120.68 135.49 60.72 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.868 0 N-CA-C 108.735 -0.839 . . . . 1.0 108.735 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.72 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -107.12 104.0 13.53 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.725 -1.954 . . . . 1.0 105.725 -177.258 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 t -90.51 115.53 64.36 Favored Pre-proline 0 C--N 1.32 -0.675 0 N-CA-C 115.256 1.576 . . . . 1.0 115.256 -173.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -51.35 146.03 25.91 Favored 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 121.941 1.761 . . . . 1.0 110.569 176.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.0 p -53.58 -24.51 13.95 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.456 -178.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -78.56 -29.5 52.31 Favored Glycine 0 N--CA 1.46 0.268 0 N-CA-C 110.697 -0.961 . . . . 1.0 110.697 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.2 mt -102.16 2.77 37.71 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.523 -0.338 . . . . 1.0 110.49 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.26 -102.43 0.35 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 110.11 -0.33 . . . . 1.0 110.11 -178.102 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -108.96 5.46 24.33 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.753 1.02 . . . . 1.0 113.753 -177.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.57 163.05 17.4 Favored Glycine 0 N--CA 1.473 1.128 0 C-N-CA 121.285 -0.483 . . . . 1.0 113.209 177.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.553 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.1 Cg_endo -71.13 -18.67 30.55 Favored 'Trans proline' 0 N--CA 1.494 1.527 0 C-N-CA 123.535 2.823 . . . . 1.0 112.37 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -104.01 171.56 7.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.229 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.465 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.0 m -73.64 97.28 2.63 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.926 -0.579 . . . . 1.0 110.171 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.6 t -109.55 61.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.596 -0.274 . . . . 1.0 110.873 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.502 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -168.53 40.98 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 120.892 -0.671 . . . . 1.0 111.715 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.12 -104.9 0.04 OUTLIER Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.457 -0.657 . . . . 1.0 111.457 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -58.9 -19.05 45.5 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.237 1.958 . . . . 1.0 111.621 -178.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.613 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -66.56 112.83 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 119.901 -0.72 . . . . 1.0 109.166 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.4 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.65 -164.84 39.93 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.679 -0.968 . . . . 1.0 110.679 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.567 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 23.5 Cg_endo -63.22 152.05 81.74 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.359 2.039 . . . . 1.0 113.272 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.553 ' N ' ' O ' ' A' ' 111' ' ' PRO . 11.9 t30 37.17 53.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.807 177.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.423 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 41.7 mm-40 -97.36 132.29 43.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.29 0.567 . . . . 1.0 111.768 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.464 HG21 HD11 ' A' ' 16' ' ' LEU . 84.6 m -95.66 127.44 41.7 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.451 -1.314 . . . . 1.0 107.451 176.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.82 140.79 47.31 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.338 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.72 HD12 ' CD2' ' A' ' 102' ' ' TYR . 2.2 tt -119.43 147.05 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 N-CA-C 108.435 -0.95 . . . . 1.0 108.435 178.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.626 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -134.4 145.53 49.01 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 121.12 0.486 . . . . 1.0 110.324 177.314 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.711 ' HZ1' ' CZ ' ' A' ' 58' ' ' ARG . 5.5 mmtt -99.61 121.83 41.76 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 104.673 -2.343 . . . . 1.0 104.673 178.394 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.411 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.5 mt -116.09 120.36 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 119.438 -0.905 . . . . 1.0 113.176 -175.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.4 t-160 -110.3 123.18 49.34 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 113.927 -1.488 . . . . 1.0 108.486 178.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.64 113.17 24.79 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 112.384 0.513 . . . . 1.0 112.384 -178.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -96.25 -46.98 13.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 115.775 -0.648 . . . . 1.0 111.301 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.95 155.86 42.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.168 0.509 . . . . 1.0 111.574 -178.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 44' ' ' LYS . 50.1 t -128.96 142.19 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.706 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.401 ' C ' ' OD2' ' A' ' 49' ' ' ASP . 3.9 tptt . . . . . 0 N--CA 1.453 -0.294 0 CA-C-O 121.712 0.768 . . . . 1.0 110.765 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 . . . . . 0 C--O 1.222 -0.372 0 CA-C-O 121.428 0.633 . . . . 1.0 110.867 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 2.3 m-20 -62.74 -35.76 80.83 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.094 -1.076 . . . . 1.0 108.094 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 13' ' ' GLU . 76.8 tttt -65.72 -49.45 68.42 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.42 -1.718 . . . . 1.0 112.095 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.0 t -66.36 -48.67 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 C-N-CA 119.79 -0.764 . . . . 1.0 110.9 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.0 OUTLIER -62.61 -36.22 82.05 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.799 -1.185 . . . . 1.0 107.799 178.9 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.456 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.59 -41.81 42.38 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.836 -1.074 . . . . 1.0 112.213 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.472 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.7 mt-10 -62.79 -31.35 72.3 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 119.464 -0.895 . . . . 1.0 108.634 179.54 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.55 -34.76 53.72 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 115.138 -0.937 . . . . 1.0 109.925 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -60.84 -49.07 78.96 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.499 -1.228 . . . . 1.0 111.11 -178.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.456 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.1 mp -70.18 -36.76 74.87 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.195 -0.602 . . . . 1.0 109.495 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.66 -44.36 97.1 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.593 -0.731 . . . . 1.0 109.715 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -76.6 -44.83 32.73 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 114.985 -1.007 . . . . 1.0 112.517 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.3 t30 -60.07 -44.99 94.36 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 113.089 0.774 . . . . 1.0 113.089 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -61.02 -28.5 69.09 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 119.969 -0.693 . . . . 1.0 109.761 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -82.99 -28.08 29.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.571 -0.741 . . . . 1.0 111.235 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.4 mtmt -59.25 139.01 88.45 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 120.834 -0.346 . . . . 1.0 111.478 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_exo -56.5 148.54 62.56 Favored 'Trans proline' 0 N--CA 1.502 2.008 0 C-N-CA 122.167 1.911 . . . . 1.0 113.353 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA3' ' HZ2' ' A' ' 35' ' ' LYS . . . 80.78 -18.84 8.25 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.247 -0.888 . . . . 1.0 111.592 179.209 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.46 137.29 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.444 . . . . 1.0 109.964 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.6 t -122.98 119.62 58.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 108.242 -1.021 . . . . 1.0 108.242 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.426 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.2 p -94.93 145.44 8.12 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 CA-C-O 121.689 0.757 . . . . 1.0 111.429 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.9 mt -111.92 165.11 13.57 Favored Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 114.189 -1.369 . . . . 1.0 110.481 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -61.21 -29.43 86.63 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.764 1.643 . . . . 1.0 111.048 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -68.34 -16.88 64.1 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 115.678 -0.692 . . . . 1.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.74 -7.0 60.85 Favored Glycine 0 CA--C 1.517 0.196 0 N-CA-C 110.142 -1.183 . . . . 1.0 110.142 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.475 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.38 134.52 38.42 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 179.528 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.475 ' H ' HD22 ' A' ' 32' ' ' LEU . 26.2 mp0 -121.24 142.91 49.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.454 -0.339 . . . . 1.0 110.641 179.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -136.97 148.13 46.74 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-O 121.56 0.695 . . . . 1.0 110.75 178.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . 0.593 ' CD ' HD13 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -135.27 134.74 40.27 Favored 'General case' 0 N--CA 1.44 -0.948 0 CA-C-N 114.48 -1.236 . . . . 1.0 109.88 -179.174 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 p -93.3 105.34 16.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 122.063 0.935 . . . . 1.0 111.472 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.631 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -70.33 -41.76 78.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.177 -0.92 . . . . 1.0 109.303 179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.452 ' ND2' HG22 ' A' ' 37' ' ' ILE . 34.4 m-80 -145.46 119.75 9.57 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.797 -1.092 . . . . 1.0 110.48 -177.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 p -80.32 123.85 28.34 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.264 0.554 . . . . 1.0 110.352 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.449 ' H ' ' CB ' ' A' ' 97' ' ' SER . . . -109.22 -29.24 4.07 Favored Glycine 0 CA--C 1.519 0.286 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 179.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.609 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.6 m120 54.73 32.12 16.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.756 -0.722 . . . . 1.0 111.412 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.95 -163.26 38.78 Favored Glycine 0 C--N 1.33 0.247 0 CA-C-O 121.923 0.735 . . . . 1.0 111.548 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.3 m -68.28 -177.77 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 114.154 -1.023 . . . . 1.0 108.615 178.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.522 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.36 154.47 0.39 Allowed Pre-proline 0 C--N 1.317 -0.806 0 N-CA-C 109.454 -0.573 . . . . 1.0 109.454 179.631 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -88.02 159.64 7.28 Favored 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 123.137 2.558 . . . . 1.0 116.355 -174.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -91.53 175.02 38.69 Favored Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 109.06 -1.616 . . . . 1.0 109.06 176.375 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.628 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.47 -23.91 4.48 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.112 -0.544 . . . . 1.0 110.69 -179.691 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.466 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 40.6 m -107.72 -10.09 15.68 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 113.983 1.105 . . . . 1.0 113.983 -177.302 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.7 m-20 -84.7 165.51 17.81 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 119.618 -0.833 . . . . 1.0 108.835 179.724 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -103.36 148.93 25.27 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.515 -0.55 . . . . 1.0 109.515 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.7 p -125.62 162.44 28.65 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 CA-C-N 115.87 -0.605 . . . . 1.0 112.201 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.423 HG22 ' CB ' ' A' ' 74' ' ' PRO . 87.8 m -130.55 120.37 23.95 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.039 -1.097 . . . . 1.0 108.039 177.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.459 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 9.9 m -148.51 164.99 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.004 1.113 . . . . 1.0 114.004 -176.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.465 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 10.4 mt-10 -118.61 152.3 36.3 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 106.425 -1.694 . . . . 1.0 106.425 174.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.1 p90 -162.1 159.57 26.31 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 114.856 1.428 . . . . 1.0 114.856 -177.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -121.24 129.74 53.33 Favored 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.157 -0.929 . . . . 1.0 108.988 176.019 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.5 133.9 11.78 Favored Glycine 0 N--CA 1.47 0.935 0 N-CA-C 111.185 -0.766 . . . . 1.0 111.185 -178.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -145.54 166.43 25.73 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.69 0.757 . . . . 1.0 112.101 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -87.46 160.08 18.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.578 -1.192 . . . . 1.0 111.272 178.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -55.12 -26.01 17.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 114.462 -1.244 . . . . 1.0 110.465 177.811 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -96.04 5.63 50.71 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.49 -1.232 . . . . 1.0 111.075 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.73 -9.51 77.47 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.021 -0.536 . . . . 1.0 113.642 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -61.13 97.01 0.06 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 118.331 1.066 . . . . 1.0 110.634 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 98.2 t -68.73 125.69 27.1 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 C-N-CA 119.639 -0.824 . . . . 1.0 108.854 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.908 ' CD2' HD11 ' A' ' 118' ' ' ILE . 19.4 p90 -117.38 -15.53 10.33 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.163 -0.926 . . . . 1.0 111.696 -178.615 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -154.6 149.87 27.1 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.249 0.547 . . . . 1.0 111.735 178.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -155.87 151.32 26.97 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.395 -0.821 . . . . 1.0 111.776 179.137 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 99.5 m -148.04 -37.8 0.19 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.201 -0.908 . . . . 1.0 110.157 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.465 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.1 pp20? -66.62 -27.37 67.65 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 116.14 -0.482 . . . . 1.0 110.04 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -59.4 -43.39 92.99 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 107.744 -1.206 . . . . 1.0 107.744 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 18.5 p -73.01 -32.88 65.42 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 114.876 -1.056 . . . . 1.0 108.523 176.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.36 17.68 66.08 Favored Glycine 0 CA--C 1.522 0.484 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.977 178.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.439 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -100.29 114.59 65.76 Favored Pre-proline 0 N--CA 1.471 0.602 0 C-N-CA 120.448 -0.501 . . . . 1.0 111.164 -179.591 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' CB ' HG22 ' A' ' 52' ' ' THR . 38.5 Cg_exo -61.7 152.87 71.25 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.012 1.808 . . . . 1.0 114.097 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.416 ' HB1' ' CZ ' ' A' ' 77' ' ' PHE . . . -123.08 145.19 48.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 113.681 -1.599 . . . . 1.0 107.847 178.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.516 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 2.7 t -105.59 136.36 45.32 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.267 0.556 . . . . 1.0 112.482 -178.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.516 ' CD2' ' O ' ' A' ' 76' ' ' THR . 19.5 m-85 -150.07 151.25 32.92 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.546 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -87.93 128.32 35.37 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 107.652 -1.24 . . . . 1.0 107.652 175.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.5 t -54.86 -32.28 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 120.135 -0.626 . . . . 1.0 110.899 -177.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -72.48 -26.93 61.98 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.8 -0.76 . . . . 1.0 112.063 -177.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -98.52 -11.1 22.59 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 112.789 0.662 . . . . 1.0 112.789 -178.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -71.54 169.07 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.798 0.666 . . . . 1.0 112.798 -175.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.425 HD13 HG21 ' A' ' 83' ' ' ILE . 0.1 OUTLIER -51.69 145.76 15.19 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 107.134 -1.432 . . . . 1.0 107.134 -178.785 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.412 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -49.73 -44.86 34.32 Favored 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 121.19 1.26 . . . . 1.0 112.654 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.25 91.99 Favored Glycine 0 C--N 1.317 -0.523 0 C-N-CA 120.007 -1.092 . . . . 1.0 111.295 -179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' TRP . . . . . 0.459 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 6.7 m95 -63.76 -31.26 72.38 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 114.028 -1.086 . . . . 1.0 111.523 -179.489 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 99.4 m -56.4 -53.54 56.18 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 121.913 -0.492 . . . . 1.0 111.655 -178.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -71.76 -38.49 70.38 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.284 0.846 . . . . 1.0 113.284 -177.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -64.01 -44.1 93.64 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 114.477 1.288 . . . . 1.0 114.477 -176.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 26.9 mt -58.71 -37.99 77.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.275 0.559 . . . . 1.0 110.778 -177.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -64.92 -24.1 67.42 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.294 -0.866 . . . . 1.0 111.345 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 27.6 mt -102.06 -18.96 15.36 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.173 -0.467 . . . . 1.0 111.212 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.4 ttp -81.34 109.36 13.8 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 112.639 0.607 . . . . 1.0 112.639 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.522 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.39 148.32 84.04 Favored 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 122.679 2.253 . . . . 1.0 113.116 178.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.592 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.91 131.48 46.8 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-O 121.606 0.717 . . . . 1.0 111.811 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.71 -16.51 60.87 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 108.177 -1.969 . . . . 1.0 108.177 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.449 ' CB ' ' H ' ' A' ' 40' ' ' GLY . 5.7 p -88.46 139.13 30.79 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.089 -0.556 . . . . 1.0 110.139 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 50.9 m -110.27 117.43 33.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.12 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -117.49 169.64 9.37 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.95 0.881 . . . . 1.0 110.546 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.631 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.8 mt-10 -130.24 132.65 46.06 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.935 -1.506 . . . . 1.0 106.935 175.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.41 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -127.48 137.13 58.62 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 108.603 -0.888 . . . . 1.0 108.603 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.65 102.82 11.85 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 105.83 -1.915 . . . . 1.0 105.83 -177.8 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.6 t -89.94 115.1 63.11 Favored Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 114.516 1.302 . . . . 1.0 114.516 -174.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -51.57 144.33 33.33 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 121.072 1.181 . . . . 1.0 109.696 176.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 87.6 p -49.97 -31.98 13.9 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.377 -0.529 . . . . 1.0 110.959 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.71 -31.78 70.52 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.558 -0.617 . . . . 1.0 111.558 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.09 3.09 43.78 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 110.548 -0.167 . . . . 1.0 110.548 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.84 -109.06 0.33 Allowed 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 120.736 0.303 . . . . 1.0 111.256 -178.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.404 ' O ' HG21 ' A' ' 114' ' ' VAL . 38.6 m-85 -98.32 -4.66 34.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 114.379 1.251 . . . . 1.0 114.379 -176.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.32 172.68 18.95 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 120.497 -0.859 . . . . 1.0 113.174 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 121' ' ' ASN . 71.9 Cg_endo -73.75 -31.4 8.49 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 123.649 2.899 . . . . 1.0 112.388 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -82.23 170.81 14.98 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.365 0.602 . . . . 1.0 111.435 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.418 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 7.3 m -79.34 88.3 4.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.279 -0.873 . . . . 1.0 109.039 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.404 HG21 ' O ' ' A' ' 109' ' ' TYR . 3.3 t -97.88 55.26 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.341 -0.39 . . . . 1.0 111.383 -178.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 173.37 -175.25 46.18 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 120.509 -0.853 . . . . 1.0 112.087 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.34 -103.34 0.01 OUTLIER Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.268 -0.733 . . . . 1.0 111.268 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -62.13 -15.91 47.04 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.478 2.119 . . . . 1.0 110.518 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.908 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.6 mp -66.39 115.03 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.376 -1.342 . . . . 1.0 107.376 178.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -97.26 -157.79 30.82 Favored Glycine 0 C--O 1.213 -1.186 0 N-CA-C 110.814 -0.914 . . . . 1.0 110.814 -178.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.48 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 53.4 Cg_endo -71.02 147.58 55.08 Favored 'Trans proline' 0 C--N 1.297 -2.156 0 C-N-CA 121.51 1.474 . . . . 1.0 112.982 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.545 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 39.48 60.97 1.47 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 113.216 0.821 . . . . 1.0 113.216 177.503 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.744 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -112.69 140.35 47.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.038 0.447 . . . . 1.0 110.611 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 85.5 m -93.93 127.73 39.86 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.1 -1.074 . . . . 1.0 108.1 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -108.85 136.41 48.45 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.516 -0.55 . . . . 1.0 109.516 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -117.6 146.87 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 108.706 -0.849 . . . . 1.0 108.706 178.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 126' ' ' PHE . 4.0 m-85 -135.8 149.49 49.12 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.236 -0.586 . . . . 1.0 111.334 178.137 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.473 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 9.5 mmtt -99.46 124.57 44.73 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 104.948 -2.242 . . . . 1.0 104.948 177.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.9 mt -115.77 118.37 58.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 C-N-CA 119.167 -1.013 . . . . 1.0 111.9 -177.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -110.39 123.05 49.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.655 -1.611 . . . . 1.0 108.484 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.76 112.95 24.55 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 112.544 0.572 . . . . 1.0 112.544 -177.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.486 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -94.49 -49.17 12.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 CA-C-N 115.749 -0.66 . . . . 1.0 111.17 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.6 p -145.32 157.39 44.06 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.014 0.435 . . . . 1.0 110.601 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.461 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.3 t -130.09 137.56 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.288 -0.414 . . . . 1.0 110.993 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 15.8 tptt . . . . . 0 N--CA 1.449 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.541 178.64 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.121 -0.696 . . . . 1.0 109.121 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.473 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 66.0 m-80 -61.92 -18.49 60.45 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.131 -0.692 . . . . 1.0 109.131 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.4 ttpt -49.57 -41.05 40.59 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.361 -0.978 . . . . 1.0 108.361 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.556 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 0.3 OUTLIER -64.68 -35.94 82.67 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.239 -179.38 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -52.62 -38.02 59.44 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 116.191 -0.459 . . . . 1.0 110.384 179.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -65.08 -37.48 87.64 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.603 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 51.4 mt-10 -66.9 -51.4 55.87 Favored 'General case' 0 CA--C 1.517 -0.321 0 CA-C-O 121.861 0.839 . . . . 1.0 110.633 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.611 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 3.7 m-20 -58.55 -38.42 77.79 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 107.528 -1.286 . . . . 1.0 107.528 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -63.93 -50.98 66.55 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 113.125 -1.852 . . . . 1.0 111.806 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 70.7 t -73.82 -48.62 38.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 119.812 -0.755 . . . . 1.0 111.713 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.45 ' O ' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -60.36 -40.63 91.45 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.827 -1.175 . . . . 1.0 107.827 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.447 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -65.74 -48.07 70.4 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.374 -0.83 . . . . 1.0 112.133 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -61.71 -31.25 71.39 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.01 -0.737 . . . . 1.0 109.01 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.22 -33.79 43.44 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.121 -0.945 . . . . 1.0 109.957 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' O ' ' A' ' 11' ' ' LYS . 64.3 t80 -61.14 -50.78 71.81 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 114.445 -1.252 . . . . 1.0 110.414 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.44 -41.59 80.07 Favored 'General case' 0 CA--C 1.513 -0.452 0 C-N-CA 119.963 -0.695 . . . . 1.0 109.649 178.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.8 m -62.14 -41.31 98.14 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.569 -0.741 . . . . 1.0 109.474 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -75.74 -45.29 37.38 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.584 -0.734 . . . . 1.0 111.637 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.1 t30 -61.34 -45.03 96.12 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 113.135 0.791 . . . . 1.0 113.135 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -57.68 -31.36 66.27 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 119.305 -0.958 . . . . 1.0 108.833 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -80.74 -31.48 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.72 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 41.2 mtmt -56.97 139.85 78.02 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 120.19 -0.604 . . . . 1.0 110.905 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -56.27 148.49 60.5 Favored 'Trans proline' 0 N--CA 1.502 2.0 0 C-N-CA 122.069 1.846 . . . . 1.0 113.879 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.1 -19.5 10.06 Favored Glycine 0 C--O 1.227 -0.318 0 CA-C-N 114.937 -1.029 . . . . 1.0 111.992 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.404 HG22 ' HB2' ' A' ' 35' ' ' LYS . 43.5 t -83.35 138.17 19.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.123 0.487 . . . . 1.0 110.929 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 72.5 t -122.35 122.41 66.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 178.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.8 p -96.76 146.22 7.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.653 0 CA-C-O 121.569 0.699 . . . . 1.0 111.847 -178.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.7 mt -114.08 166.09 12.23 Favored Pre-proline 0 C--O 1.232 0.146 0 CA-C-N 114.484 -1.235 . . . . 1.0 110.967 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -62.07 -30.46 82.71 Favored 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 121.985 1.79 . . . . 1.0 111.499 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.9 m -68.84 -13.3 62.33 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.955 -0.566 . . . . 1.0 109.811 -179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.96 -1.56 68.14 Favored Glycine 0 CA--C 1.517 0.199 0 N-CA-C 109.811 -1.316 . . . . 1.0 109.811 -179.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.459 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.9 tm? -80.95 133.98 35.62 Favored 'General case' 0 CA--C 1.518 -0.258 0 N-CA-C 108.591 -0.892 . . . . 1.0 108.591 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.459 ' H ' HD22 ' A' ' 32' ' ' LEU . 18.9 mp0 -122.42 138.42 54.54 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 116.448 -0.342 . . . . 1.0 111.087 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.6 p90 -133.56 145.5 50.15 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.525 0.679 . . . . 1.0 111.054 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.504 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -127.66 132.82 49.66 Favored 'General case' 0 CA--C 1.505 -0.751 0 CA-C-N 114.552 -1.204 . . . . 1.0 109.499 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.57 104.26 14.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 122.2 1.0 . . . . 1.0 112.122 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.629 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.8 mm -70.24 -41.69 78.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.027 -0.988 . . . . 1.0 108.523 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.423 HD22 ' HB ' ' A' ' 98' ' ' THR . 9.9 m-80 -143.11 128.34 18.74 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 114.595 -1.184 . . . . 1.0 109.495 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.0 p -88.12 131.84 34.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.746 0.308 . . . . 1.0 110.239 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.21 -35.44 0.81 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.639 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 57.23 30.66 18.77 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.251 -0.474 . . . . 1.0 111.169 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.12 -161.73 37.55 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.828 0.682 . . . . 1.0 111.756 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 25.9 m -69.01 -178.4 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.153 -1.023 . . . . 1.0 109.576 178.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.533 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.62 154.26 0.4 Allowed Pre-proline 0 C--N 1.32 -0.711 0 O-C-N 123.682 0.614 . . . . 1.0 109.523 179.554 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -87.83 157.81 7.46 Favored 'Trans proline' 0 N--CA 1.5 1.894 0 C-N-CA 123.363 2.709 . . . . 1.0 117.242 -174.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.439 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -88.84 176.17 44.05 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 109.205 -1.558 . . . . 1.0 109.205 176.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.468 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.5 -25.46 6.6 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.189 -0.506 . . . . 1.0 112.055 -179.443 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -108.61 -8.42 15.47 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 112.834 0.679 . . . . 1.0 112.834 -177.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.439 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 97.3 m-20 -82.96 166.47 18.82 Favored 'General case' 0 C--N 1.32 -0.685 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.327 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -105.35 150.59 25.08 Favored 'General case' 0 CA--C 1.511 -0.551 0 CA-C-O 121.334 0.588 . . . . 1.0 110.146 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.0 p -128.94 160.68 39.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.19 -0.914 . . . . 1.0 112.009 -177.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.437 HG22 ' HB3' ' A' ' 74' ' ' PRO . 84.8 m -127.69 119.87 26.78 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.125 -1.065 . . . . 1.0 108.125 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.514 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 7.2 m -148.9 164.74 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 114.507 1.299 . . . . 1.0 114.507 -176.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.9 mt-10 -118.22 150.74 38.92 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 106.305 -1.739 . . . . 1.0 106.305 174.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.552 ' O ' ' N ' ' A' ' 68' ' ' THR . 32.5 p90 -163.32 162.9 25.34 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 115.09 1.515 . . . . 1.0 115.09 -177.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -126.27 129.47 48.97 Favored 'General case' 0 C--O 1.217 -0.608 0 CA-C-N 115.086 -0.961 . . . . 1.0 108.515 175.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.76 134.61 12.09 Favored Glycine 0 N--CA 1.471 1.011 0 N-CA-C 111.472 -0.651 . . . . 1.0 111.472 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.53 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 8.6 ptp85 -147.03 167.43 24.05 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.701 0.763 . . . . 1.0 112.389 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.5 mp -84.46 165.06 18.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 114.349 -1.296 . . . . 1.0 110.236 178.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.429 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.79 -26.55 38.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.265 -0.879 . . . . 1.0 110.524 178.445 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -92.0 3.18 55.81 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.044 -1.434 . . . . 1.0 111.701 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.24 -4.09 76.97 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 121.337 -0.458 . . . . 1.0 113.177 178.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.3 m -68.01 104.06 1.65 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 118.141 0.97 . . . . 1.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 75.6 t -76.43 120.04 25.79 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.079 0.466 . . . . 1.0 110.153 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.751 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.8 p90 -109.28 -11.79 14.84 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 115.231 -0.895 . . . . 1.0 112.308 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.503 ' CB ' H433 ' A' ' 138' ' ' RAP . 11.5 t70 -161.99 153.08 17.99 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.316 -0.554 . . . . 1.0 111.511 178.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 94.4 p -159.23 154.21 24.97 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.41 0.624 . . . . 1.0 112.558 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.552 ' N ' ' O ' ' A' ' 55' ' ' TYR . 62.3 m -150.15 -40.74 0.13 Allowed 'General case' 0 C--O 1.223 -0.337 0 CA-C-N 115.024 -0.989 . . . . 1.0 110.305 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.41 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.6 pp20? -62.22 -26.62 68.47 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.241 -0.583 . . . . 1.0 109.637 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 21.9 mmmt -57.0 -42.91 81.17 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.426 -1.324 . . . . 1.0 107.426 178.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.492 ' OG1' ' O ' ' A' ' 68' ' ' THR . 71.4 p -73.28 -33.72 65.39 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 114.732 -1.122 . . . . 1.0 108.365 176.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.13 17.04 75.27 Favored Glycine 0 C--N 1.334 0.425 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.359 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.6 mttm -101.44 116.7 63.3 Favored Pre-proline 0 N--CA 1.469 0.524 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.693 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.3 Cg_exo -60.08 152.76 63.06 Favored 'Trans proline' 0 N--CA 1.485 0.982 0 C-N-CA 121.786 1.657 . . . . 1.0 114.377 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.412 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -122.29 147.26 46.45 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 113.827 -1.533 . . . . 1.0 107.548 177.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.46 128.12 52.3 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 121.072 0.463 . . . . 1.0 112.014 -179.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.505 ' CD2' ' H31' ' A' ' 138' ' ' RAP . 25.5 m-85 -136.06 150.59 49.22 Favored 'General case' 0 CA--C 1.493 -1.24 0 CA-C-O 121.797 0.808 . . . . 1.0 110.844 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -94.14 123.63 37.65 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 105.828 -1.915 . . . . 1.0 105.828 174.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.459 HG11 HE21 ' A' ' 91' ' ' GLN . 25.3 t -49.44 -25.61 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.795 -0.638 . . . . 1.0 110.663 -176.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 15.3 t -78.11 -24.33 47.53 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 120.308 -0.557 . . . . 1.0 112.189 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.495 ' O ' ' H34' ' A' ' 138' ' ' RAP . 92.7 mm-40 -96.6 -10.28 27.48 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 112.112 0.412 . . . . 1.0 112.112 -179.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.615 HG23 H31A ' A' ' 138' ' ' RAP . 0.5 OUTLIER -79.68 166.8 2.4 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 N-CA-C 112.59 0.589 . . . . 1.0 112.59 -176.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -57.24 146.7 60.84 Favored Pre-proline 0 CA--C 1.545 0.753 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 -179.672 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -48.88 -46.11 26.05 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.686 1.591 . . . . 1.0 113.03 -178.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.68 -47.56 87.66 Favored Glycine 0 C--N 1.319 -0.398 0 N-CA-C 109.753 -1.339 . . . . 1.0 109.753 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.604 ' CD2' ' H41' ' A' ' 138' ' ' RAP . 7.3 m95 -64.4 -36.23 83.49 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.147 -1.027 . . . . 1.0 110.199 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.43 ' H ' ' HG1' ' A' ' 87' ' ' THR . 19.5 m -51.17 -54.5 24.87 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.313 -0.403 . . . . 1.0 111.25 -177.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -72.96 -41.62 64.21 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.604 0.594 . . . . 1.0 112.604 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.51 -46.46 83.78 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 113.615 0.969 . . . . 1.0 113.615 -177.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 38.3 mt -58.85 -41.58 87.29 Favored 'General case' 0 CA--C 1.518 -0.274 0 N-CA-C 109.192 -0.67 . . . . 1.0 109.192 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.459 HE21 HG11 ' A' ' 79' ' ' VAL . 74.6 mt-30 -62.95 -23.85 67.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 114.938 -1.028 . . . . 1.0 110.696 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.448 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 83.9 mt -103.34 -12.96 16.88 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.255 -0.429 . . . . 1.0 111.327 -179.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.8 ttp -87.6 108.66 21.34 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-O 119.349 -0.358 . . . . 1.0 111.899 -178.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.533 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.44 147.88 83.19 Favored 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 122.377 2.051 . . . . 1.0 112.365 178.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -66.46 132.37 48.12 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.519 -0.764 . . . . 1.0 111.438 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 99.52 -18.81 55.73 Favored Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 108.567 -1.813 . . . . 1.0 108.567 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.1 p -88.63 136.45 32.99 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-O 120.959 0.409 . . . . 1.0 110.387 179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.423 ' HB ' HD22 ' A' ' 38' ' ' ASN . 90.5 m -108.27 114.39 28.22 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 115.803 -0.635 . . . . 1.0 109.708 178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.448 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.1 m0 -115.4 167.6 10.72 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-O 121.596 0.712 . . . . 1.0 111.228 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.629 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.2 mt-10 -127.37 128.11 45.33 Favored 'General case' 0 CA--C 1.508 -0.639 0 N-CA-C 106.673 -1.603 . . . . 1.0 106.673 175.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.415 HD11 ' CD1' ' A' ' 86' ' ' TRP . 2.6 pt -123.32 138.07 54.5 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.6 0 CA-C-O 121.894 0.855 . . . . 1.0 110.27 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.44 103.9 13.13 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.957 -1.868 . . . . 1.0 105.957 -177.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.7 t -90.42 115.4 64.02 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 115.076 1.51 . . . . 1.0 115.076 -174.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -51.15 141.96 36.97 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 121.323 1.348 . . . . 1.0 109.858 175.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.3 p -48.46 -34.28 10.81 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.149 -0.62 . . . . 1.0 110.943 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.87 -32.32 80.72 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.144 -0.782 . . . . 1.0 111.144 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 68.0 mt -98.55 1.67 46.75 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 121.393 -0.123 . . . . 1.0 110.74 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.8 -113.39 0.3 Allowed 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.052 0.39 . . . . 1.0 112.052 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.655 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 58.4 m-85 -98.2 3.77 48.95 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 112.487 0.551 . . . . 1.0 112.487 -177.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 109.49 162.75 19.67 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 121.014 -0.612 . . . . 1.0 112.768 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -74.75 -9.29 21.04 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 C-N-CA 123.556 2.837 . . . . 1.0 111.695 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -103.63 166.59 10.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.126 -0.488 . . . . 1.0 109.839 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.57 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -72.3 84.99 1.07 Allowed 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 178.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 13.0 t -100.72 62.01 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.985 0.422 . . . . 1.0 110.513 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.443 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -179.98 41.09 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 111.502 -0.639 . . . . 1.0 111.502 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.84 -103.98 0.01 OUTLIER Glycine 0 CA--C 1.535 1.322 0 N-CA-C 110.992 -0.843 . . . . 1.0 110.992 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -61.33 -14.78 36.39 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.549 2.166 . . . . 1.0 110.669 -178.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.751 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.1 mp -65.83 113.25 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 N-CA-C 106.672 -1.603 . . . . 1.0 106.672 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.31 -172.79 40.14 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.378 -0.828 . . . . 1.0 112.28 -177.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.57 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.2 Cg_endo -62.88 138.11 66.58 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 C-N-CA 122.38 2.053 . . . . 1.0 112.405 179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.34 51.82 12.4 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 121.039 -0.264 . . . . 1.0 111.061 178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.611 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -98.82 130.06 45.24 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.921 0.712 . . . . 1.0 112.921 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.447 HG21 HD11 ' A' ' 16' ' ' LEU . 43.5 m -96.66 129.13 44.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 106.063 -1.829 . . . . 1.0 106.063 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -110.94 145.15 38.87 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.308 0.575 . . . . 1.0 111.105 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.664 HD12 ' CE2' ' A' ' 102' ' ' TYR . 2.1 tt -124.31 148.55 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.584 0 CA-C-N 115.233 -0.894 . . . . 1.0 108.884 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.597 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -140.93 151.17 44.0 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.242 -0.583 . . . . 1.0 111.515 177.536 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.53 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 12.9 mmtt -99.36 125.32 45.01 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 105.46 -2.052 . . . . 1.0 105.46 177.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.02 118.4 56.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 C-N-CA 119.267 -0.973 . . . . 1.0 112.418 -176.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.401 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.5 t-160 -109.68 123.88 50.25 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 114.128 -1.397 . . . . 1.0 108.649 178.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.07 111.17 23.02 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 120.246 -0.582 . . . . 1.0 112.39 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -94.29 -42.69 12.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 115.995 -0.548 . . . . 1.0 111.676 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -153.44 156.0 37.38 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 120.502 -0.479 . . . . 1.0 110.796 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.433 HG21 ' HA ' ' A' ' 44' ' ' LYS . 44.7 t -130.65 138.82 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 116.156 -0.475 . . . . 1.0 111.452 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.4 tptm -99.65 -151.9 0.4 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 121.494 0.664 . . . . 1.0 109.564 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.414 ' H ' ' HG3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -172.17 137.47 0.91 Allowed 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.198 -0.91 . . . . 1.0 110.486 178.333 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.499 ' OG ' ' N ' ' A' ' 137' ' ' SER . 5.3 p -68.16 -57.81 5.45 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.809 -1.087 . . . . 1.0 111.043 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.499 ' N ' ' OG ' ' A' ' 136' ' ' SER . 1.2 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.929 -1.034 . . . . 1.0 110.134 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.725 ' O2 ' ' O3 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 26.4 m-85 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.413 -0.588 . . . . 1.0 109.413 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.456 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 11.2 m120 -65.17 -36.46 84.3 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 120.883 -0.327 . . . . 1.0 110.813 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.516 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 58.6 pttt -46.29 -43.6 15.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.12 0.486 . . . . 1.0 110.276 -178.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.516 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 6.6 tmtt? -70.37 -38.8 74.81 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.866 0.841 . . . . 1.0 109.589 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.84 -35.07 43.37 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 114.908 -1.042 . . . . 1.0 110.165 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -65.12 -37.68 88.23 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.395 -0.82 . . . . 1.0 110.889 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -65.79 -51.89 55.34 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.655 0.74 . . . . 1.0 110.505 -179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.4 m-20 -59.67 -35.31 74.19 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.204 -1.035 . . . . 1.0 108.204 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.3 tttt -66.59 -50.5 62.86 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 113.757 -1.565 . . . . 1.0 111.919 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.15 -48.0 82.81 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 C-N-CA 119.813 -0.755 . . . . 1.0 111.253 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.84 -38.1 89.46 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 178.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.15 -44.76 52.9 Favored Glycine 0 CA--C 1.525 0.703 0 CA-C-N 114.847 -1.069 . . . . 1.0 112.366 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -60.44 -31.78 70.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 119.494 -0.882 . . . . 1.0 108.692 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.99 -35.5 57.12 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.809 -1.087 . . . . 1.0 109.87 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.1 t80 -61.39 -51.34 69.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.621 -1.172 . . . . 1.0 110.847 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.408 HD11 HG21 ' A' ' 123' ' ' THR . 5.3 mp -68.12 -38.37 82.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 119.995 -0.682 . . . . 1.0 109.41 179.06 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 99.3 m -62.16 -41.65 98.51 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.553 -0.749 . . . . 1.0 109.296 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -74.62 -46.81 35.96 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.056 -0.975 . . . . 1.0 111.655 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.638 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -55.73 -50.49 70.24 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 112.496 0.554 . . . . 1.0 112.496 -178.783 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.0 ptmt -60.1 -26.74 66.45 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.379 -0.928 . . . . 1.0 109.831 -177.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 16.8 m-80 -83.55 -31.23 26.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.377 -0.829 . . . . 1.0 111.186 179.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -58.7 136.45 86.57 Favored Pre-proline 0 CA--C 1.548 0.871 0 CA-C-N 116.52 -0.309 . . . . 1.0 111.576 -178.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -56.75 148.58 64.84 Favored 'Trans proline' 0 N--CA 1.503 2.071 0 C-N-CA 122.138 1.892 . . . . 1.0 113.334 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.14 -19.32 18.11 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.495 -0.775 . . . . 1.0 111.49 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.471 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.1 t -86.42 137.71 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.165 0.507 . . . . 1.0 110.547 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.93 121.78 65.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 N-CA-C 107.582 -1.266 . . . . 1.0 107.582 177.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.19 145.99 7.24 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.642 0 CA-C-O 121.361 0.601 . . . . 1.0 111.228 -178.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 92.8 mt -111.94 164.81 14.25 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.85 -1.068 . . . . 1.0 110.462 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -61.54 -30.48 86.28 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.745 1.63 . . . . 1.0 110.91 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -68.83 -14.44 63.03 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.473 -0.785 . . . . 1.0 109.828 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.41 -3.89 66.43 Favored Glycine 0 C--N 1.329 0.157 0 N-CA-C 109.671 -1.371 . . . . 1.0 109.671 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.472 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.16 133.93 36.71 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 108.457 -0.942 . . . . 1.0 108.457 179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.472 ' H ' HD22 ' A' ' 32' ' ' LEU . 15.2 mp0 -123.07 143.38 50.0 Favored 'General case' 0 CA--C 1.508 -0.651 0 CA-C-N 116.286 -0.416 . . . . 1.0 110.887 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.4 p90 -138.21 143.59 40.25 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-O 121.635 0.731 . . . . 1.0 110.757 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.525 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -127.51 131.24 50.14 Favored 'General case' 0 CA--C 1.501 -0.924 0 CA-C-N 114.594 -1.184 . . . . 1.0 109.188 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 p -88.85 104.62 15.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-O 122.279 1.038 . . . . 1.0 111.688 -178.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.0 mm -69.25 -42.2 81.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.881 -1.054 . . . . 1.0 108.453 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -143.36 124.55 14.54 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.501 -1.227 . . . . 1.0 109.907 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -85.83 129.64 34.77 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.611 -0.436 . . . . 1.0 109.9 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.23 -33.24 1.26 Allowed Glycine 0 CA--C 1.52 0.393 0 N-CA-C 109.895 -1.282 . . . . 1.0 109.895 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.666 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 57.04 31.67 20.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.477 -0.361 . . . . 1.0 111.157 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.08 -162.18 37.92 Favored Glycine 0 C--N 1.332 0.329 0 CA-C-O 121.819 0.677 . . . . 1.0 111.822 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.4 m -68.17 -177.93 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 114.061 -1.069 . . . . 1.0 109.127 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.695 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.32 154.82 0.39 Allowed Pre-proline 0 C--N 1.317 -0.834 0 N-CA-C 109.338 -0.616 . . . . 1.0 109.338 179.553 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.427 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 56.8 Cg_endo -86.71 158.78 9.09 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 123.11 2.54 . . . . 1.0 115.741 -175.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 177.29 41.72 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 108.766 -1.734 . . . . 1.0 108.766 176.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.48 -23.02 9.07 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.882 -0.327 . . . . 1.0 111.07 -179.713 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 57.9 m -108.05 -9.22 15.67 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 113.629 0.974 . . . . 1.0 113.629 -176.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 89.7 m-20 -84.74 166.87 16.64 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 119.883 -0.727 . . . . 1.0 109.468 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.5 m -104.56 148.44 26.5 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.612 -0.514 . . . . 1.0 109.612 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.427 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -126.57 161.79 32.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.478 0 CA-C-N 115.857 -0.611 . . . . 1.0 112.278 -176.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.421 HG22 ' HB3' ' A' ' 74' ' ' PRO . 86.4 m -130.48 118.18 20.74 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 75' ' ' ALA . 2.5 m -148.14 166.43 4.79 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 112.577 0.584 . . . . 1.0 112.577 -177.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.2 mt-10 -116.39 157.7 24.66 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 106.469 -1.678 . . . . 1.0 106.469 175.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.475 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.6 p90 -167.2 160.91 14.15 Favored 'General case' 0 C--N 1.346 0.415 0 N-CA-C 114.846 1.425 . . . . 1.0 114.846 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -124.76 127.81 47.8 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.119 -1.067 . . . . 1.0 108.119 174.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.89 134.03 11.39 Favored Glycine 0 N--CA 1.47 0.955 0 C-N-CA 120.748 -0.739 . . . . 1.0 111.915 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -146.48 166.84 25.22 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.715 0.769 . . . . 1.0 112.169 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.0 162.66 20.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.391 -1.277 . . . . 1.0 110.062 177.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.05 -25.33 29.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.913 0.863 . . . . 1.0 110.206 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -92.22 2.84 56.37 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 113.947 -1.479 . . . . 1.0 111.852 -177.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.96 -4.98 78.86 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 121.016 -0.611 . . . . 1.0 112.781 179.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.7 m -68.82 105.75 2.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 118.068 0.934 . . . . 1.0 109.63 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 67.7 t -77.69 121.82 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.691 0 CA-C-O 121.229 0.538 . . . . 1.0 110.301 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.6 p90 -110.41 -11.53 14.5 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.089 -0.959 . . . . 1.0 111.688 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -159.84 154.13 23.66 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.192 0.52 . . . . 1.0 111.497 177.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.3 p -159.29 151.43 20.98 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.41 -0.814 . . . . 1.0 111.213 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.475 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.9 m -154.38 -41.78 0.09 Allowed 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.645 -0.707 . . . . 1.0 110.649 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.426 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -62.38 -26.33 68.41 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.862 -0.608 . . . . 1.0 110.313 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -55.34 -41.88 73.06 Favored 'General case' 0 N--CA 1.447 -0.583 0 N-CA-C 108.153 -1.054 . . . . 1.0 108.153 179.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.7 p -80.05 -30.82 39.47 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.067 177.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.1 16.99 68.19 Favored Glycine 0 C--N 1.336 0.531 0 CA-C-N 115.689 -0.687 . . . . 1.0 111.592 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -97.28 115.73 65.8 Favored Pre-proline 0 N--CA 1.471 0.591 0 C-N-CA 120.716 -0.394 . . . . 1.0 110.342 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 Cg_exo -60.32 156.23 41.93 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.177 1.918 . . . . 1.0 114.687 -178.364 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.67 145.36 49.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 113.908 -1.496 . . . . 1.0 107.595 177.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.513 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 1.4 t -104.0 133.91 48.16 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.395 0.617 . . . . 1.0 112.075 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.689 ' CZ ' ' H52' ' A' ' 138' ' ' RAP . 22.6 m-85 -144.18 152.45 40.9 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.837 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -94.52 125.15 38.99 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.878 -1.527 . . . . 1.0 106.878 175.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.95 -30.87 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 C-N-CA 120.04 -0.664 . . . . 1.0 110.57 -177.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -73.42 -24.25 60.24 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.299 -0.561 . . . . 1.0 112.349 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.534 ' O ' ' H34' ' A' ' 138' ' ' RAP . 86.1 mm-40 -99.72 -14.67 18.79 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 112.888 0.699 . . . . 1.0 112.888 -177.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.717 HG23 H31A ' A' ' 138' ' ' RAP . 0.8 OUTLIER -73.14 169.43 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 N-CA-C 112.434 0.531 . . . . 1.0 112.434 -176.745 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.523 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -56.09 149.08 37.06 Favored Pre-proline 0 CA--C 1.547 0.831 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 -179.402 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.435 ' HD2' HG22 ' A' ' 83' ' ' ILE . 74.0 Cg_exo -51.49 -45.01 40.18 Favored 'Trans proline' 0 N--CA 1.498 1.736 0 C-N-CA 121.359 1.372 . . . . 1.0 112.941 -178.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.93 -46.78 93.13 Favored Glycine 0 N--CA 1.45 -0.428 0 N-CA-C 110.29 -1.124 . . . . 1.0 110.29 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . . . . . . . . . 6.6 m95 -65.87 -33.5 75.99 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.389 -0.906 . . . . 1.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 29.7 m -54.91 -54.16 46.18 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.703 -0.399 . . . . 1.0 111.359 -178.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -72.74 -42.44 64.07 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 112.771 0.656 . . . . 1.0 112.771 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.73 -46.8 83.95 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.903 1.075 . . . . 1.0 113.903 -177.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.2 mt -58.5 -41.56 85.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.347 0.594 . . . . 1.0 109.811 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -63.74 -23.59 67.43 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.095 -0.957 . . . . 1.0 110.515 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.528 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 81.3 mt -102.59 -10.03 19.63 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 116.032 -0.531 . . . . 1.0 111.422 -179.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.6 ttp -91.89 107.81 25.43 Favored Pre-proline 0 CA--C 1.546 0.823 0 N-CA-C 111.835 0.309 . . . . 1.0 111.835 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.695 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.0 Cg_exo -65.78 147.66 85.76 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 122.488 2.125 . . . . 1.0 112.357 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.74 137.55 58.12 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.666 0.746 . . . . 1.0 111.508 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.73 53.27 Favored Glycine 0 N--CA 1.441 -1.018 0 N-CA-C 108.546 -1.822 . . . . 1.0 108.546 -178.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 p -87.18 134.6 33.51 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.009 0.433 . . . . 1.0 110.178 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.9 m -107.59 114.68 28.83 Favored 'General case' 0 CA--C 1.51 -0.582 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.052 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.528 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.6 m0 -115.71 164.38 14.43 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.708 0.766 . . . . 1.0 111.23 -178.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.6 mt-10 -124.96 126.39 45.4 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 106.815 -1.55 . . . . 1.0 106.815 175.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.2 pt -121.92 138.39 52.32 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.688 0 CA-C-O 121.899 0.857 . . . . 1.0 109.969 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.751 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.64 103.25 12.08 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.646 -1.983 . . . . 1.0 105.646 -178.231 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.2 115.45 64.07 Favored Pre-proline 0 C--N 1.324 -0.541 0 N-CA-C 114.75 1.389 . . . . 1.0 114.75 -174.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -50.84 143.2 30.75 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 C-N-CA 121.433 1.422 . . . . 1.0 109.783 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 96.5 p -49.1 -35.26 15.75 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.273 -0.571 . . . . 1.0 110.531 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.86 -32.15 81.89 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 111.388 -0.685 . . . . 1.0 111.388 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 53.3 mt -100.59 2.91 42.2 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 121.499 -0.08 . . . . 1.0 110.832 -179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.66 -107.95 0.33 Allowed 'General case' 0 N--CA 1.457 -0.11 0 CA-C-O 120.923 0.392 . . . . 1.0 111.037 -178.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.64 ' CZ ' H121 ' A' ' 138' ' ' RAP . 52.7 m-85 -100.03 4.89 45.01 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 111.965 0.357 . . . . 1.0 111.965 -178.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.78 160.97 25.76 Favored Glycine 0 CA--C 1.529 0.927 0 C-N-CA 121.395 -0.431 . . . . 1.0 112.925 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.567 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.2 Cg_endo -70.56 -15.94 34.12 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 123.316 2.677 . . . . 1.0 112.676 179.69 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.456 ' O ' HG23 ' A' ' 114' ' ' VAL . 2.8 mpt_? -96.75 169.48 9.84 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.22 -0.659 . . . . 1.0 109.22 179.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.426 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.3 m -75.76 82.78 2.72 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.352 -0.539 . . . . 1.0 110.096 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.5 t -98.36 60.11 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.771 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 172.68 -172.7 45.16 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.534 -0.841 . . . . 1.0 112.033 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.81 -103.78 0.05 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 111.036 -0.826 . . . . 1.0 111.036 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -59.3 -16.88 36.79 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.219 1.946 . . . . 1.0 110.397 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.645 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.0 mp -67.75 114.7 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 107.889 -1.152 . . . . 1.0 107.889 179.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.611 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -94.89 -158.5 33.09 Favored Glycine 0 C--O 1.212 -1.253 0 N-CA-C 110.968 -0.853 . . . . 1.0 110.968 -178.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.511 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 44.6 Cg_endo -70.09 147.45 60.75 Favored 'Trans proline' 0 C--N 1.299 -2.034 0 C-N-CA 121.892 1.728 . . . . 1.0 113.098 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.567 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.5 t-20 39.99 60.74 1.65 Allowed 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.254 0.835 . . . . 1.0 113.254 177.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.709 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.03 135.85 53.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 121.571 0.7 . . . . 1.0 111.355 -179.423 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.408 HG21 HD11 ' A' ' 16' ' ' LEU . 99.2 m -93.69 129.0 40.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.329 178.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -109.51 140.97 42.63 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.142 0.496 . . . . 1.0 110.133 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.751 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -121.11 143.68 32.6 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.729 0 CA-C-N 115.506 -0.77 . . . . 1.0 109.014 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -134.89 150.66 50.46 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.082 0.468 . . . . 1.0 111.08 177.269 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 14.3 mmtt -99.63 126.02 45.56 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 104.85 -2.278 . . . . 1.0 104.85 176.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.8 mt -119.72 119.54 60.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 119.16 -1.016 . . . . 1.0 111.851 -177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.403 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.1 t-160 -111.92 120.94 43.63 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 114.091 -1.413 . . . . 1.0 108.816 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.63 112.45 24.41 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 120.236 -0.585 . . . . 1.0 112.326 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.491 ' N ' HD12 ' A' ' 131' ' ' ILE . 3.9 mp -94.84 -47.49 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.5 p -148.14 157.54 43.56 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.93 0.395 . . . . 1.0 111.246 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.43 HG21 ' HA ' ' A' ' 44' ' ' LYS . 54.7 t -130.07 139.25 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 116.043 -0.526 . . . . 1.0 111.396 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.543 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 12.5 tptt -94.98 -142.83 0.25 Allowed 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 115.424 -0.807 . . . . 1.0 110.298 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.543 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -171.77 149.9 2.59 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 114.685 -1.143 . . . . 1.0 109.751 177.877 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.423 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 87.7 p -40.51 -26.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.324 -0.853 . . . . 1.0 111.304 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 135' ' ' LYS . 97.7 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.686 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.769 H331 ' O2 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.504 ' CG ' ' N ' ' A' ' 2' ' ' ASN . 49.4 t80 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 108.935 -0.765 . . . . 1.0 108.935 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.504 ' N ' ' CG ' ' A' ' 1' ' ' PHE . 87.8 m-20 -71.08 -19.38 62.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.633 -0.258 . . . . 1.0 111.344 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 62.5 pttt -46.69 -41.58 15.19 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.578 -0.449 . . . . 1.0 110.482 -178.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.513 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 4.4 tmtt? -69.21 -36.76 77.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.957 0.884 . . . . 1.0 109.951 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -51.34 -33.88 31.38 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-N 114.796 -1.093 . . . . 1.0 110.66 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -64.24 -36.85 85.43 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.197 -0.911 . . . . 1.0 110.804 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -66.79 -52.69 41.1 Favored 'General case' 0 C--O 1.223 -0.331 0 C-N-CA 119.933 -0.707 . . . . 1.0 110.694 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 30.4 m-20 -59.51 -34.0 72.07 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-O 121.964 0.888 . . . . 1.0 108.617 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.8 tttt -64.43 -49.71 70.42 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 114.108 -1.405 . . . . 1.0 111.664 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.3 t -69.31 -47.26 74.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.408 -0.517 . . . . 1.0 112.112 -178.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.443 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.2 -36.91 83.36 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 179.686 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.79 -44.15 39.53 Favored Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.925 -1.034 . . . . 1.0 112.408 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 mt-10 -60.66 -30.97 70.22 Favored 'General case' 0 CA--C 1.514 -0.416 0 C-N-CA 119.701 -0.8 . . . . 1.0 108.883 179.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.8 -35.68 51.13 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.129 -0.941 . . . . 1.0 109.849 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 t80 -61.96 -50.8 70.66 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.728 -1.124 . . . . 1.0 110.901 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.45 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -66.82 -38.74 87.03 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 179.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.48 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 99.0 m -61.27 -43.0 99.59 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.498 -0.773 . . . . 1.0 109.584 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -75.32 -46.48 33.08 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.591 -0.731 . . . . 1.0 112.111 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.655 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 51.3 t30 -61.47 -45.12 95.58 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 113.145 0.795 . . . . 1.0 113.145 -177.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -58.02 -33.69 69.23 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 119.321 -0.952 . . . . 1.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 17' ' ' THR . 43.6 m-80 -75.46 -33.91 60.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.305 -0.861 . . . . 1.0 111.538 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.5 mtmt -58.99 137.41 87.72 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 120.593 -0.443 . . . . 1.0 111.8 -177.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -53.85 149.13 34.77 Favored 'Trans proline' 0 N--CA 1.507 2.302 0 C-N-CA 122.723 2.282 . . . . 1.0 114.757 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.76 -21.91 5.2 Favored Glycine 0 CA--C 1.508 -0.368 0 CA-C-N 114.421 -1.263 . . . . 1.0 111.265 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 54.3 t -80.21 132.0 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 N-CA-C 109.34 -0.615 . . . . 1.0 109.34 -179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.77 120.4 64.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 108.327 -0.99 . . . . 1.0 108.327 177.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.3 p -95.5 145.91 7.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 CA-C-O 121.471 0.653 . . . . 1.0 111.265 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.0 mt -114.17 165.26 14.07 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.597 -1.183 . . . . 1.0 110.955 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.76 -30.44 90.28 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 C-N-CA 121.828 1.685 . . . . 1.0 111.006 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.5 m -68.4 -15.82 63.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.608 -0.724 . . . . 1.0 109.801 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.95 -2.77 64.26 Favored Glycine 0 C--O 1.229 -0.192 0 N-CA-C 110.016 -1.234 . . . . 1.0 110.016 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.479 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -78.78 134.1 37.04 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.479 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.0 mp0 -123.64 142.93 50.58 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.393 -0.367 . . . . 1.0 111.525 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -140.6 142.26 35.08 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.919 0.866 . . . . 1.0 112.183 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.58 ' HE3' HD13 ' A' ' 37' ' ' ILE . 8.6 ttpt -123.99 126.57 46.52 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.173 -1.376 . . . . 1.0 108.45 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.416 ' H ' HG12 ' A' ' 36' ' ' VAL . 2.9 p -82.61 113.52 21.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.128 -178.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.58 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.8 mm -77.27 -42.24 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.556 0 CA-C-O 121.541 0.686 . . . . 1.0 109.844 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.503 HD22 ' HB ' ' A' ' 37' ' ' ILE . 27.0 m-80 -144.34 124.01 13.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.725 -1.125 . . . . 1.0 109.917 -177.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -81.84 129.58 34.79 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.539 -0.464 . . . . 1.0 110.527 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.15 -36.13 1.05 Allowed Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.106 -1.198 . . . . 1.0 110.106 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.619 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 57.81 31.22 20.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.447 -0.376 . . . . 1.0 111.49 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.67 -161.8 37.25 Favored Glycine 0 C--N 1.332 0.35 0 CA-C-O 121.984 0.769 . . . . 1.0 111.731 179.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.2 m -68.97 -177.86 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.093 -1.053 . . . . 1.0 109.086 178.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.61 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.18 154.23 0.38 Allowed Pre-proline 0 C--N 1.32 -0.676 0 O-C-N 123.757 0.661 . . . . 1.0 109.556 179.734 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.407 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.5 Cg_endo -87.71 158.01 7.63 Favored 'Trans proline' 0 N--CA 1.497 1.731 0 C-N-CA 123.336 2.691 . . . . 1.0 116.45 -175.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -90.0 175.57 41.68 Favored Glycine 0 N--CA 1.449 -0.449 0 N-CA-C 108.353 -1.899 . . . . 1.0 108.353 176.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.498 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.84 -22.31 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.778 -0.369 . . . . 1.0 111.274 -179.383 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 53.5 m -107.88 -9.3 15.75 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 113.534 0.939 . . . . 1.0 113.534 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.19 165.43 17.4 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.436 -0.949 . . . . 1.0 108.436 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.7 m -104.72 150.53 24.66 Favored 'General case' 0 CA--C 1.515 -0.366 0 N-CA-C 109.869 -0.419 . . . . 1.0 109.869 -179.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.407 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.4 p -127.09 163.37 30.06 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 112.599 0.592 . . . . 1.0 112.599 -176.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.403 HG22 ' HB3' ' A' ' 74' ' ' PRO . 97.1 m -131.55 120.18 22.55 Favored 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 108.488 -0.93 . . . . 1.0 108.488 178.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.583 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 15.8 m -148.75 165.28 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 114.438 1.273 . . . . 1.0 114.438 -176.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.427 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 7.0 mt-10 -118.35 147.92 43.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 174.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.583 ' CE2' ' H51' ' A' ' 138' ' ' RAP . 37.3 p90 -163.63 162.14 24.11 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 114.68 1.363 . . . . 1.0 114.68 -176.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.49 133.11 54.6 Favored 'General case' 0 C--O 1.216 -0.675 0 N-CA-C 108.371 -0.974 . . . . 1.0 108.371 175.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.83 135.96 11.79 Favored Glycine 0 N--CA 1.474 1.173 0 C-N-CA 120.972 -0.633 . . . . 1.0 111.855 -178.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.8 ptp85 -148.61 167.5 25.28 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.745 0.783 . . . . 1.0 112.997 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -84.69 163.79 18.99 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 114.377 -1.283 . . . . 1.0 110.989 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.58 -25.65 35.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 122.272 1.034 . . . . 1.0 109.589 177.468 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -89.86 0.72 56.87 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 113.378 -1.737 . . . . 1.0 111.688 -177.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.69 81.74 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 121.182 -0.533 . . . . 1.0 112.351 178.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.4 m -68.9 104.13 1.99 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 119.92 -0.712 . . . . 1.0 110.109 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.7 t -77.08 121.13 28.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 CA-C-N 116.059 -0.519 . . . . 1.0 110.062 179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.698 ' CD2' HD11 ' A' ' 118' ' ' ILE . 22.0 p90 -110.59 -14.26 14.09 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.184 -0.916 . . . . 1.0 112.056 -178.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.523 ' OD2' H433 ' A' ' 138' ' ' RAP . 38.7 t0 -159.58 148.19 17.7 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.156 -0.618 . . . . 1.0 111.511 177.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 89.5 p -153.63 156.25 37.58 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.541 179.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.499 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 55.8 m -155.17 -39.51 0.09 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.984 -0.553 . . . . 1.0 110.78 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -63.12 -26.19 68.71 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.632 -0.427 . . . . 1.0 109.895 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -56.49 -41.3 76.4 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 107.085 -1.45 . . . . 1.0 107.085 178.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 68' ' ' THR . 23.1 p -76.74 -32.66 57.93 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.203 -1.362 . . . . 1.0 109.042 177.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.48 15.18 80.32 Favored Glycine 0 C--N 1.332 0.356 0 N-CA-C 110.922 -0.871 . . . . 1.0 110.922 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.427 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 12.9 mttp -96.55 115.26 65.56 Favored Pre-proline 0 N--CA 1.47 0.537 0 C-N-CA 120.827 -0.349 . . . . 1.0 110.962 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.412 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.3 Cg_exo -61.41 151.75 77.46 Favored 'Trans proline' 0 N--CA 1.482 0.827 0 C-N-CA 121.539 1.493 . . . . 1.0 114.405 -178.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.8 150.34 46.45 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.089 -1.414 . . . . 1.0 107.78 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -107.53 136.07 47.93 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 112.882 0.697 . . . . 1.0 112.882 -178.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.606 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 48.0 m-85 -144.48 151.01 38.55 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 114.858 -1.064 . . . . 1.0 109.032 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -90.14 125.87 35.6 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 106.434 -1.691 . . . . 1.0 106.434 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.429 HG11 HE21 ' A' ' 91' ' ' GLN . 23.0 t -50.6 -31.4 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 C-N-CA 119.926 -0.71 . . . . 1.0 110.545 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.8 t -73.57 -27.37 61.28 Favored 'General case' 0 CA--C 1.518 -0.255 0 C-N-CA 120.116 -0.634 . . . . 1.0 111.994 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.493 ' OE1' ' C46' ' A' ' 138' ' ' RAP . 43.9 mm-40 -101.35 -8.72 21.8 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 113.219 0.822 . . . . 1.0 113.219 -178.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.747 ' CG2' H31A ' A' ' 138' ' ' RAP . 3.5 p -80.32 172.84 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 C-N-CA 119.457 -0.897 . . . . 1.0 110.151 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.546 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.03 145.83 31.97 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 120.165 -0.614 . . . . 1.0 109.976 -176.733 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -51.42 -44.21 44.94 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.081 1.854 . . . . 1.0 112.783 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.05 -47.5 88.76 Favored Glycine 0 C--N 1.319 -0.4 0 N-CA-C 109.343 -1.503 . . . . 1.0 109.343 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.824 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 8.1 m95 -64.9 -35.21 80.4 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.796 -1.202 . . . . 1.0 110.565 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.24 -54.23 27.75 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.822 0.344 . . . . 1.0 111.172 -178.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -72.64 -43.14 63.59 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.745 0.646 . . . . 1.0 112.745 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.53 -45.84 84.56 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 113.957 1.095 . . . . 1.0 113.957 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.51 -41.12 84.7 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.457 0.646 . . . . 1.0 109.625 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.429 HE21 HG11 ' A' ' 79' ' ' VAL . 69.6 mt-30 -64.59 -23.85 67.4 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.836 -1.075 . . . . 1.0 110.805 -178.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.482 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 80.6 mt -103.81 -10.73 18.03 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 116.207 -0.451 . . . . 1.0 111.41 -178.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 46.7 ttp -92.18 108.4 30.32 Favored Pre-proline 0 CA--C 1.55 0.978 0 CA-C-O 119.445 -0.312 . . . . 1.0 111.345 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.61 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.0 Cg_exo -65.35 148.26 88.12 Favored 'Trans proline' 0 N--CA 1.5 1.881 0 C-N-CA 122.681 2.254 . . . . 1.0 112.777 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.76 136.86 57.77 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.368 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.23 -19.31 53.12 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 108.954 -1.659 . . . . 1.0 108.954 -178.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.7 p -87.88 135.45 33.39 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 120.851 0.358 . . . . 1.0 110.473 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.4 ' HB ' HD22 ' A' ' 38' ' ' ASN . 72.0 m -107.89 114.94 29.24 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 115.952 -0.567 . . . . 1.0 110.142 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.482 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.4 m0 -114.99 164.24 14.44 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.491 0.662 . . . . 1.0 111.404 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.486 ' HB2' HD11 ' A' ' 37' ' ' ILE . 29.7 mt-10 -124.35 127.78 48.1 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.642 -1.614 . . . . 1.0 106.642 175.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -123.77 138.72 52.58 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.461 0 CA-C-O 121.768 0.794 . . . . 1.0 110.288 -179.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.677 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.23 103.85 12.89 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.864 -1.902 . . . . 1.0 105.864 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.67 115.65 64.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 N-CA-C 115.466 1.654 . . . . 1.0 115.466 -174.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -50.71 143.25 29.7 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 C-N-CA 121.611 1.541 . . . . 1.0 110.017 176.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.5 p -50.09 -34.66 22.57 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.524 -0.47 . . . . 1.0 110.986 -178.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.8 -31.89 76.68 Favored Glycine 0 CA--C 1.52 0.396 0 N-CA-C 110.812 -0.915 . . . . 1.0 110.812 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 54.9 mt -98.97 2.38 46.36 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 121.436 -0.106 . . . . 1.0 110.878 -179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -107.86 0.33 Allowed 'General case' 0 C--N 1.34 0.166 0 CA-C-O 120.503 0.192 . . . . 1.0 111.338 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.713 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 38.0 m-85 -99.45 4.64 46.22 Favored 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 113.279 0.844 . . . . 1.0 113.279 -177.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.33 164.52 22.81 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 120.756 -0.735 . . . . 1.0 113.352 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 121' ' ' ASN . 79.5 Cg_endo -73.98 -16.89 22.77 Favored 'Trans proline' 0 N--CA 1.493 1.46 0 C-N-CA 123.531 2.821 . . . . 1.0 110.9 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.439 ' O ' HG23 ' A' ' 114' ' ' VAL . 60.4 ttt180 -96.06 165.12 12.4 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.477 -1.238 . . . . 1.0 109.685 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.522 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 8.1 m -77.02 91.97 3.68 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.565 -0.531 . . . . 1.0 109.565 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 112' ' ' ARG . 2.3 t -107.56 60.66 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.113 -0.494 . . . . 1.0 111.199 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.518 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 171.23 178.05 41.45 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 120.201 -0.999 . . . . 1.0 112.145 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.23 -103.8 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 111.072 -0.811 . . . . 1.0 111.072 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -62.35 -16.04 48.91 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.567 2.178 . . . . 1.0 110.779 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.2 mp -66.67 115.92 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 108.233 -1.025 . . . . 1.0 108.233 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -96.52 -158.96 31.78 Favored Glycine 0 C--O 1.213 -1.194 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 -179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.522 ' N ' ' OG ' ' A' ' 113' ' ' SER . 46.9 Cg_endo -70.89 147.39 55.51 Favored 'Trans proline' 0 C--N 1.297 -2.141 0 C-N-CA 121.766 1.644 . . . . 1.0 113.326 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.507 ' C ' HD22 ' A' ' 121' ' ' ASN . 0.1 OUTLIER 41.17 60.6 2.0 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 113.195 0.813 . . . . 1.0 113.195 177.515 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.683 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -114.38 137.71 51.47 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 121.683 0.754 . . . . 1.0 111.225 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.45 HG21 HD11 ' A' ' 16' ' ' LEU . 81.8 m -94.43 130.09 40.91 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.332 -1.304 . . . . 1.0 108.624 178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -112.29 141.3 46.17 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.05 -0.523 . . . . 1.0 109.8 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.677 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.7 tt -119.72 146.05 25.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.663 0 N-CA-C 108.368 -0.975 . . . . 1.0 108.368 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.574 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -137.98 151.0 47.5 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.394 -0.522 . . . . 1.0 111.759 177.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.469 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 4.1 mmtt -101.16 122.91 44.46 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 105.741 -1.948 . . . . 1.0 105.741 177.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.453 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.0 mt -117.51 119.19 60.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.956 0.884 . . . . 1.0 113.257 -176.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -109.95 124.03 50.67 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 113.935 -1.484 . . . . 1.0 108.354 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.93 111.12 23.2 Favored 'General case' 0 N--CA 1.465 0.293 0 C-N-CA 120.162 -0.615 . . . . 1.0 112.369 -178.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.477 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -94.01 -45.03 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 115.881 -0.599 . . . . 1.0 111.729 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.7 p -150.63 155.82 40.13 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.683 -0.407 . . . . 1.0 110.79 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.426 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.4 t -129.71 137.21 57.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 121.05 0.452 . . . . 1.0 111.772 -177.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.449 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 17.5 tptt -88.62 -151.28 0.2 Allowed 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.723 -0.671 . . . . 1.0 110.098 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.449 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -178.07 131.48 0.14 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.653 0.74 . . . . 1.0 111.716 179.178 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.8 t -65.08 -47.05 78.62 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.376 -1.283 . . . . 1.0 110.96 179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.408 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 1.7 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 117.99 -1.005 . . . . 1.0 109.937 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.892 H491 H381 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.582 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 11.1 m120 -62.12 -34.33 76.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.051 -0.522 . . . . 1.0 110.461 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -46.79 -32.58 3.77 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? -68.3 -35.04 77.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 122.134 0.969 . . . . 1.0 108.935 178.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.582 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.21 -36.6 42.35 Favored 'General case' 0 CA--C 1.514 -0.408 0 CA-C-N 114.592 -1.185 . . . . 1.0 110.794 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.44 -35.65 78.19 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.087 -179.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -66.11 -52.58 47.28 Favored 'General case' 0 C--O 1.222 -0.346 0 CA-C-O 121.663 0.744 . . . . 1.0 110.439 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 16.7 m-20 -58.0 -35.11 70.77 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 108.255 -1.017 . . . . 1.0 108.255 179.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.505 ' O ' ' N ' ' A' ' 13' ' ' GLU . 18.7 tttm -65.22 -51.07 63.26 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.691 178.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.52 -46.67 82.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 119.974 -0.69 . . . . 1.0 111.538 -178.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.51 -37.11 86.04 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.418 -1.327 . . . . 1.0 107.418 178.728 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.466 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -72.71 -41.37 50.44 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 114.758 -1.11 . . . . 1.0 112.213 179.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.505 ' N ' ' O ' ' A' ' 9' ' ' LYS . 49.0 mt-10 -62.83 -31.73 72.79 Favored 'General case' 0 CA--C 1.516 -0.328 0 N-CA-C 108.719 -0.845 . . . . 1.0 108.719 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.79 -37.08 59.51 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 115.099 -0.955 . . . . 1.0 109.483 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -60.92 -51.01 71.08 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.199 -1.364 . . . . 1.0 110.789 -179.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.466 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.7 mp -69.01 -37.9 78.93 Favored 'General case' 0 CA--C 1.512 -0.497 0 C-N-CA 119.813 -0.755 . . . . 1.0 109.583 178.206 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 93.9 m -61.03 -43.67 98.55 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.757 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -76.34 -45.63 31.25 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.813 -0.63 . . . . 1.0 112.58 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.639 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.4 t30 -60.75 -44.15 97.06 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 113.309 0.855 . . . . 1.0 113.309 -177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.5 ptmt -59.65 -32.46 70.48 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.275 -0.97 . . . . 1.0 109.313 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.2 m-80 -77.96 -29.97 50.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.405 -0.816 . . . . 1.0 111.714 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 26.7 mtmt -60.45 137.69 92.29 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 120.457 -0.497 . . . . 1.0 111.499 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_exo -55.66 149.4 49.49 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 C-N-CA 122.341 2.027 . . . . 1.0 113.726 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.34 -19.26 14.27 Favored Glycine 0 C--O 1.225 -0.424 0 CA-C-N 114.811 -1.086 . . . . 1.0 111.302 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.416 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.0 t -87.49 135.06 26.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 121.067 0.461 . . . . 1.0 110.77 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.08 121.79 66.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 107.981 -1.118 . . . . 1.0 107.981 177.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.416 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.5 p -96.74 145.87 8.22 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.622 0 CA-C-O 121.676 0.751 . . . . 1.0 111.872 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 74.7 mt -112.34 163.57 17.45 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 114.327 -1.306 . . . . 1.0 110.719 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.03 -29.91 90.35 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.058 1.839 . . . . 1.0 110.69 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.6 m -67.69 -15.54 63.69 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 115.284 -0.871 . . . . 1.0 109.456 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.94 -3.74 70.8 Favored Glycine 0 C--N 1.328 0.115 0 N-CA-C 109.815 -1.314 . . . . 1.0 109.815 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.6 133.51 38.43 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 1.0 108.445 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.3 mp0 -122.5 139.26 54.08 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.284 -0.417 . . . . 1.0 110.865 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -134.95 145.81 48.52 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-O 121.642 0.734 . . . . 1.0 110.619 178.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.528 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.3 tmtp? -130.84 134.1 46.52 Favored 'General case' 0 N--CA 1.443 -0.804 0 CA-C-N 114.503 -1.226 . . . . 1.0 109.084 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -90.48 105.38 16.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 122.18 0.991 . . . . 1.0 111.54 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.636 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.7 mm -70.55 -42.36 78.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 108.594 -0.891 . . . . 1.0 108.594 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -141.82 128.93 20.88 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.816 -1.084 . . . . 1.0 109.767 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.5 p -87.89 123.06 32.26 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.956 0.408 . . . . 1.0 110.182 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.81 -36.22 1.73 Allowed Glycine 0 CA--C 1.518 0.248 0 N-CA-C 109.992 -1.243 . . . . 1.0 109.992 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.602 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.7 m120 57.58 32.46 21.87 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.22 -0.49 . . . . 1.0 111.64 179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.24 -161.65 37.41 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-O 121.907 0.726 . . . . 1.0 111.408 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.594 ' O ' ' N ' ' A' ' 95' ' ' ALA . 31.2 m -69.48 -177.92 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.17 -1.015 . . . . 1.0 109.374 178.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.565 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.75 154.59 0.48 Allowed Pre-proline 0 C--N 1.319 -0.729 0 O-C-N 123.569 0.543 . . . . 1.0 110.11 179.646 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.45 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.7 Cg_endo -87.75 154.29 7.44 Favored 'Trans proline' 0 N--CA 1.5 1.87 0 C-N-CA 123.697 2.932 . . . . 1.0 117.055 -174.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -84.8 175.74 50.59 Favored Glycine 0 C--N 1.334 0.42 0 N-CA-C 109.601 -1.4 . . . . 1.0 109.601 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.884 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.31 -22.34 11.75 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.315 -0.443 . . . . 1.0 111.667 -179.328 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.4 m -109.18 -7.17 15.34 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 112.651 0.612 . . . . 1.0 112.651 -178.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.436 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 78.7 m-20 -82.83 167.88 17.67 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.182 -0.303 . . . . 1.0 110.182 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.3 m -107.5 147.75 30.1 Favored 'General case' 0 CA--C 1.518 -0.282 0 CA-C-O 121.06 0.457 . . . . 1.0 109.949 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.45 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.3 p -127.17 163.05 30.91 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 CA-C-N 115.705 -0.679 . . . . 1.0 111.591 -176.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.42 HG22 ' HB3' ' A' ' 74' ' ' PRO . 95.3 m -129.78 120.15 24.57 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 108.077 -1.083 . . . . 1.0 108.077 177.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.485 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.3 m -148.38 165.62 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 114.227 1.195 . . . . 1.0 114.227 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.4 mt-10 -118.69 147.92 43.3 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 105.913 -1.884 . . . . 1.0 105.913 173.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.508 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 30.0 p90 -161.48 162.84 30.57 Favored 'General case' 0 C--N 1.343 0.292 0 N-CA-C 114.769 1.396 . . . . 1.0 114.769 -177.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.7 m -126.06 132.9 51.85 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.872 175.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.87 134.92 11.77 Favored Glycine 0 N--CA 1.467 0.747 0 N-CA-C 111.302 -0.719 . . . . 1.0 111.302 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.572 ' CZ ' ' NZ ' ' A' ' 127' ' ' LYS . 6.2 ptp85 -143.65 163.61 32.75 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-O 121.553 0.692 . . . . 1.0 111.929 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.0 mp -85.01 162.54 19.31 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 114.664 -1.153 . . . . 1.0 109.844 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.452 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -57.64 -25.82 25.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 115.305 -0.861 . . . . 1.0 110.395 178.517 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -93.34 2.98 56.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 114.279 -1.328 . . . . 1.0 111.603 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -6.14 79.18 Favored Glycine 0 CA--C 1.525 0.68 0 C-N-CA 121.069 -0.586 . . . . 1.0 112.832 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.2 m -65.0 105.3 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 119.548 -0.861 . . . . 1.0 109.103 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.3 t -74.08 117.3 17.82 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 C-N-CA 120.225 -0.59 . . . . 1.0 110.072 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.456 ' CE2' H431 ' A' ' 138' ' ' RAP . 13.9 p90 -103.52 -10.47 18.48 Favored 'General case' 0 CA--C 1.521 -0.152 0 CA-C-N 115.064 -0.971 . . . . 1.0 112.228 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.523 ' CB ' H433 ' A' ' 138' ' ' RAP . 1.0 OUTLIER -168.12 155.34 8.03 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 119.838 -0.745 . . . . 1.0 111.636 177.847 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 60.1 p -157.84 154.8 28.59 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.656 -0.702 . . . . 1.0 111.914 179.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.476 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 95.9 m -153.28 -40.7 0.1 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 115.528 -0.76 . . . . 1.0 110.357 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.404 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.8 pp20? -63.0 -26.27 68.77 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.657 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -52.11 -44.24 64.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 108.279 -1.008 . . . . 1.0 108.279 179.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.421 ' OG1' ' O ' ' A' ' 68' ' ' THR . 16.5 p -79.64 -27.94 40.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.707 -1.133 . . . . 1.0 109.246 177.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.11 16.2 77.12 Favored Glycine 0 CA--C 1.521 0.419 0 CA-C-N 115.441 -0.8 . . . . 1.0 111.74 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.42 114.95 64.27 Favored Pre-proline 0 N--CA 1.47 0.545 0 C-N-CA 120.553 -0.459 . . . . 1.0 110.628 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.424 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 36.1 Cg_exo -61.24 152.49 71.81 Favored 'Trans proline' 0 N--CA 1.484 0.922 0 C-N-CA 121.809 1.673 . . . . 1.0 114.601 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.87 152.17 42.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.048 -1.433 . . . . 1.0 107.247 177.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.7 t -110.42 131.2 55.26 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.605 0.717 . . . . 1.0 112.771 -178.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.553 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 32.2 m-85 -136.58 154.7 50.62 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.824 -1.08 . . . . 1.0 109.652 178.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 -96.32 124.03 40.17 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 105.801 -1.926 . . . . 1.0 105.801 174.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.7 t -47.39 -29.14 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.398 -176.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.9 t -75.86 -24.3 55.72 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 111.974 0.361 . . . . 1.0 111.974 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.491 ' OE1' H461 ' A' ' 138' ' ' RAP . 92.3 mm-40 -98.23 -12.71 21.35 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.353 0.871 . . . . 1.0 113.353 -177.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.564 ' CG2' ' H32' ' A' ' 138' ' ' RAP . 4.1 p -83.93 169.12 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 120.101 -0.64 . . . . 1.0 112.022 -177.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.426 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.12 148.72 21.06 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 -177.354 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.63 -43.14 47.18 Favored 'Trans proline' 0 N--CA 1.498 1.756 0 C-N-CA 121.794 1.662 . . . . 1.0 112.833 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.85 -48.69 80.44 Favored Glycine 0 C--N 1.318 -0.465 0 C-N-CA 119.517 -1.325 . . . . 1.0 109.852 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.535 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 8.7 m95 -63.26 -38.14 90.01 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 113.902 -1.149 . . . . 1.0 110.438 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.9 m -51.13 -53.53 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.265 -0.425 . . . . 1.0 111.594 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -72.42 -41.59 66.03 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.642 0.608 . . . . 1.0 112.642 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.64 -48.21 82.56 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.917 1.08 . . . . 1.0 113.917 -177.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.0 mt -56.93 -39.95 75.47 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 121.133 0.492 . . . . 1.0 110.511 -177.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -63.05 -23.24 67.36 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.607 -0.724 . . . . 1.0 110.753 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.432 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 45.5 mt -105.25 -11.4 16.54 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.307 -0.406 . . . . 1.0 110.935 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 33.4 ttm -86.04 106.81 10.83 Favored Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.669 0.606 . . . . 1.0 111.89 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.565 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 14.6 Cg_exo -68.46 145.7 65.72 Favored 'Trans proline' 0 N--CA 1.501 1.964 0 C-N-CA 122.576 2.184 . . . . 1.0 113.008 179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.594 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.55 132.96 54.18 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.53 -0.759 . . . . 1.0 111.17 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.95 -17.82 58.61 Favored Glycine 0 N--CA 1.447 -0.605 0 N-CA-C 109.147 -1.581 . . . . 1.0 109.147 -179.067 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -88.86 136.46 33.0 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-O 120.838 0.351 . . . . 1.0 110.247 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 57.3 m -107.61 113.76 27.27 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.979 -0.555 . . . . 1.0 109.752 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.432 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.6 m0 -115.51 164.68 13.95 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.728 0.775 . . . . 1.0 110.902 -178.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.636 ' CD ' HD11 ' A' ' 37' ' ' ILE . 86.7 mt-10 -126.25 126.01 43.31 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 106.943 -1.503 . . . . 1.0 106.943 175.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.4 137.12 56.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.733 0 CA-C-O 121.704 0.764 . . . . 1.0 109.649 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.707 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.53 103.59 12.74 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 105.894 -1.891 . . . . 1.0 105.894 -177.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.3 t -90.53 115.54 64.39 Favored Pre-proline 0 C--N 1.326 -0.438 0 N-CA-C 115.077 1.51 . . . . 1.0 115.077 -174.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -51.52 146.72 24.99 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.578 1.519 . . . . 1.0 109.748 176.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 58.4 p -51.6 -36.43 45.62 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 120.192 -0.603 . . . . 1.0 110.901 -178.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.29 -32.52 83.99 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.251 -0.74 . . . . 1.0 111.251 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.0 mt -99.26 1.51 44.75 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.498 -0.186 . . . . 1.0 110.498 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.521 ' O ' H521 ' A' ' 138' ' ' RAP . . . -109.28 -103.34 0.37 Allowed 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 120.352 0.12 . . . . 1.0 110.819 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.597 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 44.2 m-85 -107.6 5.97 27.46 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 114.915 1.45 . . . . 1.0 114.915 -176.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.15 169.43 22.2 Favored Glycine 0 N--CA 1.473 1.127 0 C-N-CA 120.245 -0.978 . . . . 1.0 114.139 176.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 121' ' ' ASN . 57.0 Cg_endo -78.47 -12.76 15.29 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 123.697 2.931 . . . . 1.0 110.645 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.418 ' HG2' ' N ' ' A' ' 113' ' ' SER . 60.0 ttt180 -104.77 165.55 10.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.75 -1.113 . . . . 1.0 109.403 -179.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.56 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 3.5 m -76.28 97.65 4.25 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.171 -0.677 . . . . 1.0 109.171 178.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -108.74 61.38 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 CA-C-N 116.576 -0.283 . . . . 1.0 110.597 -179.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.532 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 169.22 -170.84 42.8 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 120.455 -0.879 . . . . 1.0 112.188 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -66.09 -105.19 0.01 OUTLIER Glycine 0 CA--C 1.537 1.417 0 N-CA-C 111.842 -0.503 . . . . 1.0 111.842 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.03 -16.08 47.71 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.439 2.093 . . . . 1.0 111.387 -178.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.555 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.6 mp -66.97 114.24 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 109.26 -0.645 . . . . 1.0 109.26 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.411 ' N ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.26 -168.14 42.44 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 110.566 -1.014 . . . . 1.0 110.566 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.566 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 39.3 Cg_endo -65.53 142.62 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.257 1.971 . . . . 1.0 113.34 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.471 ' ND2' ' O ' ' A' ' 121' ' ' ASN . 2.1 t30 50.55 53.62 12.62 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.158 -0.474 . . . . 1.0 111.859 177.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.427 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 54.9 mm-40 -99.76 133.01 44.74 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.146 -0.479 . . . . 1.0 111.527 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.436 HG21 HD11 ' A' ' 16' ' ' LEU . 52.8 m -93.86 128.58 40.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 106.571 -1.641 . . . . 1.0 106.571 175.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.4 ' N ' HD22 ' A' ' 124' ' ' LEU . 2.0 mm? -112.13 138.86 48.22 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.394 0.616 . . . . 1.0 111.096 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.707 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -118.6 145.22 24.93 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.679 0 CA-C-N 114.976 -1.011 . . . . 1.0 108.523 178.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.561 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -136.89 150.78 48.45 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 120.217 -0.593 . . . . 1.0 111.201 177.129 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.572 ' NZ ' ' CZ ' ' A' ' 58' ' ' ARG . 5.3 mmtt -100.14 122.39 42.9 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 105.031 -2.211 . . . . 1.0 105.031 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.42 118.27 57.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 C-N-CA 119.395 -0.922 . . . . 1.0 112.432 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.445 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.2 t-160 -108.67 123.6 49.22 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 114.121 -1.4 . . . . 1.0 108.563 178.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.82 111.31 23.32 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 120.478 -0.489 . . . . 1.0 112.197 -177.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.472 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -94.3 -45.05 13.61 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.486 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 7.1 p -151.07 155.81 39.76 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.305 0.574 . . . . 1.0 111.137 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.451 HG21 ' HA ' ' A' ' 44' ' ' LYS . 45.8 t -128.8 135.91 61.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.757 -0.656 . . . . 1.0 109.958 -178.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.42 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 14.6 tptm -77.72 -84.03 0.08 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.87 0.843 . . . . 1.0 111.586 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.496 ' C ' ' H ' ' A' ' 137' ' ' SER . 0.0 OUTLIER 85.45 127.93 0.04 OUTLIER 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 113.777 -1.556 . . . . 1.0 110.47 -179.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -47.47 -7.29 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 113.84 -1.527 . . . . 1.0 112.151 -178.22 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.496 ' H ' ' C ' ' A' ' 135' ' ' LYS . 16.1 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.002 -0.999 . . . . 1.0 111.135 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.922 H491 H381 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.505 -0.554 . . . . 1.0 109.505 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.5 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 20.1 m120 -65.05 -31.95 73.42 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 112.366 0.506 . . . . 1.0 112.366 -179.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.401 ' HG3' ' H ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -46.38 -41.46 13.58 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.323 -0.551 . . . . 1.0 111.078 -178.392 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.506 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 6.1 tmtt? -69.99 -35.93 74.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.596 0.712 . . . . 1.0 109.806 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -52.59 -34.5 51.07 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 115.47 -0.786 . . . . 1.0 110.753 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -61.33 -39.4 90.37 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.142 -0.935 . . . . 1.0 110.401 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -64.84 -48.63 73.64 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-O 121.502 0.668 . . . . 1.0 111.12 -179.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 9.5 m-20 -62.85 -37.09 85.47 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 107.81 -1.182 . . . . 1.0 107.81 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 64.6 tttt -65.95 -51.38 59.04 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 113.297 -1.774 . . . . 1.0 111.485 179.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.2 t -67.31 -46.59 83.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 C-N-CA 120.238 -0.585 . . . . 1.0 111.423 -179.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.543 ' HD2' ' N ' ' A' ' 11' ' ' LYS . 1.2 mptp? -62.05 -38.94 90.66 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.649 -1.241 . . . . 1.0 107.649 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.486 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -71.6 -44.55 49.26 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 114.629 -1.169 . . . . 1.0 112.444 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -59.71 -34.1 72.47 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.526 -0.916 . . . . 1.0 108.526 179.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.87 -37.08 62.26 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.892 -1.049 . . . . 1.0 110.111 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -60.19 -49.33 78.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.753 -1.112 . . . . 1.0 111.198 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.486 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.6 mp -68.78 -38.26 79.88 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.14 -0.624 . . . . 1.0 109.385 178.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 55.9 m -60.76 -43.47 97.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.352 -0.84 . . . . 1.0 109.688 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -76.9 -44.69 30.86 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.85 -0.614 . . . . 1.0 111.973 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.649 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 54.6 t30 -60.33 -44.78 95.17 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.475 0.917 . . . . 1.0 113.475 -177.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -58.26 -31.7 67.69 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 119.441 -0.904 . . . . 1.0 109.613 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -80.98 -27.61 35.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.734 -0.667 . . . . 1.0 111.683 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 35.1 mtmt -59.47 146.22 80.21 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 120.335 -0.546 . . . . 1.0 111.517 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.45 148.93 59.8 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.543 2.162 . . . . 1.0 114.048 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.65 -18.48 2.96 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 115.167 -0.924 . . . . 1.0 112.576 178.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -83.75 134.66 26.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 120.549 -0.46 . . . . 1.0 110.202 -179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.2 121.96 66.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 107.838 -1.171 . . . . 1.0 107.838 177.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.9 p -93.53 146.16 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.578 0 CA-C-O 121.637 0.732 . . . . 1.0 111.981 -177.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 97.9 mt -113.03 163.17 18.68 Favored Pre-proline 0 N--CA 1.461 0.119 0 CA-C-N 114.469 -1.242 . . . . 1.0 110.892 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -60.32 -30.71 91.63 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.844 1.696 . . . . 1.0 111.249 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -69.44 -11.16 60.59 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.828 -0.624 . . . . 1.0 109.737 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.02 -2.49 75.77 Favored Glycine 0 C--O 1.229 -0.174 0 N-CA-C 109.949 -1.26 . . . . 1.0 109.949 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.442 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.08 133.7 36.13 Favored 'General case' 0 CA--C 1.517 -0.29 0 N-CA-C 108.59 -0.893 . . . . 1.0 108.59 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.442 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.6 mp0 -121.82 138.53 54.34 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 116.319 -0.4 . . . . 1.0 111.086 -179.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 28.1 p90 -133.5 146.55 51.19 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-O 121.591 0.71 . . . . 1.0 111.089 178.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.497 ' CD ' HD13 ' A' ' 37' ' ' ILE . 1.7 tmtp? -129.86 135.8 48.81 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.495 -1.23 . . . . 1.0 109.233 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.25 104.67 15.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-O 122.153 0.978 . . . . 1.0 112.248 -178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.619 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.0 mm -70.69 -42.36 77.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.249 -0.887 . . . . 1.0 108.848 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 34.6 m-80 -144.07 127.33 16.71 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.845 -1.071 . . . . 1.0 110.634 -178.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.2 p -84.51 126.9 33.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.043 0.449 . . . . 1.0 110.499 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -115.86 -36.78 1.11 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.145 -1.182 . . . . 1.0 110.145 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.663 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 56.49 30.39 17.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.465 -0.367 . . . . 1.0 111.187 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.07 -159.68 35.86 Favored Glycine 0 C--N 1.334 0.421 0 CA-C-O 121.87 0.706 . . . . 1.0 111.955 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.603 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.0 m -69.57 -178.73 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.239 -0.981 . . . . 1.0 109.411 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.546 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 155.14 0.38 Allowed Pre-proline 0 C--N 1.319 -0.731 0 N-CA-C 109.083 -0.71 . . . . 1.0 109.083 179.785 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.1 Cg_endo -87.76 161.49 7.69 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 123.011 2.474 . . . . 1.0 115.273 -175.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.2 171.45 32.5 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 108.049 -2.02 . . . . 1.0 108.049 175.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.613 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -45.75 -24.9 0.42 Allowed 'General case' 0 C--N 1.297 -1.701 0 CA-C-N 114.59 -0.805 . . . . 1.0 111.374 178.452 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.0 m -107.63 -9.64 15.83 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.863 1.06 . . . . 1.0 113.863 -177.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -85.37 166.34 16.5 Favored 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 119.39 -0.924 . . . . 1.0 109.136 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 7.3 m -104.16 146.97 27.99 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.167 -0.679 . . . . 1.0 109.167 -179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.401 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 6.1 p -124.39 160.3 29.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 112.554 0.575 . . . . 1.0 112.554 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.4 HG22 ' HB3' ' A' ' 74' ' ' PRO . 87.6 m -127.23 119.51 26.54 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.408 -0.96 . . . . 1.0 108.408 177.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.453 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 5.3 m -148.84 165.76 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 113.968 1.099 . . . . 1.0 113.968 -176.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 73' ' ' LYS . 9.3 mt-10 -118.53 151.25 38.2 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 35.2 p90 -164.23 161.88 22.29 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 114.536 1.31 . . . . 1.0 114.536 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.8 m -123.51 127.04 47.78 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.201 -0.908 . . . . 1.0 108.691 175.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.25 136.38 13.54 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.93 -0.652 . . . . 1.0 111.775 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -147.25 166.49 26.88 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 121.805 0.812 . . . . 1.0 112.395 179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.5 mp -83.16 164.07 20.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 114.129 -1.396 . . . . 1.0 110.037 177.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.471 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.38 -24.38 30.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.127 -0.942 . . . . 1.0 110.139 177.889 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -93.1 2.58 56.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 113.855 -1.52 . . . . 1.0 111.741 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.36 -4.69 80.52 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.19 -0.529 . . . . 1.0 112.735 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -69.76 105.06 2.62 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.682 -0.807 . . . . 1.0 110.212 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.5 t -73.66 122.06 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.139 0.495 . . . . 1.0 110.471 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.424 ' HB2' HD11 ' A' ' 118' ' ' ILE . 30.7 p90 -110.76 -15.54 13.8 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-N 115.145 -0.934 . . . . 1.0 111.75 -179.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.503 ' OD2' ' N ' ' A' ' 67' ' ' SER . 55.4 t0 -155.49 147.31 23.25 Favored 'General case' 0 C--N 1.324 -0.523 0 C-N-CA 120.704 -0.399 . . . . 1.0 110.883 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.503 ' N ' ' OD2' ' A' ' 66' ' ' ASP . 97.5 p -154.25 152.71 30.63 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.217 -0.447 . . . . 1.0 111.612 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 84.9 m -156.58 -38.05 0.08 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.031 -0.531 . . . . 1.0 111.289 -179.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.412 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 2.0 pp20? -65.99 -26.77 67.7 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.203 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.5 mmtt -57.46 -39.7 76.9 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 108.173 -1.047 . . . . 1.0 108.173 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.41 ' OG1' ' O ' ' A' ' 68' ' ' THR . 12.9 p -81.76 -27.03 34.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.94 -1.027 . . . . 1.0 108.493 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 76.63 16.99 80.3 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.384 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.429 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.3 mptp? -97.35 114.79 65.34 Favored Pre-proline 0 N--CA 1.471 0.622 0 C-N-CA 120.855 -0.338 . . . . 1.0 110.419 -179.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 37.3 Cg_exo -61.99 154.19 63.54 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 121.916 1.744 . . . . 1.0 114.457 -178.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -126.05 150.61 48.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.262 -1.335 . . . . 1.0 108.407 178.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -104.57 134.35 47.9 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 113.006 0.743 . . . . 1.0 113.006 -178.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.649 ' HB3' H481 ' A' ' 138' ' ' RAP . 55.1 m-85 -142.42 148.76 38.33 Favored 'General case' 0 CA--C 1.495 -1.141 0 CA-C-N 115.009 -0.996 . . . . 1.0 110.602 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 -90.31 124.5 34.96 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.004 -1.85 . . . . 1.0 106.004 175.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.0 t -52.07 -32.05 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 C-N-CA 119.774 -0.771 . . . . 1.0 110.509 -177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 5.4 t -74.02 -27.56 61.01 Favored 'General case' 0 CA--C 1.514 -0.413 0 C-N-CA 120.248 -0.581 . . . . 1.0 112.138 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.506 ' HB3' ' H27' ' A' ' 138' ' ' RAP . 70.9 mm-40 -101.29 -12.62 18.53 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 113.348 0.87 . . . . 1.0 113.348 -178.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.657 ' CG2' H31A ' A' ' 138' ' ' RAP . 4.5 p -71.04 172.03 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 119.288 -0.965 . . . . 1.0 109.94 -177.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.505 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -53.8 148.36 20.1 Favored Pre-proline 0 CA--C 1.55 0.945 0 N-CA-C 108.812 -0.81 . . . . 1.0 108.812 -178.803 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.493 ' HD2' HG22 ' A' ' 83' ' ' ILE . 85.1 Cg_exo -49.42 -47.51 22.2 Favored 'Trans proline' 0 N--CA 1.503 2.084 0 C-N-CA 122.151 1.9 . . . . 1.0 113.773 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.3 -48.16 77.15 Favored Glycine 0 C--N 1.318 -0.44 0 N-CA-C 110.021 -1.232 . . . . 1.0 110.021 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.638 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 7.8 m95 -63.78 -34.14 77.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 114.047 -1.076 . . . . 1.0 111.562 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -51.94 -54.1 33.48 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.744 -0.382 . . . . 1.0 110.888 -178.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 50.5 tp10 -74.17 -44.29 54.02 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.177 0.806 . . . . 1.0 113.177 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -55.71 -44.37 77.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 113.796 1.035 . . . . 1.0 113.796 -177.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.3 mt -58.47 -41.52 85.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.243 0.544 . . . . 1.0 110.142 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -65.7 -23.09 66.69 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.252 -0.885 . . . . 1.0 111.145 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.485 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 55.1 mt -103.09 -9.94 19.3 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.596 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 5.2 ttt -91.11 107.14 18.99 Favored Pre-proline 0 CA--C 1.549 0.942 0 O-C-N 123.729 0.643 . . . . 1.0 111.638 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.546 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.9 Cg_exo -66.37 149.11 85.01 Favored 'Trans proline' 0 N--CA 1.499 1.846 0 C-N-CA 122.904 2.402 . . . . 1.0 112.656 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.603 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.96 136.16 55.7 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 115.422 -0.808 . . . . 1.0 111.459 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.02 -19.74 51.4 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.415 -1.874 . . . . 1.0 108.415 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.6 p -85.99 134.49 33.85 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.053 0.454 . . . . 1.0 110.269 178.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.4 m -108.26 115.01 29.32 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.689 -0.687 . . . . 1.0 109.659 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.485 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 42.5 m0 -116.12 166.87 11.52 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.528 0.68 . . . . 1.0 110.79 -179.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.619 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.4 mt-10 -126.9 128.57 46.68 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 106.683 -1.599 . . . . 1.0 106.683 175.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.401 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -123.16 138.2 53.96 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 CA-C-O 121.809 0.814 . . . . 1.0 109.699 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.752 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.31 103.71 12.7 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 105.424 -2.065 . . . . 1.0 105.424 -177.905 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.5 t -90.73 116.12 65.71 Favored Pre-proline 0 C--N 1.327 -0.4 0 N-CA-C 114.674 1.361 . . . . 1.0 114.674 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -51.03 144.67 27.44 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 121.261 1.307 . . . . 1.0 109.79 176.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 55.3 p -50.49 -35.44 29.2 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.338 -0.545 . . . . 1.0 110.561 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.58 -32.78 84.32 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 111.19 -0.764 . . . . 1.0 111.19 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 82.8 mt -98.92 1.3 45.51 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 121.314 -0.154 . . . . 1.0 110.655 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.18 -106.62 0.34 Allowed 'General case' 0 C--N 1.342 0.264 0 N-CA-C 111.643 0.238 . . . . 1.0 111.643 -178.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.607 ' HH ' H121 ' A' ' 138' ' ' RAP . 48.1 m-85 -101.97 5.05 40.56 Favored 'General case' 0 C--N 1.341 0.234 0 N-CA-C 113.705 1.002 . . . . 1.0 113.705 -177.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 99.93 167.28 29.36 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 120.645 -0.788 . . . . 1.0 114.043 176.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.513 ' O ' ' N ' ' A' ' 121' ' ' ASN . 73.8 Cg_endo -70.97 -19.99 29.66 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 C-N-CA 123.742 2.962 . . . . 1.0 113.038 -179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.423 HH11 ' HG2' ' A' ' 111' ' ' PRO . 11.7 mpt_? -93.74 167.15 11.84 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.009 -0.367 . . . . 1.0 110.009 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 5.7 m -74.46 76.32 1.93 Allowed 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 177.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.0 t -92.21 61.53 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.268 -0.423 . . . . 1.0 110.967 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.97 179.61 42.27 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 120.967 -0.635 . . . . 1.0 111.516 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -60.66 -107.14 0.01 OUTLIER Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.449 -0.66 . . . . 1.0 111.449 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -59.24 -13.15 18.64 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 C-N-CA 122.222 1.948 . . . . 1.0 110.725 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.884 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.3 mp -66.74 113.17 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 N-CA-C 108.185 -1.043 . . . . 1.0 108.185 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -91.66 -166.9 40.25 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 110.548 -1.021 . . . . 1.0 110.548 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.554 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 37.6 Cg_endo -64.09 147.21 91.59 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.14 1.893 . . . . 1.0 112.7 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.513 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 44.82 57.53 4.53 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.96 -0.564 . . . . 1.0 112.072 178.219 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.418 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 53.9 mm-40 -102.64 132.06 49.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.28 0.562 . . . . 1.0 112.334 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.474 HG21 HD11 ' A' ' 16' ' ' LEU . 36.2 m -96.34 129.08 43.76 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 106.418 -1.697 . . . . 1.0 106.418 175.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.98 146.17 40.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.387 0.613 . . . . 1.0 111.042 -179.057 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.752 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.6 tt -123.58 148.28 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.764 0 CA-C-N 115.088 -0.96 . . . . 1.0 108.543 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -139.41 151.43 46.27 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 120.286 -0.566 . . . . 1.0 111.288 177.848 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.519 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 11.4 mmtt -100.15 124.88 46.07 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 105.162 -2.162 . . . . 1.0 105.162 176.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.7 mt -119.35 119.21 59.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 119.075 -1.05 . . . . 1.0 111.998 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.1 t-160 -111.85 125.42 54.0 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 114.048 -1.433 . . . . 1.0 108.714 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.02 114.51 26.71 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 112.869 0.692 . . . . 1.0 112.869 -178.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.499 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -96.05 -45.42 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 CA-C-N 115.992 -0.549 . . . . 1.0 110.88 178.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.3 p -151.29 157.78 42.98 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 120.877 0.37 . . . . 1.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.436 HG21 ' HA ' ' A' ' 44' ' ' LYS . 58.1 t -127.37 134.66 65.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-O 121.325 0.583 . . . . 1.0 111.451 -178.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.533 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 21.6 tptt -93.89 -143.71 0.24 Allowed 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 115.152 -0.931 . . . . 1.0 111.115 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.52 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -160.26 156.04 25.81 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.455 -1.248 . . . . 1.0 109.606 178.18 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.444 ' H ' ' HD2' ' A' ' 135' ' ' LYS . 90.3 p -45.72 -33.17 2.84 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.465 -0.789 . . . . 1.0 111.139 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 34.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.381 179.507 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.795 H331 ' O2 ' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 1.0 109.144 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 1.5 m-20 -66.08 -30.88 71.47 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.186 -0.461 . . . . 1.0 111.159 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.516 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 62.9 pttt -47.79 -40.43 20.9 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 119.896 -0.722 . . . . 1.0 109.513 -179.496 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.697 ' NZ ' HD21 ' A' ' 8' ' ' ASN . 4.9 tmtt? -66.33 -38.25 87.23 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.646 -0.707 . . . . 1.0 109.444 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.472 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -54.78 -35.26 63.64 Favored 'General case' 0 CA--C 1.509 -0.625 0 CA-C-N 115.181 -0.918 . . . . 1.0 109.801 179.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -69.32 -35.03 75.54 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.25 -0.886 . . . . 1.0 110.527 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -66.7 -54.49 22.54 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 121.886 0.85 . . . . 1.0 110.24 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.697 HD21 ' NZ ' ' A' ' 4' ' ' LYS . 16.0 m-20 -57.48 -35.64 70.45 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.737 -1.12 . . . . 1.0 108.543 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 45.1 tttt -64.74 -50.64 66.09 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 113.793 -1.549 . . . . 1.0 111.749 179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.7 t -72.31 -47.52 52.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 119.964 -0.694 . . . . 1.0 112.152 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.463 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.4 OUTLIER -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.305 -0.998 . . . . 1.0 108.305 -179.919 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.95 -46.86 50.01 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 115.188 -0.915 . . . . 1.0 112.546 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -58.68 -34.26 71.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 N-CA-C 108.804 -0.813 . . . . 1.0 108.804 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.55 -36.55 63.12 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.183 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -62.35 -49.37 75.85 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.579 -1.191 . . . . 1.0 111.134 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -70.75 -39.61 73.19 Favored 'General case' 0 CA--C 1.508 -0.648 0 C-N-CA 119.954 -0.698 . . . . 1.0 109.922 178.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.469 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 75.6 m -60.97 -43.35 98.92 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.443 -0.798 . . . . 1.0 109.702 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -76.28 -46.07 29.61 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.91 -0.587 . . . . 1.0 111.816 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.654 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 55.4 t30 -59.88 -44.58 94.1 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.473 0.916 . . . . 1.0 113.473 -177.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.75 -31.61 68.5 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 119.337 -0.945 . . . . 1.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.469 ' ND2' ' O ' ' A' ' 17' ' ' THR . 50.0 m-80 -77.54 -34.23 53.97 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.514 -0.766 . . . . 1.0 111.653 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -57.94 137.03 83.71 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 120.628 -0.429 . . . . 1.0 111.76 -177.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.13 148.84 57.11 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 122.167 1.911 . . . . 1.0 113.442 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.13 -20.84 14.16 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 115.0 -1.0 . . . . 1.0 110.972 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.6 t -85.16 135.71 24.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.14 0.495 . . . . 1.0 109.789 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.1 t -120.74 121.37 65.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.743 -1.206 . . . . 1.0 107.743 178.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 6.0 p -97.63 144.8 10.39 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.677 0 CA-C-O 121.746 0.784 . . . . 1.0 111.773 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 95.2 mt -111.32 164.28 15.37 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 114.314 -1.312 . . . . 1.0 110.688 -179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -60.84 -30.82 90.87 Favored 'Trans proline' 0 N--CA 1.485 0.983 0 C-N-CA 121.72 1.613 . . . . 1.0 110.83 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.0 m -67.81 -12.1 59.91 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.568 -0.742 . . . . 1.0 109.346 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.9 -1.59 78.28 Favored Glycine 0 C--O 1.228 -0.269 0 N-CA-C 109.962 -1.255 . . . . 1.0 109.962 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.474 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.1 tm? -78.68 133.66 37.18 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 108.375 -0.972 . . . . 1.0 108.375 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.447 ' HG3' ' HA ' ' A' ' 27' ' ' VAL . 24.3 mp0 -122.23 137.46 54.83 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.681 -0.236 . . . . 1.0 111.289 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -134.23 142.65 47.43 Favored 'General case' 0 CA--C 1.506 -0.725 0 CA-C-O 121.638 0.733 . . . . 1.0 111.116 178.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.529 ' HD3' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -123.9 130.89 53.32 Favored 'General case' 0 CA--C 1.503 -0.831 0 CA-C-N 114.528 -1.215 . . . . 1.0 109.216 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -88.92 104.48 14.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 122.294 1.045 . . . . 1.0 112.025 -178.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.604 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.1 mm -69.42 -41.84 80.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 114.766 -1.107 . . . . 1.0 108.471 178.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.6 m-80 -144.26 126.1 15.27 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.522 -1.217 . . . . 1.0 109.752 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.8 p -85.23 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.027 0.441 . . . . 1.0 110.487 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.4 ' H ' ' HB3' ' A' ' 97' ' ' SER . . . -116.11 -37.54 1.02 Allowed Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.247 -1.141 . . . . 1.0 110.247 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.651 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 58.02 31.67 20.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.541 -0.329 . . . . 1.0 111.399 179.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.83 -159.78 35.64 Favored Glycine 0 C--N 1.333 0.376 0 CA-C-O 122.316 0.953 . . . . 1.0 112.51 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.608 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.9 m -69.68 -177.93 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 113.627 -1.286 . . . . 1.0 108.951 178.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.58 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.29 155.25 0.4 Allowed Pre-proline 0 C--N 1.318 -0.784 0 O-C-N 123.619 0.574 . . . . 1.0 109.932 179.459 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.445 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 58.4 Cg_endo -87.7 156.4 7.57 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 123.305 2.67 . . . . 1.0 115.941 -174.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.35 176.59 45.17 Favored Glycine 0 C--N 1.336 0.557 0 N-CA-C 108.874 -1.691 . . . . 1.0 108.874 176.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.519 ' CE ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.06 -22.38 15.82 Favored 'General case' 0 C--N 1.312 -1.044 0 C-N-CA 120.501 -0.48 . . . . 1.0 111.517 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.449 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 35.8 m -106.97 -7.33 17.03 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.874 0.694 . . . . 1.0 112.874 -177.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -84.58 170.81 13.03 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.952 -0.388 . . . . 1.0 109.952 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.3 m -110.76 147.04 35.28 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.285 0.564 . . . . 1.0 109.907 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.445 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.2 p -127.9 163.11 32.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.374 0 CA-C-N 115.357 -0.838 . . . . 1.0 112.676 -175.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.407 HG22 ' HB3' ' A' ' 74' ' ' PRO . 68.1 m -130.12 121.21 25.9 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.589 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.1 m -149.02 165.76 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 114.635 1.346 . . . . 1.0 114.635 -176.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 3.0 mt-10 -118.08 147.28 43.42 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.991 -1.855 . . . . 1.0 105.991 174.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 68' ' ' THR . 37.1 p90 -164.7 168.89 17.52 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 114.525 1.306 . . . . 1.0 114.525 -176.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -131.78 129.25 40.3 Favored 'General case' 0 C--O 1.217 -0.658 0 CA-C-N 114.771 -1.104 . . . . 1.0 108.267 175.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -115.65 131.73 9.84 Favored Glycine 0 N--CA 1.473 1.115 0 N-CA-C 111.292 -0.723 . . . . 1.0 111.292 -179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 11.7 ptp180 -146.4 167.3 23.94 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.705 0.764 . . . . 1.0 112.219 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.9 mp -82.48 164.17 21.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.325 -1.307 . . . . 1.0 110.063 177.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.456 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -61.37 -24.44 33.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 122.411 1.1 . . . . 1.0 109.858 177.804 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.425 ' H ' HD13 ' A' ' 60' ' ' ILE . 53.6 t0 -89.71 -0.02 57.27 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 113.21 -1.813 . . . . 1.0 111.882 -177.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.04 -1.71 78.07 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.904 -0.665 . . . . 1.0 112.317 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -71.82 102.46 2.87 Favored 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 119.805 -0.758 . . . . 1.0 110.021 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.2 127.41 36.77 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.519 0.676 . . . . 1.0 110.507 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 29.3 p90 -121.14 -11.07 8.91 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 114.705 -1.134 . . . . 1.0 111.486 -178.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -154.46 143.87 21.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.132 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 20.5 p -157.93 156.12 30.71 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 113.038 0.755 . . . . 1.0 113.038 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 55' ' ' TYR . 65.3 m -159.15 -45.57 0.06 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 114.861 -1.063 . . . . 1.0 110.72 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -58.63 -26.1 63.38 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 116.391 -0.368 . . . . 1.0 110.114 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.8 mmtt -49.51 -41.08 39.91 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 107.523 -1.288 . . . . 1.0 107.523 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 27.6 p -83.31 -32.26 26.42 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 113.923 -1.489 . . . . 1.0 109.668 177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.64 13.16 81.98 Favored Glycine 0 C--N 1.332 0.338 0 N-CA-C 110.954 -0.858 . . . . 1.0 110.954 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.7 mttm -94.18 116.91 66.99 Favored Pre-proline 0 N--CA 1.466 0.34 0 C-N-CA 121.104 -0.238 . . . . 1.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.413 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 39.6 Cg_exo -61.1 150.7 83.09 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 121.972 1.781 . . . . 1.0 115.112 -177.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -125.65 150.81 47.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 114.107 -1.406 . . . . 1.0 108.301 177.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.04 135.42 47.52 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 113.593 0.96 . . . . 1.0 113.593 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.562 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 60.4 m-85 -142.24 153.89 44.33 Favored 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.162 -0.926 . . . . 1.0 109.449 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -90.75 130.35 36.74 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.912 -1.884 . . . . 1.0 105.912 173.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.7 -29.98 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 C-N-CA 119.734 -0.786 . . . . 1.0 110.506 -177.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.0 t -73.32 -25.21 60.55 Favored 'General case' 0 CA--C 1.521 -0.153 0 C-N-CA 120.244 -0.582 . . . . 1.0 112.212 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.531 ' C ' H482 ' A' ' 138' ' ' RAP . 62.6 mm-40 -98.14 -15.39 19.95 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.553 0.575 . . . . 1.0 112.553 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.572 ' CG2' H31A ' A' ' 138' ' ' RAP . 2.0 p -78.47 172.71 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 120.021 -0.672 . . . . 1.0 111.147 -176.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.5 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -56.48 151.24 30.19 Favored Pre-proline 0 CA--C 1.55 0.974 0 C-N-CA 119.973 -0.691 . . . . 1.0 110.814 -178.362 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HD2' HG22 ' A' ' 83' ' ' ILE . 54.1 Cg_exo -53.89 -46.26 34.97 Favored 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 122.13 1.887 . . . . 1.0 112.876 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.4 -47.82 80.26 Favored Glycine 0 N--CA 1.451 -0.336 0 N-CA-C 109.132 -1.587 . . . . 1.0 109.132 -179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.673 ' CH2' ' H42' ' A' ' 138' ' ' RAP . 7.7 m95 -64.29 -39.0 93.04 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 113.542 -1.329 . . . . 1.0 109.669 178.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 m -51.76 -53.61 37.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 1.0 111.185 -178.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -72.4 -40.88 66.84 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.23 -48.17 82.85 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 113.995 1.109 . . . . 1.0 113.995 -177.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 52.1 mt -57.95 -40.85 81.56 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-O 121.545 0.688 . . . . 1.0 109.814 -178.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -63.89 -24.53 67.77 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.839 -1.073 . . . . 1.0 111.221 -178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 81.8 mt -101.86 -15.64 16.82 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.394 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . 0.507 ' CE ' ' H ' ' A' ' 99' ' ' TRP . 8.2 ttt -83.4 108.48 13.29 Favored Pre-proline 0 C--N 1.321 -0.642 0 O-C-N 123.811 0.694 . . . . 1.0 112.689 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.58 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -68.91 146.38 65.24 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.34 2.026 . . . . 1.0 112.082 177.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.608 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.89 136.69 57.14 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.472 -0.785 . . . . 1.0 111.731 -179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.7 57.08 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 108.92 -1.672 . . . . 1.0 108.92 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.4 ' HB3' ' H ' ' A' ' 40' ' ' GLY . 5.0 p -89.5 139.62 30.34 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 120.707 0.289 . . . . 1.0 110.49 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.6 m -110.31 112.48 24.46 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 116.004 -0.543 . . . . 1.0 109.902 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.507 ' H ' ' CE ' ' A' ' 93' ' ' MET . 40.8 m0 -115.25 161.34 18.6 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.805 0.812 . . . . 1.0 111.566 -178.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.604 ' CD ' HD11 ' A' ' 37' ' ' ILE . 90.7 mt-10 -120.96 124.31 44.59 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 106.713 -1.588 . . . . 1.0 106.713 175.226 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -118.49 137.37 52.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-O 121.882 0.848 . . . . 1.0 110.61 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.675 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.28 103.05 11.93 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.722 -1.955 . . . . 1.0 105.722 -178.756 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.8 t -90.61 115.94 65.3 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 114.921 1.452 . . . . 1.0 114.921 -174.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -51.27 142.11 37.67 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 121.166 1.244 . . . . 1.0 109.868 176.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 60.3 p -48.11 -35.62 11.75 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 120.692 -0.403 . . . . 1.0 110.722 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.66 -33.19 85.42 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.181 -0.767 . . . . 1.0 111.181 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 71.9 mt -99.01 3.39 46.9 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.768 -0.216 . . . . 1.0 111.431 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.96 -114.98 0.28 Allowed 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.526 -0.546 . . . . 1.0 109.526 -179.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.588 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 62.3 m-85 -91.25 5.06 50.62 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.821 0.344 . . . . 1.0 111.636 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 106.59 164.19 22.55 Favored Glycine 0 CA--C 1.524 0.644 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.157 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.511 ' O ' ' N ' ' A' ' 121' ' ' ASN . 86.9 Cg_endo -74.23 -9.35 21.79 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 123.362 2.708 . . . . 1.0 110.247 178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -107.7 162.95 13.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.495 -1.229 . . . . 1.0 109.745 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.5 m -72.01 89.94 1.14 Allowed 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 120.671 -0.411 . . . . 1.0 109.939 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.5 t -104.52 62.23 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 121.118 -0.233 . . . . 1.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 164.62 -175.34 40.63 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 120.309 -0.948 . . . . 1.0 112.705 179.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.98 -104.81 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 N-CA-C 111.639 -0.584 . . . . 1.0 111.639 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -63.76 -15.36 48.39 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.545 2.163 . . . . 1.0 111.322 -178.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.674 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.8 mp -67.25 111.8 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.02 0 N-CA-C 108.295 -1.002 . . . . 1.0 108.295 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.425 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.62 -170.72 43.5 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.054 -0.976 . . . . 1.0 111.223 -179.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.571 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 28.6 Cg_endo -61.86 143.56 95.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.461 2.108 . . . . 1.0 112.788 179.178 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.511 ' N ' ' O ' ' A' ' 111' ' ' PRO . 13.8 t-20 49.07 48.84 20.39 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.792 0.664 . . . . 1.0 112.792 178.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.538 ' OE1' ' NZ ' ' A' ' 4' ' ' LYS . 45.9 mm-40 -93.94 129.27 40.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 113.164 0.802 . . . . 1.0 113.164 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.493 HG21 HD11 ' A' ' 16' ' ' LEU . 17.5 m -95.63 129.1 42.94 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 105.796 -1.927 . . . . 1.0 105.796 174.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.417 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.1 mm? -116.0 143.64 45.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.369 0.605 . . . . 1.0 110.69 -179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.675 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -119.54 148.11 22.74 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.649 0 CA-C-N 115.157 -0.928 . . . . 1.0 109.076 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.591 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.96 149.94 45.32 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 121.478 0.656 . . . . 1.0 111.527 177.356 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.495 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 8.6 mmtt -100.12 124.4 45.49 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 105.229 -2.137 . . . . 1.0 105.229 177.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.424 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.4 mt -122.01 127.61 75.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 119.497 -0.881 . . . . 1.0 112.327 -176.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.432 ' ND1' HD11 ' A' ' 131' ' ' ILE . 9.7 t-160 -118.97 124.31 46.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.321 -1.309 . . . . 1.0 107.633 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.78 110.39 22.87 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 120.225 -0.59 . . . . 1.0 112.374 -177.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -94.34 -47.22 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-N 115.518 -0.765 . . . . 1.0 112.117 -179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.4 p -146.7 156.94 43.56 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.655 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.415 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.5 t -132.48 140.0 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.203 0.525 . . . . 1.0 111.942 -178.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.703 ' HG3' ' H ' ' A' ' 135' ' ' LYS . 0.1 OUTLIER -97.46 -145.7 0.3 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.703 -0.68 . . . . 1.0 109.613 178.177 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.703 ' H ' ' HG3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -174.08 142.2 0.82 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.777 178.676 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 10.7 t -52.47 -39.7 61.47 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.801 -1.09 . . . . 1.0 111.443 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 13.1 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.02 -0.991 . . . . 1.0 110.513 179.899 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.739 ' O3 ' H492 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.057 -0.72 . . . . 1.0 109.057 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.434 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 19.6 m120 -67.17 -18.33 65.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.841 -0.618 . . . . 1.0 110.401 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.2 pttt -45.2 -37.57 4.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.612 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 3.7 tmtm? -73.65 -38.74 64.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.756 0.789 . . . . 1.0 109.532 179.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.01 -33.82 26.65 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.397 -0.82 . . . . 1.0 110.237 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -65.98 -39.65 90.54 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.229 -0.896 . . . . 1.0 111.457 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -64.94 -50.11 67.72 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 121.627 0.727 . . . . 1.0 110.864 -178.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.612 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 14.3 m-20 -60.49 -35.75 76.67 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -66.16 -51.38 58.39 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.687 -1.597 . . . . 1.0 111.444 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.61 -48.03 78.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 C-N-CA 120.352 -0.539 . . . . 1.0 111.702 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.426 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.81 -38.73 91.86 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.552 -1.277 . . . . 1.0 107.552 179.119 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.5 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.15 -42.74 66.36 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 114.942 -1.027 . . . . 1.0 111.831 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -62.36 -32.18 72.94 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.972 -0.751 . . . . 1.0 108.972 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -35.05 49.6 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.261 -0.881 . . . . 1.0 109.878 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -61.17 -50.24 73.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 114.459 -1.246 . . . . 1.0 111.043 -179.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.5 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.4 mp -70.92 -39.8 72.5 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.213 -0.595 . . . . 1.0 109.945 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.69 -42.63 99.19 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.541 -0.754 . . . . 1.0 109.315 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -76.71 -44.53 33.09 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-N 115.485 -0.78 . . . . 1.0 112.019 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.653 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.6 t30 -60.67 -44.77 96.09 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 113.375 0.879 . . . . 1.0 113.375 -177.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -58.19 -31.93 67.76 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 119.517 -0.873 . . . . 1.0 109.237 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -79.83 -30.35 40.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.151 -0.931 . . . . 1.0 111.647 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 33.0 mtmt -58.18 136.43 84.61 Favored Pre-proline 0 CA--C 1.547 0.857 0 C-N-CA 120.425 -0.51 . . . . 1.0 111.396 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -52.92 148.66 28.76 Favored 'Trans proline' 0 N--CA 1.501 1.965 0 C-N-CA 122.271 1.981 . . . . 1.0 113.547 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.24 -19.51 10.33 Favored Glycine 0 C--O 1.225 -0.413 0 CA-C-N 115.094 -0.957 . . . . 1.0 111.829 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 43.3 t -86.56 136.56 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.162 0.506 . . . . 1.0 110.896 -179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.7 t -120.99 123.97 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 N-CA-C 107.952 -1.129 . . . . 1.0 107.952 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.02 145.89 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-O 121.796 0.808 . . . . 1.0 112.008 -178.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.2 mt -113.03 165.18 13.7 Favored Pre-proline 0 C--O 1.231 0.126 0 CA-C-N 114.328 -1.305 . . . . 1.0 111.111 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -61.42 -30.03 86.31 Favored 'Trans proline' 0 C--N 1.32 -0.965 0 C-N-CA 122.167 1.911 . . . . 1.0 111.274 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 m -68.66 -14.97 63.37 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.713 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.5 -3.07 65.56 Favored Glycine 0 C--N 1.329 0.168 0 N-CA-C 109.688 -1.365 . . . . 1.0 109.688 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.47 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -79.99 133.84 36.2 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 109.006 -0.739 . . . . 1.0 109.006 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.47 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.0 mp0 -121.47 140.13 52.57 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.193 -0.458 . . . . 1.0 110.984 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -135.97 144.52 45.44 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.629 0.728 . . . . 1.0 110.935 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.54 134.8 49.74 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.427 -1.261 . . . . 1.0 109.041 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -92.82 104.04 15.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 122.158 0.98 . . . . 1.0 111.929 -178.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.648 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.4 mm -69.41 -41.48 80.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.414 -0.958 . . . . 1.0 108.414 178.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -143.73 130.01 19.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.676 -1.147 . . . . 1.0 109.697 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.1 p -86.15 131.8 34.16 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 110.025 -0.361 . . . . 1.0 110.025 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.75 -35.34 0.85 Allowed Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.658 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 54.61 30.07 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.659 -0.271 . . . . 1.0 111.104 179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.21 -161.23 37.12 Favored Glycine 0 C--N 1.331 0.256 0 CA-C-O 121.997 0.776 . . . . 1.0 111.752 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' A' ' 95' ' ' ALA . 20.8 m -68.94 -178.58 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 114.128 -1.036 . . . . 1.0 109.506 178.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.553 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.26 154.86 0.39 Allowed Pre-proline 0 C--N 1.32 -0.708 0 CA-C-N 115.608 -0.723 . . . . 1.0 109.391 179.536 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -87.72 156.72 7.56 Favored 'Trans proline' 0 N--CA 1.497 1.709 0 C-N-CA 123.195 2.597 . . . . 1.0 116.054 -175.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.44 178.37 47.52 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 108.579 -1.808 . . . . 1.0 108.579 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.722 ' HZ3' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -56.32 -20.47 19.09 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.409 -0.516 . . . . 1.0 111.153 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 60.2 m -108.48 -7.84 15.69 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 113.386 0.884 . . . . 1.0 113.386 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.57 164.59 16.01 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 120.202 -0.599 . . . . 1.0 109.466 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 6.7 m -101.88 150.53 23.09 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 121.156 0.503 . . . . 1.0 110.114 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.5 p -128.19 160.21 38.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.335 0 CA-C-N 115.374 -0.83 . . . . 1.0 111.925 -177.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 97.0 m -129.87 120.79 25.48 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.441 -0.948 . . . . 1.0 108.441 178.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.538 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 10.9 m -149.19 166.27 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 113.832 1.049 . . . . 1.0 113.832 -176.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 5.0 mt-10 -118.4 149.6 40.96 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 105.748 -1.945 . . . . 1.0 105.748 173.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.579 ' CZ ' ' C5 ' ' A' ' 138' ' ' RAP . 41.3 p90 -163.29 162.4 25.18 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 118.285 -1.366 . . . . 1.0 114.338 -177.069 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -124.33 131.78 53.53 Favored 'General case' 0 C--O 1.217 -0.654 0 N-CA-C 108.183 -1.043 . . . . 1.0 108.183 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -117.76 137.83 13.52 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.39 -0.684 . . . . 1.0 111.39 -178.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.84 168.01 23.29 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.769 0.795 . . . . 1.0 112.183 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.1 mp -85.07 164.73 18.03 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.376 -1.284 . . . . 1.0 109.772 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.13 -26.07 35.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 121.925 0.869 . . . . 1.0 110.061 178.294 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -92.22 2.96 56.29 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 113.808 -1.542 . . . . 1.0 111.764 -177.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.02 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 120.932 -0.651 . . . . 1.0 112.962 178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.0 m -70.05 102.44 2.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 118.105 0.952 . . . . 1.0 110.026 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 60.3 t -72.95 120.07 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.819 0 CA-C-O 121.465 0.65 . . . . 1.0 110.354 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.66 ' CD2' HD11 ' A' ' 118' ' ' ILE . 18.8 p90 -114.78 -8.72 12.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.641 -1.163 . . . . 1.0 111.966 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -155.1 146.45 22.93 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.104 -0.498 . . . . 1.0 110.692 178.184 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 87.9 p -157.49 150.08 22.97 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-N 115.81 -0.632 . . . . 1.0 111.681 179.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.494 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 92.4 m -156.04 -40.46 0.08 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.759 -0.655 . . . . 1.0 110.884 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -63.6 -26.06 68.51 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.247 -0.433 . . . . 1.0 110.222 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -55.93 -43.76 77.7 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.967 -1.124 . . . . 1.0 107.967 178.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 68' ' ' THR . 72.9 p -73.79 -34.5 64.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.878 -1.055 . . . . 1.0 108.521 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.93 16.16 70.76 Favored Glycine 0 C--N 1.334 0.453 0 CA-C-N 115.036 -0.984 . . . . 1.0 111.012 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -98.42 116.31 65.52 Favored Pre-proline 0 N--CA 1.471 0.576 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.592 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.407 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 27.8 Cg_exo -60.98 153.69 62.1 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 121.723 1.615 . . . . 1.0 114.483 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.4 150.88 45.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.307 -1.315 . . . . 1.0 107.786 178.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 t -110.29 133.81 52.89 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.543 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 58.9 m-85 -143.01 152.51 42.0 Favored 'General case' 0 CA--C 1.503 -0.832 0 CA-C-N 114.577 -1.192 . . . . 1.0 109.505 178.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.7 mt-30 -92.34 125.2 36.9 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 106.334 -1.728 . . . . 1.0 106.334 174.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.6 t -47.02 -32.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.97 0 CA-C-N 115.773 -0.649 . . . . 1.0 110.609 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.9 t -74.42 -24.41 59.09 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 120.347 -0.541 . . . . 1.0 111.859 -178.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.539 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 89.1 mm-40 -98.82 -9.2 24.69 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 112.928 0.714 . . . . 1.0 112.928 -178.25 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.657 ' CG2' H31A ' A' ' 138' ' ' RAP . 3.3 p -88.04 170.71 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 118.196 0.453 . . . . 1.0 111.494 -177.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.497 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -53.46 145.02 29.58 Favored Pre-proline 0 CA--C 1.546 0.798 0 C-N-CA 120.871 -0.331 . . . . 1.0 110.58 -176.552 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -50.32 -44.87 36.75 Favored 'Trans proline' 0 N--CA 1.498 1.737 0 C-N-CA 121.952 1.768 . . . . 1.0 112.74 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -56.39 -47.48 82.64 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 109.281 -1.528 . . . . 1.0 109.281 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.768 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 9.7 m95 -66.22 -37.02 84.54 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 113.791 -1.205 . . . . 1.0 110.261 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.0 m -51.19 -53.31 36.12 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 120.856 -0.338 . . . . 1.0 110.942 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tp10 -71.89 -43.98 64.5 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.085 0.402 . . . . 1.0 112.085 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.94 -46.43 85.09 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 114.022 1.119 . . . . 1.0 114.022 -177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 31.9 mt -58.3 -41.58 84.75 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.154 -0.618 . . . . 1.0 109.634 -178.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -65.69 -23.41 66.77 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.187 -0.915 . . . . 1.0 111.197 -179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.422 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 85.4 mt -102.93 -10.34 19.1 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.459 -0.337 . . . . 1.0 110.741 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . 0.53 ' HE3' ' H ' ' A' ' 99' ' ' TRP . 25.5 ttt -90.62 107.47 20.53 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.734 -0.666 . . . . 1.0 112.032 -178.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.553 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.0 Cg_exo -68.89 148.09 69.9 Favored 'Trans proline' 0 N--CA 1.498 1.77 0 C-N-CA 122.546 2.164 . . . . 1.0 112.361 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.585 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.67 137.67 57.47 Favored 'General case' 0 CA--C 1.509 -0.602 0 CA-C-N 115.546 -0.752 . . . . 1.0 111.664 -179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.16 -19.19 54.65 Favored Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 108.873 -1.691 . . . . 1.0 108.873 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.2 p -88.19 129.98 35.19 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 115.475 -0.362 . . . . 1.0 110.443 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 60.7 m -102.12 115.02 29.67 Favored 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 109.438 -0.579 . . . . 1.0 109.438 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.53 ' H ' ' HE3' ' A' ' 93' ' ' MET . 39.4 m0 -116.28 168.31 10.24 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.817 0.818 . . . . 1.0 111.278 -178.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.648 ' CD ' HD11 ' A' ' 37' ' ' ILE . 81.5 mt-10 -129.25 129.57 45.12 Favored 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 106.63 -1.619 . . . . 1.0 106.63 175.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 pt -125.58 138.45 54.42 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.533 0 CA-C-O 121.771 0.796 . . . . 1.0 109.78 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.743 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.26 103.25 12.18 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 106.021 -1.844 . . . . 1.0 106.021 -178.032 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 11.1 t -90.01 115.74 64.7 Favored Pre-proline 0 C--N 1.326 -0.442 0 N-CA-C 115.248 1.573 . . . . 1.0 115.248 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -51.44 143.77 34.11 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.188 1.259 . . . . 1.0 109.634 176.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 88.1 p -50.37 -33.76 21.66 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.394 -0.522 . . . . 1.0 110.517 -178.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.5 -32.73 82.58 Favored Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.03 -0.828 . . . . 1.0 111.03 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -99.78 1.73 43.43 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.981 -0.11 . . . . 1.0 110.859 -179.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.31 -111.83 0.3 Allowed 'General case' 0 C--N 1.342 0.264 0 CA-C-O 120.754 0.312 . . . . 1.0 110.816 -179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.493 ' OH ' ' H11' ' A' ' 138' ' ' RAP . 53.3 m-85 -98.12 5.41 48.62 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 113.567 0.951 . . . . 1.0 113.567 -177.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.81 164.07 18.59 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 121.018 -0.61 . . . . 1.0 113.483 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.53 ' O ' ' N ' ' A' ' 121' ' ' ASN . 93.9 Cg_endo -77.02 -9.99 17.98 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 C-N-CA 123.571 2.847 . . . . 1.0 111.173 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -106.65 169.29 8.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.252 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.4 m -75.26 97.21 3.49 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.743 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.2 t -110.77 60.08 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 121.059 -0.256 . . . . 1.0 111.125 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.548 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.68 -177.95 42.34 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 120.514 -0.85 . . . . 1.0 111.998 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -57.04 -103.77 0.01 OUTLIER Glycine 0 CA--C 1.535 1.338 0 N-CA-C 111.141 -0.783 . . . . 1.0 111.141 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -63.21 -14.05 39.48 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.732 2.288 . . . . 1.0 111.159 -178.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.66 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.3 mp -65.86 114.93 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 N-CA-C 108.273 -1.01 . . . . 1.0 108.273 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.432 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -95.03 -171.88 37.1 Favored Glycine 0 CA--C 1.52 0.354 0 CA-C-N 115.512 -0.767 . . . . 1.0 111.553 -178.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.529 ' N ' ' OG ' ' A' ' 113' ' ' SER . 26.3 Cg_endo -63.25 138.2 65.2 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.562 2.174 . . . . 1.0 112.535 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.539 ' C ' HD22 ' A' ' 121' ' ' ASN . 0.2 OUTLIER 53.17 51.41 15.69 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 120.962 -0.295 . . . . 1.0 111.3 178.531 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.612 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -96.74 131.27 43.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.294 -0.412 . . . . 1.0 111.6 -179.608 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.43 HG21 HD11 ' A' ' 16' ' ' LEU . 49.1 m -95.97 128.66 43.05 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.71 -1.589 . . . . 1.0 106.71 174.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -112.34 138.9 48.41 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.064 0.459 . . . . 1.0 110.998 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.743 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -117.91 147.35 21.42 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.583 0 CA-C-N 115.724 -0.671 . . . . 1.0 109.195 178.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.584 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.83 150.92 47.58 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.441 -0.504 . . . . 1.0 111.629 177.855 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.424 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.0 mmtt -100.76 123.97 45.72 Favored 'General case' 0 CA--C 1.501 -0.907 0 N-CA-C 105.807 -1.923 . . . . 1.0 105.807 177.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.468 HG23 ' CH2' ' A' ' 86' ' ' TRP . 2.9 mt -117.0 125.61 73.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 C-N-CA 119.592 -0.843 . . . . 1.0 112.732 -176.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -118.03 124.58 48.46 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.172 -1.377 . . . . 1.0 108.484 178.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -95.23 114.22 25.98 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 119.746 -0.782 . . . . 1.0 112.808 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.485 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -95.46 -43.01 12.74 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 115.732 -0.667 . . . . 1.0 110.996 178.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -154.21 156.5 37.2 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.604 -0.439 . . . . 1.0 111.265 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.413 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.7 t -129.82 138.43 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.111 -0.495 . . . . 1.0 111.273 -178.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.466 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 8.9 tptm -97.16 -148.93 0.32 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.555 0.693 . . . . 1.0 109.931 178.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.462 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER -167.54 146.26 4.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.28 178.024 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 96.4 p -59.15 -35.15 73.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.011 -0.995 . . . . 1.0 110.947 -179.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' A' ' 137' ' ' SER . 1.0 OUTLIER . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.963 -1.018 . . . . 1.0 110.043 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.949 H472 ' C20' ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 . . . . . 0 N--CA 1.492 1.64 0 N-CA-C 109.773 -0.454 . . . . 1.0 109.773 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.466 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 27.2 m120 -64.36 -17.7 63.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.797 -0.638 . . . . 1.0 111.685 -179.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -50.04 -43.58 51.0 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.99 0.424 . . . . 1.0 109.888 -178.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.535 ' NZ ' ' OD1' ' A' ' 8' ' ' ASN . 4.9 tmtt? -68.91 -37.05 78.7 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-O 121.612 0.72 . . . . 1.0 109.971 179.12 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.484 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -51.3 -33.35 28.55 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.482 -0.781 . . . . 1.0 110.8 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -62.73 -36.92 84.57 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.32 -0.855 . . . . 1.0 110.751 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.415 ' H ' ' HG3' ' A' ' 7' ' ' GLU . 22.7 mt-10 -66.68 -52.38 45.45 Favored 'General case' 0 C--O 1.223 -0.302 0 CA-C-O 121.842 0.83 . . . . 1.0 110.104 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.535 ' OD1' ' NZ ' ' A' ' 4' ' ' LYS . 88.5 m-20 -58.75 -34.07 70.99 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 115.002 -0.999 . . . . 1.0 108.409 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 13' ' ' GLU . 17.7 tttp -66.1 -51.47 57.77 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.073 -1.422 . . . . 1.0 111.493 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.3 t -67.32 -46.88 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 C-N-CA 119.845 -0.742 . . . . 1.0 111.663 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.447 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.59 -37.58 86.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.459 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.95 -44.66 29.65 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.861 -1.063 . . . . 1.0 112.317 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.435 ' N ' ' O ' ' A' ' 9' ' ' LYS . 58.3 mt-10 -60.73 -34.5 74.51 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.53 -0.915 . . . . 1.0 108.53 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.56 -36.07 65.56 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.016 -0.993 . . . . 1.0 109.826 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -61.14 -50.22 74.08 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.762 -1.108 . . . . 1.0 110.3 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 12' ' ' GLY . 4.7 mp -66.22 -38.43 87.92 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.387 -0.597 . . . . 1.0 109.387 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.3 m -61.51 -42.59 99.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.739 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -75.62 -44.61 41.93 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.6 -0.727 . . . . 1.0 111.887 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.628 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -56.98 -49.52 75.48 Favored 'General case' 0 CA--C 1.509 -0.621 0 N-CA-C 112.534 0.568 . . . . 1.0 112.534 -178.486 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' N ' ' OD1' ' A' ' 19' ' ' ASN . 20.3 ptmt -58.93 -29.47 67.13 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.355 -0.938 . . . . 1.0 110.021 -176.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -81.79 -29.1 32.86 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.311 -0.859 . . . . 1.0 111.482 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 mtmt -60.69 145.63 87.52 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 120.625 -0.43 . . . . 1.0 112.005 -178.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.0 149.05 64.52 Favored 'Trans proline' 0 N--CA 1.507 2.296 0 C-N-CA 122.946 2.431 . . . . 1.0 114.708 -179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.44 -20.53 2.11 Favored Glycine 0 N--CA 1.462 0.41 0 CA-C-N 114.957 -1.02 . . . . 1.0 111.894 178.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.2 t -79.2 131.55 34.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 C-N-CA 120.138 -0.625 . . . . 1.0 109.925 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 67.4 t -116.03 120.33 64.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.103 -1.073 . . . . 1.0 108.103 177.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.6 p -93.32 145.94 7.11 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 CA-C-O 121.688 0.756 . . . . 1.0 111.366 -178.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.33 163.55 18.0 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-N 114.534 -1.212 . . . . 1.0 110.446 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.4 -30.99 92.1 Favored 'Trans proline' 0 C--N 1.319 -1.01 0 C-N-CA 121.668 1.579 . . . . 1.0 111.294 -179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.3 m -69.34 -13.44 62.38 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.676 -0.693 . . . . 1.0 110.114 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.32 -4.0 64.29 Favored Glycine 0 CA--C 1.518 0.252 0 N-CA-C 110.179 -1.169 . . . . 1.0 110.179 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.498 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.8 tm? -77.45 134.56 38.34 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 108.565 -0.902 . . . . 1.0 108.565 179.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.498 ' H ' HD22 ' A' ' 32' ' ' LEU . 14.2 mp0 -125.1 141.68 51.97 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 116.341 -0.391 . . . . 1.0 111.609 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.1 p90 -137.01 142.58 42.52 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.745 0.783 . . . . 1.0 112.087 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.557 ' HE3' HD13 ' A' ' 37' ' ' ILE . 6.2 ttpt -124.85 124.63 42.5 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 114.282 -1.327 . . . . 1.0 108.296 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.88 113.39 21.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 CA-C-N 115.199 -0.91 . . . . 1.0 111.107 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.557 HD13 ' HE3' ' A' ' 35' ' ' LYS . 4.7 mm -77.02 -42.15 31.77 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 CA-C-O 121.808 0.813 . . . . 1.0 109.63 178.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.533 HD22 ' HB ' ' A' ' 37' ' ' ILE . 24.8 m-80 -143.81 128.76 18.49 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 114.208 -1.36 . . . . 1.0 109.655 -177.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.9 p -90.83 128.57 36.77 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.941 0.401 . . . . 1.0 109.996 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.89 -32.64 1.39 Allowed Glycine 0 CA--C 1.52 0.368 0 N-CA-C 110.045 -1.222 . . . . 1.0 110.045 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.661 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 56.6 31.92 20.01 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.532 -0.334 . . . . 1.0 111.126 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.13 -161.01 37.0 Favored Glycine 0 C--N 1.334 0.445 0 CA-C-O 121.833 0.685 . . . . 1.0 111.553 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.586 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.6 m -68.41 -178.49 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.108 -1.046 . . . . 1.0 109.301 178.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.492 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.66 154.59 0.36 Allowed Pre-proline 0 C--N 1.319 -0.741 0 O-C-N 123.84 0.712 . . . . 1.0 109.213 179.529 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 60.8 Cg_endo -86.99 157.9 8.62 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.933 2.422 . . . . 1.0 115.781 -175.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.412 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.31 172.69 38.25 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 108.446 -1.862 . . . . 1.0 108.446 176.098 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.618 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -47.04 -25.27 0.78 Allowed 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 114.83 -0.685 . . . . 1.0 111.62 178.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.428 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 20.7 m -108.25 -9.14 15.56 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 113.363 0.875 . . . . 1.0 113.363 -177.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.412 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.7 m-20 -84.72 167.39 16.19 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 119.717 -0.793 . . . . 1.0 109.005 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 7.8 m -106.14 149.93 26.31 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.096 0.474 . . . . 1.0 109.918 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.431 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.1 p -126.53 162.35 30.93 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.297 0 CA-C-N 115.477 -0.783 . . . . 1.0 112.21 -176.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 77.9 m -130.23 119.96 23.72 Favored 'General case' 0 N--CA 1.464 0.24 0 N-CA-C 108.333 -0.988 . . . . 1.0 108.333 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.559 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.8 m -148.99 166.62 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 114.28 1.215 . . . . 1.0 114.28 -176.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.423 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 9.4 mt-10 -118.4 152.19 36.34 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 106.386 -1.709 . . . . 1.0 106.386 174.237 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.504 ' H ' ' HB ' ' A' ' 68' ' ' THR . 32.8 p90 -163.63 160.71 23.16 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 118.423 -1.311 . . . . 1.0 114.538 -178.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.6 m -122.15 130.29 53.09 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.769 -0.826 . . . . 1.0 108.769 175.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.2 137.08 13.93 Favored Glycine 0 N--CA 1.47 0.936 0 C-N-CA 120.881 -0.676 . . . . 1.0 112.02 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 7.6 ptp180 -147.84 167.28 25.17 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.617 0.722 . . . . 1.0 112.227 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.8 mp -86.89 166.05 15.46 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.491 -1.231 . . . . 1.0 111.404 179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.417 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.01 -26.24 35.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 114.809 -1.087 . . . . 1.0 110.266 178.066 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -93.79 2.38 56.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.173 -1.376 . . . . 1.0 111.416 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.94 -2.25 75.67 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 120.998 -0.62 . . . . 1.0 112.767 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.4 m -69.03 103.44 1.86 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 117.821 0.81 . . . . 1.0 110.326 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 65.9 t -74.03 122.7 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 C-N-CA 120.287 -0.565 . . . . 1.0 109.601 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.841 ' CD2' HD11 ' A' ' 118' ' ' ILE . 17.3 p90 -116.35 -8.46 11.64 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 115.003 -0.999 . . . . 1.0 111.598 -178.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.519 ' OD1' H433 ' A' ' 138' ' ' RAP . 33.7 t0 -158.29 152.42 24.09 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.467 -0.493 . . . . 1.0 111.335 178.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 96.4 p -159.29 153.23 23.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.729 -0.668 . . . . 1.0 111.623 178.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.504 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 66.2 m -155.86 -39.28 0.08 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.643 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.4 pp20? -65.8 -27.15 68.06 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.383 -0.599 . . . . 1.0 109.383 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.8 mmtt -58.15 -43.83 87.55 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 107.808 -1.182 . . . . 1.0 107.808 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.5 p -73.99 -31.32 62.92 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.865 -1.062 . . . . 1.0 108.797 176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.71 18.31 68.42 Favored Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.81 178.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.413 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 0.0 OUTLIER -101.73 115.03 65.43 Favored Pre-proline 0 N--CA 1.47 0.539 0 C-N-CA 120.682 -0.407 . . . . 1.0 110.98 -179.275 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.407 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 30.4 Cg_exo -60.83 152.49 69.67 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.823 1.682 . . . . 1.0 114.366 -178.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.26 152.21 41.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 114.042 -1.436 . . . . 1.0 107.833 178.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 130.9 55.38 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-O 121.408 0.623 . . . . 1.0 112.511 -178.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.591 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 42.3 m-85 -138.82 148.44 43.77 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.0 -1.0 . . . . 1.0 109.853 178.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 20.3 mt-30 -90.35 125.39 35.52 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 106.335 -1.728 . . . . 1.0 106.335 174.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.8 t -53.69 -28.85 16.85 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 C-N-CA 119.394 -0.922 . . . . 1.0 110.15 -177.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.7 t -73.97 -25.59 60.02 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.025 -0.67 . . . . 1.0 111.835 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.541 ' O ' ' C33' ' A' ' 138' ' ' RAP . 84.5 mm-40 -100.1 -16.07 17.97 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.717 -0.393 . . . . 1.0 112.022 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.923 ' HA ' H332 ' A' ' 138' ' ' RAP . 0.4 OUTLIER -64.99 164.75 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.291 0 N-CA-C 112.109 0.411 . . . . 1.0 112.109 -177.637 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.518 HG12 H492 ' A' ' 138' ' ' RAP . 0.0 OUTLIER -54.58 148.96 23.19 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.501 -0.925 . . . . 1.0 108.501 -178.394 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -51.33 -42.62 53.68 Favored 'Trans proline' 0 N--CA 1.489 1.258 0 C-N-CA 121.061 1.174 . . . . 1.0 112.093 -178.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.76 -48.09 87.73 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 119.872 -1.156 . . . . 1.0 110.54 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.684 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 9.5 m95 -65.56 -35.5 81.04 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.301 -0.949 . . . . 1.0 111.144 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 26.2 m -51.19 -54.38 26.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.987 -0.285 . . . . 1.0 111.637 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.89 -40.8 68.65 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 112.456 0.539 . . . . 1.0 112.456 -179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.1 -48.1 82.84 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 114.136 1.162 . . . . 1.0 114.136 -177.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 27.4 mt -58.32 -42.25 86.31 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.299 0.571 . . . . 1.0 109.896 -177.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -63.25 -23.9 67.63 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.332 -179.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.517 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.7 mt -100.95 -12.45 18.91 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.902 -0.59 . . . . 1.0 111.246 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.5 ttp -90.17 107.45 19.64 Favored Pre-proline 0 CA--C 1.546 0.826 0 N-CA-C 111.863 0.32 . . . . 1.0 111.863 -178.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.492 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.3 Cg_exo -67.28 148.02 79.38 Favored 'Trans proline' 0 N--CA 1.498 1.774 0 C-N-CA 122.614 2.209 . . . . 1.0 112.426 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.586 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -65.61 135.6 55.26 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-O 121.546 0.688 . . . . 1.0 110.926 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.97 -18.46 57.49 Favored Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 107.788 -2.125 . . . . 1.0 107.788 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.8 p -90.24 133.51 34.88 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 114.956 -0.622 . . . . 1.0 110.676 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.419 ' HB ' HD22 ' A' ' 38' ' ' ASN . 86.0 m -108.8 115.42 30.06 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.581 -0.736 . . . . 1.0 109.426 179.09 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.517 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 40.6 m0 -115.43 168.52 9.92 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.777 0.799 . . . . 1.0 111.081 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.426 ' HB2' HD11 ' A' ' 37' ' ' ILE . 25.2 mt-10 -127.89 129.91 47.65 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 106.449 -1.686 . . . . 1.0 106.449 175.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.7 pt -126.33 137.83 56.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.782 0.801 . . . . 1.0 109.707 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -108.91 103.62 12.71 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 105.866 -1.901 . . . . 1.0 105.866 -178.078 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 5.7 t -90.48 115.57 64.43 Favored Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 115.162 1.541 . . . . 1.0 115.162 -174.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -51.07 145.6 24.96 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.525 1.483 . . . . 1.0 109.89 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.7 p -51.7 -36.24 45.92 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.241 -0.584 . . . . 1.0 111.046 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.43 -32.48 83.62 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.862 -0.895 . . . . 1.0 110.862 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.6 mt -99.19 2.28 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.856 -0.172 . . . . 1.0 111.001 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.53 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.82 -103.81 0.37 Allowed 'General case' 0 C--O 1.219 -0.54 0 N-CA-C 112.197 0.443 . . . . 1.0 112.197 -177.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.688 ' CE2' H491 ' A' ' 138' ' ' RAP . 31.9 m-85 -104.07 3.96 33.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 113.435 0.902 . . . . 1.0 113.435 -177.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.78 167.8 17.22 Favored Glycine 0 N--CA 1.47 0.922 0 C-N-CA 120.673 -0.775 . . . . 1.0 113.786 177.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.575 ' O ' ' N ' ' A' ' 121' ' ' ASN . 91.0 Cg_endo -76.37 -17.74 16.41 Favored 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 124.013 3.142 . . . . 1.0 111.764 179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -103.67 169.69 8.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.848 -0.615 . . . . 1.0 110.066 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.406 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.2 m -74.16 102.95 4.42 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.673 -0.491 . . . . 1.0 109.673 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 109' ' ' TYR . 8.7 t -111.62 61.35 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-O 120.699 0.285 . . . . 1.0 110.795 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.501 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 162.95 178.32 36.67 Favored Glycine 0 CA--C 1.527 0.832 0 C-N-CA 120.631 -0.795 . . . . 1.0 111.793 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.46 -103.61 0.01 OUTLIER Glycine 0 CA--C 1.532 1.156 0 N-CA-C 111.09 -0.804 . . . . 1.0 111.09 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -61.76 -16.64 50.12 Favored 'Trans proline' 0 N--CA 1.496 1.626 0 C-N-CA 122.672 2.248 . . . . 1.0 111.734 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.841 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.9 mp -66.46 117.2 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 N-CA-C 107.475 -1.305 . . . . 1.0 107.475 179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -93.47 -170.15 39.09 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.622 -0.717 . . . . 1.0 111.926 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.484 ' HB2' ' HB2' ' A' ' 5' ' ' ALA . 30.1 Cg_endo -67.55 145.56 70.84 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 C-N-CA 122.413 2.075 . . . . 1.0 111.614 178.292 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.575 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 42.99 48.76 5.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.324 0.583 . . . . 1.0 110.415 179.078 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 4.4 tp10 -100.86 128.97 46.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.126 -0.943 . . . . 1.0 111.226 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.451 HG21 HD11 ' A' ' 16' ' ' LEU . 46.7 m -91.29 131.38 36.83 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.299 -0.864 . . . . 1.0 109.404 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -113.14 147.98 36.27 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.876 0.37 . . . . 1.0 110.28 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -126.39 143.22 40.62 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.595 0 N-CA-C 108.546 -0.909 . . . . 1.0 108.546 178.358 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.565 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.5 m-85 -134.15 149.9 51.08 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 120.378 -0.529 . . . . 1.0 111.657 177.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.5 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 6.9 mmtt -100.16 124.39 45.52 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 105.728 -1.953 . . . . 1.0 105.728 177.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.6 mt -118.2 118.95 59.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.878 0.846 . . . . 1.0 113.031 -176.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 -109.64 127.12 54.32 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 113.98 -1.464 . . . . 1.0 108.536 178.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.6 111.61 23.68 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 120.041 -0.664 . . . . 1.0 112.41 -178.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.442 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.2 mp -93.86 -44.79 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 CA-C-N 116.119 -0.492 . . . . 1.0 111.1 179.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 6.5 p -152.39 158.39 42.61 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.89 0.376 . . . . 1.0 110.744 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.4 t -130.88 139.68 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.516 -177.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.501 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 7.2 tptt -93.6 -148.56 0.26 Allowed 'General case' 0 N--CA 1.453 -0.31 0 CA-C-O 121.356 0.598 . . . . 1.0 109.906 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.501 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -176.58 137.4 0.27 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.646 178.234 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.4 t -86.79 -71.35 0.56 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.844 -1.071 . . . . 1.0 110.881 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.6 t . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.449 -179.668 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.923 H332 ' HA ' ' A' ' 82' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 34.7 p90 . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.623 -0.51 . . . . 1.0 109.623 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.565 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 81.0 m-20 -69.94 -24.09 63.3 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.758 -0.377 . . . . 1.0 110.982 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 59.7 pttt -45.31 -42.59 9.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.135 0.493 . . . . 1.0 110.404 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.498 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 3.1 tmtt? -67.51 -35.81 79.83 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-O 121.959 0.885 . . . . 1.0 109.502 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.78 -33.66 36.32 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 114.83 -1.077 . . . . 1.0 111.039 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.505 ' OD2' ' NZ ' ' A' ' 9' ' ' LYS . 52.7 m-20 -62.73 -39.39 93.95 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 115.456 -0.793 . . . . 1.0 109.982 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -63.03 -52.87 61.19 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.599 0.714 . . . . 1.0 110.512 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 28.5 m-20 -59.7 -35.66 74.95 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.171 -0.922 . . . . 1.0 108.657 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.505 ' NZ ' ' OD2' ' A' ' 6' ' ' ASP . 1.9 ttpm? -65.74 -50.83 63.37 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.197 -1.365 . . . . 1.0 111.139 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -67.21 -48.81 77.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 C-N-CA 119.58 -0.848 . . . . 1.0 112.015 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.458 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -62.16 -38.04 87.53 Favored 'General case' 0 N--CA 1.444 -0.757 0 N-CA-C 107.703 -1.221 . . . . 1.0 107.703 179.212 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.479 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.2 -47.96 41.66 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 114.897 -1.047 . . . . 1.0 112.296 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -59.86 -30.81 69.23 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 119.882 -0.727 . . . . 1.0 109.248 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.4 -35.31 47.29 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.266 -0.879 . . . . 1.0 109.978 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.5 t80 -60.55 -49.43 77.58 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.764 -1.107 . . . . 1.0 110.379 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.479 HD12 ' O ' ' A' ' 12' ' ' GLY . 6.0 mp -66.99 -40.01 87.29 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 109.199 -0.667 . . . . 1.0 109.199 178.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 98.0 m -61.96 -41.75 98.35 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.488 -0.778 . . . . 1.0 109.733 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -75.73 -43.38 47.23 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.69 -0.687 . . . . 1.0 111.36 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.666 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 47.4 t30 -61.53 -45.31 94.72 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 112.793 0.664 . . . . 1.0 112.793 -178.257 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -58.89 -30.74 68.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.48 -0.888 . . . . 1.0 108.947 -179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -79.07 -31.65 44.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.261 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 29.4 mtmt -58.55 142.72 82.45 Favored Pre-proline 0 CA--C 1.547 0.865 0 C-N-CA 120.525 -0.47 . . . . 1.0 111.163 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -56.68 149.06 61.3 Favored 'Trans proline' 0 N--CA 1.503 2.042 0 C-N-CA 122.422 2.081 . . . . 1.0 114.297 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.73 -19.31 5.12 Favored Glycine 0 C--O 1.228 -0.243 0 CA-C-N 115.021 -0.99 . . . . 1.0 112.226 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.54 136.53 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.02 0.438 . . . . 1.0 110.754 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.3 t -121.41 122.91 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 107.963 -1.125 . . . . 1.0 107.963 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.92 146.0 8.1 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.753 0.787 . . . . 1.0 111.896 -178.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 78.8 mt -114.86 166.5 11.59 Favored Pre-proline 0 C--O 1.231 0.119 0 CA-C-N 114.35 -1.296 . . . . 1.0 111.048 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -61.57 -31.6 87.27 Favored 'Trans proline' 0 N--CA 1.485 0.985 0 C-N-CA 122.241 1.961 . . . . 1.0 111.97 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 m -69.94 -10.71 59.53 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.25 0.548 . . . . 1.0 109.855 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.25 0.94 72.89 Favored Glycine 0 CA--C 1.517 0.185 0 N-CA-C 109.952 -1.259 . . . . 1.0 109.952 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.48 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -82.64 133.58 35.17 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 108.555 -0.905 . . . . 1.0 108.555 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.48 ' H ' HD22 ' A' ' 32' ' ' LEU . 16.5 mp0 -121.84 143.46 49.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.413 -0.358 . . . . 1.0 111.164 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 26.7 p90 -137.4 145.27 43.04 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.733 0.778 . . . . 1.0 111.072 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.506 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -128.66 132.63 48.1 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 114.38 -1.282 . . . . 1.0 109.08 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.85 104.63 15.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 122.314 1.055 . . . . 1.0 112.02 -178.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.613 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -69.77 -41.35 79.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.992 -1.004 . . . . 1.0 108.551 179.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.7 m-80 -143.92 129.38 19.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.661 -1.154 . . . . 1.0 109.73 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.3 p -89.43 128.81 35.98 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.734 -0.469 . . . . 1.0 109.734 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.48 -35.15 1.22 Allowed Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.626 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.2 m120 58.07 29.9 18.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 1.0 111.138 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.93 -161.99 37.84 Favored Glycine 0 C--N 1.331 0.259 0 CA-C-O 121.888 0.716 . . . . 1.0 111.713 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.9 m -68.61 -177.7 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.061 -1.07 . . . . 1.0 108.841 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.471 ' HA ' HG21 ' A' ' 133' ' ' VAL . 0.0 OUTLIER 177.67 155.4 0.49 Allowed Pre-proline 0 C--N 1.317 -0.836 0 O-C-N 123.628 0.58 . . . . 1.0 109.516 179.797 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -83.84 165.23 13.64 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 123.241 2.627 . . . . 1.0 116.292 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.443 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -98.08 175.02 29.37 Favored Glycine 0 C--N 1.343 0.94 0 N-CA-C 108.633 -1.787 . . . . 1.0 108.633 176.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.84 -23.53 18.8 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.618 -0.433 . . . . 1.0 111.492 -179.086 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 36.4 m -107.02 -6.31 17.55 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 112.9 0.704 . . . . 1.0 112.9 -177.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.727 ' OD1' ' N ' ' A' ' 50' ' ' THR . 67.2 t0 -82.33 170.68 15.07 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.282 0.563 . . . . 1.0 110.595 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.727 ' N ' ' OD1' ' A' ' 49' ' ' ASP . 8.9 m -112.38 144.06 42.44 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.697 -0.853 . . . . 1.0 108.697 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.404 HG22 ' N ' ' A' ' 52' ' ' THR . 9.0 p -125.39 160.34 31.52 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 CA-C-N 115.182 -0.917 . . . . 1.0 111.974 -175.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.444 HG22 ' HB3' ' A' ' 74' ' ' PRO . 99.3 m -125.5 119.74 29.03 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.602 -0.888 . . . . 1.0 108.602 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.433 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.5 m -148.48 166.93 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 114.341 1.237 . . . . 1.0 114.341 -177.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -119.36 147.68 44.06 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 106.283 -1.747 . . . . 1.0 106.283 173.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.4 p90 -162.19 163.4 28.36 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 115.083 1.512 . . . . 1.0 115.083 -176.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -127.45 127.5 44.18 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 115.254 -0.884 . . . . 1.0 109.332 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.74 136.07 13.19 Favored Glycine 0 N--CA 1.471 1.001 0 C-N-CA 121.094 -0.574 . . . . 1.0 112.355 -178.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.425 HH11 ' HD3' ' A' ' 58' ' ' ARG . 5.3 ptp180 -147.4 168.55 21.57 Favored 'General case' 0 C--N 1.341 0.199 0 CA-C-O 121.498 0.666 . . . . 1.0 112.266 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 4.2 mp -84.93 164.7 18.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 114.519 -1.219 . . . . 1.0 110.761 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.43 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.57 -25.49 34.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 114.883 -1.053 . . . . 1.0 110.018 177.792 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -92.65 3.02 56.36 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.926 -1.488 . . . . 1.0 111.622 -177.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.27 -2.03 80.56 Favored Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.822 -0.704 . . . . 1.0 112.668 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.4 m -71.37 104.49 3.21 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 119.722 -0.791 . . . . 1.0 109.785 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.1 t -75.46 126.34 36.11 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.81 0 CA-C-O 121.202 0.525 . . . . 1.0 110.332 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.439 ' CD2' HD11 ' A' ' 118' ' ' ILE . 30.2 p90 -115.0 -11.68 12.1 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.032 -0.986 . . . . 1.0 111.425 -179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.424 ' CB ' ' C43' ' A' ' 138' ' ' RAP . 21.1 t0 -162.5 153.35 17.3 Favored 'General case' 0 C--N 1.324 -0.52 0 C-N-CA 119.838 -0.745 . . . . 1.0 112.158 178.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 93.3 p -160.44 154.88 23.6 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 115.706 -0.679 . . . . 1.0 112.124 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.505 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 90.4 m -152.26 -43.51 0.1 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.311 -0.859 . . . . 1.0 110.688 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.413 ' OE2' ' OG1' ' A' ' 56' ' ' THR . 2.8 pp20? -59.04 -25.98 64.18 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.152 -0.476 . . . . 1.0 110.427 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -54.98 -42.55 72.56 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.674 -1.232 . . . . 1.0 107.674 178.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 71.9 p -77.06 -34.83 57.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.525 -1.216 . . . . 1.0 109.193 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 85.05 16.75 64.37 Favored Glycine 0 C--N 1.333 0.362 0 CA-C-N 115.452 -0.795 . . . . 1.0 111.57 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.5 116.14 65.15 Favored Pre-proline 0 N--CA 1.472 0.672 0 C-N-CA 120.488 -0.485 . . . . 1.0 110.874 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HB3' HG22 ' A' ' 52' ' ' THR . 34.7 Cg_exo -59.7 151.65 68.71 Favored 'Trans proline' 0 N--CA 1.481 0.752 0 C-N-CA 121.458 1.438 . . . . 1.0 114.438 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -124.36 149.52 46.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.027 -1.442 . . . . 1.0 107.257 177.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 t -103.34 136.99 42.07 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.358 0.599 . . . . 1.0 112.493 -178.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.55 ' CE1' ' H42' ' A' ' 138' ' ' RAP . 38.7 m-85 -140.23 148.3 41.31 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 114.933 -1.031 . . . . 1.0 110.767 179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.469 ' H ' H483 ' A' ' 138' ' ' RAP . 20.5 mt-30 -92.0 125.19 36.6 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 105.752 -1.944 . . . . 1.0 105.752 174.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.6 t -56.45 -29.98 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 C-N-CA 118.704 -1.198 . . . . 1.0 110.126 -176.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LYS . 3.1 t -73.53 -25.78 60.57 Favored 'General case' 0 CA--C 1.521 -0.166 0 C-N-CA 120.074 -0.65 . . . . 1.0 112.577 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.631 ' O ' ' O11' ' A' ' 138' ' ' RAP . 87.0 mm-40 -101.37 -15.9 17.07 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 111.885 0.328 . . . . 1.0 111.885 -179.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.73 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.6 p -69.94 170.52 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 119.42 -0.912 . . . . 1.0 111.886 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.481 ' H ' HG22 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -54.08 146.99 27.34 Favored Pre-proline 0 CA--C 1.548 0.875 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 -178.069 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -52.13 -43.64 51.6 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 121.814 1.676 . . . . 1.0 113.105 -178.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.65 -47.15 92.36 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 109.574 -1.41 . . . . 1.0 109.574 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.615 ' CD2' ' H41' ' A' ' 138' ' ' RAP . 6.7 m95 -63.03 -35.31 79.8 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.153 -1.024 . . . . 1.0 110.387 179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 24.8 m -51.56 -53.54 36.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.063 0.458 . . . . 1.0 111.063 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 76.8 tt0 -71.9 -44.91 62.92 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.617 -0.72 . . . . 1.0 112.687 -179.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -58.81 -46.8 86.75 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 114.509 1.3 . . . . 1.0 114.509 -177.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 19.4 mt -57.84 -42.88 85.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.362 0.601 . . . . 1.0 109.478 -178.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -62.95 -20.08 64.89 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.942 -1.026 . . . . 1.0 110.434 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.537 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 96.2 mt -105.93 -11.05 16.33 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.968 -0.56 . . . . 1.0 111.352 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 54.2 ttp -92.52 107.18 21.93 Favored Pre-proline 0 CA--C 1.547 0.842 0 O-C-N 123.273 0.358 . . . . 1.0 111.376 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.43 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 23.8 Cg_exo -64.43 147.7 90.65 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.398 2.065 . . . . 1.0 112.936 178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.599 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -61.87 132.66 53.77 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 115.482 -0.781 . . . . 1.0 111.579 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.49 -19.26 55.09 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 108.492 -1.843 . . . . 1.0 108.492 -178.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -84.61 131.83 34.56 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.038 0.447 . . . . 1.0 109.994 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 91.5 m -105.24 113.67 27.4 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 115.923 -0.58 . . . . 1.0 109.604 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.537 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 38.9 m0 -115.65 165.69 12.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.871 0.843 . . . . 1.0 111.258 -178.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.613 ' CD ' HD11 ' A' ' 37' ' ' ILE . 83.7 mt-10 -125.84 132.88 52.13 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 106.277 -1.749 . . . . 1.0 106.277 175.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.425 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.7 pt -128.66 139.71 51.17 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 CA-C-O 121.84 0.829 . . . . 1.0 109.925 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.697 ' CE2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.88 103.07 11.8 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 105.742 -1.947 . . . . 1.0 105.742 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 t -90.64 116.23 65.94 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 115.614 1.709 . . . . 1.0 115.614 -174.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.81 144.56 26.38 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.66 1.574 . . . . 1.0 109.766 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.5 p -50.45 -36.24 32.42 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 120.434 -0.506 . . . . 1.0 111.363 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.98 -32.2 80.2 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.977 -0.849 . . . . 1.0 110.977 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 44.4 mt -98.4 2.32 47.75 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 121.364 -0.134 . . . . 1.0 110.746 -178.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.619 ' O ' H521 ' A' ' 138' ' ' RAP . . . -107.95 -103.22 0.36 Allowed 'General case' 0 C--O 1.216 -0.665 0 N-CA-C 110.069 -0.345 . . . . 1.0 110.069 -179.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.532 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 35.7 m-85 -105.29 5.17 31.74 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 113.397 0.888 . . . . 1.0 113.397 -178.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 105.46 166.7 23.69 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 120.814 -0.707 . . . . 1.0 113.075 177.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 121' ' ' ASN . 72.6 Cg_endo -72.64 -18.46 25.38 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 123.454 2.769 . . . . 1.0 112.45 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -98.03 169.3 9.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.303 -0.408 . . . . 1.0 109.947 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.7 m -76.33 85.82 3.11 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.7 t -98.04 59.23 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.51 -0.314 . . . . 1.0 110.923 -179.114 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.75 179.9 41.76 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 120.629 -0.796 . . . . 1.0 112.088 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.01 -105.87 0.01 OUTLIER Glycine 0 CA--C 1.537 1.418 0 N-CA-C 111.747 -0.541 . . . . 1.0 111.747 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -61.15 -13.72 29.68 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 C-N-CA 122.399 2.066 . . . . 1.0 110.677 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.841 HD12 ' H ' ' A' ' 118' ' ' ILE . 4.1 mp -68.24 112.22 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 N-CA-C 108.334 -0.987 . . . . 1.0 108.334 178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.412 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -91.21 -167.11 40.9 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 110.691 -0.964 . . . . 1.0 110.691 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.519 ' HB2' ' HB2' ' A' ' 5' ' ' ALA . 38.0 Cg_endo -64.76 146.65 88.81 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 122.242 1.961 . . . . 1.0 112.973 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.468 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 46.16 49.87 12.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.67 -0.695 . . . . 1.0 111.925 178.353 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.437 ' OE2' ' CG ' ' A' ' 8' ' ' ASN . 49.1 mm-40 -93.21 132.69 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.093 0.473 . . . . 1.0 111.978 179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.465 HG21 HD11 ' A' ' 16' ' ' LEU . 63.4 m -96.2 127.82 42.55 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.243 -1.762 . . . . 1.0 106.243 175.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.423 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.9 mm? -113.97 143.16 45.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.517 0.675 . . . . 1.0 110.747 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.697 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.7 tt -119.28 146.38 24.04 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.659 0 CA-C-N 115.078 -0.965 . . . . 1.0 108.508 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.562 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -137.84 152.27 48.92 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.314 -0.554 . . . . 1.0 111.376 177.63 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.476 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 3.4 mmtt -100.47 124.03 45.46 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 105.697 -1.964 . . . . 1.0 105.697 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.2 mt -118.61 119.05 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 119.41 -0.916 . . . . 1.0 112.394 -176.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.6 t-160 -110.81 122.66 48.38 Favored 'General case' 0 CA--C 1.517 -0.302 0 CA-C-N 114.096 -1.411 . . . . 1.0 108.654 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -94.49 112.13 23.89 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 120.364 -0.534 . . . . 1.0 112.378 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.449 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.3 mp -95.55 -45.04 13.22 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-N 116.015 -0.539 . . . . 1.0 111.412 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.8 p -151.05 157.82 43.31 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.827 0.346 . . . . 1.0 110.691 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.471 HG21 ' HA ' ' A' ' 44' ' ' LYS . 60.5 t -128.79 140.67 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 121.039 0.447 . . . . 1.0 111.51 -177.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.519 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 14.7 tptt -97.5 -151.47 0.37 Allowed 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.942 0.877 . . . . 1.0 111.22 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.519 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.4 OUTLIER -174.18 126.42 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 114.056 -1.429 . . . . 1.0 110.533 177.811 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -70.63 -47.1 61.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 113.869 -1.514 . . . . 1.0 111.98 -178.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.135 -0.936 . . . . 1.0 110.301 -179.594 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.73 H31A ' CG2' ' A' ' 82' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.095 -0.706 . . . . 1.0 109.095 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -65.67 -27.3 68.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 120.155 -0.618 . . . . 1.0 110.718 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.535 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 40.2 pttt -55.26 -40.52 71.07 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.558 -0.457 . . . . 1.0 109.982 -179.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.535 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 6.7 tmtt? -73.45 -39.39 65.0 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 121.854 0.835 . . . . 1.0 109.154 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -50.75 -33.41 23.06 Favored 'General case' 0 CA--C 1.505 -0.77 0 CA-C-N 114.834 -1.075 . . . . 1.0 110.424 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -62.09 -44.08 97.43 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.666 -0.697 . . . . 1.0 110.294 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -59.61 -52.08 67.05 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 122.023 0.916 . . . . 1.0 110.646 -179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.562 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 1.8 m-20 -59.59 -37.47 78.63 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 114.608 -1.178 . . . . 1.0 108.221 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 13' ' ' GLU . 0.0 OUTLIER -67.46 -52.14 42.97 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.183 -1.371 . . . . 1.0 111.495 179.541 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.92 -48.37 75.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 C-N-CA 119.736 -0.786 . . . . 1.0 112.058 -177.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.449 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -63.36 -35.54 80.73 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.015 -1.106 . . . . 1.0 108.015 178.982 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.475 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -74.54 -43.57 29.61 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 114.754 -1.112 . . . . 1.0 112.054 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.3 mt-10 -61.72 -31.25 71.39 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.907 -0.775 . . . . 1.0 108.907 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.39 -32.08 48.67 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 115.441 -0.8 . . . . 1.0 110.04 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -62.44 -49.12 76.7 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.579 -1.191 . . . . 1.0 110.762 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.73 -40.1 76.4 Favored 'General case' 0 C--N 1.32 -0.686 0 C-N-CA 119.957 -0.697 . . . . 1.0 109.892 178.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.4 m -61.04 -41.7 97.09 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.814 -0.63 . . . . 1.0 109.481 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -75.48 -46.52 31.94 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.31 -0.859 . . . . 1.0 111.575 -179.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.658 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 50.9 t30 -60.37 -44.91 95.17 Favored 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 113.016 0.747 . . . . 1.0 113.016 -177.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -60.42 -28.84 68.58 Favored 'General case' 0 C--N 1.316 -0.89 0 C-N-CA 119.47 -0.892 . . . . 1.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -80.25 -30.02 38.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.191 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 27.9 mtmt -59.4 142.95 86.35 Favored Pre-proline 0 CA--C 1.55 0.951 0 N-CA-C 112.268 0.47 . . . . 1.0 112.268 -177.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.06 149.05 65.08 Favored 'Trans proline' 0 N--CA 1.505 2.195 0 C-N-CA 122.499 2.132 . . . . 1.0 113.362 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.72 -19.37 5.08 Favored Glycine 0 C--O 1.225 -0.412 0 CA-C-N 115.601 -0.727 . . . . 1.0 112.189 178.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.5 t -85.11 136.28 23.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.148 0.499 . . . . 1.0 110.833 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 79.2 t -121.91 124.24 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 107.854 -1.165 . . . . 1.0 107.854 177.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.4 p -97.24 146.32 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 CA-C-O 121.71 0.767 . . . . 1.0 111.811 -178.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 83.7 mt -113.29 165.05 14.11 Favored Pre-proline 0 C--O 1.232 0.14 0 CA-C-N 114.355 -1.293 . . . . 1.0 110.856 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -61.37 -30.24 87.01 Favored 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 121.983 1.789 . . . . 1.0 111.379 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.1 m -68.51 -14.47 63.03 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.591 -0.731 . . . . 1.0 109.387 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.93 -2.1 68.88 Favored Glycine 0 C--O 1.229 -0.158 0 N-CA-C 109.734 -1.346 . . . . 1.0 109.734 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.437 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.2 tm? -80.54 132.78 35.71 Favored 'General case' 0 CA--C 1.519 -0.25 0 N-CA-C 108.411 -0.959 . . . . 1.0 108.411 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.437 ' H ' HD22 ' A' ' 32' ' ' LEU . 22.7 mp0 -119.62 140.96 49.77 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-N 116.196 -0.456 . . . . 1.0 110.869 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -136.37 147.85 47.56 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 121.6 0.714 . . . . 1.0 111.143 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.538 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.9 tmtp? -130.64 132.54 45.51 Favored 'General case' 0 CA--C 1.501 -0.932 0 CA-C-N 114.479 -1.237 . . . . 1.0 109.317 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 p -90.16 104.85 15.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.281 1.038 . . . . 1.0 112.356 -178.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.63 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.3 mm -70.7 -41.64 77.65 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.039 -0.982 . . . . 1.0 108.72 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -143.6 131.52 21.59 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 114.639 -1.164 . . . . 1.0 109.792 -179.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.8 p -90.3 129.1 36.57 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.857 -0.423 . . . . 1.0 109.857 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.74 -33.2 1.32 Allowed Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.619 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 54.32 30.83 13.22 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.287 -0.457 . . . . 1.0 110.577 179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.33 -162.22 37.78 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-O 121.789 0.66 . . . . 1.0 111.669 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.595 ' O ' ' N ' ' A' ' 95' ' ' ALA . 23.4 m -68.28 -177.54 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 114.266 -0.967 . . . . 1.0 109.375 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.606 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.56 154.58 0.35 Allowed Pre-proline 0 C--N 1.317 -0.832 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 179.54 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.436 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 73.9 Cg_endo -88.21 160.4 7.03 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.162 2.575 . . . . 1.0 116.189 -175.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.422 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -90.8 174.22 39.06 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 108.096 -2.001 . . . . 1.0 108.096 175.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.607 ' N ' ' CD ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -49.26 -25.81 2.58 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 114.99 -0.605 . . . . 1.0 111.439 178.561 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.438 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 9.4 m -107.24 -9.21 16.15 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -177.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.422 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 95.6 m-20 -84.18 165.92 18.01 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 119.708 -0.797 . . . . 1.0 108.975 179.222 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.415 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.2 m -103.24 151.86 22.17 Favored 'General case' 0 CA--C 1.513 -0.454 0 CA-C-O 121.224 0.535 . . . . 1.0 109.948 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.436 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 4.8 p -129.66 161.82 38.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.389 0 CA-C-N 115.292 -0.867 . . . . 1.0 112.114 -176.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -132.12 118.17 19.26 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 108.67 -0.863 . . . . 1.0 108.67 177.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.418 ' HB ' ' O ' ' A' ' 129' ' ' HIS . 2.5 m -148.1 166.98 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.883 0.697 . . . . 1.0 112.883 -177.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 6.1 mt-10 -116.93 154.04 31.53 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 106.909 -1.515 . . . . 1.0 106.909 175.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.521 ' H ' ' HB ' ' A' ' 68' ' ' THR . 41.1 p90 -165.07 163.55 20.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 114.82 1.415 . . . . 1.0 114.82 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -126.24 128.97 48.03 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 107.895 -1.15 . . . . 1.0 107.895 174.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.68 12.25 Favored Glycine 0 N--CA 1.47 0.905 0 C-N-CA 120.687 -0.768 . . . . 1.0 111.757 -178.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.3 ptp180 -146.23 167.02 24.52 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 121.95 0.881 . . . . 1.0 112.632 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.483 HD11 HD13 ' A' ' 118' ' ' ILE . 3.0 mp -81.76 163.79 22.16 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.065 -1.425 . . . . 1.0 110.147 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.19 -24.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 114.942 -1.026 . . . . 1.0 109.77 177.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -96.25 4.69 52.19 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 113.648 -1.615 . . . . 1.0 111.791 -177.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.05 80.51 Favored Glycine 0 CA--C 1.525 0.682 0 C-N-CA 120.788 -0.72 . . . . 1.0 113.316 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 m -72.83 111.51 8.03 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 119.112 -1.035 . . . . 1.0 109.422 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.02 120.17 28.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-O 121.543 0.687 . . . . 1.0 111.171 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.591 ' CG ' HD11 ' A' ' 118' ' ' ILE . 23.3 p90 -108.47 -9.81 15.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.884 -1.053 . . . . 1.0 111.613 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.578 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 4.1 p-10 -161.62 149.24 14.8 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.977 -0.556 . . . . 1.0 110.829 178.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 68.9 p -156.15 149.44 24.51 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.61 -0.723 . . . . 1.0 111.108 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.521 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 46.1 m -155.98 -42.0 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.602 -0.726 . . . . 1.0 110.967 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.413 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 1.8 pp20? -63.18 -26.95 69.04 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.492 -0.483 . . . . 1.0 109.742 179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.7 mmtp -54.37 -43.15 71.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.699 -1.223 . . . . 1.0 107.699 178.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 28.5 p -76.3 -34.85 59.06 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.096 -1.411 . . . . 1.0 109.102 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.6 15.5 70.78 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.357 -0.838 . . . . 1.0 111.144 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -97.97 115.27 65.77 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 120.402 -0.519 . . . . 1.0 110.872 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.408 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 33.8 Cg_exo -59.83 153.24 58.11 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 C-N-CA 122.022 1.814 . . . . 1.0 114.114 -178.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.97 150.73 46.36 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.059 -1.428 . . . . 1.0 108.069 178.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.29 129.65 55.7 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.014 0.746 . . . . 1.0 113.014 -178.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.512 ' CE1' ' C4 ' ' A' ' 138' ' ' RAP . 36.0 m-85 -140.98 153.02 45.4 Favored 'General case' 0 CA--C 1.502 -0.88 0 CA-C-N 114.678 -1.146 . . . . 1.0 108.795 177.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.5 mt-30 -90.44 127.18 36.14 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 106.359 -1.719 . . . . 1.0 106.359 174.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 22.4 t -46.79 -34.45 2.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 C-N-CA 120.351 -0.539 . . . . 1.0 110.471 -178.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -73.56 -24.34 60.09 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 120.467 -0.493 . . . . 1.0 112.323 -178.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.524 ' OE1' H242 ' A' ' 138' ' ' RAP . 82.8 mm-40 -100.13 -12.0 20.0 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 113.618 0.969 . . . . 1.0 113.618 -177.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 83' ' ' ILE . 5.4 p -84.44 177.93 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 119.656 -0.818 . . . . 1.0 110.455 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.65 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -54.95 146.51 37.76 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 120.728 -0.389 . . . . 1.0 110.595 -177.198 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -51.54 -44.55 43.2 Favored 'Trans proline' 0 N--CA 1.499 1.817 0 C-N-CA 121.896 1.73 . . . . 1.0 112.527 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.48 -47.4 90.06 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.549 -1.42 . . . . 1.0 109.549 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.724 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 6.1 m95 -63.83 -36.06 82.68 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.287 -0.956 . . . . 1.0 110.04 179.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 21.2 m -52.23 -52.95 49.35 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.674 -0.411 . . . . 1.0 110.904 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 30.2 tp10 -72.32 -45.35 60.34 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.891 -0.595 . . . . 1.0 112.444 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.34 -48.46 76.72 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 113.925 1.083 . . . . 1.0 113.925 -177.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 32.7 mt -57.93 -42.66 85.31 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-O 121.084 0.469 . . . . 1.0 109.959 -177.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -62.65 -23.27 67.01 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 115.615 -0.721 . . . . 1.0 110.289 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 90.6 mt -101.79 -14.4 17.31 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.876 -0.602 . . . . 1.0 111.266 -179.131 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.2 ttp -88.98 108.18 22.25 Favored Pre-proline 0 CA--C 1.547 0.833 0 N-CA-C 111.991 0.367 . . . . 1.0 111.991 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.606 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 21.2 Cg_exo -66.06 148.08 85.07 Favored 'Trans proline' 0 N--CA 1.499 1.842 0 C-N-CA 122.438 2.092 . . . . 1.0 112.162 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.595 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.96 137.53 58.05 Favored 'General case' 0 CA--C 1.507 -0.695 0 CA-C-O 121.493 0.663 . . . . 1.0 111.331 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.16 -18.57 55.91 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 108.252 -1.939 . . . . 1.0 108.252 -178.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.4 p -89.39 128.41 35.92 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 121.263 0.554 . . . . 1.0 110.735 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 89.9 m -103.56 114.24 28.36 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-N 115.392 -0.822 . . . . 1.0 109.944 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.483 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.6 m0 -116.04 164.9 13.77 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 121.442 0.639 . . . . 1.0 110.882 -179.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.63 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.8 mt-10 -123.59 129.14 50.71 Favored 'General case' 0 CA--C 1.509 -0.625 0 N-CA-C 106.394 -1.706 . . . . 1.0 106.394 175.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.5 pt -125.93 138.9 53.07 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.665 0 CA-C-O 121.926 0.869 . . . . 1.0 110.376 -179.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.749 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -109.27 104.12 13.2 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.928 -1.878 . . . . 1.0 105.928 -178.16 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 10.6 t -90.4 115.95 65.28 Favored Pre-proline 0 C--N 1.326 -0.415 0 N-CA-C 114.879 1.437 . . . . 1.0 114.879 -174.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -51.21 143.49 32.86 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 121.276 1.317 . . . . 1.0 110.021 175.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 92.4 p -49.26 -35.17 16.99 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.426 -0.51 . . . . 1.0 110.423 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.0 81.51 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 111.174 -0.77 . . . . 1.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 63.1 mt -101.25 3.24 40.67 Favored 'General case' 0 C--O 1.225 -0.189 0 CA-C-O 119.771 -0.157 . . . . 1.0 110.872 -179.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.23 -112.33 0.29 Allowed 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.487 0.184 . . . . 1.0 110.554 -178.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.626 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 68.1 m-85 -98.32 4.85 48.66 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 113.405 0.891 . . . . 1.0 113.405 -178.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 115.14 162.97 13.87 Favored Glycine 0 N--CA 1.47 0.911 0 C-N-CA 120.996 -0.621 . . . . 1.0 112.969 177.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.531 ' O ' ' N ' ' A' ' 121' ' ' ASN . 96.3 Cg_endo -76.16 -9.4 19.15 Favored 'Trans proline' 0 N--CA 1.494 1.554 0 C-N-CA 123.626 2.884 . . . . 1.0 111.0 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -109.19 168.9 9.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.498 -0.774 . . . . 1.0 109.446 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.1 m -73.86 96.37 2.58 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.18 -0.674 . . . . 1.0 109.18 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.0 t -111.91 60.25 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-N 116.244 -0.434 . . . . 1.0 110.444 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 169.55 172.46 36.19 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.35 -0.7 . . . . 1.0 111.35 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -52.59 -103.19 0.01 OUTLIER Glycine 0 CA--C 1.535 1.337 0 N-CA-C 111.226 -0.75 . . . . 1.0 111.226 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -58.04 -11.42 10.03 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.754 2.303 . . . . 1.0 111.628 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.591 HD11 ' CG ' ' A' ' 65' ' ' PHE . 14.9 mm -66.96 125.55 24.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-N 114.716 -1.129 . . . . 1.0 109.138 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -102.63 -175.86 27.12 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.321 -0.854 . . . . 1.0 111.249 -179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.562 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 21.6 Cg_endo -62.38 142.23 90.09 Favored 'Trans proline' 0 C--N 1.295 -2.25 0 C-N-CA 122.384 2.056 . . . . 1.0 111.756 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.531 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 45.79 55.39 6.93 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 120.796 -0.362 . . . . 1.0 111.103 178.11 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.521 ' OE2' ' ND2' ' A' ' 8' ' ' ASN . 3.3 tp10 -102.34 130.03 48.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.987 -0.552 . . . . 1.0 111.412 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.426 HG21 HD11 ' A' ' 16' ' ' LEU . 46.4 m -95.36 129.79 42.38 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.007 -1.109 . . . . 1.0 108.007 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.449 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.64 148.8 33.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.423 0.63 . . . . 1.0 111.114 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.749 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -124.58 149.29 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.041 -0.981 . . . . 1.0 108.485 178.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.6 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -140.52 149.82 42.94 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 120.479 -0.488 . . . . 1.0 111.522 178.033 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 13.9 mmtt -99.42 127.07 45.44 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 104.768 -2.308 . . . . 1.0 104.768 176.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.4 mt -121.18 121.13 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 119.259 -0.976 . . . . 1.0 112.138 -177.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.418 ' O ' ' HB ' ' A' ' 53' ' ' VAL . 9.1 t-160 -113.75 120.71 41.73 Favored 'General case' 0 C--O 1.223 -0.327 0 CA-C-N 114.157 -1.383 . . . . 1.0 108.612 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.35 111.89 23.63 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 120.014 -0.675 . . . . 1.0 112.519 -178.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.466 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -94.14 -45.14 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-N 116.222 -0.444 . . . . 1.0 111.12 179.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -150.74 155.58 39.58 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.85 0.357 . . . . 1.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.424 HG21 ' HA ' ' A' ' 44' ' ' LYS . 46.7 t -128.7 139.09 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.285 -0.416 . . . . 1.0 111.326 -178.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.415 ' HB3' ' HB ' ' A' ' 50' ' ' THR . 9.6 tptm -95.74 -150.16 0.32 Allowed 'General case' 0 N--CA 1.452 -0.358 0 CA-C-O 121.599 0.714 . . . . 1.0 110.057 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.41 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.1 OUTLIER -173.41 143.42 1.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.849 -1.069 . . . . 1.0 110.865 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.409 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 15.3 t -113.25 -49.18 2.92 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.511 -1.222 . . . . 1.0 109.977 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 117.943 -1.027 . . . . 1.0 110.351 -179.633 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.724 ' H41' ' CZ3' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.842 -0.799 . . . . 1.0 108.842 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.477 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 69.7 m-80 -65.64 -31.15 72.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.949 -0.569 . . . . 1.0 111.233 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.45 -41.91 9.92 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.305 -0.407 . . . . 1.0 111.054 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 5.2 tmtt? -71.8 -38.83 70.18 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 121.994 0.902 . . . . 1.0 109.772 179.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -50.67 -33.86 24.21 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 114.889 -1.05 . . . . 1.0 110.538 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.63 -38.13 89.06 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.153 -0.93 . . . . 1.0 111.144 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -67.02 -48.83 67.17 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.785 0.803 . . . . 1.0 110.54 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.608 ' ND2' ' OE1' ' A' ' 122' ' ' GLU . 12.9 m-20 -61.49 -35.33 77.36 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.004 -1.11 . . . . 1.0 108.004 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.405 ' O ' ' N ' ' A' ' 13' ' ' GLU . 55.6 tttt -66.76 -51.02 60.68 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.385 -1.734 . . . . 1.0 111.571 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.8 t -66.87 -48.85 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.276 0 C-N-CA 119.979 -0.688 . . . . 1.0 111.393 -178.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.445 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -62.84 -38.64 91.59 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.639 -1.245 . . . . 1.0 107.639 179.034 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.492 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -69.54 -42.77 71.51 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-N 114.868 -1.06 . . . . 1.0 111.875 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.405 ' N ' ' O ' ' A' ' 9' ' ' LYS . 33.8 mt-10 -62.67 -33.27 74.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 108.438 -0.949 . . . . 1.0 108.438 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.3 -34.25 59.05 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 114.791 -1.095 . . . . 1.0 109.798 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -61.89 -51.11 69.5 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 114.492 -1.231 . . . . 1.0 110.762 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -69.66 -40.18 76.6 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.061 -0.656 . . . . 1.0 109.733 178.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.441 ' O ' ' ND2' ' A' ' 21' ' ' ASN . 97.7 m -61.07 -42.06 97.78 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.505 -0.771 . . . . 1.0 109.13 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -75.74 -47.35 26.35 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.006 -0.997 . . . . 1.0 111.9 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.661 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 49.5 t30 -58.7 -45.4 89.6 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 113.019 0.748 . . . . 1.0 113.019 -177.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.5 -29.35 67.79 Favored 'General case' 0 C--N 1.315 -0.909 0 C-N-CA 119.303 -0.959 . . . . 1.0 109.154 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.441 ' ND2' ' O ' ' A' ' 17' ' ' THR . 7.4 m-80 -82.0 -29.69 31.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.372 -0.831 . . . . 1.0 111.591 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -59.74 146.08 81.92 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 120.48 -0.488 . . . . 1.0 111.371 -178.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.14 148.47 69.35 Favored 'Trans proline' 0 N--CA 1.504 2.094 0 C-N-CA 122.525 2.15 . . . . 1.0 113.791 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.89 -18.61 5.88 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.492 -0.776 . . . . 1.0 112.625 177.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.2 136.95 21.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.219 0.533 . . . . 1.0 111.286 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.4 t -121.66 126.03 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 N-CA-C 107.64 -1.244 . . . . 1.0 107.64 177.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.4 p -100.73 145.62 10.81 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 CA-C-O 121.828 0.823 . . . . 1.0 112.266 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 89.1 mt -112.31 166.17 11.52 Favored Pre-proline 0 CA--C 1.529 0.155 0 CA-C-N 114.1 -1.409 . . . . 1.0 111.357 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -61.87 -30.7 84.4 Favored 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.188 1.926 . . . . 1.0 111.358 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.1 m -68.52 -14.42 62.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.839 -0.618 . . . . 1.0 109.8 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.14 -0.96 66.94 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 109.593 -1.403 . . . . 1.0 109.593 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.449 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -81.21 133.39 35.44 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.511 -0.922 . . . . 1.0 108.511 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.449 ' H ' HD22 ' A' ' 32' ' ' LEU . 21.2 mp0 -120.94 143.38 49.01 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.91 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 30.1 p90 -138.2 143.86 40.4 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-O 121.712 0.767 . . . . 1.0 110.734 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.513 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.0 tmtp? -127.53 132.83 49.86 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-N 114.504 -1.225 . . . . 1.0 109.106 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 p -90.82 104.9 15.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 122.148 0.975 . . . . 1.0 111.86 -178.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.6 mm -70.09 -42.34 79.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.222 -0.899 . . . . 1.0 108.671 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.6 m-80 -140.27 128.04 21.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 114.619 -1.173 . . . . 1.0 109.627 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 p -88.57 127.22 35.54 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.736 -0.468 . . . . 1.0 109.736 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -117.36 -34.53 1.19 Allowed Glycine 0 C--N 1.332 0.329 0 N-CA-C 110.683 -0.967 . . . . 1.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.648 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.6 m120 56.02 32.01 19.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.99 0.424 . . . . 1.0 110.737 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.41 -161.0 36.84 Favored Glycine 0 C--N 1.333 0.37 0 CA-C-O 121.924 0.736 . . . . 1.0 111.769 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.596 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.3 m -69.69 -178.09 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 114.084 -1.058 . . . . 1.0 109.289 178.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.424 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 175.9 154.84 0.37 Allowed Pre-proline 0 C--N 1.32 -0.694 0 O-C-N 123.829 0.705 . . . . 1.0 109.549 179.387 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -87.15 156.17 8.3 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 123.091 2.528 . . . . 1.0 115.993 -175.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -88.29 175.12 44.22 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 108.778 -1.729 . . . . 1.0 108.778 176.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.558 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -52.68 -22.44 5.14 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 120.82 -0.352 . . . . 1.0 111.14 -179.402 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.8 m -107.41 -9.9 15.88 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.245 0.831 . . . . 1.0 113.245 -177.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -84.58 168.99 14.85 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 119.867 -0.733 . . . . 1.0 109.028 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.406 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 8.7 m -107.66 152.1 24.76 Favored 'General case' 0 CA--C 1.513 -0.466 0 N-CA-C 109.618 -0.512 . . . . 1.0 109.618 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -128.31 160.1 38.83 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.405 0 CA-C-N 115.741 -0.663 . . . . 1.0 112.285 -176.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 74' ' ' PRO . 85.9 m -126.3 120.19 29.3 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 107.729 -1.212 . . . . 1.0 107.729 177.482 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.609 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 27.0 m -148.98 163.32 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.404 0 N-CA-C 114.291 1.219 . . . . 1.0 114.291 -175.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -118.44 150.67 39.18 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 106.41 -1.7 . . . . 1.0 106.41 174.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.5 ' H ' ' HB ' ' A' ' 68' ' ' THR . 36.9 p90 -163.75 163.53 24.03 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 118.393 -1.323 . . . . 1.0 114.506 -177.567 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -125.11 130.05 51.44 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 115.261 -0.881 . . . . 1.0 108.848 175.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -112.38 136.56 13.6 Favored Glycine 0 N--CA 1.468 0.787 0 C-N-CA 121.005 -0.617 . . . . 1.0 111.602 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -148.72 166.88 27.07 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.674 0.749 . . . . 1.0 112.533 179.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -84.28 164.38 19.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 114.456 -1.247 . . . . 1.0 110.502 178.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.447 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.45 -24.88 32.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.918 -1.037 . . . . 1.0 110.528 178.149 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -94.67 4.5 53.76 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.052 -1.431 . . . . 1.0 111.566 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.95 -5.23 81.95 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.183 -0.532 . . . . 1.0 113.016 178.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.6 m -67.14 103.39 1.2 Allowed 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.569 -0.853 . . . . 1.0 110.067 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 90.4 t -74.93 125.99 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.853 0 C-N-CA 120.347 -0.541 . . . . 1.0 109.702 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.589 ' CD2' HD11 ' A' ' 118' ' ' ILE . 28.0 p90 -117.48 -10.81 10.59 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 114.993 -1.003 . . . . 1.0 111.471 -179.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.481 ' OD1' ' O4 ' ' A' ' 138' ' ' RAP . 32.7 t0 -157.41 150.76 23.79 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.401 -0.52 . . . . 1.0 111.65 179.261 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -159.59 151.79 20.89 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.632 -0.713 . . . . 1.0 111.817 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.5 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 96.3 m -151.25 -42.1 0.12 Allowed 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.342 -0.845 . . . . 1.0 110.183 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.45 ' C ' ' OE1' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -62.09 -27.93 69.26 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-N 116.018 -0.537 . . . . 1.0 109.672 179.379 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -56.73 -43.3 80.5 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 107.741 -1.207 . . . . 1.0 107.741 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -75.14 -33.4 61.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.632 -1.167 . . . . 1.0 107.974 176.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.12 18.39 67.28 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 115.639 -0.71 . . . . 1.0 111.957 178.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -101.18 115.87 64.61 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 120.882 -0.327 . . . . 1.0 110.629 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.448 ' HB3' HG22 ' A' ' 52' ' ' THR . 37.2 Cg_exo -60.61 152.5 68.23 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 121.754 1.636 . . . . 1.0 114.282 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -123.35 150.99 42.97 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.094 -1.412 . . . . 1.0 107.926 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.99 125.31 50.84 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.589 0.588 . . . . 1.0 112.589 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.556 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 35.3 m-85 -132.93 147.8 52.29 Favored 'General case' 0 CA--C 1.502 -0.892 0 CA-C-N 115.367 -0.833 . . . . 1.0 109.222 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -90.63 127.93 36.45 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.268 -1.752 . . . . 1.0 106.268 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 23.1 t -52.75 -33.5 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.169 0 C-N-CA 119.6 -0.84 . . . . 1.0 110.149 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 3.3 t -74.06 -26.66 60.52 Favored 'General case' 0 CA--C 1.515 -0.401 0 C-N-CA 120.21 -0.596 . . . . 1.0 111.651 -178.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.552 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 79.3 mm-40 -100.29 -3.76 30.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.312 -0.404 . . . . 1.0 111.873 -178.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.708 HG23 H31A ' A' ' 138' ' ' RAP . 1.0 OUTLIER -84.3 166.58 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 CA-C-N 118.233 0.469 . . . . 1.0 111.406 -178.943 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.411 ' CD1' H492 ' A' ' 138' ' ' RAP . 0.0 OUTLIER -52.8 147.28 15.94 Favored Pre-proline 0 N--CA 1.474 0.756 0 N-CA-C 109.093 -0.706 . . . . 1.0 109.093 -177.701 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -50.9 -43.55 46.59 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 C-N-CA 121.747 1.631 . . . . 1.0 112.701 -178.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.19 92.29 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 119.57 -1.3 . . . . 1.0 110.018 -179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.609 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 7.4 m95 -64.32 -35.91 82.41 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 114.369 -0.916 . . . . 1.0 110.398 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 25.1 m -51.0 -53.11 36.22 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.721 0.296 . . . . 1.0 111.67 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 20.5 tp10 -72.39 -41.62 66.11 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.738 0.644 . . . . 1.0 112.738 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.66 -45.45 91.98 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 114.036 1.125 . . . . 1.0 114.036 -177.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.04 -41.91 88.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.263 0.554 . . . . 1.0 109.761 -177.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.0 mt-30 -64.66 -24.61 67.64 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.705 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.496 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 59.8 mt -101.9 -10.67 19.62 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.182 -179.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 42.7 ttp -91.78 107.39 22.08 Favored Pre-proline 0 CA--C 1.546 0.789 0 O-C-N 123.154 0.283 . . . . 1.0 111.639 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.424 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 16.9 Cg_exo -66.93 147.69 80.8 Favored 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.508 2.139 . . . . 1.0 111.98 178.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.596 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.59 139.55 58.78 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-O 121.686 0.755 . . . . 1.0 111.429 -179.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.78 -18.76 54.81 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 108.123 -1.991 . . . . 1.0 108.123 -178.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.4 p -89.88 129.6 36.22 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 121.037 0.446 . . . . 1.0 110.621 179.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 85.1 m -103.44 114.22 28.33 Favored 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 115.659 -0.701 . . . . 1.0 109.855 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.496 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -115.98 161.94 18.11 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.742 0.782 . . . . 1.0 111.487 -178.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 85.4 mt-10 -121.57 125.61 47.16 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.162 -1.421 . . . . 1.0 107.162 175.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.3 pt -120.9 138.03 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.564 0 CA-C-O 121.8 0.81 . . . . 1.0 109.838 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.724 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.0 103.4 12.42 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -177.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.7 t -90.27 116.25 65.94 Favored Pre-proline 0 C--N 1.326 -0.427 0 N-CA-C 115.022 1.49 . . . . 1.0 115.022 -174.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_exo -51.39 142.58 37.44 Favored 'Trans proline' 0 C--N 1.315 -1.191 0 C-N-CA 121.361 1.374 . . . . 1.0 109.81 176.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 97.6 p -48.61 -35.28 13.25 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.31 -0.556 . . . . 1.0 111.185 -178.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.75 -32.77 82.22 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.153 -0.779 . . . . 1.0 111.153 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 47.5 mt -98.46 2.49 47.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.957 -0.121 . . . . 1.0 110.91 -179.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -108.45 -110.77 0.31 Allowed 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 112.029 0.381 . . . . 1.0 112.029 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.742 ' CE2' H491 ' A' ' 138' ' ' RAP . 44.4 m-85 -96.88 4.31 51.7 Favored 'General case' 0 C--N 1.342 0.249 0 N-CA-C 112.288 0.477 . . . . 1.0 112.288 -177.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.11 162.87 17.93 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 121.172 -0.537 . . . . 1.0 112.831 177.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 121' ' ' ASN . 83.3 Cg_endo -76.9 -10.23 18.17 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 123.423 2.749 . . . . 1.0 111.4 179.229 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 5.9 ttm-85 -105.15 168.45 9.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.252 -0.885 . . . . 1.0 109.51 -179.545 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.518 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -74.18 100.04 3.56 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.3 -0.629 . . . . 1.0 109.3 178.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.439 HG21 ' O ' ' A' ' 109' ' ' TYR . 14.0 t -110.9 61.11 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.76 0.314 . . . . 1.0 110.831 -179.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 159.15 175.73 30.41 Favored Glycine 0 CA--C 1.527 0.79 0 C-N-CA 120.472 -0.87 . . . . 1.0 112.44 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -49.42 -103.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.328 0 CA-C-N 114.963 -0.619 . . . . 1.0 111.87 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -61.87 -16.95 52.62 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 122.613 2.208 . . . . 1.0 111.773 -177.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.691 HD12 ' H ' ' A' ' 118' ' ' ILE . 5.3 mp -67.4 114.56 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 108.343 -0.984 . . . . 1.0 108.343 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.416 ' O ' ' OE2' ' A' ' 122' ' ' GLU . . . -93.98 -171.02 38.53 Favored Glycine 0 N--CA 1.452 -0.258 0 N-CA-C 110.949 -0.86 . . . . 1.0 110.949 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.518 ' N ' ' OG ' ' A' ' 113' ' ' SER . 34.1 Cg_endo -64.01 139.55 67.97 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.318 2.012 . . . . 1.0 112.627 179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.529 ' N ' ' O ' ' A' ' 111' ' ' PRO . 17.1 t-20 52.59 48.85 21.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.439 -0.346 . . . . 1.0 111.371 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.608 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 0.1 OUTLIER -93.14 132.58 37.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.541 -0.3 . . . . 1.0 110.716 179.843 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.422 HG21 HD11 ' A' ' 16' ' ' LEU . 52.1 m -96.2 127.77 42.5 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.405 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.5 mm? -111.28 145.33 38.97 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.128 0.489 . . . . 1.0 110.468 -179.162 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.724 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.4 tt -122.63 146.14 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 CA-C-N 115.476 -0.783 . . . . 1.0 108.937 178.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.622 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 1.6 m-85 -136.33 149.65 48.49 Favored 'General case' 0 CA--C 1.517 -0.319 0 C-N-CA 120.26 -0.576 . . . . 1.0 111.509 178.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 12.6 mmtt -99.5 123.57 43.89 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 105.423 -2.065 . . . . 1.0 105.423 177.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.7 mt -118.94 118.1 56.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 119.112 -1.035 . . . . 1.0 112.879 -176.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -108.65 126.22 52.73 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 113.572 -1.649 . . . . 1.0 108.278 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -96.3 111.3 23.42 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 119.871 -0.732 . . . . 1.0 112.271 -178.124 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.2 mp -93.71 -45.93 13.76 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.852 -0.613 . . . . 1.0 111.676 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.6 p -150.84 156.03 40.41 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 120.575 -0.45 . . . . 1.0 110.84 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.402 HG21 ' HA ' ' A' ' 44' ' ' LYS . 56.9 t -128.0 141.45 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.969 -0.559 . . . . 1.0 111.395 -178.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.458 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 9.2 tptm -100.13 -147.86 0.35 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.638 -0.71 . . . . 1.0 110.33 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.458 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER -164.47 143.15 7.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 114.72 -1.127 . . . . 1.0 110.477 178.016 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.401 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 96.1 p -59.48 -33.3 71.14 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.803 -1.09 . . . . 1.0 111.232 -179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 34.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.384 -179.751 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.742 H491 ' CE2' ' A' ' 109' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 65.7 t80 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 108.963 -0.754 . . . . 1.0 108.963 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.566 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 76.7 m-20 -69.47 -24.32 63.77 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.637 -0.425 . . . . 1.0 110.722 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.466 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 63.3 pttt -47.56 -40.82 20.04 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 109.283 -0.636 . . . . 1.0 109.283 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.466 ' N ' ' HG3' ' A' ' 3' ' ' LYS . 5.9 tmtm? -64.16 -37.05 86.05 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.221 -0.899 . . . . 1.0 109.274 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.566 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -51.4 -35.95 41.34 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-N 115.048 -0.978 . . . . 1.0 110.799 -179.63 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.46 -37.38 87.06 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.241 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -66.15 -53.1 41.78 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.687 0.756 . . . . 1.0 110.419 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.4 m-20 -58.02 -34.01 69.57 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.501 -0.926 . . . . 1.0 108.501 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -66.21 -51.08 61.1 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.406 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 79.0 t -65.99 -48.22 82.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 119.942 -0.703 . . . . 1.0 111.614 -178.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.453 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.8 -38.95 92.74 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.785 -1.191 . . . . 1.0 107.785 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.413 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.08 -46.27 52.11 Favored Glycine 0 CA--C 1.523 0.575 0 CA-C-N 114.779 -1.101 . . . . 1.0 112.631 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -59.53 -34.97 73.32 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.288 -0.965 . . . . 1.0 108.492 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.58 -36.14 65.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.94 -1.027 . . . . 1.0 110.401 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -61.31 -50.4 73.12 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.879 -1.055 . . . . 1.0 110.628 -179.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.416 HD11 HG21 ' A' ' 123' ' ' THR . 5.7 mp -67.1 -39.81 86.78 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 119.783 -0.767 . . . . 1.0 109.461 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.9 m -61.86 -42.16 98.71 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.743 -0.662 . . . . 1.0 109.657 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -75.24 -45.46 39.98 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.661 -0.699 . . . . 1.0 111.845 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.647 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 52.8 t30 -61.65 -44.65 96.57 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 113.18 0.807 . . . . 1.0 113.18 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -59.74 -34.9 73.55 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.27 -0.972 . . . . 1.0 108.578 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -71.51 -36.29 71.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.158 -0.928 . . . . 1.0 111.991 178.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 mtmt -55.78 135.66 72.24 Favored Pre-proline 0 CA--C 1.546 0.808 0 CA-C-N 116.412 -0.358 . . . . 1.0 111.588 -178.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -56.76 148.37 66.33 Favored 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.202 1.935 . . . . 1.0 113.627 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 85.06 -19.71 20.4 Favored Glycine 0 C--O 1.226 -0.394 0 CA-C-N 115.136 -0.938 . . . . 1.0 111.004 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' LYS . 47.5 t -85.17 136.0 23.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.161 0.505 . . . . 1.0 110.155 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 74.3 t -120.07 121.46 65.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 107.767 -1.197 . . . . 1.0 107.767 178.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 p -95.93 145.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.643 0 CA-C-O 121.648 0.737 . . . . 1.0 111.703 -177.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 88.8 mt -112.55 164.15 16.06 Favored Pre-proline 0 C--N 1.334 -0.106 0 CA-C-N 114.455 -1.248 . . . . 1.0 110.437 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.57 -30.81 86.6 Favored 'Trans proline' 0 C--N 1.318 -1.059 0 C-N-CA 121.634 1.556 . . . . 1.0 111.339 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 m -69.33 -10.73 59.23 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.925 -0.579 . . . . 1.0 109.912 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.35 -2.8 71.5 Favored Glycine 0 CA--C 1.519 0.315 0 N-CA-C 110.232 -1.147 . . . . 1.0 110.232 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.482 HD22 ' H ' ' A' ' 33' ' ' GLN . 2.7 tm? -79.17 133.27 36.72 Favored 'General case' 0 CA--C 1.519 -0.237 0 N-CA-C 108.628 -0.879 . . . . 1.0 108.628 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.482 ' H ' HD22 ' A' ' 32' ' ' LEU . 17.4 mp0 -122.8 139.54 53.89 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.395 -0.366 . . . . 1.0 110.983 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -135.5 143.13 45.63 Favored 'General case' 0 CA--C 1.506 -0.738 0 CA-C-O 121.675 0.75 . . . . 1.0 110.913 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.534 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.2 tmtp? -126.58 132.9 51.19 Favored 'General case' 0 CA--C 1.503 -0.86 0 CA-C-N 114.645 -1.161 . . . . 1.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -89.78 104.66 15.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-O 122.167 0.984 . . . . 1.0 111.906 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.621 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.5 mm -69.58 -41.86 80.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 N-CA-C 108.007 -1.108 . . . . 1.0 108.007 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -142.36 129.64 21.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.573 -1.194 . . . . 1.0 109.804 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.7 p -88.49 131.35 34.93 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.764 -0.458 . . . . 1.0 109.764 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.0 -33.25 1.08 Allowed Glycine 0 C--N 1.331 0.291 0 N-CA-C 110.051 -1.219 . . . . 1.0 110.051 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.66 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.3 m120 54.7 30.93 14.33 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.375 -0.413 . . . . 1.0 110.958 179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.31 -162.3 37.85 Favored Glycine 0 C--N 1.331 0.281 0 CA-C-O 121.905 0.725 . . . . 1.0 111.957 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.601 ' O ' ' N ' ' A' ' 95' ' ' ALA . 21.5 m -68.81 -178.63 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 113.905 -1.148 . . . . 1.0 109.125 178.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.674 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.49 154.77 0.4 Allowed Pre-proline 0 C--N 1.321 -0.631 0 O-C-N 123.705 0.628 . . . . 1.0 109.948 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.404 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 57.0 Cg_endo -87.33 154.43 8.0 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 123.439 2.759 . . . . 1.0 116.971 -174.486 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.45 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.55 177.2 48.47 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 109.141 -1.584 . . . . 1.0 109.141 175.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.504 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -53.37 -25.43 15.43 Favored 'General case' 0 C--N 1.314 -0.965 0 C-N-CA 120.963 -0.295 . . . . 1.0 111.507 -179.722 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.6 m -108.03 -5.11 17.23 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.815 0.672 . . . . 1.0 112.815 -176.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.45 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 66.6 m-20 -83.49 165.36 19.2 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.863 -0.791 . . . . 1.0 108.863 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 13.4 m -106.52 150.31 26.25 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 109.636 -0.505 . . . . 1.0 109.636 179.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.9 p -129.39 162.94 35.9 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.465 0 CA-C-N 116.126 -0.488 . . . . 1.0 111.982 -176.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 51' ' ' VAL . 98.5 m -130.15 119.63 23.3 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 108.52 -0.918 . . . . 1.0 108.52 177.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.501 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 4.7 m -148.18 165.17 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 114.885 1.439 . . . . 1.0 114.885 -177.006 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.416 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 4.2 mt-10 -118.89 145.07 46.02 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 106.568 -1.642 . . . . 1.0 106.568 174.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.568 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 38.8 p90 -161.11 164.07 30.94 Favored 'General case' 0 C--N 1.344 0.357 0 N-CA-C 114.825 1.417 . . . . 1.0 114.825 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.4 m -127.13 127.86 45.26 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 115.158 -0.928 . . . . 1.0 108.792 175.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.8 134.1 11.61 Favored Glycine 0 N--CA 1.473 1.114 0 C-N-CA 120.933 -0.651 . . . . 1.0 111.92 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 58' ' ' ARG . 7.7 ptp85 -147.86 170.31 17.92 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.866 0.841 . . . . 1.0 113.071 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -83.58 164.08 19.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 114.126 -1.397 . . . . 1.0 110.795 178.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.449 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.3 -25.86 35.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.017 -0.992 . . . . 1.0 110.769 178.329 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -95.25 6.01 50.18 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.564 -1.198 . . . . 1.0 111.857 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.39 -3.46 75.69 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 121.01 -0.614 . . . . 1.0 113.313 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 m -71.78 106.58 4.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 118.157 0.978 . . . . 1.0 110.228 179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 54.5 t -76.33 130.41 36.25 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.232 0.539 . . . . 1.0 110.575 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -120.37 -14.45 8.73 Favored 'General case' 0 CA--C 1.522 -0.112 0 CA-C-N 115.11 -0.95 . . . . 1.0 111.208 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 67' ' ' SER . 30.4 t0 -155.38 151.83 28.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.379 -0.373 . . . . 1.0 111.098 178.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.474 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 87.8 p -160.84 154.61 22.41 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 112.723 0.638 . . . . 1.0 112.723 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.525 ' N ' ' O ' ' A' ' 55' ' ' TYR . 85.3 m -155.3 -42.01 0.08 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.526 -0.761 . . . . 1.0 111.143 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.405 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 2.0 pp20? -61.32 -26.19 67.63 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.602 -0.439 . . . . 1.0 110.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -53.83 -42.73 68.8 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.212 -1.033 . . . . 1.0 108.212 178.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.423 ' OG1' ' O ' ' A' ' 68' ' ' THR . 21.6 p -78.36 -30.61 48.08 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 114.957 -1.019 . . . . 1.0 108.956 177.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.75 17.16 73.56 Favored Glycine 0 C--N 1.337 0.593 0 N-CA-C 111.363 -0.695 . . . . 1.0 111.363 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 7.2 mptt -99.89 115.94 65.12 Favored Pre-proline 0 N--CA 1.469 0.492 0 C-N-CA 120.987 -0.285 . . . . 1.0 110.498 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.416 ' N ' ' HG2' ' A' ' 54' ' ' GLU . 37.2 Cg_exo -61.13 152.49 71.33 Favored 'Trans proline' 0 N--CA 1.483 0.867 0 C-N-CA 121.646 1.564 . . . . 1.0 113.964 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -124.31 149.53 46.44 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.335 -1.302 . . . . 1.0 107.612 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -103.58 131.76 50.43 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.226 0.536 . . . . 1.0 112.219 -178.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.516 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 20.3 m-85 -137.71 150.05 47.0 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 115.29 -0.868 . . . . 1.0 110.482 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -93.47 124.65 37.6 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.162 -1.792 . . . . 1.0 106.162 174.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.4 t -51.46 -27.1 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 C-N-CA 119.778 -0.769 . . . . 1.0 110.608 -176.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 42.4 t -76.32 -24.58 54.31 Favored 'General case' 0 CA--C 1.519 -0.224 0 C-N-CA 120.344 -0.542 . . . . 1.0 112.287 -179.159 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.46 ' OE1' ' C46' ' A' ' 138' ' ' RAP . 88.4 mm-40 -98.56 -8.27 26.8 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 112.233 0.457 . . . . 1.0 112.233 -178.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.731 ' CG2' H31A ' A' ' 138' ' ' RAP . 1.4 p -83.08 168.8 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 C-N-CA 119.961 -0.696 . . . . 1.0 111.852 -177.512 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.508 HG12 ' O2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -55.19 153.32 13.05 Favored Pre-proline 0 CA--C 1.548 0.867 0 N-CA-C 109.433 -0.58 . . . . 1.0 109.433 -177.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.483 ' HD2' HG22 ' A' ' 83' ' ' ILE . 50.8 Cg_exo -53.28 -45.65 39.5 Favored 'Trans proline' 0 N--CA 1.496 1.66 0 C-N-CA 121.633 1.556 . . . . 1.0 112.948 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.11 -48.09 85.16 Favored Glycine 0 N--CA 1.451 -0.343 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.706 ' CZ3' ' H42' ' A' ' 138' ' ' RAP . 8.1 m95 -64.07 -35.74 81.74 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.101 -1.05 . . . . 1.0 110.108 179.267 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.4 m -52.17 -54.0 36.2 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.649 -0.42 . . . . 1.0 111.294 -178.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -72.71 -42.73 63.87 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.976 -0.557 . . . . 1.0 112.338 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.57 -47.36 79.69 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 113.848 1.055 . . . . 1.0 113.848 -177.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 60.2 mt -58.25 -41.76 84.9 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.365 0.603 . . . . 1.0 109.799 -178.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.5 mt-30 -63.24 -24.78 68.02 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.952 -1.022 . . . . 1.0 110.904 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.42 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 70.1 mt -101.65 -13.27 17.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.252 -0.431 . . . . 1.0 111.29 -179.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 36.5 ttp -88.04 108.99 24.31 Favored Pre-proline 0 CA--C 1.547 0.847 0 N-CA-C 112.249 0.463 . . . . 1.0 112.249 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.674 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.8 Cg_exo -66.37 147.77 83.33 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.274 1.983 . . . . 1.0 112.289 178.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.601 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -63.78 136.85 57.75 Favored 'General case' 0 CA--C 1.509 -0.627 0 CA-C-O 121.492 0.663 . . . . 1.0 111.503 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.08 -18.48 56.06 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 109.001 -1.64 . . . . 1.0 109.001 -178.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 6.9 p -86.99 133.67 33.56 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 120.894 0.378 . . . . 1.0 110.165 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 84.4 m -106.06 112.96 26.22 Favored 'General case' 0 CA--C 1.511 -0.557 0 CA-C-N 115.986 -0.552 . . . . 1.0 109.938 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.42 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 41.3 m0 -115.1 163.75 15.18 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.677 0.751 . . . . 1.0 111.544 -178.53 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.621 ' CD ' HD11 ' A' ' 37' ' ' ILE . 87.1 mt-10 -124.02 124.56 42.82 Favored 'General case' 0 CA--C 1.51 -0.566 0 N-CA-C 107.101 -1.444 . . . . 1.0 107.101 175.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 pt -119.0 137.84 51.66 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.866 0.841 . . . . 1.0 110.086 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.714 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -109.84 103.42 12.21 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 105.707 -1.96 . . . . 1.0 105.707 -178.303 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 6.8 t -90.63 116.12 65.7 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 115.529 1.678 . . . . 1.0 115.529 -174.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -50.75 143.32 29.77 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 121.611 1.54 . . . . 1.0 110.23 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 79.9 p -49.76 -35.43 22.39 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.282 -0.567 . . . . 1.0 110.524 -178.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.02 -32.39 82.37 Favored Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.985 -0.846 . . . . 1.0 110.985 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 42.9 mt -100.87 2.64 41.17 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.877 -0.162 . . . . 1.0 110.898 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 83' ' ' ILE . . . -107.37 -104.53 0.34 Allowed 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 117.693 0.224 . . . . 1.0 110.511 -178.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.617 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 53.5 m-85 -104.99 5.39 32.61 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 113.564 0.95 . . . . 1.0 113.564 -178.24 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 108.54 164.68 20.88 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.924 -0.655 . . . . 1.0 113.506 176.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.475 ' O ' ' N ' ' A' ' 121' ' ' ASN . 89.9 Cg_endo -75.11 -14.75 20.8 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 C-N-CA 123.618 2.878 . . . . 1.0 111.404 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.441 ' O ' HG23 ' A' ' 114' ' ' VAL . 58.1 mtm180 -101.28 165.98 11.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.115 -0.948 . . . . 1.0 109.586 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.448 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 1.7 m -75.21 97.71 3.58 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 120.411 -0.516 . . . . 1.0 109.844 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 112' ' ' ARG . 3.2 t -110.34 59.0 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.858 -179.181 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 167.81 -178.29 41.73 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 120.117 -1.04 . . . . 1.0 112.247 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -58.35 -106.4 0.01 OUTLIER Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.972 -0.451 . . . . 1.0 111.972 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -61.78 -14.87 38.9 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 122.028 1.819 . . . . 1.0 111.011 -178.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.895 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -67.03 115.89 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 107.922 -1.14 . . . . 1.0 107.922 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.598 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -93.88 -160.72 34.98 Favored Glycine 0 C--O 1.215 -1.047 0 N-CA-C 110.398 -1.081 . . . . 1.0 110.398 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.566 ' HB2' ' HB2' ' A' ' 5' ' ' ALA . 74.2 Cg_endo -73.35 145.39 38.29 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 122.112 1.874 . . . . 1.0 112.756 178.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 111' ' ' PRO . 1.1 t30 45.24 59.92 3.28 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.782 0.66 . . . . 1.0 112.782 177.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.688 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -115.06 138.44 50.88 Favored 'General case' 0 N--CA 1.473 0.702 0 CA-C-O 121.62 0.724 . . . . 1.0 111.185 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.416 HG21 HD11 ' A' ' 16' ' ' LEU . 97.5 m -94.57 129.53 41.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.658 -1.155 . . . . 1.0 108.71 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.416 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.8 mm? -111.96 143.57 42.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.248 0.547 . . . . 1.0 110.076 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.714 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.2 tt -122.44 148.15 26.25 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 108.659 -0.867 . . . . 1.0 108.659 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.606 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.3 OUTLIER -138.34 150.94 47.08 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.051 0.453 . . . . 1.0 111.166 177.435 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 7.5 mmtt -100.25 123.33 44.35 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 105.721 -1.955 . . . . 1.0 105.721 177.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.423 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.8 119.0 58.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 C-N-CA 119.143 -1.023 . . . . 1.0 113.056 -176.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.403 ' CE1' HG13 ' A' ' 131' ' ' ILE . 10.1 t-160 -109.96 123.25 49.3 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 113.885 -1.507 . . . . 1.0 108.682 178.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.49 111.29 23.22 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 120.346 -0.542 . . . . 1.0 112.186 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.447 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -93.46 -44.69 13.8 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 CA-C-N 115.484 -0.78 . . . . 1.0 111.33 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 5.4 p -152.12 156.55 40.08 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.068 0.461 . . . . 1.0 111.03 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.439 HG21 ' HA ' ' A' ' 44' ' ' LYS . 49.1 t -129.82 134.71 62.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.969 -0.56 . . . . 1.0 110.446 -178.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.449 ' HG3' ' N ' ' A' ' 135' ' ' LYS . 16.9 tptm -72.77 -82.86 0.05 OUTLIER 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 122.011 0.91 . . . . 1.0 110.452 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.467 ' HD2' ' N ' ' A' ' 136' ' ' SER . 0.0 OUTLIER 88.31 124.69 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 113.609 -1.632 . . . . 1.0 111.705 179.216 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.467 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 3.4 t -122.89 -43.48 2.24 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 113.963 -1.472 . . . . 1.0 111.099 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 48.1 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.044 -0.979 . . . . 1.0 110.547 -178.71 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.907 ' O11' H471 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 73.1 t80 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.181 -0.674 . . . . 1.0 109.181 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 17.0 m-20 -66.79 -26.79 67.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.003 -0.544 . . . . 1.0 110.391 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.457 ' HG3' ' N ' ' A' ' 4' ' ' LYS . 59.4 pttt -46.13 -41.78 12.89 Favored 'General case' 0 C--O 1.224 -0.283 0 C-N-CA 120.356 -0.538 . . . . 1.0 110.396 -178.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.562 ' HZ3' ' CG ' ' A' ' 8' ' ' ASN . 5.6 tmtt? -62.29 -41.21 98.31 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 120.167 -0.613 . . . . 1.0 109.358 -178.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.416 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -54.57 -36.36 64.29 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 115.713 -0.676 . . . . 1.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 71.3 m-20 -67.9 -37.21 81.44 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.399 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 35.4 mt-10 -65.77 -52.57 49.9 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-O 121.929 0.871 . . . . 1.0 110.29 -179.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.562 ' CG ' ' HZ3' ' A' ' 4' ' ' LYS . 9.6 m-20 -57.28 -35.75 70.16 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 114.549 -1.205 . . . . 1.0 108.462 179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 tttm -65.96 -51.9 54.36 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 113.651 -1.613 . . . . 1.0 111.602 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.5 t -69.96 -48.41 63.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 C-N-CA 119.881 -0.728 . . . . 1.0 112.162 -178.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.448 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -62.18 -39.77 93.79 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 108.113 -1.069 . . . . 1.0 108.113 179.56 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.12 -45.14 73.53 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-N 115.148 -0.933 . . . . 1.0 111.913 179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.419 ' O ' ' OG1' ' A' ' 17' ' ' THR . 88.9 mt-10 -61.35 -31.6 71.48 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.974 -0.75 . . . . 1.0 108.974 178.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.12 -34.08 50.2 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.223 -0.899 . . . . 1.0 110.135 179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -63.12 -50.45 70.42 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.388 -1.278 . . . . 1.0 110.774 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.466 HD11 HG21 ' A' ' 123' ' ' THR . 5.8 mp -73.41 -39.73 64.83 Favored 'General case' 0 CA--C 1.509 -0.618 0 C-N-CA 119.912 -0.715 . . . . 1.0 110.225 178.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.419 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 91.1 m -62.0 -42.84 99.59 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.347 -179.243 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -75.85 -46.79 28.46 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.859 -0.609 . . . . 1.0 112.243 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 59.8 t30 -60.89 -44.63 96.83 Favored 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 113.573 0.953 . . . . 1.0 113.573 -177.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 20.0 ptmt -59.2 -35.08 72.96 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 119.706 -0.798 . . . . 1.0 109.7 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -73.75 -33.99 64.53 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.295 -0.866 . . . . 1.0 111.221 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -60.37 125.51 82.07 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-N 115.956 -0.565 . . . . 1.0 112.066 -178.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.27 149.92 15.64 Favored 'Trans proline' 0 N--CA 1.5 1.854 0 C-N-CA 122.168 1.912 . . . . 1.0 112.847 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.77 -20.14 33.53 Favored Glycine 0 C--O 1.224 -0.523 0 N-CA-C 109.958 -1.257 . . . . 1.0 109.958 -179.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 35' ' ' LYS . 48.9 t -93.36 133.01 35.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.614 -0.513 . . . . 1.0 109.614 179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.1 t -117.41 120.83 66.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 108.528 -0.916 . . . . 1.0 108.528 177.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.406 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.1 p -96.34 146.08 7.78 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.623 0 CA-C-O 121.676 0.75 . . . . 1.0 111.393 -178.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 62.5 mt -113.56 164.22 16.42 Favored Pre-proline 0 C--N 1.332 -0.167 0 CA-C-N 114.438 -1.255 . . . . 1.0 110.958 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -59.07 -30.35 93.04 Favored 'Trans proline' 0 C--N 1.319 -0.982 0 C-N-CA 121.894 1.73 . . . . 1.0 110.913 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.5 m -67.93 -15.17 63.49 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-N 115.505 -0.77 . . . . 1.0 109.785 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.66 68.57 Favored Glycine 0 C--O 1.23 -0.139 0 N-CA-C 110.089 -1.205 . . . . 1.0 110.089 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.474 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.74 133.97 38.18 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 109.056 -0.72 . . . . 1.0 109.056 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.474 ' H ' HD22 ' A' ' 32' ' ' LEU . 24.0 mp0 -123.12 137.77 54.83 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-N 116.205 -0.452 . . . . 1.0 111.1 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -133.73 143.16 48.31 Favored 'General case' 0 CA--C 1.504 -0.797 0 CA-C-O 121.739 0.78 . . . . 1.0 110.927 178.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.517 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -126.96 131.84 50.97 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 114.432 -1.258 . . . . 1.0 109.562 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 p -88.39 105.12 15.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 122.045 0.926 . . . . 1.0 111.922 -178.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.633 HD11 ' CD ' ' A' ' 100' ' ' GLU . 16.1 mm -69.44 -42.34 80.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.036 -0.984 . . . . 1.0 108.447 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.442 HD22 ' HB ' ' A' ' 98' ' ' THR . 23.0 m-80 -141.96 127.19 18.61 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.524 -1.216 . . . . 1.0 109.72 -179.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -86.73 130.96 34.27 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.803 0.335 . . . . 1.0 110.399 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.528 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -121.33 -36.01 0.77 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 109.914 -1.275 . . . . 1.0 109.914 179.597 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.64 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.4 m120 58.48 32.81 22.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 1.0 111.593 179.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.9 -161.67 37.58 Favored Glycine 0 C--N 1.331 0.255 0 CA-C-O 121.861 0.7 . . . . 1.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' O ' ' N ' ' A' ' 95' ' ' ALA . 26.4 m -69.6 -178.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.07 -1.065 . . . . 1.0 109.494 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.719 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 177.47 154.43 0.45 Allowed Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 109.61 -0.515 . . . . 1.0 109.61 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.401 ' HB2' ' HB2' ' A' ' 49' ' ' ASP . 60.1 Cg_endo -88.02 157.47 7.18 Favored 'Trans proline' 0 N--CA 1.503 2.077 0 C-N-CA 123.72 2.946 . . . . 1.0 117.454 -174.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.443 ' N ' ' HB2' ' A' ' 49' ' ' ASP . . . -86.45 177.6 48.75 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 109.725 -1.35 . . . . 1.0 109.725 175.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.478 ' HE2' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -55.05 -25.54 31.42 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.216 -0.492 . . . . 1.0 111.904 -179.612 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.7 m -108.94 -4.84 16.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.551 0.574 . . . . 1.0 112.551 -177.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.443 ' HB2' ' N ' ' A' ' 46' ' ' GLY . 89.5 m-20 -82.18 169.56 16.46 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 109.046 -0.724 . . . . 1.0 109.046 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.6 m -111.4 151.46 28.47 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 109.699 -0.482 . . . . 1.0 109.699 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.444 HG11 HD13 ' A' ' 90' ' ' LEU . 5.4 p -129.96 162.56 37.46 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 CA-C-N 115.754 -0.657 . . . . 1.0 111.716 -176.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 73.6 m -129.67 120.16 24.72 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 108.288 -1.004 . . . . 1.0 108.288 177.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.57 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 12.5 m -149.06 164.86 4.05 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 N-CA-C 114.379 1.252 . . . . 1.0 114.379 -176.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.411 ' HG2' ' N ' ' A' ' 74' ' ' PRO . 2.6 mt-10 -118.72 146.26 44.88 Favored 'General case' 0 N--CA 1.486 1.352 0 N-CA-C 106.056 -1.831 . . . . 1.0 106.056 174.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.613 ' CE2' ' H52' ' A' ' 138' ' ' RAP . 41.1 p90 -162.98 164.61 25.63 Favored 'General case' 0 C--N 1.342 0.275 0 N-CA-C 114.971 1.471 . . . . 1.0 114.971 -176.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.2 m -125.97 130.45 51.24 Favored 'General case' 0 C--O 1.216 -0.679 0 CA-C-N 114.892 -1.049 . . . . 1.0 108.706 175.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -114.48 132.86 10.72 Favored Glycine 0 N--CA 1.473 1.113 0 N-CA-C 111.356 -0.698 . . . . 1.0 111.356 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.7 ptp180 -147.06 167.54 23.82 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.788 0.804 . . . . 1.0 112.658 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.6 mp -81.9 164.83 21.28 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 114.252 -1.34 . . . . 1.0 110.274 178.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.425 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.82 -26.27 37.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 114.794 -1.094 . . . . 1.0 110.243 178.173 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.415 ' O ' ' OD2' ' A' ' 61' ' ' ASP . 7.0 t70 -94.04 5.26 52.27 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.019 -1.446 . . . . 1.0 111.919 -176.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.56 -4.53 79.7 Favored Glycine 0 CA--C 1.528 0.883 0 C-N-CA 121.0 -0.619 . . . . 1.0 113.227 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.9 m -70.29 103.88 2.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 118.073 0.937 . . . . 1.0 110.028 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.7 t -75.55 128.3 37.18 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.727 0 C-N-CA 120.642 -0.423 . . . . 1.0 110.059 179.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.761 ' CD2' HD11 ' A' ' 118' ' ' ILE . 9.2 p90 -116.08 -10.34 11.55 Favored 'General case' 0 CA--C 1.521 -0.165 0 CA-C-N 115.439 -0.8 . . . . 1.0 111.116 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -164.24 153.32 13.55 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.443 -0.503 . . . . 1.0 111.677 177.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 83.7 p -159.41 158.08 31.46 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 115.763 -0.653 . . . . 1.0 111.869 179.214 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.508 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 67.2 m -152.78 -40.61 0.1 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.358 -0.837 . . . . 1.0 110.254 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.435 ' OE1' ' OG1' ' A' ' 56' ' ' THR . 1.3 pp20? -59.86 -27.59 66.8 Favored 'General case' 0 CA--C 1.512 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.373 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.2 mmmm -55.45 -40.23 71.33 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.641 -1.244 . . . . 1.0 107.641 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.8 -34.94 57.92 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.029 -1.442 . . . . 1.0 108.642 178.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.54 17.87 69.9 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 110.69 -0.964 . . . . 1.0 110.69 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -105.07 116.26 60.94 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 121.155 -0.218 . . . . 1.0 110.754 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 53' ' ' VAL . 32.3 Cg_exo -60.36 149.93 83.31 Favored 'Trans proline' 0 N--CA 1.479 0.67 0 C-N-CA 121.255 1.303 . . . . 1.0 113.358 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -122.83 151.27 41.85 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 114.483 -1.235 . . . . 1.0 108.204 178.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.1 t -106.41 127.44 53.29 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 113.13 0.789 . . . . 1.0 113.13 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.479 ' CZ ' ' H62' ' A' ' 138' ' ' RAP . 54.6 m-85 -133.97 150.02 51.26 Favored 'General case' 0 CA--C 1.499 -1.015 0 CA-C-N 115.148 -0.933 . . . . 1.0 108.973 177.087 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 21.2 mt-30 -90.38 125.05 35.41 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 106.353 -1.721 . . . . 1.0 106.353 174.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.431 HG11 HE21 ' A' ' 91' ' ' GLN . 25.5 t -48.48 -30.43 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 C-N-CA 120.06 -0.656 . . . . 1.0 110.199 -177.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.9 t -75.13 -25.12 58.17 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.27 -0.572 . . . . 1.0 111.681 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.504 ' HB3' ' H30' ' A' ' 138' ' ' RAP . 94.4 mm-40 -98.87 -8.2 26.08 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 113.518 0.933 . . . . 1.0 113.518 -177.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.685 ' HA ' H482 ' A' ' 138' ' ' RAP . 3.9 p -88.22 170.49 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 118.907 0.776 . . . . 1.0 111.974 -178.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.537 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -52.98 148.51 13.85 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 120.256 -0.578 . . . . 1.0 109.623 -176.684 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.75 -44.34 41.48 Favored 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 122.25 1.967 . . . . 1.0 113.143 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.63 -47.43 90.19 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.818 -1.313 . . . . 1.0 109.818 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.682 ' CZ3' ' H41' ' A' ' 138' ' ' RAP . 9.2 m95 -63.79 -36.97 85.63 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.747 -1.227 . . . . 1.0 110.128 178.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 20.9 m -50.89 -54.19 26.1 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 116.258 -0.428 . . . . 1.0 111.041 -177.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 29.0 tp10 -72.84 -42.6 63.58 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.541 0.571 . . . . 1.0 112.541 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -56.52 -47.21 79.83 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 113.552 0.945 . . . . 1.0 113.552 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.444 HD13 HG11 ' A' ' 51' ' ' VAL . 79.3 mt -57.84 -41.28 82.01 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.406 0.622 . . . . 1.0 109.995 -178.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.431 HE21 HG11 ' A' ' 79' ' ' VAL . 67.9 mt-30 -64.57 -23.74 67.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.26 -0.882 . . . . 1.0 111.126 -179.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 55.8 mt -105.3 -12.23 16.15 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.505 -0.316 . . . . 1.0 111.075 -179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 17.6 ttm -88.77 108.4 23.08 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 116.014 -0.539 . . . . 1.0 111.925 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.719 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 20.2 Cg_exo -65.54 149.14 87.9 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.853 2.369 . . . . 1.0 113.318 179.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.591 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.86 133.43 51.88 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-N 115.591 -0.731 . . . . 1.0 111.359 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 93.4 -19.06 54.8 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 109.67 -1.372 . . . . 1.0 109.67 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.528 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 23.8 t -84.08 125.96 32.62 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.967 0.413 . . . . 1.0 109.946 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.442 ' HB ' HD22 ' A' ' 38' ' ' ASN . 44.1 m -96.94 111.86 23.88 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 116.151 -0.477 . . . . 1.0 110.044 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.431 ' NE1' ' OG ' ' A' ' 97' ' ' SER . 39.8 m0 -114.95 164.47 14.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.863 0.84 . . . . 1.0 111.476 -178.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.633 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.6 mt-10 -125.81 126.52 44.65 Favored 'General case' 0 CA--C 1.508 -0.636 0 N-CA-C 106.582 -1.636 . . . . 1.0 106.582 175.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 3.0 pt -120.4 137.15 55.13 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.607 0 CA-C-O 121.767 0.794 . . . . 1.0 109.792 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.676 ' CG ' ' ND2' ' A' ' 19' ' ' ASN . 0.2 OUTLIER -108.35 103.27 12.39 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 105.77 -1.937 . . . . 1.0 105.77 -178.13 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.95 115.09 63.57 Favored Pre-proline 0 C--N 1.325 -0.463 0 N-CA-C 114.969 1.47 . . . . 1.0 114.969 -174.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -51.32 144.53 30.45 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.121 1.214 . . . . 1.0 109.768 175.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 89.4 p -49.0 -36.67 18.21 Favored 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 120.653 -0.419 . . . . 1.0 110.961 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -66.18 -32.29 81.8 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.377 -0.689 . . . . 1.0 111.377 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 59.1 mt -98.58 2.07 47.06 Favored 'General case' 0 N--CA 1.466 0.332 0 O-C-N 122.926 -0.161 . . . . 1.0 110.645 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.495 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.37 -111.26 0.31 Allowed 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 110.035 -0.358 . . . . 1.0 110.035 -179.276 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.598 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 52.3 m-85 -98.88 4.21 47.42 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 112.327 0.492 . . . . 1.0 112.327 -178.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 110.85 157.9 15.36 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 121.387 -0.435 . . . . 1.0 112.592 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.445 ' O ' ' N ' ' A' ' 121' ' ' ASN . 88.4 Cg_endo -74.12 -11.72 23.28 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 123.506 2.804 . . . . 1.0 110.562 179.222 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . 0.437 ' O ' HG23 ' A' ' 114' ' ' VAL . 70.2 ttt180 -100.85 165.12 11.51 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.8 -1.091 . . . . 1.0 108.946 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.51 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.1 m -72.28 97.17 1.95 Allowed 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 119.989 -0.684 . . . . 1.0 109.173 178.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 112' ' ' ARG . 4.4 t -112.08 60.9 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 121.049 -0.261 . . . . 1.0 111.322 -179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 163.19 169.39 26.56 Favored Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.333 -0.937 . . . . 1.0 111.94 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -48.21 -103.47 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 111.191 -0.764 . . . . 1.0 111.191 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -60.81 -19.39 61.44 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 122.46 2.107 . . . . 1.0 111.608 -178.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.761 HD11 ' CD2' ' A' ' 65' ' ' PHE . 5.4 mp -68.05 118.7 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 107.54 -1.282 . . . . 1.0 107.54 178.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 122' ' ' GLU . . . -101.31 -168.0 27.87 Favored Glycine 0 CA--C 1.523 0.563 0 CA-C-N 115.225 -0.898 . . . . 1.0 113.796 -176.591 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 19.5 Cg_endo -63.6 144.71 90.48 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.859 2.373 . . . . 1.0 112.289 178.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.445 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.1 OUTLIER 43.25 50.93 5.84 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.717 0.294 . . . . 1.0 111.004 179.108 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.545 ' OE1' ' ND2' ' A' ' 8' ' ' ASN . 3.9 tp10 -106.15 127.51 53.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.623 0.725 . . . . 1.0 112.627 -177.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.466 HG21 HD11 ' A' ' 16' ' ' LEU . 25.7 m -95.61 135.24 37.54 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 114.649 -1.16 . . . . 1.0 108.52 178.205 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 124' ' ' LEU . 2.0 mm? -115.32 142.16 47.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 121.232 0.539 . . . . 1.0 110.862 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.53 HD12 ' CE2' ' A' ' 102' ' ' TYR . 1.5 tt -120.84 149.37 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 115.468 -0.787 . . . . 1.0 108.951 178.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.581 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.4 OUTLIER -139.62 149.84 44.26 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.507 -0.477 . . . . 1.0 111.046 177.019 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.482 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.9 mmtt -100.5 122.35 43.08 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 105.577 -2.008 . . . . 1.0 105.577 178.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.458 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.2 mt -119.18 119.37 60.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 C-N-CA 119.311 -0.956 . . . . 1.0 113.564 -175.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . 0.42 ' ND1' HD11 ' A' ' 131' ' ' ILE . 10.4 t-160 -108.53 122.58 47.34 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 113.912 -1.495 . . . . 1.0 108.451 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.7 110.58 22.69 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.173 0.511 . . . . 1.0 111.64 -178.483 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.451 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.1 mp -93.69 -46.86 13.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.212 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 8.3 p -150.99 158.45 44.15 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.237 0.542 . . . . 1.0 111.188 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.44 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -129.05 141.99 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 115.492 -0.776 . . . . 1.0 110.001 -178.015 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.452 ' O ' ' CB ' ' A' ' 135' ' ' LYS . 12.3 tptm -84.6 -83.98 0.15 Allowed 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.45 0.643 . . . . 1.0 111.929 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.452 ' CB ' ' O ' ' A' ' 134' ' ' LYS . 1.5 tmtt? 94.78 128.0 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 113.99 -1.459 . . . . 1.0 110.342 -178.367 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.429 ' H ' ' HD3' ' A' ' 135' ' ' LYS . 28.8 t -72.54 35.46 0.07 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 113.719 -1.582 . . . . 1.0 111.795 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.415 ' H ' ' C ' ' A' ' 135' ' ' LYS . 13.9 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.861 -1.066 . . . . 1.0 110.435 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.816 H491 H381 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 110.431 -0.211 . . . . 1.0 110.431 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -64.36 -30.87 71.91 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 119.941 -0.704 . . . . 1.0 110.51 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.9 ttpt -51.23 -43.52 61.47 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.098 -0.641 . . . . 1.0 110.095 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.495 ' HZ2' HD21 ' A' ' 8' ' ' ASN . 6.4 tmtt? -68.81 -43.23 76.01 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 108.776 -0.824 . . . . 1.0 108.776 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.15 -34.49 45.06 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 114.816 -1.084 . . . . 1.0 110.339 179.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.517 ' OD2' ' NZ ' ' A' ' 9' ' ' LYS . 60.6 m-20 -64.57 -40.2 95.13 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.406 -0.815 . . . . 1.0 110.163 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.4 ' O ' ' HD2' ' A' ' 11' ' ' LYS . 48.1 mt-10 -60.89 -54.74 41.36 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-O 121.571 0.7 . . . . 1.0 110.709 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.549 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 4.0 m-20 -59.6 -36.98 77.35 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.145 -1.057 . . . . 1.0 108.145 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.517 ' NZ ' ' OD2' ' A' ' 6' ' ' ASP . 4.3 ttpm? -66.74 -50.54 62.43 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 113.762 -1.563 . . . . 1.0 111.867 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.4 t -65.14 -48.67 82.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 119.614 -0.834 . . . . 1.0 110.993 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.462 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.83 -38.32 90.66 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.028 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.424 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.35 -46.97 46.22 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-N 115.094 -0.957 . . . . 1.0 112.199 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.431 ' O ' ' OG1' ' A' ' 17' ' ' THR . 91.9 mt-10 -57.69 -34.81 69.81 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 108.645 -0.872 . . . . 1.0 108.645 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.05 -31.01 44.38 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.853 -1.067 . . . . 1.0 110.364 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -61.68 -49.23 77.32 Favored 'General case' 0 CA--C 1.506 -0.745 0 CA-C-N 114.932 -1.031 . . . . 1.0 110.147 -179.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.424 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.2 mp -66.57 -38.23 86.63 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 119.69 -0.804 . . . . 1.0 109.304 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 13' ' ' GLU . 19.8 m -61.85 -42.97 99.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.549 0.69 . . . . 1.0 109.275 178.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -74.21 -44.29 53.8 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-N 115.334 -0.848 . . . . 1.0 111.609 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.676 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -56.83 -50.16 73.24 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.111 0.481 . . . . 1.0 111.883 -178.874 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 9.5 ptmt -60.01 -28.63 67.88 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.221 -0.992 . . . . 1.0 109.545 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -81.87 -29.57 32.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.33 -0.85 . . . . 1.0 111.442 179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 21.2 mtmt -58.95 136.35 87.52 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 120.848 -0.341 . . . . 1.0 111.177 -179.152 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -55.75 148.47 55.29 Favored 'Trans proline' 0 N--CA 1.506 2.234 0 C-N-CA 122.48 2.12 . . . . 1.0 114.179 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.76 -18.59 11.56 Favored Glycine 0 N--CA 1.462 0.428 0 CA-C-N 115.097 -0.956 . . . . 1.0 111.397 178.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 35' ' ' LYS . 41.4 t -85.08 136.27 23.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.04 0.448 . . . . 1.0 111.074 -179.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 77.5 t -120.47 122.62 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 N-CA-C 107.716 -1.216 . . . . 1.0 107.716 176.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.27 147.0 5.75 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-O 121.414 0.626 . . . . 1.0 111.812 -178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 54.6 mt -115.79 163.77 19.86 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 114.758 -1.11 . . . . 1.0 110.779 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.22 -31.91 93.67 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 C-N-CA 121.584 1.523 . . . . 1.0 111.974 -179.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.4 m -68.14 -12.23 60.54 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 109.294 -0.632 . . . . 1.0 109.294 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.0 -1.57 68.05 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 109.365 -1.494 . . . . 1.0 109.365 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.489 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.0 tm? -79.98 134.39 36.25 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.434 -0.95 . . . . 1.0 108.434 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.489 ' H ' HD22 ' A' ' 32' ' ' LEU . 13.0 mp0 -124.84 145.54 49.73 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-N 115.891 -0.595 . . . . 1.0 110.929 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -139.39 150.11 44.9 Favored 'General case' 0 CA--C 1.502 -0.89 0 CA-C-O 121.521 0.677 . . . . 1.0 110.733 178.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.5 ' CD ' HD13 ' A' ' 37' ' ' ILE . 2.1 tmtp? -135.13 134.94 40.73 Favored 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 114.563 -1.199 . . . . 1.0 109.119 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -92.33 103.75 14.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 122.211 1.005 . . . . 1.0 111.742 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.618 HD11 ' CD ' ' A' ' 100' ' ' GLU . 14.3 mm -69.02 -41.74 81.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.039 -0.982 . . . . 1.0 109.197 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.406 HD22 ' HB ' ' A' ' 98' ' ' THR . 16.0 m-80 -142.04 128.0 19.5 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 115.109 -0.95 . . . . 1.0 109.942 -178.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.9 p -87.55 124.46 33.51 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.858 0.361 . . . . 1.0 110.101 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.468 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.19 -32.77 2.1 Favored Glycine 0 CA--C 1.517 0.218 0 N-CA-C 109.539 -1.424 . . . . 1.0 109.539 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.619 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 56.49 32.43 20.75 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.3 -0.45 . . . . 1.0 110.995 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.75 -163.01 38.66 Favored Glycine 0 C--N 1.329 0.167 0 CA-C-O 121.977 0.765 . . . . 1.0 111.536 179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.602 ' O ' ' N ' ' A' ' 95' ' ' ALA . 29.2 m -69.43 -177.94 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.009 -1.095 . . . . 1.0 108.42 177.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.604 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.25 154.27 0.38 Allowed Pre-proline 0 C--N 1.316 -0.852 0 N-CA-C 109.096 -0.705 . . . . 1.0 109.096 179.6 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.486 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 70.3 Cg_endo -87.79 152.78 7.36 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.827 2.351 . . . . 1.0 115.265 -175.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.53 178.98 51.54 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.612 -1.795 . . . . 1.0 108.612 176.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.648 ' NZ ' ' H ' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -54.95 -21.48 11.86 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.445 -0.502 . . . . 1.0 110.847 -179.666 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.4 m -107.64 -11.03 15.52 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 113.587 0.958 . . . . 1.0 113.587 -177.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -85.69 166.1 16.42 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 119.632 -0.827 . . . . 1.0 109.331 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.469 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 4.8 m -103.79 151.01 23.57 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.23 0.538 . . . . 1.0 110.43 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.486 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.3 p -128.06 157.56 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.421 0 CA-C-N 115.278 -0.874 . . . . 1.0 112.343 -176.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.447 HG22 ' HB3' ' A' ' 74' ' ' PRO . 98.1 m -124.07 120.54 32.68 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 107.923 -1.14 . . . . 1.0 107.923 177.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.618 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 17.7 m -149.23 163.18 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 114.698 1.37 . . . . 1.0 114.698 -175.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -118.4 152.61 35.52 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 106.384 -1.71 . . . . 1.0 106.384 173.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.554 ' H ' ' HB ' ' A' ' 68' ' ' THR . 33.6 p90 -164.09 160.73 21.89 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.528 1.307 . . . . 1.0 114.528 -177.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -123.37 128.46 49.91 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.953 -0.758 . . . . 1.0 108.953 175.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.8 137.69 14.45 Favored Glycine 0 N--CA 1.467 0.716 0 C-N-CA 120.925 -0.655 . . . . 1.0 112.138 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -146.18 165.91 27.77 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-O 121.714 0.769 . . . . 1.0 112.574 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.2 mp -82.91 163.28 21.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 114.276 -1.329 . . . . 1.0 110.052 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.448 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -60.33 -26.2 36.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.155 -0.929 . . . . 1.0 110.276 178.08 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -93.82 7.76 43.69 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.376 -1.284 . . . . 1.0 111.78 -177.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.83 -7.27 81.46 Favored Glycine 0 CA--C 1.525 0.703 0 C-N-CA 121.241 -0.504 . . . . 1.0 113.31 178.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 m -68.19 105.79 2.22 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 119.444 -0.902 . . . . 1.0 110.565 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 99.2 t -76.84 118.98 24.34 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.82 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -106.34 -20.22 13.45 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 115.016 -0.993 . . . . 1.0 111.897 -178.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.466 ' OD1' ' O6 ' ' A' ' 138' ' ' RAP . 10.2 t70 -154.82 155.4 34.35 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.228 0.537 . . . . 1.0 111.972 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 92.9 p -157.4 159.8 37.75 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.341 -0.845 . . . . 1.0 111.57 178.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.554 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 89.9 m -155.25 -38.51 0.09 Allowed 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 115.567 -0.742 . . . . 1.0 110.01 -179.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -65.29 -25.37 67.61 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.638 -1.245 . . . . 1.0 107.638 178.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 24.6 mmtt -59.53 -45.63 91.2 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 176.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' A' ' 68' ' ' THR . 0.8 OUTLIER -73.05 -33.36 65.64 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.505 -1.225 . . . . 1.0 108.194 177.423 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.55 18.93 67.27 Favored Glycine 0 C--N 1.338 0.649 0 N-CA-C 111.497 -0.641 . . . . 1.0 111.497 178.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.9 115.37 60.4 Favored Pre-proline 0 N--CA 1.47 0.549 0 C-N-CA 120.936 -0.306 . . . . 1.0 110.919 -179.023 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.447 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.0 Cg_exo -59.9 151.26 72.75 Favored 'Trans proline' 0 N--CA 1.48 0.725 0 C-N-CA 121.826 1.684 . . . . 1.0 114.185 -179.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -120.68 148.63 43.67 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 113.915 -1.493 . . . . 1.0 107.498 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.15 124.57 49.89 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 121.335 0.588 . . . . 1.0 112.378 -178.245 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.575 ' HB3' H481 ' A' ' 138' ' ' RAP . 47.3 m-85 -133.32 149.34 51.9 Favored 'General case' 0 CA--C 1.493 -1.221 0 CA-C-N 115.286 -0.87 . . . . 1.0 109.707 178.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -90.75 130.36 36.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 105.09 -2.189 . . . . 1.0 105.09 174.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 87' ' ' THR . 38.2 t -57.23 -31.61 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 119.099 -1.04 . . . . 1.0 110.108 -176.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 1.1 t -73.67 -25.99 60.52 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 120.424 -0.51 . . . . 1.0 112.038 -178.27 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.514 ' CB ' ' H30' ' A' ' 138' ' ' RAP . 56.2 mm-40 -102.26 -6.64 22.91 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 112.959 0.726 . . . . 1.0 112.959 -177.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.669 HG23 H31A ' A' ' 138' ' ' RAP . 1.2 p -78.91 168.58 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 121.046 -0.262 . . . . 1.0 111.242 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.411 HG12 H492 ' A' ' 138' ' ' RAP . 0.0 OUTLIER -52.56 146.81 16.22 Favored Pre-proline 0 CA--C 1.535 0.395 0 N-CA-C 107.903 -1.147 . . . . 1.0 107.903 -178.133 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -50.53 -43.29 45.78 Favored 'Trans proline' 0 N--CA 1.496 1.62 0 C-N-CA 121.433 1.422 . . . . 1.0 112.648 -177.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.11 -47.34 91.25 Favored Glycine 0 C--N 1.317 -0.479 0 C-N-CA 119.747 -1.216 . . . . 1.0 110.946 -178.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.703 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 7.8 m95 -66.68 -32.3 73.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 113.973 -1.113 . . . . 1.0 110.748 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.46 HG23 ' O ' ' A' ' 79' ' ' VAL . 29.5 m -51.37 -54.48 26.06 Favored 'General case' 0 C--N 1.322 -0.603 0 O-C-N 122.029 -0.42 . . . . 1.0 111.812 -178.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -72.7 -40.27 66.33 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 113.535 0.939 . . . . 1.0 113.535 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -60.7 -44.06 97.0 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 114.432 1.271 . . . . 1.0 114.432 -176.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.4 mt -58.6 -41.56 86.11 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.147 0.499 . . . . 1.0 110.323 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -64.55 -23.89 67.42 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.368 -0.833 . . . . 1.0 110.401 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.524 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 88.6 mt -99.61 -14.84 18.81 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.964 -0.562 . . . . 1.0 111.718 -178.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 48.7 ttp -91.2 108.68 30.23 Favored Pre-proline 0 CA--C 1.548 0.892 0 O-C-N 123.224 0.327 . . . . 1.0 111.826 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.604 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 24.0 Cg_exo -63.79 149.1 91.51 Favored 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.586 2.191 . . . . 1.0 113.052 178.115 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.602 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -62.99 133.4 54.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.436 0.636 . . . . 1.0 110.76 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 92.61 -13.79 66.53 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 108.744 -1.742 . . . . 1.0 108.744 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.468 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 7.7 t -90.83 122.66 33.74 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.012 0.434 . . . . 1.0 109.839 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.406 ' HB ' HD22 ' A' ' 38' ' ' ASN . 63.8 m -97.07 115.07 26.82 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.402 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.524 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 31.7 m0 -115.76 167.95 10.48 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.657 0.741 . . . . 1.0 110.996 -178.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.618 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.5 mt-10 -128.44 134.74 48.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 106.453 -1.684 . . . . 1.0 106.453 175.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.414 HD13 HG21 ' A' ' 101' ' ' ILE . 3.5 pt -130.91 139.03 52.14 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.654 0 CA-C-O 121.724 0.773 . . . . 1.0 109.601 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.703 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.3 OUTLIER -109.39 102.9 11.76 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 105.995 -1.854 . . . . 1.0 105.995 -177.408 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 12.1 t -90.33 116.23 65.9 Favored Pre-proline 0 N--CA 1.453 -0.302 0 N-CA-C 115.093 1.516 . . . . 1.0 115.093 -174.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.33 143.56 26.26 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.519 1.479 . . . . 1.0 109.601 176.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.7 p -53.7 -27.97 31.16 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.411 -0.515 . . . . 1.0 110.929 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.61 -29.48 65.6 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 110.194 -1.163 . . . . 1.0 110.194 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.9 mt -101.03 2.28 40.34 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.301 -0.45 . . . . 1.0 111.173 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.533 ' O ' H521 ' A' ' 138' ' ' RAP . . . -110.43 -108.34 0.35 Allowed 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 111.852 0.316 . . . . 1.0 111.852 -178.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.631 ' CE2' H491 ' A' ' 138' ' ' RAP . 42.4 m-85 -99.24 3.39 46.26 Favored 'General case' 0 C--N 1.339 0.118 0 N-CA-C 112.136 0.421 . . . . 1.0 112.136 -178.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.03 163.98 22.13 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.23 -0.509 . . . . 1.0 112.396 178.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.551 ' O ' ' N ' ' A' ' 121' ' ' ASN . 84.9 Cg_endo -75.77 -11.55 20.1 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 123.404 2.736 . . . . 1.0 111.955 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 85.1 mtt85 -98.62 167.17 10.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.065 -0.516 . . . . 1.0 109.729 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.572 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 4.8 m -74.05 78.18 1.71 Allowed 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.301 -0.56 . . . . 1.0 109.842 178.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.1 t -93.68 60.44 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.084 -0.507 . . . . 1.0 109.949 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 170.59 177.09 40.42 Favored Glycine 0 CA--C 1.533 1.158 0 C-N-CA 120.224 -0.988 . . . . 1.0 112.295 -179.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -59.97 -106.74 0.01 OUTLIER Glycine 0 CA--C 1.536 1.39 0 N-CA-C 111.293 -0.723 . . . . 1.0 111.293 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.31 -13.72 17.47 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 C-N-CA 121.905 1.737 . . . . 1.0 110.522 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.865 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.5 mp -67.26 111.84 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 107.383 -1.34 . . . . 1.0 107.383 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.43 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -93.16 -167.1 38.54 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.473 -1.051 . . . . 1.0 110.473 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.572 ' N ' ' OG ' ' A' ' 113' ' ' SER . 29.5 Cg_endo -62.91 144.99 94.35 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.227 1.951 . . . . 1.0 112.7 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.551 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 47.33 56.78 6.5 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.221 0.452 . . . . 1.0 112.221 177.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.43 ' HG3' ' H ' ' A' ' 119' ' ' GLY . 52.1 mm-40 -103.1 128.47 50.0 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 112.308 0.484 . . . . 1.0 112.308 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 63.8 m -93.94 128.4 40.23 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.191 -1.411 . . . . 1.0 107.191 176.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.403 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.6 mm? -109.41 147.95 31.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 121.482 0.658 . . . . 1.0 111.156 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.703 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -126.79 144.21 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.64 0 N-CA-C 108.477 -0.935 . . . . 1.0 108.477 178.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.543 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.9 OUTLIER -135.0 151.95 51.28 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 120.499 -0.48 . . . . 1.0 111.305 177.81 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.479 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 5.7 mmtt -100.18 125.12 46.28 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.044 -2.206 . . . . 1.0 105.044 176.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.469 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.3 mt -118.61 118.49 58.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 119.153 -1.019 . . . . 1.0 112.331 -176.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -109.77 121.7 45.81 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 113.569 -1.65 . . . . 1.0 108.232 178.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -93.33 112.16 24.01 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 120.235 -0.586 . . . . 1.0 112.064 -178.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.0 mp -91.57 -47.1 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 115.68 -0.691 . . . . 1.0 110.974 179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 1.9 t -150.02 158.12 43.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.833 0.349 . . . . 1.0 111.013 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.449 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.9 t -130.26 136.91 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-N 116.192 -0.458 . . . . 1.0 111.609 -178.243 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.553 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 20.3 tptt -92.83 -148.4 0.24 Allowed 'General case' 0 CA--C 1.533 0.318 0 CA-C-O 121.661 0.743 . . . . 1.0 110.075 178.49 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.553 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -172.37 137.62 0.88 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 114.841 -1.072 . . . . 1.0 110.006 178.42 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.41 ' N ' ' HD2' ' A' ' 135' ' ' LYS . 6.5 t -95.85 -63.59 1.14 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.371 -0.831 . . . . 1.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 117.918 -1.039 . . . . 1.0 110.57 -179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.703 ' H51' ' CZ2' ' A' ' 86' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.819 -0.808 . . . . 1.0 108.819 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.417 ' O ' ' HB3' ' A' ' 5' ' ' ALA . 19.0 m120 -64.95 -37.23 86.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.271 -0.422 . . . . 1.0 110.788 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.66 -38.52 6.83 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.474 -0.491 . . . . 1.0 110.339 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 3.1 tmtt? -72.34 -40.54 67.32 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-O 121.49 0.662 . . . . 1.0 109.61 178.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 2' ' ' ASN . . . -51.51 -32.57 28.13 Favored 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 115.003 -0.998 . . . . 1.0 110.537 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -61.8 -39.79 92.96 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.537 -0.756 . . . . 1.0 110.109 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -62.2 -53.38 56.04 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 121.682 0.753 . . . . 1.0 110.593 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.567 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 7.0 m-20 -60.13 -34.44 73.53 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.223 -0.899 . . . . 1.0 108.599 179.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -66.93 -51.23 57.76 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.164 -1.38 . . . . 1.0 111.649 179.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 75.1 t -67.41 -46.83 82.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.082 -0.647 . . . . 1.0 111.887 -177.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.446 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.3 OUTLIER -63.67 -38.22 90.29 Favored 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 107.442 -1.318 . . . . 1.0 107.442 178.567 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.544 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -70.04 -44.35 61.37 Favored Glycine 0 CA--C 1.528 0.905 0 CA-C-N 114.845 -1.071 . . . . 1.0 112.44 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -61.98 -32.06 72.48 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 119.342 -0.943 . . . . 1.0 108.72 179.297 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -74.17 -35.3 64.01 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.133 -0.94 . . . . 1.0 109.682 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -63.83 -50.3 69.45 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.213 -179.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.544 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.5 mp -71.11 -37.87 72.36 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 109.178 -0.675 . . . . 1.0 109.178 178.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.2 m -62.03 -43.08 99.59 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.791 -0.641 . . . . 1.0 109.482 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -75.02 -45.78 39.52 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.655 -0.702 . . . . 1.0 112.154 -179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 46.0 t30 -61.62 -44.62 96.66 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 113.126 0.787 . . . . 1.0 113.126 -177.545 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.6 ptmt -59.68 -30.36 68.72 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 119.406 -0.917 . . . . 1.0 109.505 -179.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 26.2 m-80 -81.15 -29.49 34.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.667 -0.697 . . . . 1.0 111.782 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 18.7 mtmt -59.55 136.52 89.36 Favored Pre-proline 0 CA--C 1.545 0.774 0 C-N-CA 120.687 -0.405 . . . . 1.0 111.188 -178.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.75 147.49 60.61 Favored 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 121.719 1.612 . . . . 1.0 112.807 178.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.76 -20.23 25.14 Favored Glycine 0 C--O 1.225 -0.417 0 CA-C-N 115.27 -0.877 . . . . 1.0 111.486 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 35' ' ' LYS . 42.9 t -88.13 134.38 28.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.05 0.453 . . . . 1.0 110.751 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 83.8 t -118.67 122.26 69.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 108.062 -1.088 . . . . 1.0 108.062 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.428 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.3 p -94.79 146.06 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.721 0.772 . . . . 1.0 111.789 -178.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.6 mt -114.77 162.29 24.53 Favored Pre-proline 0 N--CA 1.465 0.316 0 CA-C-N 114.418 -1.264 . . . . 1.0 110.612 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.16 -30.92 94.39 Favored 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 121.681 1.588 . . . . 1.0 111.277 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 m -66.99 -15.04 63.47 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.509 -0.769 . . . . 1.0 109.389 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 94.28 -0.72 66.39 Favored Glycine 0 CA--C 1.51 -0.221 0 N-CA-C 109.432 -1.467 . . . . 1.0 109.432 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.468 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -80.56 134.21 35.89 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.355 -0.98 . . . . 1.0 108.355 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.468 ' H ' HD22 ' A' ' 32' ' ' LEU . 20.2 mp0 -122.82 138.8 54.54 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.965 -0.561 . . . . 1.0 110.564 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -133.54 147.16 51.56 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.878 0.847 . . . . 1.0 111.0 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.523 ' HD3' HD13 ' A' ' 37' ' ' ILE . 1.8 tmtp? -134.1 136.48 43.93 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-N 114.174 -1.375 . . . . 1.0 109.724 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 p -92.79 105.73 17.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 122.366 1.079 . . . . 1.0 111.589 -179.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.642 HD11 ' CD ' ' A' ' 100' ' ' GLU . 17.7 mm -70.54 -42.25 78.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.082 -0.963 . . . . 1.0 109.124 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.403 ' O ' ' OG ' ' A' ' 97' ' ' SER . 56.6 m-80 -143.07 124.48 14.72 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 113.998 -1.456 . . . . 1.0 109.09 -178.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.1 p -88.61 125.58 34.88 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.596 -0.52 . . . . 1.0 109.596 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.508 ' H ' ' HB2' ' A' ' 97' ' ' SER . . . -113.11 -33.76 1.93 Allowed Glycine 0 CA--C 1.516 0.129 0 N-CA-C 110.345 -1.102 . . . . 1.0 110.345 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.621 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.5 m120 57.98 32.97 22.68 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 123.679 0.281 . . . . 1.0 111.441 179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -91.37 -161.08 36.92 Favored Glycine 0 C--N 1.335 0.502 0 CA-C-O 121.763 0.646 . . . . 1.0 111.929 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.584 ' O ' ' N ' ' A' ' 95' ' ' ALA . 18.8 m -68.74 -179.75 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 114.309 -0.945 . . . . 1.0 109.025 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.626 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 178.0 155.84 0.52 Allowed Pre-proline 0 N--CA 1.476 0.831 0 CA-C-O 120.953 0.406 . . . . 1.0 110.886 179.234 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.431 ' HB2' ' HB3' ' A' ' 49' ' ' ASP . 32.6 Cg_endo -85.02 167.03 11.09 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 123.433 2.756 . . . . 1.0 117.521 -173.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.502 ' H ' ' CB ' ' A' ' 49' ' ' ASP . . . -102.91 165.62 16.29 Favored Glycine 0 C--N 1.337 0.611 0 CA-C-N 113.571 -1.649 . . . . 1.0 109.566 177.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.612 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -44.97 -25.86 0.36 Allowed 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.657 -0.771 . . . . 1.0 111.886 -179.636 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 66.5 m -108.32 -5.57 16.7 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 112.759 0.651 . . . . 1.0 112.759 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.706 ' OD2' ' N ' ' A' ' 50' ' ' THR . 66.4 t0 -82.29 169.08 16.93 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.151 0.501 . . . . 1.0 110.841 -179.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.706 ' N ' ' OD2' ' A' ' 49' ' ' ASP . 7.6 m -110.91 142.7 42.63 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.656 -0.868 . . . . 1.0 108.656 177.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 76' ' ' THR . 9.0 p -125.12 160.34 30.82 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.534 0 CA-C-N 114.994 -1.003 . . . . 1.0 112.252 -175.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.494 HG22 ' HB3' ' A' ' 74' ' ' PRO . 91.1 m -124.69 120.3 31.43 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.873 -0.788 . . . . 1.0 108.873 178.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.585 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 11.4 m -148.75 165.44 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 114.636 1.347 . . . . 1.0 114.636 -176.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -119.32 151.99 37.5 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 106.223 -1.769 . . . . 1.0 106.223 173.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.52 ' O ' ' N ' ' A' ' 68' ' ' THR . 33.6 p90 -164.96 164.83 20.6 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 118.425 -1.31 . . . . 1.0 113.973 -177.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 1.3 m -123.88 130.82 53.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 108.021 -1.103 . . . . 1.0 108.021 175.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.6 131.44 9.98 Favored Glycine 0 N--CA 1.47 0.917 0 N-CA-C 110.093 -1.203 . . . . 1.0 110.093 -179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.711 ' CZ ' ' HZ1' ' A' ' 127' ' ' LYS . 5.1 ptp180 -145.77 169.29 18.81 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 121.977 0.894 . . . . 1.0 112.762 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 2.7 mp -84.59 165.89 17.61 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 113.912 -1.495 . . . . 1.0 109.941 177.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.464 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -59.06 -25.62 30.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.069 -0.969 . . . . 1.0 111.431 178.889 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -100.22 10.17 41.65 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.134 -0.939 . . . . 1.0 112.026 -177.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.94 -6.62 81.81 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 120.403 -0.903 . . . . 1.0 113.771 178.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.7 m -65.18 102.02 0.6 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 118.727 1.263 . . . . 1.0 109.182 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 88.4 t -74.86 117.4 18.99 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.746 0 CA-C-O 121.408 0.623 . . . . 1.0 111.1 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CD2' HD11 ' A' ' 118' ' ' ILE . 27.4 p90 -103.76 -15.63 15.67 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 114.903 -1.044 . . . . 1.0 112.092 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.413 ' OD2' H432 ' A' ' 138' ' ' RAP . 0.2 OUTLIER -159.24 153.91 24.47 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.27 -0.572 . . . . 1.0 110.375 177.811 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.0 p -157.19 158.55 36.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.826 -0.625 . . . . 1.0 111.802 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.52 ' N ' ' O ' ' A' ' 55' ' ' TYR . 95.2 m -153.07 -43.89 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.171 -0.922 . . . . 1.0 109.799 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.437 ' C ' ' OE2' ' A' ' 69' ' ' GLU . 0.6 OUTLIER -61.07 -28.02 68.78 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-N 115.888 -0.597 . . . . 1.0 109.66 179.42 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt -57.24 -42.9 82.37 Favored 'General case' 0 N--CA 1.445 -0.71 0 N-CA-C 107.434 -1.321 . . . . 1.0 107.434 179.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.8 -33.47 60.13 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.299 -1.319 . . . . 1.0 107.558 176.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.02 17.75 73.87 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.314 -0.857 . . . . 1.0 112.118 178.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -98.13 116.35 65.61 Favored Pre-proline 0 N--CA 1.469 0.495 0 C-N-CA 121.265 -0.174 . . . . 1.0 110.557 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.494 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.4 Cg_exo -58.54 150.52 68.44 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 121.501 1.467 . . . . 1.0 114.204 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 53' ' ' VAL . . . -123.77 145.82 48.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.354 -1.293 . . . . 1.0 108.472 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 51' ' ' VAL . 1.3 t -103.8 131.3 51.12 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-O 121.453 0.644 . . . . 1.0 112.452 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.652 ' CE1' ' H52' ' A' ' 138' ' ' RAP . 36.0 m-85 -139.8 149.6 43.71 Favored 'General case' 0 CA--C 1.495 -1.148 0 CA-C-N 114.994 -1.003 . . . . 1.0 110.42 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -90.81 127.54 36.39 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 105.766 -1.938 . . . . 1.0 105.766 174.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.1 t -51.64 -29.2 9.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 C-N-CA 118.981 -1.088 . . . . 1.0 110.512 -176.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 48.3 t -77.68 -23.17 49.65 Favored 'General case' 0 CA--C 1.521 -0.171 0 C-N-CA 120.306 -0.558 . . . . 1.0 111.835 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.504 ' HB3' H513 ' A' ' 138' ' ' RAP . 97.3 mm-40 -98.56 -6.6 29.77 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 113.728 1.01 . . . . 1.0 113.728 -178.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.578 HG22 ' H32' ' A' ' 138' ' ' RAP . 4.6 p -87.59 172.36 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 119.775 -0.77 . . . . 1.0 110.924 -178.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.524 HD11 ' H2 ' ' A' ' 138' ' ' RAP . 0.0 OUTLIER -53.48 152.31 9.12 Favored Pre-proline 0 N--CA 1.478 0.954 0 N-CA-C 109.301 -0.629 . . . . 1.0 109.301 -176.956 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.466 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -52.26 -45.14 41.35 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.098 1.866 . . . . 1.0 112.061 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.77 -46.86 91.81 Favored Glycine 0 CA--C 1.522 0.512 0 C-N-CA 119.957 -1.116 . . . . 1.0 110.876 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.585 ' HZ3' HG21 ' A' ' 53' ' ' VAL . 9.1 m95 -64.58 -35.44 80.98 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.342 -0.929 . . . . 1.0 111.495 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 30.7 m -50.78 -55.29 17.48 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.55 -0.46 . . . . 1.0 112.14 -177.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -73.27 -40.42 64.6 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 112.365 0.506 . . . . 1.0 112.365 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -57.47 -45.76 84.45 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 114.154 1.168 . . . . 1.0 114.154 -178.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.1 mt -57.84 -41.59 82.66 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.197 0.522 . . . . 1.0 110.629 -177.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 72.9 mt-30 -65.43 -19.1 65.79 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.277 -0.874 . . . . 1.0 111.346 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.502 ' O ' ' CH2' ' A' ' 99' ' ' TRP . 57.5 mt -106.01 -13.4 15.48 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.116 -0.493 . . . . 1.0 110.7 -178.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 43.0 ttp -88.91 109.13 28.02 Favored Pre-proline 0 CA--C 1.553 1.063 0 N-CA-C 112.101 0.408 . . . . 1.0 112.101 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.626 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 22.3 Cg_exo -64.58 149.53 89.72 Favored 'Trans proline' 0 N--CA 1.504 2.11 0 C-N-CA 122.979 2.453 . . . . 1.0 113.296 178.346 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.584 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.33 132.58 50.58 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.495 0.664 . . . . 1.0 111.154 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 94.76 -18.21 57.65 Favored Glycine 0 N--CA 1.444 -0.796 0 N-CA-C 108.505 -1.838 . . . . 1.0 108.505 -178.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.508 ' HB2' ' H ' ' A' ' 40' ' ' GLY . 9.3 t -86.02 128.64 34.9 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 109.944 -0.391 . . . . 1.0 109.944 179.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 86.7 m -103.33 114.8 29.36 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 115.594 -0.73 . . . . 1.0 109.696 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . 0.502 ' CH2' ' O ' ' A' ' 92' ' ' LEU . 39.1 m0 -114.14 167.96 10.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.781 0.8 . . . . 1.0 111.336 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.642 ' CD ' HD11 ' A' ' 37' ' ' ILE . 80.7 mt-10 -128.46 124.5 36.33 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.171 -1.418 . . . . 1.0 107.171 175.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.435 HD13 HG21 ' A' ' 101' ' ' ILE . 3.6 pt -120.68 135.49 60.72 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.868 0 N-CA-C 108.735 -0.839 . . . . 1.0 108.735 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.72 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.1 OUTLIER -107.12 104.0 13.53 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.725 -1.954 . . . . 1.0 105.725 -177.258 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 3.3 t -90.51 115.53 64.36 Favored Pre-proline 0 C--N 1.32 -0.675 0 N-CA-C 115.256 1.576 . . . . 1.0 115.256 -173.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -51.35 146.03 25.91 Favored 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 121.941 1.761 . . . . 1.0 110.569 176.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 52.0 p -53.58 -24.51 13.95 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.086 -0.506 . . . . 1.0 111.456 -178.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -78.56 -29.5 52.31 Favored Glycine 0 N--CA 1.46 0.268 0 N-CA-C 110.697 -0.961 . . . . 1.0 110.697 179.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 29.2 mt -102.16 2.77 37.71 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.523 -0.338 . . . . 1.0 110.49 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.26 -102.43 0.35 Allowed 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 110.11 -0.33 . . . . 1.0 110.11 -178.102 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.641 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 47.6 m-85 -108.96 5.46 24.33 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.753 1.02 . . . . 1.0 113.753 -177.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 111.57 163.05 17.4 Favored Glycine 0 N--CA 1.473 1.128 0 C-N-CA 121.285 -0.483 . . . . 1.0 113.209 177.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.553 ' O ' ' N ' ' A' ' 121' ' ' ASN . 60.1 Cg_endo -71.13 -18.67 30.55 Favored 'Trans proline' 0 N--CA 1.494 1.527 0 C-N-CA 123.535 2.823 . . . . 1.0 112.37 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -104.01 171.56 7.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.229 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.465 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 2.0 m -73.64 97.28 2.63 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.926 -0.579 . . . . 1.0 110.171 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.6 t -109.55 61.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 116.596 -0.274 . . . . 1.0 110.873 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.502 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 168.36 -168.53 40.98 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 120.892 -0.671 . . . . 1.0 111.715 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.12 -104.9 0.04 OUTLIER Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.457 -0.657 . . . . 1.0 111.457 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -58.9 -19.05 45.5 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.237 1.958 . . . . 1.0 111.621 -178.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.613 HD12 ' H ' ' A' ' 118' ' ' ILE . 3.8 mp -66.56 112.83 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 C-N-CA 119.901 -0.72 . . . . 1.0 109.166 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.4 ' H ' ' HG3' ' A' ' 122' ' ' GLU . . . -90.65 -164.84 39.93 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.679 -0.968 . . . . 1.0 110.679 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.567 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 23.5 Cg_endo -63.22 152.05 81.74 Favored 'Trans proline' 0 N--CA 1.498 1.752 0 C-N-CA 122.359 2.039 . . . . 1.0 113.272 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.553 ' N ' ' O ' ' A' ' 111' ' ' PRO . 11.9 t30 37.17 53.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.68 -0.691 . . . . 1.0 111.807 177.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.423 ' OE1' ' CG ' ' A' ' 8' ' ' ASN . 41.7 mm-40 -97.36 132.29 43.22 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.29 0.567 . . . . 1.0 111.768 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.464 HG21 HD11 ' A' ' 16' ' ' LEU . 84.6 m -95.66 127.44 41.7 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.451 -1.314 . . . . 1.0 107.451 176.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 124' ' ' LEU . 1.7 mm? -112.82 140.79 47.31 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.338 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.72 HD12 ' CD2' ' A' ' 102' ' ' TYR . 2.2 tt -119.43 147.05 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 N-CA-C 108.435 -0.95 . . . . 1.0 108.435 178.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.626 ' N ' ' CD2' ' A' ' 126' ' ' PHE . 0.5 OUTLIER -134.4 145.53 49.01 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 121.12 0.486 . . . . 1.0 110.324 177.314 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.711 ' HZ1' ' CZ ' ' A' ' 58' ' ' ARG . 5.5 mmtt -99.61 121.83 41.76 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 104.673 -2.343 . . . . 1.0 104.673 178.394 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.411 HG23 ' CH2' ' A' ' 86' ' ' TRP . 3.5 mt -116.09 120.36 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 119.438 -0.905 . . . . 1.0 113.176 -175.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.4 t-160 -110.3 123.18 49.34 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 113.927 -1.488 . . . . 1.0 108.486 178.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.64 113.17 24.79 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 112.384 0.513 . . . . 1.0 112.384 -178.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -96.25 -46.98 13.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 115.775 -0.648 . . . . 1.0 111.301 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.95 155.86 42.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.168 0.509 . . . . 1.0 111.574 -178.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 44' ' ' LYS . 50.1 t -128.96 142.19 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 115.974 -0.557 . . . . 1.0 111.706 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.448 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 3.9 tptt -100.66 -152.09 0.42 Allowed 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 121.712 0.768 . . . . 1.0 110.765 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.448 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -174.89 134.65 0.36 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.487 -1.233 . . . . 1.0 110.985 178.928 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.534 ' OG ' ' N ' ' A' ' 137' ' ' SER . 0.0 OUTLIER -58.1 -72.13 0.1 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.013 -0.994 . . . . 1.0 110.405 179.605 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.534 ' N ' ' OG ' ' A' ' 136' ' ' SER . 33.6 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.184 -0.912 . . . . 1.0 110.877 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.893 ' O3 ' H492 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.598 ' CG ' ' N ' ' A' ' 2' ' ' ASN . 29.6 t80 . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 109.501 -0.555 . . . . 1.0 109.501 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.598 ' N ' ' CG ' ' A' ' 1' ' ' PHE . 49.8 m-20 -70.28 -17.52 63.1 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.425 -0.352 . . . . 1.0 111.208 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.489 ' CG ' ' N ' ' A' ' 4' ' ' LYS . 58.9 pttt -45.36 -43.2 10.77 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 120.382 -0.527 . . . . 1.0 110.47 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.489 ' N ' ' CG ' ' A' ' 3' ' ' LYS . 3.8 tmtt? -75.16 -42.53 55.85 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 122.058 0.932 . . . . 1.0 109.332 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.456 ' HB2' ' HB2' ' A' ' 120' ' ' PRO . . . -50.27 -31.08 13.25 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 114.411 -1.268 . . . . 1.0 110.001 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.433 ' HA ' ' HB3' ' A' ' 9' ' ' LYS . 95.3 m-20 -62.6 -38.71 91.24 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.17 -0.923 . . . . 1.0 110.251 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -63.48 -51.9 63.65 Favored 'General case' 0 C--O 1.222 -0.372 0 CA-C-O 121.428 0.633 . . . . 1.0 110.867 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 120' ' ' PRO . 2.3 m-20 -62.74 -35.76 80.83 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 108.094 -1.076 . . . . 1.0 108.094 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 13' ' ' GLU . 76.8 tttt -65.72 -49.45 68.42 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 113.42 -1.718 . . . . 1.0 112.095 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.0 t -66.36 -48.67 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 C-N-CA 119.79 -0.764 . . . . 1.0 110.9 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.467 ' H ' ' HD2' ' A' ' 11' ' ' LYS . 0.0 OUTLIER -62.61 -36.22 82.05 Favored 'General case' 0 N--CA 1.444 -0.773 0 N-CA-C 107.799 -1.185 . . . . 1.0 107.799 178.9 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.456 ' O ' HD12 ' A' ' 16' ' ' LEU . . . -73.59 -41.81 42.38 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 114.836 -1.074 . . . . 1.0 112.213 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.472 ' N ' ' O ' ' A' ' 9' ' ' LYS . 86.7 mt-10 -62.79 -31.35 72.3 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 119.464 -0.895 . . . . 1.0 108.634 179.54 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.55 -34.76 53.72 Favored 'General case' 0 N--CA 1.444 -0.769 0 CA-C-N 115.138 -0.937 . . . . 1.0 109.925 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -60.84 -49.07 78.96 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 114.499 -1.228 . . . . 1.0 111.11 -178.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.456 HD12 ' O ' ' A' ' 12' ' ' GLY . 5.1 mp -70.18 -36.76 74.87 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.195 -0.602 . . . . 1.0 109.495 178.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 96.3 m -61.66 -44.36 97.1 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.593 -0.731 . . . . 1.0 109.715 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -76.6 -44.83 32.73 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 114.985 -1.007 . . . . 1.0 112.517 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.64 ' ND2' ' CG ' ' A' ' 102' ' ' TYR . 53.3 t30 -60.07 -44.99 94.36 Favored 'General case' 0 CA--C 1.517 -0.301 0 N-CA-C 113.089 0.774 . . . . 1.0 113.089 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.9 ptmt -61.02 -28.5 69.09 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 119.969 -0.693 . . . . 1.0 109.761 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -82.99 -28.08 29.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.571 -0.741 . . . . 1.0 111.235 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.4 mtmt -59.25 139.01 88.45 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 120.834 -0.346 . . . . 1.0 111.478 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_exo -56.5 148.54 62.56 Favored 'Trans proline' 0 N--CA 1.502 2.008 0 C-N-CA 122.167 1.911 . . . . 1.0 113.353 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA3' ' HZ2' ' A' ' 35' ' ' LYS . . . 80.78 -18.84 8.25 Favored Glycine 0 C--O 1.228 -0.228 0 CA-C-N 115.247 -0.888 . . . . 1.0 111.592 179.209 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.46 137.29 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.444 . . . . 1.0 109.964 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.6 t -122.98 119.62 58.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 108.242 -1.021 . . . . 1.0 108.242 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.426 ' HA ' ' HG3' ' A' ' 33' ' ' GLN . 7.2 p -94.93 145.44 8.12 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 CA-C-O 121.689 0.757 . . . . 1.0 111.429 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 72.9 mt -111.92 165.11 13.57 Favored Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 114.189 -1.369 . . . . 1.0 110.481 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -61.21 -29.43 86.63 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.764 1.643 . . . . 1.0 111.048 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -68.34 -16.88 64.1 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 115.678 -0.692 . . . . 1.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.74 -7.0 60.85 Favored Glycine 0 CA--C 1.517 0.196 0 N-CA-C 110.142 -1.183 . . . . 1.0 110.142 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.475 HD22 ' H ' ' A' ' 33' ' ' GLN . 3.1 tm? -77.38 134.52 38.42 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.836 -0.801 . . . . 1.0 108.836 179.528 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.475 ' H ' HD22 ' A' ' 32' ' ' LEU . 26.2 mp0 -121.24 142.91 49.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.454 -0.339 . . . . 1.0 110.641 179.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -136.97 148.13 46.74 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-O 121.56 0.695 . . . . 1.0 110.75 178.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . 0.593 ' CD ' HD13 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -135.27 134.74 40.27 Favored 'General case' 0 N--CA 1.44 -0.948 0 CA-C-N 114.48 -1.236 . . . . 1.0 109.88 -179.174 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 p -93.3 105.34 16.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 122.063 0.935 . . . . 1.0 111.472 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.631 HD11 ' CD ' ' A' ' 100' ' ' GLU . 15.9 mm -70.33 -41.76 78.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.177 -0.92 . . . . 1.0 109.303 179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.452 ' ND2' HG22 ' A' ' 37' ' ' ILE . 34.4 m-80 -145.46 119.75 9.57 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.797 -1.092 . . . . 1.0 110.48 -177.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 18.5 p -80.32 123.85 28.34 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.264 0.554 . . . . 1.0 110.352 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.449 ' H ' ' CB ' ' A' ' 97' ' ' SER . . . -109.22 -29.24 4.07 Favored Glycine 0 CA--C 1.519 0.286 0 N-CA-C 109.234 -1.546 . . . . 1.0 109.234 179.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.609 ' N ' HD22 ' A' ' 41' ' ' ASN . 1.6 m120 54.73 32.12 16.77 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.756 -0.722 . . . . 1.0 111.412 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -90.95 -163.26 38.78 Favored Glycine 0 C--N 1.33 0.247 0 CA-C-O 121.923 0.735 . . . . 1.0 111.548 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 95' ' ' ALA . 19.3 m -68.28 -177.77 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 114.154 -1.023 . . . . 1.0 108.615 178.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.522 ' HZ1' ' HG3' ' A' ' 94' ' ' PRO . 0.0 OUTLIER 176.36 154.47 0.39 Allowed Pre-proline 0 C--N 1.317 -0.806 0 N-CA-C 109.454 -0.573 . . . . 1.0 109.454 179.631 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.437 ' HG3' ' HB ' ' A' ' 51' ' ' VAL . 72.3 Cg_endo -88.02 159.64 7.28 Favored 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 123.137 2.558 . . . . 1.0 116.355 -174.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 49' ' ' ASP . . . -91.53 175.02 38.69 Favored Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 109.06 -1.616 . . . . 1.0 109.06 176.375 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.628 ' H ' ' HD3' ' A' ' 47' ' ' LYS . 0.0 OUTLIER -51.47 -23.91 4.48 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.112 -0.544 . . . . 1.0 110.69 -179.691 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.466 ' H ' ' HE3' ' A' ' 47' ' ' LYS . 40.6 m -107.72 -10.09 15.68 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 113.983 1.105 . . . . 1.0 113.983 -177.302 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.417 ' HB2' ' H ' ' A' ' 46' ' ' GLY . 98.7 m-20 -84.7 165.51 17.81 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 119.618 -0.833 . . . . 1.0 108.835 179.724 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -103.36 148.93 25.27 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.515 -0.55 . . . . 1.0 109.515 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' HG3' ' A' ' 45' ' ' PRO . 5.7 p -125.62 162.44 28.65 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 CA-C-N 115.87 -0.605 . . . . 1.0 112.201 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.423 HG22 ' CB ' ' A' ' 74' ' ' PRO . 87.8 m -130.55 120.37 23.95 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.039 -1.097 . . . . 1.0 108.039 177.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.459 HG21 ' HZ3' ' A' ' 86' ' ' TRP . 9.9 m -148.51 164.99 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 114.004 1.113 . . . . 1.0 114.004 -176.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.465 ' HB3' ' HA ' ' A' ' 69' ' ' GLU . 10.4 mt-10 -118.61 152.3 36.3 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 106.425 -1.694 . . . . 1.0 106.425 174.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.523 ' H ' ' HB ' ' A' ' 68' ' ' THR . 34.1 p90 -162.1 159.57 26.31 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 114.856 1.428 . . . . 1.0 114.856 -177.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 67' ' ' SER . 1.5 m -121.24 129.74 53.33 Favored 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.157 -0.929 . . . . 1.0 108.988 176.019 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.5 133.9 11.78 Favored Glycine 0 N--CA 1.47 0.935 0 N-CA-C 111.185 -0.766 . . . . 1.0 111.185 -178.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -145.54 166.43 25.73 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 121.69 0.757 . . . . 1.0 112.101 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 3.9 mp -87.46 160.08 18.42 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.578 -1.192 . . . . 1.0 111.272 178.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 60' ' ' ILE . 0.2 OUTLIER -55.12 -26.01 17.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 114.462 -1.244 . . . . 1.0 110.465 177.811 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -96.04 5.63 50.71 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.49 -1.232 . . . . 1.0 111.075 -178.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.73 -9.51 77.47 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.021 -0.536 . . . . 1.0 113.642 178.123 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -61.13 97.01 0.06 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 118.331 1.066 . . . . 1.0 110.634 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 98.2 t -68.73 125.69 27.1 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 C-N-CA 119.639 -0.824 . . . . 1.0 108.854 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.908 ' CD2' HD11 ' A' ' 118' ' ' ILE . 19.4 p90 -117.38 -15.53 10.33 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.163 -0.926 . . . . 1.0 111.696 -178.615 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.542 ' CB ' H433 ' A' ' 138' ' ' RAP . 11.8 t70 -154.6 149.87 27.1 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.249 0.547 . . . . 1.0 111.735 178.023 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 56' ' ' THR . 84.2 p -155.87 151.32 26.97 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.395 -0.821 . . . . 1.0 111.776 179.137 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.523 ' HB ' ' H ' ' A' ' 55' ' ' TYR . 99.5 m -148.04 -37.8 0.19 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.201 -0.908 . . . . 1.0 110.157 -179.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.465 ' HA ' ' HB3' ' A' ' 54' ' ' GLU . 1.1 pp20? -66.62 -27.37 67.65 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 116.14 -0.482 . . . . 1.0 110.04 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -59.4 -43.39 92.99 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 107.744 -1.206 . . . . 1.0 107.744 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 68' ' ' THR . 18.5 p -73.01 -32.88 65.42 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 114.876 -1.056 . . . . 1.0 108.523 176.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.36 17.68 66.08 Favored Glycine 0 CA--C 1.522 0.484 0 CA-C-N 115.434 -0.803 . . . . 1.0 111.977 178.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.439 ' C ' ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -100.29 114.59 65.76 Favored Pre-proline 0 N--CA 1.471 0.602 0 C-N-CA 120.448 -0.501 . . . . 1.0 111.164 -179.591 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.423 ' CB ' HG22 ' A' ' 52' ' ' THR . 38.5 Cg_exo -61.7 152.87 71.25 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.012 1.808 . . . . 1.0 114.097 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.416 ' HB1' ' CZ ' ' A' ' 77' ' ' PHE . . . -123.08 145.19 48.76 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 113.681 -1.599 . . . . 1.0 107.847 178.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.516 ' O ' ' CD2' ' A' ' 77' ' ' PHE . 2.7 t -105.59 136.36 45.32 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.267 0.556 . . . . 1.0 112.482 -178.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.754 ' CE1' ' H42' ' A' ' 138' ' ' RAP . 19.5 m-85 -150.07 151.25 32.92 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.546 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -87.93 128.32 35.37 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 107.652 -1.24 . . . . 1.0 107.652 175.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 24.5 t -54.86 -32.28 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 120.135 -0.626 . . . . 1.0 110.899 -177.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.5 t -72.48 -26.93 61.98 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.8 -0.76 . . . . 1.0 112.063 -177.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.539 ' C ' H482 ' A' ' 138' ' ' RAP . 80.6 mm-40 -98.52 -11.1 22.59 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 112.789 0.662 . . . . 1.0 112.789 -178.08 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.725 ' HA ' H332 ' A' ' 138' ' ' RAP . 0.5 OUTLIER -71.54 169.07 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.798 0.666 . . . . 1.0 112.798 -175.735 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.425 HD13 HG21 ' A' ' 83' ' ' ILE . 0.1 OUTLIER -51.69 145.76 15.19 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 107.134 -1.432 . . . . 1.0 107.134 -178.785 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.412 ' HD2' HG22 ' A' ' 83' ' ' ILE . 52.8 Cg_exo -49.73 -44.86 34.32 Favored 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 121.19 1.26 . . . . 1.0 112.654 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.2 -47.25 91.99 Favored Glycine 0 C--N 1.317 -0.523 0 C-N-CA 120.007 -1.092 . . . . 1.0 111.295 -179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' TRP . . . . . 0.573 ' CZ2' ' H51' ' A' ' 138' ' ' RAP . 6.7 m95 -63.76 -31.26 72.38 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 114.028 -1.086 . . . . 1.0 111.523 -179.489 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 99.4 m -56.4 -53.54 56.18 Favored 'General case' 0 C--N 1.33 -0.281 0 O-C-N 121.913 -0.492 . . . . 1.0 111.655 -178.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -71.76 -38.49 70.38 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.284 0.846 . . . . 1.0 113.284 -177.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -64.01 -44.1 93.64 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 114.477 1.288 . . . . 1.0 114.477 -176.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 26.9 mt -58.71 -37.99 77.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.275 0.559 . . . . 1.0 110.778 -177.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -64.92 -24.1 67.42 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.294 -0.866 . . . . 1.0 111.345 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 27.6 mt -102.06 -18.96 15.36 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.173 -0.467 . . . . 1.0 111.212 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' MET . . . . . . . . . . . . . 44.4 ttp -81.34 109.36 13.8 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 112.639 0.607 . . . . 1.0 112.639 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.522 ' HG3' ' HZ1' ' A' ' 44' ' ' LYS . 17.0 Cg_exo -66.39 148.32 84.04 Favored 'Trans proline' 0 N--CA 1.503 2.041 0 C-N-CA 122.679 2.253 . . . . 1.0 113.116 178.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.592 ' N ' ' O ' ' A' ' 43' ' ' VAL . . . -64.91 131.48 46.8 Favored 'General case' 0 CA--C 1.511 -0.554 0 CA-C-O 121.606 0.717 . . . . 1.0 111.811 -179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 96.71 -16.51 60.87 Favored Glycine 0 N--CA 1.445 -0.747 0 N-CA-C 108.177 -1.969 . . . . 1.0 108.177 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.449 ' CB ' ' H ' ' A' ' 40' ' ' GLY . 5.7 p -88.46 139.13 30.79 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.089 -0.556 . . . . 1.0 110.139 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 50.9 m -110.27 117.43 33.64 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.627 -0.715 . . . . 1.0 110.12 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -117.49 169.64 9.37 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.95 0.881 . . . . 1.0 110.546 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.631 ' CD ' HD11 ' A' ' 37' ' ' ILE . 88.8 mt-10 -130.24 132.65 46.06 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.935 -1.506 . . . . 1.0 106.935 175.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.41 HD11 ' CD1' ' A' ' 86' ' ' TRP . 3.2 pt -127.48 137.13 58.62 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 108.603 -0.888 . . . . 1.0 108.603 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.765 ' CD2' HD12 ' A' ' 125' ' ' ILE . 0.2 OUTLIER -108.65 102.82 11.85 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 105.83 -1.915 . . . . 1.0 105.83 -177.8 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 4.6 t -89.94 115.1 63.11 Favored Pre-proline 0 C--N 1.325 -0.48 0 N-CA-C 114.516 1.302 . . . . 1.0 114.516 -174.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -51.57 144.33 33.33 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 121.072 1.181 . . . . 1.0 109.696 176.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 87.6 p -49.97 -31.98 13.9 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.377 -0.529 . . . . 1.0 110.959 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.71 -31.78 70.52 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.558 -0.617 . . . . 1.0 111.558 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.09 3.09 43.78 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 110.548 -0.167 . . . . 1.0 110.548 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.527 ' O ' H521 ' A' ' 138' ' ' RAP . . . -108.84 -109.06 0.33 Allowed 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 120.736 0.303 . . . . 1.0 111.256 -178.349 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.584 ' OH ' ' O3 ' ' A' ' 138' ' ' RAP . 38.6 m-85 -98.32 -4.66 34.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 114.379 1.251 . . . . 1.0 114.379 -176.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 112.32 172.68 18.95 Favored Glycine 0 N--CA 1.471 1.008 0 C-N-CA 120.497 -0.859 . . . . 1.0 113.174 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 121' ' ' ASN . 71.9 Cg_endo -73.75 -31.4 8.49 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 123.649 2.899 . . . . 1.0 112.388 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -82.23 170.81 14.98 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.365 0.602 . . . . 1.0 111.435 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.418 ' OG ' ' N ' ' A' ' 120' ' ' PRO . 7.3 m -79.34 88.3 4.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.279 -0.873 . . . . 1.0 109.039 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.404 HG21 ' O ' ' A' ' 109' ' ' TYR . 3.3 t -97.88 55.26 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.341 -0.39 . . . . 1.0 111.383 -178.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 118' ' ' ILE . . . 173.37 -175.25 46.18 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 120.509 -0.853 . . . . 1.0 112.087 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.34 -103.34 0.01 OUTLIER Glycine 0 CA--C 1.53 1.022 0 N-CA-C 111.268 -0.733 . . . . 1.0 111.268 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -62.13 -15.91 47.04 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.478 2.119 . . . . 1.0 110.518 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.908 HD11 ' CD2' ' A' ' 65' ' ' PHE . 4.6 mp -66.39 115.03 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.376 -1.342 . . . . 1.0 107.376 178.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.607 ' O ' ' CG ' ' A' ' 122' ' ' GLU . . . -97.26 -157.79 30.82 Favored Glycine 0 C--O 1.213 -1.186 0 N-CA-C 110.814 -0.914 . . . . 1.0 110.814 -178.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.48 ' O ' ' ND2' ' A' ' 8' ' ' ASN . 53.4 Cg_endo -71.02 147.58 55.08 Favored 'Trans proline' 0 C--N 1.297 -2.156 0 C-N-CA 121.51 1.474 . . . . 1.0 112.982 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.545 ' N ' ' O ' ' A' ' 111' ' ' PRO . 0.2 OUTLIER 39.48 60.97 1.47 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 113.216 0.821 . . . . 1.0 113.216 177.503 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.744 ' CD ' ' H ' ' A' ' 122' ' ' GLU . 0.0 OUTLIER -112.69 140.35 47.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.038 0.447 . . . . 1.0 110.611 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 85.5 m -93.93 127.73 39.86 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.1 -1.074 . . . . 1.0 108.1 177.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -108.85 136.41 48.45 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.516 -0.55 . . . . 1.0 109.516 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ILE . . . . . 0.765 HD12 ' CD2' ' A' ' 102' ' ' TYR . 1.8 tt -117.6 146.87 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 108.706 -0.849 . . . . 1.0 108.706 178.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 126' ' ' PHE . 4.0 m-85 -135.8 149.49 49.12 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 120.236 -0.586 . . . . 1.0 111.334 178.137 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.473 ' O ' ' CB ' ' A' ' 55' ' ' TYR . 9.5 mmtt -99.46 124.57 44.73 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 104.948 -2.242 . . . . 1.0 104.948 177.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 3.9 mt -115.77 118.37 58.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 C-N-CA 119.167 -1.013 . . . . 1.0 111.9 -177.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -110.39 123.05 49.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.655 -1.611 . . . . 1.0 108.484 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -95.76 112.95 24.55 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 112.544 0.572 . . . . 1.0 112.544 -177.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.486 ' N ' HD12 ' A' ' 131' ' ' ILE . 4.4 mp -94.49 -49.17 12.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 CA-C-N 115.749 -0.66 . . . . 1.0 111.17 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 4.6 p -145.32 157.39 44.06 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.014 0.435 . . . . 1.0 110.601 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.461 HG21 ' HA ' ' A' ' 44' ' ' LYS . 48.3 t -130.09 137.56 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.288 -0.414 . . . . 1.0 110.993 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.491 ' CG ' ' H ' ' A' ' 135' ' ' LYS . 15.8 tptt -88.84 -150.15 0.19 Allowed 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.704 -0.68 . . . . 1.0 109.541 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.491 ' H ' ' CG ' ' A' ' 134' ' ' LYS . 0.2 OUTLIER 178.53 138.23 0.09 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.864 0.84 . . . . 1.0 111.493 177.861 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 137' ' ' SER . 1.1 t -63.55 -46.44 85.92 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 114.036 -1.438 . . . . 1.0 110.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.41 ' C ' ' O ' ' A' ' 136' ' ' SER . 94.3 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.887 -1.054 . . . . 1.0 111.462 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' RAP . . . . . 0.889 H512 H472 ' A' ' 138' ' ' RAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_